0001564590-21-006406.txt : 20210217 0001564590-21-006406.hdr.sgml : 20210217 20210217164948 ACCESSION NUMBER: 0001564590-21-006406 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 73 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210217 DATE AS OF CHANGE: 20210217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Viking Therapeutics, Inc. CENTRAL INDEX KEY: 0001607678 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 461073877 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37355 FILM NUMBER: 21645599 BUSINESS ADDRESS: STREET 1: 12340 EL CAMINO REAL, SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-704-4660 MAIL ADDRESS: STREET 1: 12340 EL CAMINO REAL, SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92130 10-K 1 vktx-10k_20201231.htm 10-K vktx-10k_20201231.htm
false FY 0001607678 --12-31 Three months or less true P4Y P4Y P2Y5M12D P1Y7M28D P7Y7M28D P7Y3M25D P6Y4M6D P6Y1M2D P6Y3D 0001607678 2020-01-01 2020-12-31 0001607678 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001607678 us-gaap:WarrantMember 2020-01-01 2020-12-31 xbrli:shares 0001607678 2021-01-31 iso4217:USD 0001607678 2020-06-30 0001607678 2020-12-31 0001607678 2019-12-31 iso4217:USD xbrli:shares 0001607678 2019-01-01 2019-12-31 0001607678 us-gaap:CommonStockMember 2018-12-31 0001607678 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001607678 us-gaap:RetainedEarningsMember 2018-12-31 0001607678 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001607678 2018-12-31 0001607678 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001607678 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001607678 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001607678 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001607678 us-gaap:CommonStockMember 2019-12-31 0001607678 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001607678 us-gaap:RetainedEarningsMember 2019-12-31 0001607678 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001607678 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001607678 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001607678 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001607678 us-gaap:CommonStockMember 2020-12-31 0001607678 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001607678 us-gaap:RetainedEarningsMember 2020-12-31 0001607678 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001607678 us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001607678 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001607678 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001607678 us-gaap:WarrantMember 2019-01-01 2019-12-31 0001607678 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001607678 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001607678 vktx:CommonStockSubjectToRepurchaseMember 2020-01-01 2020-12-31 0001607678 vktx:CommonStockSubjectToRepurchaseMember 2019-01-01 2019-12-31 0001607678 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001607678 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 vktx:Segment 0001607678 us-gaap:CommercialPaperMember 2020-12-31 0001607678 us-gaap:CorporateDebtSecuritiesMember 2020-12-31 vktx:Security 0001607678 srt:MaximumMember 2020-12-31 0001607678 us-gaap:CommercialPaperMember us-gaap:CashEquivalentsMember 2020-12-31 0001607678 us-gaap:CorporateDebtSecuritiesMember us-gaap:CashEquivalentsMember 2020-12-31 0001607678 us-gaap:CommercialPaperMember 2019-12-31 0001607678 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001607678 srt:MaximumMember 2019-12-31 0001607678 us-gaap:CommercialPaperMember us-gaap:CashEquivalentsMember 2019-12-31 0001607678 us-gaap:CorporateDebtSecuritiesMember us-gaap:CashEquivalentsMember 2019-12-31 0001607678 us-gaap:MoneyMarketFundsMember 2020-12-31 0001607678 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2020-12-31 0001607678 us-gaap:CommercialPaperMember 2020-12-31 0001607678 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2020-12-31 0001607678 us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001607678 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001607678 us-gaap:FairValueInputsLevel1Member 2020-12-31 0001607678 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001607678 us-gaap:MoneyMarketFundsMember 2019-12-31 0001607678 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2019-12-31 0001607678 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001607678 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001607678 us-gaap:CommercialPaperMember 2019-12-31 0001607678 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2019-12-31 0001607678 us-gaap:FairValueInputsLevel1Member 2019-12-31 0001607678 us-gaap:FairValueInputsLevel2Member 2019-12-31 0001607678 us-gaap:IPOMember vktx:LigandPharmaceuticalsIncorporatedMember 2020-01-01 2020-12-31 0001607678 vktx:LigandPharmaceuticalsIncorporatedMember 2020-12-31 xbrli:pure 0001607678 vktx:LigandPharmaceuticalsIncorporatedMember 2020-01-01 2020-12-31 0001607678 vktx:LigandPharmaceuticalsIncorporatedMember vktx:ManagementRightsLetterMember srt:MaximumMember 2014-05-31 0001607678 vktx:LigandPharmaceuticalsIncorporatedMember vktx:ManagementRightsLetterMember srt:MinimumMember 2014-05-31 0001607678 vktx:LigandPharmaceuticalsIncorporatedMember vktx:ManagementRightsLetterMember 2014-05-01 2014-05-31 vktx:Lease 0001607678 2014-02-28 0001607678 2014-02-01 2014-02-28 vktx:Tranche 0001607678 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2014-02-28 0001607678 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2014-02-28 0001607678 2014-02-20 0001607678 2015-05-31 0001607678 2015-05-01 2015-05-31 0001607678 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2015-05-31 0001607678 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2015-05-31 0001607678 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2015-10-01 2016-12-31 0001607678 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2019-01-01 2019-12-31 0001607678 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2020-01-01 2020-12-31 0001607678 vktx:PoCCapitalLLCMember us-gaap:CommonStockMember vktx:StockPurchaseAgreementMember 2017-02-07 2017-02-08 0001607678 vktx:PoCCapitalLLCMember 2017-02-08 0001607678 vktx:PoCCapitalLLCMember us-gaap:CommonStockMember vktx:StockPurchaseAgreementMember vktx:ClinicalStudiesMember 2020-01-01 2020-12-31 0001607678 vktx:PoCCapitalLLCMember 2019-01-01 2019-12-31 0001607678 vktx:PoCCapitalLLCMember 2020-01-01 2020-12-31 0001607678 vktx:LincoInParkCapitalFundLimitedLiabilityCompanyMember us-gaap:CommonStockMember vktx:RegisteredOfferingPurchaseAgreementMember 2017-09-27 2017-09-29 0001607678 vktx:LincoInParkCapitalFundLimitedLiabilityCompanyMember us-gaap:CommonStockMember vktx:RegisteredOfferingPurchaseAgreementMember 2017-09-29 0001607678 vktx:LincoInParkCapitalFundLimitedLiabilityCompanyMember us-gaap:CommonStockMember vktx:CommitmentPurchaseAgreementMember srt:MaximumMember vktx:RegistrationRightsAgreementMember 2017-09-26 2017-09-28 0001607678 vktx:LincoInParkCapitalFundLimitedLiabilityCompanyMember us-gaap:CommonStockMember vktx:CommitmentPurchaseAgreementMember vktx:RegistrationRightsAgreementMember 2017-09-26 2017-09-28 0001607678 vktx:LincoInParkCapitalFundLimitedLiabilityCompanyMember us-gaap:CommonStockMember vktx:CommitmentPurchaseAgreementMember srt:MaximumMember vktx:RegistrationRightsAgreementMember 2017-09-28 0001607678 vktx:LincoInParkCapitalFundLimitedLiabilityCompanyMember us-gaap:CommonStockMember vktx:CommitmentPurchaseAgreementMember srt:MinimumMember vktx:RegistrationRightsAgreementMember 2017-09-26 2017-09-28 0001607678 us-gaap:CommonStockMember vktx:AtTheMarketEquityOfferingSalesAgreementMember srt:MaximumMember 2019-08-01 2019-08-01 0001607678 us-gaap:CommonStockMember vktx:AtTheMarketEquityOfferingSalesAgreementMember 2019-08-01 2019-08-01 0001607678 vktx:RepurchaseProgramMember 2020-03-17 2020-03-17 0001607678 vktx:RepurchaseProgramMember 2020-01-01 2020-12-31 0001607678 vktx:TwoThousandFourteenPlanMember 2015-04-28 0001607678 vktx:TwoThousandFourteenEmployeeStockPurchasePlanMember 2015-04-28 0001607678 vktx:TwoThousandFourteenPlanMember 2020-12-31 0001607678 vktx:TwoThousandFourteenEmployeeStockPurchasePlanMember 2020-12-31 0001607678 vktx:TwoThousandFourteenPlanMember 2020-01-01 2020-12-31 0001607678 vktx:TwoThousandFourteenEmployeeStockPurchasePlanMember 2020-01-01 2020-12-31 vktx:Period 0001607678 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001607678 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001607678 vktx:RestrictedStockAndRestrictedStockUnitsMember 2020-01-01 2020-12-31 0001607678 vktx:RestrictedStockAndRestrictedStockUnitsMember 2019-01-01 2019-12-31 0001607678 vktx:EmployeeStockPurchasePlanMember 2020-01-01 2020-12-31 0001607678 vktx:EmployeeStockPurchasePlanMember 2019-01-01 2019-12-31 0001607678 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001607678 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001607678 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001607678 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0001607678 us-gaap:EmployeeStockOptionMember 2020-12-31 0001607678 vktx:RestrictedStockAndRestrictedStockUnitsMember 2020-12-31 0001607678 us-gaap:RestrictedStockMember 2018-12-31 0001607678 us-gaap:RestrictedStockMember 2019-12-31 0001607678 us-gaap:RestrictedStockMember 2020-12-31 0001607678 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001607678 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001607678 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001607678 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001607678 vktx:PerformanceBasedRestrictedStockUnitsMember 2019-01-01 2019-01-31 vktx:Milestone 0001607678 vktx:PerformanceBasedRestrictedStockUnitsMember 2020-03-31 0001607678 vktx:PerformanceBasedRestrictedStockUnitsMember 2020-01-01 2020-12-31 0001607678 vktx:PerformanceBasedRestrictedStockUnitsMember 2019-01-01 2019-12-31 0001607678 vktx:PerformanceBasedRestrictedStockUnitsMember 2020-01-01 2020-01-31 0001607678 vktx:PerformanceBasedRestrictedStockUnitsMember 2020-12-31 0001607678 vktx:PerformanceBasedRestrictedStockUnitsMember vktx:JanuaryTwoThousandTwentyMember 2020-01-01 2020-12-31 0001607678 us-gaap:WarrantMember 2020-12-31 0001607678 vktx:CommonStockOptionsMember 2020-12-31 0001607678 vktx:AvailableForGrantUnderTwoThousandFourteenPlanMember 2020-12-31 0001607678 vktx:AvailableForIssuanceUnderEmployeeStockPurchasePlanMember 2020-12-31 0001607678 2016-04-12 2016-04-13 0001607678 2016-04-13 0001607678 us-gaap:OverAllotmentOptionMember 2016-04-13 0001607678 vktx:LigandPharmaceuticalsIncorporatedMember vktx:LoanAndSecurityAgreementMember 2016-04-13 0001607678 vktx:LoanAndSecurityAgreementMember srt:MinimumMember 2016-04-13 0001607678 vktx:LigandPharmaceuticalsIncorporatedMember vktx:LoanAndSecurityAgreementMember 2020-01-01 2020-12-31 0001607678 vktx:LigandPharmaceuticalsIncorporatedMember vktx:LoanAndSecurityAgreementMember 2016-04-12 2016-04-13 0001607678 us-gaap:CommonStockMember vktx:SecuritiesPurchaseAgreementMember vktx:PrivatePlacementAndRegisteredDirectOfferingMember 2017-06-13 2017-06-14 0001607678 us-gaap:CommonStockMember vktx:SecuritiesPurchaseAgreementMember srt:MaximumMember vktx:PrivatePlacementAndRegisteredDirectOfferingMember 2017-06-14 0001607678 vktx:SecuritiesPurchaseAgreementMember vktx:PrivatePlacementAndRegisteredDirectOfferingMember 2017-06-14 0001607678 vktx:SecuritiesPurchaseAgreementMember 2017-06-14 0001607678 vktx:SecuritiesPurchaseAgreementMember vktx:PrivatePlacementAndRegisteredDirectOfferingMember 2017-06-13 2017-06-14 0001607678 vktx:SecuritiesPurchaseAgreementMember vktx:PrivatePlacementAndRegisteredDirectOfferingMember 2020-01-01 2020-12-31 0001607678 vktx:SecuritiesPurchaseAgreementMember 2019-01-01 2019-12-31 0001607678 vktx:SecuritiesPurchaseAgreementMember 2020-01-01 2020-12-31 0001607678 vktx:SecuritiesPurchaseAgreementMember 2018-01-16 0001607678 us-gaap:DomesticCountryMember 2020-12-31 0001607678 us-gaap:StateAndLocalJurisdictionMember 2020-12-31 0001607678 us-gaap:DomesticCountryMember 2020-01-01 2020-12-31 0001607678 vktx:LigandPharmaceuticalsIncorporatedMember 2020-12-31 utr:sqft 0001607678 stpr:CA vktx:OfficeLeaseMember 2018-05-25 0001607678 vktx:OfficeLeaseMember stpr:CA 2018-05-24 2018-05-25

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

(Mark One)

 

☒

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2020

OR

 

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO                     

 

Commission File Number 001-37355

 

Viking Therapeutics, Inc.

(Exact name of Registrant as specified in its Charter)

 

 

Delaware

 

46-1073877

( State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer
Identification No.)

12340 El Camino Real, Suite 250

San Diego, California

 

92130

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (858) 704-4660

 

Securities registered pursuant to Section 12(b) of the Act

 

 

Title of Each Class

Trading Symbol

Name of Each Exchange on Which Registered

Common Stock, par value $0.00001 per share

VKTX

The Nasdaq Stock Market LLC

Warrants to purchase Common Stock, par value $0.00001 per share

VKTXW

The Nasdaq Stock Market LLC

 

Securities registered pursuant to Section 12(g) of the Act:

None

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.     Yes   ☐    No   ☒

Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.     Yes   ☐    No    ☒

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes   ☒    No    ☐

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).     Yes ☒    No    ☐

 

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definition of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:

Large accelerated filer

 

☐

  

Accelerated filer

 

☐

 

 

 

 

Non-accelerated filer

 

☒ 

  

Smaller reporting company

 

☒

 

 

 

 

 

 

 

 

Emerging growth company

 

☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes  ☐    No   ☒

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on the Nasdaq Capital Market on June 30, 2020 (the last trading day of the registrant’s second fiscal quarter of 2020), was $469,584,214. Shares of voting stock held by directors, officers and stockholders or stockholder groups whose beneficial ownership exceeds 5% of the registrant’s common stock outstanding have been excluded in that such persons may be deemed to be affiliates. The number of shares owned by stockholders whose beneficial ownership exceeds 5% was determined based upon information supplied by such persons and upon Schedules 13D and 13G, if any, filed with the Securities and Exchange Commission. This assumption regarding affiliate status is not necessarily a conclusive determination for other purposes.

The number of shares of the Registrant’s Common Stock outstanding as of January 31, 2021 was 74,133,121.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

Portions of the Registrant’s Definitive Proxy Statement for its 2021 Annual Meeting of Stockholders or an amendment to this Annual Report on Form 10-K to be filed with the Securities and Exchange Commission within 120 days of the registrant’s fiscal year ended December 31, 2020 are incorporated by reference into Part III of this Annual Report on Form 10-K.

 

 

 

 

Table of Contents

 

 

 

 

 

Page

PART I

 

 

 

 

Item 1.

 

Business

 

1

Item 1A.

 

Risk Factors

 

22

Item 1B.

 

Unresolved Staff Comments

 

53

Item 2.

 

Properties

 

53

Item 3.

 

Legal Proceedings

 

54

Item 4.

 

Mine Safety Disclosures

 

54

 

 

 

 

 

PART II

 

 

 

 

Item 5.

 

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 

55

Item 6.

 

Selected Financial Data

 

55

Item 7.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

56

Item 7A.

 

Quantitative and Qualitative Disclosures About Market Risk

 

63

Item 8.

 

Financial Statements and Supplementary Data

 

63

Item 9.

 

Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

 

63

Item 9A.

 

Controls and Procedures

 

64

Item 9B.

 

Other Information

 

64

 

 

 

 

 

PART III

 

 

 

 

Item 10.

 

Directors, Executive Officers and Corporate Governance

 

66

Item 11.

 

Executive Compensation

 

66

Item 12.

 

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 

66

Item 13.

 

Certain Relationships and Related Transactions, and Director Independence

 

66

Item 14.

 

Principal Accounting Fees and Services

 

66

 

 

 

 

 

PART IV

 

 

 

 

Item 15.

 

Exhibits, Financial Statement Schedules

 

67

Item 16.

 

Form 10-K Summary

 

69

 

 

 

i

 

This Annual Report on Form 10-K contains “forward-looking statements” as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, in connection with the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially and adversely from those expressed or implied by such forward-looking statements. Such forward-looking statements include estimates of our expenses, future revenue, capital requirements and our needs for additional financing; statements regarding our ability to develop, acquire and advance drug candidates into, and successfully complete, clinical trials and preclinical studies; statements concerning new product candidates; risks and uncertainties associated with our research and development activities, including our clinical trials and preclinical studies; our expectations regarding the potential market size and the size of the patient populations for our drug candidates, if approved for commercial use, and our ability to serve such markets; statements regarding our ability to maintain and establish collaborations or obtain additional funding; statements regarding developments and projections relating to our competitors and our industry and other matters that do not relate strictly to historical facts or statements of assumptions underlying any of the foregoing. These statements are often identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may” or “will,” the negative versions of these terms and similar expressions or variations. These statements are based on the beliefs and assumptions of our management based on information currently available to management. Such forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results and the timing of certain events to differ materially and adversely from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk Factors” included elsewhere in this Annual Report on Form 10-K and in our other Securities and Exchange Commission filings. Furthermore, such forward-looking statements speak only as of the date of this report. We undertake no obligation to update any forward-looking statements to reflect events or circumstances occurring after the date of such statement.

 

Throughout this Annual Report on Form 10-K, unless the context otherwise requires, the terms “Viking,” “we,” “us” and “our” in this Annual Report on Form 10-K refer to Viking Therapeutics, Inc.

 

 

PART I

 

 

Item 1. Business.

Overview

We are a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders.

Our lead clinical program’s drug candidate, VK2809, is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, or TRß. In November 2019, we initiated the VOYAGE study, a Phase 2b clinical trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis, or NASH.

The VOYAGE study is a randomized, double-blind, placebo-controlled, multicenter trial designed to assess the efficacy, safety and tolerability of VK2809 in patients with biopsy-confirmed NASH and fibrosis ranging from stages F1 to F3. The study is targeting enrollment of approximately 340 patients across five treatment arms.  The primary endpoint of the study will evaluate the relative change in liver fat content, as assessed by magnetic resonance imaging, proton density fat fraction (MRI-PDFF), from baseline to week 12 in subjects treated with VK2809 as compared to placebo. Secondary objectives include evaluation of histologic changes assessed by hepatic biopsy after 52 weeks of dosing.

VK2809 has been evaluated in seven completed clinical studies, which enrolled more than 300 subjects. No serious adverse events, or SAEs, have been observed in subjects receiving VK2809 in these completed studies, and overall tolerability remains encouraging. In addition, the compound has been evaluated in chronic toxicity studies of up to 12 months in duration.

 

We are also developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRß for X-linked adrenoleukodystrophy, or X-ALD, a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. The disease, for which there is no approved treatment, is caused by mutations in a peroxisomal transporter of very long chain fatty acids, or VLCFA, known as ABCD1. As a result, transporter function is impaired and patients are unable to efficiently metabolize VLCFA. The TRß receptor is known to regulate expression of an alternative VLCFA transporter, known as ABCD2. Various preclinical models have demonstrated that increased expression of ABCD2 can lead to normalization of VLCFA metabolism. Preliminary data suggest that VK0214 stimulates ABCD2 expression in an in vitro model and reduces VLCFA levels in an in vivo model of X-ALD. In September of 2020, we initiated a randomized, double-blind, placebo controlled Phase 1 single ascending dose, or SAD, and multiple ascending dose, or MAD, clinical trial of VK0214 in healthy subjects.

1

The primary objectives of the study include evaluation of the safety and tolerability of single and multiple oral doses of VK0214, as well as identification of VK0214 doses for further clinical development in the setting of X-ALD.

Other clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM. In November 2017, we announced positive top-line results from a Phase 2 proof-of-concept clinical trial in 108 patients recovering from non-elective hip fracture surgery. Top-line data showed that the trial achieved its primary endpoint, demonstrating statistically significant, dose dependent increases in lean body mass, less head, following treatment with VK5211 as compared to placebo. The study also achieved certain secondary endpoints, demonstrating statistically significant increases in appendicular lean body mass and total lean body mass for all doses of VK5211, compared to placebo. VK5211 demonstrated encouraging safety and tolerability in this study, with no drug-related SAEs reported. Our intent is to continue to pursue partnering or licensing opportunities prior to conducting additional clinical studies.

We have exclusive worldwide rights to a portfolio of five drug candidates in clinical trials or preclinical studies, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated, or Ligand. Details regarding our license agreement with Ligand are discussed under the heading “Agreements with Ligand” under Part I, “Item 1. Business” of this Annual Report on Form 10-K.

Our Development Pipeline

The following table highlights our current development pipeline:

 

Key: TRß, thyroid receptor beta; NASH, nonalcoholic steatohepatitis; X-ALD, X-linked adrenoleukodystrophy.

We also have three additional programs targeting metabolic diseases and anemia. The most advanced is VK0612, a first-in-class, orally available Phase 2b-ready drug candidate for type 2 diabetes. Preliminary clinical data suggest VK0612 has the potential to provide substantial glucose-lowering effects, with an attractive safety and convenience profile compared with existing type 2 diabetes therapies. Our preclinical programs are focused on developing inhibitors of diacylglycerol acyltransferase-1, or DGAT-1, for the potential treatment of obesity and dyslipidemia and on identifying orally available erythropoietin, or EPO, receptor, or EPOR, agonists for the potential treatment of anemia.

Novel Selective TRß Agonists for Metabolic Disorders and Adrenoleukodystrophy

Summary Overview

VK2809 and VK0214 are novel, orally available, selective TRß agonists in development for metabolic disorders and X-ALD.  Thyroid hormone receptors are found in various tissues throughout the body. TRß is the major receptor isoform expressed in the liver and thyroid hormone receptor alpha, or TRa, is the major isoform expressed in the heart. The unique properties of our TRß agonists are designed to reduce or eliminate the deleterious effects of extra-hepatic thyroid receptor activation. In particular, high tissue and TRß selectivity may lead to reduced activity at the TRa receptor, which can be associated with increased respiration and cardiac tissue hypertrophy. Selective activation of the TRß receptor in liver tissue is believed to favorably affect cholesterol and lipoprotein levels via multiple mechanisms, including increasing the expression of low-density lipoprotein receptors and increasing mitochondrial fatty acid oxidation. These characteristics in turn lead to reductions of LDL-C, plasma and liver triglycerides. In addition, our chemical structures are not substrates for certain transporters involved in the uptake of thyroid hormone. Various animal models have shown that our molecules, as a result of their unique profiles, may have reduced cardiovascular effects versus thyroid hormone and other thyromimetics.  As a result of these characteristics, we believe our selective TRß agonists are capable of eliciting a unique lipid lowering profile without eliciting unwanted effects on the heart and thyroid hormone axis.

 

2

 

VK2809 in NASH

In November 2019, we initiated the VOYAGE study, a Phase 2b clinical trial of VK2809 in patients with biopsy-confirmed NASH.

The VOYAGE study is a randomized, double-blind, placebo-controlled, multicenter trial designed to assess the efficacy, safety and tolerability of VK2809 in patients with biopsy-confirmed NASH and fibrosis ranging from stages F1 to F3. The study is targeting enrollment of approximately 340 patients across five treatment arms.  The primary endpoint of the study will evaluate the relative change in liver fat content, as assessed by magnetic resonance imaging, proton density fat fraction (MRI-PDFF), from baseline to week 12 in subjects treated with VK2809 as compared to placebo. Secondary objectives include evaluation of histologic changes assessed by hepatic biopsy after 52 weeks of dosing.

VK2809 in NAFLD

In September 2018, we announced top-line results from our 12-week, Phase 2 clinical trial of our lead clinical program’s drug candidate, VK2809, in patients with NAFLD and elevated low-density lipoprotein cholesterol, or LDL-C. The study successfully achieved its primary endpoint, with patients receiving VK2809 demonstrating statistically significant reductions in LDL-C compared with placebo.  In addition, the trial’s secondary endpoint was achieved, with VK2809-treated patients experiencing statistically significant reductions in liver fat content compared with placebo.  VK2809 demonstrated encouraging safety and tolerability in this study, with no SAEs reported.

 

Top-line study results from the Phase 2 clinical trial include:

 

Reduction in LDL-C

 

Patients receiving VK2809 demonstrated statistically significant reductions in LDL-C of 20% or more, compared with placebo-treated patients.  In addition, VK2809-treated patients demonstrated statistically significant improvements in other lipids, including atherogenic proteins apolipoprotein B and lipoprotein (a).  

 

Reduction in Liver Fat Content

 

 

Patients receiving VK2809 experienced statistically significant reductions in liver fat content, as assessed by magnetic resonance imaging, proton density fat fraction, or MRI-PDFF, relative to placebo after 12 weeks of treatment.

 

 

Placebo

 

 

VK2809 5 mg

QD

 

VK2809 10 mg QOD

 

VK2809 10 mg QD

 

VK2809

combined

 

Median relative change in liver fat by MRI-PDFF

-9.4%

-53.8%

(p<0.001)

-56.5%

(p<0.01)

-59.7%

(p<0.001)

-58.1%

(p<0.001)

Percentage of patients experiencing ≥ 30% reduction in liver fat

16.7%

 

100%

(p<0.001)

76.9%

(p<0.01)

90.9%

(p<0.001)

83.3%

(p<0.001)

 

 

Safety and Tolerability

 

No SAEs were reported among patients receiving VK2809 or placebo. Mean alanine aminotransferase, or ALT, levels among patients receiving VK2809 were reduced relative to those of patients receiving placebo.  Among patients with elevated baseline ALT levels, those receiving VK2809 also demonstrated reduction relative to placebo.  There were no clinically or numerically meaningful differences in direct bilirubin, indirect bilirubin, alkaline phosphatase or international normalized ratio between patients treated with VK2809 or placebo.  In addition, no meaningful changes to the thyroid hormone axis were observed among VK2809-treated patients compared with placebo-treated patients.

 

 

 

 

 

 

3

 

VK2809 Summary Characteristics

VK2809 has been evaluated in one Phase 2 clinical trial and six Phase 1 clinical trials. Based on these clinical and additional preclinical data, we believe VK2809 has the following important characteristics that may benefit patients with metabolic or lipid disorders:  

 

•

Broader efficacy: Current Phase 2 and Phase 1 data suggest VK2809 could reduce liver fat, plasma LDL-C, triglyceride and atherogenic protein levels by greater amounts than existing oral therapies. Such broad and potent lipid lowering-activity may be particularly desirable for NASH patients with hypercholesterolemia or dyslipidemia, or among patients with risk factors such as chronic kidney disease.

 

•

Encouraging safety profile: VK2809 has demonstrated encouraging safety to date in over 290 subjects from completed studies. No drug related serious adverse events were observed. In addition, no cardiovascular abnormalities were reported, in-line with the expected high tissue and receptor selectivity for VK2809.

 

•

Encouraging tolerability: VK2809 has been well-tolerated at and above doses that we are currently administrating and plan to administer in future clinical trials.

 

•

Novel mechanism of action: Based on its selective thyroid receptor targeting mechanism of action, we believe VK2809 has the potential to lower plasma and liver lipid levels in a manner complementary to existing agents such as statins. In particular, based upon the Phase 2 study results, we believe the unique liver-targeting properties of VK2809 impart a robust lipid lowering effect within hepatic tissue, with potential therapeutic applications in fatty liver diseases such as NASH.

 

•

Combinability: VK2809’s novel mechanism of action is expected to allow combinability with many existing therapies, leading to enhanced efficacy and potentially delaying transition to subsequent therapies.

 

•

Once-daily oral dosing: Clinical data suggest that VK2809 has the potential to lower plasma lipid levels in NASH or hypercholesterolemia patients as a once-daily oral therapy.

Phase 1 Clinical Data for VK2809

 

VK2809 has also been evaluated in seven Phase 1 clinical trials. The initial Phase 1 safety, tolerability and pharmacokinetic study of VK2809 was conducted in 2006. This was followed by a 14-day Phase 1b clinical trial in 56 patients with mild hypercholesterolemia, defined as baseline plasma LDL-C of at least 100 mg/dL. This study was initiated in 2007 and completed in 2008. VK2809 was shown to be safe and well-tolerated across doses ranging from 0.25 mg to 40 mg per day. There were no serious adverse events, and the frequency of adverse events in VK2809-treated patients was similar to placebo-treated patients. The clinical trial results also showed dose-related reductions in fasting LDL-C and fasting triglyceride, or TG, levels at day 14. Significant placebo-adjusted LDL-C reductions from baseline were observed at doses of 5 mg and above and ranged from approximately 15%-41%, while placebo-adjusted TG levels were reduced by more than 30% at doses of 2.5 mg and above. In addition, statistically significant reductions of lipoprotein a, or Lp(a), and apolipoprotein, or Apo(B), which are believed to be positively associated with a patient’s risk of developing cardiovascular disease, were observed in certain cohorts. In addition, VK2809 was evaluated in five additional Phase 1 studies, evaluating the pharmacokinetics, pharmacodynamics, potential drug-drug interaction of VK2809 when co-administered with a statin, alternative dosing regimens and hepatic impairment, respectively.

 

VK0214 in X-linked Adrenoleukodystrophy

We are developing VK0214 for X-ALD, a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. X-ALD is caused by mutations in a peroxisomal transporter of VLCFA known as ABCD1. As a result, transporter function is impaired and patients are unable to efficiently metabolize VLCFA. TRß is known to regulate expression of an alternative VLCFA transporter, known as ABCD2. Various preclinical models have demonstrated that increased expression of ABCD2 can lead to normalization of VLCFA metabolism. Preliminary data suggest that VK0214 stimulates ABCD2 expression in an in vitro model and reduces VLCFA levels in an in vivo model of X-ALD.  In September of 2020, we initiated a randomized, double-blind, placebo controlled Phase 1 SAD and MAD clinical trial of VK0214 in healthy subjects. The primary objectives of the study include evaluation of the safety and tolerability of single and multiple oral doses of VK0214, as well as identification of VK0214 doses for further clinical development in the setting of X-ALD.

4

X-ALD is a rare, often fatal condition believed to occur with an incidence of approximately one in 17,000 births. X-ALD is caused by mutations in the gene encoding for ABCD1, which is located on the X chromosome. Men have one X chromosome, while women have two. Because of this, an inherited mutation in the ABCD1 gene is more likely to manifest in males relative to females. The ABCD1 protein plays a critical role in the transport of VLCFA into a cellular organelle called the peroxisome, where VLCFA metabolism and disposal occur. Without functional ABCD1, VLCFA accumulate in cells, including neural cells, where they can lead to membrane disruption and damage to the myelin sheath, a protective and insulating membrane that surrounds nerve cells in the brain. This damage can result in decreased motor coordination and function, visual and hearing disturbances, the loss of cognitive function, dementia, seizures, adrenal dysfunction and other complications, including death. X-ALD is divided into various sub-segments, which are broadly characterized by the presence or absence of brain inflammation:

 

•

Cerebral adrenoleukodystrophy, or CALD: The most severe form of X-ALD is CALD. CALD is characterized by a progressive inflammatory destruction of myelin, leading to severe loss of neurological function and eventual death. Approximately 35% to 40% of male X-ALD patients present with cerebral involvement at a younger age, between the ages of 5 and 12 years. However, up to 20% of male X-ALD patients develop cerebral involvement later in life, between the ages of 20 and 35 years. In male children affected by CALD, learning and behavioral problems are often the first clinical manifestations of disease. In the absence of intervention, patients affected by CALD typically experience rapid degeneration into vegetative state within 3 to 5 years, often resulting in death within 10 years of diagnosis.

 

•

Adrenomyeloneuropathy, or AMN: AMN is the more common form of X-ALD and is considered the default form of the disease in patients surviving beyond childhood. AMN is expected to affect all adult males with ABCD1 mutations, and approximately 65% of females. In males, the diagnosis is usually made between the ages of 20 and 50 and in females after the age of 65. AMN accounts for approximately half of all patients diagnosed with X-ALD. Patients with AMN generally present with slowly progressive symptoms resulting from (non-inflammatory) disruption of the axons, which are a fundamental component of the central nervous system (which allows nerve signals to be transmitted), in the spinal cord. Patients experience a variety of symptoms, including weakness in the legs, impaired vibration sense, incontinence and impotence. Severe motor disability, requiring the use of a wheelchair or cane, develops over a 3 to 15 year period. Many patients experience lower limb paralysis. While AMN is generally considered to develop more gradually relative to CALD, approximately 35% of AMN patients experience a rapid progression of myelopathy over a three to five year period. In addition, approximately 40% of AMN patients have or will develop CALD, with varying degrees of associated inflammation.

There is a clear unmet medical need for patients suffering from X-ALD. CALD has been more commonly targeted for treatment due to its devastating effects, which are often manifested at a young age. For these patients, the only currently effective treatment option is allogeneic hematopoietic stem cell, or HSC, transplant. In this procedure, the patient is treated with HSCs containing the properly functioning copy of the ABCD1 gene, contributed by a donor other than the patient. Additionally, a method of ex vivo insertion of a functional copy of the ABCD1 gene via an HIV-1 based lentiviral vector into the patient’s own HSCs to correct the aberrant expression of ABCD1 in patients with CALD is also in development. Over time with either method, as the transplanted cells grow and repopulate, a partial restoration of ABCD1 function can be achieved, leading many patients to resolution of progression in the cerebral form of the disease. While these forms of genetic correction have also shown potential clinical benefits, there is currently no approved therapy for X-ALD. In addition, recent data suggest that, even among successfully transplanted patients, AMN can develop. We believe our thyroid receptor agonists, which have the potential to normalize metabolism of VLCFAs peripherally, and potentially centrally, may positively impact all forms of X-ALD, including the currently untreatable AMN form.

VK5211: A Selective Androgen Receptor Modulator (SARM) for Hip Fracture

VK5211 is an orally available, non-steroidal SARM in development for the treatment of patients recovering from non-elective hip fracture surgery. VK5211 is designed to selectively produce the therapeutic benefits of testosterone in muscle and bone tissue with improved safety and tolerability. Tissue selectivity is critical in treating patients recovering from hip fracture. These patients experience elevated rates of metabolic breakdown of muscle tissue and loss of bone mineral density, or BMD. This results in a loss of muscle strength, an increased risk of additional fractures and increased mortality.

Androgens and Androgen Receptors

Androgens are important for the proper regulation of the reproductive system and play critical roles in the homeostasis of the muscular, skeletal, cardiovascular, metabolic and central nervous systems. The most predominant androgen hormone is testosterone. Testosterone is predominately produced in the testes in men and in the adrenal glands and ovaries in women, albeit at lower levels than in men. Testosterone stimulates the growth of muscle and bone, also known as anabolic effects, as well as the growth of the prostate and sebaceous gland, also known as androgenic effects and, as such, testosterone is considered a non-tissue-selective androgen.

5

While testosterone preparations are widely used for the treatment of male hypogonadism, the androgenic activity of testosterone limits its use in women and in elderly men who have a higher risk of developing benign prostatic hyperplasia, or BPH, a benign increase in prostate size and prostate cancer. In men, the lack of selectivity of anabolic steroids may result in side effects such as acne, hair loss and progression of BPH and/or prostate cancer. In women, exposure to exogenous testosterone can be associated with hair growth, acne and masculinization. Furthermore, testosterone must be administered by intramuscular injections, transdermal patches or gels. These routes of administration can be inconvenient or associated with potential safety issues. We believe VK5211’s selectivity, limited off-target effects and convenient route of administration may make it superior to off-label testosterone for treating hip fracture and other muscle wasting disorders.

SARMs are a class of small molecules designed to elicit the benefits of androgens on tissues such as muscle and bone, without the undesirable effects on prostate and sebaceous glands, by selectively activating androgen receptors in certain tissues. We believe that, based on their robust activity on muscle and bone, SARMs can be used for the potential treatment of a number of diseases or disorders, including hip fracture, muscle wasting, osteoporosis, frailty and hormone deficiency in both men and women in cases where testosterone supplements or anabolic steroid treatments are ineffective or where the side effect profile is inappropriate.

Clinical Data for VK5211

In November 2017, we announced positive top-line results from our 12-week, Phase 2 clinical trial of VK5211 in patients who recently suffered a hip fracture.  Top-line data showed that the trial achieved its primary endpoint, demonstrating statistically significant, dose dependent increases in lean body mass, less head, following treatment with VK5211 as compared to placebo.  The study also achieved certain secondary endpoints, demonstrating statistically significant increases in appendicular lean body mass and total lean body mass for all doses of VK5211, compared to placebo.  VK5211 demonstrated encouraging safety and tolerability in this study, with no drug-related SAEs reported.

The Phase 2 clinical trial was a randomized, double-blind, placebo-controlled, parallel group, international study designed to evaluate the efficacy, safety and tolerability of VK5211 in patients recovering from hip fracture surgery.  A total of 108 patients were randomized to receive once-daily VK5211 doses of 0.5 mg, 1.0 mg, 2.0 mg, or placebo for 12 weeks.  Top-line results include:

 

 

 

•

All doses of VK5211 demonstrated statistically significant increases in total lean body mass, less head, the study’s primary endpoint.  Placebo-adjusted increases in lean body mass were 4.8% at 0.5 mg (p < 0.005), 7.2% at 1.0 mg (p < 0.001), and 9.1% at 2.0 mg (p < 0.001).  These corresponded to placebo-adjusted increases of 1.6 kg at 0.5 mg (p < 0.005), 2.5 kg at 1.0 mg (p < 0.001), and 3.1 kg at 2.0 mg (p < 0.001).

 

•

The proportion of patients experiencing at least a 5% increase in total lean body mass, less head, were 19% with placebo, 61% at 0.5 mg, 65% at 1.0 mg, and 75% at 2.0 mg (p < 0.01 for each).  The proportion of patients demonstrating at least a 2.0 kg gain in total lean body mass, less head, were 14% with placebo, 57% at 0.5 mg, 65% at 1.0 mg, and 81% at 2.0 mg (p < 0.01 for each).

 

•

All doses of VK5211 produced statistically significant increases in appendicular lean body mass, a secondary efficacy endpoint.  Placebo-adjusted increases in appendicular lean body mass were 6.1% at 0.5 mg (p < 0.01), 9.0% at 1.0 mg (p < 0.001), and 10.2% at 2.0 mg (p < 0.001).  These corresponded to placebo-adjusted increases of 0.8 kg at 0.5 mg (p < 0.05), 1.3 kg at 1.0 mg (p < 0.001), and 1.4 kg at 2.0 mg (p < 0.001).

 

•

 

 

 

 

 

 

All doses of VK5211 produced statistically significant increases in total lean body mass, including head, a secondary efficacy endpoint.  Increases in total lean body mass were 6.3% (p < 0.005), 8.2% (p < 0.001), and 9.9% (p < 0.001) from baseline, corresponding to placebo-adjusted increases of 4.7% at 0.5 mg (p < 0.005), 6.8% at 1.0 mg (p < 0.001), and 8.3% at 2.0 mg (p < 0.001).  These corresponded to placebo-adjusted increases of 1.7 kg at 0.5 mg (p < 0.005), 2.6 kg at 1.0 mg (p < 0.001), and 3.1 kg at 2.0 mg (p < 0.001).

 

•

Patients receiving VK5211 demonstrated numerical improvements in certain exploratory assessments of functional performance, including the 6-minute walk test and short physical performance battery, compared with placebo.  These endpoints were not powered for significance.  Further evaluation of exploratory functional endpoints is underway.

6

 

•

There were no significant differences in the rates of adverse events reported among patients receiving VK5211 compared with placebo.  There were no dose-related differences in reported adverse events among various VK5211 treatment groups.  No drug-related SAEs were observed in patients receiving VK5211.

In addition to the Phase 2 clinical trial described above, VK5211 has been evaluated in three Phase 1 clinical trials.  In these trials, VK5211 was shown to be safe and well-tolerated at all doses following daily oral administration for up to 21 days. There were no reported serious adverse events determined to be related to treatment, and no clinically significant changes in liver function tests, prostate-specific antigen, hematocrit or electrocardiogram readings were observed. Moreover, subjects treated with VK5211 for 21 days experienced statistically significant increases in lean muscle mass, and positive dose-dependent trends in functional exercise and strength measures were consistent with anabolic activity.

The first Phase 1 clinical trial was a randomized, double-blind, placebo-controlled trial in 48 healthy male volunteers conducted in 2009. In this clinical trial, six cohorts received an escalating single dose of VK5211 ranging from 0.1 mg to 22 mg. The primary objective of this clinical trial was to evaluate the safety and tolerability of escalating single doses of VK5211 in healthy male subjects. Secondary objectives of the first Phase 1 clinical trial included a determination of the pharmacokinetics, or PK, and pharmacodynamics, or PD, of single escalating doses of VK5211 in healthy male subjects. The results showed that single doses at the levels administered were well-tolerated and no serious or severe adverse events were observed among subjects receiving VK5211. The PD results showed dose-related decreases in total testosterone and sex-hormone binding protein, consistent with the mechanism of action of selective androgen receptor modulation. A dose-related decrease in fasting serum high-density lipoprotein, or HDL, was also observed. VK5211 was well-tolerated and demonstrated predictable dose-proportional increases in systemic exposure.

In a subsequent Phase 1 multiple ascending dose clinical trial, which commenced in 2010 and was completed in 2011, 76 healthy men in three cohorts were dosed daily with placebo, 0.1 mg, 0.3 mg or 1 mg of VK5211 for 21 days. The primary objective of the second Phase 1 clinical trial for VK5211 was to assess the safety and tolerability of escalating doses of VK5211 following repeated once-daily oral administration for 21 days in healthy men. Secondary objectives included a determination of the PK and PD of VK5211 following repeated once-daily oral administration for 21 days. Exploratory objectives included a determination of the effects of 21 days of treatment with VK5211 on lean body mass measured by dual energy X-ray absorptiometry scan, maximal voluntary strength measured by the one repetition maximum method, and stair climbing power. The average body mass index in all cohorts ranged from 24.6 kg/m2 to 27.0 kg/m2. In this clinical trial, subjects receiving 1 mg doses of VK5211 demonstrated a statistically significant 1.2 kilogram average increase in lean body mass. Positive, dose-dependent trends in strength and performance measurements were also observed. There were no significant changes or trends in fat mass across cohorts. VK5211 was shown to be safe and well tolerated, with a similar frequency of adverse events between the treated and placebo groups.  There were no drug-related serious adverse events.  In addition, there were no significant changes in hemoglobin, prostate-specific antigen, liver function tests or QT interval at any dose. VK5211 also displayed a favorable pharmacokinetic profile, without any changes in prostate-specific antigen. 

In September 2015, we completed a Phase 1 clinical trial of VK5211 in 24 healthy male and female subjects aged 65 and over. Subjects received once-daily oral doses of VK5211 for seven days. The results of this study showed VK5211 to be safe and well-tolerated, with predictable pharmacokinetic properties.

VK5211 Summary Characteristics

Based on the Phase 2 study, the three Phase 1 studies, and additional preclinical data, we believe VK5211 has the following important characteristics that may suggest therapeutic benefits in patients recovering from hip fracture surgery:

 

•

Improvement in lean body mass: Clinical data to date suggests VK5211 rapidly stimulates the formation of lean body mass, or LBM, an important property for the hip fracture recovery setting, where patients can lose up to 6% of lean body mass in the two months following injury.

 

•

Improvement in bone growth and density: VK5211 has demonstrated encouraging efficacy in a standard animal model of osteoporosis, demonstrating improved bone mineral content, density and strength. This may benefit patients following hip surgery, where loss of bone mineral density can exceed 12 times the background rate for patients with osteoporosis.

 

•

Encouraging tolerability: VK5211 has been well-tolerated at and above doses that we administered in our Phase 2 clinical trial.

 

•

Novel mechanism of action: Based on the anabolic characteristics imparted by selective activation of the androgen receptor, we believe VK5211 may stimulate bone and muscle growth, without demonstrating adverse bone remodeling properties that are a potential concern for osteoporosis drugs such as bisphosphonates. We expect VK5211’s novel mechanism of action to provide critical bone and muscle growth promoting advantages.

7

 

•

Once-daily, oral convenience: Clinical data suggest that VK5211 has the potential to provide therapeutic benefits via once-daily oral dosing. This may represent an important advantage among elderly patients, relative to injectable protein or bisphosphonate therapies.

Hip Fracture and Other Muscle Wasting Market Opportunities

More than 300,000 patients in the U.S. experience hip fractures each year, and approximately 50% lose the ability to live independently following the injury. The number of hip fractures is expected to grow in the U.S. as the population ages. Due to required limitations in mobility following hip fracture, patients experience muscle atrophy, or deterioration from lack of use, which impacts the time required for rehabilitation to restore physical function. We believe VK5211’s potential stimulatory effect on lean body mass could result in benefits to patients recovering from hip fracture or other conditions requiring orthopedic intervention, such as hip or knee replacement surgery. Currently, there are no approved therapies to assist in the maintenance or restoration of LBM, BMD or restoration of functional performance for these patients.

Hip fracture in the elderly is a serious and debilitating condition with a high mortality rate. One year mortality in this group is estimated to range from 20% to 30% and an estimated 50% of patients lose the ability to walk independently. As a result of the loss of mobility, and additional morbidities caused by the hip fracture, 20% of patients will require stays at long-term care facilities. Studies show that following hip fracture, patients experience a severe and rapid decline in LBM and BMD. These reported rates of decline are 12 to 75 times the rates observed in persons of similar age and demographics who have not sustained a hip fracture. Loss of LBM is believed to contribute to morbidity, disability and risk of re-fracture in hip fracture patients. Loss of BMD is associated with an increased risk of mortality and re-fracture.

Three Pipeline Programs Target Metabolic Disease with Large Unmet Medical Need

We have a pipeline with three additional programs targeting metabolic diseases and anemia. Our pipeline programs include VK0612, a first-in-class, orally available Phase 2b-ready drug candidate for type 2 diabetes. Preliminary clinical data suggest VK0612 has the potential to provide substantial glucose-lowering effects, with an attractive safety and convenience profile compared with existing type 2 diabetes therapies. Our preclinical programs are focused on developing inhibitors of DGAT-1 for the potential treatment of obesity and dyslipidemia and on identifying orally available EPOR agonists for the potential treatment of anemia.

Fructose-1,6-bisphosphatase, or FBPase, Inhibitor Program

VK0612 is a first-in-class, orally available drug candidate for type 2 diabetes, one of the largest global healthcare challenges today. Preliminary clinical data suggest VK0612 has the potential to provide substantial glucose-lowering effects, with an attractive safety and convenience profile compared with existing type 2 diabetes therapies. VK0612 is a potent, selective inhibitor of FBPase an enzyme that plays an important role in endogenous glucose production, or the synthesis of glucose by the body. We believe the inhibition of FBPase provides an attractive approach to controlling blood glucose levels in patients with diabetes. VK0612 has demonstrated potent glucose lowering effects in diabetic animal models. Clinical trials have shown that VK0612 is safe, well-tolerated and leads to significant glucose-lowering effects in patients with type 2 diabetes.

DGAT-1 Inhibitor Program

We are developing small molecule inhibitors of the enzyme DGAT-1 for the potential treatment of metabolic disorders such as obesity and dyslipidemia. According to the CDC, approximately 42% of the adult U.S. population is obese, with the prevalence expected to exceed 50% by 2030. The World Health Organization estimates at least 650 million people are currently obese worldwide. DGAT-1 is a potential therapeutic target for reduction of triglyceride levels in the circulation and fat accumulation in adipose tissues. DGAT-1 null mice exhibit both reduced post-meal plasma triglyceride levels and increased energy expenditure, but have normal levels of circulating free fatty acids. Conversely, transgenic mice that overexpress DGAT-1 in adipose tissue are predisposed to obesity when fed a high-fat diet and have elevated levels of circulating free fatty acids. We have developed a series of novel compounds with tissue- targeting properties intended to mitigate potential side effects by selectively targeting the enterocyte, or intestinal absorptive cells, in the intestine, to inhibit dietary triglyceride uptake, or the liver, to inhibit de novo triglyceride synthesis. We plan to conduct further preclinical studies and file an investigation new drug application, or IND, with the U.S. Food and Drug Administration, or FDA, at a future date.

Competition

The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that our technology, knowledge, experience and scientific resources provide us with competitive advantages, we face potential competition from many different sources, including commercial biopharmaceutical enterprises, academic institutions, government agencies and private and public research institutions. Any drug candidates that we

8

successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.

Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical studies, clinical trials, regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Our competitors may succeed in developing technologies and therapies that are more effective, better tolerated or less costly than any that we are developing, or that would render our drug candidates obsolete and noncompetitive. Even if we obtain regulatory approval of any of our drug candidates, our competitors may succeed in obtaining regulatory approvals for their products earlier than we do. We will also face competition from these third parties in recruiting and retaining qualified scientific and management personnel, in establishing clinical trial sites and patient registration for clinical trials, and in acquiring and in-licensing technologies and products complementary to our programs or advantageous to our business.

The key competitive factors affecting the success of each of our drug candidates, if approved, are likely to be its efficacy, safety, tolerability, frequency and route of administration, convenience and price, the level of branded and generic competition and the availability of coverage and reimbursement from government and other third-party payors.

VK2809

While no therapies are currently approved for the treatment of non-alcoholic steatohepatitis, we are aware of numerous development-stage programs targeting this disease, including obeticholic acid from Intercept Pharmaceuticals, Inc., cenicriviroc from Allergan plc (now part of AbbVie Inc.), resmetirom (MGL-3196) from Madrigal Pharmaceuticals, Inc., arachidyl amido cholanoic acid from Galmed Pharmaceuticals Ltd., belapectin (GR-MD-02) from Galectin Therapeutics Inc., MSDC-0602K from Cirius Therapeutics, Inc. (formerly Octeta Therapeutics, LLC), tesamorelin from Theratechnologies Inc., firsocostat (GS-0976) and cilofexor (GS-9674) from Gilead Sciences, Inc., semaglutide from Novo Nordisk A/S, NGM282 (aldafermin) and NGM313 (MK-3655) from NGM Biopharmaceuticals, Inc., tropifexor and licogliflozin from Novartis Pharmaceuticals Corporation, pegbelfermin (BMS-986036) and CC-90001 from Bristol-Myers Squibb, lanifibranor from Inventiva S.A., tirzepatide from Eli Lilly and Company, RG7992 from F. Hoffmann-La Roche AG, and EDP-305 from Enanta Pharmaceuticals, Inc. In addition, we are aware of active programs at 89bio, Inc., Akero Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., Ascletis Biopharmaceutical, AstraZeneca PLC, Boehringer Ingelheim International GmbH, Can-Fite BioPharma Ltd., CytoDyn Inc., Durect Corporation, Enyo Pharma SA, Forma Therapeutics, Inc., Hanmi Pharmaceutical Co., Ltd., Hepion Pharmaceuticals, Inc., HighTide Therapeutics Inc., Ionis Pharmaceuticals, Inc., Kowa Company, Ltd., Lipocine, MediciNova Inc., Merck & Co., Inc., Metacrine, Inc., Mitsubishi Tanabe Pharma Corporation, Nitto Denko Corporation, NorthSea Therapeutics BV, NuSirt Biopharma, Inc., Pfizer Inc., Poxel SA, Sagimet Biosciences, Terns Pharmaceuticals, Inc., Yuhan Corporation and Zydus Cadila.

VK5211

In the U.S., there are currently no marketed therapies for the maintenance or improvement of lean body mass, bone mineral density or physical function in patients recovering from non-elective hip fracture surgery. However, VK5211, if approved, will face competition from experimental therapies that are in various stages of clinical development for conditions characterized by muscle wasting by companies including Biophytis SA and Helsinn Group. In addition, nutritional and growth hormone-based therapies are sometimes used in patients experiencing muscle wasting.

VK0214

In the U.S., there are currently no marketed therapies for the treatment of X-linked X-ALD. Hematopoietic stem cell therapy has been used to treat CALD, the most severe form of X-ALD. More recently, gene therapy has been shown to be effective in CALD as well. However, both treatments are invasive, requiring surgical intervention, and these do not appear to have an effect on AMN, the most pervasive form of X-ALD. There are several experimental therapies that are in various stages of clinical development for X-ALD by companies, including Autobahn Therapeutics, bluebird bio, Inc., Minoryx Therapeutics S.L., Neuralgene, Orpheris, Inc., Poxel SA, ReceptoPharm, Inc. and SwanBio Therapeutics, Inc., which may be competitive with VK0214, if approved.

Manufacturing and Supply

We do not have any manufacturing facilities and do not intend to develop any manufacturing capabilities. We believe that we have sufficient supplies of drug substance to allow for completion of our planned clinical studies. Bulk active pharmaceutical ingredient, or API, and certain dosage forms are currently in storage in compliance with good manufacturing practices, or cGMP, requirements. We believe that a majority of the existing API will be suitable for formulation into clinical trial material. We also have identified multiple

9

contract manufacturers to provide commercial supplies of the formulated drug candidates if they are approved for marketing. We intend to secure contract manufacturers with established track records of quality product supply and significant experience with the regulatory requirements of the FDA and the European Medicines Agency, or EMA.

Our History

We were incorporated under the laws of the State of Delaware on September 24, 2012. Since our incorporation, we have devoted substantially all of our efforts to raising capital, building infrastructure and obtaining the worldwide rights to certain technology, including VK2809, VK0214 and VK5211, and conducting certain clinical trials and preclinical studies related to these programs. Each of our programs is based on small molecules licensed from Ligand pursuant to our Master License Agreement with Ligand, which we entered into on May 21, 2014.

Agreements with Ligand

Master License Agreement

On May 21, 2014, we entered into a Master License Agreement, as amended on each of September 6, 2014, April 8, 2015 and March 21, 2016, or the Master License Agreement, with Ligand pursuant to which, among other things, Ligand granted to us and our affiliates an exclusive, perpetual, irrevocable, worldwide, royalty-bearing right and license under (1) patents related to (a) our VK2809 and VK0214 programs and any other compounds comprised by specified TRß patents and any derivatives of such compounds, or TRß Compounds, (b) our VK5211 program and any other compounds comprised by specified SARM patents and derivatives of such compounds, or SARM Compounds, (c) our VK0612 program and any other compounds comprised by specified FBPase patents and derivatives of such compounds, or FBPase Compounds, (d) our DGAT-1 program and any other compounds comprised by specified DGAT-1 patents and derivatives of such compounds, or DGAT-1 Compounds, and (e) our EPOR program and any other compounds comprised by specified EPOR patents and derivatives of such compounds, or EPOR Compounds, and; (2) related know-how controlled by Ligand; and (3) physical quantities of TRß Compounds, SARM Compounds, FBPase Compounds, DGAT-1 Compounds and EPOR Compounds or, collectively, the Licensed Technology, to research, develop, manufacture, have manufactured, use and commercialize the Licensed Technology in and for all therapeutic and diagnostic uses in humans or animals. We have the right to sublicense these rights in certain circumstances. Pursuant to the terms of the Master License Agreement, we have the exclusive right and sole responsibility and decision-making authority for researching and developing any pharmaceutical products that contain or comprise one or any combination of a TRß Compound, SARM Compound, FBPase Compound, DGAT-1 Compound or EPOR Compound, or, collectively, the Licensed Products. We also have the exclusive right and sole responsibility and decision-making authority to conduct all clinical trials and preclinical studies that we believe are appropriate to obtain the regulatory approvals necessary for commercialization of the Licensed Products, and we will own and maintain all regulatory filings and all regulatory approvals for the Licensed Products. Additionally, pursuant to the terms of the Master License Agreement, we have the sole decision-making authority and responsibility and the exclusive right to commercialize any of the Licensed Products, either by ourselves or, in certain circumstances, through sublicensees selected by us. We also have the exclusive right to manufacture or have manufactured any Licensed Product ourselves or, in certain circumstances, through sublicensees or third parties selected by us. We will own any intellectual property that we develop in connection with the license granted under the Master License Agreement.

As partial consideration for the grant of the rights and licenses to us under the Master License Agreement, we issued to Ligand at the closing of our initial public offering of our common stock, or the IPO, 3,655,964 shares of our common stock having an estimated aggregate value of $29.2 million.

As further partial consideration for the grant of the rights and licenses to us by Ligand under the Master License Agreement, we have agreed to pay to Ligand certain one-time, non-refundable milestone payments in connection with Licensed Products containing (1) VK2809, VK0214 or any other TRß Compound, in an aggregate amount of up to $75.0 million per indication (for up to a total of three indications) upon the achievement of certain development and regulatory milestones and up to $150.0 million upon the achievement of certain sales milestones; (2) VK5211 or any other SARM Compound, in an aggregate amount of up to $85.0 million per indication (for up to a total of two indications) upon the achievement of certain development and regulatory milestones and up to $100.0 million upon the achievement of certain sales milestones; (3) VK0612 or any other FBPase Compound, in an aggregate amount of up to $60.0 million per indication (for up to a total of four indications) upon the achievement of certain development and regulatory milestones and up to $150.0 million upon the achievement of certain sales milestones; (4) any EPOR Compound, in an aggregate amount of up to $48.0 million per indication (for up to a total of three indications) upon the achievement of certain development and regulatory milestones and up to $50.0 million upon the achievement of certain sales milestones; and (5) any DGAT-1 Compound, in an aggregate amount of up to $78.0 million per indication (for up to a total of two indications) upon the achievement of certain development and regulatory milestones and up to $150.0 million upon the achievement of certain sales milestones. Additionally, we will pay to Ligand a one-time, non-refundable milestone payment of $2.5 million upon the occurrence of the first commercial sale of VK0612 or any other FBPase Compound by one of our sublicensees. We will also pay to Ligand royalties on aggregate annual worldwide net sales of Licensed Products by us, our affiliates and our sublicensees at tiered percentage rates in the

10

following ranges based upon net sales: (a) low-to-middle single digit royalties upon sales of VK2809, VK0214 or any other TRß Compound,  (b) upper single digit royalties upon sales of VK5211 or any other SARM Compound, (c) upper single digit royalties upon sales of VK0612 or any other FBPase Compound, (d) low-to-middle single digit royalties upon sales of any DGAT-1 Compound, and (e) middle-to-upper single digit royalties upon sales of any EPOR Compound; in each case subject to reduction in certain circumstances.

The term of the Master License Agreement will continue unless the agreement is terminated by us or Ligand. Ligand has the right to terminate the Master License Agreement under certain circumstances, including, but not limited to: (1) in the event of our insolvency or bankruptcy; (2) if we do not pay an undisputed amount owing under the Master License Agreement when due and fail to cure such default within a specified period of time; or (3) if we default on certain of our material and substantial obligations and fail to cure the default within a specified period of time. We have the right to terminate the Master License Agreement under certain circumstances, including, but not limited to: (i) if Ligand does not pay an undisputed amount owing under the Master License Agreement when due and fails to cure such default within a specified period of time, or (ii) if Ligand defaults on certain of its material and substantial obligations and fails to cure the default within a specified period of time. In addition, provisions of the Master License Agreement can be terminated on a licensed program-by-program basis under certain circumstances. In the event that the Master License Agreement is terminated in its entirety or with respect to a specific licensed program for any reason: (A) all licenses granted to us under the Master License Agreement (or with respect to the specific licensed program) will terminate and we will, upon Ligand’s request (subject to Ligand assuming legal responsibility for any clinical trials of the Licensed Products then ongoing), assign and transfer to Ligand (or to such transferee as Ligand may direct), at no cost to Ligand, all regulatory documentation and all regulatory approvals prepared or obtained by us or on our behalf related to the Licensed Products (or those related to the specific licensed program), or, if Ligand does not make such a request, we will wind down any ongoing clinical trials with respect to the Licensed Products (or those related to the specific licensed program) at no cost to Ligand; (B) we will, upon Ligand’s request, sell and transfer to Ligand (or to such transferee as Ligand may direct), at a price equal to 125% of our costs of goods, any and all chemical, biological or physical materials relating to or comprising the Licensed Products (or those related to the specific licensed program); (C) we will have, for a period of six months following termination, the right to sell on the normal business terms in existence before such termination any finished commercial inventory of Licensed Products (or those related to the specific licensed program) which remains on hand, so long as we pay to Ligand the applicable royalties and sales milestones; (D) Ligand has the right to require us to assign to Ligand the trademarks owned by us relating to the Licensed Products (or those related to the specific licensed program); and (E) we will grant to Ligand a non-exclusive, worldwide, royalty-bearing sublicensable license under any patent rights and know-how controlled by us to the extent necessary to make, have made, import, use, offer to sell and sell the Licensed Products (or those related to the specific licensed program) anywhere in the world at a royalty rate in the low single digits.

Under the Master License Agreement, we have agreed to indemnify Ligand for claims relating to the performance of our obligations under the Master License Agreement, any breach of the representations and warranties made by us under the Master License Agreement, clinical trials conducted by us and the research, development and commercialization of the Licensed Products by us and our affiliates, sublicensees, distributors and agents. In addition, Ligand has agreed to indemnify us for claims relating to the performance of its obligations under the Master License Agreement, its breach of representations and warranties under the agreement and its research and development of the licensed compounds before the effective date of the Master License Agreement. Each party’s indemnification obligations will not apply to the extent the claims result from the negligence or willful misconduct of the indemnified party or any of its employees, agents, officers or directors or from the indemnified party’s breach of its representations or warranties set forth in the Master License Agreement.

Management Rights Letter

As a condition to entering into the Master License Agreement, we entered into a Management Rights Letter with Ligand, dated as of May 21, 2014, or the Management Rights Letter. Pursuant to the Management Rights Letter, we agreed to: (1) expand the size of our board of directors so as to create one new directorship on our board of directors, and (2) appoint an individual named by Ligand, or the Ligand Director, to fill the newly-created directorship. Pursuant to the terms of the Management Rights Letter, the Ligand Director is entitled to receive the same compensation, including cash payments and equity incentive grants, as is provided to our other directors; however, the Ligand Director is not entitled to receive the compensation provided to our directors in their capacity as members of a committee of our board of directors. Furthermore, we agreed to provide Ligand with advance written notice of the date of the annual meeting of our stockholders for each year in which the Ligand Director is up for election so as to permit Ligand to designate the Ligand Director for election at such annual meeting, and to nominate the Ligand Director to our board of directors at each such annual meeting of our stockholders. In addition, under the Management Rights Letter, we granted Ligand certain contractual management rights in the event Ligand is not represented on our board of directors, including the right to consult with us and offer advice to our management on significant business issues and the right to receive copies of all notices, minutes, consents and other material that we provide to our directors, subject to certain exceptions. We also agreed that, upon the consummation of the IPO, we would appoint a Chairperson of our board of directors who is “independent” under applicable Securities and Exchange Commission, or SEC, rules and the rules and listings standards of The Nasdaq Stock Market LLC. In accordance with the terms of the Management Rights Letter, Matthew W. Foehr was appointed to our board of directors as the Ligand Director and Lawson Macartney, DVM, Ph.D. was

11

appointed Chairperson of our board of directors. The Management Rights Letter will terminate upon the earliest to occur of: (a) the liquidation, dissolution or indefinite cessation of our business operations; (b) the execution by us of a general assignment for the benefit of creditors or the appointment of a receiver or trustee to take possession of our property and assets; (c) an acquisition of us by means of any transaction or series of related transactions (including, without limitation, any reorganization, merger or consolidation) if our stockholders of record as constituted immediately prior to such transaction hold less than 50% of the voting power of the surviving or acquiring entity; (d) the date that Ligand and its affiliates collectively cease to beneficially own at least 7.5% of our outstanding voting stock; or (e) May 21, 2024.

Voting Agreement

In connection with the terms of the Management Rights Letter, we, Ligand, Brian Lian, Ph.D., and our former Chief Operating Officer, entered into a Voting Agreement dated as of May 21, 2014, or the Voting Agreement, pursuant to which each of Ligand, Dr. Lian and our former Chief Operating Officer agreed to vote all of his or its shares of our voting securities so as to elect the Ligand Director as a member of our board of directors, and, if requested by Ligand, to vote in favor of any removal of the Ligand Director or selection of a new Ligand Director. The Voting Agreement will terminate under the same circumstances in which the Management Rights Letter will terminate.

Registration Rights Agreement

As a condition to the parties entering into the Master License Agreement, we entered into a Registration Rights Agreement, dated May 21, 2014, as amended on January 22, 2016, with Ligand, or the Registration Rights Agreement, pursuant to which we granted certain registration rights to Ligand with respect to (1) the securities issued by us to Ligand pursuant to the Master License Agreement and the securities issuable by us to Ligand pursuant to a Secured Convertible Promissory Note previously issued by us to Ligand, or, collectively, the Viking Securities, (2) the shares of our common stock issued or issuable upon conversion of the Viking Securities, if applicable, and (3) the shares of our common stock issued as a dividend or other distribution with respect to, in exchange for or in replacement of the Viking Securities, or, collectively, the Registrable Securities.

Mandatory Resale Registration Rights

Pursuant to the Registration Rights Agreement, on February 14, 2017, we filed a Registration Statement on Form S-3 under the Securities Act of 1933, as amended, or the Securities Act, covering the resale of the full amount of the Registrable Securities.  If, on any day after the Registration Statement is declared effective by the SEC Staff, sales of all of the Registrable Securities required to be included in the Registration Statement cannot be made pursuant to the Registration Statement, then we will, subject to certain exceptions, be obligated to pay to Ligand an amount in cash equal to 1% of the aggregate value of the Registrable Securities, measured as of the date of their issuance, on the day of such failure or ineffectiveness of, or inability to use, the Registration Statement and on every thirtieth day thereafter (pro-rated for partial periods) until such failure or ineffectiveness of, or inability to use, the Registration Statement is cured; up to a maximum of 5% of the aggregate value of the Registrable Securities, measured as of the date of their issuance.

Pursuant to the terms of the Registration Rights Agreement, we also agreed to use our commercially reasonable efforts to keep each Registration Statement filed pursuant to the agreement effective with respect to all Registrable Securities until the earlier of (1) the date on which all shares of Registrable Securities may immediately be sold under Rule 144, as promulgated by the SEC under the Securities Act, or Rule 144, during any 90-day period, or (2) the date on which all of the Registrable Securities covered by the Registration Statement that are held by Ligand are sold.

Additionally, we have the right during certain periods after the effective date of the Registration Statement covering the resale of the Registrable Securities, to delay the disclosure of material, non-public information if, in the good faith opinion of our board of directors, it is not in our best interests to disclose the information. In addition, we have the ability to prohibit sales under the Registration Statement during certain periods, subject to certain limitations.

Government Regulation

FDA Regulation and Marketing Approval

In the U.S., the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act of 1938, as amended, or FDCA, and related regulations. Drugs are also subject to other federal, state and local statutes and regulations. Failure to comply with the applicable U.S. regulatory requirements at any time during the drug development process, approval process or after approval may subject an applicant to administrative or judicial sanctions and non-approval of drug candidates. These sanctions could include the imposition by the FDA or an Institutional Review Board, or IRB, of a clinical hold on clinical trials, the FDA’s refusal to approve pending applications or related supplements, withdrawal of an approval, untitled or warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, restitution, disgorgement, civil penalties or criminal prosecution. Such

12

actions by government agencies could also require us to expend a large amount of resources to respond to the actions. Any agency or judicial enforcement action could have a material adverse effect on us.

The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products.

These agencies and other federal, state and local entities regulate research and development activities and the testing, manufacture, quality control, safety, effectiveness, labeling, packaging, storage, distribution, record-keeping, approval, post-approval monitoring, advertising, promotion, sampling and import and export of our products. Our drugs must be approved by the FDA through the new drug application, or NDA, process before they may be legally marketed in the U.S. See “The NDA Approval Process” under Part I, “Item 1. Business” of this Annual Report on Form 10-K.

The process required by the FDA before drugs may be marketed in the U.S. generally involves the following:

 

•

completion of non-clinical laboratory tests, animal studies and formulation studies conducted according to good laboratory practice or other applicable regulations;

 

•

submission of an IND, which allows clinical trials to begin unless the FDA objects within 30 days;

 

•

adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed drug for its intended use or uses conducted in accordance with FDA regulations, good clinical practices, or GCP, which are international ethical and scientific quality standards meant to assure that the rights, safety and well-being of trial participants are protected, and to define the roles of clinical trial sponsors, administrators and monitors and to assure clinical trial data integrity;

 

•

pre-approval inspection of manufacturing facilities and clinical trial sites; and

 

•

FDA approval of an NDA, which must occur before a drug can be marketed or sold.

IND and Clinical Trials

Prior to commencing the first clinical trial, an IND, which contains the results of preclinical studies along with other information, such as information about product chemistry, manufacturing and controls and a proposed protocol, must be submitted to the FDA. The IND automatically becomes effective 30 days after receipt by the FDA unless the FDA within the 30-day time period raises concerns or questions about the conduct of the clinical trial. In such a case, the IND sponsor must resolve any outstanding concerns with the FDA before the clinical trial may begin. A separate submission to the existing IND must be made for each successive clinical trial to be conducted during drug development. Further, an independent IRB for each site proposing to conduct the clinical trial must review and approve the investigational plan for any clinical trial before it commences at that site. Informed written consent must also be obtained from each trial subject. Regulatory authorities, including the FDA, an IRB, a data safety monitoring board or the sponsor, may suspend or terminate a clinical trial at any time on various grounds, including a finding that the participants are being exposed to an unacceptable health risk or that the clinical trial is not being conducted in accordance with FDA requirements.

For purposes of NDA approval, human clinical trials are typically conducted in sequential phases that may overlap:

 

•

Phase 1 – the drug is initially given to healthy human subjects or patients in order to determine metabolism and pharmacologic actions of the drug in humans, side effects and, if possible, to gain early evidence on effectiveness. During Phase 1 clinical trials, sufficient information about the investigational drug’s pharmacokinetics and pharmacologic effects may be obtained to permit the design of well-controlled and scientifically valid Phase 2 clinical trials.

 

•

Phase 2 – clinical trials are conducted to evaluate the effectiveness of the drug for a particular indication or in a limited number of patients in the target population to identify possible adverse effects and safety risks, to determine the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. Throughout this Annual Report on Form 10-K, we refer to our initial Phase 2 clinical trials as “Phase 2a clinical trials” and our subsequent Phase 2 clinical trials as “Phase 2b clinical trials.”

 

•

Phase 3 – when Phase 2 clinical trials demonstrate that a dosage range of the product appears effective and has an acceptable safety profile, and provide sufficient information for the design of Phase 3 clinical trials, Phase 3 clinical trials in an expanded patient population at multiple clinical sites may be undertaken. They are performed after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to further evaluate dosage, effectiveness and safety, to establish the overall benefit-risk relationship of the investigational drug and to provide an adequate basis for product labeling and approval by the FDA. In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the drug in an expanded patient population at multiple clinical trial sites.

All clinical trials must be conducted in accordance with FDA regulations, GCP requirements and their protocols in order for the data to be considered reliable for regulatory purposes.

13

An investigational drug product that is a combination of two different drugs in the same dosage form must comply with an additional rule that requires that each component make a contribution to the claimed effects of the drug product. This typically requires larger studies that test the drug against each of its components. In addition, typically, if a drug product is intended to treat a chronic disease, as is the case with some of our products, safety and efficacy data must be gathered over an extended period of time, which can range from six months to three years or more. Government regulation may delay or prevent marketing of drug candidates or new drugs for a considerable period of time and impose costly procedures upon our activities.

Disclosure of Clinical Trial Information

Sponsors of clinical trials of FDA-regulated products, including drugs, are required to register and disclose certain clinical trial information. Information related to the product, patient population, phase of investigation, study sites and investigators, and other aspects of the clinical trial, is then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs.

The NDA Approval Process

In order to obtain approval to market a drug in the U.S., a marketing application must be submitted to the FDA that provides data establishing to the FDA’s satisfaction the safety and effectiveness of the investigational drug for the proposed indication. Each NDA submission requires a substantial user fee payment (currently exceeding $2.8 million for fiscal year 2021) unless a waiver or exemption applies. The application includes all relevant data available from pertinent non-clinical studies, or preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product’s chemistry, manufacturing, controls and proposed labeling, among other things. Data can come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of a product, or from a number of alternative sources, including studies initiated by investigators that meet GCP requirements.

During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2 clinical trials, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the end-of-Phase 2 clinical trials meetings to discuss their Phase 2 clinical trials results and present their plans for the pivotal Phase 3 registration trial that they believe will support approval of the new drug.

Concurrent with clinical trials, companies usually complete additional preclinical safety studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for the NDA sponsor’s manufacturing the product in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drugs. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf-life.

The results of drug development, non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. The FDA reviews all NDAs submitted to ensure that they are sufficiently complete for substantive review before it accepts them for filing. It may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. The FDA has 60 days from its receipt of an NDA to conduct an initial review to determine whether the application will be accepted for filing based on the FDA’s threshold determination that the application is sufficiently complete to permit substantive review. If the NDA submission is accepted for filing, the FDA reviews the NDA to determine, among other things, whether the proposed product is safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product’s identity, strength, quality and purity. The FDA has agreed to specific performance goals on the review of NDAs and seeks to review standard NDAs within 12 months from submission of the NDA. The review process may be extended by the FDA for three additional months to consider certain late submitted information or information intended to clarify information already provided in the submission. After the FDA completes its initial review of an NDA, it will communicate to the sponsor that the drug will either be approved, or it will issue a complete response letter to communicate that the NDA will not be approved in its current form and inform the sponsor of changes that must be made or additional clinical, non-clinical or manufacturing data that must be received before the application can be approved, with no implication regarding the ultimate approvability of the application or the timing of any such approval, if ever. If, or when, those deficiencies have been addressed to the FDA’s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two to six months depending on the type of information included. The FDA may refer applications for novel drug

14

products or drug products that present difficult questions of safety or effectiveness to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and, if so, under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.

Before approving an NDA, the FDA typically will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical sites to assure compliance with GCP regulations. If the FDA determines the application, manufacturing process or manufacturing facilities are not acceptable, it typically will outline the deficiencies and often will request additional testing or information. This may significantly delay further review of the application. If the FDA finds that a clinical site did not conduct the clinical trial in accordance with GCP regulations, the FDA may determine the data generated by the clinical site should be excluded from the primary efficacy analyses provided in the NDA. Additionally, notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.

The FDA may require, or companies may pursue, additional clinical trials after a product is approved. These so-called Phase 4 or post-approval clinical trials may be made a condition to be satisfied for continuing drug approval. The results of Phase 4 clinical trials can confirm the effectiveness of a drug candidate and can provide important safety information. In addition, the FDA now has express statutory authority to require sponsors to conduct post-marketing trials to specifically address safety issues identified by the agency. See “Post-Marketing Requirements” under Part I, “Item 1. Business” of this Annual Report on Form 10-K.

The FDA also has authority to require a Risk Evaluation and Mitigation Strategy, or a REMS, from manufacturers to ensure that the benefits of a drug outweigh its risks. A sponsor may also voluntarily propose a REMS as part of the NDA submission. The need for a REMS is determined as part of the review of the NDA. Based on statutory standards, elements of a REMS may include “dear doctor letters,” a medication guide, more elaborate targeted educational programs, and in some cases elements to assure safe use, or ETASU, which is the most restrictive REMS. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patient registries. These elements are negotiated as part of the NDA approval, and in some cases if consensus is not obtained until after the Prescription Drug User Fee Act of 1992, as amended, review cycle, the approval date may be delayed. Once adopted, REMS are subject to periodic assessment and modification.

Changes to some of the conditions established in an approved application, including changes in indications, labeling, manufacturing processes or facilities, require submission and FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing NDA supplements as it does in reviewing NDAs.

Even if a drug candidate receives regulatory approval, the approval may be limited to specific disease states, patient populations and dosages, or might contain significant limitations on use in the form of warnings, precautions or contraindications, or in the form of onerous risk management plans, restrictions on distribution or post-marketing trial requirements. Further, even after regulatory approval is obtained, later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market. Delay in obtaining, or failure to obtain, regulatory approval for our products, or obtaining approval but for significantly limited use, would harm our business. In addition, we cannot predict what adverse governmental regulations may arise from future U.S. or foreign governmental action.

Orphan Designation and Exclusivity

The FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition that affects fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals in the United States and there is no reasonable expectation that the cost of developing and making the drug for this type of disease or condition will be recovered from sales in the United States.

Orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical study costs, tax advantages, and user-fee waivers. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. In addition, the first NDA or Biologics License Application, or BLA, applicant to receive orphan drug designation for a particular drug is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years in the United States, except in limited circumstances. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition.

15

The Hatch-Waxman Amendments

Under the Drug Price Competition and Patent Term Restoration Act of 1984, as amended, commonly known as the Hatch-Waxman Amendments, a portion of a product’s U.S. patent term that was lost during clinical development and regulatory review by the FDA may be restored. The Hatch-Waxman Amendments also provide a process for listing patents pertaining to approved products in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book) and for a competitor seeking approval of an application that references a product with listed patents to make certifications pertaining to such patents. In addition, the Hatch-Waxman Amendments provide for a statutory protection, known as non-patent exclusivity, against the FDA’s acceptance or approval of certain competitor applications.

Patent Term Restoration

Patent term restoration can compensate for time lost during drug development and the regulatory review process by returning up to five years of patent life for a patent that covers a new product or its use. This period is generally one-half the time between the effective date of an IND (falling after issuance of the patent) and the submission date of an NDA, plus the time between the submission date of an NDA and the approval of that application, provided the sponsor acted with diligence. Patent term restorations, however, cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended and the extension must be applied for prior to expiration of the patent. The United States Patent and Trademark Office, or the USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration.

Orange Book Listing

In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent whose claims cover the applicant’s product. Upon approval of a drug, each of the patents listed by the NDA holder listed in the drug’s application or otherwise are then published in the FDA’s Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of an abbreviated new drug application, or ANDA. An ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form as the listed drug and has been shown through bioequivalence testing to be therapeutically equivalent to the listed drug. Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, preclinical studies or clinical trials to prove the safety or effectiveness of their drug product. Drugs approved in this way are commonly referred to as “generic equivalents” to the listed drug and can often be substituted by pharmacists under prescriptions written for the original listed drug.

The ANDA applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA’s Orange Book. Specifically, the applicant must certify that: (1) the required patent information has not been filed; (2) the listed patent has expired; (3) the listed patent has not expired but will expire on a particular date and approval is sought after patent expiration; or (4) the listed patent is invalid or will not be infringed by the new product. The ANDA applicant may also elect to submit a Section VIII statement certifying that its proposed ANDA label does not contain (or carves out) any language regarding the patented method-of-use rather than certify to a listed method-of-use patent. If the applicant does not challenge the listed patents, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired.

A certification that the new product will not infringe the already approved product’s listed patents, or that such patents are invalid, is called a Paragraph IV certification. If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit or a decision in the infringement case that is favorable to the ANDA applicant.

An applicant submitting an NDA under Section 505(b)(2) of the FDCA, which permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by, or for, the applicant and for which the applicant has not obtained a right of reference, is required to certify to the FDA regarding any patents listed in the Orange Book for the approved product it references to the same extent that an ANDA applicant would.

Market Exclusivity

Market exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the U.S. to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an ANDA or a 505(b)(2) NDA submitted by another company for another version of such drug where the

16

applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a Paragraph IV certification. The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, for new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA; however, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the non-clinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.

Post-Marketing Requirements

Following approval of a new product, a pharmaceutical company and the approved product are subject to continuing regulation by the FDA, including, among other things, monitoring and record-keeping activities, reporting to the applicable regulatory authorities of adverse experiences with the product, providing the regulatory authorities with updated safety and efficacy information, product sampling and distribution requirements, and complying with promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting drugs for uses or in patient populations that are not described in the drug’s approved labeling (known as “off-label use”), limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving the internet, including social media. Although physicians may prescribe legally available drugs for off-label uses, manufacturers may not market or promote such off-label uses. Modifications or enhancements to the product or its labeling or changes of the site of manufacture are often subject to the approval of the FDA and other regulators, who may or may not grant approval, or may include in a lengthy review process.

Prescription drug advertising is subject to federal, state and foreign regulations. In the U.S., the FDA regulates prescription drug promotion, including direct-to-consumer advertising. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use. Any distribution of prescription drug products and pharmaceutical samples must comply with the U.S. Prescription Drug Marketing Act of 1987, as amended, or the PDMA, a part of the FDCA.

In the U.S., once a product is approved, its manufacture is subject to comprehensive and continuing regulation by the FDA. The FDA regulations require that products be manufactured in specific, approved facilities and in accordance with cGMP. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. cGMP regulations require, among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. These regulations also impose certain organizational, procedural and documentation requirements with respect to manufacturing and quality assurance activities. NDA holders using contract manufacturers, laboratories or packagers are responsible for the selection and monitoring of qualified firms and, in certain circumstances, qualified suppliers to these firms. These firms and, where applicable, their suppliers are subject to inspections by the FDA at any time, and the discovery of violative conditions, including failure to conform to cGMP, could result in enforcement actions that interrupt the operation of any such product or may result in restrictions on a product, manufacturer, or holder of an approved NDA, including, among other things, recall or withdrawal of the product from the market.

The FDA also may require post-marketing testing, also known as Phase 4 testing, REMS to monitor the effects of an approved product or place conditions on an approval that could restrict the distribution or use of the product. Discovery of previously unknown problems with a product or the failure to comply with applicable FDA requirements can have negative consequences, including adverse publicity, judicial or administrative enforcement, untitled or warning letters from the FDA, mandated corrective advertising or communications with doctors, withdrawal of approval, and civil or criminal penalties, among others. Newly-discovered or developed safety or effectiveness data may require changes to a product’s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA’s policies may change, which could delay or prevent regulatory approval of our products in development.

Reimbursement, Anti-Kickback and False Claims Laws and Other Regulatory Matters

In the U.S., the research, manufacturing, distribution, sale and promotion of drug products and medical devices are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare & Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services (e.g., the Office of Inspector General), the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational

17

Safety & Health Administration, the Environmental Protection Agency, state Attorneys General and other state and local government agencies. For example, sales, marketing and scientific/educational grant programs must comply with the federal Anti-Kickback Statute, the federal False Claims Act of 1986, as amended, or the federal False Claims Act, the privacy regulations promulgated under the Health Insurance Portability and Accountability Act of 1996, as amended, or HIPAA, and similar state laws. Pricing and rebate programs must comply with the Medicaid Drug Rebate Program requirements of the Omnibus Budget Reconciliation Act of 1990, as amended, and the Veterans Health Care Act of 1992, as amended. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. The handling of any controlled substances must comply with the U.S. Controlled Substances Act and Controlled Substances Import and Export Act. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. All of these activities are also potentially subject to federal and state consumer protection and unfair competition laws.

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, established the Medicare Part D program to provide a voluntary prescription drug benefit to Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities which will provide coverage of outpatient prescription drugs. Unlike Medicare Part A and B, Part D coverage is not standardized. Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for products for which we receive regulatory approval. However, any negotiated prices for our products covered by a Part D prescription drug plan will likely be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from non-government payors.

The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.

The American Recovery and Reinvestment Act of 2009 provides funding for the federal government to compare the effectiveness of different treatments for the same illness. A plan for the research will be developed by the Department of Health and Human Services, the Agency for Healthcare Research and Quality and the National Institutes for Health, and periodic reports on the status of the research and related expenditures will be made to Congress. Although the results of the comparative effectiveness studies are not intended to mandate coverage policies for public or private payors, it is not clear what effect, if any, the research will have on the sales of our drug candidate, if any such product or the condition that it is intended to treat is the subject of a clinical trial. It is also possible that comparative effectiveness research demonstrating benefits in a competitor’s product could adversely affect the sales of our drug candidate. If third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable basis.

In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the U.S. and generally tend to be priced significantly lower than in the U.S.

As noted above, in the U.S., we are subject to complex laws and regulations pertaining to healthcare “fraud and abuse,” including, but not limited to, the federal Anti-Kickback Statute, the federal False Claims Act, and other state and federal laws and regulations. The federal Anti-Kickback Statute makes it illegal for any person, including a prescription drug manufacturer, or a party acting on its behalf, to knowingly and willfully solicit, receive, offer or pay any remuneration that is intended to induce the referral of business, including the purchase, order or prescription of a particular drug, or other good or service for which payment in whole or in part may be made under a federal healthcare program, such as Medicare or Medicaid. Violations of this law are punishable by up to five years in prison, criminal fines, administrative civil money penalties and exclusion from participation in federal healthcare programs. In addition, many states have adopted laws similar to the federal Anti-Kickback Statute. Some of these state prohibitions apply to the referral of patients for healthcare services reimbursed by any insurer, not just federal healthcare programs such as Medicare and Medicaid. Due to the breadth of these federal and state anti-kickback laws, the absence of guidance in the form of regulations or court decisions and the potential for additional legal or regulatory change in this area, it is possible that our future sales and marketing practices or our future relationships with medical professionals might be challenged under anti-kickback laws, which could harm us.

18

Because we intend to commercialize products that could be reimbursed under a federal healthcare program and other governmental healthcare programs, we plan to develop a comprehensive compliance program that establishes internal controls to facilitate adherence to the rules and program requirements to which we will or may become subject.

The federal False Claims Act prohibits anyone from knowingly presenting, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services, including drugs, that are false or fraudulent, claims for items or services not provided as claimed or claims for medically unnecessary items or services. Although we would not submit claims directly to payors, manufacturers can be held liable under these laws if they are deemed to “cause” the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting a product off-label. In addition, our future activities relating to the reporting of wholesaler or estimated retail prices for our products, the reporting of prices used to calculate Medicaid rebate information and other information affecting federal, state and third-party reimbursement for our products, and the sale and marketing of our products, are subject to scrutiny under this law. For example, pharmaceutical companies have been found liable under the federal False Claims Act in connection with their off-label promotion of drugs. Penalties for a federal False Claims Act violation include three times the actual damages sustained by the government, plus mandatory civil penalties effective in 2020 of between $11,665 and $23,331 for each separate false claim (each of which is subject to adjustment for inflation), the potential for exclusion from participation in federal healthcare programs and, although the federal False Claims Act is a civil statute, conduct that results in a federal False Claims Act violation may also implicate various federal criminal statutes. If the government were to allege that we were, or convict us of, violating these false claims laws, we could be subject to a substantial fine and may suffer a decline in our stock price. In addition, private individuals have the ability to bring actions under the federal False Claims Act and certain states have enacted laws modeled after the federal False Claims Act.

There are also an increasing number of state laws that require manufacturers to make reports to states on pricing and marketing information. Many of these laws contain ambiguities as to what is required to comply with the laws. In addition, as discussed below, beginning in 2013, a similar federal requirement requires manufacturers to track and report to the federal government certain payments made to physicians and teaching hospitals in the previous calendar year. These laws may affect our sales, marketing and other promotional activities by imposing administrative and compliance burdens on us. In addition, given the lack of clarity with respect to these laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent state, and soon federal, authorities.

The failure to comply with regulatory requirements subjects companies to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of product approvals or refusal to allow a company to enter into supply contracts, including government contracts.

Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (1) changes to our manufacturing arrangements; (2) additions or modifications to product labeling; (3) the recall or discontinuation of our products; or (4) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.

Patient Protection and Affordable Care Act

In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, collectively the PPACA, was enacted, which includes measures that have or will significantly change the way healthcare is financed by both governmental and private insurers. Among the provisions of the PPACA of greatest importance to the pharmaceutical industry are the following:

 

•

The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services as a condition for states to receive federal matching funds for the manufacturer’s covered outpatient drugs furnished to Medicaid patients. Effective in 2010, the PPACA made several changes to the Medicaid Drug Rebate Program, including increasing pharmaceutical manufacturers’ rebate liability by raising the minimum basic Medicaid rebate on most branded prescription drugs and biologic agents to 23.1% of the average manufacturer price, or AMP, and adding a new rebate calculation for “line extensions” (i.e., new formulations, such as extended release formulations) of solid oral dosage forms of branded products, as well as potentially impacting their rebate liability by modifying the statutory definition of AMP. The PPACA also expanded the universe of Medicaid utilization subject to drug rebates by requiring pharmaceutical manufacturers to pay rebates on Medicaid managed care utilization as of 2010 and by expanding the population potentially eligible for Medicaid drug benefits, phased-in by 2014. The CMS have proposed to expand Medicaid rebate liability to the territories of the U.S. as well. In addition, the PPACA provides for the public availability of retail survey prices and certain weighted average AMPs under the Medicaid program. The implementation of this requirement by the CMS may also provide for the public availability of pharmacy acquisition of cost data, which could negatively impact our sales.

19

 

•

In order for a pharmaceutical product to receive federal reimbursement under the Medicare Part B and Medicaid programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program. The required 340B discount on a given product is calculated based on the AMP and Medicaid rebate amounts reported by the manufacturer. Effective in 2010, the PPACA expanded the types of entities eligible to receive discounted 340B pricing, although, under the current state of the law, with the exception of children’s hospitals, these newly-eligible entities will not be eligible to receive discounted 340B pricing on orphan drugs when used for the orphan indication. In addition, as 340B drug pricing is determined based on AMP and Medicaid rebate data, the revisions to the Medicaid rebate formula and AMP definition described above could cause the required 340B discount to increase.

 

•

Effective in 2011, the PPACA imposed a requirement on manufacturers of branded drugs and biologic agents to provide a 50% discount off the negotiated price of branded drugs dispensed to Medicare Part D patients in the coverage gap (i.e., “donut hole”).

 

•

Effective in 2011, the PPACA imposed an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs, although this fee would not apply to sales of certain products approved exclusively for orphan indications.

 

•

Effective in 2012, the PPACA required pharmaceutical manufacturers to track certain financial arrangements with physicians and teaching hospitals, including any “transfer of value” made or distributed to such entities, as well as any investment interests held by physicians and their immediate family members. Manufacturers are required to track this information and were required to make their first reports in March 2014. The information reported is publicly available on a searchable website.

 

•

As of 2010, a new Patient-Centered Outcomes Research Institute was established pursuant to the PPACA to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research. The research conducted by the Patient-Centered Outcomes Research Institute may affect the market for certain pharmaceutical products.

 

•

The PPACA created the Independent Payment Advisory Board, which has the authority to recommend certain changes to the Medicare program to reduce expenditures by the program that could result in reduced payments for prescription drugs. Under certain circumstances, these recommendations will become law unless Congress enacts legislation that will achieve the same or greater Medicare cost savings.

 

•

The PPACA established the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.

There have been continued public announcements by members of the U.S. Congress regarding plans to repeal and replace the PPACA.  For example, on December 22, 2017, the Tax Cuts and Jobs Act of 2017 was signed into law, which, among other things, eliminated the individual mandate requiring most Americans (other than those who qualify for a hardship exemption) to carry a minimum level of health coverage, effective January 1, 2019.  President Biden and his administration has announced plans to amend the PPACA to, among other things, expand the scope of the law. We cannot predict the ultimate form or timing of any repeal, replacement, amendment, expansion or other modification of the PPACA or the effect such a repeal, replacement, amendment, expansion or other modification would have on our business.

Pediatric Exclusivity and Pediatric Use

Under the Best Pharmaceuticals for Children Act, or the BPCA, certain drugs may obtain an additional six months of exclusivity if the sponsor submits information requested in writing by the FDA, or a Written Request, relating to the use of the active moiety of the drug in children. Conditions for exclusivity include the FDA’s determination that information relating to the use of a new drug in the pediatric population may produce health benefits in that population, the FDA making a written request for pediatric studies and the applicant agreeing to perform, and reporting on, the requested studies within the statutory timeframe. The FDA may not issue a Written Request for studies on unapproved or approved indications or where it determines that information relating to the use of a drug in a pediatric population, or part of the pediatric population, may not produce health benefits in that population. Applications under the BPCA are treated as priority applications, with all of the benefits that designation confers.

We have not received a Written Request for such pediatric studies, although we may ask the FDA to issue a Written Request for such studies in the future. To receive the six-month pediatric market exclusivity, we would need to receive a Written Request from the FDA, conduct the requested studies in accordance with a written agreement with the FDA or, if there is no written agreement, in accordance with commonly accepted scientific principles, and submit reports of the studies. A Written Request may include studies for indications that are not currently in the labeling if the FDA determines that such information will benefit the public health. The FDA will accept the reports upon its determination that the studies were conducted in accordance with, and are responsive to, the

20

original Written Request or commonly accepted scientific principles, as appropriate, and that the reports comply with the FDA’s filing requirements.

Under the Pediatric Research Equity Act of 2003, or the PREA, an NDA or supplement thereto must contain data that is adequate to assess the safety and effectiveness of the drug product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The PREA also authorizes the FDA to require holders of approved NDAs for marketed drugs to conduct pediatric studies under certain circumstances. With the enactment of the Food and Drug Administration Safety and Innovation Act, or the FDASIA, in 2012, sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation. The applicant, the FDA and the FDA’s internal review committee must then review the information submitted, consult with each other and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time.

The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Additional requirements and procedures relating to deferral requests and requests for extension of deferrals are contained in the FDASIA. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation.

Intellectual Property

We have in-licensed from Ligand patents and patent applications that contain claims that recite our compounds, as set forth below. We have filed additional patent applications in the U.S., E.U. and other foreign jurisdictions on our clinical and preclinical programs. Information regarding the issued patents and pending patent applications, as of December 31, 2020, are as follows:

Subject Matter/Compounds

 

# Pending
Applications

 

# Issued
Patents

 

Geographical Scope 

 

Nominal
Patent Term

TRß agonists

 

63

 

6

 

U.S., Australia, Canada, China, Japan, Korea, Hong Kong, Mexico, Brazil, India, Russia, New Zealand, South Africa, Europe and PCT

 

2025-2041

VK5211 (SARM)

 

4

 

20

 

U.S., Europe, Chile, Argentina, Brazil, Canada, China, India, Japan, Korea, Mexico, Taiwan, Venezuela and PCT

 

2025-2040

Other SARM

 

1

 

24

 

U.S., Canada, India, Japan, Korea, Mexico, Australia, China, New Zealand, Argentina, Brazil, Europe, and Israel

 

2022-2026

VK0612 (FBPase inhibitor)

 

7

 

1

 

U.S., Korea, Australia, Canada, Mexico, India and New Zealand

 

2025-2036

DGAT-1 Inhibitors

 

1

 

7

 

U.S., Hong Kong and Europe

 

 

2030

EPOR Inhibitors

 

1

 

12

 

U.S., Australia, Canada, China, Europe, India, Japan, and Korea

 

2030-2031

Corporate Information

We were incorporated under the laws of the State of Delaware on September 24, 2012. Our principal executive offices are located at 12340 El Camino Real, San Diego, CA 92130, and our telephone number is (858) 704-4660. Our website address is www.vikingtherapeutics.com. We do not incorporate the information on, or accessible through, our website into this Annual Report on Form 10-K, and you should not consider any information on, or accessible through, our website as part of this Annual Report on Form 10-K. We have included our website address in this Annual Report on Form 10-K solely as an inactive textual reference.

Employees

As of December 31, 2020, we had eighteen full-time employees and two part-time employees, eight of whom hold a Ph.D. or M.D. degree. All employees are engaged in research and development, business development and finance. None of our employees are subject to a collective bargaining agreement. We have never experienced a material work stoppage or disruption to our business relating to employee matters. We consider our relationship with our employees to be good.

 

 

21

Item 1A. Risk Factors.

You should consider carefully the following information about the risks described below, together with the other information contained in this Annual Report on Form 10-K and in our other public filings in evaluating our business. If any of the following risks actually occurs, our business, financial condition, results of operations and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our common stock would likely decline.

Risk Factor Summary

Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading “Risk Factors” and should be carefully considered, together with other information in this Annual Report on Form 10-K and our other filings with the SEC before making an investment decision regarding our common stock.

 

•

We are a clinical-stage company with a limited operating history and no products approved for commercial sale. We have incurred net losses since our inception, we expect to incur significant and increasing operating losses and we may never be profitable. Our stock is a highly speculative investment.

 

 

•

We currently have no source of product revenue and may never become profitable.

 

 

•

The ongoing COVID-19 pandemic has and may in the future result in significant disruptions to our clinical trials or other business operations, which could have a material adverse effect on our business.

 

 

•

Unstable market and economic conditions may have serious adverse consequences on our business and financial condition.

 

 

•

We are substantially dependent on technologies we licensed from Ligand, and if we lose the license to such technologies or our master license agreement with Ligand, or the Master License Agreement, is terminated for any reason, our ability to develop existing and new drug candidates would be harmed, and our business, financial condition and results of operations would be materially and adversely affected.

 

 

 

•

We will require substantial additional capital to finance our operations, which may not be available to us on acceptable terms, or at all. As a result, we may not complete the development and commercialization of VK2809 or VK0214 or develop new product candidates.

 

 

•

We are dependent on the success of one or more of our current drug candidates and we cannot be certain that any of them will receive regulatory approval or be commercialized.

 

 

 

•

Clinical drug development involves a lengthy and expensive process with uncertain timelines and uncertain outcomes, and the results of prior preclinical or clinical trials are not necessarily predictive of our future results. Our clinical trials may fail to adequately demonstrate the safety and efficacy of VK2809 or VK0214 or any future product candidates.

 

 

•

If we experience delays in clinical testing, our commercial prospects will be adversely affected, our costs may increase and our business may be harmed.

 

 

•

If we encounter difficulties in enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.

 

 

•

We are developing VK2809 for the treatment of NASH, an indication for which there are no approved products. This makes it difficult to predict the timing and costs of the clinical development of VK2809 for the treatment of NASH.

 

 

•

We face substantial competition, which may result in others discovering, developing or commercializing competing products before or more successfully than us.

 

 

•

We have relied on, and expect to continue to rely on, third-party manufacturers to produce our current drug candidates or any future product candidates. Any failure by a third-party manufacturer to produce acceptable product candidates for us pursuant to our specifications and regulatory standards may delay or impair our ability to initiate or complete our clinical trials, obtain and maintain regulatory approvals or commercialize approved products.

 

22

 

 

•

We rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing.

 

 

•

Our success depends upon our ability to obtain and maintain intellectual property protection for our products and technologies.

Risks Relating to Our Business

We are a clinical-stage company, have a very limited operating history and are expected to incur significant operating losses during the next stages of our corporate development.

 

We are a clinical-stage company. Since our incorporation in September 2012, our operations have been limited to raising capital, building infrastructure, obtaining the worldwide rights to certain technology from Ligand Pharmaceuticals Incorporated, or Ligand, and planning, preparing and conducting preclinical studies and clinical trials of our drug candidates, including VK2809, VK5211 and VK0612, which are currently in Phase 2 clinical development, VK0214, which recently commenced a Phase 1 clinical trial, and the diacylglycerol acyltransferase-1, or DGAT-1 and erythropoietin receptor, or EPOR programs, which are each currently in preclinical development. We have not yet demonstrated an ability to obtain marketing approval for any of our drug candidates or successfully overcome the risks and uncertainties frequently encountered by companies in the biopharmaceutical industry. We also have not generated any revenue to date, and we continue to incur significant research and development and other expenses. As of December 31, 2020, we had an accumulated deficit of $168.2 million. For the foreseeable future, we expect to continue to incur losses, which will increase significantly from historical levels as we expand our drug development activities, seek potential partnering opportunities and/or regulatory approvals for our drug candidates and begin to commercialize them if they are approved by the U.S. Food and Drug Administration, or the FDA, the European Medicines Agency, or EMA, or comparable foreign authorities. Even if we succeed in partnering or developing and commercializing one or more drug candidates, we may never become profitable. If we fail to achieve or maintain profitability, it would adversely affect the value of our common stock.

 

We are substantially dependent on technologies we licensed from Ligand, and if we lose the license to such technologies or our master license agreement with Ligand, or the Master License Agreement, is terminated for any reason, our ability to develop existing and new drug candidates would be harmed, and our business, financial condition and results of operations would be materially and adversely affected.

 

Our business is substantially dependent upon technology licensed from Ligand. Pursuant to the Master License Agreement, we have been granted exclusive worldwide rights to VK2809, VK0214, VK5211, VK0612 and preclinical programs for metabolic disorders and anemia. Selective androgen receptor modulators, or SARMs, such as the one used in our VK5211 program, are key compounds used by us in the development and commercialization of our drug candidates. Most of the intellectual property related to our drug candidates is currently owned by Ligand, and we have the rights to use such intellectual property pursuant to the Master License Agreement. Therefore, our ability to develop and commercialize our drug candidates depends entirely on the effectiveness and continuation of the Master License Agreement. If we lose the right to license any of these key compounds, our ability to develop existing and new drug candidates would be harmed.

 

Ligand has the right to terminate the Master License Agreement under certain circumstances, including, but not limited to: (1) in the event of our insolvency or bankruptcy, (2) if we do not pay an undisputed amount owing under the Master License Agreement when due and fail to cure such default within a specified period of time, or (3) if we default on certain of our material obligations and fail to cure the default within a specified period of time.

 

We are dependent on the success of one or more of our current drug candidates and we cannot be certain that any of them will receive regulatory approval or be commercialized.

 

We have spent significant time, money and effort on the licensing and development of our core metabolic and endocrine disease assets, VK2809, VK0214, VK5211, VK0612 and our earlier-stage assets, the DGAT-1 and EPOR programs. To date, no pivotal clinical trials designed to provide clinically and statistically significant proof of efficacy, or to provide sufficient evidence of safety to justify approval, have been completed with any of our drug candidates. All of our drug candidates will require additional development, including clinical trials as well as further preclinical studies to evaluate their toxicology, carcinogenicity and pharmacokinetics and optimize their formulation, and regulatory clearances before they can be commercialized. Positive results obtained during early development do not necessarily mean later development will succeed or that regulatory clearances will be obtained. Our drug development efforts may not lead to commercial drugs, either because our drug candidates fail to be safe and effective or because we have inadequate financial or other resources to advance our drug candidates through the clinical development and approval processes. If any of our drug candidates fail to demonstrate safety or efficacy at any time or during any phase of development, we would experience potentially significant delays in, or be required to abandon, development of the drug candidate.

23

 

We do not anticipate that any of our current drug candidates will be eligible to receive regulatory approval from the FDA, EMA or comparable foreign authorities and begin commercialization for a number of years, if ever. Even if we ultimately receive regulatory approval for any of these drug candidates, we or our potential future partners, if any, may be unable to commercialize them successfully for a variety of reasons. These include, for example, the availability of alternative treatments, lack of cost-effectiveness, the cost of manufacturing the product on a commercial scale and competition with other drugs. The success of our drug candidates may also be limited by the prevalence and severity of any adverse side effects. If we fail to commercialize one or more of our current drug candidates, we may be unable to generate sufficient revenues to attain or maintain profitability, and our financial condition and stock price may decline.

 

If development of our drug candidates does not produce favorable results, we and our collaborators, if any, may be unable to commercialize these products.

 

To receive regulatory approval for the commercialization of our core metabolic and endocrine disease assets, VK2809, VK0214, VK5211, VK0612 and our earlier-stage assets, the DGAT-1and EPOR programs, or any other drug candidates that we may develop, adequate and well-controlled clinical trials must be conducted to demonstrate safety and efficacy in humans to the satisfaction of the FDA, EMA and comparable foreign authorities. In order to support marketing approval, these agencies typically require successful results in one or more Phase 3 clinical trials, which our current drug candidates have not yet reached and may never reach. The development process is expensive, can take many years and has an uncertain outcome. Failure can occur at any stage of the process. We may experience numerous unforeseen events during, or as a result of, the development process that could delay or prevent commercialization of our current or future drug candidates, including the following:

 

 

•

clinical trials may produce negative or inconclusive results;

 

 

•

preclinical studies conducted with drug candidates during clinical development to, among other things, evaluate their toxicology, carcinogenicity and pharmacokinetics and optimize their formulation may produce unfavorable results;

 

 

•

patient recruitment and enrollment in clinical trials may be slower than we anticipate;

 

 

•

costs of development may be greater than we anticipate;

 

 

•

our drug candidates may cause undesirable side effects that delay or preclude regulatory approval or limit their commercial use or market acceptance, if approved;

 

 

•

collaborators who may be responsible for the development of our drug candidates may not devote sufficient resources to these clinical trials or other preclinical studies of these candidates or conduct them in a timely manner; or

 

 

•

we may face delays in obtaining regulatory approvals to commence one or more clinical trials.

 

Success in early development does not mean that later development will be successful because, for example, drug candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy despite having progressed through initial clinical trials.

 

We licensed all of the intellectual property related to our drug candidates from Ligand pursuant to the Master License Agreement. In September 2018, we reported positive top-line results from a Phase 2 clinical trial for VK2809. In late 2017, we reported positive top-line results from a Phase 2 clinical trial for VK5211. However, there is no guarantee that the results of our Phase 2 clinical trials for VK2809 or VK5211 will be repeated for our other drug candidates or lead to other positive outcomes.  As a company, we have conducted only a limited number of clinical trials and preclinical studies for our drug candidates. Therefore, we have limited experience in conducting clinical trials for our drug candidates. Since our experience with our drug candidates is limited, we will need to train our existing personnel and hire additional personnel in order to successfully administer and manage our clinical trials and other studies as planned, which may result in delays in completing such planned clinical trials and preclinical studies. Moreover, to date our drug candidates have been tested in less than the number of patients that will likely need to be studied to obtain regulatory approval. The data collected from clinical trials with larger patient populations may not demonstrate sufficient safety and efficacy to support regulatory approval of these drug candidates.

 

We currently do not have strategic collaborations in place for clinical development of any of our current drug candidates. Therefore, in the future, we or any potential future collaborative partner will be responsible for establishing the targeted endpoints and goals for development of our drug candidates. These targeted endpoints and goals may be inadequate to demonstrate the safety and efficacy levels required for regulatory approvals. Even if we believe data collected during the development of our drug candidates are promising, such data may not be sufficient to support marketing approval by the FDA, EMA or comparable foreign authorities. Further, data generated during development can be interpreted in different ways, and the FDA, EMA or comparable foreign authorities may interpret such data in different ways than us or our collaborators. Our failure to adequately demonstrate the safety and efficacy of

24

our drug candidates would prevent our receipt of regulatory approval, and ultimately the potential commercialization of these drug candidates.

 

Since we do not currently possess the resources necessary to independently develop and commercialize our drug candidates, including our core metabolic and endocrine disease assets, VK2809, VK0214, VK5211, VK0612 and our earlier-stage assets, the DGAT-1 and EPOR programs, or any other drug candidates that we may develop, we may seek to enter into collaborative agreements to assist in the development and potential future commercialization of some or all of these assets as a component of our strategic plan. However, our discussions with potential collaborators may not lead to the establishment of collaborations on acceptable terms, if at all, or it may take longer than expected to establish new collaborations, leading to development and potential commercialization delays, which would adversely affect our business, financial condition and results of operations.

 

We expect to continue to incur significant research and development expenses, which may make it difficult for us to attain profitability.

 

We expect to expend substantial funds in research and development, including preclinical studies and clinical trials of our drug candidates, and to manufacture and market any drug candidates in the event they are approved for commercial sale. We also may need additional funding to develop or acquire complementary companies, technologies and assets, as well as for working capital requirements and other operating and general corporate purposes. Moreover, our planned increases in staffing will dramatically increase our costs in the near and long-term.

 

However, our spending on current and future research and development programs and drug candidates for specific indications may not yield any commercially viable products. Due to our limited financial and managerial resources, we must focus on a limited number of research programs and drug candidates and on specific indications. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.

 

Because the successful development of our drug candidates is uncertain, we are unable to precisely estimate the actual funds we will require to develop and potentially commercialize them. In addition, we may not be able to generate sufficient revenue, even if we are able to commercialize any of our drug candidates, to become profitable.

 

Given our lack of current cash inflows, it is expected that we may need to raise additional capital; however, it may be unavailable to us or, even if capital is obtained, may cause dilution or place significant restrictions on our ability to operate our business.

 

Since we will be unable to generate sufficient, if any, cash inflows to fund our operations for the foreseeable future, we may need to seek additional equity or debt financing to provide the capital required to maintain or expand our operations. As of December 31, 2020, we had cash, cash equivalents and investments totaling $248.4 million. There can be no assurance that we will be able to raise sufficient additional capital on acceptable terms or at all. If such additional financing is not available on satisfactory terms, or is not available in sufficient amounts, we may be required to delay, limit or eliminate the development of business opportunities and our ability to achieve our business objectives, our competitiveness, and our business, financial condition and results of operations may be materially adversely affected. In addition, we may be required to grant rights to develop and market drug candidates that we would otherwise prefer to develop and market ourselves. Our inability to fund our business could lead to the loss of your investment. Our future capital requirements will depend on many factors, including, but not limited to:

 

 

•

the scope, rate of progress, results and cost of our clinical trials, preclinical studies and other related activities; our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such arrangements;

 

 

 

•

the timing of, and the costs involved in, obtaining regulatory approvals for any of our current or future drug candidates;

 

 

•

the number and characteristics of the drug candidates we seek to develop or commercialize;

 

 

•

the cost of manufacturing clinical supplies, and establishing commercial supplies, of our drug candidates;

 

 

•

the cost of commercialization activities if any of our current or future drug candidates are approved for sale, including marketing, sales and distribution costs;

 

 

 

•

the expenses needed to attract and retain skilled personnel;

 

 

•

the costs associated with being a public company;

 

25

 

 

•

the amount of revenue, if any, received from commercial sales of our drug candidates, should any of our drug candidates receive marketing approval;

 

 

 

•

the impacts that the COVID-19 global pandemic may have on our business, financial condition and results of operations,

 

 

 

•

including disruptions to our operations and clinical trials, as well as disruptions or delays with respect to the operations of our service providers, suppliers and contract research organizations, or CROs; and

 

 

 

•

the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing possible patent claims, including litigation costs and the outcome of any such litigation.

 

 

 

On July 11, 2018, we filed with the SEC a universal Shelf Registration Statement on Form S-3 (File No. 333-226133), or the Shelf Registration Statement. The Shelf Registration Statement initially provided us with the ability to offer up to $450.0 million of securities, including equity, debt and other securities as described in the Shelf Registration Statement. The Shelf Registration Statement was declared effective by the SEC on July 19, 2018. Pursuant to the Shelf Registration Statement, we may offer additional securities from time to time and through one or more methods of distribution, subject to market conditions and our capital needs.

 

On August 1, 2019, we entered into an At-The-Market Equity Offering Sales Agreement, or the ATM Agreement, with Stifel, Nicolaus & Company, Incorporated and Oppenheimer & Co. Inc., or each, an Agent and, together, the Agents, pursuant to which we may offer and sell, from time to time, through or to the Agents, as sales agent or principal, or the ATM Offering, shares of our common stock having an aggregate offering price of up to $75.0 million, or the Shares. Any Shares offered and sold in the ATM Offering will be issued pursuant to the Shelf Registration Statement and the 424(b) prospectus supplement relating to the ATM Offering dated August 1, 2019.

 

As of December 31, 2020, approximately $199.3 million of securities remain available and unallocated for offerings of securities under the 2018 Shelf Registration Statement.

 

If we raise additional capital by issuing equity securities, the percentage ownership of our existing stockholders may be reduced, and accordingly these stockholders may experience substantial dilution. We may also issue equity securities that provide for rights, preferences and privileges senior to those of our common stock. Given our need for cash and that equity issuances are the most common type of fundraising for companies like ours, the risk of dilution is particularly significant for stockholders of our company.

 

Our business may be adversely affected by the effects of health epidemics, including the COVID-19 pandemic.

 

In December 2019, COVID-19 was reported to have surfaced in Wuhan, China and has since spread to many other countries, including the United States. On March 11, 2020, the World Health Organization classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. On March 19, 2020, the Governor of California and the State Public Health Officer and Director of the California Department of Public Health ordered all individuals living in the State of California to stay at their place of residence for an indefinite period of time (subject to certain exceptions to facilitate authorized necessary activities) to mitigate the impact of the COVID-19 pandemic. The executive order exempts certain individuals needed to maintain continuity of operations of essential critical infrastructure sectors as determined by the federal government and additional sectors as the State Public Health Officer may designate as critical to protect health and well-being of all Californians. Under California’s shelter-in-place order, our corporate office was temporarily closed and employees primarily tele-worked from their homes. In May 2020, the Governor of California issued an executive order that informed local health jurisdictions and industry sectors that they may gradually reopen under new modifications and guidance provided by the state of California. In May 2020, our office reopened and our employees resumed working from our offices. In August 2020, the state of California released revised criteria for loosening and tightening restrictions on certain activities on generally a county-by-county basis. Under the executive orders, San Diego County, where our principal executive offices are located, continues to be subject to certain restrictions. These orders and others may be further modified, amended and adopted depending upon the COVID-19 transmission rates in our county and state, as well as other factors. If we are required to close our office in the future for an extended period of time and employees return to tele-working from their homes, then employee productivity may decline and we may be unable to complete certain tasks and operations that cannot be completed from home.

 

Government-imposed travel restrictions, quarantines, shelter-in-place, shutdowns and similar government orders have resulted, and may continue to result, in direct operational and administrative disruptions to our facilities. Our operations would be disrupted if any of our employees or employees of our business partners were suspected of having contracted COVID-19, which could require quarantine of some or all such employees or closure of our facilities for disinfection. Any restrictions on the conduct of business operations related to COVID-19 could also impact the operation of our suppliers. Global and domestic supply chains and the timely

26

availability of raw materials and products may be materially disrupted by quarantines, factory slowdowns or shutdowns, border closings and travel restrictions resulting from the COVID-19 pandemic. Any manufacturing supply interruption of materials could adversely affect our ability to conduct ongoing and future research and testing activities.

 

In addition, our clinical trials have been affected by and may continue to be affected by the COVID-19 pandemic. Clinical site initiation and patient enrollment have and may continue to be delayed due to prioritization of hospital resources toward the COVID-19 pandemic. Some patients have not been and others may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, any inability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, may adversely impact our clinical trial operations. We and our third-party CROs may need to make certain adjustments to the operation of our trials in an effort to ensure the monitoring and safety of patients and minimize risks to trial integrity during the pandemic in accordance with the guidance issued by the FDA on March 18, 2020 and generally, and may need to make further adjustments in the future. Many of these adjustments are new and untested, may not be effective, and may have unforeseen effects on the enrollment, progress and completion of these trials and the findings from these trials.

 

The spread of COVID-19, which has caused a broad impact globally and led to extreme volatility in capital markets, may materially affect us economically. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.

 

Management continues to monitor the global situation on our financial condition, liquidity, operations, suppliers, industry and workforce, and intends to follow health and safety guidelines as they evolve. Given the daily evolution of the COVID-19 pandemic and the global responses to curb its spread, we are not currently able to predict how long the pandemic will last, or to estimate the effects of the COVID-19 pandemic on our results of operations, financial condition or liquidity for fiscal year 2021.

 

Our drug candidates may cause undesirable side effects that could delay or prevent their regulatory approval or commercialization or have other significant adverse implications on our business, financial condition and results of operations.

 

Undesirable side effects observed in clinical trials or in supportive preclinical studies with our drug candidates could interrupt, delay or halt their development and could result in the denial of regulatory approval by the FDA, EMA or comparable foreign authorities for any or all targeted indications or adversely affect the marketability of any such drug candidates that receive regulatory approval. In turn, this could eliminate or limit our ability to commercialize our drug candidates.

 

Our drug candidates may exhibit adverse effects in preclinical toxicology studies and adverse interactions with other drugs. There are also risks associated with additional requirements the FDA, EMA or comparable foreign authorities may impose for marketing approval with regard to a particular disease.

 

Our drug candidates may require a risk management program that could include patient and healthcare provider education, usage guidelines, appropriate promotional activities, a post-marketing observational study, and ongoing safety and reporting mechanisms, among other requirements. Prescribing could be limited to physician specialists or physicians trained in the use of the drug, or could be limited to a more restricted patient population. Any risk management program required for approval of our drug candidates could potentially have an adverse effect on our business, financial condition and results of operations.

 

Undesirable side effects involving our drug candidates may have other significant adverse implications on our business, financial condition and results of operations. For example:

 

 

•

we may be unable to obtain additional financing on acceptable terms, if at all;

 

 

•

our collaborators may terminate any development agreements covering these drug candidates;

 

 

•

if any development agreements are terminated, we may determine not to further develop the affected drug candidates due to resource constraints and may not be able to establish additional collaborations for their further development on acceptable terms, if at all;

 

 

 

•

if we were to later continue the development of these drug candidates and receive regulatory approval, earlier findings may significantly limit their marketability and thus significantly lower our potential future revenues from their commercialization;

 

 

27

 

 

•

we may be subject to product liability or stockholder litigation; and

 

 

•

we may be unable to attract and retain key employees.

 

In addition, if any of our drug candidates receive marketing approval and we or others later identify undesirable side effects caused by the product:

 

 

•

regulatory authorities may withdraw their approval of the product, or we or our partners may decide to cease marketing and sale of the product voluntarily;

 

 

 

•

we may be required to change the way the product is administered, conduct additional clinical trials or preclinical studies regarding the product, change the labeling of the product, or change the product’s manufacturing facilities; and

 

 

 

•

our reputation may suffer.

 

Any of these events could prevent us from achieving or maintaining market acceptance of the affected product and could substantially increase the costs and expenses of commercializing the product, which in turn could delay or prevent us from generating significant revenues from the sale of the product.

 

Our efforts to discover drug candidates beyond our current drug candidates may not succeed, and any drug candidates we recommend for clinical development may not actually begin clinical trials.

 

We intend to continue to use our technology, including our licensed technology, knowledge and expertise to develop novel drugs to address some of the world’s most widespread and costly chronic diseases. We intend to expand our existing pipeline of core assets by advancing drug compounds from current ongoing discovery programs into clinical development. However, the process of researching and discovering drug compounds is expensive, time-consuming and unpredictable. Data from our current preclinical programs may not support the clinical development of our lead compounds or other compounds from these programs, and we may not identify any additional drug compounds suitable for recommendation for clinical development. Moreover, any drug compounds we recommend for clinical development may not demonstrate, through preclinical studies, indications of safety and potential efficacy that would support advancement into clinical trials. Such findings would potentially impede our ability to maintain or expand our clinical development pipeline. Our ability to identify new drug compounds and advance them into clinical development also depends upon our ability to fund our research and development operations, and we cannot be certain that additional funding will be available on acceptable terms, or at all.

 

Delays in the commencement or completion of clinical trials could result in increased costs to us and delay our ability to establish strategic collaborations.

 

Delays in the commencement or completion of clinical trials could significantly impact our drug development costs. We do not know whether planned clinical trials will begin on time or be completed on schedule, if at all. The commencement of clinical trials can be delayed for a variety of reasons, including, but not limited to, delays related to:

 

 

•

obtaining regulatory approval to commence one or more clinical trials;

 

 

•

reaching agreement on acceptable terms with prospective CROs and clinical trial sites;

 

 

•

manufacturing sufficient quantities of a drug candidate or other materials necessary to conduct clinical trials, as well as receiving the supplies and materials needed to conduct our clinical trials, including interruptions in global shipping that may affect the transport of clinical materials;

 

 

 

•

obtaining institutional review board approval to conduct one or more clinical trials at a prospective site;

 

 

•

recruiting and enrolling patients to participate in one or more clinical trials, especially as patients may be reluctant or unable to visit clinical sites, or may delay seeking treatment for chronic conditions, due to the COVID-19 pandemic;

 

 

 

•

the failure of our collaborators to adequately resource our drug candidates due to their focus on other programs or as a result of general market conditions;

 

 

28

 

 

•

recruiting clinical site investigators, clinical site staff and potential closure of clinical facilities due to the COVID-19 pandemic; and

 

 

 

•

changes in regulations as part of a response to the COVID-19 pandemic, which may require us to change the ways in which our clinical trials are conducted.

 

 

In addition, once a clinical trial has begun, it may be suspended or terminated by us, our collaborators, the institutional review boards or data safety monitoring boards charged with overseeing our clinical trials, the FDA, EMA or comparable foreign authorities due to a number of factors, including:

 

 

•

failure to conduct the clinical trial in accordance with regulatory requirements or clinical protocols;

 

 

•

inspection of the clinical trial operations or clinical trial site by the FDA, EMA or comparable foreign authorities resulting in the imposition of a clinical hold;

 

 

 

•

unforeseen safety issues; or

 

 

•

lack of adequate funding to continue the clinical trial.

 

If we experience delays in the completion or termination of any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to commence product sales and generate product revenues from any of our product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs and slow down our product candidate development and approval process. Delays in completing our clinical trials could also allow our competitors to obtain marketing approval before we do or shorten the patent protection period during which we may have the exclusive right to commercialize our product candidates. Any of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.

 

Results of earlier clinical trials may not be predictive of the results of later-stage clinical trials.

 

The results of preclinical studies and early clinical trials of product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy results despite having progressed through preclinical studies and initial clinical trials. Many companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to adverse safety profiles or lack of efficacy, notwithstanding promising results in earlier studies. Similarly, our future clinical trial results may not be successful for these or other reasons.

 

This drug candidate development risk is heightened by any changes in the planned clinical trials compared to the completed clinical trials. As product candidates are developed through preclinical to early to late stage clinical trials towards approval and commercialization, it is customary that various aspects of the development program, such as manufacturing and methods of administration, are altered along the way in an effort to optimize processes and results. While these types of changes are common and are intended to optimize the product candidates for late stage clinical trials, approval and commercialization, such changes carry the risk that they will not achieve these intended objectives.

 

Any of these changes could make the results of our planned clinical trials or other future clinical trials we may initiate less predictable and could cause our product candidates to perform differently, including causing toxicities, which could delay completion of our clinical trials, delay approval of our product candidates and/or jeopardize our ability to commence product sales and generate revenues.

 

If we experience delays in the enrollment of patients in our clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.

 

We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or other regulatory authorities. Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors, including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials and clinicians’ and patients’ perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating. In addition, the COVID-19 pandemic has negatively impacted, and may continue to negatively impact, our ability to recruit and enroll patients for our clinical trials, as they may be reluctant or unable to visit clinical sites, or may delay seeking treatment for chronic conditions.

 

29

 

If we fail to enroll and maintain the number of patients for which the clinical trial was designed, the statistical power of that clinical trial may be reduced, which would make it harder to demonstrate that the product candidate being tested in such clinical trial is safe and effective. Additionally, enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing. Our inability to enroll a sufficient number of patients for any of our current or future clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether.

 

We intend to rely on third parties to conduct our preclinical studies and clinical trials and perform other tasks for us. If these third parties do not successfully carry out their contractual duties, meet expected deadlines, or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our drug candidates and our business, financial condition and results of operations could be substantially harmed.

 

We have relied upon and plan to continue to rely upon third-party CROs, medical institutions, clinical investigators and contract laboratories to monitor and manage data for our licensed ongoing preclinical and clinical programs. Nevertheless, we maintain responsibility for ensuring that each of our clinical trials and preclinical studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our CROs and other vendors are required to comply with current requirements on good manufacturing practices, or cGMP, good clinical practices, or GCP, and good laboratory practice, or GLP, which are a collection of laws and regulations enforced by the FDA, EMA or comparable foreign authorities for all of our drug candidates in clinical development. Regulatory authorities enforce these regulations through periodic inspections of preclinical study and clinical trial sponsors, principal investigators, preclinical study and clinical trial sites, and other contractors. If we or any of our CROs or vendors fail to comply with applicable regulations, the data generated in our preclinical studies and clinical trials may be deemed unreliable and the FDA, EMA or comparable foreign authorities may require us to perform additional preclinical studies and clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with products produced consistent with cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the development and regulatory approval processes.

 

If any of our relationships with these third-party CROs, medical institutions, clinical investigators or contract laboratories terminate, we may not be able to enter into arrangements with alternative CROs on commercially reasonable terms, or at all. In addition, our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our ongoing preclinical and clinical programs. In addition, our CROs and their employees may be adversely affected or delayed by the COVID-19 pandemic. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our protocols, regulatory requirements, or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our drug candidates. CROs may also generate higher costs than anticipated. As a result, our business, financial condition, results of operations and the commercial prospects for our drug candidates could be materially and adversely affected, our costs could increase and our ability to generate revenue could be delayed.

 

Switching or adding additional CROs, medical institutions, clinical investigators or contract laboratories involves additional cost and requires management’s time and focus. In addition, there is a natural transition period when a new CRO commences work replacing a previous CRO. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse effect on our business, financial condition or results of operations.

 

In addition, our CROs may need to make certain adjustments to the operation of our trials in an effort to ensure the monitoring and safety of patients and minimize risks to trial integrity during the pandemic in accordance with the guidance issued by the FDA on March 18, 2020 and generally, and may need to make further adjustments in the future. Many of these adjustments are new and untested, may not be effective, and may have unforeseen effects on the enrollment, progress and completion of these trials and the findings from these trials.

 

Our drug candidates are subject to extensive regulation under the FDA, EMA or comparable foreign authorities, which can be costly and time consuming, cause unanticipated delays or prevent the receipt of the required approvals to commercialize our drug candidates.

 

The clinical development, manufacturing, labeling, storage, record-keeping, advertising, promotion, export, marketing and distribution of our drug candidates are subject to extensive regulation by the FDA and other U.S. regulatory agencies, EMA or comparable authorities in foreign markets. In the U.S., neither we nor our collaborators are permitted to market our drug candidates until we or our

30

collaborators receive approval of a new drug application, or an NDA, from the FDA or receive similar approvals abroad. The process of obtaining these approvals is expensive, often takes many years, and can vary substantially based upon the type, complexity and novelty of the drug candidates involved. Approval policies or regulations may change and may be influenced by the results of other similar or competitive products, making it more difficult for us to achieve such approval in a timely manner or at all. For example, the FDA has released draft guidance regarding clinical trials for drug candidates treating diabetes that may result in more stringent requirements for the clinical trials and regulatory approval of such drug candidates. This and any future guidance that may result from recent FDA advisory panel discussions on the topic of diabetes, non-alcoholic steatohepatitis, or NASH, and other metabolic indications, may make it more expensive to develop and commercialize such drug candidates for such indications. Such increased expense could make it more difficult to obtain favorable terms in the collaborative arrangements we require to maximize the value of our programs seeking to develop new drug candidates for diabetes. In addition, as a company, we have not previously filed NDAs with the FDA or filed similar applications with other foreign regulatory agencies. This lack of experience may impede our ability to obtain FDA or other foreign regulatory agency approval in a timely manner, if at all, for our drug candidates for which development and commercialization is our responsibility.

 

Despite the time and expense invested, regulatory approval is never guaranteed. The FDA, EMA or comparable foreign authorities can delay, limit or deny approval of a drug candidate for many reasons, including:

 

 

•

a drug candidate may not be deemed safe or effective;

 

 

•

agency officials of the FDA, EMA or comparable foreign authorities may not find the data from non-clinical or preclinical studies and clinical trials generated during development to be sufficient;

 

 

•

the FDA, EMA or comparable foreign authorities may not approve our third-party manufacturers’ processes or facilities; or

 

 

 

•

the FDA, EMA or a comparable foreign authority may change its approval policies or adopt new regulations.

 

Our inability to obtain these approvals would prevent us from commercializing our drug candidates.

 

Even if our drug candidates receive regulatory approval in the U.S., we may never receive approval or commercialize our products outside of the U.S.

 

In order to market any products outside of the U.S., we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Approval procedures vary among countries and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from that required to obtain FDA approval. The regulatory approval process in other countries may include all of the risks detailed above regarding FDA approval in the U.S. as well as other risks. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. Failure to obtain regulatory approval in other countries or any delay seeking or obtaining such approval would impair our ability to develop foreign markets for our drug candidates.

 

Even if any of our drug candidates receive regulatory approval, our drug candidates may still face future development and regulatory difficulties.

 

If any of our drug candidates receive regulatory approval, the FDA, EMA or comparable foreign authorities may still impose significant restrictions on the indicated uses or marketing of the drug candidates or impose ongoing requirements for potentially costly post-approval studies and trials. In addition, regulatory agencies subject a product, its manufacturer and the manufacturer’s facilities to continual review and periodic inspections. If a regulatory agency discovers previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, our collaborators or us, including requiring withdrawal of the product from the market. Our drug candidates will also be subject to ongoing FDA, EMA or comparable foreign authorities’ requirements for the labeling, packaging, storage, advertising, promotion, record-keeping and submission of safety and other post-market information on the drug. If our drug candidates fail to comply with applicable regulatory requirements, a regulatory agency may:

 

 

•

issue warning letters or other notices of possible violations;

 

 

•

impose civil or criminal penalties or fines or seek disgorgement of revenue or profits;

 

 

•

suspend any ongoing clinical trials;

 

31

 

 

•

refuse to approve pending applications or supplements to approved applications filed by us or our collaborators;

 

 

•

withdraw any regulatory approvals;

 

 

•

impose restrictions on operations, including costly new manufacturing requirements, or shut down our manufacturing operations; or

 

 

 

•

seize or detain products or require a product recall.

 

The FDA, EMA and comparable foreign authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses.

 

The FDA, EMA and comparable foreign authorities strictly regulate the promotional claims that may be made about prescription products, such as our drug candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA, EMA or comparable foreign authorities as reflected in the product’s approved labeling. If we receive marketing approval for our drug candidates for our proposed indications, physicians may nevertheless use our products for their patients in a manner that is inconsistent with the approved label, if the physicians personally believe in their professional medical judgment that our products could be used in such manner. However, if we are found to have promoted our products for any off-label uses, the federal government could levy civil, criminal or administrative penalties, and seek fines against us. Such enforcement has become more common in the industry. The FDA, EMA or comparable foreign authorities could also request that we enter into a consent decree or a corporate integrity agreement or seek a permanent injunction against us under which specified promotional conduct is monitored, changed or curtailed. If we cannot successfully manage the promotion of our drug candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business, financial condition and results of operations.

 

If our competitors have drug candidates that are approved faster, marketed more effectively, are better tolerated, have a more favorable safety profile or are demonstrated to be more effective than ours, our commercial opportunity may be reduced or eliminated.

 

The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that our technology, knowledge, experience and scientific resources provide us with competitive advantages, we face potential competition from many different sources, including commercial biopharmaceutical enterprises, academic institutions, government agencies and private and public research institutions. Any drug candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.

 

Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical studies, clinical trials, regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Our competitors may succeed in developing technologies and therapies that are more effective, better tolerated or less costly than any which we are developing, or that would render our drug candidates obsolete and noncompetitive. Even if we obtain regulatory approval for any of our drug candidates, our competitors may succeed in obtaining regulatory approvals for their products earlier than we do. We will also face competition from these third parties in recruiting and retaining qualified scientific and management personnel, in establishing clinical trial sites and patient registration for clinical trials, and in acquiring and in-licensing technologies and products complementary to our programs or advantageous to our business.

 

The key competitive factors affecting the success of each of our drug candidates, if approved, are likely to be its efficacy, safety, tolerability, frequency and route of administration, convenience and price, the level of branded and generic competition and the availability of coverage and reimbursement from government and other third-party payors.

 

VK2809

 

While no therapies are currently approved for the treatment of non-alcoholic steatohepatitis, we are aware of numerous development-stage programs targeting this disease, including obeticholic acid from Intercept Pharmaceuticals, Inc., cenicriviroc from Allergan plc (now part of AbbVie Inc.), resmetirom (MGL-3196) from Madrigal Pharmaceuticals, Inc., arachidyl amido cholanoic acid from Galmed Pharmaceuticals Ltd., belapectin (GR-MD-02) from Galectin Therapeutics Inc., MSDC-0602K from Cirius Therapeutics, Inc. (formerly Octeta Therapeutics, LLC), tesamorelin from Theratechnologies Inc., firsocostat (GS-0976) and cilofexor (GS-9674) from Gilead Sciences, Inc., semaglutide from Novo Nordisk A/S, NGM282 (aldafermin) and NGM313 (MK-3655) from NGM Biopharmaceuticals, Inc., tropifexor and licogliflozin from Novartis Pharmaceuticals Corporation, pegbelfermin (BMS-986036) and CC-90001 from Bristol-Myers Squibb, lanifibranor from Inventiva S.A., tirzepatide from Eli Lilly and Company, RG7992 from F. Hoffmann-La Roche AG, and EDP-305 from Enanta Pharmaceuticals, Inc. In addition, we are aware of

32

active programs at 89bio, Inc., Akero Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., Ascletis Biopharmaceutical, AstraZeneca PLC, Boehringer Ingelheim International GmbH, Can-Fite BioPharma Ltd., CytoDyn Inc., Durect Corporation, Enyo Pharma SA, Forma Therapeutics, Inc., Hanmi Pharmaceutical Co., Ltd., Hepion Pharmaceuticals, Inc., HighTide Therapeutics Inc., Ionis Pharmaceuticals, Inc., Kowa Company, Ltd., Lipocine, MediciNova Inc., Merck & Co., Inc., Metacrine, Inc., Mitsubishi Tanabe Pharma Corporation, Nitto Denko Corporation, NorthSea Therapeutics BV, NuSirt Biopharma, Inc., Pfizer Inc., Poxel SA, Sagimet Biosciences, Terns Pharmaceuticals, Inc., Yuhan Corporation and Zydus Cadila.

 

VK5211

 

In the U.S., there are currently no marketed therapies for the maintenance or improvement of lean body mass, bone mineral density or physical function in patients recovering from non-elective hip fracture surgery. However, VK5211, if approved, will face competition from experimental therapies that are in various stages of clinical development for conditions characterized by muscle wasting by companies including Biophytis SA and Helsinn Group. In addition, nutritional and growth hormone-based therapies are sometimes used in patients experiencing muscle wasting.

VK0214

 

In the U.S., there are currently no marketed therapies for the treatment of X-linked adrenoleukodystrophy, or X-ALD. Hematopoietic stem cell therapy has been used to treat the most severe form of X-ALD, cerebral adrenoleukodystrophy, or CALD. More recently, gene therapy has been shown to be effective in CALD as well. However, both treatments are invasive, requiring surgical intervention, and these do not appear to have an effect on the most pervasive form of X-ALD, adrenomyeloneuropathy, or AMN. There are several experimental therapies that are in various stages of clinical development for X-ALD by companies, including Autobahn Therapeutics, bluebird bio, Inc., Minoryx Therapeutics S.L., Neuralgene, Orpheris, Inc., Poxel SA, ReceptoPharm, Inc. and SwanBio Therapeutics, Inc., which may be competitive with VK0214, if approved.

 

We, or any future collaborators, may not be able to obtain orphan drug designation or orphan drug exclusivity for our product candidates.

 

Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. While we received orphan drug designation from the FDA for VK0214 for the treatment X-ALD in December 2016, we, or any future collaborators, may not be granted orphan drug designations for our product candidates in the U.S. or in other jurisdictions.

 

Even if we, or any future collaborators, obtain orphan drug designation for a product candidate, we, or they, may not be able to obtain orphan drug exclusivity for that product candidate. Generally, a product with orphan drug designation only becomes entitled to orphan drug exclusivity if it receives the first marketing approval for the indication for which it has such designation, in which case the FDA or the EMA will be precluded from approving another marketing application for the same drug for that indication for the applicable exclusivity period. The applicable exclusivity period is seven years in the United States and ten years in Europe. The European exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or the EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.

 

Even if we, or any future collaborators, obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because FDA has taken the position that, under certain circumstances, another drug with the same active moiety can be approved for the same condition. Specifically, the FDA’s regulations provide that it can approve another drug with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.

 

We are subject to a multitude of manufacturing risks, any of which could substantially increase our costs and limit supply of our drug candidates.

 

The process of manufacturing our drug candidates is complex, highly regulated and subject to several risks. For example, the process of manufacturing our drug candidates is extremely susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, or vendor or operator error. Even minor deviations from normal manufacturing processes for any of our drug candidates could result in reduced production yields, product defects and other supply disruptions. If microbial, viral, or other contaminations are discovered in our drug candidates or in the manufacturing facilities in which our drug candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the

33

contamination. In addition, the manufacturing facilities in which our drug candidates are made could be adversely affected by equipment failures, labor shortages, natural disasters, epidemics, pandemics, power failures and numerous other factors.

 

In addition, any adverse developments affecting manufacturing operations for our drug candidates may result in shipment delays, inventory shortages, lot failures, withdrawals or recalls, or other interruptions in the supply of our drug candidates. We also may need to take inventory write-offs and incur other charges and expenses for drug candidates that fail to meet specifications, undertake costly remediation efforts, or seek costlier manufacturing alternatives.

 

We rely completely on third parties to manufacture our preclinical and clinical drug supplies, and our business, financial condition and results of operations could be harmed if those third parties fail to provide us with sufficient quantities of drug product, or fail to do so at acceptable quality levels or prices.

 

We do not currently have, nor do we plan to acquire, the infrastructure or capability internally to manufacture our preclinical and clinical drug supplies for use in our clinical trials, and we lack the resources and the capability to manufacture any of our drug candidates on a clinical or commercial scale. We rely on our manufacturers to purchase from third-party suppliers the materials necessary to produce our drug candidates for our clinical trials. There are a limited number of suppliers for raw materials that we use to manufacture our drugs, and there may be a need to identify alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our drug candidates for our clinical trials, and, if approved, ultimately for commercial sale. We do not have any control over the process or timing of the acquisition of these raw materials by our manufacturers. Although we generally do not begin a clinical trial unless we believe we have a sufficient supply of a drug candidate to complete such clinical trial, any significant delay or discontinuity in the supply of a drug candidate, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a third-party manufacturer could considerably delay completion of our clinical trials, product testing and potential regulatory approval of our drug candidates, which could harm our business, financial condition and results of operations.

 

We and our contract manufacturers are subject to significant regulation with respect to manufacturing our drug candidates. The manufacturing facilities on which we rely may not continue to meet regulatory requirements.

 

All entities involved in the preparation of therapeutics for clinical trials or commercial sale, including our existing contract manufacturers for our drug candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with cGMP. These regulations govern manufacturing processes and procedures and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of contaminants or to inadvertent changes in the properties or stability of our drug candidates that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support of an NDA or marketing authorization application, or MAA, on a timely basis and must adhere to GLP and cGMP regulations enforced by the FDA, EMA or comparable foreign authorities through their facilities inspection program. Some of our contract manufacturers may not have produced a commercially approved pharmaceutical product and therefore may not have obtained the requisite regulatory authority approvals to do so. The facilities and quality systems of some or all of our third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our drug candidates or any of our other potential products. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our drug candidates or any of our other potential products or the associated quality systems for compliance with the regulations applicable to the activities being conducted. Although we oversee the contract manufacturers, we cannot control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with the regulatory requirements. If these facilities do not pass a pre-approval plant inspection, regulatory approval of the products may not be granted or may be substantially delayed until any violations are corrected to the satisfaction of the regulatory authority, if ever.

 

The regulatory authorities also may, at any time following approval of a product for sale, audit the manufacturing facilities of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly or time consuming for us or a third party to implement, and that may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business, financial condition and results of operations.

 

If we or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA, EMA or comparable foreign authorities can impose regulatory sanctions including, among other things, refusal to approve a pending application for a drug candidate, withdrawal of an approval, or suspension of production. As a result, our business, financial condition and results of operations may be materially and adversely affected.

 

34

 

Additionally, if supply from one manufacturer is interrupted, an alternative manufacturer would need to be qualified through an NDA supplement or MAA variation, or equivalent foreign regulatory filing, which could result in further delay. The regulatory agencies may also require additional studies or trials if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.

 

These factors could cause us to incur higher costs and could cause the delay or termination of clinical trials, regulatory submissions, required approvals, or commercialization of our drug candidates. Furthermore, if our suppliers fail to meet contractual requirements and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed, or we could lose potential revenue.

 

Any collaboration arrangement that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our current and potential future drug candidates.

 

We may seek collaboration arrangements with biopharmaceutical companies for the development or commercialization of our current and potential future drug candidates. To the extent that we decide to enter into collaboration agreements, we will face significant competition in seeking appropriate collaborators. Moreover, collaboration arrangements are complex and time consuming to negotiate, execute and implement. We may not be successful in our efforts to establish and implement collaborations or other alternative arrangements should we choose to enter into such arrangements, and the terms of the arrangements may not be favorable to us. If, and when, we collaborate with a third party for development and commercialization of a drug candidate, we can expect to relinquish some or all of the control over the future success of that drug candidate to the third party. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations.

 

Disagreements between parties to a collaboration arrangement can lead to delays in developing or commercializing the applicable drug candidate and can be difficult to resolve in a mutually beneficial manner. In some cases, collaborations with biopharmaceutical companies and other third parties are terminated or allowed to expire by the other party. Any such termination or expiration would adversely affect our business, financial condition and results of operations.

 

If we are unable to develop our own commercial organization or enter into agreements with third parties to sell and market our drug candidates, we may be unable to generate significant revenues.

 

We do not have a sales and marketing organization, and we have no experience as a company in the sales, marketing and distribution of pharmaceutical products. If any of our drug candidates are approved for commercialization, we may be required to develop our sales, marketing and distribution capabilities, or make arrangements with a third party to perform sales and marketing services. Developing a sales force for any resulting product or any product resulting from any of our other drug candidates is expensive and time consuming and could delay any product launch. We may be unable to establish and manage an effective sales force in a timely or cost-effective manner, if at all, and any sales force we do establish may not be capable of generating sufficient demand for our drug candidates. To the extent that we enter into arrangements with collaborators or other third parties to perform sales and marketing services, our product revenues are likely to be lower than if we marketed and sold our drug candidates independently. If we are unable to establish adequate sales and marketing capabilities, independently or with others, we may not be able to generate significant revenues and may not become profitable.

 

The commercial success of our drug candidates depends upon their market acceptance among physicians, patients, healthcare payors and the medical community.

 

Even if our drug candidates obtain regulatory approval, our products, if any, may not gain market acceptance among physicians, patients, healthcare payors and the medical community. The degree of market acceptance of any of our approved drug candidates will depend on a number of factors, including:

 

 

•

the effectiveness of our approved drug candidates as compared to currently available products;

 

 

•

patient willingness to adopt our approved drug candidates in place of current therapies;

 

 

•

our ability to provide acceptable evidence of safety and efficacy;

 

 

•

relative convenience and ease of administration;

 

 

•

the prevalence and severity of any adverse side effects;

 

 

•

restrictions on use in combination with other products;

35

 

 

 

•

availability of alternative treatments;

 

 

•

pricing and cost-effectiveness assuming either competitive or potential premium pricing requirements, based on the profile of our drug candidates and target markets;

 

 

 

•

effectiveness of our or our partners’ sales and marketing strategy;

 

 

•

our ability to obtain sufficient third-party coverage or reimbursement; and

 

 

•

potential product liability claims.

 

In addition, the potential market opportunity for our drug candidates is difficult to precisely estimate. Our estimates of the potential market opportunity for our drug candidates include several key assumptions based on our industry knowledge, industry publications, third-party research reports and other surveys. Independent sources have not verified all of our assumptions. If any of these assumptions proves to be inaccurate, then the actual market for our drug candidates could be smaller than our estimates of our potential market opportunity. If the actual market for our drug candidates is smaller than we expect, our product revenue may be limited, it may be harder than expected to raise funds and it may be more difficult for us to achieve or maintain profitability. If we fail to achieve market acceptance of our drug candidates in the U.S. and abroad, our revenue will be limited and it will be more difficult to achieve profitability.

 

If we fail to obtain and sustain an adequate level of reimbursement for our potential products by third-party payors, potential future sales would be materially adversely affected.

 

There will be no viable commercial market for our drug candidates, if approved, without reimbursement from third-party payors. Reimbursement policies may be affected by future healthcare reform measures. We cannot be certain that reimbursement will be available for our current drug candidates or any other drug candidate we may develop. Additionally, even if there is a viable commercial market, if the level of reimbursement is below our expectations, our anticipated revenue and gross margins will be adversely affected.

 

Third-party payors, such as government or private healthcare insurers, carefully review and increasingly question and challenge the coverage of and the prices charged for drugs. Reimbursement rates from private health insurance companies vary depending on the company, the insurance plan and other factors. Reimbursement rates may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. There is a current trend in the U.S. healthcare industry toward cost containment.

 

Large public and private payors, managed care organizations, group purchasing organizations and similar organizations are exerting increasing influence on decisions regarding the use of, and reimbursement levels for, particular treatments. Such third-party payors, including Medicare, may question the coverage of, and challenge the prices charged for, medical products and services, and many third-party payors limit coverage of or reimbursement for newly approved healthcare products. In particular, third-party payors may limit the covered indications. Cost-control initiatives could decrease the price we might establish for products, which could result in product revenues being lower than anticipated. We believe our drugs will be priced significantly higher than existing generic drugs and consistent with current branded drugs. If we are unable to show a significant benefit relative to existing generic drugs, Medicare, Medicaid and private payors may not be willing to provide reimbursement for our drugs, which would significantly reduce the likelihood of our products gaining market acceptance.

 

We expect that private insurers will consider the efficacy, cost-effectiveness, safety and tolerability of our potential products in determining whether to approve reimbursement for such products and at what level. Obtaining these approvals can be a time consuming and expensive process. Our business, financial condition and results of operations would be materially adversely affected if we do not receive approval for reimbursement of our potential products from private insurers on a timely or satisfactory basis. Limitations on coverage could also be imposed at the local Medicare carrier level or by fiscal intermediaries. Medicare Part D, which provides a pharmacy benefit to Medicare patients as discussed below, does not require participating prescription drug plans to cover all drugs within a class of products. Our business, financial condition and results of operations could be materially adversely affected if Part D prescription drug plans were to limit access to, or deny or limit reimbursement of, our drug candidates or other potential products.

 

Reimbursement systems in international markets vary significantly by country and by region, and reimbursement approvals must be obtained on a country-by-country basis. In many countries, the product cannot be commercially launched until reimbursement is approved. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after

36

initial approval is granted. The negotiation process in some countries can exceed 12 months. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our products to other available therapies. If the prices for our potential products are reduced or if governmental and other third-party payors do not provide adequate coverage and reimbursement of our drugs, our future revenue, cash flows and prospects for profitability will suffer.

 

Current and future legislation may increase the difficulty and cost of commercializing our drug candidates and may affect the prices we may obtain if our drug candidates are approved for commercialization.

 

In the U.S. and some foreign jurisdictions, there have been a number of adopted and proposed legislative and regulatory changes regarding the healthcare system that could prevent or delay regulatory approval of our drug candidates, restrict or regulate post-marketing activities and affect our ability to profitably sell any of our drug candidates for which we obtain regulatory approval.

 

In the U.S., the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, changed the way Medicare covers and pays for pharmaceutical products. Cost reduction initiatives and other provisions of this legislation could limit the coverage and reimbursement rate that we receive for any of our approved products. While the MMA only applies to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the MMA may result in a similar reduction in payments from private payors.

 

In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, collectively the PPACA, was enacted. The PPACA was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against healthcare fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. The PPACA increased manufacturers’ rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate amount for both branded and generic drugs and revised the definition of “average manufacturer price,” or AMP, which may also increase the amount of Medicaid drug rebates manufacturers are required to pay to states. The legislation also expanded Medicaid drug rebates and created an alternative rebate formula for certain new formulations of certain existing products that is intended to increase the rebates due on those drugs. The Centers for Medicare & Medicaid Services, or CMS, which administers the Medicaid Drug Rebate Program, also has proposed to expand Medicaid rebates to the utilization that occurs in the territories of the U.S., such as Puerto Rico and the Virgin Islands. Further, beginning in 2011, the PPACA imposed a significant annual fee on companies that manufacture or import branded prescription drug products and required manufacturers to provide a 50% discount off the negotiated price of prescriptions filled by beneficiaries in the Medicare Part D coverage gap, referred to as the “donut hole.” Legislative and regulatory proposals have been introduced at both the state and federal level to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products.

 

There have been public announcements by members of the U.S. Congress regarding plans to repeal and replace the PPACA and Medicare. For example, on December 22, 2017, the Tax Cuts and Jobs Act of 2017 was signed into law, which, among other things, eliminated the individual mandate requiring most Americans (other than those who qualify for a hardship exemption) to carry a minimum level of health coverage, effective January 1, 2019. On December 14, 2018, a U.S. District Court Judge in the Northern District of Texas, or the Texas District Court Judge, ruled that the individual mandate is a critical and inseverable feature of the PPACA, and therefore, because it was repealed as part of the Tax Cuts and Jobs Act of 2017, the remaining provisions of the PPACA are invalid as well. On December 18, 2019, the U.S. Court of Appeals for the Fifth Circuit upheld the District Court’s ruling with respect to the individual mandate but remanded the case to the District Court to consider whether other parts of the law can remain in effect. In November 2020, the U.S. Supreme Court heard the case and is expected to issue an opinion by June 2021. It is unclear how this decision, subsequent appeals, and other efforts to repeal and replace the PPACA will impact the law and our business. In addition, President Biden and his administration has announced plans to amend the PPACA to, among other things, expand the scope of the law. We are not sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our drug candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA’s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing approval testing and other requirements.

 

Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under government payor programs, and review the relationship between pricing and manufacturer patient programs. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our drug candidates, if approved for commercialization.

 

37

 

In Europe, the United Kingdom withdrew from the European Union on January 31, 2020, and entered into a transition period that expired on December 31, 2020. A significant portion of the previous regulatory framework in the United Kingdom was derived from the regulations of the European Union. In 2021, the United Kingdom’s Medicines and Healthcare products Regulatory Agency, or MHRA, and the European Medicines Agency, or EMA, released guidance explaining the new regulatory framework. We cannot predict the consequences or impact that the new regulatory framework will have on our future operations, if any, in these jurisdictions.

 

Changes in government funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, properly administer drug innovation, or prevent our product candidates from being developed or commercialized, which could negatively impact our business, financial condition and results of operations.

 

The ability of the FDA to review and approve new products can be affected by a variety of factors, including budget and funding levels, ability to hire and retain key personnel, and statutory, regulatory and policy changes. In addition, the FDA may currently be devoting more internal resources to monitoring and evaluating matters related to the COVID-19 pandemic. In addition, there may be delays in necessary interactions with regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government or contractor personnel. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.

 

In December 2016, the 21st Century Cures Act was signed into law. This legislation is designed to advance medical innovation and empower the FDA with the authority to directly hire positions related to drug and device development and review. However, government proposals to reduce or eliminate budgetary deficits may include reduced allocations to the FDA and other related government agencies. These budgetary pressures may result in a reduced ability by the FDA to perform their respective roles; including the related impact to academic institutions and research laboratories whose funding is fully or partially dependent on both the level and timing of funding from government sources.

 

Disruptions at the FDA and other agencies may also slow the time necessary for our product candidates to be reviewed or approved by necessary government agencies, which could adversely affect our business, financial condition and results of operations.

 

We are subject to “fraud and abuse” and similar laws and regulations, and a failure to comply with such regulations or prevail in any litigation related to noncompliance could harm our business, financial condition and results of operations.

 

In the U.S., we are subject to various federal and state healthcare “fraud and abuse” laws, including anti-kickback laws, false claims laws and other laws intended, among other things, to reduce fraud and abuse in federal and state healthcare programs. The federal Anti-Kickback Statute makes it illegal for any person, including a prescription drug manufacturer, or a party acting on its behalf, to knowingly and willfully solicit, receive, offer or pay any remuneration that is intended to induce the referral of business, including the purchase, order or prescription of a particular drug, or other good or service for which payment in whole or in part may be made under a federal healthcare program, such as Medicare or Medicaid. Although we seek to structure our business arrangements in compliance with all applicable requirements, these laws are broadly written, and it is often difficult to determine precisely how the law will be applied in specific circumstances. Accordingly, it is possible that our practices may be challenged under the federal Anti-Kickback Statute.

 

The federal False Claims Act prohibits anyone from, among other things, knowingly presenting or causing to be presented for payment to the government, including the federal healthcare programs, claims for reimbursed drugs or services that are false or fraudulent, claims for items or services that were not provided as claimed, or claims for medically unnecessary items or services. Under the Health Insurance Portability and Accountability Act of 1996, we are prohibited from knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private payors, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services to obtain money or property of any healthcare benefit program. Violations of fraud and abuse laws may be punishable by criminal or civil sanctions, including penalties, fines or exclusion or suspension from federal and state healthcare programs such as Medicare and Medicaid and debarment from contracting with the U.S. government. In addition, private individuals have the ability to bring actions on behalf of the government under the federal False Claims Act as well as under the false claims laws of several states.

 

Many states have adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare services reimbursed by any source, not just governmental payors. In addition, some states have passed laws that require pharmaceutical companies to comply with the April 2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers or the Pharmaceutical Research and Manufacturers of America’s Code on Interactions with Healthcare Professionals. Several states also impose other marketing restrictions or require pharmaceutical companies to make

38

marketing or price disclosures to the state. There are ambiguities as to what is required to comply with these state requirements and if we fail to comply with an applicable state law requirement we could be subject to penalties.

 

Neither the government nor the courts have provided definitive guidance on the application of fraud and abuse laws to our business. Law enforcement authorities are increasingly focused on enforcing these laws, and it is possible that some of our practices may be challenged under these laws. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. If we are found in violation of one of these laws, we could be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from governmental funded federal or state healthcare programs and the curtailment or restructuring of our operations. If this occurs, our business, financial condition and results of operations may be materially adversely affected.

 

If we face allegations of noncompliance with the law and encounter sanctions, our reputation, revenues and liquidity may suffer, and any of our drug candidates that are ultimately approved for commercialization could be subject to restrictions or withdrawal from the market.

 

Any government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to generate revenues from any of our drug candidates that are ultimately approved for commercialization. If regulatory sanctions are applied or if regulatory approval is withdrawn, our business, financial condition and results of operations will be adversely affected. Additionally, if we are unable to generate revenues from product sales, our potential for achieving profitability will be diminished and our need to raise capital to fund our operations will increase.

 

If we fail to retain current members of our senior management and scientific personnel, or to attract and keep additional key personnel, we may be unable to successfully develop or commercialize our drug candidates.

 

Our success depends on our continued ability to attract, retain and motivate highly qualified management and scientific personnel. As of December 31, 2020, we had eighteen full-time employees, two part-time employees and a small number of consultants, which may make us more reliant on our individual employees than companies with a greater number of employees. The loss of any of our key personnel, including as a result of the COVID-19 pandemic, could delay or prevent the development of our drug candidates. These personnel are “at-will” employees and may terminate their employment with us at any time; however, our current executive officer has agreed to provide us with at least 60 days’ advance notice of resignation pursuant to his employment agreement with us. The replacement of key personnel likely would involve significant time and costs, and may significantly delay or prevent the achievement of our business objectives. We do not maintain “key person” insurance on any of our employees.

 

From time to time, our management seeks the advice and guidance of certain scientific advisors and consultants regarding clinical and regulatory development programs and other customary matters. These scientific advisors and consultants are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us. In addition, our scientific advisors may have arrangements with other companies to assist those companies in developing products or technologies that may compete with ours.

 

Competition for qualified personnel is intense, especially in the greater San Diego, California area where we have a substantial presence and need for highly skilled personnel. We may not be successful in attracting qualified personnel to fulfill our current or future needs. Competitors and others have in the past attempted, and are likely in the future to attempt, to recruit our employees. While our employees are required to sign standard agreements concerning confidentiality and ownership of inventions, we generally do not have employment contracts or non-competition agreements with any of our personnel. The loss of the services of any of our key personnel, the inability to attract or retain highly qualified personnel in the future or delays in hiring such personnel, particularly senior management and other technical personnel, could materially and adversely affect our business, financial condition and results of operations.

We will need to increase the size of our organization and may not successfully manage our growth.

 

We are a clinical-stage biopharmaceutical company with a small number of employees, and our management systems currently in place are not likely to be adequate to support our future growth plans. Our ability to grow and to manage our growth effectively will require us to hire, train, retain, manage and motivate additional employees and to implement and improve our operational, financial and management systems. These demands also may require the hiring of additional senior management personnel or the development of additional expertise by our senior management personnel. Hiring a significant number of additional employees, particularly those at the management level, would increase our expenses significantly. Moreover, if we fail to expand and enhance our operational, financial and management systems in conjunction with our potential future growth, it could have a material adverse effect on our business, financial condition and results of operations.

 

39

 

Our management’s relative lack of public company experience could put us at greater risk of incurring fines or regulatory actions for failure to comply with federal securities laws and could put us at a competitive disadvantage, and could require our management to devote additional time and resources to ensure compliance with applicable corporate governance requirements.

 

Our management team has limited experience in managing and operating a public company, which could have an adverse effect on their ability to quickly respond to problems or adequately address issues and matters applicable to public companies. Any failure to comply with federal securities laws, rules or regulations could subject us to fines or regulatory actions, which may materially adversely affect our business, financial condition and results of operations. Further, since our management team has limited public company experience, we may have to dedicate additional time and resources to comply with legally mandated corporate governance policies relative to our competitors whose management teams have more public company experience.

 

We are exposed to product liability, non-clinical and clinical liability risks which could place a substantial financial burden upon us, should lawsuits be filed against us.

 

Our business exposes us to potential product liability and other liability risks that are inherent in the testing, manufacturing and marketing of pharmaceutical formulations and products. In addition, the use in our clinical trials of pharmaceutical products and the subsequent sale of these products by us or our potential collaborators may cause us to bear a portion of or all product liability risks. A successful liability claim or series of claims brought against us could have a material adverse effect on our business, financial condition and results of operations.

 

We currently maintain product liability insurance; however, there can be no assurance that we will be able to continue to maintain such insurance, and we may be unable to obtain replacement product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.

 

Our research and development activities involve the use of hazardous materials, which subject us to regulation, related costs and delays and potential liabilities.

 

Our research and development activities involve the controlled use of hazardous materials, chemicals and various radioactive compounds, and we will need to develop additional safety procedures for the handling and disposing of hazardous materials. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of biohazardous materials. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate any of these laws or regulations.

 

We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively.

 

Despite the implementation of security measures, our internal computer systems and those of third parties with which we contract, including our CROs and other business partners, are vulnerable to damage from cyber-attacks, computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. System failures, accidents or security breaches could cause interruptions in our operations or the operations of our CROs and other business partners, and could result in a material disruption of our drug development and clinical activities and business operations, in addition to possibly requiring substantial expenditures of resources to remedy. The loss of drug development or clinical trial data could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and our development programs and the development of our drug candidates could be delayed.

 

Our employees and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.

 

We are exposed to the risk of employee or consultant fraud or other misconduct. Misconduct by our employees or consultants could include intentional failures to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commissions, customer

40

incentive programs and other business arrangements. Employee and consultant misconduct also could involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter such misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material adverse effect on our business, financial condition and results of operations, and result in the imposition of significant fines or other sanctions against us.

 

Business disruptions such as natural disasters could seriously harm our future revenues and financial condition and increase our costs and expenses.

 

Our corporate headquarters are located in greater San Diego, California, a region known for seismic activity. In addition, one of our third-party manufacturers is located in the southeastern part of the United States, an area subject to hurricanes and related natural disasters. Our suppliers may also experience a disruption in their business as a result of natural disasters. A significant natural disaster, such as an earthquake, hurricane, flood or fire, could severely damage or destroy our headquarters or facilities or the facilities of our manufacturers or suppliers, which could have a material and adverse effect on our business, financial condition and results of operations. In addition, terrorist acts or acts of war targeted at the U.S., and specifically the greater San Diego, California region, could cause damage or disruption to us, our employees, facilities, partners and suppliers, which could have a material adverse effect on our business, financial condition and results of operations.

 

We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management.

 

From time to time, we may consider strategic transactions, such as acquisitions of companies, asset purchases and out-licensing or in-licensing of products, drug candidates or technologies. Additional potential transactions that we may consider include a variety of different business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Any such transaction may require us to incur non-recurring or other charges, may increase our near- and long-term expenditures and may pose significant integration challenges or disrupt our management or business, which could adversely affect our business, financial condition and results of operations. For example, these transactions may entail numerous operational and financial risks, including:

 

 

•

exposure to unknown liabilities;

 

 

•

disruption of our business and diversion of our management’s time and attention in order to develop acquired products, drug candidates or technologies;

 

 

 

•

incurrence of substantial debt or dilutive issuances of equity securities to pay for any of these transactions;

 

 

•

higher-than-expected transaction and integration costs;

 

 

•

write-downs of assets or goodwill or impairment charges;

 

 

•

increased amortization expenses;

 

 

•

difficulty and cost in combining the operations and personnel of any acquired businesses or product lines with our operations and personnel;

 

 

 

•

impairment of relationships with key suppliers or customers of any acquired businesses or product lines due to changes in management and ownership; and

 

 

 

•

inability to retain key employees of any acquired businesses.

 

Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks, and could have a material adverse effect on our business, financial condition and results of operations.

 

 

 

 

41

 

Our employment agreements with our officers and certain other employees may require us to pay severance benefits to any of those persons who are terminated in connection with a change in control of our company, which could harm our financial condition or results.

 

Our officers and certain employees are parties to employment agreements that contain change in control and severance provisions in the event of a termination of employment in connection with a change in control of our company providing for cash payments for severance and other benefits and acceleration of vesting of stock options and shares of restricted stock. The accelerated vesting of options and shares of restricted stock could result in dilution to our existing stockholders and lower the market price of our common stock. The payment of these severance benefits could harm our financial condition and results. In addition, these potential severance payments may discourage or prevent third parties from seeking a business combination with us.

 

Risks Relating to Our Intellectual Property

 

We may not be successful in obtaining or maintaining necessary rights to our drug candidates through acquisitions and in-licenses.

 

We currently have intellectual property rights to develop our drug candidates through a license from Ligand. As of December 31, 2020, we owned or co-owned seventy-three patent applications and did not own any patents. Because our programs require the use of proprietary rights held by Ligand, the growth of our business will likely depend in part on our ability to maintain and exploit these proprietary rights. In addition, we may need to acquire or in-license additional intellectual property in the future. We may be unable to acquire or in-license any compositions, methods of use, processes or other intellectual property rights from third parties that we identify as necessary for our drug candidates. We face competition with regard to acquiring and in-licensing third-party intellectual property rights, including from a number of more established companies. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license intellectual property rights to us. We also may be unable to acquire or in-license third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment.

 

We may enter into collaboration agreements with U.S. and foreign academic institutions to accelerate development of our current or future preclinical drug candidates. Typically, these agreements include an option for us to negotiate a license to the institution’s intellectual property rights resulting from the collaboration. Even with such an option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to license rights from a collaborating institution, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our desired program.

 

If we are unable to successfully obtain required third-party intellectual property rights or maintain our existing intellectual property rights, we may need to abandon development of the related program and our business, financial condition and results of operations could be materially and adversely affected.

 

If we fail to comply with our obligations in the agreements under which we in-license intellectual property and other rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.

 

The Master License Agreement is important to our business and we expect to enter into additional license agreements in the future. The Master License Agreement imposes, and we expect that future license agreements will impose, various diligence, milestone payment, royalty and other obligations on us. If we fail to comply with our obligations under these agreements, or if we file for bankruptcy, we may be required to make certain payments to the licensor, we may lose the exclusivity of our license, or the licensor may have the right to terminate the license, in which event we would not be able to develop or market products covered by the license. Additionally, the milestone and other payments associated with these licenses could materially and adversely affect our business, financial condition and results of operations.

 

Pursuant to the terms of the Master License Agreement, Ligand may terminate the Master License Agreement under certain circumstances, including, but not limited to: (1) in the event of our insolvency or bankruptcy, (2) if we do not pay an undisputed amount owing under the Master License Agreement when due and fail to cure such default within a specified period of time, or (3) if we default on certain of our material obligations and fail to cure the default within a specified period of time. If the Master License Agreement is terminated in its entirety or with respect to a specific licensed program for any reason, among other consequences, all licenses granted to us under the Master License Agreement (or with respect to the specific licensed program) will terminate and we may be requested to assign and transfer to Ligand certain regulatory documentation and regulatory approvals related to the licensed programs (or those related to the specific licensed program), and we may be required to wind down any ongoing clinical trials with respect to the licensed programs (or those related to the specific licensed program). Additionally, Ligand may require us to assign to Ligand the trademarks owned by us relating to the licensed programs (or those related to the specific licensed program), and we would

42

be obligated to grant to Ligand a license under any patent rights and know-how controlled by us to the extent necessary to make, have made, import, use, offer to sell and sell the licensed programs (or those related to the specific licensed program) anywhere in the world at a royalty rate in the low single digits.

 

In some cases, patent prosecution of our licensed technology may be controlled solely by the licensor. If our licensor fails to obtain and maintain patent or other protection for the proprietary intellectual property we in-license, then we could lose our rights to the intellectual property or our exclusivity with respect to those rights, and our competitors could market competing products using the intellectual property. In certain cases, we may control the prosecution of patents resulting from licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our licensing partners. Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. Disputes may arise regarding intellectual property subject to a licensing agreement, including, but not limited to:

 

 

 

•

the scope of rights granted under the license agreement and other interpretation-related issues;

 

 

•

the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;

 

 

 

•

the sublicensing of patent and other rights;

 

 

•

our diligence obligations under the license agreement and what activities satisfy those diligence obligations;

 

 

•

the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our collaborators; and

 

 

 

•

the priority of invention of patented technology.

 

If disputes over intellectual property and other rights that we have in-licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected drug candidates. If we fail to comply with any such obligations to our licensor, such licensor may terminate their licenses to us, in which case we would not be able to market products covered by these licenses. The loss of our license with Ligand, and potentially other licenses that we enter into in the future, would have a material adverse effect on our business.

 

We may be required to pay milestones and royalties to Ligand in connection with our use of the licensed technology under the Master License Agreement, which could adversely affect the overall profitability for us of any products that we may seek to commercialize.

 

Under the terms of the Master License Agreement, we may be obligated to pay Ligand up to an aggregate of approximately $1.54 billion in development, regulatory and sales milestones. We will also be required to pay Ligand single-digit royalties on future worldwide net product sales. These royalty payments could adversely affect the overall profitability for us of any products that we may seek to commercialize.

 

We may not be able to protect our proprietary or licensed technology in the marketplace.

 

We depend on our ability to protect our proprietary or licensed technology. We rely on trade secret, patent, copyright and trademark laws, and confidentiality, licensing and other agreements with employees and third parties, all of which offer only limited protection. Our success depends in large part on our ability, Ligand’s and any future licensor’s or licensee’s ability to obtain and maintain patent protection in the U.S. and other countries with respect to our proprietary or licensed technology and products. We currently in-license most of our intellectual property rights to develop our drug candidates and may in-license additional intellectual property rights in the future. Under the terms of the Master License Agreement, Ligand has the first right to file, prosecute and maintain the patents subject to the Master License Agreement in its name. We cannot be certain that patent enforcement activities by our current or future licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. We also cannot be certain that our current or future licensors will allocate sufficient resources or prioritize their or our enforcement of such patents. Even if we are not a party to these legal actions, an adverse outcome could prevent us from continuing to license intellectual property that we may need to operate our business, which would have a material adverse effect on our business, financial condition and results of operations.

 

We believe we will be able to obtain, through prosecution of patent applications covering technology licensed from others, adequate patent protection for our proprietary drug technology, including those related to our in-licensed intellectual property. If we are compelled to spend significant time and money protecting or enforcing our licensed patents and future patents we may own,

43

designing around patents held by others or licensing or acquiring, potentially for large fees, patents or other proprietary rights held by others, our business, financial condition and results of operations may be materially and adversely affected. If we are unable to effectively protect the intellectual property that we own or in-license, other companies may be able to offer the same or similar products for sale, which could materially adversely affect our business, financial condition and results of operations. The patents of others from whom we may license technology, and any future patents we may own, may be challenged, narrowed, invalidated or circumvented, which could limit our ability to stop competitors from marketing the same or similar products or limit the length of term of patent protection that we may have for our products.

 

Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection for licensed patents, pending patent applications and potential future patent applications and patents could be reduced or eliminated for non-compliance with these requirements.

 

Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or patent applications will be due to be paid to the U.S. Patent and Trademark Office, or the USPTO, and various governmental patent agencies outside of the U.S. in several stages over the lifetime of the applicable patent and/or patent application. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If this occurs with respect to our in-licensed patents or patent applications we may file in the future, our competitors might be able to use our technologies, which would have a material adverse effect on our business, financial condition and results of operations.

 

The patent positions of pharmaceutical products are often complex and uncertain. The breadth of claims allowed in pharmaceutical patents in the U.S. and many jurisdictions outside of the U.S. is not consistent. For example, in many jurisdictions, the support standards for pharmaceutical patents are becoming increasingly strict. Some countries prohibit method of treatment claims in patents. Changes in either the patent laws or interpretations of patent laws in the U.S. and other countries may diminish the value of our licensed or owned intellectual property or create uncertainty. In addition, publication of information related to our current drug candidates and potential products may prevent us from obtaining or enforcing patents relating to these drug candidates and potential products, including without limitation composition-of-matter patents, which are generally believed to offer the strongest patent protection.

 

Our intellectual property includes licenses covering issued patents and pending patent applications for composition of matter and method of use. As of December 31, 2020, for each of VK2809 and VK0214, we in-licensed two patents and one patent application in the U.S. and additional patents or patent applications in certain foreign jurisdictions, and owned or co-owned and in-licensed two PCT applications, five U.S. patent applications, one U.S. provisional application, and additional patent applications in certain foreign jurisdictions. We also in-licensed one additional U.S. patent and patent applications in certain foreign jurisdictions directed to VK0214; and owned one additional U.S. patent application and applications in certain foreign jurisdictions directed to VK2809 as of December 31, 2020. For VK5211, as of December 31, 2020, we in-licensed nine patents in the U.S. and several other patents in certain foreign jurisdictions. For VK0612, as of December 31, 2020, we in-licensed one patent in India, and own one pending U.S. application and several foreign applications. With respect to our other current drug candidates, we have a license covering several issued patents and pending patent applications both in the U.S. and in certain foreign jurisdictions.

 

Patents that we currently license and patents that we may own or license in the future do not necessarily ensure the protection of our licensed or owned intellectual property for a number of reasons, including, without limitation, the following:

 

 

•

the patents may not be broad or strong enough to prevent competition from other products that are identical or similar to our drug candidates;

 

 

 

•

there can be no assurance that the term of a patent can be extended under the provisions of patent term extension afforded by U.S. law or similar provisions in foreign countries, where available;

 

 

 

•

the issued patents and patents that we may obtain or license in the future may not prevent generic entry into the U.S. market for our drug candidates;

 

 

 

•

we do not at this time license or own a granted European patent or national phase patents in any European jurisdictions that would prevent generic entry into the European market for one of our primary drug candidates, VK2809;

 

 

44

 

 

•

we, or third parties from who we in-license or may license patents, may be required to disclaim part of the term of one or more patents;

 

 

 

•

there may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim;

 

 

 

•

there may be prior art of which we are aware, which we do not believe affects the validity or enforceability of a patent claim, but which, nonetheless, ultimately may be found to affect the validity or enforceability of a patent claim;

 

 

 

•

there may be other patents issued to others that will affect our freedom to operate;

 

 

•

if the patents are challenged, a court could determine that they are invalid or unenforceable;

 

 

•

there might be a significant change in the law that governs patentability, validity and infringement of our licensed patents or any future patents we may own that adversely affects the scope of our patent rights;

 

 

 

•

a court could determine that a competitor’s technology or product does not infringe our licensed patents or any future patents we may own; and

 

 

 

•

the patents could irretrievably lapse due to failure to pay fees or otherwise comply with regulations or could be subject to compulsory licensing.

 

 

If we encounter delays in our development or clinical trials, the period of time during which we could market our potential products under patent protection would be reduced.

 

Our competitors may be able to circumvent our licensed patents or future patents we may own by developing similar or alternative technologies or products in a non-infringing manner. Our competitors may seek to market generic versions of any approved products by submitting abbreviated new drug applications to the FDA in which our competitors claim that our licensed patents or any future patents we may own are invalid, unenforceable or not infringed. Alternatively, our competitors may seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend or assert our licensed patents or any future patents we may own, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find our licensed patents or any future patents we may own invalid or unenforceable. We may also fail to identify patentable aspects of our research and development before it is too late to obtain patent protection. Even if we own or in-license valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives.

 

The issuance of a patent is not conclusive as to its inventorship, scope, ownership, priority, validity or enforceability. In this regard, third parties may challenge our licensed patents or any future patents we may own in the courts or patent offices in the U.S. and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and potential products. In addition, given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such drug candidates might expire before or shortly after such drug candidates are commercialized.

 

We may infringe the intellectual property rights of others, which may prevent or delay our drug development efforts and prevent us from commercializing or increase the costs of commercializing our products.

 

Our commercial success depends significantly on our ability to operate without infringing the patents and other intellectual property rights of third parties. For example, there could be issued patents of which we are not aware that our current or potential future drug candidates infringe. There also could be patents that we believe we do not infringe, but that we may ultimately be found to infringe.

 

Moreover, patent applications are in some cases maintained in secrecy until patents are issued. The publication of discoveries in the scientific or patent literature frequently occurs substantially later than the date on which the underlying discoveries were made and patent applications were filed. Because patents can take many years to issue, there may be currently pending applications of which we are unaware that may later result in issued patents that our drug candidates or potential products infringe. For example, pending applications may exist that claim or can be amended to claim subject matter that our drug candidates or potential products infringe. Competitors may file continuing patent applications claiming priority to already issued patents in the form of continuation, divisional, or continuation-in-part applications, in order to maintain the pendency of a patent family and attempt to cover our drug candidates.

 

45

 

Third parties may assert that we are employing their proprietary technology without authorization and may sue us for patent or other intellectual property infringement. These lawsuits are costly and could adversely affect our business, financial condition and results of operations and divert the attention of managerial and scientific personnel. If we are sued for patent infringement, we would need to demonstrate that our drug candidates, potential products or methods either do not infringe the claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving invalidity is difficult. For example, in the U.S., proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on us. In addition, we may not have sufficient resources to bring these actions to a successful conclusion. If a court holds that any third-party patents are valid, enforceable and cover our products or their use, the holders of any of these patents may be able to block our ability to commercialize our products unless we acquire or obtain a license under the applicable patents or until the patents expire.

 

We may not be able to enter into licensing arrangements or make other arrangements at a reasonable cost or on reasonable terms. Any inability to secure licenses or alternative technology could result in delays in the introduction of our products or lead to prohibition of the manufacture or sale of products by us. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, in any such proceeding or litigation, we could be found liable for monetary damages, including treble damages and attorneys’ fees, if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our drug candidates or force us to cease some of our business operations, which could materially and adversely affect our business, financial condition and results of operations. Any claims by third parties that we have misappropriated their confidential information or trade secrets could have a similar material and adverse effect on our business, financial condition and results of operations. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.

 

Any claims or lawsuits relating to infringement of intellectual property rights brought by or against us will be costly and time consuming and may adversely affect our business, financial condition and results of operations.

 

We may be required to initiate litigation to enforce or defend our licensed and owned intellectual property. For example, we are currently aware of at least two third-party companies that are selling products in the U.S. bearing the name “LGD-4033,” which is the name previously used by Ligand to refer to VK5211, without authority from either us or Ligand, and we may experience other potential intellectual property infringement in the future. Lawsuits to protect our intellectual property rights can be very time consuming and costly. There is a substantial amount of litigation involving patent and other intellectual property rights in the biopharmaceutical industry generally. Such litigation or proceedings could substantially increase our operating expenses and reduce the resources available for development activities or any future sales, marketing or distribution activities.

 

In any infringement litigation, any award of monetary damages we receive may not be commercially valuable. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are resolved. Further, any claims we assert against a perceived infringer could provoke these parties to assert counterclaims against us alleging that we have infringed their patents. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.

 

In addition, our licensed patents and patent applications, and patents and patent applications that we may apply for, own or license in the future, could face other challenges, such as interference proceedings, opposition proceedings, re-examination proceedings and other forms of post-grant review. Any of these challenges, if successful, could result in the invalidation of, or in a narrowing of the scope of, any of our licensed patents and patent applications and patents and patent applications that we may apply for, own or license in the future. Any of these challenges, regardless of their success, would likely be time consuming and expensive to defend and resolve and would divert our management and scientific personnel’s time and attention.

 

In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the market price of our common stock.

 

 

 

 

46

 

Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.

 

As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is costly, time-consuming and inherently uncertain. For example, on September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act included a number of significant changes to U.S. patent law, including provisions that affect the way patent applications will be prosecuted and that may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a “first to file” system in which the first inventor to file a patent application is typically entitled to the patent. Third parties are allowed to submit prior art before the issuance of a patent by the USPTO, and may become involved in post-grant proceedings, including opposition, derivation, reexamination, inter partes review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position.

 

In addition, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we might obtain in the future.

 

We may not be able to protect our intellectual property rights throughout the world.

 

Filing, prosecuting and defending patents on drug candidates throughout the world would be prohibitively expensive. Competitors may use our licensed and owned technologies in jurisdictions where we have not licensed or obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may obtain or license patent protection, but where patent enforcement is not as strong as that in the U.S. These products may compete with our products in jurisdictions where we do not have any issued or licensed patents and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.

 

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our licensed patents and future patents we may own, or marketing of competing products in violation of our proprietary rights generally. Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the U.S. As a result, we may encounter significant problems in protecting and defending our licensed and owned intellectual property both in the U.S. and abroad. For example, China, where we currently have a number of licensed patents and licensed patent applications, currently affords less protection to a company’s intellectual property than some other jurisdictions. As such, the lack of strong patent and other intellectual property protection in China may significantly increase our vulnerability regarding unauthorized disclosure or use of our intellectual property and undermine our competitive position. Proceedings to enforce our future patent rights, if any, in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.

 

Many countries, including European Union countries, India, Japan and China, have compulsory licensing laws under which a patent owner may be compelled under certain circumstances to grant licenses to third parties. In those countries, as of December 31, 2020, we had several licensed patents and several licensed patent applications and may have limited remedies if such patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of such patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license.

 

We may be unable to adequately prevent disclosure of trade secrets and other proprietary information.

 

In order to protect our proprietary and licensed technology and processes, we rely in part on confidentiality agreements with our corporate partners, employees, consultants, manufacturers, outside scientific collaborators and sponsored researchers and other advisors. These agreements may not effectively prevent disclosure of our confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. Failure to obtain or maintain trade secret protection could adversely affect our competitive business position.

 

47

 

We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.

 

We employ individuals who were previously employed at other biopharmaceutical companies. Although we have no knowledge of any such claims against us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees’ former employers or other third parties. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees. To date, none of our employees have been subject to such claims.

 

We may be subject to claims challenging the inventorship of our licensed patents, any future patents we may own and other intellectual property.

 

Although we are not currently experiencing any claims challenging the inventorship of our licensed patents or our licensed or owned intellectual property, we may in the future be subject to claims that former employees, collaborators or other third parties have an interest in our licensed patents or other licensed or owned intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our drug candidates. Litigation may be necessary to defend against these and other claims challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business, financial condition and results of operations. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.

 

If we do not obtain additional protection under the Hatch-Waxman Amendments and similar foreign legislation extending the terms of our licensed patents and any future patents we may own, our business, financial condition and results of operations may be materially and adversely affected.

 

Depending upon the timing, duration and specifics of FDA regulatory approval for our drug candidates, one or more of our licensed U.S. patents or future U.S. patents that we may license or own may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during drug development and the FDA regulatory review process. This period is generally one-half the time between the effective date of an investigational new drug application (falling after issuance of the patent), and the submission date of an NDA, plus the time between the submission date of an NDA and the approval of that application. Patent term restorations, however, cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval by the FDA.

 

The application for patent term extension is subject to approval by the USPTO, in conjunction with the FDA. It takes at least six months to obtain approval of the application for patent term extension. We may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain earlier approval of competing products, and our ability to generate revenues could be materially adversely affected.

 

Risks Relating to Ownership of Our Common Stock

 

The market price of our common stock may be highly volatile.

 

The trading price of our common stock is likely to be volatile. Our stock price could be subject to wide fluctuations in response to a variety of factors, including the following:

 

 

•

any delay in filing an NDA for any of our drug candidates and any adverse development or perceived adverse development with respect to the FDA’s review of that NDA;

 

 

 

•

adverse results or delays in clinical trials, if any;

 

 

•

significant lawsuits, including patent or stockholder litigation;

 

 

•

inability to obtain additional funding;

 

48

 

 

•

failure to successfully develop and commercialize our drug candidates;

 

 

•

changes in laws or regulations applicable to our drug candidates;

 

 

•

inability to obtain adequate product supply for our drug candidates, or the inability to do so at acceptable prices;

 

 

•

unanticipated serious safety concerns related to any of our drug candidates;

 

 

•

adverse regulatory decisions;

 

 

•

introduction of new products or technologies by our competitors;

 

 

•

failure to meet or exceed drug development or financial projections we provide to the public;

 

 

•

failure to meet or exceed the estimates and projections of the investment community;

 

 

 

•

the perception of the biopharmaceutical industry by the public, legislatures, regulators and the investment community;

 

 

 

•

announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;

 

 

 

•

disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our licensed and owned technologies;

 

 

 

•

additions or departures of key scientific or management personnel;

 

 

•

changes in the market valuations of similar companies;

 

 

•

general economic and market conditions and overall fluctuations in the U.S. equity market;

 

 

•

public health emergencies such as the COVID-19 pandemic;

 

 

•

sales of our common stock by us or our stockholders, including Ligand, in the future; and

 

 

•

trading volume of our common stock.

 

In addition, the stock market, in general, and small biopharmaceutical companies, in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. Further, a decline in the financial markets and related factors beyond our control may cause our stock price to decline rapidly and unexpectedly.

 

An active trading market for our common stock may not be sustained, and you may not be able to resell your common stock at a desired market price.

 

If no active trading market for our common stock is sustained, you may be unable to sell your shares when you wish to sell them or at a price that you consider attractive or satisfactory. The lack of an active market may also adversely affect our ability to raise capital by selling securities in the future, or impair our ability to acquire or in-license other drug candidates, businesses or technologies using our shares as consideration.

 

 

 

 

 

49

 

Our management owns a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.

 

As of December 31, 2020, our executive officers, directors and 5% or greater stockholders beneficially owned 37.0% of our common stock. Therefore, our executive officers, directors and 5% or greater stockholders have the ability to influence us through this ownership position.

 

This concentration of stock ownership may adversely affect the trading price for our common stock because investors often perceive disadvantages in owning stock in companies with controlling stockholders. As a result, these stockholders, if they acted together, could materially influence all matters requiring approval by our stockholders, including the election of directors and the approval of mergers or other business combination transactions. These stockholders may be able to determine all matters requiring stockholder approval. The interests of these stockholders may not always coincide with our interests or the interests of other stockholders. This may also prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock, and might affect the prevailing market price for our common stock.

 

Ligand is one of our largest stockholders, which may limit the ability of our stockholders to influence corporate matters and may give rise to conflicts of interest.

 

As of December 31, 2020, Ligand and its affiliates beneficially owned approximately 9.8% of our outstanding common stock. Accordingly, Ligand may be able to exert influence over us and any action requiring the approval of the holders of our common stock, including the election of directors and the approval of mergers or other business combination transactions. This concentration of voting power may make it less likely that any other holder of our common stock or our board of directors will be able to affect the way we are managed and could delay or prevent an acquisition of us on terms that other stockholders may desire.

 

Furthermore, the interests of Ligand may not be aligned with our other stockholders and this could lead to actions that may not be in the best interests of our other stockholders. For example, Ligand may have different tax positions or strategic plans for us, which could influence its decisions regarding whether and when we should dispose of assets or incur new indebtedness. In addition, Ligand’s significant ownership in us may discourage someone from making a significant equity investment in us, or could discourage transactions involving a change in control, including transactions in which our stockholders might otherwise receive a premium for their shares over the then-current market price.

 

Pursuant to the management rights letter between us and Ligand, dated May 21, 2014, Ligand has the right to nominate one individual for election to our board of directors. Matthew W. Foehr, Ligand’s President and Chief Operating Officer, is the current member of our board of directors nominated by Ligand. As a result of our relationship with Ligand, there may be transactions between us and Ligand that could present an actual or perceived conflict of interest. These conflicts of interest may lead Mr. Foehr to recuse himself from deliberation and voting as a member of our board of directors with respect to any transactions involving Ligand or its affiliates.

 

We are a “smaller reporting company” within the meaning of the Securities Act of 1933, as amended, or the Securities Act, and if we decide to take advantage of certain exemptions from various reporting requirements applicable to smaller reporting companies, our common stock could be less attractive to investors.

 

For so long as we qualify as a “smaller reporting company,” we will have the option to take advantage of certain exemptions from various reporting and other requirements that are applicable to other public companies that are not “smaller reporting companies,” including, but not limited to reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. In addition, for as long as we are deemed neither a large accelerated filer nor accelerated filer, we will continue to use the exemption from compliance with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act.

 

We will remain a smaller reporting company and non-accelerated filer until we have a public float of $700 million or more and annual revenues of less than $100 million, or a public float of $250 million or more and annual revenues of $100 million or more. Our public float on June 30, 2020 was less than $700 million and our annual revenues were less than $100 million,

 

We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.

 

50

 

Our internal control over financial reporting may not meet the standards required by Section 404 of the Sarbanes-Oxley Act, and failure to achieve and maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act, could have a material adverse effect on our business and share price.

 

Our management is currently required to report on the effectiveness of our internal control over financial reporting. However, as a smaller reporting company and a non-accelerated filer and in accordance with new SEC rules effective in 2020, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404 for as long as we are not deemed an “accelerated filer” or “large accelerated filer.” The rules governing the standards that must be met for our management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation.

 

In connection with the implementation of the necessary procedures and practices related to internal control over financial reporting, we may identify deficiencies or material weaknesses that we may not be able to remediate in time to meet the deadline imposed by the Sarbanes-Oxley Act for compliance with the requirements of Section 404. In addition, we may encounter problems or delays in completing the implementation of any requested improvements and receiving a favorable attestation in connection with the attestation provided by our independent registered public accounting firm. Failure to achieve and maintain an effective internal control environment could have a material adverse effect on our business, financial condition and results of operations and could limit our ability to report our financial results accurately and in a timely manner.

 

As a result of operating as a public company, we may incur significantly increased costs and our management and other personnel will be required to devote substantial time to new compliance initiatives.

 

As a public company and particularly after we cease to be a “smaller reporting company” and “non-accelerated filer,” we will incur significant legal, accounting and other expenses. In addition, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, or the Dodd-Frank Act, as well as rules subsequently implemented by the Securities and Exchange Commission, or the SEC, and The Nasdaq Stock Market LLC have imposed various requirements on public companies. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact (in ways we cannot currently anticipate) the manner in which we operate our business. We have a small management team that, along with other personnel, will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain our current levels of such insurance coverage.

 

As a publicly traded company, we have incurred and will incur legal, accounting and other expenses associated with the SEC reporting requirements applicable to a company whose securities are registered under the Exchange Act, as well as corporate governance requirements, including those under the Sarbanes-Oxley Act, the Dodd-Frank Act and other rules implemented by the SEC and The Nasdaq Stock Market LLC. In addition, we expect that we will need to hire additional personnel in our finance department to help us comply with the various requirements applicable to public companies. The expenses incurred by public companies generally to meet SEC reporting, finance and accounting and corporate governance requirements have been increasing in recent years as a result of changes in rules and regulations and the adoption of new rules and regulations applicable to public companies.

 

If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, our stock price and trading volume could decline.

 

The trading market for our common stock depends, in part, on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. In addition, if our operating results fail to meet the forecast of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our stock price and trading volume to decline.

 

Sales of a substantial number of shares of our common stock in the public market by our existing stockholders, exercises and sales of outstanding warrants or future issuances of our common stock or rights to purchase our common stock, could cause our stock price to fall.

 

Sales of a substantial number of shares of our common stock by our existing stockholders, including Ligand, in the public market, or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to

51

raise capital through the sale of additional equity securities. We are unable to predict the effect that such sales may have on the prevailing market price of our common stock.

 

Our management will continue to have broad discretion over the use of the proceeds we received from our prior financings and available cash, and might not apply the proceeds in ways that increase the value of your investment.  

 

Our management will continue to have broad discretion to use the net proceeds from our prior financings and available cash and you will be relying on the judgment of our management regarding the application of these proceeds. Our management might not apply the proceeds in ways that ultimately increase the value of your investment and the failure by our management to apply these proceeds effectively could harm our business. Because of the number and variability of factors that will determine our use of these remaining net proceeds, their ultimate use may vary substantially from their currently intended use. If we do not invest or apply these net proceeds in ways that enhance stockholder value, we may fail to achieve the expected financial results, which could cause our stock price to decline.

 

We are at risk of securities class action litigation.

 

In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management’s attention and resources, which could harm our business, financial condition and results of operations.

 

Our ability to use our net operating loss carryforwards may be subject to certain limitations.

 

As of December 31, 2020, we had approximately $31.0 million of federal net operating loss carryforwards, of which $17.8 million will begin to expire in 2032 and the remaining $13.2 million of which can be carried forward indefinitely. We have $30.6 million of state net operating loss carryforwards that will begin to expire in 2034. Our ability to utilize our federal net operating loss carryforwards may be limited under Section 382 of the Internal Revenue Code of 1986, as amended, or the Code. In the event of an “ownership change,” Section 382 imposes an annual limitation on the amount of post-ownership change taxable income that may be offset with pre-ownership change net operating losses of the loss corporation experiencing the ownership change. An “ownership change” is defined by Section 382 as a cumulative change in ownership of our company of more than 50% within a three-year period. Our initial public offering in May 2015 resulted in an “ownership change” of us. Additionally, we have determined that our underwritten public offering of common stock completed in February 2018 resulted in an “ownership change” of us. We performed an analysis as of both dates in May 2015 and February 2018 and determined that, while the amount of net operating losses available to use each year may be limited, the full amounts of the $15.8 million federal and $15.8 million state tax net operating loss carryforwards are available for utilization as of December 31, 2020. Based on the 2018 limitation, 2021 is the last year for the Section 382 limitation, and the full amounts of the $25.2 million federal and $24.8 million state tax net operating loss carryforwards will be available for utilization as of December 31, 2021. We also performed an analysis as of June 11, 2018 and September 25, 2018, the dates of the closings of our underwritten public offerings of 8,625,000 shares and 9,500,000 shares of our common stock, respectively, and determined at each date that there was no deemed ownership change. In addition, current or future changes in our stock ownership may trigger an “ownership change,” some of which may be outside our control. Accordingly, our ability to utilize our net operating loss carryforwards to offset federal taxable income, if any, will likely be limited by Section 382, which could potentially result in increased future tax liability to us.

 

We may never pay dividends on our common stock so any returns would be limited to the appreciation of our stock.

 

We have never declared or paid any cash dividend on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.

 

Provisions in our amended and restated certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult or expensive for a third party to acquire us or change our board of directors or current management.

 

Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management. These provisions include:

 

 

•

authorizing the issuance of “blank check” preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval;

 

 

 

•

limiting the removal of directors by the stockholders;

52

 

 

 

•

creating a classified board of directors;

 

 

•

providing that no stockholder is permitted to cumulate votes at any election of directors;

 

 

•

allowing the authorized number of our directors to be changed only by resolution of our board of directors;

 

 

•

prohibiting stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders;

 

 

 

•

requiring the approval of the holders of at least 66 2/3% of the votes that all our stockholders would be entitled to cast to amend or repeal specified provisions of our charter documents;

 

 

 

•

eliminating the ability of stockholders to call a special meeting of stockholders; and

 

 

•

establishing advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted upon at stockholder meetings.

 

 

These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, we are subject to Section 203 of the General Corporation Law of the State of Delaware, or the DGCL, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with an interested stockholder for a period of three years following the date on which the stockholder became an interested stockholder, unless such transactions are approved in advance by our board of directors or ratified by our board of directors and certain of our stockholders. This provision could have the effect of delaying or preventing a change in control, whether or not it is desired by or beneficial to our stockholders. Further, other provisions of Delaware law may also discourage, delay or prevent someone from acquiring us or merging with us.

 

Our amended and restated bylaws designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees.

 

Our amended and restated bylaws provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee to us or our stockholders, (3) any action asserting a claim against us or our directors, officers or employees arising pursuant to any provision of our amended and restated bylaws, our amended and restated certificate of incorporation or the DGCL, (4) any action asserting a claim against us or our directors, officers or employees that is governed by the internal affairs doctrine, or (5) any action to interpret, apply, enforce or determine the validity of our amended and restated bylaws or our amended and restated certificate of incorporation. Any person purchasing or otherwise acquiring any interest in any shares of our capital stock shall be deemed to have notice of and to have consented to this provision of our amended and restated bylaws. This choice-of-forum provision may limit our stockholders’ ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits. Alternatively, if a court were to find this provision of our amended and restated bylaws inapplicable or unenforceable with respect to one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could materially and adversely affect our business, financial condition and results of operations.

 

Item 1B. Unresolved Staff Comments.

None.

Item 2. Properties.

Our facilities consist of office space in San Diego, California.  We lease approximately 7,149 square feet of space for our headquarters in San Diego, California under an agreement that expires on January 31, 2022.  We believe that our existing facilities are adequate to meet our current needs, and that suitable additional alternative spaces will be available in the future on commercially reasonable terms.

 

 

53

 

From time to time, we may be party to lawsuits in the ordinary course of business. We are not presently a party to any legal proceedings, the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business, operating results or financial condition.  

 

Item 4. Mine Safety Disclosures.

Not applicable.

 

 

54

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Market Information

Our common stock began trading on the Nasdaq Capital Market on April 28, 2015 and trades under the symbol “VKTX”. Prior to April 28, 2015, there was no public market for our common stock. Warrants to purchase shares of our common stock issued as part of the underwritten public offering in April 2016 began trading on the Nasdaq Capital Market under the symbol “VKTXW” effective April 8, 2016.  

Holders of Record

As of December 31, 2020, there were approximately five stockholders of record of our common stock and one holder of record of our publicly traded warrants. Certain shares and warrants are held in “street” name and, accordingly, the number of beneficial owners of such shares is not known or included in the foregoing number.

Performance Graph

We are a smaller reporting company, as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and are not required to provide a performance graph.

Item 6. Selected Financial Data.

Not required.

 

 

55

 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis in conjunction with Part II, “Item 8. Financial Statements and Supplementary Data” included below in this Annual Report on Form 10-K. Operating results are not necessarily indicative of results that may occur in future periods.

The following discussion and analysis of our financial condition and results of operations contains forward-looking statements that involve a number of risks, uncertainties and assumptions. Actual events or results may differ materially from our expectations. Important factors that could cause actual results to differ materially from those stated or implied by our forward-looking statements include, but are not limited to, those set forth in Part I, “Item 1A. Risk Factors” in this Annual Report on Form 10-K. All forward-looking statements included in this Annual Report on Form 10-K are based on information available to us as of the time we file this Annual Report on Form 10-K and, except as required by law, we undertake no obligation to update publicly or revise any forward-looking statements.

Overview

We are a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders.

Our lead clinical program’s drug candidate, VK2809, is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, or TRß. In November 2019, we initiated the VOYAGE study, a Phase 2b clinical trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis, or NASH.

The VOYAGE study is a randomized, double-blind, placebo-controlled, multicenter trial designed to assess the efficacy, safety and tolerability of VK2809 in patients with biopsy-confirmed NASH and fibrosis ranging from stages F1 to F3. The study is targeting enrollment of approximately 340 patients across five treatment arms. The primary endpoint of the study will evaluate the relative change in liver fat content, as assessed by magnetic resonance imaging, proton density fat fraction (MRI-PDFF), from baseline to week 12 in subjects treated with VK2809 as compared to placebo. Secondary objectives include evaluation of histologic changes assessed by hepatic biopsy after 52 weeks of dosing.

VK2809 has been evaluated in seven completed clinical studies, which enrolled more than 300 subjects. No serious adverse events, or SAEs, have been observed in subjects receiving VK2809 in these completed studies, and overall tolerability remains encouraging. In addition, the compound has been evaluated in chronic toxicity studies of up to 12 months in duration.

We are also developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRß for X-linked adrenoleukodystrophy, or X-ALD, a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. The disease, for which there is no approved treatment, is caused by mutations in a peroxisomal transporter of very long chain fatty acids, or VLCFA, known as ABCD1. As a result, transporter function is impaired and patients are unable to efficiently metabolize VLCFA. The TRß receptor is known to regulate expression of an alternative VLCFA transporter, known as ABCD2. Various preclinical models have demonstrated that increased expression of ABCD2 can lead to normalization of VLCFA metabolism. Preliminary data suggest that VK0214 stimulates ABCD2 expression in an in vitro model and reduces VLCFA levels in an in vivo model of X-ALD. In September of 2020, we initiated a randomized, double-blind, placebo controlled Phase 1 single ascending dose, or SAD, and multiple ascending dose, or MAD, clinical trial of VK0214 in healthy patients. The primary objectives of the study include evaluation of the safety and tolerability of single and multiple oral doses of VK0214, as well as identification of VK0214 doses for further clinical development in the setting of X-ALD.

Other clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM. In November 2017, we announced positive top-line results from a Phase 2 proof-of-concept clinical trial in 108 patients recovering from non-elective hip fracture surgery. Top-line data showed that the trial achieved its primary endpoint, demonstrating statistically significant, dose dependent increases in lean body mass, less head, following treatment with VK5211 as compared to placebo. The study also achieved certain secondary endpoints, demonstrating statistically significant increases in appendicular lean body mass and total lean body mass for all doses of VK5211, compared to placebo. VK5211 demonstrated encouraging safety and tolerability in this study, with no drug-related SAEs reported. Our intent is to continue to pursue partnering or licensing opportunities prior to conducting additional clinical studies.

We were incorporated under the laws of the State of Delaware on September 24, 2012. Since our incorporation, we have devoted most of our efforts towards conducting certain clinical trials and preclinical studies related to our VK2809, VK0214 and VK5211 programs, as well as efforts towards raising capital and building infrastructure. We obtained exclusive worldwide rights to our VK2809, VK0214 and VK5211 programs and certain other assets pursuant to an exclusive license agreement with Ligand Pharmaceuticals Incorporated, or Ligand. The terms of this license agreement are detailed in the Master License Agreement with Ligand, which we entered into on

56

May 21, 2014, as amended, or the Master License Agreement. A summary of the Master License Agreement can be found under the heading “Agreements with Ligand—Master License Agreement” under Part I, “Item 1. Business” of this Annual Report on Form 10-K.

We are subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on our business is highly uncertain and difficult to predict, as the responses that we, other businesses and governments are taking continue to evolve. Furthermore, capital markets and economies worldwide have also been negatively impacted by the COVID-19 pandemic, and it is possible that it could cause a local and/or global economic slowdown or recession. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remain uncertain.

In addition, our clinical trials have been affected by and may continue to be affected by the COVID-19 pandemic. Clinical site initiation and patient enrollment have been, and may continue to be delayed due to prioritization of hospital resources toward the COVID-19 pandemic. Some patients have not been able and others may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, any inability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, may adversely impact our clinical trial operations.

The severity of the impact of the COVID-19 pandemic on our business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on our service providers, suppliers, contract research organizations, or CROs, and our clinical trials, all of which are uncertain and cannot be predicted, as well as the timing and potential rollout of any vaccines and the willingness of the general population to be vaccinated. As of the date of issuance of our financial statements, the extent to which the COVID-19 pandemic may materially impact our financial condition, liquidity or results of operations is still uncertain.

Financial Operations Overview

Revenues

To date, we have not generated any revenue. We do not expect to receive any revenue from any drug candidates that we develop unless and until we obtain regulatory approval for, and commercialize, our drug candidates or enter into collaborative agreements with third parties.

Research and Development Expenses

During the year ended December 31, 2020, we charged $31.9 million to research and development expense primarily related to our efforts in continuing to conduct the VK2809 Phase 2b VOYAGE clinical trial as well as preparing for and initiating the VK0214 Phase 1 SAD and MAD study in healthy patients. During the year ended December 31, 2019, we charged $23.6 million to research and development expense primarily related to our efforts to prepare for the initiation of the VK2809 Phase 2b VOYAGE clinical trial as well as certain toxicology studies for VK2809 and in vivo studies for VK0214. We expect that our ongoing research and development expenses will consist of costs incurred for the development of our drug candidates, including, but not limited to:

 

•

employee and consultant-related expenses, which will include salaries, benefits and stock-based compensation, and certain consultant fees and travel expenses;

 

•

expenses incurred under agreements with investigative sites and contract research organizations, or CROs, which will conduct a substantial portion of our research and development activities, including studies in NASH, on our behalf;

 

•

payments to third-party manufacturers, which will produce our active pharmaceutical ingredients and finished products;

 

•

license fees paid to third parties for use of their intellectual property; and

 

•

facilities, depreciation and other allocated expenses, which will include direct and allocated expenses for rent and maintenance of facilities and equipment, depreciation of leasehold improvements, equipment and laboratory and other supplies.

We expense all research and development costs as incurred.

57

The process of conducting the necessary clinical research to obtain regulatory approval is costly and time consuming and the successful development of our drug candidates is highly uncertain. Our future research and development expenses will depend on the clinical success of each of our drug candidates, as well as ongoing assessments of the commercial potential of such drug candidates. In addition, we cannot forecast with any degree of certainty which drug candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements. We expect to incur increased research and development expenses in the future as we continue our efforts towards advancing our VK2809 and VK0214 programs and seek to advance our additional programs.

General and Administrative Expenses

Our general and administrative expenses have generally increased year-over-year as we have hired additional employees, issued additional equity awards, which has resulted in increased stock-based compensation expense, implemented certain systems to increase efficiency, and incurred additional costs for insurance, legal and accounting related to operating as a public company. We expect that our general and administrative expenses will continue to increase in the future in order to support our expected increase in research and development activities, including increased salaries and other related costs, stock-based compensation and consulting fees for executive, finance, accounting and business development functions. We also expect general and administrative expenses to increase as a result of additional costs associated with being a public company, including expenses related to compliance with the rules and regulations of the SEC and The Nasdaq Stock Market LLC, additional insurance expenses, investor relations activities and other administration and professional services. Other significant costs are expected to include legal fees relating to patent and corporate matters, facility costs not otherwise included in research and development expenses, and fees for accounting and other consulting services.

Other Income (Expense)

 

Other income (expense) includes interest income earned from our cash, cash equivalents and short-term investments.

Smaller Reporting Company and Non-Accelerated Filer

 

Until December 31, 2020, we were deemed an “emerging growth company” within the meaning of the rules under the Securities Act, and we utilized certain exemptions from various reporting requirements that were applicable to public companies that were not emerging growth companies. For example, as an emerging growth company, we were not required to provide an auditor’s attestation report on our internal control over financial reporting in our annual reports on Form 10-K as otherwise required by Section 404(b) of the Sarbanes-Oxley Act of 2002, as amended. Effective December 31, 2020, we are no longer an emerging growth company as December 31, 2020 was the last day of the fiscal year following the fifth anniversary of the completion of our initial public offering. In March 2020, the SEC released final rules amending the definitions for accelerated and large accelerated filers. In addition, these final rules also exclude from these definitions of accelerated and large accelerated filers an issuer that is eligible to be a smaller reporting company and non-accelerated filer. As our public float on June 30, 2020 was less than $700 million and our annual revenues are less than $100 million, we are now deemed a smaller reporting company and a non-accelerated filer. As a non-accelerated filer and in accordance with these new rules, we will continue to not be required to provide an auditor’s attestation report on our internal control over financial reporting in this and potentially future annual reports on Form 10-K as otherwise required by Section 404(b) of the Sarbanes-Oxley Act of 2002, as amended. In addition, as a smaller reporting company, we have the ability to take advantage of several “scaled disclosure” accommodations in accordance with the smaller reporting company rules.

Critical Accounting Policies and Estimates

Our management’s discussion and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments related to our preclinical, nonclinical and clinical development costs and drug manufacturing costs. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are more fully described in Note 1 to our financial statements included elsewhere in this Annual Report on Form 10-K, we believe that the following accounting policies will be critical to understanding our historical and

58

future performance, as these policies relate to the significant areas involving management’s judgments and estimates in the preparation of our financial statements.

Revenue Recognition

We have not recorded any revenues since our inception. However, in the future, we may enter into collaborative research and licensing agreements, under which we could be eligible for payments made in the form of upfront license fees, research funding, cost reimbursement, contingent event-based payments and/or royalties.

On January 1, 2018, we adopted Accounting Standards Update, or ASU, No. 2014-09, Revenue from Contracts with Customers and all related amendments, or ASC 606 or the new revenue standard. ASC 606 is a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The revenue standard is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, ASC 606 provides that an entity should apply the following steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The new revenue standard also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, and costs to obtain or fulfill contracts. We will apply ASC 606 prospectively to all contracts.

Research and Development

All costs of research and development are expensed in the period incurred. Research and development costs primarily consist of fees paid to contract research organizations, or CROs, and clinical trial sites, employee and consultant related expenses, which include salaries, benefits and stock-based compensation for research and development personnel, external research and development expenses incurred pursuant to agreements with third-party manufacturing organizations, facilities costs, travel costs, dues and subscriptions, depreciation and materials used in preclinical studies, clinical trials and research and development.

We estimate our preclinical study and clinical trial expenses based on the services we received pursuant to contracts with research institutions and CROs that conduct and manage preclinical studies and clinical trials on our behalf. Clinical trial-related contracts vary significantly in length, and may be for a fixed amount, based on milestones or deliverables, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of these elements. We accrue service fees based on work performed, which relies on estimates of total costs incurred based on milestones achieved, patient enrollment and other events. The majority of our service providers invoice us in arrears, and to the extent that amounts invoiced differ from our estimates of expenses incurred, we accrue for additional costs. The financial terms of these agreements vary from contract to contract and may result in uneven expenses and payment flows. Preclinical study and clinical trial expenses include:

 

•

fees paid to CROs, consultants and laboratories in connection with preclinical studies;

 

•

fees paid to CROs, clinical trial sites, investigators and consultants in connection with clinical trials; and

 

•

fees paid to contract manufacturers and service providers in connection with the production, testing and packaging of active pharmaceutical ingredients and drug materials for preclinical studies and clinical trials.

Payments under some of these agreements depend on factors such as the milestones accomplished, including enrollment of certain numbers of patients, site initiation and the completion of clinical trial milestones. To date, we have not experienced any events requiring us to make material adjustments to our accruals for service fees. If we do not identify costs that we have begun to incur or if we underestimate or overestimate the level of services performed or the costs of these services, our actual expenses could differ from our estimates, which could materially affect our results of operations. Adjustments to our accruals are recorded as changes in estimates become evident. Furthermore, based on amounts invoiced to us by our service providers, we may also record payments made to those providers as prepaid expenses that will be recognized as expense in future periods as services are rendered.

In May 2014, we entered into the Master License Agreement, pursuant to which we acquired certain rights to a number of research and development programs from Ligand. In doing so, we updated our policy on research and development to include the purchase of rights to intangible assets. In accordance with Accounting Standards Codification, or ASC, Topic 730, Research and Development, intangible assets that are acquired and have an alternative future use, as defined, should be capitalized and reported as an intangible asset; however, the cost of acquired intangible assets that do not have alternative future uses should be reported as research and development expense as incurred. We note that intangible assets acquired that are in the preclinical or clinical stages of development when acquired, and not approved by the U.S. Food and Drug Administration, are deemed to have not satisfied the definition of having

59

an alternative future use, as defined. Accordingly, assets acquired in the preclinical and clinical stages of development are expensed as incurred in our statement of operations.

Patent Costs

Costs related to filing and pursuing patent applications are expensed as incurred to general and administrative expense, as recoverability of such expenditures is uncertain.

Stock-Based Compensation

We generally use the straight-line method to allocate compensation cost to reporting periods over each optionee’s requisite service period, which is generally the vesting period, and estimate the fair value of stock-based awards or restricted stock units to employees and directors using the Black-Scholes option-valuation model. The Black-Scholes model requires the input of subjective assumptions, including volatility, the expected term and the fair value of the underlying common stock on the date of grant, among other inputs. For restricted stock and restricted stock unit awards, we generally use the straight-line method to allocate compensation cost to reporting periods over the holder’s requisite service period, which is generally the vesting period, and use the fair value at grant date to value the awards. For restricted stock that vests upon the satisfaction of certain performance conditions, we recognize stock-based compensation expense when it becomes probable that the performance conditions will be met. At the grant date, we determine the grant date fair value, as a publicly traded company, using the intrinsic value, or the closing price of our stock on the date of grant. At the point where the criteria are deemed probable of being met, we record stock-based compensation with a cumulative catch-up expense in the period first recognized and then on a straight-line basis over the remaining period for which the performance criteria are expected to be completed.

For our Employee Stock Purchase Plan, or ESPP, we generally recognize compensation expense for the fair value of the purchase options, as measured on the grant date, and use the graded vesting method to allocate this compensation cost to each purchase period within the related two-year offering period. As our ESPP also allows for up to one increase in contributions during each purchase period, then as an employee elects to increase their contributions, we treat this as an accounting modification. The pre- and post-modification values are calculated on the date of the modification, and the incremental expense is then amortized over the remaining purchase periods.

Income Taxes

We account for our income taxes using the liability method whereby deferred tax assets and liabilities are determined based on temporary differences between the basis used for financial reporting and income tax reporting purposes. Deferred income taxes are provided based on the enacted tax rates in effect at the time such temporary differences are expected to reverse. A valuation allowance is provided for deferred tax assets if it is more likely than not that we will not realize those tax assets through future operations.

ASC Topic 740-10, Income Taxes, clarifies the accounting for uncertainty in income taxes recognized in our financial statements in accordance with accounting principles generally accepted in the United States of America, or GAAP.  Income tax positions must meet a more-likely-than-not recognition threshold to be recognized. Income tax positions that previously failed to meet the more-likely-than-not threshold are recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not threshold are derecognized in the first subsequent financial reporting period in which that threshold is no longer met.

Our policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.

Net Loss per Common Share

Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. For purposes of this calculation, we currently do not have any deemed common share equivalents; therefore, our basic and diluted net loss per share calculations are the same. 

Segments

We operate in only one segment. Management uses cash flows as the primary measure to manage our business and does not segment our business for internal reporting or decision making purposes.

60

Results of Operations

Comparison of the Years Ended December 31, 2020 and 2019

Research and Development Expenses

The following table summarizes our research and development expenses for the years ended December 31, 2020 and 2019 (in thousands, except % change).

 

 

Year Ended December 31,

 

 

$

Change

 

 

%

Change

 

 

 

2020

 

 

2019

 

 

 

 

 

 

 

 

 

Research and development expenses

 

$

31,931

 

 

$

23,559

 

 

$

8,372

 

 

 

35.5

%

 

The increase in research and development expenses during the year ended December 31, 2020 as compared to the year ended December 31, 2019 was primarily due to increased expenses related to our clinical study efforts of $9.5 million, salaries and benefits of $668,000, stock-based compensation of $405,000 and the manufacturing of our drug candidates of $278,000 partially offset by decreased expenses related to services provided by certain third-party consultants of $1.5 million, pre-clinical study efforts of $908,000 and travel of $40,000.

General and Administrative Expenses

The following table summarizes our general and administrative expenses for the years ended December 31, 2020 and 2019 (in thousands, except % change).

 

 

Year Ended December 31,

 

 

$

Change

 

 

%

Change

 

 

 

2020

 

 

2019

 

 

 

 

 

 

 

 

 

General and administrative expenses

 

$

10,731

 

 

$

9,128

 

 

$

1,603

 

 

 

17.6

%

 

The increase in general and administrative expenses during the year ended December 31, 2020 as compared to the year ended December 31, 2019 was primarily due to increased expenses related to stock-based compensation of $1.7 million, salaries and wages of $295,000 and insurance expense of $173,000 partially offset by decreased expenses related to services provided by certain third-party consultants of $201,000, professional fees of $116,000, legal and patent expenses of $83,000 and travel of $71,000.

Other Income (Expense)

The following table summarizes our other income (expense) for the years ended December 31, 2020 and 2019 (in thousands, except % change).

 

 

Year Ended December 31,

 

 

$

Change

 

 

%

Change

 

 

 

2020

 

 

2019

 

 

 

 

 

 

 

 

 

Other income (expense)

 

$

3,167

 

 

$

6,908

 

 

$

(3,741

)

 

 

(54.2

)%

 

Other income (expense) recognized during the year ended December 31, 2020 consisted primarily of interest income of $3.3 million, offset by expense relating to the amortization of certain financing costs of $106,000.

 

Other income (expense) recognized during the year ended December 31, 2019 consisted primarily of interest income of $7.1 million, offset by expense relating to the amortization of certain financing costs of $146,000.

Liquidity and Capital Resources

We have incurred losses and negative cash flows from operations and have not generated any revenues since our inception. As of December 31, 2020, we had cash, cash equivalents and short-term investments of $248.4 million. As such, we believe our cash, cash equivalents and short-term investments will be sufficient to fund our operations through at least the first quarter of 2022, which is more than one year after the date our December 31, 2020 financial statements were issued.

Our primary use of cash is to fund operating expenses, which to date have consisted of the cost to obtain the license of intellectual property from Ligand, certain research and development expenses related to furthering the development of VK2809, VK0214 and VK5211 efforts and general and administrative expenses. Since we have not generated any revenues to date, we have incurred operating losses since our inception. Cash used to fund operating expenses is impacted by the timing of payment of these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.

61

On July 11, 2018, we filed with the SEC a universal Shelf Registration Statement on Form S-3 (File No. 333-226133), or the Shelf Registration Statement. The Shelf Registration Statement initially provided us with the ability to offer up to $450.0 million of securities, including equity, debt and other securities as described in the Shelf Registration Statement. The Shelf Registration Statement was declared effective by the SEC on July 19, 2018.  

Pursuant to the Shelf Registration Statement, we may offer additional securities from time to time and through one or more methods of distribution, subject to market conditions and our capital needs. Specific terms and prices will be determined at the time of each offering under a separate prospectus supplement, which will be filed with the SEC at the time of any offering.

On August 1, 2019, we entered into an At-The-Market Equity Offering Sales Agreement, or the ATM Agreement, with Stifel, Nicolaus & Company, Incorporated and Oppenheimer & Co. Inc., or each, an Agent and, together, the Agents, pursuant to which we may offer and sell, from time to time, through or to the Agents, as sales agent or principal, or the ATM Offering, shares of our common stock having an aggregate offering price of up to $75.0 million, or the Shares.  Any Shares offered and sold in the ATM Offering will be issued pursuant to the Shelf Registration Statement and the 424(b) prospectus supplement relating to the ATM Offering dated August 1, 2019. No shares of our common stock were sold under the ATM Agreement from its inception through December 31, 2020.

The following table summarizes our cash flows for the periods indicated below (in thousands):

 

 

2020

 

 

2019

 

Cash used in operating activities

 

$

(21,777

)

 

$

(24,752

)

Net cash provided by investing activities

 

$

41,567

 

 

$

7,463

 

Cash provided by financing activities

 

$

950

 

 

$

887

 

Cash Used in Operating Activities

During the year ended December 31, 2020, cash used in operating activities of $21.8 million primarily reflected our net losses for the period, adjusted by non-cash charges such as stock-based compensation, amortization of investment premiums, amortization of financing costs and amortization of right of use asset as well as changes in our working capital accounts, primarily consisting of an increase in accrued interest, net of interest received on maturity of investments, accounts payable and accrued expenses and a decrease in prepaid expenses and lease liability.

During the year ended December 31, 2019, cash used in operating activities of $24.8 million primarily reflected our net losses for the period, adjusted by non-cash charges such as amortization of investment premiums, amortization of financing costs, amortization of non-cash clinical trial costs, and stock-based compensation as well as changes in our working capital accounts, primarily consisting of an increase in prepaid expenses, accrued interest, net of interest received on maturity of investments, accounts payable and accrued expenses.

Cash Provided by Investing Activities

During the year ended December 31, 2020, cash provided by investing activities of $41.6 million resulted primarily from the proceeds of sales and maturities of investments of $322.2 million, partially offset by the purchase of investments of $280.6 million.

During the year ended December 31, 2019, cash provided by investing activities of $7.5 million resulted primarily from the proceeds of sales and maturities of investments of $369.9 million, partially offset by the purchase of investments of $362.4 million.

Cash Provided by Financing Activities

During the year ended December 31, 2020, cash provided by financing activities was $950,000, which consisted primarily of proceeds from certain warrant exercises of $854,000 and proceeds from certain stock option exercises and employee stock purchase plan purchases of $418,000, partially offset by the value of shares withheld to cover taxes of $296,000 and payments of certain financing costs of $26,000.

During the year ended December 31, 2019, cash provided by financing activities was $887,000, which consisted primarily of proceeds from certain warrant exercises of $783,000 and proceeds from certain stock option exercises and employee stock purchase plan purchases of $328,000, partially offset by the value of shares withheld to cover taxes of $151,000 and payments of certain financing costs of $73,000.

62

Future Funding Requirements

As of December 31, 2020, and based upon our current operating plan, we believe that we will have sufficient cash to meet our projected operating requirements for at least the next 12 months following the issuance of the financial statements. We anticipate, however, that we will continue to generate losses for the foreseeable future, and we expect the losses to increase materially as we continue the development of, and seek regulatory approvals for, our drug candidates, and seek to commercialize any drugs for which we receive regulatory approval. We will need to raise additional capital to fund our operations and complete our ongoing and planned clinical trials. Although we expect to finance future cash needs through public or private equity or debt offerings, funding may not be available to us on acceptable terms, or at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts or grant rights to develop and market drug candidates that we would otherwise prefer to develop and market ourselves.

Our future capital requirements will depend on many factors, including, but not limited to:

 

•

the scope, rate of progress, results and costs of our clinical trials, preclinical studies and other related activities;

 

•

our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements;

 

•

the timing of, and the costs involved in, obtaining regulatory approvals for any of our current or future drug candidates;

 

•

the number and characteristics of the drug candidates we seek to develop or commercialize;

 

•

the cost of manufacturing clinical supplies, and establishing commercial supplies, of our drug candidates;

 

•

the cost of commercialization activities if any of our current or future drug candidates are approved for sale, including marketing, sales and distribution costs;

 

•

the expenses needed to attract and retain skilled personnel;

 

•

the costs associated with being a public company;

 

•

the amount of revenue, if any, received from commercial sales of our drug candidates, should any of our drug candidates receive marketing approval; and

 

•

the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing possible patent claims, including litigation costs and the outcome of any such litigation.

Contractual Obligations and Commitments

We are a smaller reporting company, as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and are not required to provide the information required under this item.

 

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K promulgated by the SEC.

 

Item 7A. Quantitative and Qualitative Disclosures About Market Risk.

We are a smaller reporting company, as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and are not required to provide the information required under this item.

 

Item 8. Financial Statements and Supplementary Data.

The information required by this Item 8 is contained on the pages indicated in Part IV, Item 15(a)(1) of this Annual Report on Form 10-K.

 

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

None

 

63

 

Item 9A. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures.

We maintain disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act. Disclosure controls and procedures are controls and other procedures designed to ensure that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.  In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Based on our management’s evaluation (with the participation of the individuals serving as our principal executive officer and principal financial officer) of our disclosure controls and procedures as required by Rules 13a-15 and 15d-15 under the Exchange Act, each of the individuals serving as our principal executive officer and principal financial officer has concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2020, the end of the period covered by this report.

Management’s Report on Internal Control over Financial Reporting.

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act).  Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including the individuals serving as our principal executive officer and principal financial officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. Management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (2013 Framework). Based on this assessment, our management concluded that, as of December 31, 2020, our internal control over financial reporting was effective based on those criteria.

Attestation Report on Internal Control over Financial Reporting.

This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm due to the deferral allowed given we are neither an accelerated or large accelerated filer.

Changes in Internal Control over Financial Reporting.

There were no changes in our internal control over financial reporting during the quarter ended December 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Item 9B. Other Information.

Effective February 15, 2021, Greg Zante, our Chief Financial Officer and principal financial officer, was appointed our principal accounting officer until such time as his successor is appointed, or until his earlier resignation or removal. There are no reportable family relationships or related party transactions (as defined in Item 404(a) of Regulation S-K) involving us and Mr. Zante.

 

Mr. Zante has served as our Chief Financial Officer since January 2021. Prior to Mr. Zante’s appointment as our Chief Financial Officer, Mr. Zante served as our Senior Vice President of Finance since August 2019 and as Vice President, Finance & Operations from December 2016 to July 2019. Mr. Zante possesses nearly 25 years of financial management experience at public and private companies in the biotechnology and accounting industries. Prior to joining us, Mr. Zante was Chief Financial Officer at Dance Biopharm, Inc., a diabetes-focused biopharmaceutical company, from 2013 to 2016, where he managed the company’s private financing strategy and positioned it for initial public offering activities. Mr. Zante has also previously held senior positions at several biopharmaceutical companies including Sangamo Therapeutics, Inc. from 2003 to 2013, Calyx Therapeutics Inc. from 2001 to 2003 and Matrix Pharmaceuticals, Inc. from 2000 to 2001. He is a certified public accountant in the State of California and previously served as a senior staff accountant at Ernst & Young. He holds a BA in Business-Economics from the University of California, Los Angeles.

64

Mr. Zante’s annualized salary is currently $400,000 and he is currently eligible to receive an annual performance bonus of up to 40% of his base salary for fiscal year 2021. His salary and performance bonus percentage may be adjusted in the future at the discretion of the Compensation Committee of our Board of Directors. Mr. Zante’s employment is on an “at will” basis. Mr. Zante was not awarded any equity in connection with his appointment as our principal accounting officer.

 

 

65

PART III

 

 

Item 10. Directors, Executive Officers and Corporate Governance.

 

The information required by this item will be contained in our definitive proxy statement on Schedule 14A to be filed with the SEC in connection with our 2021 annual meeting of stockholders, or the Proxy Statement, which we expect to file not later than 120 days after the end of our year ended December 31, 2020, and is incorporated in this report by reference.

 

Item 11. Executive Compensation.

The information required by this item will be contained in the Proxy Statement, which we expect to file not later than 120 days after the end of our year ended December 31, 2020, and is incorporated in this report by reference.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The information required by this item will be contained in the Proxy Statement, which we expect to file not later than 120 days after the end of our year ended December 31, 2020, and is incorporated in this report by reference.

The information required by this item will be contained in the Proxy Statement, which we expect to file not later than 120 days after the end of our year ended December 31, 2020, and is incorporated in this report by reference.

Item 14. Principal Accounting Fees and Services.

The information required by this item will be contained in the Proxy Statement, which we expect to file not later than 120 days after the end of our year ended December 31, 2020, and is incorporated in this report by reference.


66

 

PART IV

 

 

Item 15. Exhibits, Financial Statement Schedules.  

(a)(1) The Financial Statements required to be filed by Items 8 and 15(c) of this Annual Report on Form 10-K, and filed herewith, are as follows:

 

 

(a)(2) Financial Statement Schedules have been omitted because they are either not applicable or the required information is included in the financial statements or notes thereto listed in (a)(1) above.

(a)(3) Exhibits.

The following exhibits are filed herewith or incorporated herein by reference:

 

Exhibit

Number  

 

Description

 

Registrant’s
Form

 

Date Filed
with the
SEC

 

Exhibit
Number

 

 

 

 

 

 

 

 

 

  3.1

 

Amended and Restated Certificate of Incorporation.

 

S-1

 

7/1/2014

 

3.3

 

 

 

 

 

 

 

 

 

  3.2

 

Amended and Restated Bylaws.

 

S-1

 

7/1/2014

 

3.4

 

 

 

 

 

 

 

 

 

  4.1

 

Form of Common Stock Certificate.

 

S-1

 

7/1/2014

 

4.1

 

 

 

 

 

 

 

 

 

     4.2

 

Form of Warrant Agreement, by and between Viking Therapeutics, Inc. and American Stock Transfer & Trust Company, LLC, including the Form of Warrant Certificate issued by Viking Therapeutics, Inc.

 

8-K

 

4/8/2016

 

4.1

 

 

 

 

 

 

 

 

 

     4.3

 

Warrant to Purchase Common Stock, dated April 13, 2016, issued by Viking Therapeutics, Inc. to Ligand Pharmaceuticals Incorporated.

 

8-K

 

4/14/2016

 

4.1

 

 

 

 

 

 

 

 

 

     4.4

 

Form of Common Stock Warrant issued by Viking Therapeutics, Inc. to purchasers in the June 2017 offering.

 

8-K

 

6/19/2017

 

4.1

 

 

 

 

 

 

 

 

 

     4.5

 

Description of Registrant’s Securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10.1#

 

Form of Indemnification Agreement between Viking Therapeutics, Inc. and its directors and executive officers.

 

S-1

 

7/1/2014

 

10.1

 

 

 

 

 

 

 

 

 

10.2#

 

2014 Equity Incentive Plan.

 

S-1/A

 

3/2/2015

 

10.2

 

 

 

 

 

 

 

 

 

10.3#

 

Form of Stock Option Award Agreement (2014 Equity Incentive Plan).

 

S-1

 

7/1/2014

 

10.3

 

 

 

 

 

 

 

 

 

10.4#

 

Form of Restricted Stock Unit Award Agreement (2014 Equity Incentive Plan).

 

S-1

 

7/1/2014

 

10.4

 

 

 

 

 

 

 

 

 

10.5#

 

Form of Restricted Stock Award Agreement (2014 Equity Incentive Plan).

 

S-1/A

 

9/2/2014

 

10.23

 

 

 

 

 

 

 

 

 

10.6#

 

Form of Stock Appreciation Rights Award Agreement (2014 Equity Incentive Plan).

 

S-1

 

7/1/2014

 

10.5

 

 

 

 

 

 

 

 

 

10.7#

 

2014 Employee Stock Purchase Plan.

 

S-1/A

 

3/2/2015

 

10.22

 

 

 

 

 

 

 

 

 

67

Exhibit

Number  

 

Description

 

Registrant’s
Form

 

Date Filed
with the
SEC

 

Exhibit
Number

 

 

 

 

 

 

 

 

 

10.8#

 

Amendment No. 1 to 2014 Employee Stock Purchase Plan.

 

S-1

 

11/24/2015

 

10.8

 

 

 

 

 

 

 

 

 

10.9#

 

Employment Agreement, effective as of June 2, 2014, by and between Viking Therapeutics, Inc. and Brian Lian, Ph.D.

 

S-1/A

 

9/2/2014

 

10.6

 

 

 

 

 

 

 

 

 

10.10#

 

First Amendment to Employment Agreement, effective as of March 14, 2016, by and between Viking Therapeutics, Inc. and Brian Lian, Ph.D.

 

8-K

 

3/15/2016

 

10.1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10.11#

 

Non-Employee Director Compensation Policy.

 

10-K

 

3/13/2019

 

10.15

 

 

 

 

 

 

 

 

 

10.12†

 

Master License Agreement, dated May 21, 2014, by and among Viking Therapeutics, Inc., Ligand Pharmaceuticals Incorporated and Metabasis Therapeutics, Inc.

 

S-1

 

7/1/2014

 

10.12

 

 

 

 

 

 

 

 

 

10.13†

 

First Amendment to Master License Agreement, dated September 6, 2014, by and among Viking Therapeutics, Inc., Ligand Pharmaceuticals Incorporated and Metabasis Therapeutics, Inc.

 

S-1/A

 

9/8/2014

 

10.24

 

 

 

 

 

 

 

 

 

10.14†

 

Second Amendment to Master License Agreement, dated April 8, 2015, by and among Viking Therapeutics, Inc., Ligand Pharmaceuticals Incorporated and Metabasis Therapeutics, Inc.

 

S-1/A

 

4/10/2015

 

10.30

 

 

 

 

 

 

 

 

 

10.15

 

Letter Agreement regarding board composition and management rights, dated May 21, 2014, by and between Viking Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated.

 

S-1

 

7/1/2014

 

10.15

 

 

 

 

 

 

 

 

 

10.16

 

Registration Rights Agreement, dated May 21, 2014, by and among Viking Therapeutics, Inc., Metabasis Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated.

 

S-1

 

7/1/2014

 

10.16

 

 

 

 

 

 

 

 

 

10.17

 

First Amendment to Registration Rights Agreement, dated January 22, 2016, by and between Viking Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated.

 

8-K

 

1/25/2016

 

10.2

 

 

 

 

 

 

 

 

 

10.18

 

Voting Agreement, dated May 21, 2014, by and among Viking Therapeutics, Inc., Ligand Pharmaceuticals Incorporated, Metabasis Therapeutics, Inc., Brian Lian, Ph.D. and Michael Dinerman, M.D.

 

S-1

 

7/1/2014

 

10.17

 

 

 

 

 

 

 

 

 

10.19#

 

Founder Common Stock Purchase Agreement, dated September 26, 2012, by and between Viking Therapeutics, Inc. and Brian Lian, Ph.D.

 

S-1

 

7/1/2014

 

10.18

 

 

 

 

 

 

 

 

 

10.20#

 

Amendment No. 1 to Founder Common Stock Purchase Agreement, dated May 4, 2015, by and between Viking Therapeutics, Inc. and Brian Lian, Ph.D.

 

10-Q

 

6/12/2015

 

10.2

 

 

 

 

 

 

 

 

 

10.21#†

 

Common Stock Purchase Agreement, dated February 20, 2014, by and between Viking Therapeutics, Inc. and Brian Lian, Ph.D.

 

S-1

 

7/1/2014

 

10.21

 

 

 

 

 

 

 

 

 

10.22#

 

Amendment No. 1 to Common Stock Purchase Agreement, dated May 4, 2015, by and between Viking Therapeutics, Inc. and Brian Lian, Ph.D.

 

10-Q

 

6/12/2015

 

10.5

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    10.23

 

Office Lease, dated May 25, 2018, by and between Viking Therapeutics, Inc. and Kilroy Realty, L.P.

 

10-Q

 

8/9/2018

 

10.1

 

 

 

 

 

 

 

 

 

    10.24

 

At-The-Market Equity Offering Sales Agreement, dated as of August 1, 2019, by and among Viking Therapeutics, Inc., Stifel, Nicolaus & Company, Incorporated and Oppenheimer & Co. Inc.

 

8-K

 

8/2/2019

 

10.1

 

 

 

 

 

 

 

 

 

23.1

 

Consent of Marcum LLP, Independent Registered Public Accounting Firm.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

68

Exhibit

Number  

 

Description

 

Registrant’s
Form

 

Date Filed
with the
SEC

 

Exhibit
Number

 

 

 

 

 

 

 

 

 

24.1

 

Power of Attorney (included on the signature page to this Annual Report on Form 10-K).

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

31.1

 

Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

31.2

 

Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

32.1

 

Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.INS

 

Inline  XBRL Instance Document.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.SCH

 

Inline  XBRL Taxonomy Extension Schema Document.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.CAL

 

Inline  XBRL Taxonomy Extension Calculation Linkbase Document.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.DEF

 

Inline  XBRL Taxonomy Extension Definition Linkbase Document.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.LAB

 

Inline  XBRL Taxonomy Extension Label Linkbase Document.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.PRE

 

Inline  XBRL Taxonomy Extension Presentation Linkbase Document.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

104

 

Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Attached as Exhibit 101 to this report are the following formatted in XBRL (Extensible Business Reporting Language): (i) Balance Sheets as of December 31, 2020 and December 31, 2019, (ii) Statements of Operations for the years ended December 31, 2020 and 2019, (iii) Statements of Stockholders’ Equity (Deficit) for the period from December 31, 2018 to December 31, 2020, (iv) Statements of Cash Flows for the years ended December 31, 2020 and 2019, and (v) Notes to Financial Statements.

 

#

Indicates compensatory plan or arrangement.

†

Confidential treatment has been granted with respect to certain portions of this exhibit, which portions have been omitted and filed separately with the Securities and Exchange Commission.

 

Item 16. Form 10-K Summary.

None.

 

69

 

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

Viking Therapeutics, Inc.

 

 

 

 

Date:  February 17, 2021

 

By:

/s/ Brian Lian, Ph.D.

 

 

 

Brian Lian, Ph. D.

 

 

 

President and Chief Executive Officer

 

POWER OF ATTORNEY

 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints, jointly and severally, Brian Lian, Ph.D. and Greg Zante, and each of them acting individually, as his attorney-in-fact, each with full power of substitution and resubstitution, for him in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

 

Name

 

Title

 

Date

 

 

 

 

 

/s/ Brian Lian, Ph.D.

 

President, Chief Executive Officer and Director

(Principal Executive Officer)

 

February 17, 2021

Brian Lian, Ph.D.

 

 

 

 

 

 

 

 

/s/ Greg Zante

 

Chief Financial Officer

(Principal Accounting and Financial Officer)

 

February 17, 2021

Greg Zante

 

 

 

 

 

 

 

 

/s/ Lawson Macartney, DVM, Ph.D.

 

Director

 

February 17, 2021

Lawson Macartney, DVM, Ph.D.

 

 

 

 

 

 

 

 

 

/s/ Matthew W. Foehr

 

Director

 

February 17, 2021

Matthew W. Foehr

 

 

 

 

 

 

 

 

 

/s/ Sarah Kathryn Rouan

 

Director

 

February 17, 2021

Sarah Kathryn Rouan

 

 

 

 

 

 

 

 

 

/s/ Charles A. Rowland Jr.

 

Director

 

February 17, 2021

Charles A. Rowland Jr.

 

 

 

 

 

 

 

 

 

/s/ J. Matthew Singleton

 

Director

 

February 17, 2021

J. Matthew Singleton

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

70

 

INDEX TO FINANCIAL STATEMENTS

 

 

 

 

F-1

 

Report of Independent Registered Public Accounting Firm

 

 

To the Stockholders and Board of Directors of

Viking Therapeutics, Inc.

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Viking Therapeutics, Inc. (the “Company”) as of December 31, 2020 and 2019, the related statements of operations and comprehensive loss, stockholders’ equity and cash flows for each of the two years in the period ended December 31, 2020, and the related notes (collectively referred to as the “financial statements”).  In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2020, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

 

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

 

Accrual for preclinical study and clinical trial costs

 

As described in Note 1 to the financial statements, the Company estimates its preclinical study and clinical trial expenses based on the services it received pursuant to contracts with research institutions and contract research organizations (“CROs”) that conduct and manage preclinical studies and clinical trials on the Company’s behalf. Clinical trial-related contracts vary significantly in length, and may be for a fixed amount based on milestones or deliverables, a variable amount based on actual costs incurred, capped at a certain limit, or a combination of these elements. The Company accrues service fees based on work performed, which relies on estimates of total costs incurred based on milestones achieved, patient enrollment and other events. The majority of the Company’s service providers invoice the Company in arrears, and to the extent that amounts invoiced differ from its estimates of expenses incurred, the Company accrues for additional costs. The financial terms of these agreements vary from contract to contract and may result in uneven expenses and payment flows.

 

The principal consideration for our determination that performing procedures related to the preclinical study and clinical trial expenses, specifically related to the year-end accrual for preclinical study and clinical trial costs, is a critical audit matter is that there

F-2

was judgment by management in determining the achievement of milestones, patient enrollments and occurrence of other events that creates a present obligation for the Company to pay the research institutions and CROs for their services.

 

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included, among others, (i) obtaining an understanding the Company’s estimation process relating to accrual for preclinical study and clinical trial costs; (ii) testing management’s identification of milestones, patient enrollment requirements and other events in its contracts with the research institutions and CROs; (iii) testing management’s determination of the accrual for preclinical study and clinical trial costs for a sample of such milestones, patient enrollments and other events; and (iv) testing the mathematical accuracy of the schedule of accrual for preclinical study and clinical trial costs prepared by management.

/s/ Marcum LLP

Marcum LLP

 

We have served as the Company’s auditor since 2014.

 

Costa Mesa, California

February 17, 2021

 

 

 

 

F-3

Viking Therapeutics, Inc.

Balance Sheets

 

(In thousands, except share and per share amounts)

 

 

 

December 31,

2020

 

 

December 31,

2019

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

29,117

 

 

$

8,377

 

Short-term investments – available for sale

 

 

219,269

 

 

 

267,261

 

Prepaid clinical trial and preclinical study costs

 

 

7,276

 

 

 

7,458

 

Prepaid expenses and other current assets

 

 

442

 

 

 

405

 

Total current assets

 

 

256,104

 

 

 

283,501

 

Right-of-use assets

 

 

321

 

 

 

598

 

Deferred public offering and other financing costs

 

 

48

 

 

 

128

 

Deposits

 

 

29

 

 

 

29

 

Total assets

 

$

256,502

 

 

$

284,256

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

3,988

 

 

$

2,431

 

Other accrued liabilities

 

 

7,811

 

 

 

4,044

 

Lease liability, current

 

 

330

 

 

 

302

 

Total current liabilities

 

 

12,129

 

 

 

6,777

 

Lease liability, net of current portion

 

 

29

 

 

 

360

 

Total long-term liabilities

 

 

29

 

 

 

360

 

Total liabilities

 

 

12,158

 

 

 

7,137

 

Commitments and contingencies (Note 11)

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Preferred stock, $0.00001 par value: 10,000,000 shares authorized at December 31, 2020 and 2019; no shares issued and outstanding at December 31, 2020 and 2019

 

 

—

 

 

 

—

 

Common stock, $0.00001 par value: 300,000,000 shares authorized at December 31, 2020 and 2019; 73,215,940 shares issued and outstanding at December 31, 2020 and 72,413,602 shares issued and outstanding at December 31, 2019

 

 

1

 

 

 

1

 

Additional paid-in capital

 

 

412,589

 

 

 

405,803

 

Accumulated deficit

 

 

(168,192

)

 

 

(128,697

)

Accumulated other comprehensive income (loss)

 

 

(54

)

 

 

12

 

Total stockholders’ equity

 

 

244,344

 

 

 

277,119

 

Total liabilities and stockholders’ equity

 

$

256,502

 

 

$

284,256

 

 

 

 

 

The accompanying notes are an integral part of these financial statements.

 

F-4

Viking Therapeutics, Inc.

Statements of Operations and Comprehensive Loss

 

(In thousands, except per share amounts)

 

 

 

 

Year Ended

December 31,

 

 

 

2020

 

 

2019

 

Revenues

 

$

—

 

 

$

—

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development

 

 

31,931

 

 

 

23,559

 

General and administrative

 

 

10,731

 

 

 

9,128

 

Total operating expenses

 

 

42,662

 

 

 

32,687

 

Loss from operations

 

 

(42,662

)

 

 

(32,687

)

Other income (expense):

 

 

 

 

 

 

 

 

Amortization of financing costs

 

 

(106

)

 

 

(146

)

Interest income, net

 

 

3,233

 

 

 

7,050

 

Realized gain on investments

 

 

40

 

 

 

4

 

Total other income, net

 

 

3,167

 

 

 

6,908

 

Net loss

 

 

(39,495

)

 

 

(25,779

)

Other comprehensive gain (loss), net of tax:

 

 

 

 

 

 

 

 

Unrealized gain (loss) on securities

 

 

(66

)

 

 

435

 

Comprehensive loss

 

$

(39,561

)

 

$

(25,344

)

Basic and diluted net loss per share

 

$

(0.54

)

 

$

(0.36

)

Weighted-average shares used to compute basic

   and diluted net loss per share

 

 

72,597

 

 

 

71,959

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these financial statements.

 

 

F-5

Viking Therapeutics, Inc.

Statements of Stockholders’ Equity

 

(In thousands, except share amounts)

 

 

 

 

Common Stock

 

 

Additional

Paid-In

 

 

Accumulated

 

 

Accumulated Other

Comprehensive

 

 

 

 

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Income (Loss)

 

 

Total

 

Balance at December 31, 2018

 

 

71,742,043

 

 

$

1

 

 

$

401,090

 

 

$

(102,918

)

 

$

(423

)

 

$

297,750

 

Employee stock-based compensation, net

 

 

(17,709

)

 

 

—

 

 

 

3,592

 

 

 

—

 

 

 

—

 

 

 

3,592

 

Issuance of common stock under employee stock plans

 

 

160,573

 

 

 

—

 

 

 

328

 

 

 

—

 

 

 

—

 

 

 

328

 

Issuance of common stock from warrant exercises

 

 

528,695

 

 

 

—

 

 

 

793

 

 

 

—

 

 

 

—

 

 

 

793

 

Unrealized gain (loss) on investments

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

435

 

 

 

435

 

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(25,779

)

 

 

—

 

 

 

(25,779

)

Balance at December 31, 2019

 

 

72,413,602

 

 

 

1

 

 

 

405,803

 

 

 

(128,697

)

 

 

12

 

 

 

277,119

 

Employee stock-based compensation, net

 

 

(44,042

)

 

 

—

 

 

 

5,522

 

 

 

—

 

 

 

—

 

 

 

5,522

 

Issuance of common stock under employee stock plans

 

 

249,579

 

 

 

—

 

 

 

418

 

 

 

—

 

 

 

—

 

 

 

418

 

Issuance of common stock from warrant exercises

 

 

596,801

 

 

 

—

 

 

 

846

 

 

 

—

 

 

 

—

 

 

 

846

 

Unrealized gain (loss) on investments

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(66

)

 

 

(66

)

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(39,495

)

 

 

—

 

 

 

(39,495

)

Balance at December 31, 2020

 

 

73,215,940

 

 

$

1

 

 

$

412,589

 

 

$

(168,192

)

 

$

(54

)

 

$

244,344

 

 

 

 

The accompanying notes are an integral part of these financial statements.

 

F-6

Viking Therapeutics, Inc.

Statements of Cash Flows

 

(In thousands)

 

 

 

Year Ended

December 31,

 

 

 

2020

 

 

2019

 

Cash flows from operating activities

 

 

 

 

 

 

 

 

Net loss

 

$

(39,495

)

 

$

(25,779

)

Adjustments to reconcile net loss to net cash used in operating

   activities

 

 

 

 

 

 

 

 

Amortization of investment premiums

 

 

3,808

 

 

 

477

 

Amortization of financing costs

 

 

106

 

 

 

146

 

Amortization of non-cash clinical trial costs

 

 

—

 

 

 

140

 

Stock-based compensation

 

 

5,818

 

 

 

3,743

 

Amortization of right-of-use assets

 

 

277

 

 

 

260

 

Interest expense related to operating lease liability

 

 

32

 

 

 

48

 

Realized gain on investments

 

 

(40

)

 

 

(4

)

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Prepaid expenses and other current assets

 

 

137

 

 

 

(7,380

)

Accrued interest, net of interest received on maturity of investments

 

 

2,590

 

 

 

1,971

 

Accounts payable

 

 

1,555

 

 

 

1,472

 

Accrued expenses

 

 

3,768

 

 

 

423

 

Lease liability

 

 

(333

)

 

 

(269

)

Net cash used in operating activities

 

 

(21,777

)

 

 

(24,752

)

Cash flows from investing activities

 

 

 

 

 

 

 

 

Purchases of investments

 

 

(280,636

)

 

 

(362,406

)

Proceeds from sales and maturities of investments

 

 

322,203

 

 

 

369,869

 

Net cash provided by investing activities

 

 

41,567

 

 

 

7,463

 

Cash flows from financing activities

 

 

 

 

 

 

 

 

Public offering and financing costs

 

 

(26

)

 

 

(73

)

Value of shares withheld related to employee tax withholding

 

 

(296

)

 

 

(151

)

Proceeds from stock issuance under employee stock purchase plan and warrant exercises

 

 

1,272

 

 

 

1,111

 

Net cash provided by financing activities

 

 

950

 

 

 

887

 

Net increase (decrease) in cash and cash equivalents

 

 

20,740

 

 

 

(16,402

)

Cash and cash equivalents beginning of period

 

 

8,377

 

 

 

24,779

 

Cash and cash equivalents end of period

 

$

29,117

 

 

$

8,377

 

 

 

 

 

 

 

 

 

 

Supplemental disclosure of non-cash investing and financing

   transactions

 

 

 

 

 

 

 

 

Unpaid deferred public offering and other financing costs

 

$

50

 

 

$

50

 

Receivable from exercise of warrants

 

$

1

 

 

$

10

 

 

 

The accompanying notes are an integral part of these financial statements.

 

 

F-7

Viking Therapeutics, Inc.

Notes to Financial Statements

 

 

1.

Organization, Liquidity and Management’s Plan, and Summary of Significant Accounting Policies

The Company

Viking Therapeutics, Inc., a Delaware corporation (the “Company”), is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders.

The Company was incorporated under the laws of the State of Delaware on September 24, 2012 and its principal executive offices are located in San Diego, CA.

Basis of Presentation

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

 

Risks and Uncertainties

 

The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on the Company’s business is highly uncertain and difficult to predict, as the responses that the Company, other businesses and governments are taking continue to evolve. Furthermore, capital markets and economies worldwide have also been negatively impacted by the COVID-19 pandemic, and it is possible that it could cause a local and/or global economic slowdown or recession. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remain uncertain.

In addition, the Company’s clinical trials have been affected by and may continue to be affected by the COVID-19 pandemic. Clinical site initiation and patient enrollment have been and may continue to be delayed due to prioritization of hospital resources toward the COVID-19 pandemic. Some patients have not been and others may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, any inability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, may adversely impact the Company’s clinical trial operations.

 

The severity of the impact of the COVID-19 pandemic on the Company’s business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company’s service providers, suppliers, contract research organizations (“CROs”) and the Company’s clinical trials, all of which are uncertain and cannot be predicted. As of the date of issuance of Company’s financial statements, the extent to which the COVID-19 pandemic may materially impact the Company’s financial condition, liquidity or results of operations is uncertain.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Significant estimates made in preparing these financial statements relate to accounting for operating lease and certain commitments. Actual results could differ from those estimates.

 

Reclassification

 

Certain amounts reported in prior years in the Statements of Cash Flows have been reclassified to conform to the current year’s presentation.

Cash and Cash Equivalents

The Company considers all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents.

Investments Available-for-Sale

Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in accumulated other comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of

F-8

discounts to maturity. The amortization of premiums and accretion of discounts is included in interest income. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in other income (expense). The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income.

Concentration of Credit Risk

Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents and marketable securities. The Company maintains deposits in federally insured depository institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.

Prepaid Clinical Trial and Preclinical Study Costs

Prepaid clinical trial and preclinical study costs represent advance payments by the Company for future clinical trial and preclinical study services to be performed by the clinical research organization and other research organizations.  Such amounts are recognized as research and development expense as the related clinical trial and preclinical study services are performed.  

 

Leases

The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use (“ROU”) assets, and lease liability obligations are included in the Company’s balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liability obligations represent its obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company’s leases typically do not provide an implicit rate, the Company estimates its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company uses the implicit rate when readily determinable. The ROU asset also includes any lease payments made and excludes lease incentives and lease direct costs. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. Please refer to Note 5 for additional information.

Deferred Financing Costs

Deferred financing costs represent legal, accounting and other direct costs related to the Company’s efforts to raise capital through a public or private sale of the Company’s common stock. Costs related to the public sale of the Company’s common stock are deferred until the completion of the applicable offering, at which time such costs are reclassified to additional paid-in-capital as a reduction of the proceeds.  Costs related to the private sale of the Company’s common stock are deferred until the completion of the applicable offering, at which time such costs are amortized over the term of the applicable purchase agreement.

Revenue Recognition

The Company has not recorded any revenues since its inception. However, in the future, the Company may enter into collaborative research and licensing agreements, under which the Company could be eligible for payments made in the form of upfront license fees, research funding, cost reimbursement, contingent event-based payments and/or royalties.

On January 1, 2018, the Company adopted ASU No. 2014-09, Revenue from Contracts with Customers and all related amendments (“ASC 606” or “the revenue standard”). ASC 606 is a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The revenue standard is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, ASC 606 provides that an entity should apply the following steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The revenue standard also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, and costs to obtain or fulfill contracts. The Company will apply ASC 606 prospectively to all contracts.  

F-9

Research and Development Expenses

All costs of research and development are expensed in the period incurred. Research and development costs primarily consist of fees paid to contract research organizations (“CROs”) and clinical trial sites, employee and consultant related expenses, which include salaries, benefits and stock-based compensation for research and development personnel, external research and development expenses incurred pursuant to agreements with third-party manufacturing organizations, facilities costs, travel costs, dues and subscriptions, depreciation and materials used in preclinical studies, clinical trials and research and development.

The Company estimates its preclinical study and clinical trial expenses based on the services it received pursuant to contracts with research institutions and CROs that conduct and manage preclinical studies and clinical trials on the Company’s behalf. Clinical trial-related contracts vary significantly in length, and may be for a fixed amount based on milestones or deliverables, a variable amount based on actual costs incurred, capped at a certain limit, or a combination of these elements. The Company accrues service fees based on work performed, which relies on estimates of total costs incurred based on milestones achieved, patient enrollment and other events. The majority of the Company’s service providers invoice the Company in arrears, and to the extent that amounts invoiced differ from its estimates of expenses incurred, the Company accrues for additional costs. The financial terms of these agreements vary from contract to contract and may result in uneven expenses and payment flows. Preclinical study and clinical trial expenses include:

 

•

fees paid to CROs, consultants and laboratories in connection with preclinical studies;

 

•

fees paid to CROs, clinical trial sites, investigators and consultants in connection with clinical trials; and

 

•

fees paid to contract manufacturers and service providers in connection with the production, testing and packaging of active pharmaceutical ingredients and drug materials for preclinical studies and clinical trials.

Payments under some of these agreements depend on factors such as the milestones accomplished, including enrollment of certain numbers of patients, site initiation and the completion of clinical trial milestones. To date, the Company has not experienced any events requiring it to make material adjustments to its accruals for service fees. If the Company does not identify costs that it has begun to incur or if it underestimates or overestimates the level of services performed or the costs of these services, its actual expenses could differ from its estimates which could materially affect its results of operations. Adjustments to the Company’s accruals are recorded as changes in estimates become evident. Furthermore, based on amounts invoiced to the Company by its service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expense in future periods as services are rendered.

In May 2014, the Company entered into a master license agreement, pursuant to which it acquired certain rights to a number of research and development programs from Ligand Pharmaceuticals Incorporated (“Ligand”). In doing so, the Company updated its policy on research and development to include the purchase of rights to intangible assets. In accordance with ASC Topic 730, Research and Development, intangible assets that are acquired and have an alternative future use, as defined, should be capitalized and reported as an intangible asset; however, the cost of acquired intangible assets that do not have alternative future uses should be reported as research and development expense as incurred. The Company notes that intangible assets acquired that are in the preclinical or clinical stages of development when acquired, and not approved by the U.S. Food and Drug Administration, are deemed to have not satisfied the definition of having an alternative future use, as defined. Accordingly, assets acquired in the preclinical and clinical stages of development are expensed as incurred in the Company’s statement of operations.

Patent Costs

Costs related to filing and pursuing patent applications are expensed as incurred to general and administrative expense, as recoverability of such expenditures is uncertain.

Stock-Based Compensation

The Company generally uses the straight-line method to allocate compensation cost to reporting periods over each optionee’s requisite service period, which is generally the vesting period, and estimates the fair value of stock-based awards or restricted stock units to employees and directors using the Black-Scholes option-valuation model (the “Black-Scholes model”). The Black-Scholes model requires the input of subjective assumptions, including volatility, the expected term and the fair value of the underlying common stock on the date of grant, among other inputs. For restricted stock and restricted stock unit awards, the Company generally uses the straight-line method to allocate compensation cost to reporting periods over the holder’s requisite service period, which is generally the vesting period, and uses the fair value at grant date to value the awards. For restricted stock that vests upon the satisfaction of certain performance conditions, the Company recognizes stock-based compensation expense when it becomes probable that the performance conditions will be met. At the grant date, the Company determines the grant date fair value, as a publicly traded company, using the intrinsic value, or the closing price of the Company’s common stock on the date of grant. At the point where the criteria are deemed probable of being met, the Company records stock-based compensation with a cumulative catch-up expense in the period first

F-10

recognized and then on a straight-line basis over the remaining period for which the performance criteria are expected to be completed.

For the Company’s 2014 Employee Stock Purchase Plan (the “ESPP”), the Company generally recognizes compensation expense for the fair value of the purchase options, as measured on the grant date, and uses the graded vesting method to allocate this compensation cost to each purchase period within the related two-year offering period. As the ESPP also allows for up to one increase in contributions during each purchase period, as an employee elects to increase his or her contributions, the Company treats this as an accounting modification. The pre- and post-modification values are calculated on the date of the modification, and the incremental expense is then amortized over the remaining purchase periods.    

Income Taxes

The Company accounts for its income taxes using the liability method whereby deferred tax assets and liabilities are determined based on temporary differences between the basis used for financial reporting and income tax reporting purposes. Deferred income taxes are provided based on the enacted tax rates in effect at the time such temporary differences are expected to reverse. A valuation allowance is provided for deferred tax assets if it is more likely than not that the Company will not realize those tax assets through future operations.

ASC Topic 740-10, Income Taxes, clarifies the accounting for uncertainty in income taxes recognized in the Company’s financial statements in accordance with GAAP.  Income tax positions must meet a more-likely-than-not recognition threshold to be recognized. Income tax positions that previously failed to meet the more-likely-than-not threshold are recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not threshold are derecognized in the first subsequent financial reporting period in which that threshold is no longer met.

The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.

Net Loss per Common Share

Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. For purposes of this calculation, the Company currently does not have any deemed common share equivalents; therefore, its basic and diluted net loss per share calculations are the same.

The following table presents the computation of basic and diluted net loss per common share (in thousands, except share and per share data):

 

 

 

Year Ended December 31,

 

 

 

2020

 

 

2019

 

Historical net loss per share

 

 

 

 

 

 

 

 

Numerator

 

 

 

 

 

 

 

 

Net loss

 

$

(39,495

)

 

$

(25,779

)

Denominator

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding

 

 

72,779,742

 

 

 

72,142,188

 

Less: Weighted-average shares subject to repurchase

 

 

(183,095

)

 

 

(183,095

)

Denominator for basic and diluted net loss per share

 

 

72,596,647

 

 

 

71,959,093

 

Basic and diluted net loss per share

 

$

(0.54

)

 

$

(0.36

)

 

 

F-11

 

Potentially dilutive securities that are not included in the calculation of diluted net loss per share because their effect is anti-dilutive are as follows (in common equivalent shares):

 

 

 

Year Ended December 31,

 

 

 

2020

 

 

2019

 

Common stock warrants

 

 

5,244,500

 

 

 

5,841,301

 

Restricted stock units

 

 

679,363

 

 

 

352,726

 

Common stock subject to repurchase

 

 

183,095

 

 

 

183,095

 

Common stock options

 

 

3,371,323

 

 

 

2,580,476

 

 

 

 

9,478,281

 

 

 

8,957,598

 

 

Segments

The Company operates in only one segment. Management uses cash flows as the primary measure to manage its business and does not segment its business for internal reporting or decision making purposes.

 

2.

Investments in Marketable Securities

The Company’s investment strategy is focused on capital preservation. The Company invests in instruments that meet the credit quality standards outlined in the Company’s investment policy. This policy also limits the amount of credit exposure to any one issue or type of instrument.  As of December 31, 2020 and 2019, the Company’s investments were in money market funds, commercial paper and corporate debt securities. There were no sales of available-for-sale securities during the years ended December 31, 2020 and 2019.

Investments classified as available-for-sale as of December 31, 2020 consisted of the following (in thousands):

 

 

 

Amortized

Cost

 

 

Gross

Unrealized

Gains  (1)

 

 

Gross

Unrealized

Losses  (1)

 

 

Aggregate

Estimated

Fair Value

 

Commercial paper  (2)

 

$

27,973

 

 

$

—

 

 

$

—

 

 

$

27,973

 

Corporate debt securities  (2)

 

 

191,350

 

 

 

94

 

 

 

(148

)

 

 

191,296

 

 

 

$

219,323

 

 

$

94

 

 

$

(148

)

 

$

219,269

 

 

(1)

Unrealized gains and losses on available-for-sale securities are included as a component of comprehensive loss. At December 31, 2020, there were 38 securities in an unrealized gain position and 80 securities in an unrealized loss position. The unrealized gains were less than $35,000 individually and $94,000 in the aggregate. The unrealized losses were less than $21,000 individually and $148,000 in the aggregate.  Four of these securities have been in a continuous unrealized loss or unrealized gain position for more than 12 months. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell these investments before recovery of their amortized cost basis, which may be at maturity. The Company reviews its investments to identify and evaluate investments that have an indication of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the investee, and the Company’s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.  

(2)

At December 31, 2020, none of these securities were classified as cash and cash equivalents on the Company’s balance sheet and $53.4 million of the corporate debt securities were scheduled to mature outside of one year at the time of purchase.

Investments classified as available-for-sale as of December 31, 2019 consisted of the following (in thousands):

 

 

 

Amortized

Cost

 

 

Gross

Unrealized

Gains  (1)

 

 

Gross

Unrealized

Losses  (1)

 

 

Aggregate

Estimated

Fair Value

 

Commercial paper  (2)

 

$

1,495

 

 

$

—

 

 

$

—

 

 

$

1,495

 

Corporate debt securities  (2)

 

 

265,754

 

 

 

190

 

 

 

(178

)

 

 

265,766

 

 

 

$

267,249

 

 

$

190

 

 

$

(178

)

 

$

267,261

 

 

(1)

Unrealized gains and losses on available-for-sale securities are included as a component of comprehensive loss. At December 31, 2019, there were 87 securities in an unrealized gain position and 66 securities in an unrealized loss position. These unrealized gains were less than $22,000 individually and $190,000 in the aggregate. The unrealized losses were less than $32,000 individually and $178,000 in the aggregate.  Nine of these securities have been in a continuous unrealized loss or unrealized gain position for more than 12 months. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell these investments before recovery of their amortized cost basis, which may be at maturity. The Company reviews its investments to identify and evaluate investments that have an indication of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the investee, and the Company’s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.

F-12

(2)

At December 31, 2019, none of these securities were classified as cash and cash equivalents on the Company’s balance sheet and $5.9 million of the corporate debt securities were scheduled to mature outside of one year at the time of purchase.

 

3.

Fair Value of Financial Instruments

The Company’s financial instruments consist of cash and cash equivalents, investments and accounts payable. The carrying amounts reported in the accompanying balance sheets for cash and cash equivalents and accounts payable approximate fair value because of the short-term maturity of those instruments. Fair value measurements are classified and disclosed in one of the following three categories:

Level 1 —Quoted prices in active markets for identical assets or liabilities.

Level 2 —Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 —Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

As of December 31, 2020 and 2019, all of the Company’s financial assets that were subject to fair value measurements were valued using observable inputs. The Company’s financial assets valued based on Level 1 inputs consist of money market funds and certificates of deposit. The Company’s financial assets valued based on Level 2 inputs consist of corporate debt securities, which consist of investments in highly-rated investment-grade corporations.

The Company’s investment strategy is focused on capital preservation. The Company invests in instruments that meet the credit quality standards outlined in the Company’s investment policy. This policy also limits the amount of credit exposure to any one issue or type of instrument. As of December 31, 2020, the Company’s investments were in government money market funds, commercial paper and corporate debt securities.

The fair values of the Company’s financial instruments are presented below (in thousands):

 

 

 

 

 

 

Fair Value Measurements at December 31, 2020

 

 

 

Total

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Financial assets carried at fair value:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Government money market funds

 

$

26,868

 

 

$

26,868

 

 

$

—

 

 

$

—

 

Short-term investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Commercial paper, available for sale

 

 

27,973

 

 

 

—

 

 

 

27,973

 

 

 

—

 

Corporate debt securities, available-for-sale

 

 

191,296

 

 

 

—

 

 

 

191,296

 

 

 

—

 

Total financial assets

 

$

246,137

 

 

$

26,868

 

 

$

219,269

 

 

$

—

 

 

 

 

 

 

 

 

Fair Value Measurements at December 31, 2019

 

 

 

Total

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Financial assets carried at fair value:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Government money market funds

 

$

3,671

 

 

$

3,671

 

 

$

—

 

 

$

—

 

Corporate debt securities, available-for-sale

 

 

3,498

 

 

 

—

 

 

 

3,498

 

 

 

—

 

Short-term investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Commercial paper, available for sale

 

 

1,495

 

 

 

—

 

 

 

1,495

 

 

 

—

 

Corporate debt securities, available-for-sale

 

 

265,766

 

 

 

—

 

 

 

265,766

 

 

 

—

 

Total financial assets

 

$

274,430

 

 

$

3,671

 

 

$

270,759

 

 

$

—

 

 

 

F-13

4.

Agreements with Ligand Pharmaceuticals Incorporated

In May 2014, the Company entered into a master license agreement with Ligand, as amended (the “Master License Agreement”), pursuant to which, among other things, the Company acquired the rights to a number of research and development programs under patents related to the Company’s VK2809, VK0214, VK5211, VK0612, erythropoietin receptor (“EPOR”) and diacylglycerol acyltransferase-1 (“DGAT-1”) programs, related know-how controlled by Ligand and physical quantities of VK2809, VK0214, VK5211, VK0612, EPOR and DGAT-1 compounds.

Pursuant to the terms of the Master License Agreement, the Company has the exclusive right and sole responsibility and decision-making authority for researching and developing any pharmaceutical products that contain or comprise one or any combination of the technology and compounds licensed from Ligand pursuant to the Master License Agreement (the “Licensed Products”). The Company also has the exclusive right and sole responsibility and decision-making authority to conduct all clinical trials and preclinical studies that the Company believes are appropriate to obtain the regulatory approvals necessary for commercialization of the Licensed Products, and the Company will own and maintain all regulatory filings and all regulatory approvals for the Licensed Products. Additionally, pursuant to the terms of the Master License Agreement, the Company has the sole decision-making authority and responsibility and the exclusive right to commercialize any of the Licensed Products, either by itself or, in certain circumstances, through sublicensees selected by the Company. The Company also has the exclusive right to manufacture or have manufactured any Licensed Product itself or, in certain circumstances, through sublicensees or third parties selected by the Company. The Company will own any intellectual property that it develops in connection with the license granted under the Master License Agreement.

As partial consideration for the grant of the rights and licenses to the Company under the Master License Agreement, the Company issued to Ligand at the closing of the Company’s initial public offering (“IPO”) 3,655,964 shares of its common stock having an estimated aggregate value of $29.2 million.

As further partial consideration for the grant of the rights and licenses to the Company by Ligand under the Master License Agreement, the Company has agreed to pay to Ligand certain one-time, non-refundable milestone payments in connection with the Licensed Products of up to $1.54 billion in the aggregate upon the achievement of certain development, regulatory and sales milestones. The Company will also pay to Ligand royalties on aggregate annual worldwide net sales of Licensed Products by the Company, its affiliates and its sublicensees at tiered percentage rates from the low-to-upper single digits based upon net sales.

The term of the Master License Agreement will continue unless the agreement is terminated by the Company or Ligand, and each of the Company and Ligand have the right to terminate the Master License Agreement in certain circumstances, including, without limitation, if the other party defaults on certain of its obligations under the Master License Agreement.

Ligand has the right to terminate the Master License Agreement under certain circumstances, including, but not limited to: (1) in the event of the Company’s insolvency or bankruptcy, (2) if the Company does not pay an undisputed amount owing under the Master License Agreement when due and fails to cure such default within a specified period of time, or (3) if the Company defaults on certain of its material and substantial obligations and fails to cure the default within a specified period of time. The Company has the right to terminate the Master License Agreement under certain circumstances, including, but not limited to: (i) if Ligand does not pay an undisputed amount owing under the Master License Agreement when due and fails to cure such default within a specified period of time, or (ii) if Ligand defaults on certain of its material and substantial obligations and fails to cure the default within a specified period of time. In addition, provisions of the Master License Agreement can be terminated on a licensed program-by-program basis under certain circumstances. In the event that the Master License Agreement is terminated in its entirety or with respect to a specific licensed program for any reason: (A) all licenses granted to the Company under the Master License Agreement (or with respect to the specific licensed program) will terminate and the Company will, upon Ligand’s request (subject to Ligand assuming legal responsibility for any clinical trials of the Licensed Products then ongoing), assign and transfer to Ligand (or to such transferee as Ligand may direct), at no cost to Ligand, all regulatory documentation and all regulatory approvals prepared or obtained by the Company or on its behalf related to the Licensed Products (or those related to the specific licensed program), or, if Ligand does not make such a request, the Company will wind down any ongoing clinical trials with respect to the Licensed Products (or those related to the specific licensed program) at no cost to Ligand; (B) the Company will, upon Ligand’s request, sell and transfer to Ligand (or to such transferee as Ligand may direct), at a price equal to 125% of the Company’s costs of goods, any and all chemical, biological or physical materials relating to or comprising the Licensed Products (or those related to the specific licensed program); (C) the Company will have, for a period of six months following termination, the right to sell on the normal business terms in existence before such termination any finished commercial inventory of Licensed Products (or those related to the specific licensed program) which remains on hand, so long as the Company pays to Ligand the applicable royalties and sales milestones; (D) Ligand has the right to require the Company to assign to Ligand the trademarks owned by the Company relating to the Licensed Products (or those related to the specific licensed program); and (E) the Company will grant to Ligand a non-exclusive, worldwide, royalty-bearing sublicensable license under any patent rights and know-how controlled by the Company to the extent necessary to make, have made, import, use, offer to sell and sell the Licensed Products (or those related to the specific licensed program) anywhere in the world at a royalty rate in the low single digits.

F-14

Under the Master License Agreement, the Company has agreed to indemnify Ligand for claims relating to the performance of the Company’s obligations under the Master License Agreement, any breach of the representations and warranties made by the Company under the Master License Agreement, clinical trials conducted by the Company and the research, development and commercialization of the Licensed Products by the Company and its affiliates, sublicensees, distributors and agents. In addition, Ligand has agreed to indemnify the Company for claims relating to the performance of its obligations under the Master License Agreement, its breach of representations and warranties under the agreement and its research and development of the licensed compounds before the effective date of the Master License Agreement. Each party’s indemnification obligations will not apply to the extent the claims result from the negligence or willful misconduct of the indemnified party or any of its employees, agents, officers or directors or from the indemnified party’s breach of its representations or warranties set forth in the Master License Agreement.

In May 2014, the Company also entered into a Management Rights Letter (the “Management Rights Letter”) with Ligand that requires the Company to expand the size of the Company’s board of directors to create an additional directorship on the Company’s board of directors and to allow Ligand to appoint an individual to fill the new directorship. The Management Rights Letter will terminate upon the earliest to occur of the liquidation or indefinite cessation of the Company’s business operations, the execution by the Company of a general assignment for the benefit of creditors or the appointment of a receiver or trustee to take possession of the Company’s property and assets, an acquisition of the Company by means of any transaction (including, without limitation, any reorganization, merger or consolidation) if the Company’s stockholders of record as constituted immediately prior to the transaction hold less than 50% of the voting power of the surviving or acquiring entity, or following the issuance of the Company’s securities pursuant to the Master License Agreement, the date that Ligand ceases to beneficially own at least 7.5% of the Company’s outstanding voting stock, or the date of May 21, 2024.  

 

 

5.Operating Leases – Right-of-Use Assets and Lease Liability Obligations

 

The Company has only one operating lease which is for office space that expires in January 2022. Below is a summary of the Company’s right-of-use assets and lease liabilities as of December 31, 2020 and 2019 (in thousands, except for years and %):

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31,

2020

 

 

 

December 31,

2019

 

 

Right of use assets

 

$

321

 

 

 

$

598

 

 

 

 

 

 

 

 

 

 

 

 

 

Lease liability obligations, current

 

$

330

 

 

 

$

302

 

 

Lease liability obligations, less current portion

 

 

29

 

 

 

 

360

 

 

Total lease liability obligations

 

$

359

 

 

 

$

662

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average remaining lease term

 

1.08  years

 

 

 

2.08  years

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average discount rate

 

 

6.00

 

%

 

 

6.00

 

%

 

During the years ended December 31, 2020 and 2019, the Company recognized $319,000 and $308,000, respectively, in operating lease expenses, which are included in operating expenses in the Company’s statement of operations.

 

 

Approximate future minimum lease payments for the Company’s right-of-use assets over the remaining lease period as of December 31, 2020 are as follows (in thousands):

 

 

 

 

 

2021

 

$

343

 

2022

 

 

29

 

Total minimum lease payments

 

$

372

 

Less: amount representing interest

 

$

(13

)

Total lease liability obligations

 

$

359

 

The operating lease provides the Company with an option to extend the term of the lease for a period of three years beyond the expiration date of January 2022. If the option is exercised, the renewal term will be upon the same terms and conditions as the original agreement, except that the base rent will be equal to the prevailing market rate as determined pursuant to the terms of the lease.  The option to extend the operating lease was not recognized as part of the Company’s lease liability and right-of-use assets.  

 

 

F-15

6.

Stockholders’ Equity

 

Preferred Stock

 

The Company is authorized to issue up to 10,000,000 shares of $0.00001 par value preferred stock, with no shares of preferred stock outstanding as of December 31, 2020 and 2019. The Board of Directors is authorized to designate the terms and conditions of any preferred stock the company issues without further action by the common stockholders.

 

Common Stock

The Company is authorized to issue up to 300,000,000 shares of common stock, $0.00001 par value per share.

In February 2014, the Company entered into a stock purchase agreement with one of its founders. The agreement provided for the purchase of 1,000,000 shares of the Company’s common stock at a price per share of $0.01 in exchange for future services to be rendered to the Company as measured by certain performance criteria. The shares were subject to a repurchase option and were to vest in two tranches of 500,000 shares each, upon achievement of the performance target or upon a triggering event as defined.

The Company determined that the fair value of the unrecognized expense was $168,000 at February 20, 2014, the grant date. In May 2015, the Company repurchased 633,810 of these shares at a purchase price of $0.00001 per share. In connection with the repurchase, the Company entered into an amendment to the stock purchase agreement to provide that the remaining 366,190 shares will continue to vest in two tranches of 183,095 shares each, upon achievement of the performance target or upon a triggering event as defined. The pro rata grant date fair value of the unrecognized expense is $62,000.  In October 2015, a triggering event became probable of occurrence and was deemed achieved in October 2016; therefore, the Company recorded $31,000 of stock-based compensation expense through December 31, 2016.  No similar expense was recognized during the years ended December 31, 2020 and 2019.  The Company will continue to reassess at each reporting period whether it is probable that the performance target will be achieved, and if and when it is deemed probable, the Company will begin to record compensation expense using the fair value to determine stock-based compensation expense in its financial statements over the period the Company estimates the performance target will actually be achieved.    

On February 8, 2017, the Company entered into a Stock Purchase Agreement (the “SPA”), with PoC Capital, LLC (“PoC”) pursuant to which, among other things, the Company issued to PoC 1,286,173 shares of its common stock.  Under the terms of the SPA, PoC has agreed to fund $1,800,000 in study costs associated with certain clinical studies.  Any study costs in excess of that amount will be the Company’s sole responsibility.  The Company has accounted for the $1,800,000 as a prepaid expense on the balance sheet, which was fully amortized as of December 31, 2020.  The Company recorded amortization expense of $140,000 in clinical study costs related to the SPA with PoC during the year ended December 31, 2019.  No similar expense was recognized during the year ended December 31, 2020.

 

On September 28, 2017, the Company entered into the Registered Offering Purchase Agreement, pursuant to which, on September 29, 2017, the Company sold to Lincoln Park Capital Fund, LLC (“LPC”), 701,282 shares of common stock, at a price of approximately $1.78 per share for an aggregate purchase price of $1.3 million, pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-212134), filed with the SEC on June 20, 2016, as amended by Amendment No. 1 thereto filed with the SEC on July 26, 2016, and declared effective on July 26, 2016, and the prospectus supplement thereto dated September 28, 2017.

 

On September 28, 2017, the Company also entered into the Commitment Purchase Agreement and the LPC Registration Rights Agreement with LPC, pursuant to which the Company has the right to sell to LPC up to $15,000,000 in shares of common stock, subject to certain limitations and conditions set forth in the Commitment Purchase Agreement. Upon the Commencement, the Company will have the right, from time to time at its sole discretion over the 30-month period from and after the Commencement, to direct LPC to purchase up to 75,000 shares of common stock on any business day (subject to certain limitations contained in the Commitment Purchase Agreement), with such amounts increasing based on certain threshold prices set forth in the Commitment Purchase Agreement; however, not to exceed $1.0 million in total purchase proceeds per purchase date. The purchase price of shares of common stock that the Company elects to sell to LPC pursuant to the Commitment Purchase Agreement will be based on the market prices of the common stock at the time of such purchases as set forth in the Commitment Purchase Agreement. In addition to regular purchases, as described above, the Company may also direct LPC to purchase additional amounts as accelerated purchases or as additional purchases if the closing sale price of the common stock is not below certain threshold prices, as set forth in the Commitment Purchase Agreement. In all instances, the Company may not sell shares of its common stock to LPC under the Commitment Purchase Agreement if it would result in LPC beneficially owning more than 4.99% of the Common Stock. As consideration for LPC’s commitment to purchase shares of common stock pursuant to the Commitment Purchase Agreement, the Company issued to LPC 100,000 shares of common stock.  From inception of the Commitment Purchase Agreement through December 31, 2017, 343,051 shares were issued pursuant to the Commitment Purchase Agreement resulting in aggregate gross proceeds of $802,000 in addition to the Initial Shares and the Commitment Shares. In May 2020, the Company extended the

F-16

termination date of the Commitment Purchase Agreement to May 1, 2023. No additional shares were issued for the period of January 1, 2018 through December 31, 2020.

On August 1, 2019, the Company entered into an At-The-Market Equity Offering Sales Agreement (the “ATM Agreement”) with Stifel, Nicolaus & Company, Incorporated and Oppenheimer & Co. Inc. (each, an “Agent” and, together, the “Agents”), pursuant to which the Company may offer and sell, from time to time, through or to the Agents, as sales agent or principal (the “ATM Offering”), shares of its common stock having an aggregate offering price of up to $75.0 million (the “Shares”).  Any Shares offered and sold in the ATM Offering will be issued pursuant to the 2018 Shelf Registration Statement and the 424(b) prospectus supplement relating to the ATM Offering dated August 1, 2019. No shares of the Company’s common stock were sold under the ATM Agreement from its inception through December 31, 2020.

On March 17, 2020, the Company’s Board of Directors authorized a stock repurchase program, whereby the Company may purchase up to $50.0 million in shares of its common stock and outstanding warrants to purchase its common stock, over a period of up to two years (the “Repurchase Program”). The Repurchase Program may be carried out at the discretion of a committee of the Company’s Board of Directors through open market purchases, one or more Rule 10b5-1 trading plans, block trades and in privately negotiated transactions. Through December 31, 2020, no shares of the Company’s common stock or warrants to purchase its common stock were repurchased by the Company under the Repurchase Program. Shares repurchased by the Company under the Repurchase Program, if any, are expected to be held in treasury until such time as they are reissued or retired by the Company.

During the years ended December 31, 2020 and 2019, and in accordance with the Company’s 2014 Employee Stock Purchase Plan (the “ESPP”), the Company issued an aggregate of 34,595 and 20,114 shares of its common stock to certain employees, respectively.

 

 

7.

Stock-Based Compensation

In connection with the IPO, the Company’s 2014 Equity Incentive Plan (the “2014 Plan”) and the ESPP became effective on April 28, 2015, the date of the execution and delivery of the underwriting agreement for the IPO. A total of 1,527,770 shares of the Company’s common stock were initially reserved for issuance under the 2014 Plan, and 458,331 shares of the Company’s common stock were initially reserved for issuance under the ESPP.  From January 1, 2016 and through December 31, 2020, in accordance with the terms of the 2014 Plan, an additional 7,366,810 shares of the Company’s common stock were added to the number of shares reserved for issuance under the 2014 Plan, respectively, and, in accordance with the terms of the ESPP, an additional 2,104,802 shares of the Company’s common stock were added to the number of shares reserved for issuance under the ESPP, respectively.

The Company generally uses the straight-line method to allocate compensation cost to reporting periods over each optionee’s requisite service period, which is generally the vesting period, and estimates the fair value of stock-based awards or restricted stock units to employees and directors using the Black-Scholes option-valuation model. The Black-Scholes model requires the input of subjective assumptions, including volatility, the expected term and the fair value of the underlying common stock on the date of grant, among other inputs. For restricted stock and restricted stock unit awards, the Company generally uses the straight-line method to allocate compensation cost to reporting periods over the holder’s requisite service period, which is generally the vesting period, and uses the fair value at grant date to value the awards. For restricted stock that vests upon the satisfaction of certain performance conditions, the Company recognizes stock-based compensation expense when it becomes probable that the performance conditions will be met. At the grant date, the Company determines the grant date fair value, as a publicly traded company, using the intrinsic value, or the closing price of its common stock on the date of grant. At the point where the criteria are deemed probable of being met, the Company records stock-based compensation with a cumulative catch-up expense in the period first recognized and then on a straight-line basis over the remaining period for which the performance criteria are expected to be completed.

For the ESPP, the Company generally recognizes compensation expense for the fair value of the purchase options, as measured on the grant date, and uses the graded vesting method to allocate this compensation cost to each purchase period within the related two-year offering period. As the ESPP also allows for up to one increase in contributions during each purchase period, then as an employee elects to increase their contributions, the Company treats this as an accounting modification. The pre- and post-modification values are calculated on the date of the modification, and the incremental expense is then amortized over the remaining purchase periods.

2014 Plan. The 2014 Plan provides that the compensation committee of the Company’s Board of Directors (the “Compensation Committee”) may grant or issue stock options, stock appreciation rights, restricted shares, restricted stock units and unrestricted shares, deferred share units, performance and cash-settled awards and dividend equivalent rights to participants under the 2014 Plan. Initially, a total of 1,527,770 shares of the Company’s common stock were reserved for issuance pursuant to the 2014 Plan. The number of shares available for issuance under the 2014 Plan will, unless otherwise determined by the Company’s Board of Directors or the Compensation Committee, be automatically increased on January 1st of each year commencing on January 1, 2016 and ending on (and including) January 1, 2024, in an amount equal to 3.5% of the total number of shares of the Company’s common stock outstanding on December 31st of the preceding calendar year. The shares of common stock deliverable pursuant to awards under the 2014 Plan are authorized but unissued shares of the Company’s common stock, or shares of the Company’s common stock that the Company otherwise holds in treasury or in trust. Any shares of the Company’s common stock underlying awards that are settled in

F-17

cash or otherwise expire, or are forfeited, terminated or cancelled (including pursuant to an exchange program established by the Compensation Committee) prior to the issuance of stock will again be available for issuance under the 2014 Plan. In addition, shares of the Company’s common stock that are withheld (or not issued) in payment of the exercise price or taxes relating to an award, and shares of the Company’s common stock equal to the number surrendered in payment of any exercise price or withholding taxes relating to an award, will again be available for issuance under the 2014 Plan.

ESPP. Initially, a total of 458,331 shares of the Company’s common stock were reserved for issuance pursuant to the ESPP. The number of shares available for issuance under the ESPP will, unless otherwise determined by the Company’s Board of Directors or the Compensation Committee, be automatically increased on January 1st of each year commencing on January 1, 2016 and ending on (and including) January 1, 2024, in an amount equal to 1% of the total number of shares of the Company’s common stock outstanding on December 31st of the preceding calendar year. The shares of common stock available for purchase pursuant to the ESPP are authorized but unissued shares of the Company’s common stock, shares of the Company’s common stock that the Company otherwise holds in treasury or shares of the Company’s common stock that were purchased on the open market in arms’ length transactions in accordance with applicable securities laws. Shares of the Company’s common stock will be offered for purchase under the ESPP as determined by the Compensation Committee through a series of successive offerings that each have a term of 24 months and consist of four consecutive purchase periods of six months each. Prior to the commencement of any future offering under the ESPP, the Compensation Committee may determine that the current offering shall end, may commence a new offering on the first day after the end of such terminal purchase period (or any desired later date), and may decide that future offerings will consist of one or more consecutive purchase periods, each to be of such duration as determined by the Compensation Committee; however, no offering will exceed 27 months and no purchase period will exceed one year. Each employee of the Company who (1) is an employee on the first date of any offering under the ESPP, (2) is customarily scheduled to work for more than 20 hours per week and more than five months per calendar year, and (3) meets such other criteria as may be determined by the Compensation Committee (consistent with Section 423 of the Internal Revenue Code of 1986, as amended), is eligible to participate in the ESPP for each purchase period within such offering. The purchase price per share of the Company’s common stock under the ESPP may not be less than, and will initially be equal to, the lesser of: (1) 85% of the fair market value per share of the Company’s common stock on the first day of the offering, or (2) 85% of the fair market value per share of the Company’s common stock on the date the purchase right is exercised, which will be the last day of the applicable purchase period.

During the years ended December 31, 2020 and 2019, the Company recognized the following stock-based compensation expense (in thousands):

 

 

Year Ended December 31,

 

 

 

2020

 

 

2019

 

Stock-based compensation expense by type of award:

 

 

 

 

 

 

 

 

Stock options

 

$

3,096

 

 

$

2,401

 

Restricted stock and restricted stock units

 

 

2,529

 

 

 

1,126

 

Employee stock purchase plan

 

 

193

 

 

 

216

 

Total stock-based compensation expense included

   in expenses

 

$

5,818

 

 

$

3,743

 

Stock-based compensation expense by line item:

 

 

 

 

 

 

 

 

Research and development expenses

 

$

1,359

 

 

$

953

 

General and administrative expenses

 

 

4,459

 

 

 

2,790

 

Total stock-based compensation expense included

   in expenses

 

$

5,818

 

 

$

3,743

 

 

 

The following table sets forth the Company’s unrecognized stock-based compensation expense, net of estimated forfeitures, by type of award and the weighted-average period over which that expense is expected to be recognized (in thousands, except for years):

 

 

 

As of December 31, 2020

 

 

 

Unrecognized

Expense

 

 

Weighted-

average

Recognition

Period

(in years)

 

 

 

 

 

 

 

 

 

 

Type of award:

 

 

 

 

 

 

 

 

Stock options

 

$

4,747

 

 

 

2.45

 

Restricted stock and restricted stock units

 

$

2,548

 

 

 

1.66

 

F-18

 

 

The following table is a summary of restricted shares granted during the years ended December 31, 2020 and 2019:

 

 

Shares

 

 

Weighted-

Average

Grant Date

Fair Value

 

Unvested at December 31, 2018

 

 

183,095

 

 

$

0.17

 

Granted

 

 

—

 

 

$

—

 

Vested

 

 

—

 

 

$

—

 

Forfeited

 

 

—

 

 

$

—

 

Repurchased

 

 

—

 

 

$

—

 

Unvested at December 31, 2019

 

 

183,095

 

 

$

0.17

 

Granted

 

 

—

 

 

$

—

 

Vested

 

 

—

 

 

$

—

 

Forfeited

 

 

—

 

 

$

—

 

Repurchased

 

 

—

 

 

$

—

 

Unvested at December 31, 2020

 

 

183,095

 

 

$

0.17

 

 

The following table summarizes restricted stock unit activity during the years ended December 31, 2020 and 2019:

 

 

Shares

 

 

Weighted-

Average

Grant Date

Value

 

Unvested at December 31, 2018

 

 

128,125

 

 

$

5.37

 

Granted

 

 

343,524

 

 

$

7.80

 

Vested

 

 

(58,122

)

 

$

5.40

 

Forfeited

 

 

(60,801

)

 

$

7.57

 

Unvested at December 31, 2019

 

 

352,726

 

 

$

7.35

 

Granted

 

 

493,996

 

 

$

7.77

 

Vested

 

 

(128,859

)

 

$

7.12

 

Forfeited

 

 

(38,500

)

 

$

8.16

 

Unvested December 31, 2020

 

 

679,363

 

 

$

7.65

 

 

In January 2019, the Company issued 221,600 performance based restricted stock units (“PRSU awards”) to several of its employees, which are reflected in the above summary of restricted stock unit activity.  The shares subject to the PRSU awards shall vest upon the Company achieving certain milestones, with 100% of the PRSU awards vesting upon the achievement of three of the milestones over a four-year period, with any then-unvested portion of the PRSU awards to be cancelled on the four-year anniversary of the grant dates.  As of December 31, 2020, 40,000 PRSU awards were forfeited and three of the milestones were deemed as probable of achievement, resulting in the Company recording stock-based compensation expense of $383,000 and $734,000 during the year ended December 31, 2020 and 2019, respectively.

 

In January 2020, the Company issued 244,000 PRSU awards to several of its employees, which are reflected in the above table summarizing restricted stock unit activity.  The shares subject to these PRSU awards shall vest upon the Company achieving certain milestones, with 100% of the PRSU awards vesting upon the achievement of three of the milestones over a four-year period, with any then-unvested portion of the PRSU awards to be cancelled on the four-year anniversary of the grant dates.  As of December 31, 2020, 10,500 PRSU awards were forfeited, and one of the three milestones has been met and the remaining two were deemed probable of achievement, resulting in the Company recording a stock-based compensation expense of $1.2 million during the year ended December 31, 2020.

F-19

 

 

The following table summarizes stock option activity during the years ended December 31, 2020 and 2019:

 

 

 

Shares

 

 

Weighted-

Average

Exercise

Price

 

 

Weighted-

Average

Remaining

Contractual

Term (in years)

 

 

Aggregate Intrinsic Value

 

Options outstanding at December 31, 2018

 

 

2,014,047

 

 

$

3.72

 

 

 

 

 

 

 

 

 

Granted

 

 

855,787

 

 

$

7.82

 

 

 

 

 

 

 

 

 

Exercised

 

 

(82,337

)

 

$

2.40

 

 

 

 

 

 

$

423,000

 

Cancelled

 

 

(207,021

)

 

$

6.51

 

 

 

 

 

 

 

 

 

Options outstanding at December 31, 2019

 

 

2,580,476

 

 

$

4.90

 

 

 

7.66

 

 

$

8,643,000

 

Granted

 

 

960,472

 

 

$

7.26

 

 

 

 

 

 

 

 

 

Exercised

 

 

(86,125

)

 

$

2.47

 

 

 

 

 

 

$

430,000

 

Cancelled

 

 

(83,500

)

 

$

7.35

 

 

 

 

 

 

 

 

 

Options outstanding at December 31, 2020

 

 

3,371,323

 

 

$

5.57

 

 

 

7.32

 

 

$

4,577,000

 

Options exercisable at December 31, 2020

 

 

1,787,377

 

 

$

4.58

 

 

 

6.35

 

 

$

3,821,000

 

 

The Company received $213,000 and $197,000 in cash proceeds from exercises of stock options during the years ended December 31, 2020 and 2019, respectively.  

 

The total fair value of stock options that vested during the years ended December 31, 2020 and 2019 was $2.6 million and $1.3 million, respectively.

 

Compensation expense for stock options granted to employees is based on the estimated grant date fair value and is recognized ratably over the vesting period of the applicable option. The estimated per share weighted average fair value of stock options granted to employees during the years ended December 31, 2020 and 2019 was $4.89 and $5.34, respectively.

 

As stock-based compensation expense recognized is based on options ultimately expected to vest, the fair value of each employee option grant during the years ended December 31, 2020 and 2019 was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions:

 

 

Year ended December 31,

 

 

 

2020

 

 

2019

 

Expected volatility

 

 

77.3

%

 

 

77.9

%

Expected term (in years)

 

 

6.09

 

 

 

6.01

 

Risk-free interest rate

 

 

1.39

%

 

 

2.26

%

Expected dividend yield

 

 

0

%

 

 

0

%

    

Expected Volatility. The expected volatility rate used to value stock option grants is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the pharmaceutical and biotechnology industry in a similar stage of development to the Company.

Expected Term. The Company elected to utilize the “simplified” method for “plain vanilla” options to value stock option grants. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option.

Risk-free Interest Rate. The risk-free interest rate assumption was based on zero-coupon U.S. Treasury instruments that had terms consistent with the expected term of the Company’s stock option grants.

Expected Dividend Yield. The Company has never declared or paid any cash dividends and does not presently plan to pay cash dividends in the foreseeable future.

Forfeitures are accounted for as actual forfeitures occur.   

F-20

Since the Company had a net operating loss carryforward as of December 31, 2020, no excess tax benefits for the tax deductions related to stock-based awards were recognized in the Statements of Operations.

Common Stock Reserved for Future Issuance

Common stock reserved for future issuance as of December 31, 2020 is as follows:

 

Common stock warrants

 

 

5,244,500

 

Restricted stock units

 

 

679,363

 

Common stock options

 

 

3,371,323

 

Available for grant under the 2014 Plan

 

 

4,081,253

 

Available for issuance under Employee Stock Purchase Plan

 

 

2,289,561

 

 

 

 

15,666,000

 

 

 

8.

Warrants

 

On April 13, 2016, pursuant to the Offering, the Company sold 7,500,000 shares of its common stock and warrants to purchase up to 7,500,000 shares of its common stock at a public offering price of $1.25 per share of common stock and related warrant. The warrants have an exercise price of $1.50 per share of common stock, were immediately exercisable upon issuance and will expire on April 13, 2021. Additionally, on April 13, 2016, the underwriters for the Offering partially exercised the over-allotment option for warrants to purchase an additional 1,125,000 shares of the Company’s common stock at a public offering price of $0.01 per warrant to purchase a share of common stock.  As of December 31, 2020, 3,647,413 warrants were outstanding and 348,493 and 528,695 warrants were exercised during the years ended December 31, 2020 and 2019, respectively.

On April 13, 2016, the Company issued to Ligand the Ligand Warrant to purchase up to 960,000 shares of the Company’s common stock. The Ligand Warrant has an exercise price of $1.50 per share of Company common stock, was immediately exercisable upon issuance (subject to a limitation on exercise to the extent that any exercise thereof would increase Ligand’s beneficial ownership of the Company’s common stock to greater than 49.9%) and expires on April 13, 2021.  The Ligand Warrant was issued to Ligand as a part of the repayment of $1,200,000 of the Company’s obligation under a Secured Convertible Promissory Note previously issued by the Company to Ligand.

 

On June 14, 2017, pursuant to the terms of the Securities Purchase Agreement, the Company sold the 3,749,783 Shares and the Warrants to purchase up to 2,812,337 shares of its common stock to the Purchasers.  The combined purchase price for one Share and one Warrant to purchase 0.75 shares of common stock in the Offerings, was $1.15. The closing of the Offerings occurred on June 19, 2017.  The Warrants have an exercise price of $1.30 per share, subject to adjustment as provided therein, and were exercisable beginning on December 19, 2017 through December 19, 2022.  Each holder of a Warrant does not have the right to exercise any portion of its Warrant if the holder, together with its affiliates, would beneficially own in excess of 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise (the “Beneficial Ownership Limitation”); provided, however, that upon 61 days’ prior notice to the Company, the holder may increase the Beneficial Ownership Limitation; however, in no event shall the Beneficial Ownership Limitation exceed 9.99%. The exercise price and number of shares of common stock issuable upon the exercise of the Warrants will be subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Warrants. On January 16, 2018, the resale Registration Statement on Form S-1 (File No. 333-222202) that the Company filed related to the 1,987,337 shares subject to unexercised warrants was declared effective by the SEC.  As of December 31, 2020, warrants to purchase an aggregate of 637,087 shares were outstanding and 248,308 and 0 warrants were exercised during the years ended December 31, 2020 and 2019, respectively.

 

 

9.

Income Taxes

Income tax expense (benefit) from continuing operations consists of the following for the years ended December 31, 2020 and 2019 (in thousands):

F-21

 

 

December 31,

 

 

 

2020

 

 

2019

 

Current:

 

 

 

 

 

 

 

 

Federal

 

$

—

 

 

$

—

 

State

 

 

—

 

 

 

—

 

 

 

$

—

 

 

$

—

 

Deferred:

 

 

 

 

 

 

 

 

Federal

 

$

(9,368

)

 

$

(5,976

)

State

 

 

(3,356

)

 

 

(1,857

)

 

 

$

(12,724

)

 

$

(7,833

)

 

 

 

 

 

 

 

 

 

Change in valuation allowance

 

 

12,724

 

 

 

7,833

 

Total income tax expense (benefit)

 

$

—

 

 

$

—

 

 

 

The reconciliations of the U.S. federal statutory tax rate to the effective income tax rate for the years ended December 31, 2020 and 2019 are as follows:

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Tax provision at U.S. Federal statutory rates

 

 

21

%

 

 

21

%

State income taxes net of federal benefit

 

 

7

%

 

 

6

%

Non-deductible permanent items

 

 

(1

)%

 

 

(1

)%

Stock options

 

 

—

 

 

 

(1

)%

Research and development credits

 

 

5

%

 

 

5

%

Change in valuation allowance

 

 

(32

)%

 

 

(30

)%

Effective income tax rate

 

 

—

 

 

 

—

 

 

Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred taxes as of December 31, 2020 and 2019 are as follows (in thousands):

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Deferred tax assets:

 

 

 

 

 

 

 

 

Accrued liabilities

 

$

180

 

 

$

248

 

Intangible assets

 

 

32,435

 

 

 

24,463

 

Net operating loss carryforwards

 

 

8,649

 

 

 

7,017

 

Share-based compensation

 

 

2,604

 

 

 

1,632

 

Credits

 

 

6,518

 

 

 

4,398

 

Other

 

 

20

 

 

 

5

 

Total deferred tax assets

 

 

50,406

 

 

 

37,763

 

Valuation Allowance

 

 

(50,316

)

 

 

(37,592

)

Total deferred tax assets, net of allowance

 

$

90

 

 

$

171

 

Deferred tax liabilities:

 

 

 

 

 

 

 

 

Right of use assets

 

$

(90

)

 

$

(167

)

Other

 

 

—

 

 

 

(4

)

Total deferred tax liabilities:

 

$

(90

)

 

$

(171

)

Net deferred tax assets (liabilities):

 

$

—

 

 

$

—

 

 

A valuation allowance of $50.3 million and $37.6 million at December 31, 2020 and December 31, 2019, respectively, has been recorded to offset net deferred tax assets, as the Company is unable to conclude that it is more likely than not that such deferred tax assets will be realized.

F-22

At December 31, 2020, the Company had approximately $31.0 million of federal net operating loss carryforwards, of which $17.8 million will begin to expire in 2032 and the remaining $13.2 million of which can be carried forward indefinitely.  The Company has $30.6 million of state net operating loss carryforwards that will begin to expire in 2034.  

The Company’s ability to utilize its federal net operating loss carryforwards may be limited under Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”). Specifically, this limitation may arise in the event of an “ownership change,” which is defined by Section 382 of the Code as a cumulative change in ownership of the Company of more than 50% within a three-year period. If the Company undergoes one or more ownership changes in connection with any future transactions in its stock, the Company’s ability to utilize net operating loss carryforwards to offset federal taxable income, if any, could potentially result in increased future tax liability to the Company.  An ownership change under Section 382 of the Code occurred during the year ended December 31, 2018. Of the Company’s $31.0 million and $30.6 million of federal and state net operating loss carryforwards, $18.3 million and $17.9 million are limited based on the Company’s ownership change.  The annual limitation is $5.7 million.

The Company is subject to U.S. federal income tax as well as income tax in various state jurisdictions.  The Company is currently open to audit under the statute of limitations by the Internal Revenue Service and various state agencies for the years ended December 31, 2016 through December 31, 2020.

The differences between the Company’s effective income tax rate and the statutory federal rate for the year ended December 31, 2020 and the year ended December 31, 2019 relate primarily to losses incurred for which no tax benefit was recognized, due to the uncertainty of realization. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. The Company considers projected future taxable income and tax planning strategies in making this assessment. At each of December 31, 2020 and December 31, 2019, the Company provided a full valuation allowance against its deferred tax assets due to uncertainty surrounding the realization of those assets as a result of historical taxable net losses.

At December 31, 2020, the Company has federal and state research and development tax credit carry-forwards of approximately $4.3 million and $2.3 million, respectively.  The federal credits begin to expire in 2036.  The state credits do not expire.

 

The Coronavirus Aid, Relief, and Economic Security (CARES) Act was enacted March 27, 2020.  Among the business provisions, the CARES Act provided for various payroll tax incentives, changes to net operating loss carryback and carryforward rules, business interest expense limitation increases, and bonus depreciation on qualified improvement property.  Additionally, the Consolidated Appropriations Act of 2021 was signed on December 27, 2020 which provided additional COVID relief provisions for businesses.  The Company has evaluated the impact of the both Acts and has determined that any impact is not material to its financial statements.

 

The Company has reviewed its operations and has not identified any material uncertain tax positions. As a result, there is no liability for uncertain tax positions in the income tax provision as of December 31, 2020 or December 31, 2019.

 

 

10.

Related-Party Transactions

In May 2014, the Company entered into the Master License Agreement with Ligand, pursuant to which, among other things, Ligand granted the Company an exclusive worldwide license to certain clinical and preclinical programs. See Note 4 for more information related to this agreement. In connection with entering into the Master License Agreement, the Company also entered into a Management Rights Letter (see Note 4) and a Registration Rights Agreement (see Note 4). As Ligand beneficially owns 9.8% of the Company’s outstanding shares as of December 31, 2020, and has a member of its management team on our Board of Directors, the Company considers Ligand to be a related party.

 

 

11.

Commitments and Contingencies

On May 25, 2018, the Company entered into an Office Lease (the “Lease”) with Kilroy Realty, L.P. The Lease is for approximately 7,149 rentable square feet of space located at 12340 El Camino Real, Suite 250, San Diego, California 92130 (the “Premises”). The Premises will continue to be the Company’s corporate headquarters.

The Lease commenced on November 1, 2018 and will expire on January 31, 2022, unless terminated earlier in accordance with the terms of the Lease (the “Term”). Monthly base rent payments due under the Lease for the Premises will be $27,000, subject to annual increases of 3.0% during the Term. Under the Lease, the Company is responsible for certain charges for common area maintenance and other costs, including electricity and utility expenses and the Lease provides for abatement of rent during certain periods and escalating rent payments throughout the Term. Rent expense is being recorded on a straight-line basis over the life of the Lease and the difference between the rent expense and rent paid is being recorded as deferred rent.

F-23

The Lease provides the Company with an option to extend the term of the lease for a period of three years beyond the Term. If the option is exercised, the renewal term will be upon the same terms and conditions as the original Term, except that the base rent will be equal to the prevailing market rate as determined pursuant to the terms of the Lease.

Rent expense was $319,000 and $308,000 for the years ended December 31, 2020 and 2019, respectively.

Future minimum payments pursuant to the Lease are as follows (in thousands):

Year Ending December 31:

 

 

 

 

2021

 

$

343

 

2022

 

 

29

 

Total minimum lease payments

 

$

372

 

 

 

12.

Subsequent Events

The Company evaluated subsequent events through the date of the filing of this Annual Report on Form 10-K with the SEC, to ensure that this filing includes appropriate disclosure of events both recognized in the financial statements as of December 31, 2020, and events which occurred subsequent to December 31, 2020 but were not recognized in the financial statements. The Company has determined that there were no subsequent events which required recognition, adjustment to or disclosure in the financial statements.  

 

 

 

 

F-24

 EX-4.5 2 vktx-ex45_8.htm EX-4.5 vktx-ex45_8.htm

Exhibit 4.5

Description of Securities of Viking Therapeutics, Inc.

The authorized capital stock of Viking Therapeutics, Inc., a Delaware corporation (the “Company”), consists of:

 

•

300,000,000 shares of common stock, $0.00001 par value (“Common Stock”); and

 

•

10,000,000 shares of preferred stock, $0.00001 par value (“Preferred Stock”).

Common Stock

 

•

Dividend rights. Subject to preferences that may apply to Preferred Stock outstanding at the time, the holders of Common Stock are entitled to receive dividends out of funds legally available if the Company’s Board of Directors (the “Board”), at its discretion, determines to issue dividends and then only at times and in the amounts that the Board may determine.

 

•

Voting rights. Holders of Common Stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) does not provide for cumulative voting for the election of directors, and establishes a classified Board that is divided into three classes with staggered three-year terms. Only the directors in one class will be subject to election at each annual meeting of the Company’s stockholders, with the directors in the other classes continuing for the remainder of their respective three-year terms.

 

•

No preemptive or similar rights. Holders of Common Stock are not entitled to preemptive rights, and the Common Stock is not subject to conversion, redemption or sinking fund provisions.

 

•

Right to receive liquidation damages. If the Company becomes subject to a liquidation, dissolution or winding-up, the assets legally available for distribution to its stockholders would be distributable ratably among the holders of Common Stock and any participating Preferred Stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights of and the payment of liquidation preferences, if any, on any outstanding shares of Preferred Stock.

 

•

Fully paid and non-assessable. All of the shares of Common Stock are fully paid and non-assessable.

Listing

The Common Stock is listed on the Nasdaq Capital Market under the symbol “VKTX.”

Preferred Stock

The Board is authorized, subject to limitations prescribed by Delaware law, to issue up to 10,000,000 shares of Preferred Stock in one or more series, to establish from time to time the number of shares to be included in each series, and to fix the designation, powers, preferences, and rights of the shares of each series and any of its qualifications, limitations or restrictions, in each case without further vote or action by the stockholders. The Board can also increase or decrease the number of shares of any series of Preferred Stock, but not below the number of

 

 

shares of that series then outstanding, without any further vote or action by the stockholders. The Board may authorize the issuance of Preferred Stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of Common Stock. The issuance of Preferred Stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of the Company and might adversely affect the market price of the Common Stock and the voting and other rights of the holders of Common Stock.

Warrants

As of December 31, 2020, the Company had outstanding warrants to purchase an aggregate of 5,244,500 shares of Common Stock, as follows:

 

•

warrants to purchase 3,647,413 shares with an exercise price of $1.50 per share, all of which are currently listed on the Nasdaq Capital Market under the symbol “VKTXW”, are currently exercisable (subject to certain beneficial ownership limitations) and expire on April 13, 2021;

 

•

a warrant to purchase 960,000 shares with an exercise price of $1.50 per share, which is currently exercisable (subject to certain beneficial ownership limitations) and expires on April 13, 2021; and

 

•

warrants to purchase 637,087 shares with an exercise price of $1.30 per share, all of which are currently exercisable (subject to certain beneficial ownership limitations) and expire on December 19, 2022.

Anti-Takeover Effects of Provisions of the Certificate of Incorporation, the Amended and Restated Bylaws and Delaware Law

Certain provisions of Delaware law, along with the Certificate of Incorporation and the Company’s amended and restated bylaws (the “Bylaws”), may have the effect of delaying, deferring or discouraging another person from acquiring control of the Company. These provisions are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed, in part, to encourage persons seeking to acquire control of the Company to first negotiate with the Board. However, these provisions could have the effect of delaying, discouraging or preventing attempts to acquire the Company, which could deprive the Company’s stockholders of opportunities to sell their shares of Common Stock at prices higher than prevailing market prices.

Delaware Law

The Company is subject to the provisions of Section 203 of the General Corporation Law of the State of Delaware (the “DGCL”), regulating corporate takeovers. In general, those provisions prohibit a public Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years following the date that the stockholder became an interested stockholder, unless:

 

•

the transaction is approved by the Board before the date the interested stockholder attained that status;

2

 

 

 

•

upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced; or

 

•

on or after the date of the transaction, the transaction is approved by the Board and authorized at a meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder.

In general, Section 203 of the DGCL defines a business combination to include the following:

 

•

any merger or consolidation involving the corporation and the interested stockholder;

 

•

any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;

 

•

subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;

 

•

any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; or

 

•

the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.

In general, Section 203 of the DGCL defines an interested stockholder as any entity or person beneficially owning, or who within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by any such entity or person.

A Delaware corporation may opt out of this provision by express provision in its original certificate of incorporation or by amendment to its certificate of incorporation or bylaws approved by its stockholders. However, the Company has not opted out of, and does not currently intend to opt out of, this provision. The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts to acquire the Company.

The Certificate of Incorporation and the Bylaws

The Certificate of Incorporation and the Bylaws include a number of provisions that could deter hostile takeovers or delay or prevent changes relating to the control of the Board or the Company’s management team, including the following:

 

•

Board Vacancies. The Certificate of Incorporation and the Bylaws authorize only the Board to fill vacant directorships, including newly created seats. In addition, the number of directors constituting the Board can be set only by a resolution adopted by a majority vote of the entire Board. These provisions would prevent a stockholder from increasing the size of the Board and then gaining control of the Board by filling the resulting vacancies with its own nominees. This makes it more difficult to change the composition of the Board and promotes continuity of management.

3

 

 

 

•

Classified Board. The Certificate of Incorporation and the Bylaws provide that the Board is classified into three classes of directors. A third party may be discouraged from making a tender offer or otherwise attempting to obtain control of the Company as it is more difficult and time consuming for stockholders to replace a majority of the directors on a classified Board.

 

•

Stockholder Action; Special Meeting of Stockholders. The Certificate of Incorporation provides that the Company’s stockholders may not take action by written consent, but may only take action at annual or special meetings of the stockholders. As a result, a holder controlling a majority of the Company’s capital stock would not be able to amend the Bylaws or remove directors without holding a meeting of the Company’s stockholders called in accordance with the Bylaws. The Bylaws further provide that special meetings of the Company’s stockholders may be called only by a majority of the Board, the Chairperson of the Board, the Chief Executive Officer or the President, thus prohibiting a stockholder (in the capacity as a stockholder) from calling a special meeting. These provisions might delay the ability of the Company’s stockholders to force consideration of a proposal or for stockholders controlling a majority of its capital stock to take any action, including the removal of directors.

 

•

Advance Notice Requirements for Stockholder Proposals and Director Nominations. The Bylaws provide advance notice procedures for stockholders seeking to bring business before the annual meeting of stockholders or to nominate candidates for election as directors at the annual meeting of stockholders. The Bylaws also specify certain requirements regarding the form and content of a stockholder’s notice. These provisions might preclude the Company’s stockholders from bringing matters before the annual meeting of stockholders or from making nominations for directors at the annual meeting of stockholders if the proper procedures are not followed. The Company expects that these provisions may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of the Company.

 

•

No Cumulative Voting. The DGCL provides that stockholders may cumulate votes in the election of directors if the corporation’s certificate of incorporation allows for such mechanism. The Certificate of Incorporation does not provide for cumulative voting.

 

•

Directors Removed Only for Cause. The Certificate of Incorporation provides that stockholders may remove directors only for cause.

 

•

Choice of Forum. The Bylaws provide that, unless the Company consents in writing to the selection of an alternative forum, the Court of Chancery in the State of Delaware (the “Court of Chancery”) shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (a) any derivative action or proceeding on behalf of the Company, (b) any action against asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of the Company to the Company or the Company’s stockholders, (c) any action asserting a claim against the Company, its directors, officers or employees arising pursuant to the Bylaws, the Certificate of Incorporation or the DGCL, (d) any action asserting a claim against the Company or its directors, officers or employees governed by the internal affairs doctrine, or (e) any action to interpret, apply, enforce or determine the validity of the Bylaws or the Certificate of Incorporation, except for, as to each of clauses (a) through (e), any claim (i) as to which the Court of Chancery determines that there is an indispensable party not

4

 

 

 

subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within 10 days following such determination), or (ii) for which the Court of Chancery does not have subject matter jurisdiction. This exclusive forum provision is not intended to apply to any actions brought under the Securities Act of 1933, as amended (the “Securities Act”), or the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. As a result, the exclusive forum provision will not apply to suits brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. However, the Bylaws do not relieve the Company of its duty to comply with federal securities laws and the rules and regulations thereunder, and the Company’s stockholders will not be deemed to have waived the Company’s compliance with these laws, rules and regulations. This exclusive forum provision in the Bylaws may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with the Company or its directors, officers or other employees, which may discourage such lawsuits against the Company and its directors, officers and other employees. In addition, stockholders who do bring a claim in the Court of Chancery in the State of Delaware could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near Delaware. Furthermore, the enforceability of similar choice of forum provisions in other companies’ governing documents has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable.

 

•

Amendment of Charter Provisions. Any amendment of the above provisions in the Certificate of Incorporation, with the exception of the ability of the Board to issue shares of Preferred Stock and designate any rights, preferences and privileges thereto, would require approval by the affirmative vote of the holders of at least 66 2/3% of the then outstanding Common Stock.

 

•

Issuance of Undesignated Preferred Stock. The Board has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of undesignated Preferred Stock with rights and preferences, including voting rights, designated from time to time by the Board. The existence of authorized but unissued shares of Preferred Stock would enable the Board to render more difficult or to discourage an attempt to obtain control of the Company by means of a merger, tender offer, proxy contest or other means.

5

 

 EX-23.1 3 vktx-ex231_6.htm EX-23.1 vktx-ex231_6.htm

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

 

 

We consent to the incorporation by reference in the Registration Statements of Viking Therapeutics, Inc. on Form S-8 (File Nos. 333-203810, 333-211270, 333-216857, 333-223503, 333-230247 and 333-236666), on Form S-3 (File Nos. 333-216063 and 333-226133) and on Form S-1 (File Nos. 333-220992 and 333-222202) of our report dated February 17, 2021 with respect to our audits of the financial statements of Viking Therapeutics, Inc. as of December 31, 2020 and 2019 and for the years then ended, which report is included in this Annual Report on Form 10-K of Viking Therapeutics, Inc. for the year ended December 31, 2020.

 

Our report on the financial statements refers to a change in the method of accounting for leases effective January 1, 2019.

/s/ Marcum LLP

Marcum LLP

Costa Mesa, California

February 17, 2021

 EX-31.1 4 vktx-ex311_7.htm EX-31.1 vktx-ex311_7.htm

Exhibit 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Brian Lian, Ph.D., certify that:

 

1.

I have reviewed this Annual Report on Form 10-K of Viking Therapeutics, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d.

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date:  February 17, 2021

 

By:

/s/ Brian Lian, Ph.D.

 

 

 

Brian Lian, Ph.D.

 

 

 

Chief Executive Officer

 

 EX-31.2 5 vktx-ex312_9.htm EX-31.2 vktx-ex312_9.htm

Exhibit 31.2

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Greg Zante, certify that:

 

1.

I have reviewed this Annual Report on Form 10-K of Viking Therapeutics, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d.

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date:  February 17, 2021

 

By:

/s/ Greg Zante

 

 

 

Greg Zante

 

 

 

Chief Financial Officer

 

 EX-32.1 6 vktx-ex321_10.htm EX-32.1 vktx-ex321_10.htm

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Viking Therapeutics, Inc. (the “Company”) for the period ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to their knowledge that:

 

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

By:

/s/ Brian Lian, Ph.D.

 

By:

/s/ Greg Zante

 

Brian Lian, Ph.D.

 

 

Greg Zante

 

Chief Executive Officer

 

 

Chief Financial Officer

 

February 17, 2021

 

 

February 17, 2021

 

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

This certification accompanies the Report, is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.

 

 GRAPHIC 7 gw5rupjpmffd000001.jpg GRAPHIC begin 644 gw5rupjpmffd000001.jpg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end EX-101.SCH 8 vktx-20201231.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Statements of Operations and Comprehensive Loss link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Statements of Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Investments in Marketable Securities link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Fair Value of Financial Instruments link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Agreements with Ligand Pharmaceuticals Incorporated link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Operating Leases - Right-of-Use Assets and Lease Liability Obligations link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Warrants link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Investments in Marketable Securities (Tables) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Fair Value of Financial Instruments (Tables) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Operating Leases - Right-of-Use Assets and Lease Liability Obligations (Tables) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Stock-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Income Taxes (Tables) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Commitments and Contingencies (Tables) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies - Schedule of Computation of Basic and Diluted Net Loss per Common Share (Detail) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Investments in Marketable Securities - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Investments in Marketable Securities - Summary of Investments Classified As Available-For-Sale Securities (Detail) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Investments in Marketable Securities - Summary of Investments Classified As Available-For-Sale Securities (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Fair Value of Financial Instruments - Summary of Fair Values of Financial Instruments (Detail) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Agreements with Ligand Pharmaceuticals Incorporated - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Operating Leases - Right-of-Use Assets and Lease Liability Obligations - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Operating Leases - Right-of-Use Assets and Lease Liability Obligations - Schedule of Right-of-use Assets and Lease Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Operating Leases - Right-of-Use Assets and Lease Liability Obligations - Schedule of Future Minimum Lease Payments (Detail) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Operating Leases - Right-of-Use Assets and Lease Liability Obligations - Schedule of Future Minimum Lease Payments (Detail)2 link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expense Recognized (Detail) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Stock-Based Compensation - Schedule of Unrecognized Stock-based Compensation Expense, Net of Estimated Forfeitures, by Type of Award and Weighted-average Recognition Period (Detail) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Stock-Based Compensation - Schedule of Weighted Average Assumptions using Black-Scholes Option Pricing Model (Detail) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Stock-Based Compensation - Common Stock Reserved for Future Issuance (Detail) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Warrants - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Income Taxes - Schedule of Income Tax Expense (Benefit) from Continuing Operations (Detail) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Income Taxes - Schedule of Reconciliations of the U.S. Federal Statutory Tax Rate to the Effective Income Tax Rate (Detail) link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Income Taxes - Schedule of Significant Components of Company's Deferred Taxes (Detail) link:calculationLink link:presentationLink link:definitionLink 100510 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100520 - Disclosure - Related Party Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100530 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100540 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Payments for Lease (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 9 vktx-20201231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 vktx-20201231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 vktx-20201231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Information [Table] Document Information [Table] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common stock [Member] Common Stock [Member] Common stock warrants [Member] Warrant [Member] Document Information [Line Items] Document Information [Line Items] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Well-known Seasoned Issuer Entity Well Known Seasoned Issuer Entity Current Reporting Status Entity Current Reporting Status Entity Voluntary Filers Entity Voluntary Filers Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Entity Public Float Entity Public Float Entity Interactive Data Current Entity Interactive Data Current Title of 12(b) Security Security12b Title Security Exchange Name Security Exchange Name Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Document Annual Report Document Annual Report Document Transition Report Document Transition Report ICFR Auditor Attestation Flag Icfr Auditor Attestation Flag Documents Incorporated by Reference [Text Block] Documents Incorporated By Reference [Text Block] Prepaid clinical trial and preclinical study costs. Deferred public offering and other financing costs noncurrent. Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Short-term investments – available for sale Available For Sale Securities Current Prepaid clinical trial and preclinical study costs Prepaid Clinical Trial And Preclinical Study Costs Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Right-of-use assets Operating Lease Right Of Use Asset Deferred public offering and other financing costs Deferred Public Offering And Other Financing Costs Noncurrent Deposits Deposits Assets Noncurrent Total assets Assets Liabilities and stockholders’ equity Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Other accrued liabilities Other Accrued Liabilities Current Lease liability, current Operating Lease Liability Current Total current liabilities Liabilities Current Lease liability, net of current portion Operating Lease Liability Noncurrent Total long-term liabilities Liabilities Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 11) Commitments And Contingencies Stockholders’ equity: Stockholders Equity [Abstract] Preferred stock, $0.00001 par value: 10,000,000 shares authorized at December 31, 2020 and 2019; no shares issued and outstanding at December 31, 2020 and 2019 Preferred Stock Value Common stock, $0.00001 par value: 300,000,000 shares authorized at December 31, 2020 and 2019; 73,215,940 shares issued and outstanding at December 31, 2020 and 72,413,602 shares issued and outstanding at December 31, 2019 Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated deficit Retained Earnings Accumulated Deficit Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax Total stockholders’ equity Stockholders Equity Total liabilities and stockholders’ equity Liabilities And Stockholders Equity Preferred stock, par value Preferred Stock Par Or Stated Value Per Share Preferred stock, shares authorized Preferred Stock Shares Authorized Preferred stock, shares issued Preferred Stock Shares Issued Preferred stock, shares outstanding Preferred Stock Shares Outstanding Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Amortization of financing costs equity transactions. Income Statement [Abstract] Revenues Revenue From Contract With Customer Excluding Assessed Tax Operating expenses: Operating Expenses [Abstract] Research and development Research And Development Expense General and administrative General And Administrative Expense Total operating expenses Operating Expenses Loss from operations Operating Income Loss Other income (expense): Other Nonoperating Income Expense [Abstract] Amortization of financing costs Amortization Of Financing Costs Equity Transactions Interest income, net Interest Income Expense Nonoperating Net Realized gain on investments Debt Securities Available For Sale Realized Gain Loss Total other income, net Other Nonoperating Income Expense Net loss Net Income Loss Other comprehensive gain (loss), net of tax: Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract] Unrealized gain (loss) on securities Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Comprehensive loss Comprehensive Income Net Of Tax Basic and diluted net loss per share Earnings Per Share Basic And Diluted Weighted-average shares used to compute basic and diluted net loss per share Weighted Average Number Of Share Outstanding Basic And Diluted Stock issued repurchased during period shares employee share based compensation. Stock issued during period shares warrant exercises. Stock issued during period value warrant exercises. Statement Of Stockholders Equity [Abstract] Statement [Table] Statement [Table] Additional Paid-In Capital [Member] Additional Paid In Capital [Member] Accumulated Deficit [Member] Retained Earnings [Member] Accumulated Other Comprehensive Income (Loss) [Member] Accumulated Other Comprehensive Income [Member] Statement [Line Items] Statement [Line Items] Balance Stockholders Equity Including Portion Attributable To Noncontrolling Interest Balance (in shares) Shares Issued Employee stock-based compensation, net Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition Employee stock-based compensation, net (in shares) Stock Issued Repurchased During Period Shares Employee Share Based Compensation Issuance of common stock under employee stock plans Stock Issued During Period Value Share Based Compensation Gross Issuance of common stock under employee stock plans (in shares) Stock Issued During Period Shares Share Based Compensation Gross Issuance of common stock from warrant exercises Stock Issued During Period Value Warrant Exercises Issuance of common stock from warrant exercises (in shares) Stock Issued During Period Shares Warrant Exercises Unrealized gain (loss) on investments Net loss Balance Balance (in shares) Amortization of non cash clinical trial costs. Operating lease right of use asset amortization. Operating leases interest expense. Realized Gain Loss on Investmens. Change in accrued interest relating to marketable securities held as investments. Increase decrease in operating lease liability. Proceeds from stock issuance under employee stock purchase plan and warrant exercises. Unpaid deferred initial public offering and financing costs. Receivable from exercise of warrants. Statement Of Cash Flows [Abstract] Cash flows from operating activities Net Cash Provided By Used In Operating Activities [Abstract] Net loss Profit Loss Adjustments to reconcile net loss to net cash used in operating activities Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Amortization of investment premiums Investment Income Amortization Of Premium Amortization of financing costs Amortization of non-cash clinical trial costs Amortization Of Non Cash Clinical Trial Costs Stock-based compensation Share Based Compensation Amortization of right-of-use assets Operating Lease Right Of Use Asset Amortization Interest expense related to operating lease liability Operating Leases Interest Expense Realized gain on investments Realized Gain Loss On Investmens Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Prepaid expenses and other current assets Increase Decrease In Prepaid Deferred Expense And Other Assets Accrued interest, net of interest received on maturity of investments Change In Accrued Interest Relating To Marketable Securities Held As Investments Accounts payable Increase Decrease In Accounts Payable Accrued expenses Increase Decrease In Accrued Liabilities Lease liability Increase Decrease In Operating Lease Liability Net cash used in operating activities Net Cash Provided By Used In Operating Activities Cash flows from investing activities Net Cash Provided By Used In Investing Activities [Abstract] Purchases of investments Payments To Acquire Investments Proceeds from sales and maturities of investments Proceeds From Sale Maturity And Collections Of Investments Net cash provided by investing activities Net Cash Provided By Used In Investing Activities Cash flows from financing activities Net Cash Provided By Used In Financing Activities [Abstract] Public offering and financing costs Payments Of Stock Issuance Costs Value of shares withheld related to employee tax withholding Payments Related To Tax Withholding For Share Based Compensation Proceeds from stock issuance under employee stock purchase plan and warrant exercises Proceeds From Stock Issuance Under Employee Stock Purchase Plan And Warrant Exercises Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Net increase (decrease) in cash and cash equivalents Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Cash and cash equivalents beginning of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Cash and cash equivalents end of period Supplemental disclosure of non-cash investing and financing transactions Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Unpaid deferred public offering and other financing costs Unpaid Deferred Initial Public Offering And Other Financing Costs Receivable from exercise of warrants Receivable From Exercise Of Warrants Organization Consolidation And Presentation Of Financial Statements [Abstract] Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block] Investments Debt And Equity Securities [Abstract] Investments in Marketable Securities Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Agreements with Ligand Pharmaceuticals Incorporated Collaborative Arrangement Disclosure [Text Block] Leases [Abstract] Operating Leases - Right-of-Use Assets and Lease Liability Obligations Leases Of Lessee Disclosure [Text Block] Equity [Abstract] Stockholders' Equity Stockholders Equity Note Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Stock-Based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Warrant. Warrants And Rights Note Disclosure [Abstract] Warrants Warrant Disclosure [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Related Party Transactions [Abstract] Related Party Transactions Related Party Transactions Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Business description. The Company Business Description Policy [Text Block] Basis of Presentation Basis Of Accounting Policy Policy [Text Block] Risks and uncertainties. Risks And Uncertainties Risks And Uncertainties Policy [Text Block] Use of Estimates Use Of Estimates Reclassifications Reclassifications Cash and Cash Equivalents Cash And Cash Equivalents Policy [Text Block] Investments Available-for-Sale Marketable Securities Policy Concentration of Credit Risk Concentration Risk Credit Risk Prepaid Clinical Trial and Preclinical Study Costs Health Care Costs Policy Policy [Text Block] Leases Lessee Leases Policy [Text Block] Deferred Financing Costs Deferred Charges Policy [Text Block] Revenue Recognition Revenue From Contract With Customer Policy [Text Block] Research and Development Expenses Research And Development Expense Policy Patent costs policy. Patent Costs Patent Costs Policy [Text Block] Stock-Based Compensation Share Based Compensation Option And Incentive Plans Policy Income Taxes Income Tax Policy [Text Block] Net Loss per Common Share Earnings Per Share Policy [Text Block] Segments Segment Reporting Policy Policy [Text Block] Schedule of Computation of Basic and Diluted Net Loss per Common Share Schedule Of Earnings Per Share Basic And Diluted Table [Text Block] Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Summary of Investments Classified As Available-For-Sale Securities Debt Securities Available For Sale Table [Text Block] Summary of Fair Values of Financial Instruments Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block] Schedule of Right-of-use Assets and Lease Liabilities Lease Cost Table [Text Block] Schedule of Future Minimum Lease Payments Lessee Operating Lease Liability Maturity Table [Text Block] Award Type Award Type [Axis] Award Type Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Restricted stock [Member] Restricted Stock [Member] Restricted stock units [Member] Restricted Stock Units R S U [Member] Summary of Stock-based Compensation Expense Recognized Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Schedule of Unrecognized Stock-based Compensation Expense, Net of Estimated Forfeitures, by Type of Award and Weighted-average Recognition Period Schedule Of Unrecognized Compensation Cost Nonvested Awards Table [Text Block] Summary of Shares Granted and Stock Activity Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block] Summary of Stock Option Activity Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Schedule of Weighted Average Assumptions using Black-Scholes Option Pricing Model Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block] Common stock reserved for issuance. Common Stock Reserved For Future Issuance Common Stock Reserved For Future Issuance Table [Text Block] Schedule of Income Tax Expense (Benefit) from Continuing Operations Schedule Of Components Of Income Tax Expense Benefit Table [Text Block] Schedule of Reconciliations of the U.S. Federal Statutory Tax Rate to the Effective Income Tax Rate Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block] Schedule of Significant Components of Company's Deferred Taxes Schedule Of Deferred Tax Assets And Liabilities Table [Text Block] Summary of Future Minimum Payments for Lease Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block] Accounting Policies [Abstract] Date of incorporation Entity Incorporation Date Of Incorporation Highly liquid investments maturities Additional Cash And Cash Equivalent Related Text Numerator Net Income Loss [Abstract] Denominator Weighted Average Number Of Shares Outstanding [Abstract] Weighted-average common shares outstanding Weighted Average Number Of Shares Issued Basic Less: Weighted-average shares subject to repurchase Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation Denominator for basic and diluted net loss per share Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Securities Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities, Name Antidilutive Securities Name [Domain] Common stock subject to repurchase. Common stock subject to repurchase [Member] Common Stock Subject To Repurchase [Member] Common stock options [Member] Employee Stock Option [Member] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive securities excluded in calculation of diluted net loss per share Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Number of operating segment Number Of Operating Segments Available For Sale Securities [Abstract] Proceeds from sales of available-for-sale securities Proceeds From Sale Of Available For Sale Securities Debt Schedule Of Available For Sale Securities [Table] Schedule Of Available For Sale Securities [Table] Investment Type Investment Type [Axis] Investments Investment Type Categorization [Member] Commercial paper [Member] Commercial Paper [Member] Corporate debt securities [Member] Corporate Debt Securities [Member] Certificates of deposit [Member] Certificates Of Deposit [Member] Schedule of Available-for-sale Securities [Line Items] Schedule Of Available For Sale Securities [Line Items] Amortized Cost Available For Sale Debt Securities Amortized Cost Basis Gross Unrealized Gains Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Gross Unrealized Losses Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Aggregate Estimated Fair Value Available For Sale Securities Debt Securities Current Available for sale securities in unrealized gain positions qualitative disclosure number of positions greater than or equal to one year Debt securities available for sale unrealized gain position accumulated gain. Statistical Measurement Range [Axis] Statistical Measurement Range [Member] Maximum [Member] Maximum [Member] Minimum [Member] Minimum [Member] Cash and Cash Equivalents Cash And Cash Equivalents [Axis] Cash and Cash Equivalents Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member] Cash equivalents [Member] Cash Equivalents [Member] Number of securities in unrealized loss position Debt Securities Available For Sale Unrealized Loss Position Number Of Positions Unrealized losses, individually Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss Unrealized losses, aggregate Number of securities in unrealized gain position Available For Sale Securities In Unrealized Gain Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year Unrealized gains, individually Debt Securities Available For Sale Unrealized Gain Position Accumulated Gain Unrealized gains, aggregate Short-term investments - available for sale Short-term investments classified as available-for-sale, noncurrent Available For Sale Securities Debt Securities Noncurrent Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Abstract] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Level 2 [Member] Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy and NAV Fair Value Measurements Fair Value Hierarchy [Domain] Level 1 [Member] Fair Value Inputs Level1 [Member] Level 2 [Member] Fair Value Inputs Level2 [Member] Level 3 [Member] Fair Value Inputs Level3 [Member] Asset Class Fair Value By Asset Class [Axis] Asset Class Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain] Government money market funds [Member] Money Market Funds [Member] Corporate debt securities, available-for-sale [Member] Commercial paper, available-for-sale [Member] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Financial assets carried at fair value: Assets Fair Value Disclosure [Abstract] Cash equivalents, fair value disclosure Cash And Cash Equivalents Fair Value Disclosure Short-term investments, available for sale Available For Sale Securities Debt Securities Total financial assets Assets Fair Value Disclosure License agreement entered date. Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] IPO [Member] I P O [Member] Legal Entity Legal Entity [Axis] Entity Entity [Domain] Ligand Pharmaceuticals Incorporated. Ligand [Member] Ligand Pharmaceuticals Incorporated [Member] Collaborative Arrangement and Arrangement Other than Collaborative Type Of Arrangement [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Arrangements And Nonarrangement Transactions [Member] Management rights letter. Management Rights Letter [Member] Management Rights Letter [Member] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] License agreement entered date License Agreement Entered Date Common stock issued as part of partial consideration of agreement Stock Issued During Period Shares New Issues Common stock issued value as part of partial consideration of agreement Stock Issued During Period Value New Issues One time nonrefundable mile stone payments maximum payable amount. One time nonrefundable mile stone payments maximum payable amount One Time Nonrefundable Mile Stone Payments Maximum Payable Amount Legal costs. Sale and transfer of price equals to percentage of cost of goods. Legal costs Legal Costs Sale and transfer of price equals to percentage of cost of goods Sale And Transfer Of Price Equals To Percentage Of Cost Of Goods Agreement termination date. Voting power of the surviving or acquiring entity Business Acquisition Percentage Of Voting Interests Acquired Percentage of voting interest beneficiary owned Business Combination Step Acquisition Equity Interest In Acquiree Percentage Date agreement might terminate Agreement Termination Date Operating lease number of leases. Opeating lease expiration period. Operating lease number of leases Operating Lease Number Of Leases Lease expiration date Opeating Lease Expiration Period Lessee Disclosure [Abstract] Total lease liability obligations Operating Lease Liability Weighted-average remaining lease term Operating Lease Weighted Average Remaining Lease Term1 Weighted-average discount rate Operating Lease Weighted Average Discount Rate Percent Operating lease expense Operating Lease Expense 2021 Lessee Operating Lease Liability Payments Due Next Twelve Months 2022 Lessee Operating Lease Liability Payments Due Year Two Total minimum lease payments Lessee Operating Lease Liability Payments Due Less: amount representing interest Lessee Operating Lease Liability Undiscounted Excess Amount Total lease liability obligations Operating lease option to extend term. Operating lease, option to extend Lessee Operating Lease Existence Of Option To Extend Operating lease option to extend term Operating Lease Option To Extend Term operating lease, option to extend, description Lessee Operating Lease Option To Extend Equity. Equity. Equity [Table] Equity [Table] Vesting Vesting [Axis] Vesting Vesting [Domain] Tranche One [Member] Share Based Compensation Award Tranche One [Member] Tranche Two [Member] Share Based Compensation Award Tranche Two [Member] PoC Capital, LLC. PoC Capital, LLC [Member] Po C Capital L L C [Member] Stock purchase agreement. Stock Purchase Agreement [Member] Stock Purchase Agreement [Member] Related Party Related Party Transactions By Related Party [Axis] Related Party Related Party [Domain] Clinical studies. Clinical Studies [Member] Clinical Studies [Member] Lincoln Park Capital Fund, LLC. LPC [Member] Linco In Park Capital Fund Limited Liability Company [Member] Registered offering purchase agreement. Registered Offering Purchase Agreement [Member] Registered Offering Purchase Agreement [Member] Commitment purchase agreement. Commitment Purchase Agreement [Member] Commitment Purchase Agreement [Member] Financial Instrument Financial Instrument [Axis] Financial Instruments Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain] Registration rights agreement. Registration Rights Agreement [Member] Registration Rights Agreement [Member] At the market equity offering sales agreement. ATM Agreement [Member] At The Market Equity Offering Sales Agreement [Member] Repurchase program. Repurchase Program [Member] Repurchase Program [Member] Equity [Line Items] Equity [Line Items] Number of tranches. Number of common stock for issuance in exchange for future services from founders Deferred Compensation Arrangement With Individual Common Stock Reserved For Future Issuance Common stock price per share Deferred Compensation Arrangement With Individual Exercise Price Number of tranches Number Of Tranches Shares repurchase price per share. Unrecognized compensation expense Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Common stock shares repurchased Stock Repurchase Program Number Of Shares Authorized To Be Repurchased Repurchase of common stock from stockholders, per share Shares Repurchase Price Per Share Remaining number of repurchased shares Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased Stock compensation expense Allocated Share Based Compensation Expense Capitalized clinical study costs paid via shares issuance. Amortization of clinical study costs prepaid via share issuance. Common stock sold Prepaid clinical study costs Capitalized Clinical Study Costs Paid Via Shares Issuance Common stock sold aggregate purchase price Amortization expense Amortization Of Clinical Study Costs Prepaid Via Share Issuance Registration statement commencement date. Common stock, price per share Shares Issued Price Per Share Registration statement commencement date Registration Statement Commencement Date Stock issued during period value partial new issues and reserved for future issuance. Stock purchase agreement term. Sale of common stock, shares, subject to certain limitations. Potential proceeds from sale of common stock, per purchase date, subject to certain limitations. Percentage of shares may not sell beneficial ownership. Stock issued during period shares issued as consideration for commitment. Proceeds from issuance of common stock gross. Total of purchase agreement and potential aggregate future purchases Stock Issued During Period Value Partial New Issues And Reserved For Future Issuance Common stock purchase agreement term Stock Purchase Agreement Term Common stock to be sold, subject to certain limitations Sale Of Common Stock Shares Subject To Certain Limitations Total purchase proceeds per purchase date, subject to certain limitations Potential Proceeds From Sale Of Common Stock Per Purchase Date Subject To Certain Limitations Percentage of shares may not sell if it is beneficial owning Percentage Of Shares May Not Sell Beneficial Ownership Common stock issued as consideration for commitment Stock Issued During Period Shares Issued As Consideration For Commitment Gross proceeds from common stock issuance Proceeds From Issuance Of Common Stock Gross Aggregate offering price. Aggregate offering price, common stock Aggregate Offering Price Payments for repurchase of common stock and warrants. Purchase of common stock and warrants Payments For Repurchase Of Common Stock And Warrants Shares issued under ESPP Stock Issued During Period Shares Employee Stock Purchase Plans Additional common stock capital shares reserved for future issuance. Employee Service Share Based Compensation Aggregate Disclosures [Abstract] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] Two thousand fourteen plan. 2014 Plan [Member] Two Thousand Fourteen Plan [Member] Two thousand fourteen employee stock purchase plan. 2014 ESPP [Member] Two Thousand Fourteen Employee Stock Purchase Plan [Member] Performance based restricted stock units. Performance Based Restricted Stock Units [Member] Performance Based Restricted Stock Units [Member] Award Date Award Date [Axis] Award Date Award Date [Domain] January 2020. January 2020 [Member] January Two Thousand Twenty [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Number of shares of common stock reserved for issuance Common Stock Capital Shares Reserved For Future Issuance Additional number of shares of common stock reserved for issuance Additional Common Stock Capital Shares Reserved For Future Issuance Percentage of common stock outstanding to increase shares reserved for issuance. Common stock reserved for issuance, description Share Based Compensation Arrangement By Share Based Payment Award Description Percentage of common stock outstanding to increase shares reserved for issuance Percentage Of Common Stock Outstanding To Increase Shares Reserved For Issuance Share based compensation arrangement by share based payment award employee stock purchase plan offering term. Employee stock purchase plan duration of offering period. Employee stock purchase plan number of purchase periods. Maximum duration for purchase under employee stock purchase plan. Maximum duration of employee stock purchase plan. Duration of employee stock purchase plan as determined by the compensation committee Share Based Compensation Arrangement By Share Based Payment Award Employee Stock Purchase Plan Offering Term Duration for offering period, employee stock purchase plan Employee Stock Purchase Plan Duration Of Offering Period Employee stock purchase plan, number of purchase periods Employee Stock Purchase Plan Number Of Purchase Periods Maximum duration for purchase under employee stock purchase plan Maximum Duration For Purchase Under Employee Stock Purchase Plan Maximum duration of employee stock purchase plan Maximum Duration Of Employee Stock Purchase Plan Percentage of purchase of common stock Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date Percentage of common stock on the date of purchase Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Purchase Date Stock options [Member] Restricted stock and restricted stock units. Restricted stock and restricted stock units [Member] Restricted Stock And Restricted Stock Units [Member] Employee stock purchase plan. Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan [Member] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Research and development expenses [Member] Research And Development Expense [Member] General and administrative expenses [Member] General And Administrative Expense [Member] Total stock-based compensation expense included in expenses Unrecognized Expense, Net of Estimated Forfeitures Weighted-average Recognition Period Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 Share based compensation arrangement by share based payment award equity instruments other than options repurchased in period. Shares, Unvested, Beginning balance Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number Shares, Granted Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Shares, Vested Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Shares, Forfeited Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period Shares, Repurchased Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Repurchased In Period Shares, Unvested, Ending balance Share based compensation arrangement by share based payment award equity instruments other than options repurchased weighted average grant date fair value. Weighted-Average Grant Date Fair Value, Unvested, Beginning balance Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value, Granted Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value, Vested Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value, Forfeited Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value, Repurchased Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Repurchased Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value, Unvested, Ending balance Percentage of shares vested upon achievement of certain milestone. Number of milestones to be achieved. Milestone achievement period. Number of milestones deemed as achievable. Issuance of performance based award Percentage of shares vested upon achievement of certain milestone Percentage Of Shares Vested Upon Achievement Of Certain Milestone Number of milestones to be achieve Number Of Milestones To Be Achieved Number of milestones deemed as achievable Number Of Milestones Deemed As Achievable Milestone achievement period Milestone Achievement Period Forfeited awards Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Number Of Milestones Achieved. Forfeiture of performance based award Number of milestones achieved Number Of Milestones Achieved Options outstanding beginning balance, Shares Subject to Stock Options Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Granted, Shares Subject to Stock Options Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Exercised, Shares Subject to Stock Options Stock Issued During Period Shares Stock Options Exercised Cancelled, Shares Subject to Stock Options Options outstanding ending balance, Shares Subject to Stock Options Options exercisable, Shares Subject to Stock Options Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Options outstanding beginning balance, Weighted-Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Granted, Weighted-Average Exercise Price Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Exercised, Weighted-Average Exercise Price Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price Cancelled, Weighted-Average Exercise Price Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price Options outstanding ending balance, Weighted-Average Exercise Price Options exercisable, Weighted-Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Options outstanding, Weighted-Average Remaining Contractual Term Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Options exercisable, Weighted-Average Remaining Contractual Term Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 Options outstanding, Aggregate Intrinsic Value Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Exercised, Aggregate Intrinsic Value Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value Options outstanding, Aggregate Intrinsic Value Options exercisable, Aggregate Intrinsic Value Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 Cash proceeds from exercises of stock options Proceeds From Stock Options Exercised Total fair value of stock options, vested Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 Weighted average fair value of stock options granted to employees Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract] Expected volatility Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Expected term (in years) Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 Risk-free interest rate Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Expected dividend yield Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate Excess tax benefit from stock-based awards Employee Service Share Based Compensation Tax Benefit From Compensation Expense Common stock options Member. Common stock options [Member] Common Stock Options [Member] Available for grant under the two thousand fourteen plan Member. Available for grant under the 2014 Plan [Member] Available For Grant Under Two Thousand Fourteen Plan [Member] Available for issuance under Employee Stock Purchase Plan. Available for issuance under Employee Stock Purchase Plan [Member] Available For Issuance Under Employee Stock Purchase Plan [Member] Common stock reserved for future issuance Class of warrants or rights expiry date. Class Of Warrant Or Right [Table] Class Of Warrant Or Right [Table] Over-Allotment Option [Member] Over Allotment Option [Member] Loan and security agreement. Loan and Security Agreement [Member] Loan And Security Agreement [Member] Securities purchase agreement. Securities Purchase Agreement [Member] Securities Purchase Agreement [Member] Private placement and registered direct offering. Private Placement and Registered Direct Offering [Member] Private Placement And Registered Direct Offering [Member] Class of Warrant or Right [Line Items] Class Of Warrant Or Right [Line Items] Issuance of shares of common stock Warrants sold Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Exercise price of warrant Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 Warrants expiry date Class Of Warrants Or Rights Expiry Date Public offering price per warrant Share Price Warrants outstanding Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number Warrants exercised Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Repayments of notes payable in stock. Beneficial ownership of company's common stock. Beneficial ownership of company's common stock Beneficial Ownership Of Company S Common Stock Repayments of notes payable in stock Repayments Of Notes Payable In Stock Public offering price per unit. Percentage of warrant exercise beneficial ownership limitation of common stock outstanding minimum. Prior notice period of increase beneficial ownership limitation. Percentage of minimum beneficial ownership limitation. Description of beneficial ownership limitation. Unexercised warrants. Number of warrants issued for common stock Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right Public offering price per share and per warrant Public Offering Price Per Unit Warrants exercisable date Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable Percentage of warrant exercise beneficial ownership limitation of common stock outstanding minimum Percentage Of Warrant Exercise Beneficial Ownership Limitation Of Common Stock Outstanding Minimum Prior notice period of increase beneficial ownership limitation Prior Notice Period Of Increase Beneficial Ownership Limitation Percentage of minimum beneficial ownership limitation Percentage Of Minimum Beneficial Ownership Limitation Description of beneficial ownership limitation Description Of Beneficial Ownership Limitation Unexercised warrants Unexercised Warrants Current: Current Income Tax Expense Benefit Continuing Operations [Abstract] Federal Current Federal Tax Expense Benefit State Current State And Local Tax Expense Benefit Total current Current Federal State And Local Tax Expense Benefit Deferred: Deferred Federal State And Local Tax Expense Benefit [Abstract] Federal Deferred Federal Income Tax Expense Benefit State Deferred State And Local Income Tax Expense Benefit Total deferred Deferred Federal State And Local Tax Expense Benefit Change in valuation allowance Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance Total income tax expense (benefit) Income Tax Expense Benefit Tax provision at U.S. Federal statutory rates Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate State income taxes net of federal benefit Effective Income Tax Rate Reconciliation State And Local Income Taxes Non-deductible permanent items Effective Income Tax Rate Reconciliation Nondeductible Expense Stock options Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost Research and development credits Effective Income Tax Rate Reconciliation Tax Credits Research Change in valuation allowance Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance Effective income tax rate Effective Income Tax Rate Continuing Operations Deferred tax liabilities right of use assets. Deferred tax assets: Deferred Tax Assets Net [Abstract] Accrued liabilities Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities Intangible assets Deferred Tax Assets Goodwill And Intangible Assets Net operating loss carryforwards Deferred Tax Assets Operating Loss Carryforwards Share-based compensation Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost Credits Deferred Tax Assets Tax Credit Carryforwards Research Other Deferred Tax Assets Other Total deferred tax assets Deferred Tax Assets Gross Valuation Allowance Deferred Tax Assets Valuation Allowance Total deferred tax assets, net of allowance Deferred Tax Assets Net Deferred tax liabilities: Deferred Tax Liabilities Net [Abstract] Right of use assets Deferred Tax Liabilities Right Of Use Assets Other Deferred Tax Liabilities Other Total deferred tax liabilities: Deferred Tax Liabilities Net deferred tax assets (liabilities): Deferred Tax Assets Liabilities Net Income tax. Income tax. Income Tax [Table] Income Tax [Table] Income Tax Authority Income Tax Authority [Axis] Income Tax Authority Income Tax Authority [Domain] Federal [Member] Domestic Country [Member] State [Member] State And Local Jurisdiction [Member] Income Tax [Line Items] Income Tax [Line Items] Valuation Allowance Percentage of cumulative change in stock ownership. State net operating loss carry forwards begin to expiration year. Remaining deferred tax assets operating loss carry forwards domestic. Federal net operating loss carry forwards begin subject to expiration year. Net operating loss carry forward limited domestic based on ownership change. Net operating loss carry forward state and local limited based on ownership change. Net operating loss carry forward annual limitation following ownership change. Federal net operating loss carryforwards Deferred Tax Assets Operating Loss Carryforwards Domestic Federal net operating loss carryforwards subject to expire Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration Federal net operating loss carryforwards subject to expiration year Federal Net Operating Loss Carry Forwards Subject To Expiration Year Remaining federal net operating loss carryforwards Remaining Deferred Tax Assets Operating Loss Carry Forwards Domestic State net operating loss carryforwards Deferred Tax Assets Operating Loss Carryforwards State And Local State net operating loss carryforwards, begin to expiration year. State Net Operating Loss Carry Forwards Begin To Expiration Year Description of the limitations on the use of all operating loss carryforwards Operating Loss Carryforwards Limitations On Use Percentage of cumulative change in stock ownership. Percentage Of Cumulative Change In Stock Ownership Federal net operating loss carryforwards limited based on ownership change Net Operating Loss Carry Forward Domestic Limited Based On Ownership Change State net operating loss carryforwards limited based on ownership change Net Operating Loss Carry Forward State And Local Limited Based On Ownership Change Annual limitation Net Operating Loss Carry Forward Annual Limitation Following Ownership Change Tax benefit not recognized Unrecognized Tax Benefits Tax credit carryforwards, begin to expiration year. Deferred tax assets, research and development tax credit carry-forwards Tax credit carry-forwards begin to expiration year Tax Credit Carryforwards Begin To Expiration Year Liability for uncertain tax positions Liability For Uncertain Tax Positions Noncurrent Schedule Of Related Party Transactions By Related Party [Table] Schedule Of Related Party Transactions By Related Party [Table] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Equity method investment, beneficially ownership percentage Equity Method Investment Ownership Percentage Commitments and contingencies. Schedule of commitments and contingencies. Schedule Of Commitments And Contingencies [Table] Schedule Of Commitments And Contingencies [Table] Geographical Statement Geographical [Axis] Geographical Segment Geographical [Domain] California [Member] CALIFORNIA Lease Contractual Term Lease Contractual Term [Axis] Lease Contractual Term Lease Contractual Term [Domain] Office lease. Office Lease [Member] Office Lease [Member] Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Area of lease premises Net Rentable Area Lease commencement date. Operating lease rentals annual increase percentage. Lease commencement date Lease Commencement Date Lease expiration date Lease Expiration Date1 Monthly base rent payments Operating Leases Rent Expense Minimum Rentals Percentage of rent increase under lease Operating Lease Rentals Annual Increase Percentage Rent expense Operating Leases Rent Expense Net Operating Leases Future Minimum Payments Due [Abstract] 2021 Operating Leases Future Minimum Payments Due Current 2022 Operating Leases Future Minimum Payments Due In Two Years Total minimum lease payments Operating Leases Future Minimum Payments Due EX-101.PRE 12 vktx-20201231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 13 vktx-10k_20201231_htm.xml IDEA: XBRL DOCUMENT 0001607678 2020-01-01 2020-12-31 0001607678 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001607678 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001607678 2021-01-31 0001607678 2020-06-30 0001607678 2020-12-31 0001607678 2019-12-31 0001607678 2019-01-01 2019-12-31 0001607678 us-gaap:CommonStockMember 2018-12-31 0001607678 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001607678 us-gaap:RetainedEarningsMember 2018-12-31 0001607678 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001607678 2018-12-31 0001607678 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001607678 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001607678 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001607678 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001607678 us-gaap:CommonStockMember 2019-12-31 0001607678 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001607678 us-gaap:RetainedEarningsMember 2019-12-31 0001607678 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001607678 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001607678 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001607678 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001607678 us-gaap:CommonStockMember 2020-12-31 0001607678 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001607678 us-gaap:RetainedEarningsMember 2020-12-31 0001607678 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001607678 us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001607678 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001607678 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001607678 us-gaap:WarrantMember 2019-01-01 2019-12-31 0001607678 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001607678 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001607678 vktx:CommonStockSubjectToRepurchaseMember 2020-01-01 2020-12-31 0001607678 vktx:CommonStockSubjectToRepurchaseMember 2019-01-01 2019-12-31 0001607678 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001607678 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001607678 us-gaap:CommercialPaperMember 2020-12-31 0001607678 us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001607678 srt:MaximumMember 2020-12-31 0001607678 us-gaap:CashEquivalentsMember us-gaap:CommercialPaperMember 2020-12-31 0001607678 us-gaap:CashEquivalentsMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001607678 us-gaap:CommercialPaperMember 2019-12-31 0001607678 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001607678 srt:MaximumMember 2019-12-31 0001607678 us-gaap:CashEquivalentsMember us-gaap:CommercialPaperMember 2019-12-31 0001607678 us-gaap:CashEquivalentsMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001607678 us-gaap:MoneyMarketFundsMember 2020-12-31 0001607678 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001607678 us-gaap:CommercialPaperMember 2020-12-31 0001607678 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001607678 us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001607678 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001607678 us-gaap:FairValueInputsLevel1Member 2020-12-31 0001607678 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001607678 us-gaap:MoneyMarketFundsMember 2019-12-31 0001607678 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001607678 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001607678 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001607678 us-gaap:CommercialPaperMember 2019-12-31 0001607678 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001607678 us-gaap:FairValueInputsLevel1Member 2019-12-31 0001607678 us-gaap:FairValueInputsLevel2Member 2019-12-31 0001607678 us-gaap:IPOMember vktx:LigandPharmaceuticalsIncorporatedMember 2020-01-01 2020-12-31 0001607678 vktx:LigandPharmaceuticalsIncorporatedMember 2020-12-31 0001607678 vktx:LigandPharmaceuticalsIncorporatedMember 2020-01-01 2020-12-31 0001607678 srt:MaximumMember vktx:ManagementRightsLetterMember vktx:LigandPharmaceuticalsIncorporatedMember 2014-05-31 0001607678 srt:MinimumMember vktx:ManagementRightsLetterMember vktx:LigandPharmaceuticalsIncorporatedMember 2014-05-31 0001607678 vktx:ManagementRightsLetterMember vktx:LigandPharmaceuticalsIncorporatedMember 2014-05-01 2014-05-31 0001607678 2014-02-28 0001607678 2014-02-01 2014-02-28 0001607678 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2014-02-28 0001607678 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2014-02-28 0001607678 2014-02-20 0001607678 2015-05-31 0001607678 2015-05-01 2015-05-31 0001607678 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2015-05-31 0001607678 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2015-05-31 0001607678 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2015-10-01 2016-12-31 0001607678 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2019-01-01 2019-12-31 0001607678 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2020-01-01 2020-12-31 0001607678 us-gaap:CommonStockMember vktx:StockPurchaseAgreementMember vktx:PoCCapitalLLCMember 2017-02-07 2017-02-08 0001607678 vktx:PoCCapitalLLCMember 2017-02-08 0001607678 vktx:ClinicalStudiesMember us-gaap:CommonStockMember vktx:StockPurchaseAgreementMember vktx:PoCCapitalLLCMember 2020-01-01 2020-12-31 0001607678 vktx:PoCCapitalLLCMember 2019-01-01 2019-12-31 0001607678 vktx:PoCCapitalLLCMember 2020-01-01 2020-12-31 0001607678 us-gaap:CommonStockMember vktx:RegisteredOfferingPurchaseAgreementMember vktx:LincoInParkCapitalFundLimitedLiabilityCompanyMember 2017-09-27 2017-09-29 0001607678 us-gaap:CommonStockMember vktx:RegisteredOfferingPurchaseAgreementMember vktx:LincoInParkCapitalFundLimitedLiabilityCompanyMember 2017-09-29 0001607678 srt:MaximumMember vktx:RegistrationRightsAgreementMember us-gaap:CommonStockMember vktx:CommitmentPurchaseAgreementMember vktx:LincoInParkCapitalFundLimitedLiabilityCompanyMember 2017-09-26 2017-09-28 0001607678 vktx:RegistrationRightsAgreementMember us-gaap:CommonStockMember vktx:CommitmentPurchaseAgreementMember vktx:LincoInParkCapitalFundLimitedLiabilityCompanyMember 2017-09-26 2017-09-28 0001607678 srt:MaximumMember vktx:RegistrationRightsAgreementMember us-gaap:CommonStockMember vktx:CommitmentPurchaseAgreementMember vktx:LincoInParkCapitalFundLimitedLiabilityCompanyMember 2017-09-28 0001607678 srt:MinimumMember vktx:RegistrationRightsAgreementMember us-gaap:CommonStockMember vktx:CommitmentPurchaseAgreementMember vktx:LincoInParkCapitalFundLimitedLiabilityCompanyMember 2017-09-26 2017-09-28 0001607678 srt:MaximumMember us-gaap:CommonStockMember vktx:AtTheMarketEquityOfferingSalesAgreementMember 2019-08-01 2019-08-01 0001607678 us-gaap:CommonStockMember vktx:AtTheMarketEquityOfferingSalesAgreementMember 2019-08-01 2019-08-01 0001607678 vktx:RepurchaseProgramMember 2020-03-17 2020-03-17 0001607678 vktx:RepurchaseProgramMember 2020-01-01 2020-12-31 0001607678 vktx:TwoThousandFourteenPlanMember 2015-04-28 0001607678 vktx:TwoThousandFourteenEmployeeStockPurchasePlanMember 2015-04-28 0001607678 vktx:TwoThousandFourteenPlanMember 2020-12-31 0001607678 vktx:TwoThousandFourteenEmployeeStockPurchasePlanMember 2020-12-31 0001607678 vktx:TwoThousandFourteenPlanMember 2020-01-01 2020-12-31 0001607678 vktx:TwoThousandFourteenEmployeeStockPurchasePlanMember 2020-01-01 2020-12-31 0001607678 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001607678 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001607678 vktx:RestrictedStockAndRestrictedStockUnitsMember 2020-01-01 2020-12-31 0001607678 vktx:RestrictedStockAndRestrictedStockUnitsMember 2019-01-01 2019-12-31 0001607678 vktx:EmployeeStockPurchasePlanMember 2020-01-01 2020-12-31 0001607678 vktx:EmployeeStockPurchasePlanMember 2019-01-01 2019-12-31 0001607678 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001607678 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001607678 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001607678 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0001607678 us-gaap:EmployeeStockOptionMember 2020-12-31 0001607678 vktx:RestrictedStockAndRestrictedStockUnitsMember 2020-12-31 0001607678 us-gaap:RestrictedStockMember 2018-12-31 0001607678 us-gaap:RestrictedStockMember 2019-12-31 0001607678 us-gaap:RestrictedStockMember 2020-12-31 0001607678 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001607678 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001607678 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001607678 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001607678 vktx:PerformanceBasedRestrictedStockUnitsMember 2019-01-01 2019-01-31 0001607678 vktx:PerformanceBasedRestrictedStockUnitsMember 2020-03-31 0001607678 vktx:PerformanceBasedRestrictedStockUnitsMember 2020-01-01 2020-12-31 0001607678 vktx:PerformanceBasedRestrictedStockUnitsMember 2019-01-01 2019-12-31 0001607678 vktx:PerformanceBasedRestrictedStockUnitsMember 2020-01-01 2020-01-31 0001607678 vktx:PerformanceBasedRestrictedStockUnitsMember 2020-12-31 0001607678 vktx:JanuaryTwoThousandTwentyMember vktx:PerformanceBasedRestrictedStockUnitsMember 2020-01-01 2020-12-31 0001607678 us-gaap:WarrantMember 2020-12-31 0001607678 vktx:CommonStockOptionsMember 2020-12-31 0001607678 vktx:AvailableForGrantUnderTwoThousandFourteenPlanMember 2020-12-31 0001607678 vktx:AvailableForIssuanceUnderEmployeeStockPurchasePlanMember 2020-12-31 0001607678 2016-04-12 2016-04-13 0001607678 2016-04-13 0001607678 us-gaap:OverAllotmentOptionMember 2016-04-13 0001607678 vktx:LoanAndSecurityAgreementMember vktx:LigandPharmaceuticalsIncorporatedMember 2016-04-13 0001607678 srt:MinimumMember vktx:LoanAndSecurityAgreementMember 2016-04-13 0001607678 vktx:LoanAndSecurityAgreementMember vktx:LigandPharmaceuticalsIncorporatedMember 2020-01-01 2020-12-31 0001607678 vktx:LoanAndSecurityAgreementMember vktx:LigandPharmaceuticalsIncorporatedMember 2016-04-12 2016-04-13 0001607678 us-gaap:CommonStockMember vktx:PrivatePlacementAndRegisteredDirectOfferingMember vktx:SecuritiesPurchaseAgreementMember 2017-06-13 2017-06-14 0001607678 srt:MaximumMember us-gaap:CommonStockMember vktx:PrivatePlacementAndRegisteredDirectOfferingMember vktx:SecuritiesPurchaseAgreementMember 2017-06-14 0001607678 vktx:PrivatePlacementAndRegisteredDirectOfferingMember vktx:SecuritiesPurchaseAgreementMember 2017-06-14 0001607678 vktx:SecuritiesPurchaseAgreementMember 2017-06-14 0001607678 vktx:PrivatePlacementAndRegisteredDirectOfferingMember vktx:SecuritiesPurchaseAgreementMember 2017-06-13 2017-06-14 0001607678 vktx:PrivatePlacementAndRegisteredDirectOfferingMember vktx:SecuritiesPurchaseAgreementMember 2020-01-01 2020-12-31 0001607678 vktx:SecuritiesPurchaseAgreementMember 2019-01-01 2019-12-31 0001607678 vktx:SecuritiesPurchaseAgreementMember 2020-01-01 2020-12-31 0001607678 vktx:SecuritiesPurchaseAgreementMember 2018-01-16 0001607678 us-gaap:DomesticCountryMember 2020-12-31 0001607678 us-gaap:StateAndLocalJurisdictionMember 2020-12-31 0001607678 us-gaap:DomesticCountryMember 2020-01-01 2020-12-31 0001607678 vktx:LigandPharmaceuticalsIncorporatedMember 2020-12-31 0001607678 stpr:CA vktx:OfficeLeaseMember 2018-05-25 0001607678 stpr:CA vktx:OfficeLeaseMember 2018-05-24 2018-05-25 shares iso4217:USD iso4217:USD shares vktx:Segment vktx:Security pure vktx:Lease vktx:Tranche vktx:Period vktx:Milestone utr:sqft false FY 0001607678 --12-31 Three months or less true P4Y P4Y P2Y5M12D P1Y7M28D P7Y7M28D P7Y3M25D P6Y4M6D P6Y1M2D P6Y3D 10-K true 2020-12-31 2020 false 001-37355 Viking Therapeutics, Inc. DE 46-1073877 12340 El Camino Real Suite 250 San Diego CA 92130 858 704-4660 Common Stock, par value $0.00001 per share VKTX NASDAQ Warrants to purchase Common Stock, par value $0.00001 per share VKTXW NASDAQ No No Yes Yes Non-accelerated Filer true false false false 469584214 74133121 Portions of the Registrant’s Definitive Proxy Statement for its 2021 Annual Meeting of Stockholders or an amendment to this Annual Report on Form 10-K to be filed with the Securities and Exchange Commission within 120 days of the registrant’s fiscal year ended December 31, 2020 are incorporated by reference into Part III of this Annual Report on Form 10-K. 29117000 8377000 219269000 267261000 7276000 7458000 442000 405000 256104000 283501000 321000 598000 48000 128000 29000 29000 256502000 284256000 3988000 2431000 7811000 4044000 330000 302000 12129000 6777000 29000 360000 29000 360000 12158000 7137000 0.00001 0.00001 10000000 10000000 0 0 0 0 0.00001 0.00001 300000000 300000000 73215940 73215940 72413602 72413602 1000 1000 412589000 405803000 -168192000 -128697000 -54000 12000 244344000 277119000 256502000 284256000 0 0 31931000 23559000 10731000 9128000 42662000 32687000 -42662000 -32687000 106000 146000 3233000 7050000 40000 4000 3167000 6908000 -39495000 -25779000 -66000 435000 -39561000 -25344000 -0.54 -0.36 72597000 71959000 71742043 1000 401090000 -102918000 -423000 297750000 17709 3592000 3592000 160573 328000 328000 528695 793000 793000 435000 435000 -25779000 -25779000 72413602 1000 405803000 -128697000 12000 277119000 44042 5522000 5522000 249579 418000 418000 596801 846000 846000 -66000 -66000 -39495000 -39495000 73215940 1000 412589000 -168192000 -54000 244344000 -39495000 -25779000 3808000 477000 106000 146000 140000 5818000 3743000 277000 260000 32000 48000 -40000 -4000 -137000 7380000 -2590000 -1971000 1555000 1472000 3768000 423000 -333000 -269000 -21777000 -24752000 280636000 362406000 322203000 369869000 41567000 7463000 26000 73000 296000 151000 1272000 1111000 950000 887000 20740000 -16402000 8377000 24779000 29117000 8377000 50000 50000 1000 10000 <p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;;font-size:6pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Organization, Liquidity and Management’s Plan, and Summary of Significant Accounting Policies</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The Company</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Viking Therapeutics, Inc., a Delaware corporation (the “Company”), is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company was incorporated under the laws of the State of Delaware on September 24, 2012 and its principal executive offices are located in San Diego, CA.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Basis of Presentation</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Risks and Uncertainties </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on the Company’s business is highly uncertain and difficult to predict, as the responses that the Company, other businesses and governments are taking continue to evolve. Furthermore, capital markets and economies worldwide have also been negatively impacted by the COVID-19 pandemic, and it is possible that it could cause a local and/or global economic slowdown or recession. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remain uncertain.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Company’s clinical trials have been affected by and may continue to be affected by the COVID-19 pandemic. Clinical site initiation and patient enrollment have been and may continue to be delayed due to prioritization of hospital resources toward the COVID-19 pandemic. Some patients have not been and others may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, any inability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, may adversely impact the Company’s clinical trial operations.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The severity of the impact of the COVID-19 pandemic on the Company’s business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company’s service providers, suppliers, contract research organizations (“CROs”) and the Company’s clinical trials, all of which are uncertain and cannot be predicted. As of the date of issuance of Company’s financial statements, the extent to which the COVID-19 pandemic may materially impact the Company’s financial condition, liquidity or results of operations is uncertain.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Significant estimates made in preparing these financial statements relate to accounting for operating lease and certain commitments. Actual results could differ from those estimates.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Reclassification</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain amounts reported in prior years in the Statements of Cash Flows have been reclassified to conform to the current year’s presentation.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Investments Available-for-Sale</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in accumulated other comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of </p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">discounts to maturity. The amortization of premiums and accretion of discounts is included in interest income. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in other income (expense). The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income.</span></p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents and marketable securities. The Company maintains deposits in federally insured depository institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Prepaid Clinical Trial and Preclinical Study Costs</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid clinical trial and preclinical study costs represent advance payments by the Company for future clinical trial and preclinical study services to be performed by the clinical research organization and other research organizations.  Such amounts are recognized as research and development expense as the related clinical trial and preclinical study services are performed.  </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:inherit;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Leases</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:inherit;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use (“ROU”) assets, and lease liability obligations are included in the Company’s balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liability obligations represent its obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company’s leases typically do not provide an implicit rate, the Company estimates its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company uses the implicit rate when readily determinable. The ROU asset also includes any lease payments made and excludes lease incentives and lease direct costs. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. Please refer to Note 5 for additional information.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Deferred Financing Costs</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred financing costs represent legal, accounting and other direct costs related to the Company’s efforts to raise capital through a public or private sale of the Company’s common stock. Costs related to the public sale of the Company’s common stock are deferred until the completion of the applicable offering, at which time such costs are reclassified to additional paid-in-capital as a reduction of the proceeds.  Costs related to the private sale of the Company’s common stock are deferred until the completion of the applicable offering, at which time such costs are amortized over the term of the applicable purchase agreement.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Revenue Recognition</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has not recorded any revenues since its inception. However, in the future, the Company may enter into collaborative research and licensing agreements, under which the Company could be eligible for payments made in the form of upfront license fees, research funding, cost reimbursement, contingent event-based payments and/or royalties.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On January 1, 2018, the Company adopted ASU No. 2014-09, </span><span style="font-style:italic;Background-color:#FFFFFF;">Revenue from Contracts with Customers</span><span style="Background-color:#FFFFFF;"> and all related amendments (“ASC 606” or “the revenue standard”). ASC 606 is a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-s</span>pecific guidance. The revenue standard is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, ASC 606 provides that an entity should apply the following steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The revenue standard also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, and costs to obtain or fulfill contracts. The Company will apply ASC 606 prospectively to all contracts.<span style="font-family:inherit;">   </span></p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All costs of research and development are expensed in the period incurred. Research and development costs primarily consist of fees paid to contract research organizations (“CROs”) and clinical trial sites, employee and consultant related expenses, which include salaries, benefits and stock-based compensation for research and development personnel, external research and development expenses incurred pursuant to agreements with third-party manufacturing organizations, facilities costs, travel costs, dues and subscriptions, depreciation and materials used in preclinical studies, clinical trials and research and development.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates its preclinical study and clinical trial expenses based on the services it received pursuant to contracts with research institutions and CROs that conduct and manage preclinical studies and clinical trials on the Company’s behalf. Clinical trial-related contracts vary significantly in length, and may be for a fixed amount based on milestones or deliverables, a variable amount based on actual costs incurred, capped at a certain limit, or a combination of these elements. The Company accrues service fees based on work performed, which relies on estimates of total costs incurred based on milestones achieved, patient enrollment and other events. The majority of the Company’s service providers invoice the Company in arrears, and to the extent that amounts invoiced differ from its estimates of expenses incurred, the Company accrues for additional costs. The financial terms of these agreements vary from contract to contract and may result in uneven expenses and payment flows. Preclinical study and clinical trial expenses include:</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">fees paid to CROs, consultants and laboratories in connection with preclinical studies;</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">fees paid to CROs, clinical trial sites, investigators and consultants in connection with clinical trials; and</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">fees paid to contract manufacturers and service providers in connection with the production, testing and packaging of active pharmaceutical ingredients and drug materials for preclinical studies and clinical trials.</span></p></td></tr></table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments under some of these agreements depend on factors such as the milestones accomplished, including enrollment of certain numbers of patients, site initiation and the completion of clinical trial milestones. To date, the Company has not experienced any events requiring it to make material adjustments to its accruals for service fees. If the Company does not identify costs that it has begun to incur or if it underestimates or overestimates the level of services performed or the costs of these services, its actual expenses could differ from its estimates which could materially affect its results of operations. Adjustments to the Company’s accruals are recorded as changes in estimates become evident. Furthermore, based on amounts invoiced to the Company by its service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expense in future periods as services are rendered.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the Company entered into a master license agreement, pursuant to which it acquired certain rights to a number of research and development programs from <span style="color:#000000;">Ligand Pharmaceuticals Incorporated (“</span>Ligand”). In doing so, the Company updated its policy on research and development to include the purchase of rights to intangible assets. In accordance with ASC Topic 730, <span style="font-style:italic;">Research and Development,</span> intangible assets that are acquired and have an alternative future use, as defined, should be capitalized and reported as an intangible asset; however, the cost of acquired intangible assets that do not have alternative future uses should be reported as research and development expense as incurred. The Company notes that intangible assets acquired that are in the preclinical or clinical stages of development when acquired, and not approved by the U.S. Food and Drug Administration, are deemed to have not satisfied the definition of having an alternative future use, as defined. Accordingly, assets acquired in the preclinical and clinical stages of development are expensed as incurred in the Company’s statement of operations.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Patent Costs</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs related to filing and pursuing patent applications are expensed as incurred to general and administrative expense, as recoverability of such expenditures is uncertain.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generally uses the straight-line method to allocate compensation cost to reporting periods over each optionee’s requisite service period, which is generally the vesting period, and estimates the fair value of stock-based awards or restricted stock units to employees and directors using the Black-Scholes option-valuation model (the “Black-Scholes model”). The Black-Scholes model requires the input of subjective assumptions, including volatility, the expected term and the fair value of the underlying common stock on the date of grant, among other inputs. For restricted stock and restricted stock unit awards, the Company generally uses the straight-line method to allocate compensation cost to reporting periods over the holder’s requisite service period, which is generally the vesting period, and uses the fair value at grant date to value the awards. For restricted stock that vests upon the satisfaction of certain performance conditions, the Company recognizes stock-based compensation expense when it becomes probable that the performance conditions will be met. At the grant date, the Company determines the grant date fair value, as a publicly traded company, using the intrinsic value, or the closing price of the Company’s common stock on the date of grant. At the point where the criteria are deemed probable of being met, the Company records stock-based compensation with a cumulative catch-up expense in the period first </p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">recognized and then on a straight-line basis over the remaining period for which the performance criteria are expected to be completed.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the Company’s 2014 Employee Stock Purchase Plan (the “ESPP”), the Company generally recognizes compensation expense for the fair value of the purchase options, as measured on the grant date, and uses the graded vesting method to allocate this compensation cost to each purchase period within the related two-year offering period. As the ESPP also allows for up to one increase in contributions during each purchase period, as an employee elects to increase his or her contributions, the Company treats this as an accounting modification. The pre- and post-modification values are calculated on the date of the modification, and the incremental expense is then amortized over the remaining purchase periods.    </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Income Taxes</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for its income taxes using the liability method whereby deferred tax assets and liabilities are determined based on temporary differences between the basis used for financial reporting and income tax reporting purposes. Deferred income taxes are provided based on the enacted tax rates in effect at the time such temporary differences are expected to reverse. A valuation allowance is provided for deferred tax assets if it is more likely than not that the Company will not realize those tax assets through future operations.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASC Topic 740-10, <span style="font-style:italic;">Income Taxes</span>, clarifies the accounting for uncertainty in income taxes recognized in the Company’s financial statements in accordance with GAAP.  Income tax positions must meet a more-likely-than-not recognition threshold to be recognized. Income tax positions that previously failed to meet the more-likely-than-not threshold are recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not threshold are derecognized in the first subsequent financial reporting period in which that threshold is no longer met.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Net Loss per Common Share</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. For purposes of this calculation, the Company currently does not have any deemed common share equivalents; therefore, its basic and diluted net loss per share calculations are the same.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the computation of basic and diluted net loss per common share (in thousands, except share and per share data):</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Historical net loss per share</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39,495</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,779</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares outstanding</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,779,742</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,142,188</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Weighted-average shares subject to repurchase</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(183,095</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(183,095</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator for basic and diluted net loss per share</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,596,647</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,959,093</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per share</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.54</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.36</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potentially dilutive securities that are not included in the calculation of diluted net loss per share because their effect is anti-dilutive are as follows (in common equivalent shares):</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,244,500</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,841,301</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">679,363</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">352,726</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock subject to repurchase</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183,095</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183,095</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,371,323</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,580,476</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.92%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,478,281</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,957,598</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Segments</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in only one segment. Management uses cash flows as the primary measure to manage its business and does not segment its business for internal reporting or decision making purposes.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The Company</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Viking Therapeutics, Inc., a Delaware corporation (the “Company”), is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company was incorporated under the laws of the State of Delaware on September 24, 2012 and its principal executive offices are located in San Diego, CA.</p> DE 2012-09-24 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Basis of Presentation</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Risks and Uncertainties </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on the Company’s business is highly uncertain and difficult to predict, as the responses that the Company, other businesses and governments are taking continue to evolve. Furthermore, capital markets and economies worldwide have also been negatively impacted by the COVID-19 pandemic, and it is possible that it could cause a local and/or global economic slowdown or recession. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remain uncertain.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Company’s clinical trials have been affected by and may continue to be affected by the COVID-19 pandemic. Clinical site initiation and patient enrollment have been and may continue to be delayed due to prioritization of hospital resources toward the COVID-19 pandemic. Some patients have not been and others may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, any inability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, may adversely impact the Company’s clinical trial operations.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The severity of the impact of the COVID-19 pandemic on the Company’s business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company’s service providers, suppliers, contract research organizations (“CROs”) and the Company’s clinical trials, all of which are uncertain and cannot be predicted. As of the date of issuance of Company’s financial statements, the extent to which the COVID-19 pandemic may materially impact the Company’s financial condition, liquidity or results of operations is uncertain.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Significant estimates made in preparing these financial statements relate to accounting for operating lease and certain commitments. Actual results could differ from those estimates.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Reclassification</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain amounts reported in prior years in the Statements of Cash Flows have been reclassified to conform to the current year’s presentation.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Investments Available-for-Sale</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in accumulated other comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of </p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">discounts to maturity. The amortization of premiums and accretion of discounts is included in interest income. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in other income (expense). The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income.</span></p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents and marketable securities. The Company maintains deposits in federally insured depository institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Prepaid Clinical Trial and Preclinical Study Costs</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid clinical trial and preclinical study costs represent advance payments by the Company for future clinical trial and preclinical study services to be performed by the clinical research organization and other research organizations.  Such amounts are recognized as research and development expense as the related clinical trial and preclinical study services are performed.  </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:inherit;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Leases</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:inherit;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use (“ROU”) assets, and lease liability obligations are included in the Company’s balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liability obligations represent its obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company’s leases typically do not provide an implicit rate, the Company estimates its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company uses the implicit rate when readily determinable. The ROU asset also includes any lease payments made and excludes lease incentives and lease direct costs. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. Please refer to Note 5 for additional information.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Deferred Financing Costs</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred financing costs represent legal, accounting and other direct costs related to the Company’s efforts to raise capital through a public or private sale of the Company’s common stock. Costs related to the public sale of the Company’s common stock are deferred until the completion of the applicable offering, at which time such costs are reclassified to additional paid-in-capital as a reduction of the proceeds.  Costs related to the private sale of the Company’s common stock are deferred until the completion of the applicable offering, at which time such costs are amortized over the term of the applicable purchase agreement.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Revenue Recognition</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has not recorded any revenues since its inception. However, in the future, the Company may enter into collaborative research and licensing agreements, under which the Company could be eligible for payments made in the form of upfront license fees, research funding, cost reimbursement, contingent event-based payments and/or royalties.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On January 1, 2018, the Company adopted ASU No. 2014-09, </span><span style="font-style:italic;Background-color:#FFFFFF;">Revenue from Contracts with Customers</span><span style="Background-color:#FFFFFF;"> and all related amendments (“ASC 606” or “the revenue standard”). ASC 606 is a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-s</span>pecific guidance. The revenue standard is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, ASC 606 provides that an entity should apply the following steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The revenue standard also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, and costs to obtain or fulfill contracts. The Company will apply ASC 606 prospectively to all contracts.<span style="font-family:inherit;">   </span></p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All costs of research and development are expensed in the period incurred. Research and development costs primarily consist of fees paid to contract research organizations (“CROs”) and clinical trial sites, employee and consultant related expenses, which include salaries, benefits and stock-based compensation for research and development personnel, external research and development expenses incurred pursuant to agreements with third-party manufacturing organizations, facilities costs, travel costs, dues and subscriptions, depreciation and materials used in preclinical studies, clinical trials and research and development.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates its preclinical study and clinical trial expenses based on the services it received pursuant to contracts with research institutions and CROs that conduct and manage preclinical studies and clinical trials on the Company’s behalf. Clinical trial-related contracts vary significantly in length, and may be for a fixed amount based on milestones or deliverables, a variable amount based on actual costs incurred, capped at a certain limit, or a combination of these elements. The Company accrues service fees based on work performed, which relies on estimates of total costs incurred based on milestones achieved, patient enrollment and other events. The majority of the Company’s service providers invoice the Company in arrears, and to the extent that amounts invoiced differ from its estimates of expenses incurred, the Company accrues for additional costs. The financial terms of these agreements vary from contract to contract and may result in uneven expenses and payment flows. Preclinical study and clinical trial expenses include:</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">fees paid to CROs, consultants and laboratories in connection with preclinical studies;</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">fees paid to CROs, clinical trial sites, investigators and consultants in connection with clinical trials; and</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">fees paid to contract manufacturers and service providers in connection with the production, testing and packaging of active pharmaceutical ingredients and drug materials for preclinical studies and clinical trials.</span></p></td></tr></table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments under some of these agreements depend on factors such as the milestones accomplished, including enrollment of certain numbers of patients, site initiation and the completion of clinical trial milestones. To date, the Company has not experienced any events requiring it to make material adjustments to its accruals for service fees. If the Company does not identify costs that it has begun to incur or if it underestimates or overestimates the level of services performed or the costs of these services, its actual expenses could differ from its estimates which could materially affect its results of operations. Adjustments to the Company’s accruals are recorded as changes in estimates become evident. Furthermore, based on amounts invoiced to the Company by its service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expense in future periods as services are rendered.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the Company entered into a master license agreement, pursuant to which it acquired certain rights to a number of research and development programs from <span style="color:#000000;">Ligand Pharmaceuticals Incorporated (“</span>Ligand”). In doing so, the Company updated its policy on research and development to include the purchase of rights to intangible assets. In accordance with ASC Topic 730, <span style="font-style:italic;">Research and Development,</span> intangible assets that are acquired and have an alternative future use, as defined, should be capitalized and reported as an intangible asset; however, the cost of acquired intangible assets that do not have alternative future uses should be reported as research and development expense as incurred. The Company notes that intangible assets acquired that are in the preclinical or clinical stages of development when acquired, and not approved by the U.S. Food and Drug Administration, are deemed to have not satisfied the definition of having an alternative future use, as defined. Accordingly, assets acquired in the preclinical and clinical stages of development are expensed as incurred in the Company’s statement of operations.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Patent Costs</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs related to filing and pursuing patent applications are expensed as incurred to general and administrative expense, as recoverability of such expenditures is uncertain.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generally uses the straight-line method to allocate compensation cost to reporting periods over each optionee’s requisite service period, which is generally the vesting period, and estimates the fair value of stock-based awards or restricted stock units to employees and directors using the Black-Scholes option-valuation model (the “Black-Scholes model”). The Black-Scholes model requires the input of subjective assumptions, including volatility, the expected term and the fair value of the underlying common stock on the date of grant, among other inputs. For restricted stock and restricted stock unit awards, the Company generally uses the straight-line method to allocate compensation cost to reporting periods over the holder’s requisite service period, which is generally the vesting period, and uses the fair value at grant date to value the awards. For restricted stock that vests upon the satisfaction of certain performance conditions, the Company recognizes stock-based compensation expense when it becomes probable that the performance conditions will be met. At the grant date, the Company determines the grant date fair value, as a publicly traded company, using the intrinsic value, or the closing price of the Company’s common stock on the date of grant. At the point where the criteria are deemed probable of being met, the Company records stock-based compensation with a cumulative catch-up expense in the period first </p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">recognized and then on a straight-line basis over the remaining period for which the performance criteria are expected to be completed.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the Company’s 2014 Employee Stock Purchase Plan (the “ESPP”), the Company generally recognizes compensation expense for the fair value of the purchase options, as measured on the grant date, and uses the graded vesting method to allocate this compensation cost to each purchase period within the related two-year offering period. As the ESPP also allows for up to one increase in contributions during each purchase period, as an employee elects to increase his or her contributions, the Company treats this as an accounting modification. The pre- and post-modification values are calculated on the date of the modification, and the incremental expense is then amortized over the remaining purchase periods.    </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Income Taxes</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for its income taxes using the liability method whereby deferred tax assets and liabilities are determined based on temporary differences between the basis used for financial reporting and income tax reporting purposes. Deferred income taxes are provided based on the enacted tax rates in effect at the time such temporary differences are expected to reverse. A valuation allowance is provided for deferred tax assets if it is more likely than not that the Company will not realize those tax assets through future operations.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASC Topic 740-10, <span style="font-style:italic;">Income Taxes</span>, clarifies the accounting for uncertainty in income taxes recognized in the Company’s financial statements in accordance with GAAP.  Income tax positions must meet a more-likely-than-not recognition threshold to be recognized. Income tax positions that previously failed to meet the more-likely-than-not threshold are recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not threshold are derecognized in the first subsequent financial reporting period in which that threshold is no longer met.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Net Loss per Common Share</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. For purposes of this calculation, the Company currently does not have any deemed common share equivalents; therefore, its basic and diluted net loss per share calculations are the same.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the computation of basic and diluted net loss per common share (in thousands, except share and per share data):</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Historical net loss per share</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39,495</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,779</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares outstanding</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,779,742</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,142,188</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Weighted-average shares subject to repurchase</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(183,095</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(183,095</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator for basic and diluted net loss per share</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,596,647</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,959,093</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per share</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.54</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.36</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potentially dilutive securities that are not included in the calculation of diluted net loss per share because their effect is anti-dilutive are as follows (in common equivalent shares):</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,244,500</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,841,301</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">679,363</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">352,726</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock subject to repurchase</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183,095</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183,095</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,371,323</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,580,476</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.92%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,478,281</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,957,598</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the computation of basic and diluted net loss per common share (in thousands, except share and per share data):</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Historical net loss per share</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39,495</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,779</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares outstanding</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,779,742</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,142,188</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Weighted-average shares subject to repurchase</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(183,095</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(183,095</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator for basic and diluted net loss per share</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,596,647</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,959,093</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per share</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.54</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.36</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> -39495000 -25779000 72779742 72142188 183095 183095 72596647 71959093 -0.54 -0.36 <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potentially dilutive securities that are not included in the calculation of diluted net loss per share because their effect is anti-dilutive are as follows (in common equivalent shares):</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,244,500</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,841,301</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">679,363</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">352,726</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock subject to repurchase</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183,095</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183,095</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,371,323</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,580,476</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.92%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,478,281</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,957,598</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 5244500 5841301 679363 352726 183095 183095 3371323 2580476 9478281 8957598 <p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Segments</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in only one segment. Management uses cash flows as the primary measure to manage its business and does not segment its business for internal reporting or decision making purposes.</p> 1 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Investments in Marketable Securities</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s investment strategy is focused on capital preservation. The Company invests in instruments that meet the credit quality standards outlined in the Company’s investment policy. This policy also limits the amount of credit exposure to any one issue or type of instrument.  As of December 31, 2020 and 2019, the Company’s investments were in money market funds, commercial paper and corporate debt securities. There were no sales of available-for-sale securities during the years ended December 31, 2020 and 2019.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments classified as available-for-sale as of December 31, 2020 consisted of the following (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains  <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses  <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper  (2)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,973</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,973</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities  (2)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">191,350</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(148</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">191,296</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">219,323</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(148</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">219,269</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td> <td valign="top"> <p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Unrealized gains and losses on available-for-sale securities are included as a component of comprehensive loss. At December 31, 2020, there were 38 securities in an unrealized gain position and 80 securities in an unrealized loss position. The unrealized gains were less than $35,000 individually and $94,000 in the aggregate. The unrealized losses were less than $21,000 individually and $148,000 in the aggregate.  Four of these securities have been in a continuous unrealized loss or unrealized gain position for more than 12 months. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell these investments before recovery of their amortized cost basis, which may be at maturity. The Company reviews its investments to identify and evaluate investments that have an indication of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the investee, and the Company’s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.  </p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (2)</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">At December 31, 2020, none of these securities were classified as cash and cash equivalents on the Company’s balance sheet and <span>$53.4</span> million of the corporate debt securities were scheduled to mature outside of one year at the time of purchase.</p></td></tr></table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments classified as available-for-sale as of December 31, 2019 consisted of the following (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains  <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses  <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper  (2)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,495</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,495</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities  (2)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">265,754</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">190</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(178</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">265,766</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.78%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">267,249</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">190</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(178</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">267,261</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td> <td valign="top"> <p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Unrealized gains and losses on available-for-sale securities are included as a component of comprehensive loss. At December 31, 2019, there were 87 securities in an unrealized gain position and 66 securities in an unrealized loss position. These unrealized gains were less than $22,000 individually and $190,000 in the aggregate. The unrealized losses were less than $32,000 individually and $178,000 in the aggregate.  Nine of these securities have been in a continuous unrealized loss or unrealized gain position for more than 12 months. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell these investments before recovery of their amortized cost basis, which may be at maturity. The Company reviews its investments to identify and evaluate investments that have an indication of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the investee, and the Company’s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.</p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (2)</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 201</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">none</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of these securities were classified as cash and cash equivalents on the Company’s balance sheet and </span><span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9</span></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> corporate debt</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> securities were scheduled to mature outside of one year</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> at the time of purchase</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td></tr></table></div> 0 0 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments classified as available-for-sale as of December 31, 2020 consisted of the following (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains  <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses  <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper  (2)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,973</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,973</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities  (2)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">191,350</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(148</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">191,296</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">219,323</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(148</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">219,269</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td> <td valign="top"> <p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Unrealized gains and losses on available-for-sale securities are included as a component of comprehensive loss. At December 31, 2020, there were 38 securities in an unrealized gain position and 80 securities in an unrealized loss position. The unrealized gains were less than $35,000 individually and $94,000 in the aggregate. The unrealized losses were less than $21,000 individually and $148,000 in the aggregate.  Four of these securities have been in a continuous unrealized loss or unrealized gain position for more than 12 months. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell these investments before recovery of their amortized cost basis, which may be at maturity. The Company reviews its investments to identify and evaluate investments that have an indication of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the investee, and the Company’s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.  </p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (2)</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">At December 31, 2020, none of these securities were classified as cash and cash equivalents on the Company’s balance sheet and <span>$53.4</span> million of the corporate debt securities were scheduled to mature outside of one year at the time of purchase.</p></td></tr></table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments classified as available-for-sale as of December 31, 2019 consisted of the following (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains  <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses  <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.78%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper  (2)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,495</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,495</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities  (2)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">265,754</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">190</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(178</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">265,766</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.78%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">267,249</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">190</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(178</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">267,261</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td> <td valign="top"> <p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Unrealized gains and losses on available-for-sale securities are included as a component of comprehensive loss. At December 31, 2019, there were 87 securities in an unrealized gain position and 66 securities in an unrealized loss position. These unrealized gains were less than $22,000 individually and $190,000 in the aggregate. The unrealized losses were less than $32,000 individually and $178,000 in the aggregate.  Nine of these securities have been in a continuous unrealized loss or unrealized gain position for more than 12 months. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell these investments before recovery of their amortized cost basis, which may be at maturity. The Company reviews its investments to identify and evaluate investments that have an indication of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the investee, and the Company’s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.</p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (2)</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 201</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">none</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of these securities were classified as cash and cash equivalents on the Company’s balance sheet and </span><span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9</span></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> corporate debt</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> securities were scheduled to mature outside of one year</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> at the time of purchase</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td></tr></table></div> 27973000 27973000 191350000 94000 148000 191296000 219323000 94000 148000 219269000 38 80 35000 94000 21000 148000 0 0 53400000 53400000 1495000 1495000 265754000 190000 178000 265766000 267249000 190000 178000 267261000 87 66 22000 190000 32000 178000 0 0 5900000 5900000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fair Value of Financial Instruments</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s financial instruments consist of cash and cash equivalents, investments and accounts payable. The carrying amounts reported in the accompanying balance sheets for cash and cash equivalents and accounts payable approximate fair value because of the short-term maturity of those instruments. Fair value measurements are classified and disclosed in one of the following three categories:</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 1<span style="font-weight:normal;"> —Quoted prices in active markets for identical assets or liabilities.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 2<span style="font-weight:normal;"> —Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 3<span style="font-weight:normal;"> —Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020 and 2019, all of the Company’s financial assets that were subject to fair value measurements were valued using observable inputs. The Company’s financial assets valued based on Level 1 inputs consist of money market funds and certificates of deposit. The Company’s financial assets valued based on Level 2 inputs consist of corporate debt securities, which consist of investments in highly-rated investment-grade corporations. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s investment strategy is focused on capital preservation. The Company invests in instruments that meet the credit quality standards outlined in the Company’s investment policy. This policy also limits the amount of credit exposure to any one issue or type of instrument. As of December 31, 2020, the Company’s investments were in government money market funds, commercial paper and corporate debt securities.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair values of the Company’s financial instruments are presented below (in thousands):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets carried at fair value:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government money market funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,868</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,868</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper, available for sale</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,973</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,973</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities, available-for-sale</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">191,296</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">191,296</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">246,137</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,868</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">219,269</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets carried at fair value:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government money market funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,671</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,671</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities, available-for-sale</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,498</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,498</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper, available for sale</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,495</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,495</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities, available-for-sale</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">265,766</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">265,766</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">274,430</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,671</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">270,759</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair values of the Company’s financial instruments are presented below (in thousands):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets carried at fair value:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government money market funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,868</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,868</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper, available for sale</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,973</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,973</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities, available-for-sale</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">191,296</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">191,296</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">246,137</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,868</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">219,269</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets carried at fair value:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government money market funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,671</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,671</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities, available-for-sale</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,498</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,498</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper, available for sale</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,495</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,495</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities, available-for-sale</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">265,766</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">265,766</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">274,430</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,671</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">270,759</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 26868000 26868000 27973000 27973000 191296000 191296000 246137000 26868000 219269000 3671000 3671000 3498000 3498000 1495000 1495000 265766000 265766000 274430000 3671000 270759000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Agreements with Ligand Pharmaceuticals Incorporated</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the Company entered into a master license agreement with Ligand, as amended (the “Master License Agreement”), pursuant to which, among other things, the Company acquired the rights to a number of research and development programs under patents related to the Company’s VK2809, VK0214, VK5211, VK0612, erythropoietin receptor (“EPOR”) and diacylglycerol acyltransferase-1 (“DGAT-1”) programs, related know-how controlled by Ligand and physical quantities of VK2809, VK0214, VK5211, VK0612, EPOR and DGAT-1 compounds.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the terms of the Master License Agreement, the Company has the exclusive right and sole responsibility and decision-making authority for researching and developing any pharmaceutical products that contain or comprise one or any combination of the technology and compounds licensed from Ligand pursuant to the Master License Agreement (the “Licensed Products”). The Company also has the exclusive right and sole responsibility and decision-making authority to conduct all clinical trials and preclinical studies that the Company believes are appropriate to obtain the regulatory approvals necessary for commercialization of the Licensed Products, and the Company will own and maintain all regulatory filings and all regulatory approvals for the Licensed Products. Additionally, pursuant to the terms of the Master License Agreement, the Company has the sole decision-making authority and responsibility and the exclusive right to commercialize any of the Licensed Products, either by itself or, in certain circumstances, through sublicensees selected by the Company. The Company also has the exclusive right to manufacture or have manufactured any Licensed Product itself or, in certain circumstances, through sublicensees or third parties selected by the Company. The Company will own any intellectual property that it develops in connection with the license granted under the Master License Agreement.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As partial consideration for the grant of the rights and licenses to the Company under the Master License Agreement, the Company issued to Ligand at the closing of the Company’s initial public offering (“IPO”) 3,655,964 shares of its common stock having an estimated aggregate value of $29.2 million. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As further partial consideration for the grant of the rights and licenses to the Company by Ligand under the Master License Agreement, the Company has agreed to pay to Ligand certain one-time, non-refundable milestone payments in connection with the Licensed Products of up to $1.54 billion in the aggregate upon the achievement of certain development, regulatory and sales milestones. The Company will also pay to Ligand royalties on aggregate annual worldwide net sales of Licensed Products by the Company, its affiliates and its sublicensees at tiered percentage rates from the low-to-upper single digits based upon net sales.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of the Master License Agreement will continue unless the agreement is terminated by the Company or Ligand, and each of the Company and Ligand have the right to terminate the Master License Agreement in certain circumstances, including, without limitation, if the other party defaults on certain of its obligations under the Master License Agreement.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ligand has the right to terminate the Master License Agreement under certain circumstances, including, but not limited to: (1) in the event of the Company’s insolvency or bankruptcy, (2) if the Company does not pay an undisputed amount owing under the Master License Agreement when due and fails to cure such default within a specified period of time, or (3) if the Company defaults on certain of its material and substantial obligations and fails to cure the default within a specified period of time. The Company has the right to terminate the Master License Agreement under certain circumstances, including, but not limited to: (i) if Ligand does not pay an undisputed amount owing under the Master License Agreement when due and fails to cure such default within a specified period of time, or (ii) if Ligand defaults on certain of its material and substantial obligations and fails to cure the default within a specified period of time. In addition, provisions of the Master License Agreement can be terminated on a licensed program-by-program basis under certain circumstances. In the event that the Master License Agreement is terminated in its entirety or with respect to a specific licensed program for any reason: (A) all licenses granted to the Company under the Master License Agreement (or with respect to the specific licensed program) will terminate and the Company will, upon Ligand’s request (subject to Ligand assuming legal responsibility for any clinical trials of the Licensed Products then ongoing), assign and transfer to Ligand (or to such transferee as Ligand may direct), at no cost to Ligand, all regulatory documentation and all regulatory approvals prepared or obtained by the Company or on its behalf related to the Licensed Products (or those related to the specific licensed program), or, if Ligand does not make such a request, the Company will wind down any ongoing clinical trials with respect to the Licensed Products (or those related to the specific licensed program) at no cost to Ligand; (B) the Company will, upon Ligand’s request, sell and transfer to Ligand (or to such transferee as Ligand may direct), at a price equal to 125% of the Company’s costs of goods, any and all chemical, biological or physical materials relating to or comprising the Licensed Products (or those related to the specific licensed program); (C) the Company will have, for a period of six months following termination, the right to sell on the normal business terms in existence before such termination any finished commercial inventory of Licensed Products (or those related to the specific licensed program) which remains on hand, so long as the Company pays to Ligand the applicable royalties and sales milestones; (D) Ligand has the right to require the Company to assign to Ligand the trademarks owned by the Company relating to the Licensed Products (or those related to the specific licensed program); and (E) the Company will grant to Ligand a non-exclusive, worldwide, royalty-bearing sublicensable license under any patent rights and know-how controlled by the Company to the extent necessary to make, have made, import, use, offer to sell and sell the Licensed Products (or those related to the specific licensed program) anywhere in the world at a royalty rate in the low single digits.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Master License Agreement, the Company has agreed to indemnify Ligand for claims relating to the performance of the Company’s obligations under the Master License Agreement, any breach of the representations and warranties made by the Company under the Master License Agreement, clinical trials conducted by the Company and the research, development and commercialization of the Licensed Products by the Company and its affiliates, sublicensees, distributors and agents. In addition, Ligand has agreed to indemnify the Company for claims relating to the performance of its obligations under the Master License Agreement, its breach of representations and warranties under the agreement and its research and development of the licensed compounds before the effective date of the Master License Agreement. Each party’s indemnification obligations will not apply to the extent the claims result from the negligence or willful misconduct of the indemnified party or any of its employees, agents, officers or directors or from the indemnified party’s breach of its representations or warranties set forth in the Master License Agreement.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the Company also entered into a Management Rights Letter (the “Management Rights Letter”) with Ligand that requires the Company to expand the size of the Company’s board of directors to create an additional directorship on the Company’s board of directors and to allow Ligand to appoint an individual to fill the new directorship. The Management Rights Letter will terminate upon the earliest to occur of the liquidation or indefinite cessation of the Company’s business operations, the execution by the Company of a general assignment for the benefit of creditors or the appointment of a receiver or trustee to take possession of the Company’s property and assets, an acquisition of the Company by means of any transaction (including, without limitation, any reorganization, merger or consolidation) if the Company’s stockholders of record as constituted immediately prior to the transaction hold less than 50% of the voting power of the surviving or acquiring entity, or following the issuance of the Company’s securities pursuant to the Master License Agreement, the date that Ligand ceases to beneficially own at least 7.5% of the Company’s outstanding voting stock, or the date of May 21, 2024.  </p> 2014-05 3655964 29200000 1540000000 0 1.25 0.50 0.075 2024-05-21 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.<span style="margin-left:36pt;"/><span style="color:#000000;font-family:inherit;">Operating Leases – Right-of-Use Assets and Lease Liability Obligations</span></p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-family:inherit;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has only one operating lease which is for office space that expires in January 2022. Below is a summary of the Company’s right-of-use assets and lease liabilities as of December 31, 2020 and 2019 (in thousands, except for years and %):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.68%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right of use assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">321</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">598</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability obligations, current</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">330</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">302</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability obligations, less current portion</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">360</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease liability obligations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">359</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">662</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.08  years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.08  years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.00</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.00</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-family:inherit;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2020 and 2019, the Company recognized $319,000 and $308,000, respectively, in operating lease expenses, which are included in operating expenses in the Company’s statement of operations. </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-family:inherit;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approximate future minimum lease payments for the Company’s right-of-use assets over the remaining lease period as of December 31, 2020 are as follows (in thousands):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.26%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.96%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">343</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.26%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">372</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: amount representing interest</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.96%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease liability obligations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.96%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">359</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:13pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The operating lease provides the Company with an option to extend the term of the lease for a period of three years beyond the expiration date of January 2022. If the option is exercised, the renewal term will be upon the same terms and conditions as the original agreement, except that the base rent will be equal to the prevailing market rate as determined pursuant to the terms of the lease.  The option to extend the operating lease was not recognized as part of the Company’s lease liability and right-of-use assets.  </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-family:inherit;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has only one operating lease which is for office space that expires in January 2022. Below is a summary of the Company’s right-of-use assets and lease liabilities as of December 31, 2020 and 2019 (in thousands, except for years and %):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.68%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right of use assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">321</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">598</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability obligations, current</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">330</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">302</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability obligations, less current portion</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">360</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease liability obligations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">359</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">662</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.08  years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.08  years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.00</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.00</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> 1 2022-01 321000 598000 330000 302000 29000 360000 359000 662000 P1Y29D P2Y29D 0.0600 0.0600 308000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-family:inherit;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approximate future minimum lease payments for the Company’s right-of-use assets over the remaining lease period as of December 31, 2020 are as follows (in thousands):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.26%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.96%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">343</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.26%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">372</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: amount representing interest</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.96%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease liability obligations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.96%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">359</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 343000 29000 372000 13000 359000 The operating lease provides the Company with an option to extend the term of the lease for a period of three years beyond the expiration date of January 2022. P3Y <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stockholders’ Equity </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is authorized to issue up to 10,000,000 shares of $0.00001 par value preferred stock, with no shares of preferred stock outstanding as of December 31, 2020 and 2019. The Board of Directors is authorized to designate the terms and conditions of any preferred stock the company issues without further action by the common stockholders.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is authorized to issue up to 300,000,000 shares of common stock, $0.00001 par value per share.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2014, the Company entered into a stock purchase agreement with one of its founders. The agreement provided for the purchase of 1,000,000 shares of the Company’s common stock at a price per share of $0.01 in exchange for future services to be rendered to the Company as measured by certain performance criteria. The shares were subject to a repurchase option and were to vest in two tranches of 500,000 shares each, upon achievement of the performance target or upon a triggering event as defined.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the fair value of the unrecognized expense was $168,000 at February 20, 2014, the grant date. In May 2015, the Company repurchased 633,810 of these shares at a purchase price of $0.00001 per share. In connection with the repurchase, the Company entered into an amendment to the stock purchase agreement to provide that the remaining 366,190 shares will continue to vest in two tranches of 183,095 shares each, upon achievement of the performance target or upon a triggering event as defined. The pro rata grant date fair value of the unrecognized expense is $62,000.  In October 2015, a triggering event became probable of occurrence and was deemed achieved in October 2016; therefore, the Company recorded $31,000 of stock-based compensation expense through December 31, 2016.  No similar expense was recognized during the years ended December 31, 2020 and 2019.  The Company will continue to reassess at each reporting period whether it is probable that the performance target will be achieved, and if and when it is deemed probable, the Company will begin to record compensation expense using the fair value to determine stock-based compensation expense in its financial statements over the period the Company estimates the performance target will actually be achieved.<span style="color:#000000;font-family:inherit;">    </span></p> <p style="margin-top:13pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 8, 2017, the Company entered into a Stock Purchase Agreement (the “SPA”), with PoC Capital, LLC (“PoC”) pursuant to which, among other things, the Company issued to PoC 1,286,173 shares of its common stock.  Under the terms of the SPA, PoC has agreed to fund $1,800,000 in study costs associated with certain clinical studies.  Any study costs in excess of that amount will be the Company’s sole responsibility.  The Company has accounted for the $1,800,000 as a prepaid expense on the balance sheet, which was fully amortized as of December 31, 2020.  The Company recorded amortization expense of $140,000 in clinical study costs related to the SPA with PoC during the year ended December 31, 2019.  No similar expense was recognized during the year ended December 31, 2020.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 28, 2017, the Company entered into the Registered Offering Purchase Agreement, pursuant to which, on September 29, 2017, the Company sold to Lincoln Park Capital Fund, LLC (“LPC”), 701,282 shares of common stock, at a price of approximately $1.78 per share for an aggregate purchase price of $1.3 million, pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-212134), filed with the SEC on June 20, 2016, as amended by Amendment No. 1 thereto filed with the SEC on July 26, 2016, and declared effective on July 26, 2016, and the prospectus supplement thereto dated September 28, 2017.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 28, 2017, the Company also entered into the Commitment Purchase Agreement and the LPC Registration Rights Agreement with LPC, pursuant to which the Company has the right to sell to LPC up to $15,000,000 in shares of common stock, subject to certain limitations and conditions set forth in the Commitment Purchase Agreement. Upon the Commencement, the Company will have the right, from time to time at its sole discretion over the 30-month period from and after the Commencement, to direct LPC to purchase up to 75,000 shares of common stock on any business day (subject to certain limitations contained in the Commitment Purchase Agreement), with such amounts increasing based on certain threshold prices set forth in the Commitment Purchase Agreement; however, not to exceed $1.0 million in total purchase proceeds per purchase date. The purchase price of shares of common stock that the Company elects to sell to LPC pursuant to the Commitment Purchase Agreement will be based on the market prices of the common stock at the time of such purchases as set forth in the Commitment Purchase Agreement. In addition to regular purchases, as described above, the Company may also direct LPC to purchase additional amounts as accelerated purchases or as additional purchases if the closing sale price of the common stock is not below certain threshold prices, as set forth in the Commitment Purchase Agreement. In all instances, the Company may not sell shares of its common stock to LPC under the Commitment Purchase Agreement if it would result in LPC beneficially owning more than 4.99% of the Common Stock. <span style="color:#000000;">As consideration for LPC’s commitment to purchase shares of common stock pursuant to the Commitment Purchase Agreement, the Company issued to LPC 100,000 shares of common stock</span>.  <span style="color:#000000;">From inception of the Commitment Purchase Agreement through December 31, 2017, </span>343,051 shares were issued pursuant to the <span style="color:#000000;">Commitment Purchase </span>Agreement resulting in aggregate gross proceeds of $802,000 in addition to the Initial Shares and the Commitment Shares. <span style="Background-color:#FFFFFF;">In May 2020, the Company extended the </span></p> <p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">termination date of the Commitment Purchase Agreement to May 1, 2023.</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> additional shares were issued </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">period of January 1, 2018 through December 31, </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 1, 2019, the Company entered into an At-The-Market Equity Offering Sales Agreement (the “ATM Agreement”) with <span style="color:#000000;">Stifel, Nicolaus &amp; Company, Incorporated and Oppenheimer &amp; Co. Inc.</span> (each, an “Agent” and, together, the “Agents”), pursuant to which the Company may offer and sell, from time to time, through or to the Agents, as sales agent or principal (the “ATM Offering”), shares of its common stock having an aggregate offering price of up to $75.0 million (the “Shares”).  Any Shares offered and sold in the ATM Offering will be issued pursuant to the 2018 Shelf Registration Statement and the 424(b) prospectus supplement relating to the ATM Offering dated August 1, 2019. No shares of the Company’s common stock were sold under the ATM Agreement from its inception through December 31, 2020. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 17, 2020, the Company’s Board of Directors authorized a stock repurchase program, whereby the Company may purchase up to $50.0 million in shares of its common stock and outstanding warrants to purchase its common stock, over a period of up to two years (the “Repurchase Program”). The Repurchase Program may be carried out at the discretion of a committee of the Company’s Board of Directors through open market purchases, one or more Rule 10b5-1 trading plans, block trades and in privately negotiated transactions. Through December 31, 2020, no shares of the Company’s common stock or warrants to purchase its common stock were repurchased by the Company under the Repurchase Program. Shares repurchased by the Company under the Repurchase Program, if any, are expected to be held in treasury until such time as they are reissued or retired by the Company.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2020 and 2019, and in accordance with the Company’s 2014 Employee Stock Purchase Plan (the “ESPP”), the Company issued an aggregate of 34,595 and 20,114 shares of its common stock to certain employees, respectively.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"> </p> 10000000 10000000 0.00001 0.00001 0 0 300000000 0.00001 1000000 0.01 2 500000 500000 168000 633810 0.00001 366190 183095 183095 62000 31000 0 0 1286173 1800000 1800000 140000 0 701282 1.78 1300000 2016-06-20 15000000 P30M 75000 1000000.0 0.0499 100000 343051 802000 0 0 75000000.0 0 50000000.0 0 34595 20114 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stock-Based Compensation</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the IPO, the Company’s 2014 Equity Incentive Plan (the “2014 Plan”) and the ESPP became effective on April 28, 2015, the date of the execution and delivery of the underwriting agreement for the IPO. A total of 1,527,770 shares of the Company’s common stock were initially reserved for issuance under the 2014 Plan, and 458,331 shares of the Company’s common stock were initially reserved for issuance under the ESPP.  From January 1, 2016 and through December 31, 2020, in accordance with the terms of the 2014 Plan, an additional 7,366,810 shares of the Company’s common stock were added to the number of shares reserved for issuance under the 2014 Plan, respectively, and, in accordance with the terms of the ESPP, an additional 2,104,802 shares of the Company’s common stock were added to the number of shares reserved for issuance under the ESPP, respectively.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generally uses the straight-line method to allocate compensation cost to reporting periods over each optionee’s requisite service period, which is generally the vesting period, and estimates the fair value of stock-based awards or restricted stock units to employees and directors using the Black-Scholes option-valuation model. The Black-Scholes model requires the input of subjective assumptions, including volatility, the expected term and the fair value of the underlying common stock on the date of grant, among other inputs. For restricted stock and restricted stock unit awards, the Company generally uses the straight-line method to allocate compensation cost to reporting periods over the holder’s requisite service period, which is generally the vesting period, and uses the fair value at grant date to value the awards. For restricted stock that vests upon the satisfaction of certain performance conditions, the Company recognizes stock-based compensation expense when it becomes probable that the performance conditions will be met. At the grant date, the Company determines the grant date fair value, as a publicly traded company, using the intrinsic value, or the closing price of its common stock on the date of grant. At the point where the criteria are deemed probable of being met, the Company records stock-based compensation with a cumulative catch-up expense in the period first recognized and then on a straight-line basis over the remaining period for which the performance criteria are expected to be completed.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the ESPP, the Company generally recognizes compensation expense for the fair value of the purchase options, as measured on the grant date, and uses the graded vesting method to allocate this compensation cost to each purchase period within the related two-year offering period. As the ESPP also allows for up to one increase in contributions during each purchase period, then as an employee elects to increase their contributions, the Company treats this as an accounting modification. The pre- and post-modification values are calculated on the date of the modification, and the incremental expense is then amortized over the remaining purchase periods.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2014 Plan.<span style="font-style:normal;"> The 2014 Plan provides that the compensation committee of the Company’s Board of Directors (the “Compensation Committee”) may grant or issue stock options, stock appreciation rights, restricted shares, restricted stock units and unrestricted shares, deferred share units, performance and cash-settled awards and dividend equivalent rights to participants under the 2014 Plan. Initially, a total of 1,527,770 shares of the Company’s common stock were reserved for issuance pursuant to the 2014 Plan. The number of shares available for issuance under the 2014 Plan will, unless otherwise determined by the Company’s Board of Directors or the Compensation Committee, be automatically increased on January 1st of each year commencing on January 1, 2016 and ending on (and including) January 1, 2024, in an amount equal to 3.5% of the total number of shares of the Company’s common stock outstanding on December 31st of the preceding calendar year. The shares of common stock deliverable pursuant to awards under the 2014 Plan are authorized but unissued shares of the Company’s common stock, or shares of the Company’s common stock that the Company otherwise holds in treasury or in trust. Any shares of the Company’s common stock underlying awards that are settled in </span></p> <p style="margin-top:12pt;margin-bottom:0pt;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:normal;">cash or otherwise expire, or are forfeited, terminated or cancelled (including pursuant to an exchange program established by the Compensation Committee) prior to the issuance of stock will again be available for issuance under the 2014 Plan. In addition, shares of the Company’s common stock that are withheld (or not issued) in payment of the exercise price or taxes relating to an award, and shares of the Company’s common stock equal to the number surrendered in payment of any exercise price or withholding taxes relating to an award, will again be available for issuance under the 2014 Plan.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ESPP.<span style="font-style:normal;"> Initially, a total of 458,331 shares of the Company’s common stock were reserved for issuance pursuant to the ESPP. The number of shares available for issuance under the ESPP will, unless otherwise determined by the Company’s Board of Directors or the Compensation Committee, be automatically increased on January 1st of each year commencing on January 1, 2016 and ending on (and including) January 1, 2024, in an amount equal to 1% of the total number of shares of the Company’s common stock outstanding on December 31st of the preceding calendar year. The shares of common stock available for purchase pursuant to the ESPP are authorized but unissued shares of the Company’s common stock, shares of the Company’s common stock that the Company otherwise holds in treasury or shares of the Company’s common stock that were purchased on the open market in arms’ length transactions in accordance with applicable securities laws. Shares of the Company’s common stock will be offered for purchase under the ESPP as determined by the Compensation Committee through a series of successive offerings that each have a term of 24 months and consist of four consecutive purchase periods of six months each. Prior to the commencement of any future offering under the ESPP, the Compensation Committee may determine that the current offering shall end, may commence a new offering on the first day after the end of such terminal purchase period (or any desired later date), and may decide that future offerings will consist of one or more consecutive purchase periods, each to be of such duration as determined by the Compensation Committee; however, no offering will exceed 27 months and no purchase period will exceed one year. Each employee of the Company who (1) is an employee on the first date of any offering under the ESPP, (2) is customarily scheduled to work for more than 20 hours per week and more than five months per calendar year, and (3) meets such other criteria as may be determined by the Compensation Committee (consistent with Section 423 of the Internal Revenue Code of 1986, as amended), is eligible to participate in the ESPP for each purchase period within such offering. The purchase price per share of the Company’s common stock under the ESPP may not be less than, and will initially be equal to, the lesser of: (1) 85% of the fair market value per share of the Company’s common stock on the first day of the offering, or (2) 85% of the fair market value per share of the Company’s common stock on the date the purchase right is exercised, which will be the last day of the applicable purchase period.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2020 and 2019, the Company recognized the following stock-based compensation expense (in thousands):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense by type of award:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,096</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,401</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock and restricted stock units</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,529</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,126</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock purchase plan</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">193</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">216</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense included</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   in expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,818</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,743</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense by line item:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,359</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">953</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,459</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,790</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense included</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   in expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,818</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,743</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the Company’s unrecognized stock-based compensation expense, net of estimated forfeitures, by type of award and the weighted-average period over which that expense is expected to be recognized (in thousands, except for years):</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expense</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recognition</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Period</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Type of award:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,747</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000470">2.45</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock and restricted stock units</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,548</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000471">1.66</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table is a summary of restricted shares granted during the years ended December 31, 2020 and 2019:</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2018</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183,095</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.17</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchased</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183,095</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.17</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchased</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183,095</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.17</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes restricted stock unit activity during the years ended December 31, 2020 and 2019:</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2018</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128,125</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.37</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">343,524</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.80</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,122</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.40</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(60,801</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.57</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">352,726</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.35</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">493,996</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.77</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(128,859</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.12</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,500</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.16</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">679,363</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.65</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2019, the Company issued 221,600 performance based restricted stock units (“PRSU awards”) to several of its employees, which are reflected in the above summary of restricted stock unit activity.  The shares subject to the PRSU awards shall vest upon the Company achieving certain milestones, with 100% of the PRSU awards vesting upon the achievement of three of the milestones over a <span style="-sec-ix-hidden:F_000500">four-year</span> period, with any then-unvested portion of the PRSU awards to be cancelled on the four-year anniversary of the grant dates.  As of December 31, 2020, 40,000 PRSU awards were forfeited and three of the milestones were deemed as probable of achievement, resulting in the Company recording stock-based compensation expense of $383,000 and $734,000 during the year ended December 31, 2020 and 2019, respectively. </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2020, the Company issued 244,000 PRSU awards to several of its employees, which are reflected in the above table summarizing restricted stock unit activity.  The shares subject to these PRSU awards shall vest upon the Company achieving certain milestones, with 100% of the PRSU awards vesting upon the achievement of three of the milestones over a four-year period, with any then-unvested portion of the PRSU awards to be cancelled on the <span style="-sec-ix-hidden:F_000508">four-year</span> anniversary of the grant dates.  As of December 31, 2020, 10,500 PRSU awards were forfeited, and one of the three milestones has been met and the remaining two were deemed probable of achievement, resulting in the Company recording a stock-based compensation expense of $1.2 million during the year ended December 31, 2020. </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity during the years ended December 31, 2020 and 2019:</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term (in years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate Intrinsic Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding at December 31, 2018</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,014,047</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.72</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">855,787</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.82</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(82,337</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.40</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">423,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(207,021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.51</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding at December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,580,476</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.90</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000532">7.66</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,643,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">960,472</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.26</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(86,125</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.47</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">430,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(83,500</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.35</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,371,323</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.57</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000533">7.32</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,577,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable at December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,787,377</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.58</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000534">6.35</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,821,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company received $213,000 and $197,000 in cash proceeds from exercises of stock options during the years ended December 31, 2020 and 2019, respectively.   </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total fair value of stock options that vested during the years ended December 31, 2020 and 2019 was $2.6 million and $1.3 million, respectively.</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation expense for stock options granted to employees is based on the estimated grant date fair value and is recognized ratably over the vesting period of the applicable option. The estimated per share weighted average fair value of stock options granted to employees during the years ended December 31, 2020 and 2019 was $4.89 and $5.34, respectively. </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As stock-based compensation expense recognized is based on options ultimately expected to vest, the fair value of each employee option grant during the years ended December 31, 2020 and 2019 was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions:</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77.3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77.9</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000548">6.09</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000549">6.01</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.26</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">     </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected Volatility.<span style="font-style:normal;"> The expected volatility rate used to value stock option grants is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the pharmaceutical and biotechnology industry in a similar stage of development to the Company.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected Term<span style="font-style:normal;">. The Company elected to utilize the “simplified” method for “plain vanilla” options to value stock option grants. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Risk-free Interest Rate<span style="font-style:normal;">. The risk-free interest rate assumption was based on zero-coupon U.S. Treasury instruments that had terms consistent with the expected term of the Company’s stock option grants.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected Dividend Yield<span style="font-style:normal;">. The Company has never declared or paid any cash dividends and does not presently plan to pay cash dividends in the foreseeable future.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeitures are accounted for as actual forfeitures occur.   </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the Company had a net operating loss carryforward as of December 31, 2020, no excess tax benefits for the tax deductions related to stock-based awards were recognized in the Statements of Operations.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Common Stock Reserved for Future Issuance</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved for future issuance as of December 31, 2020 is as follows:</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,244,500</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">679,363</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,371,323</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available for grant under the 2014 Plan</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,081,253</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available for issuance under Employee Stock Purchase Plan</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,289,561</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,666,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> 1527770 458331 7366810 2104802 Initially, a total of 1,527,770 shares of the Company’s common stock were reserved for issuance pursuant to the 2014 Plan. The number of shares available for issuance under the 2014 Plan will, unless otherwise determined by the Company’s Board of Directors or the Compensation Committee, be automatically increased on January 1st of each year commencing on January 1, 2016 and ending on (and including) January 1, 2024, in an amount equal to 3.5% of the total number of shares of the Company’s common stock outstanding on December 31st of the preceding calendar year. 0.035 The number of shares available for issuance under the ESPP will, unless otherwise determined by the Company’s Board of Directors or the Compensation Committee, be automatically increased on January 1st of each year commencing on January 1, 2016 and ending on (and including) January 1, 2024, in an amount equal to 1% of the total number of shares of the Company’s common stock outstanding on December 31st of the preceding calendar year. 0.01 P24M 4 P6M P27M P1Y 0.85 0.85 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2020 and 2019, the Company recognized the following stock-based compensation expense (in thousands):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense by type of award:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,096</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,401</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock and restricted stock units</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,529</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,126</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock purchase plan</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">193</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">216</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense included</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   in expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,818</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,743</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense by line item:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,359</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">953</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,459</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,790</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense included</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   in expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,818</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,743</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 3096000 2401000 2529000 1126000 193000 216000 5818000 3743000 1359000 953000 4459000 2790000 5818000 3743000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the Company’s unrecognized stock-based compensation expense, net of estimated forfeitures, by type of award and the weighted-average period over which that expense is expected to be recognized (in thousands, except for years):</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expense</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recognition</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Period</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Type of award:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,747</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000470">2.45</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock and restricted stock units</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,548</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000471">1.66</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> 4747000 2548000 <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table is a summary of restricted shares granted during the years ended December 31, 2020 and 2019:</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2018</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183,095</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.17</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchased</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183,095</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.17</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchased</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183,095</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.17</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> 183095 0.17 183095 0.17 183095 0.17 <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes restricted stock unit activity during the years ended December 31, 2020 and 2019:</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2018</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128,125</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.37</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">343,524</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.80</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,122</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.40</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(60,801</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.57</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">352,726</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.35</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">493,996</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.77</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(128,859</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.12</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,500</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.16</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">679,363</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.65</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 128125 5.37 343524 7.80 58122 5.40 60801 7.57 352726 7.35 493996 7.77 128859 7.12 38500 8.16 679363 7.65 221600 1 3 40000 3 383000 734000 244000 1 3 10500 1 2 1200000 <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity during the years ended December 31, 2020 and 2019:</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term (in years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate Intrinsic Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding at December 31, 2018</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,014,047</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.72</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">855,787</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.82</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(82,337</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.40</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">423,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(207,021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.51</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding at December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,580,476</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.90</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000532">7.66</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,643,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">960,472</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.26</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(86,125</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.47</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">430,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(83,500</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.35</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,371,323</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.57</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000533">7.32</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,577,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable at December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,787,377</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.58</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000534">6.35</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,821,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> 2014047 3.72 855787 7.82 82337 2.40 423000000 207021 6.51 2580476 4.90 8643000000 960472 7.26 86125 2.47 430000000 83500 7.35 3371323 5.57 4577000000 1787377 4.58 3821000000 213000 197000 2600000 1300000 4.89 5.34 the fair value of each employee option grant during the years ended December 31, 2020 and 2019 was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77.3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77.9</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000548">6.09</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000549">6.01</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.26</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">     </p> 0.773 0.779 0.0139 0.0226 0 0 0 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved for future issuance as of December 31, 2020 is as follows:</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,244,500</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">679,363</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,371,323</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available for grant under the 2014 Plan</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,081,253</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available for issuance under Employee Stock Purchase Plan</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,289,561</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,666,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> 5244500 679363 3371323 4081253 2289561 15666000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Warrants</p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 13, 2016, pursuant to the Offering, the Company sold 7,500,000 shares of its common stock and warrants to purchase up to 7,500,000 shares of its common stock at a public offering price of $1.25 per share of common stock and related warrant. The warrants have an exercise price of $1.50 per share of common stock, were immediately exercisable upon issuance and will expire on April 13, 2021. Additionally, on April 13, 2016, the underwriters for the Offering partially exercised the over-allotment option for warrants to purchase an additional 1,125,000 shares of the Company’s common stock at a public offering price of $0.01 per warrant to purchase a share of common stock.  As of December 31, 2020, 3,647,413 warrants were outstanding and 348,493 and 528,695 warrants were exercised during the years ended December 31, 2020 and 2019, respectively.</p> <p style="margin-top:13pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On April 13, 2016, the Company issued to Ligand the Ligand Warrant </span><span style="color:#000000;">to purchase up to 960,000 shares of the Company’s common stock. </span>The Ligand Warrant has an exercise price of $1.50 per share of Company common stock, was immediately exercisable upon issuance (subject to a limitation on exercise to the extent that any exercise thereof would increase Ligand’s<span style="Background-color:#FFFFFF;"> beneficial ownership of the Company’s common stock to greater than 49.9%)</span> and expires on April 13, 2021.  <span style="color:#000000;">The Ligand Warrant was issued to Ligand as a part of the repayment of $1,200,000 of the Company’s </span><span style="Background-color:#FFFFFF;">obligation under </span><span style="color:#000000;">a Secured Convertible Promissory Note previously issued by the Company to Ligand</span>.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 14, 2017, pursuant to the terms of the Securities Purchase Agreement, the Company sold the 3,749,783 Shares and the Warrants to purchase up to 2,812,337 shares of its common stock to the Purchasers.  The combined purchase price for one Share and one Warrant to purchase 0.75 shares of common stock in the Offerings, was $1.15. The closing of the Offerings occurred on June 19, 2017.  The Warrants have an exercise price of $1.30 per share, subject to adjustment as provided therein, and were exercisable beginning on December 19, 2017 through December 19, 2022.  Each holder of a Warrant does not have the right to exercise any portion of its Warrant if the holder, together with its affiliates, would beneficially own in excess of 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise (the “Beneficial Ownership Limitation”); provided, however, that upon 61 days’ prior notice to the Company, the holder may increase the Beneficial Ownership Limitation; however, in no event shall the Beneficial Ownership Limitation exceed 9.99%. The exercise price and number of shares of common stock issuable upon the exercise of the Warrants will be subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Warrants. On January 16, 2018, <span style="color:#000000;">the resale Registration Statement on Form S-1 (File No. 333-222202) that the Company filed related to the 1,987,337 shares subject to unexercised warrants was declared effective by the SEC.  </span>As of December 31, 2020, warrants to purchase an aggregate of 637,087 shares were outstanding and 248,308 and 0 warrants were exercised during the years ended December 31, 2020 and 2019, respectively.</p> 7500000 7500000 1.25 1.50 2021-04-13 1125000 0.01 3647413 348493 528695 960000 1.50 0.499 2021-04-13 1200000 3749783 2812337 0.75 1.15 1.30 2017-12-19 2017-12-19 2022-12-19 2022-12-19 Each holder of a Warrant does not have the right to exercise any portion of its Warrant if the holder, together with its affiliates, would beneficially own in excess of 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise (the “Beneficial Ownership Limitation”); provided, however, that upon 61 days’ prior notice to the Company, the holder may increase the Beneficial Ownership Limitation; however, in no event shall the Beneficial Ownership Limitation exceed 9.99%. 0.0499 P61D 0.0999 1987337 637087 248308 0 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Income Taxes </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense (benefit) from continuing operations consists of the following for the years ended December 31, 2020 and 2019 (in thousands):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,368</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,976</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,356</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,857</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,724</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,833</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,724</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,833</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total income tax expense (benefit)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reconciliations of the U.S. federal statutory tax rate to the effective income tax rate for the years ended December 31, 2020 and 2019 are as follows:</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax provision at U.S. Federal statutory rates</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes net of federal benefit</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-deductible permanent items</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred taxes as of December 31, 2020 and 2019 are as follows (in thousands):</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">248</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,435</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,463</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,649</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,017</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,604</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,632</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Credits</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,518</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,398</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,406</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,763</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation Allowance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(50,316</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,592</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets, net of allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right of use assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(90</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(167</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(90</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(171</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets (liabilities):</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A valuation allowance of $50.3 million and $37.6 million at December 31, 2020 and December 31, 2019, respectively, has been recorded to offset net deferred tax assets, as the Company is unable to conclude that it is more likely than not that such deferred tax assets will be realized.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2020, the Company had approximately $31.0 million of federal net operating loss carryforwards, of which $17.8 million will begin to expire in 2032 and the remaining $13.2 million of which can be carried forward indefinitely.  The Company has $30.6 million of state net operating loss carryforwards that will begin to expire in 2034.  </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s ability to utilize its federal net operating loss carryforwards may be limited under Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”). Specifically, this limitation may arise in the event of an “ownership change,” which is defined by Section 382 of the Code as a cumulative change in ownership of the Company of more than 50% within a three-year period. If the Company undergoes one or more ownership changes in connection with any future transactions in its stock, the Company’s ability to utilize net operating loss carryforwards to offset federal taxable income, if any, could potentially result in increased future tax liability to the Company.  An ownership change under Section 382 of the Code occurred during the year ended December 31, 2018. Of the Company’s $31.0 million and $30.6 million of federal and state net operating loss carryforwards, $18.3 million and $17.9 million are limited based on the Company’s ownership change.  The annual limitation is $5.7 million.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to U.S. federal income tax as well as income tax in various state jurisdictions.  The Company is currently open to audit under the statute of limitations by the Internal Revenue Service and various state agencies for the years ended December 31, 2016 through December 31, 2020.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The differences between the Company’s effective income tax rate and the statutory federal rate for the year ended December 31, 2020 and the year ended December 31, 2019 relate primarily to losses incurred for which no tax benefit was recognized, due to the uncertainty of realization. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. The Company considers projected future taxable income and tax planning strategies in making this assessment. At each of December 31, 2020 and December 31, 2019, the Company provided a full valuation allowance against its deferred tax assets due to uncertainty surrounding the realization of those assets as a result of historical taxable net losses.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2020, the Company has federal and state research and development tax credit carry-forwards of approximately $4.3 million and $2.3 million, respectively.  The federal credits begin to expire in 2036.  The state credits do not expire.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Coronavirus Aid, Relief, and Economic Security (CARES) Act was enacted March 27, 2020.  Among the business provisions, the CARES Act provided for various payroll tax incentives, changes to net operating loss carryback and carryforward rules, business interest expense limitation increases, and bonus depreciation on qualified improvement property.  Additionally, the Consolidated Appropriations Act of 2021 was signed on December 27, 2020 which provided additional COVID relief provisions for businesses.  The Company has evaluated the impact of the both Acts and has determined that any impact is not material to its financial statements.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has reviewed its operations and has not identified any material uncertain tax positions. As a result, there is no liability for uncertain tax positions in the income tax provision as of December 31, 2020 or December 31, 2019.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense (benefit) from continuing operations consists of the following for the years ended December 31, 2020 and 2019 (in thousands):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,368</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,976</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,356</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,857</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,724</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,833</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,724</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,833</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total income tax expense (benefit)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 0 0 0 0 0 0 -9368000 -5976000 -3356000 -1857000 -12724000 -7833000 12724000 7833000 0 0 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reconciliations of the U.S. federal statutory tax rate to the effective income tax rate for the years ended December 31, 2020 and 2019 are as follows:</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax provision at U.S. Federal statutory rates</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes net of federal benefit</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-deductible permanent items</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 0.21 0.21 0.07 0.06 0.01 0.01 -0.01 0.05 0.05 -0.32 -0.30 0 0 Significant components of the Company’s deferred taxes as of December 31, 2020 and 2019 are as follows (in thousands): <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">248</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,435</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,463</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,649</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,017</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,604</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,632</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Credits</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,518</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,398</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,406</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,763</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation Allowance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(50,316</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,592</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets, net of allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right of use assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(90</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(167</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(90</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(171</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets (liabilities):</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 180000 248000 32435000 24463000 8649000 7017000 2604000 1632000 6518000 4398000 20000 5000 50406000 37763000 50316000 37592000 90000 171000 90000 167000 4000 90000 171000 0 0 50300000 37600000 31000000.0 17800000 2032 13200000 30600000 2034 Specifically, this limitation may arise in the event of an “ownership change,” which is defined by Section 382 of the Code as a cumulative change in ownership of the Company of more than 50% within a three-year period. If the Company undergoes one or more ownership changes in connection with any future transactions in its stock, the Company’s ability to utilize net operating loss carryforwards to offset federal taxable income, if any, could potentially result in increased future tax liability to the Company.  An ownership change under Section 382 of the Code occurred during the year ended December 31, 2018. 0.50 31000000.0 30600000 18300000 17900000 5700000 0 0 4300000 2300000 2036 0 0 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Related-Party Transactions</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the Company entered into the Master License Agreement with Ligand, pursuant to which, among other things, Ligand granted the Company an exclusive worldwide license to certain clinical and preclinical programs. See Note 4 for more information related to this agreement. In connection with entering into the Master License Agreement, the Company also entered into a Management Rights Letter (see Note 4) and a Registration Rights Agreement (see Note 4). As Ligand beneficially owns 9.8% of the Company’s outstanding shares as of December 31, 2020, and has a member of its management team on our Board of Directors, the Company considers Ligand to be a related party.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"> </p> 0.098 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Commitments and Contingencies</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 25, 2018, the Company entered into an Office Lease (the “Lease”) with Kilroy Realty, L.P. The Lease is for approximately 7,149 rentable square feet of space located at 12340 El Camino Real, Suite 250, San Diego, California 92130 (the “Premises”). The Premises will continue to be the Company’s corporate headquarters.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:13pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Lease commenced on November 1, 2018 and will expire on January 31, 2022, unless terminated earlier in accordance with the terms of the Lease (the “Term”). Monthly base rent payments due under the Lease for the Premises will be $27,000, subject to annual increases of 3.0% during the Term. Under the Lease, the Company is responsible for certain charges for common area maintenance and other costs, including electricity and utility expenses and the Lease provides for abatement of rent during certain periods and escalating rent payments throughout the Term. Rent expense is being recorded on a straight-line basis over the life of the Lease and the difference between the rent expense and rent paid is being recorded as deferred rent.</p> <p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-23</p> <hr style="page-break-after:always"/> <p style="text-align:justify;margin-bottom:0pt;margin-top:13pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Lease provides the Company with an option to extend the term of the lease for a period of </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">three years</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> beyond the Term. If the option is exercised, the renewal term will be upon the same terms and conditions as the original Term, except that the base rent will be equal to the prevailing market rate as determined pursuant to the terms of the Lease</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense was $319,000 and $308,000 for the years ended December 31, 2020 and 2019, respectively. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum payments pursuant to the Lease are as follows (in thousands):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">343</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">372</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 7149 2018-11-01 2022-01-31 27000 0.030 P3Y 319000 308000 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum payments pursuant to the Lease are as follows (in thousands):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">343</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">372</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 343000 29000 372000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Subsequent Events</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluated subsequent events through the date of the filing of this Annual Report on Form 10-K with the SEC, to ensure that this filing includes appropriate disclosure of events both recognized in the financial statements as of December 31, 2020, and events which occurred subsequent to December 31, 2020 but were not recognized in the financial statements. The Company has determined that there were no subsequent events which required recognition, adjustment to or disclosure in the financial statements.  </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> XML 14 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2020
Jan. 31, 2021
Jun. 30, 2020
Document Information [Line Items]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2020    
Document Fiscal Year Focus 2020    
Document Fiscal Period Focus FY    
Entity Registrant Name Viking Therapeutics, Inc.    
Entity Central Index Key 0001607678    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer No    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Common Stock, Shares Outstanding   74,133,121  
Entity Public Float     $ 469,584,214
Entity Interactive Data Current Yes    
Entity File Number 001-37355    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 46-1073877    
Entity Address, Address Line One 12340 El Camino Real    
Entity Address, Address Line Two Suite 250    
Entity Address, City or Town San Diego    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 92130    
City Area Code 858    
Local Phone Number 704-4660    
Document Annual Report true    
Document Transition Report false    
ICFR Auditor Attestation Flag false    
Documents Incorporated by Reference [Text Block] Portions of the Registrant’s Definitive Proxy Statement for its 2021 Annual Meeting of Stockholders or an amendment to this Annual Report on Form 10-K to be filed with the Securities and Exchange Commission within 120 days of the registrant’s fiscal year ended December 31, 2020 are incorporated by reference into Part III of this Annual Report on Form 10-K.    
Common stock [Member]      
Document Information [Line Items]      
Trading Symbol VKTX    
Title of 12(b) Security Common Stock, par value $0.00001 per share    
Security Exchange Name NASDAQ    
Common stock warrants [Member]      
Document Information [Line Items]      
Trading Symbol VKTXW    
Title of 12(b) Security Warrants to purchase Common Stock, par value $0.00001 per share    
Security Exchange Name NASDAQ    
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.20.4
Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 29,117 $ 8,377
Short-term investments – available for sale 219,269 267,261
Prepaid clinical trial and preclinical study costs 7,276 7,458
Prepaid expenses and other current assets 442 405
Total current assets 256,104 283,501
Right-of-use assets 321 598
Deferred public offering and other financing costs 48 128
Deposits 29 29
Total assets 256,502 284,256
Current liabilities:    
Accounts payable 3,988 2,431
Other accrued liabilities 7,811 4,044
Lease liability, current 330 302
Total current liabilities 12,129 6,777
Lease liability, net of current portion 29 360
Total long-term liabilities 29 360
Total liabilities 12,158 7,137
Commitments and contingencies (Note 11)
Stockholders’ equity:    
Preferred stock, $0.00001 par value: 10,000,000 shares authorized at December 31, 2020 and 2019; no shares issued and outstanding at December 31, 2020 and 2019
Common stock, $0.00001 par value: 300,000,000 shares authorized at December 31, 2020 and 2019; 73,215,940 shares issued and outstanding at December 31, 2020 and 72,413,602 shares issued and outstanding at December 31, 2019 1 1
Additional paid-in capital 412,589 405,803
Accumulated deficit (168,192) (128,697)
Accumulated other comprehensive income (loss) (54) 12
Total stockholders’ equity 244,344 277,119
Total liabilities and stockholders’ equity $ 256,502 $ 284,256
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.20.4
Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2020
Dec. 31, 2019
Statement Of Financial Position [Abstract]    
Preferred stock, par value $ 0.00001 $ 0.00001
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.00001 $ 0.00001
Common stock, shares authorized 300,000,000 300,000,000
Common stock, shares issued 73,215,940 72,413,602
Common stock, shares outstanding 73,215,940 72,413,602
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.20.4
Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Income Statement [Abstract]    
Revenues $ 0 $ 0
Operating expenses:    
Research and development 31,931 23,559
General and administrative 10,731 9,128
Total operating expenses 42,662 32,687
Loss from operations (42,662) (32,687)
Other income (expense):    
Amortization of financing costs (106) (146)
Interest income, net 3,233 7,050
Realized gain on investments 40 4
Total other income, net 3,167 6,908
Net loss (39,495) (25,779)
Other comprehensive gain (loss), net of tax:    
Unrealized gain (loss) on securities (66) 435
Comprehensive loss $ (39,561) $ (25,344)
Basic and diluted net loss per share $ (0.54) $ (0.36)
Weighted-average shares used to compute basic and diluted net loss per share 72,596,647 71,959,093
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.20.4
Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common stock [Member]
Additional Paid-In Capital [Member]
Accumulated Deficit [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Balance at Dec. 31, 2018 $ 297,750 $ 1 $ 401,090 $ (102,918) $ (423)
Balance (in shares) at Dec. 31, 2018   71,742,043      
Employee stock-based compensation, net 3,592   3,592    
Employee stock-based compensation, net (in shares)   (17,709)      
Issuance of common stock under employee stock plans 328   328    
Issuance of common stock under employee stock plans (in shares)   160,573      
Issuance of common stock from warrant exercises 793   793    
Issuance of common stock from warrant exercises (in shares)   528,695      
Unrealized gain (loss) on investments 435       435
Net loss (25,779)     (25,779)  
Balance at Dec. 31, 2019 277,119 $ 1 405,803 (128,697) 12
Balance (in shares) at Dec. 31, 2019   72,413,602      
Employee stock-based compensation, net 5,522   5,522    
Employee stock-based compensation, net (in shares)   (44,042)      
Issuance of common stock under employee stock plans 418   418    
Issuance of common stock under employee stock plans (in shares)   249,579      
Issuance of common stock from warrant exercises 846   846    
Issuance of common stock from warrant exercises (in shares)   596,801      
Unrealized gain (loss) on investments (66)       (66)
Net loss (39,495)     (39,495)  
Balance at Dec. 31, 2020 $ 244,344 $ 1 $ 412,589 $ (168,192) $ (54)
Balance (in shares) at Dec. 31, 2020   73,215,940      
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.20.4
Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Cash flows from operating activities    
Net loss $ (39,495) $ (25,779)
Adjustments to reconcile net loss to net cash used in operating activities    
Amortization of investment premiums 3,808 477
Amortization of financing costs 106 146
Amortization of non-cash clinical trial costs   140
Stock-based compensation 5,818 3,743
Amortization of right-of-use assets 277 260
Interest expense related to operating lease liability 32 48
Realized gain on investments (40) (4)
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets 137 (7,380)
Accrued interest, net of interest received on maturity of investments 2,590 1,971
Accounts payable 1,555 1,472
Accrued expenses 3,768 423
Lease liability (333) (269)
Net cash used in operating activities (21,777) (24,752)
Cash flows from investing activities    
Purchases of investments (280,636) (362,406)
Proceeds from sales and maturities of investments 322,203 369,869
Net cash provided by investing activities 41,567 7,463
Cash flows from financing activities    
Public offering and financing costs (26) (73)
Value of shares withheld related to employee tax withholding (296) (151)
Proceeds from stock issuance under employee stock purchase plan and warrant exercises 1,272 1,111
Net cash provided by financing activities 950 887
Net increase (decrease) in cash and cash equivalents 20,740 (16,402)
Cash and cash equivalents beginning of period 8,377 24,779
Cash and cash equivalents end of period 29,117 8,377
Supplemental disclosure of non-cash investing and financing transactions    
Unpaid deferred public offering and other financing costs 50 50
Receivable from exercise of warrants $ 1 $ 10
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.20.4
Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies

 

 

1.

Organization, Liquidity and Management’s Plan, and Summary of Significant Accounting Policies

The Company

Viking Therapeutics, Inc., a Delaware corporation (the “Company”), is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders.

The Company was incorporated under the laws of the State of Delaware on September 24, 2012 and its principal executive offices are located in San Diego, CA.

Basis of Presentation

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

 

Risks and Uncertainties

 

The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on the Company’s business is highly uncertain and difficult to predict, as the responses that the Company, other businesses and governments are taking continue to evolve. Furthermore, capital markets and economies worldwide have also been negatively impacted by the COVID-19 pandemic, and it is possible that it could cause a local and/or global economic slowdown or recession. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remain uncertain.

In addition, the Company’s clinical trials have been affected by and may continue to be affected by the COVID-19 pandemic. Clinical site initiation and patient enrollment have been and may continue to be delayed due to prioritization of hospital resources toward the COVID-19 pandemic. Some patients have not been and others may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, any inability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, may adversely impact the Company’s clinical trial operations.

 

The severity of the impact of the COVID-19 pandemic on the Company’s business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company’s service providers, suppliers, contract research organizations (“CROs”) and the Company’s clinical trials, all of which are uncertain and cannot be predicted. As of the date of issuance of Company’s financial statements, the extent to which the COVID-19 pandemic may materially impact the Company’s financial condition, liquidity or results of operations is uncertain.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Significant estimates made in preparing these financial statements relate to accounting for operating lease and certain commitments. Actual results could differ from those estimates.

 

Reclassification

 

Certain amounts reported in prior years in the Statements of Cash Flows have been reclassified to conform to the current year’s presentation.

Cash and Cash Equivalents

The Company considers all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents.

Investments Available-for-Sale

Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in accumulated other comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of

discounts to maturity. The amortization of premiums and accretion of discounts is included in interest income. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in other income (expense). The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income.

Concentration of Credit Risk

Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents and marketable securities. The Company maintains deposits in federally insured depository institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.

Prepaid Clinical Trial and Preclinical Study Costs

Prepaid clinical trial and preclinical study costs represent advance payments by the Company for future clinical trial and preclinical study services to be performed by the clinical research organization and other research organizations.  Such amounts are recognized as research and development expense as the related clinical trial and preclinical study services are performed.  

 

Leases

The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use (“ROU”) assets, and lease liability obligations are included in the Company’s balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liability obligations represent its obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company’s leases typically do not provide an implicit rate, the Company estimates its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company uses the implicit rate when readily determinable. The ROU asset also includes any lease payments made and excludes lease incentives and lease direct costs. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. Please refer to Note 5 for additional information.

Deferred Financing Costs

Deferred financing costs represent legal, accounting and other direct costs related to the Company’s efforts to raise capital through a public or private sale of the Company’s common stock. Costs related to the public sale of the Company’s common stock are deferred until the completion of the applicable offering, at which time such costs are reclassified to additional paid-in-capital as a reduction of the proceeds.  Costs related to the private sale of the Company’s common stock are deferred until the completion of the applicable offering, at which time such costs are amortized over the term of the applicable purchase agreement.

Revenue Recognition

The Company has not recorded any revenues since its inception. However, in the future, the Company may enter into collaborative research and licensing agreements, under which the Company could be eligible for payments made in the form of upfront license fees, research funding, cost reimbursement, contingent event-based payments and/or royalties.

On January 1, 2018, the Company adopted ASU No. 2014-09, Revenue from Contracts with Customers and all related amendments (“ASC 606” or “the revenue standard”). ASC 606 is a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The revenue standard is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, ASC 606 provides that an entity should apply the following steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The revenue standard also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, and costs to obtain or fulfill contracts. The Company will apply ASC 606 prospectively to all contracts.  

Research and Development Expenses

All costs of research and development are expensed in the period incurred. Research and development costs primarily consist of fees paid to contract research organizations (“CROs”) and clinical trial sites, employee and consultant related expenses, which include salaries, benefits and stock-based compensation for research and development personnel, external research and development expenses incurred pursuant to agreements with third-party manufacturing organizations, facilities costs, travel costs, dues and subscriptions, depreciation and materials used in preclinical studies, clinical trials and research and development.

The Company estimates its preclinical study and clinical trial expenses based on the services it received pursuant to contracts with research institutions and CROs that conduct and manage preclinical studies and clinical trials on the Company’s behalf. Clinical trial-related contracts vary significantly in length, and may be for a fixed amount based on milestones or deliverables, a variable amount based on actual costs incurred, capped at a certain limit, or a combination of these elements. The Company accrues service fees based on work performed, which relies on estimates of total costs incurred based on milestones achieved, patient enrollment and other events. The majority of the Company’s service providers invoice the Company in arrears, and to the extent that amounts invoiced differ from its estimates of expenses incurred, the Company accrues for additional costs. The financial terms of these agreements vary from contract to contract and may result in uneven expenses and payment flows. Preclinical study and clinical trial expenses include:

 

•

fees paid to CROs, consultants and laboratories in connection with preclinical studies;

 

•

fees paid to CROs, clinical trial sites, investigators and consultants in connection with clinical trials; and

 

•

fees paid to contract manufacturers and service providers in connection with the production, testing and packaging of active pharmaceutical ingredients and drug materials for preclinical studies and clinical trials.

Payments under some of these agreements depend on factors such as the milestones accomplished, including enrollment of certain numbers of patients, site initiation and the completion of clinical trial milestones. To date, the Company has not experienced any events requiring it to make material adjustments to its accruals for service fees. If the Company does not identify costs that it has begun to incur or if it underestimates or overestimates the level of services performed or the costs of these services, its actual expenses could differ from its estimates which could materially affect its results of operations. Adjustments to the Company’s accruals are recorded as changes in estimates become evident. Furthermore, based on amounts invoiced to the Company by its service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expense in future periods as services are rendered.

In May 2014, the Company entered into a master license agreement, pursuant to which it acquired certain rights to a number of research and development programs from Ligand Pharmaceuticals Incorporated (“Ligand”). In doing so, the Company updated its policy on research and development to include the purchase of rights to intangible assets. In accordance with ASC Topic 730, Research and Development, intangible assets that are acquired and have an alternative future use, as defined, should be capitalized and reported as an intangible asset; however, the cost of acquired intangible assets that do not have alternative future uses should be reported as research and development expense as incurred. The Company notes that intangible assets acquired that are in the preclinical or clinical stages of development when acquired, and not approved by the U.S. Food and Drug Administration, are deemed to have not satisfied the definition of having an alternative future use, as defined. Accordingly, assets acquired in the preclinical and clinical stages of development are expensed as incurred in the Company’s statement of operations.

Patent Costs

Costs related to filing and pursuing patent applications are expensed as incurred to general and administrative expense, as recoverability of such expenditures is uncertain.

Stock-Based Compensation

The Company generally uses the straight-line method to allocate compensation cost to reporting periods over each optionee’s requisite service period, which is generally the vesting period, and estimates the fair value of stock-based awards or restricted stock units to employees and directors using the Black-Scholes option-valuation model (the “Black-Scholes model”). The Black-Scholes model requires the input of subjective assumptions, including volatility, the expected term and the fair value of the underlying common stock on the date of grant, among other inputs. For restricted stock and restricted stock unit awards, the Company generally uses the straight-line method to allocate compensation cost to reporting periods over the holder’s requisite service period, which is generally the vesting period, and uses the fair value at grant date to value the awards. For restricted stock that vests upon the satisfaction of certain performance conditions, the Company recognizes stock-based compensation expense when it becomes probable that the performance conditions will be met. At the grant date, the Company determines the grant date fair value, as a publicly traded company, using the intrinsic value, or the closing price of the Company’s common stock on the date of grant. At the point where the criteria are deemed probable of being met, the Company records stock-based compensation with a cumulative catch-up expense in the period first

recognized and then on a straight-line basis over the remaining period for which the performance criteria are expected to be completed.

For the Company’s 2014 Employee Stock Purchase Plan (the “ESPP”), the Company generally recognizes compensation expense for the fair value of the purchase options, as measured on the grant date, and uses the graded vesting method to allocate this compensation cost to each purchase period within the related two-year offering period. As the ESPP also allows for up to one increase in contributions during each purchase period, as an employee elects to increase his or her contributions, the Company treats this as an accounting modification. The pre- and post-modification values are calculated on the date of the modification, and the incremental expense is then amortized over the remaining purchase periods.    

Income Taxes

The Company accounts for its income taxes using the liability method whereby deferred tax assets and liabilities are determined based on temporary differences between the basis used for financial reporting and income tax reporting purposes. Deferred income taxes are provided based on the enacted tax rates in effect at the time such temporary differences are expected to reverse. A valuation allowance is provided for deferred tax assets if it is more likely than not that the Company will not realize those tax assets through future operations.

ASC Topic 740-10, Income Taxes, clarifies the accounting for uncertainty in income taxes recognized in the Company’s financial statements in accordance with GAAP.  Income tax positions must meet a more-likely-than-not recognition threshold to be recognized. Income tax positions that previously failed to meet the more-likely-than-not threshold are recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not threshold are derecognized in the first subsequent financial reporting period in which that threshold is no longer met.

The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.

Net Loss per Common Share

Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. For purposes of this calculation, the Company currently does not have any deemed common share equivalents; therefore, its basic and diluted net loss per share calculations are the same.

The following table presents the computation of basic and diluted net loss per common share (in thousands, except share and per share data):

 

 

 

Year Ended December 31,

 

 

 

2020

 

 

2019

 

Historical net loss per share

 

 

 

 

 

 

 

 

Numerator

 

 

 

 

 

 

 

 

Net loss

 

$

(39,495

)

 

$

(25,779

)

Denominator

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding

 

 

72,779,742

 

 

 

72,142,188

 

Less: Weighted-average shares subject to repurchase

 

 

(183,095

)

 

 

(183,095

)

Denominator for basic and diluted net loss per share

 

 

72,596,647

 

 

 

71,959,093

 

Basic and diluted net loss per share

 

$

(0.54

)

 

$

(0.36

)

 

 

 

Potentially dilutive securities that are not included in the calculation of diluted net loss per share because their effect is anti-dilutive are as follows (in common equivalent shares):

 

 

 

Year Ended December 31,

 

 

 

2020

 

 

2019

 

Common stock warrants

 

 

5,244,500

 

 

 

5,841,301

 

Restricted stock units

 

 

679,363

 

 

 

352,726

 

Common stock subject to repurchase

 

 

183,095

 

 

 

183,095

 

Common stock options

 

 

3,371,323

 

 

 

2,580,476

 

 

 

 

9,478,281

 

 

 

8,957,598

 

 

Segments

The Company operates in only one segment. Management uses cash flows as the primary measure to manage its business and does not segment its business for internal reporting or decision making purposes.

 
XML 21 R8.htm IDEA: XBRL DOCUMENT v3.20.4
Investments in Marketable Securities
 12 Months Ended
Dec. 31, 2020
Investments Debt And Equity Securities [Abstract]  
Investments in Marketable Securities

2.

Investments in Marketable Securities

The Company’s investment strategy is focused on capital preservation. The Company invests in instruments that meet the credit quality standards outlined in the Company’s investment policy. This policy also limits the amount of credit exposure to any one issue or type of instrument.  As of December 31, 2020 and 2019, the Company’s investments were in money market funds, commercial paper and corporate debt securities. There were no sales of available-for-sale securities during the years ended December 31, 2020 and 2019.

Investments classified as available-for-sale as of December 31, 2020 consisted of the following (in thousands):

 

 

 

Amortized

Cost

 

 

Gross

Unrealized

Gains  (1)

 

 

Gross

Unrealized

Losses  (1)

 

 

Aggregate

Estimated

Fair Value

 

Commercial paper  (2)

 

$

27,973

 

 

$

—

 

 

$

—

 

 

$

27,973

 

Corporate debt securities  (2)

 

 

191,350

 

 

 

94

 

 

 

(148

)

 

 

191,296

 

 

 

$

219,323

 

 

$

94

 

 

$

(148

)

 

$

219,269

 

 

(1)

Unrealized gains and losses on available-for-sale securities are included as a component of comprehensive loss. At December 31, 2020, there were 38 securities in an unrealized gain position and 80 securities in an unrealized loss position. The unrealized gains were less than $35,000 individually and $94,000 in the aggregate. The unrealized losses were less than $21,000 individually and $148,000 in the aggregate.  Four of these securities have been in a continuous unrealized loss or unrealized gain position for more than 12 months. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell these investments before recovery of their amortized cost basis, which may be at maturity. The Company reviews its investments to identify and evaluate investments that have an indication of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the investee, and the Company’s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.  

(2)

At December 31, 2020, none of these securities were classified as cash and cash equivalents on the Company’s balance sheet and $53.4 million of the corporate debt securities were scheduled to mature outside of one year at the time of purchase.

Investments classified as available-for-sale as of December 31, 2019 consisted of the following (in thousands):

 

 

 

Amortized

Cost

 

 

Gross

Unrealized

Gains  (1)

 

 

Gross

Unrealized

Losses  (1)

 

 

Aggregate

Estimated

Fair Value

 

Commercial paper  (2)

 

$

1,495

 

 

$

—

 

 

$

—

 

 

$

1,495

 

Corporate debt securities  (2)

 

 

265,754

 

 

 

190

 

 

 

(178

)

 

 

265,766

 

 

 

$

267,249

 

 

$

190

 

 

$

(178

)

 

$

267,261

 

 

(1)

Unrealized gains and losses on available-for-sale securities are included as a component of comprehensive loss. At December 31, 2019, there were 87 securities in an unrealized gain position and 66 securities in an unrealized loss position. These unrealized gains were less than $22,000 individually and $190,000 in the aggregate. The unrealized losses were less than $32,000 individually and $178,000 in the aggregate.  Nine of these securities have been in a continuous unrealized loss or unrealized gain position for more than 12 months. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell these investments before recovery of their amortized cost basis, which may be at maturity. The Company reviews its investments to identify and evaluate investments that have an indication of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the investee, and the Company’s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.

(2)

At December 31, 2019, none of these securities were classified as cash and cash equivalents on the Company’s balance sheet and $5.9 million of the corporate debt securities were scheduled to mature outside of one year at the time of purchase.
XML 22 R9.htm IDEA: XBRL DOCUMENT v3.20.4
Fair Value of Financial Instruments
 12 Months Ended
Dec. 31, 2020
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments

3.

Fair Value of Financial Instruments

The Company’s financial instruments consist of cash and cash equivalents, investments and accounts payable. The carrying amounts reported in the accompanying balance sheets for cash and cash equivalents and accounts payable approximate fair value because of the short-term maturity of those instruments. Fair value measurements are classified and disclosed in one of the following three categories:

Level 1 —Quoted prices in active markets for identical assets or liabilities.

Level 2 —Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 —Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

As of December 31, 2020 and 2019, all of the Company’s financial assets that were subject to fair value measurements were valued using observable inputs. The Company’s financial assets valued based on Level 1 inputs consist of money market funds and certificates of deposit. The Company’s financial assets valued based on Level 2 inputs consist of corporate debt securities, which consist of investments in highly-rated investment-grade corporations.

The Company’s investment strategy is focused on capital preservation. The Company invests in instruments that meet the credit quality standards outlined in the Company’s investment policy. This policy also limits the amount of credit exposure to any one issue or type of instrument. As of December 31, 2020, the Company’s investments were in government money market funds, commercial paper and corporate debt securities.

The fair values of the Company’s financial instruments are presented below (in thousands):

 

 

 

 

 

 

Fair Value Measurements at December 31, 2020

 

 

 

Total

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Financial assets carried at fair value:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Government money market funds

 

$

26,868

 

 

$

26,868

 

 

$

—

 

 

$

—

 

Short-term investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Commercial paper, available for sale

 

 

27,973

 

 

 

—

 

 

 

27,973

 

 

 

—

 

Corporate debt securities, available-for-sale

 

 

191,296

 

 

 

—

 

 

 

191,296

 

 

 

—

 

Total financial assets

 

$

246,137

 

 

$

26,868

 

 

$

219,269

 

 

$

—

 

 

 

 

 

 

 

 

Fair Value Measurements at December 31, 2019

 

 

 

Total

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Financial assets carried at fair value:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Government money market funds

 

$

3,671

 

 

$

3,671

 

 

$

—

 

 

$

—

 

Corporate debt securities, available-for-sale

 

 

3,498

 

 

 

—

 

 

 

3,498

 

 

 

—

 

Short-term investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Commercial paper, available for sale

 

 

1,495

 

 

 

—

 

 

 

1,495

 

 

 

—

 

Corporate debt securities, available-for-sale

 

 

265,766

 

 

 

—

 

 

 

265,766

 

 

 

—

 

Total financial assets

 

$

274,430

 

 

$

3,671

 

 

$

270,759

 

 

$

—

 

 
XML 23 R10.htm IDEA: XBRL DOCUMENT v3.20.4
Agreements with Ligand Pharmaceuticals Incorporated
 12 Months Ended
Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Agreements with Ligand Pharmaceuticals Incorporated

4.

Agreements with Ligand Pharmaceuticals Incorporated

In May 2014, the Company entered into a master license agreement with Ligand, as amended (the “Master License Agreement”), pursuant to which, among other things, the Company acquired the rights to a number of research and development programs under patents related to the Company’s VK2809, VK0214, VK5211, VK0612, erythropoietin receptor (“EPOR”) and diacylglycerol acyltransferase-1 (“DGAT-1”) programs, related know-how controlled by Ligand and physical quantities of VK2809, VK0214, VK5211, VK0612, EPOR and DGAT-1 compounds.

Pursuant to the terms of the Master License Agreement, the Company has the exclusive right and sole responsibility and decision-making authority for researching and developing any pharmaceutical products that contain or comprise one or any combination of the technology and compounds licensed from Ligand pursuant to the Master License Agreement (the “Licensed Products”). The Company also has the exclusive right and sole responsibility and decision-making authority to conduct all clinical trials and preclinical studies that the Company believes are appropriate to obtain the regulatory approvals necessary for commercialization of the Licensed Products, and the Company will own and maintain all regulatory filings and all regulatory approvals for the Licensed Products. Additionally, pursuant to the terms of the Master License Agreement, the Company has the sole decision-making authority and responsibility and the exclusive right to commercialize any of the Licensed Products, either by itself or, in certain circumstances, through sublicensees selected by the Company. The Company also has the exclusive right to manufacture or have manufactured any Licensed Product itself or, in certain circumstances, through sublicensees or third parties selected by the Company. The Company will own any intellectual property that it develops in connection with the license granted under the Master License Agreement.

As partial consideration for the grant of the rights and licenses to the Company under the Master License Agreement, the Company issued to Ligand at the closing of the Company’s initial public offering (“IPO”) 3,655,964 shares of its common stock having an estimated aggregate value of $29.2 million.

As further partial consideration for the grant of the rights and licenses to the Company by Ligand under the Master License Agreement, the Company has agreed to pay to Ligand certain one-time, non-refundable milestone payments in connection with the Licensed Products of up to $1.54 billion in the aggregate upon the achievement of certain development, regulatory and sales milestones. The Company will also pay to Ligand royalties on aggregate annual worldwide net sales of Licensed Products by the Company, its affiliates and its sublicensees at tiered percentage rates from the low-to-upper single digits based upon net sales.

The term of the Master License Agreement will continue unless the agreement is terminated by the Company or Ligand, and each of the Company and Ligand have the right to terminate the Master License Agreement in certain circumstances, including, without limitation, if the other party defaults on certain of its obligations under the Master License Agreement.

Ligand has the right to terminate the Master License Agreement under certain circumstances, including, but not limited to: (1) in the event of the Company’s insolvency or bankruptcy, (2) if the Company does not pay an undisputed amount owing under the Master License Agreement when due and fails to cure such default within a specified period of time, or (3) if the Company defaults on certain of its material and substantial obligations and fails to cure the default within a specified period of time. The Company has the right to terminate the Master License Agreement under certain circumstances, including, but not limited to: (i) if Ligand does not pay an undisputed amount owing under the Master License Agreement when due and fails to cure such default within a specified period of time, or (ii) if Ligand defaults on certain of its material and substantial obligations and fails to cure the default within a specified period of time. In addition, provisions of the Master License Agreement can be terminated on a licensed program-by-program basis under certain circumstances. In the event that the Master License Agreement is terminated in its entirety or with respect to a specific licensed program for any reason: (A) all licenses granted to the Company under the Master License Agreement (or with respect to the specific licensed program) will terminate and the Company will, upon Ligand’s request (subject to Ligand assuming legal responsibility for any clinical trials of the Licensed Products then ongoing), assign and transfer to Ligand (or to such transferee as Ligand may direct), at no cost to Ligand, all regulatory documentation and all regulatory approvals prepared or obtained by the Company or on its behalf related to the Licensed Products (or those related to the specific licensed program), or, if Ligand does not make such a request, the Company will wind down any ongoing clinical trials with respect to the Licensed Products (or those related to the specific licensed program) at no cost to Ligand; (B) the Company will, upon Ligand’s request, sell and transfer to Ligand (or to such transferee as Ligand may direct), at a price equal to 125% of the Company’s costs of goods, any and all chemical, biological or physical materials relating to or comprising the Licensed Products (or those related to the specific licensed program); (C) the Company will have, for a period of six months following termination, the right to sell on the normal business terms in existence before such termination any finished commercial inventory of Licensed Products (or those related to the specific licensed program) which remains on hand, so long as the Company pays to Ligand the applicable royalties and sales milestones; (D) Ligand has the right to require the Company to assign to Ligand the trademarks owned by the Company relating to the Licensed Products (or those related to the specific licensed program); and (E) the Company will grant to Ligand a non-exclusive, worldwide, royalty-bearing sublicensable license under any patent rights and know-how controlled by the Company to the extent necessary to make, have made, import, use, offer to sell and sell the Licensed Products (or those related to the specific licensed program) anywhere in the world at a royalty rate in the low single digits.

Under the Master License Agreement, the Company has agreed to indemnify Ligand for claims relating to the performance of the Company’s obligations under the Master License Agreement, any breach of the representations and warranties made by the Company under the Master License Agreement, clinical trials conducted by the Company and the research, development and commercialization of the Licensed Products by the Company and its affiliates, sublicensees, distributors and agents. In addition, Ligand has agreed to indemnify the Company for claims relating to the performance of its obligations under the Master License Agreement, its breach of representations and warranties under the agreement and its research and development of the licensed compounds before the effective date of the Master License Agreement. Each party’s indemnification obligations will not apply to the extent the claims result from the negligence or willful misconduct of the indemnified party or any of its employees, agents, officers or directors or from the indemnified party’s breach of its representations or warranties set forth in the Master License Agreement.

In May 2014, the Company also entered into a Management Rights Letter (the “Management Rights Letter”) with Ligand that requires the Company to expand the size of the Company’s board of directors to create an additional directorship on the Company’s board of directors and to allow Ligand to appoint an individual to fill the new directorship. The Management Rights Letter will terminate upon the earliest to occur of the liquidation or indefinite cessation of the Company’s business operations, the execution by the Company of a general assignment for the benefit of creditors or the appointment of a receiver or trustee to take possession of the Company’s property and assets, an acquisition of the Company by means of any transaction (including, without limitation, any reorganization, merger or consolidation) if the Company’s stockholders of record as constituted immediately prior to the transaction hold less than 50% of the voting power of the surviving or acquiring entity, or following the issuance of the Company’s securities pursuant to the Master License Agreement, the date that Ligand ceases to beneficially own at least 7.5% of the Company’s outstanding voting stock, or the date of May 21, 2024.  
XML 24 R11.htm IDEA: XBRL DOCUMENT v3.20.4
Operating Leases - Right-of-Use Assets and Lease Liability Obligations
 12 Months Ended
Dec. 31, 2020
Leases [Abstract]  
Operating Leases - Right-of-Use Assets and Lease Liability Obligations

5.Operating Leases – Right-of-Use Assets and Lease Liability Obligations

 

The Company has only one operating lease which is for office space that expires in January 2022. Below is a summary of the Company’s right-of-use assets and lease liabilities as of December 31, 2020 and 2019 (in thousands, except for years and %):

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31,

2020

 

 

 

December 31,

2019

 

 

Right of use assets

 

$

321

 

 

 

$

598

 

 

 

 

 

 

 

 

 

 

 

 

 

Lease liability obligations, current

 

$

330

 

 

 

$

302

 

 

Lease liability obligations, less current portion

 

 

29

 

 

 

 

360

 

 

Total lease liability obligations

 

$

359

 

 

 

$

662

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average remaining lease term

 

1.08  years

 

 

 

2.08  years

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average discount rate

 

 

6.00

 

%

 

 

6.00

 

%

 

During the years ended December 31, 2020 and 2019, the Company recognized $319,000 and $308,000, respectively, in operating lease expenses, which are included in operating expenses in the Company’s statement of operations.

 

 

Approximate future minimum lease payments for the Company’s right-of-use assets over the remaining lease period as of December 31, 2020 are as follows (in thousands):

 

 

 

 

 

2021

 

$

343

 

2022

 

 

29

 

Total minimum lease payments

 

$

372

 

Less: amount representing interest

 

$

(13

)

Total lease liability obligations

 

$

359

 

The operating lease provides the Company with an option to extend the term of the lease for a period of three years beyond the expiration date of January 2022. If the option is exercised, the renewal term will be upon the same terms and conditions as the original agreement, except that the base rent will be equal to the prevailing market rate as determined pursuant to the terms of the lease.  The option to extend the operating lease was not recognized as part of the Company’s lease liability and right-of-use assets.  

 
XML 25 R12.htm IDEA: XBRL DOCUMENT v3.20.4
Stockholders' Equity
 12 Months Ended
Dec. 31, 2020
Equity [Abstract]  
Stockholders' Equity

6.

Stockholders’ Equity

 

Preferred Stock

 

The Company is authorized to issue up to 10,000,000 shares of $0.00001 par value preferred stock, with no shares of preferred stock outstanding as of December 31, 2020 and 2019. The Board of Directors is authorized to designate the terms and conditions of any preferred stock the company issues without further action by the common stockholders.

 

Common Stock

The Company is authorized to issue up to 300,000,000 shares of common stock, $0.00001 par value per share.

In February 2014, the Company entered into a stock purchase agreement with one of its founders. The agreement provided for the purchase of 1,000,000 shares of the Company’s common stock at a price per share of $0.01 in exchange for future services to be rendered to the Company as measured by certain performance criteria. The shares were subject to a repurchase option and were to vest in two tranches of 500,000 shares each, upon achievement of the performance target or upon a triggering event as defined.

The Company determined that the fair value of the unrecognized expense was $168,000 at February 20, 2014, the grant date. In May 2015, the Company repurchased 633,810 of these shares at a purchase price of $0.00001 per share. In connection with the repurchase, the Company entered into an amendment to the stock purchase agreement to provide that the remaining 366,190 shares will continue to vest in two tranches of 183,095 shares each, upon achievement of the performance target or upon a triggering event as defined. The pro rata grant date fair value of the unrecognized expense is $62,000.  In October 2015, a triggering event became probable of occurrence and was deemed achieved in October 2016; therefore, the Company recorded $31,000 of stock-based compensation expense through December 31, 2016.  No similar expense was recognized during the years ended December 31, 2020 and 2019.  The Company will continue to reassess at each reporting period whether it is probable that the performance target will be achieved, and if and when it is deemed probable, the Company will begin to record compensation expense using the fair value to determine stock-based compensation expense in its financial statements over the period the Company estimates the performance target will actually be achieved.    

On February 8, 2017, the Company entered into a Stock Purchase Agreement (the “SPA”), with PoC Capital, LLC (“PoC”) pursuant to which, among other things, the Company issued to PoC 1,286,173 shares of its common stock.  Under the terms of the SPA, PoC has agreed to fund $1,800,000 in study costs associated with certain clinical studies.  Any study costs in excess of that amount will be the Company’s sole responsibility.  The Company has accounted for the $1,800,000 as a prepaid expense on the balance sheet, which was fully amortized as of December 31, 2020.  The Company recorded amortization expense of $140,000 in clinical study costs related to the SPA with PoC during the year ended December 31, 2019.  No similar expense was recognized during the year ended December 31, 2020.

 

On September 28, 2017, the Company entered into the Registered Offering Purchase Agreement, pursuant to which, on September 29, 2017, the Company sold to Lincoln Park Capital Fund, LLC (“LPC”), 701,282 shares of common stock, at a price of approximately $1.78 per share for an aggregate purchase price of $1.3 million, pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-212134), filed with the SEC on June 20, 2016, as amended by Amendment No. 1 thereto filed with the SEC on July 26, 2016, and declared effective on July 26, 2016, and the prospectus supplement thereto dated September 28, 2017.

 

On September 28, 2017, the Company also entered into the Commitment Purchase Agreement and the LPC Registration Rights Agreement with LPC, pursuant to which the Company has the right to sell to LPC up to $15,000,000 in shares of common stock, subject to certain limitations and conditions set forth in the Commitment Purchase Agreement. Upon the Commencement, the Company will have the right, from time to time at its sole discretion over the 30-month period from and after the Commencement, to direct LPC to purchase up to 75,000 shares of common stock on any business day (subject to certain limitations contained in the Commitment Purchase Agreement), with such amounts increasing based on certain threshold prices set forth in the Commitment Purchase Agreement; however, not to exceed $1.0 million in total purchase proceeds per purchase date. The purchase price of shares of common stock that the Company elects to sell to LPC pursuant to the Commitment Purchase Agreement will be based on the market prices of the common stock at the time of such purchases as set forth in the Commitment Purchase Agreement. In addition to regular purchases, as described above, the Company may also direct LPC to purchase additional amounts as accelerated purchases or as additional purchases if the closing sale price of the common stock is not below certain threshold prices, as set forth in the Commitment Purchase Agreement. In all instances, the Company may not sell shares of its common stock to LPC under the Commitment Purchase Agreement if it would result in LPC beneficially owning more than 4.99% of the Common Stock. As consideration for LPC’s commitment to purchase shares of common stock pursuant to the Commitment Purchase Agreement, the Company issued to LPC 100,000 shares of common stock.  From inception of the Commitment Purchase Agreement through December 31, 2017, 343,051 shares were issued pursuant to the Commitment Purchase Agreement resulting in aggregate gross proceeds of $802,000 in addition to the Initial Shares and the Commitment Shares. In May 2020, the Company extended the

termination date of the Commitment Purchase Agreement to May 1, 2023. No additional shares were issued for the period of January 1, 2018 through December 31, 2020.

On August 1, 2019, the Company entered into an At-The-Market Equity Offering Sales Agreement (the “ATM Agreement”) with Stifel, Nicolaus & Company, Incorporated and Oppenheimer & Co. Inc. (each, an “Agent” and, together, the “Agents”), pursuant to which the Company may offer and sell, from time to time, through or to the Agents, as sales agent or principal (the “ATM Offering”), shares of its common stock having an aggregate offering price of up to $75.0 million (the “Shares”).  Any Shares offered and sold in the ATM Offering will be issued pursuant to the 2018 Shelf Registration Statement and the 424(b) prospectus supplement relating to the ATM Offering dated August 1, 2019. No shares of the Company’s common stock were sold under the ATM Agreement from its inception through December 31, 2020.

On March 17, 2020, the Company’s Board of Directors authorized a stock repurchase program, whereby the Company may purchase up to $50.0 million in shares of its common stock and outstanding warrants to purchase its common stock, over a period of up to two years (the “Repurchase Program”). The Repurchase Program may be carried out at the discretion of a committee of the Company’s Board of Directors through open market purchases, one or more Rule 10b5-1 trading plans, block trades and in privately negotiated transactions. Through December 31, 2020, no shares of the Company’s common stock or warrants to purchase its common stock were repurchased by the Company under the Repurchase Program. Shares repurchased by the Company under the Repurchase Program, if any, are expected to be held in treasury until such time as they are reissued or retired by the Company.

During the years ended December 31, 2020 and 2019, and in accordance with the Company’s 2014 Employee Stock Purchase Plan (the “ESPP”), the Company issued an aggregate of 34,595 and 20,114 shares of its common stock to certain employees, respectively.

 
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation
 12 Months Ended
Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Stock-Based Compensation

7.

Stock-Based Compensation

In connection with the IPO, the Company’s 2014 Equity Incentive Plan (the “2014 Plan”) and the ESPP became effective on April 28, 2015, the date of the execution and delivery of the underwriting agreement for the IPO. A total of 1,527,770 shares of the Company’s common stock were initially reserved for issuance under the 2014 Plan, and 458,331 shares of the Company’s common stock were initially reserved for issuance under the ESPP.  From January 1, 2016 and through December 31, 2020, in accordance with the terms of the 2014 Plan, an additional 7,366,810 shares of the Company’s common stock were added to the number of shares reserved for issuance under the 2014 Plan, respectively, and, in accordance with the terms of the ESPP, an additional 2,104,802 shares of the Company’s common stock were added to the number of shares reserved for issuance under the ESPP, respectively.

The Company generally uses the straight-line method to allocate compensation cost to reporting periods over each optionee’s requisite service period, which is generally the vesting period, and estimates the fair value of stock-based awards or restricted stock units to employees and directors using the Black-Scholes option-valuation model. The Black-Scholes model requires the input of subjective assumptions, including volatility, the expected term and the fair value of the underlying common stock on the date of grant, among other inputs. For restricted stock and restricted stock unit awards, the Company generally uses the straight-line method to allocate compensation cost to reporting periods over the holder’s requisite service period, which is generally the vesting period, and uses the fair value at grant date to value the awards. For restricted stock that vests upon the satisfaction of certain performance conditions, the Company recognizes stock-based compensation expense when it becomes probable that the performance conditions will be met. At the grant date, the Company determines the grant date fair value, as a publicly traded company, using the intrinsic value, or the closing price of its common stock on the date of grant. At the point where the criteria are deemed probable of being met, the Company records stock-based compensation with a cumulative catch-up expense in the period first recognized and then on a straight-line basis over the remaining period for which the performance criteria are expected to be completed.

For the ESPP, the Company generally recognizes compensation expense for the fair value of the purchase options, as measured on the grant date, and uses the graded vesting method to allocate this compensation cost to each purchase period within the related two-year offering period. As the ESPP also allows for up to one increase in contributions during each purchase period, then as an employee elects to increase their contributions, the Company treats this as an accounting modification. The pre- and post-modification values are calculated on the date of the modification, and the incremental expense is then amortized over the remaining purchase periods.

2014 Plan. The 2014 Plan provides that the compensation committee of the Company’s Board of Directors (the “Compensation Committee”) may grant or issue stock options, stock appreciation rights, restricted shares, restricted stock units and unrestricted shares, deferred share units, performance and cash-settled awards and dividend equivalent rights to participants under the 2014 Plan. Initially, a total of 1,527,770 shares of the Company’s common stock were reserved for issuance pursuant to the 2014 Plan. The number of shares available for issuance under the 2014 Plan will, unless otherwise determined by the Company’s Board of Directors or the Compensation Committee, be automatically increased on January 1st of each year commencing on January 1, 2016 and ending on (and including) January 1, 2024, in an amount equal to 3.5% of the total number of shares of the Company’s common stock outstanding on December 31st of the preceding calendar year. The shares of common stock deliverable pursuant to awards under the 2014 Plan are authorized but unissued shares of the Company’s common stock, or shares of the Company’s common stock that the Company otherwise holds in treasury or in trust. Any shares of the Company’s common stock underlying awards that are settled in

cash or otherwise expire, or are forfeited, terminated or cancelled (including pursuant to an exchange program established by the Compensation Committee) prior to the issuance of stock will again be available for issuance under the 2014 Plan. In addition, shares of the Company’s common stock that are withheld (or not issued) in payment of the exercise price or taxes relating to an award, and shares of the Company’s common stock equal to the number surrendered in payment of any exercise price or withholding taxes relating to an award, will again be available for issuance under the 2014 Plan.

ESPP. Initially, a total of 458,331 shares of the Company’s common stock were reserved for issuance pursuant to the ESPP. The number of shares available for issuance under the ESPP will, unless otherwise determined by the Company’s Board of Directors or the Compensation Committee, be automatically increased on January 1st of each year commencing on January 1, 2016 and ending on (and including) January 1, 2024, in an amount equal to 1% of the total number of shares of the Company’s common stock outstanding on December 31st of the preceding calendar year. The shares of common stock available for purchase pursuant to the ESPP are authorized but unissued shares of the Company’s common stock, shares of the Company’s common stock that the Company otherwise holds in treasury or shares of the Company’s common stock that were purchased on the open market in arms’ length transactions in accordance with applicable securities laws. Shares of the Company’s common stock will be offered for purchase under the ESPP as determined by the Compensation Committee through a series of successive offerings that each have a term of 24 months and consist of four consecutive purchase periods of six months each. Prior to the commencement of any future offering under the ESPP, the Compensation Committee may determine that the current offering shall end, may commence a new offering on the first day after the end of such terminal purchase period (or any desired later date), and may decide that future offerings will consist of one or more consecutive purchase periods, each to be of such duration as determined by the Compensation Committee; however, no offering will exceed 27 months and no purchase period will exceed one year. Each employee of the Company who (1) is an employee on the first date of any offering under the ESPP, (2) is customarily scheduled to work for more than 20 hours per week and more than five months per calendar year, and (3) meets such other criteria as may be determined by the Compensation Committee (consistent with Section 423 of the Internal Revenue Code of 1986, as amended), is eligible to participate in the ESPP for each purchase period within such offering. The purchase price per share of the Company’s common stock under the ESPP may not be less than, and will initially be equal to, the lesser of: (1) 85% of the fair market value per share of the Company’s common stock on the first day of the offering, or (2) 85% of the fair market value per share of the Company’s common stock on the date the purchase right is exercised, which will be the last day of the applicable purchase period.

During the years ended December 31, 2020 and 2019, the Company recognized the following stock-based compensation expense (in thousands):

 

 

Year Ended December 31,

 

 

 

2020

 

 

2019

 

Stock-based compensation expense by type of award:

 

 

 

 

 

 

 

 

Stock options

 

$

3,096

 

 

$

2,401

 

Restricted stock and restricted stock units

 

 

2,529

 

 

 

1,126

 

Employee stock purchase plan

 

 

193

 

 

 

216

 

Total stock-based compensation expense included

   in expenses

 

$

5,818

 

 

$

3,743

 

Stock-based compensation expense by line item:

 

 

 

 

 

 

 

 

Research and development expenses

 

$

1,359

 

 

$

953

 

General and administrative expenses

 

 

4,459

 

 

 

2,790

 

Total stock-based compensation expense included

   in expenses

 

$

5,818

 

 

$

3,743

 

 

 

The following table sets forth the Company’s unrecognized stock-based compensation expense, net of estimated forfeitures, by type of award and the weighted-average period over which that expense is expected to be recognized (in thousands, except for years):

 

 

 

As of December 31, 2020

 

 

 

Unrecognized

Expense

 

 

Weighted-

average

Recognition

Period

(in years)

 

 

 

 

 

 

 

 

 

 

Type of award:

 

 

 

 

 

 

 

 

Stock options

 

$

4,747

 

 

 

2.45

 

Restricted stock and restricted stock units

 

$

2,548

 

 

 

1.66

 

 

 

The following table is a summary of restricted shares granted during the years ended December 31, 2020 and 2019:

 

 

Shares

 

 

Weighted-

Average

Grant Date

Fair Value

 

Unvested at December 31, 2018

 

 

183,095

 

 

$

0.17

 

Granted

 

 

—

 

 

$

—

 

Vested

 

 

—

 

 

$

—

 

Forfeited

 

 

—

 

 

$

—

 

Repurchased

 

 

—

 

 

$

—

 

Unvested at December 31, 2019

 

 

183,095

 

 

$

0.17

 

Granted

 

 

—

 

 

$

—

 

Vested

 

 

—

 

 

$

—

 

Forfeited

 

 

—

 

 

$

—

 

Repurchased

 

 

—

 

 

$

—

 

Unvested at December 31, 2020

 

 

183,095

 

 

$

0.17

 

 

The following table summarizes restricted stock unit activity during the years ended December 31, 2020 and 2019:

 

 

Shares

 

 

Weighted-

Average

Grant Date

Value

 

Unvested at December 31, 2018

 

 

128,125

 

 

$

5.37

 

Granted

 

 

343,524

 

 

$

7.80

 

Vested

 

 

(58,122

)

 

$

5.40

 

Forfeited

 

 

(60,801

)

 

$

7.57

 

Unvested at December 31, 2019

 

 

352,726

 

 

$

7.35

 

Granted

 

 

493,996

 

 

$

7.77

 

Vested

 

 

(128,859

)

 

$

7.12

 

Forfeited

 

 

(38,500

)

 

$

8.16

 

Unvested December 31, 2020

 

 

679,363

 

 

$

7.65

 

 

In January 2019, the Company issued 221,600 performance based restricted stock units (“PRSU awards”) to several of its employees, which are reflected in the above summary of restricted stock unit activity.  The shares subject to the PRSU awards shall vest upon the Company achieving certain milestones, with 100% of the PRSU awards vesting upon the achievement of three of the milestones over a four-year period, with any then-unvested portion of the PRSU awards to be cancelled on the four-year anniversary of the grant dates.  As of December 31, 2020, 40,000 PRSU awards were forfeited and three of the milestones were deemed as probable of achievement, resulting in the Company recording stock-based compensation expense of $383,000 and $734,000 during the year ended December 31, 2020 and 2019, respectively.

 

In January 2020, the Company issued 244,000 PRSU awards to several of its employees, which are reflected in the above table summarizing restricted stock unit activity.  The shares subject to these PRSU awards shall vest upon the Company achieving certain milestones, with 100% of the PRSU awards vesting upon the achievement of three of the milestones over a four-year period, with any then-unvested portion of the PRSU awards to be cancelled on the four-year anniversary of the grant dates.  As of December 31, 2020, 10,500 PRSU awards were forfeited, and one of the three milestones has been met and the remaining two were deemed probable of achievement, resulting in the Company recording a stock-based compensation expense of $1.2 million during the year ended December 31, 2020.

 

 

The following table summarizes stock option activity during the years ended December 31, 2020 and 2019:

 

 

 

Shares

 

 

Weighted-

Average

Exercise

Price

 

 

Weighted-

Average

Remaining

Contractual

Term (in years)

 

 

Aggregate Intrinsic Value

 

Options outstanding at December 31, 2018

 

 

2,014,047

 

 

$

3.72

 

 

 

 

 

 

 

 

 

Granted

 

 

855,787

 

 

$

7.82

 

 

 

 

 

 

 

 

 

Exercised

 

 

(82,337

)

 

$

2.40

 

 

 

 

 

 

$

423,000

 

Cancelled

 

 

(207,021

)

 

$

6.51

 

 

 

 

 

 

 

 

 

Options outstanding at December 31, 2019

 

 

2,580,476

 

 

$

4.90

 

 

 

7.66

 

 

$

8,643,000

 

Granted

 

 

960,472

 

 

$

7.26

 

 

 

 

 

 

 

 

 

Exercised

 

 

(86,125

)

 

$

2.47

 

 

 

 

 

 

$

430,000

 

Cancelled

 

 

(83,500

)

 

$

7.35

 

 

 

 

 

 

 

 

 

Options outstanding at December 31, 2020

 

 

3,371,323

 

 

$

5.57

 

 

 

7.32

 

 

$

4,577,000

 

Options exercisable at December 31, 2020

 

 

1,787,377

 

 

$

4.58

 

 

 

6.35

 

 

$

3,821,000

 

 

The Company received $213,000 and $197,000 in cash proceeds from exercises of stock options during the years ended December 31, 2020 and 2019, respectively.  

 

The total fair value of stock options that vested during the years ended December 31, 2020 and 2019 was $2.6 million and $1.3 million, respectively.

 

Compensation expense for stock options granted to employees is based on the estimated grant date fair value and is recognized ratably over the vesting period of the applicable option. The estimated per share weighted average fair value of stock options granted to employees during the years ended December 31, 2020 and 2019 was $4.89 and $5.34, respectively.

 

As stock-based compensation expense recognized is based on options ultimately expected to vest, the fair value of each employee option grant during the years ended December 31, 2020 and 2019 was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions:

 

 

Year ended December 31,

 

 

 

2020

 

 

2019

 

Expected volatility

 

 

77.3

%

 

 

77.9

%

Expected term (in years)

 

 

6.09

 

 

 

6.01

 

Risk-free interest rate

 

 

1.39

%

 

 

2.26

%

Expected dividend yield

 

 

0

%

 

 

0

%

    

Expected Volatility. The expected volatility rate used to value stock option grants is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the pharmaceutical and biotechnology industry in a similar stage of development to the Company.

Expected Term. The Company elected to utilize the “simplified” method for “plain vanilla” options to value stock option grants. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option.

Risk-free Interest Rate. The risk-free interest rate assumption was based on zero-coupon U.S. Treasury instruments that had terms consistent with the expected term of the Company’s stock option grants.

Expected Dividend Yield. The Company has never declared or paid any cash dividends and does not presently plan to pay cash dividends in the foreseeable future.

Forfeitures are accounted for as actual forfeitures occur.   

Since the Company had a net operating loss carryforward as of December 31, 2020, no excess tax benefits for the tax deductions related to stock-based awards were recognized in the Statements of Operations.

Common Stock Reserved for Future Issuance

Common stock reserved for future issuance as of December 31, 2020 is as follows:

 

Common stock warrants

 

 

5,244,500

 

Restricted stock units

 

 

679,363

 

Common stock options

 

 

3,371,323

 

Available for grant under the 2014 Plan

 

 

4,081,253

 

Available for issuance under Employee Stock Purchase Plan

 

 

2,289,561

 

 

 

 

15,666,000

 

 
XML 27 R14.htm IDEA: XBRL DOCUMENT v3.20.4
Warrants
 12 Months Ended
Dec. 31, 2020
Warrants And Rights Note Disclosure [Abstract]  
Warrants

8.

Warrants

 

On April 13, 2016, pursuant to the Offering, the Company sold 7,500,000 shares of its common stock and warrants to purchase up to 7,500,000 shares of its common stock at a public offering price of $1.25 per share of common stock and related warrant. The warrants have an exercise price of $1.50 per share of common stock, were immediately exercisable upon issuance and will expire on April 13, 2021. Additionally, on April 13, 2016, the underwriters for the Offering partially exercised the over-allotment option for warrants to purchase an additional 1,125,000 shares of the Company’s common stock at a public offering price of $0.01 per warrant to purchase a share of common stock.  As of December 31, 2020, 3,647,413 warrants were outstanding and 348,493 and 528,695 warrants were exercised during the years ended December 31, 2020 and 2019, respectively.

On April 13, 2016, the Company issued to Ligand the Ligand Warrant to purchase up to 960,000 shares of the Company’s common stock. The Ligand Warrant has an exercise price of $1.50 per share of Company common stock, was immediately exercisable upon issuance (subject to a limitation on exercise to the extent that any exercise thereof would increase Ligand’s beneficial ownership of the Company’s common stock to greater than 49.9%) and expires on April 13, 2021.  The Ligand Warrant was issued to Ligand as a part of the repayment of $1,200,000 of the Company’s obligation under a Secured Convertible Promissory Note previously issued by the Company to Ligand.

 

On June 14, 2017, pursuant to the terms of the Securities Purchase Agreement, the Company sold the 3,749,783 Shares and the Warrants to purchase up to 2,812,337 shares of its common stock to the Purchasers.  The combined purchase price for one Share and one Warrant to purchase 0.75 shares of common stock in the Offerings, was $1.15. The closing of the Offerings occurred on June 19, 2017.  The Warrants have an exercise price of $1.30 per share, subject to adjustment as provided therein, and were exercisable beginning on December 19, 2017 through December 19, 2022.  Each holder of a Warrant does not have the right to exercise any portion of its Warrant if the holder, together with its affiliates, would beneficially own in excess of 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise (the “Beneficial Ownership Limitation”); provided, however, that upon 61 days’ prior notice to the Company, the holder may increase the Beneficial Ownership Limitation; however, in no event shall the Beneficial Ownership Limitation exceed 9.99%. The exercise price and number of shares of common stock issuable upon the exercise of the Warrants will be subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Warrants. On January 16, 2018, the resale Registration Statement on Form S-1 (File No. 333-222202) that the Company filed related to the 1,987,337 shares subject to unexercised warrants was declared effective by the SEC.  As of December 31, 2020, warrants to purchase an aggregate of 637,087 shares were outstanding and 248,308 and 0 warrants were exercised during the years ended December 31, 2020 and 2019, respectively.
XML 28 R15.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes
 12 Months Ended
Dec. 31, 2020
Income Tax Disclosure [Abstract]  
Income Taxes

9.

Income Taxes

Income tax expense (benefit) from continuing operations consists of the following for the years ended December 31, 2020 and 2019 (in thousands):

 

 

December 31,

 

 

 

2020

 

 

2019

 

Current:

 

 

 

 

 

 

 

 

Federal

 

$

—

 

 

$

—

 

State

 

 

—

 

 

 

—

 

 

 

$

—

 

 

$

—

 

Deferred:

 

 

 

 

 

 

 

 

Federal

 

$

(9,368

)

 

$

(5,976

)

State

 

 

(3,356

)

 

 

(1,857

)

 

 

$

(12,724

)

 

$

(7,833

)

 

 

 

 

 

 

 

 

 

Change in valuation allowance

 

 

12,724

 

 

 

7,833

 

Total income tax expense (benefit)

 

$

—

 

 

$

—

 

 

 

The reconciliations of the U.S. federal statutory tax rate to the effective income tax rate for the years ended December 31, 2020 and 2019 are as follows:

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Tax provision at U.S. Federal statutory rates

 

 

21

%

 

 

21

%

State income taxes net of federal benefit

 

 

7

%

 

 

6

%

Non-deductible permanent items

 

 

(1

)%

 

 

(1

)%

Stock options

 

 

—

 

 

 

(1

)%

Research and development credits

 

 

5

%

 

 

5

%

Change in valuation allowance

 

 

(32

)%

 

 

(30

)%

Effective income tax rate

 

 

—

 

 

 

—

 

 

Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred taxes as of December 31, 2020 and 2019 are as follows (in thousands):

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Deferred tax assets:

 

 

 

 

 

 

 

 

Accrued liabilities

 

$

180

 

 

$

248

 

Intangible assets

 

 

32,435

 

 

 

24,463

 

Net operating loss carryforwards

 

 

8,649

 

 

 

7,017

 

Share-based compensation

 

 

2,604

 

 

 

1,632

 

Credits

 

 

6,518

 

 

 

4,398

 

Other

 

 

20

 

 

 

5

 

Total deferred tax assets

 

 

50,406

 

 

 

37,763

 

Valuation Allowance

 

 

(50,316

)

 

 

(37,592

)

Total deferred tax assets, net of allowance

 

$

90

 

 

$

171

 

Deferred tax liabilities:

 

 

 

 

 

 

 

 

Right of use assets

 

$

(90

)

 

$

(167

)

Other

 

 

—

 

 

 

(4

)

Total deferred tax liabilities:

 

$

(90

)

 

$

(171

)

Net deferred tax assets (liabilities):

 

$

—

 

 

$

—

 

 

A valuation allowance of $50.3 million and $37.6 million at December 31, 2020 and December 31, 2019, respectively, has been recorded to offset net deferred tax assets, as the Company is unable to conclude that it is more likely than not that such deferred tax assets will be realized.

At December 31, 2020, the Company had approximately $31.0 million of federal net operating loss carryforwards, of which $17.8 million will begin to expire in 2032 and the remaining $13.2 million of which can be carried forward indefinitely.  The Company has $30.6 million of state net operating loss carryforwards that will begin to expire in 2034.  

The Company’s ability to utilize its federal net operating loss carryforwards may be limited under Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”). Specifically, this limitation may arise in the event of an “ownership change,” which is defined by Section 382 of the Code as a cumulative change in ownership of the Company of more than 50% within a three-year period. If the Company undergoes one or more ownership changes in connection with any future transactions in its stock, the Company’s ability to utilize net operating loss carryforwards to offset federal taxable income, if any, could potentially result in increased future tax liability to the Company.  An ownership change under Section 382 of the Code occurred during the year ended December 31, 2018. Of the Company’s $31.0 million and $30.6 million of federal and state net operating loss carryforwards, $18.3 million and $17.9 million are limited based on the Company’s ownership change.  The annual limitation is $5.7 million.

The Company is subject to U.S. federal income tax as well as income tax in various state jurisdictions.  The Company is currently open to audit under the statute of limitations by the Internal Revenue Service and various state agencies for the years ended December 31, 2016 through December 31, 2020.

The differences between the Company’s effective income tax rate and the statutory federal rate for the year ended December 31, 2020 and the year ended December 31, 2019 relate primarily to losses incurred for which no tax benefit was recognized, due to the uncertainty of realization. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. The Company considers projected future taxable income and tax planning strategies in making this assessment. At each of December 31, 2020 and December 31, 2019, the Company provided a full valuation allowance against its deferred tax assets due to uncertainty surrounding the realization of those assets as a result of historical taxable net losses.

At December 31, 2020, the Company has federal and state research and development tax credit carry-forwards of approximately $4.3 million and $2.3 million, respectively.  The federal credits begin to expire in 2036.  The state credits do not expire.

 

The Coronavirus Aid, Relief, and Economic Security (CARES) Act was enacted March 27, 2020.  Among the business provisions, the CARES Act provided for various payroll tax incentives, changes to net operating loss carryback and carryforward rules, business interest expense limitation increases, and bonus depreciation on qualified improvement property.  Additionally, the Consolidated Appropriations Act of 2021 was signed on December 27, 2020 which provided additional COVID relief provisions for businesses.  The Company has evaluated the impact of the both Acts and has determined that any impact is not material to its financial statements.

 

The Company has reviewed its operations and has not identified any material uncertain tax positions. As a result, there is no liability for uncertain tax positions in the income tax provision as of December 31, 2020 or December 31, 2019.

 
XML 29 R16.htm IDEA: XBRL DOCUMENT v3.20.4
Related Party Transactions
 12 Months Ended
Dec. 31, 2020
Related Party Transactions [Abstract]  
Related Party Transactions

10.

Related-Party Transactions

In May 2014, the Company entered into the Master License Agreement with Ligand, pursuant to which, among other things, Ligand granted the Company an exclusive worldwide license to certain clinical and preclinical programs. See Note 4 for more information related to this agreement. In connection with entering into the Master License Agreement, the Company also entered into a Management Rights Letter (see Note 4) and a Registration Rights Agreement (see Note 4). As Ligand beneficially owns 9.8% of the Company’s outstanding shares as of December 31, 2020, and has a member of its management team on our Board of Directors, the Company considers Ligand to be a related party.

 
XML 30 R17.htm IDEA: XBRL DOCUMENT v3.20.4
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]  
Commitments and Contingencies

11.

Commitments and Contingencies

On May 25, 2018, the Company entered into an Office Lease (the “Lease”) with Kilroy Realty, L.P. The Lease is for approximately 7,149 rentable square feet of space located at 12340 El Camino Real, Suite 250, San Diego, California 92130 (the “Premises”). The Premises will continue to be the Company’s corporate headquarters.

The Lease commenced on November 1, 2018 and will expire on January 31, 2022, unless terminated earlier in accordance with the terms of the Lease (the “Term”). Monthly base rent payments due under the Lease for the Premises will be $27,000, subject to annual increases of 3.0% during the Term. Under the Lease, the Company is responsible for certain charges for common area maintenance and other costs, including electricity and utility expenses and the Lease provides for abatement of rent during certain periods and escalating rent payments throughout the Term. Rent expense is being recorded on a straight-line basis over the life of the Lease and the difference between the rent expense and rent paid is being recorded as deferred rent.

F-23

The Lease provides the Company with an option to extend the term of the lease for a period of three years beyond the Term. If the option is exercised, the renewal term will be upon the same terms and conditions as the original Term, except that the base rent will be equal to the prevailing market rate as determined pursuant to the terms of the Lease.

Rent expense was $319,000 and $308,000 for the years ended December 31, 2020 and 2019, respectively.

Future minimum payments pursuant to the Lease are as follows (in thousands):

Year Ending December 31:

 

 

 

 

2021

 

$

343

 

2022

 

 

29

 

Total minimum lease payments

 

$

372

 

 
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.20.4
Subsequent Events
 12 Months Ended
Dec. 31, 2020
Subsequent Events [Abstract]  
Subsequent Events

12.

Subsequent Events

The Company evaluated subsequent events through the date of the filing of this Annual Report on Form 10-K with the SEC, to ensure that this filing includes appropriate disclosure of events both recognized in the financial statements as of December 31, 2020, and events which occurred subsequent to December 31, 2020 but were not recognized in the financial statements. The Company has determined that there were no subsequent events which required recognition, adjustment to or disclosure in the financial statements.  

 

 

 
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.20.4
Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
The Company

The Company

Viking Therapeutics, Inc., a Delaware corporation (the “Company”), is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders.

The Company was incorporated under the laws of the State of Delaware on September 24, 2012 and its principal executive offices are located in San Diego, CA.
Basis of Presentation

Basis of Presentation

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
Risks And Uncertainties

Risks and Uncertainties

 

The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on the Company’s business is highly uncertain and difficult to predict, as the responses that the Company, other businesses and governments are taking continue to evolve. Furthermore, capital markets and economies worldwide have also been negatively impacted by the COVID-19 pandemic, and it is possible that it could cause a local and/or global economic slowdown or recession. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remain uncertain.

In addition, the Company’s clinical trials have been affected by and may continue to be affected by the COVID-19 pandemic. Clinical site initiation and patient enrollment have been and may continue to be delayed due to prioritization of hospital resources toward the COVID-19 pandemic. Some patients have not been and others may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, any inability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, may adversely impact the Company’s clinical trial operations.

 

The severity of the impact of the COVID-19 pandemic on the Company’s business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company’s service providers, suppliers, contract research organizations (“CROs”) and the Company’s clinical trials, all of which are uncertain and cannot be predicted. As of the date of issuance of Company’s financial statements, the extent to which the COVID-19 pandemic may materially impact the Company’s financial condition, liquidity or results of operations is uncertain.
Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Significant estimates made in preparing these financial statements relate to accounting for operating lease and certain commitments. Actual results could differ from those estimates.
Reclassifications

Reclassification

 

Certain amounts reported in prior years in the Statements of Cash Flows have been reclassified to conform to the current year’s presentation.
Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents.
Investments Available-for-Sale

Investments Available-for-Sale

Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in accumulated other comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of

discounts to maturity. The amortization of premiums and accretion of discounts is included in interest income. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in other income (expense). The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income.
Concentration of Credit Risk

Concentration of Credit Risk

Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents and marketable securities. The Company maintains deposits in federally insured depository institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.
Prepaid Clinical Trial and Preclinical Study Costs

Prepaid Clinical Trial and Preclinical Study Costs

Prepaid clinical trial and preclinical study costs represent advance payments by the Company for future clinical trial and preclinical study services to be performed by the clinical research organization and other research organizations.  Such amounts are recognized as research and development expense as the related clinical trial and preclinical study services are performed.  
Leases

Leases

The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use (“ROU”) assets, and lease liability obligations are included in the Company’s balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liability obligations represent its obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company’s leases typically do not provide an implicit rate, the Company estimates its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company uses the implicit rate when readily determinable. The ROU asset also includes any lease payments made and excludes lease incentives and lease direct costs. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. Please refer to Note 5 for additional information.
Deferred Financing Costs

Deferred Financing Costs

Deferred financing costs represent legal, accounting and other direct costs related to the Company’s efforts to raise capital through a public or private sale of the Company’s common stock. Costs related to the public sale of the Company’s common stock are deferred until the completion of the applicable offering, at which time such costs are reclassified to additional paid-in-capital as a reduction of the proceeds.  Costs related to the private sale of the Company’s common stock are deferred until the completion of the applicable offering, at which time such costs are amortized over the term of the applicable purchase agreement.
Revenue Recognition

Revenue Recognition

The Company has not recorded any revenues since its inception. However, in the future, the Company may enter into collaborative research and licensing agreements, under which the Company could be eligible for payments made in the form of upfront license fees, research funding, cost reimbursement, contingent event-based payments and/or royalties.

On January 1, 2018, the Company adopted ASU No. 2014-09, Revenue from Contracts with Customers and all related amendments (“ASC 606” or “the revenue standard”). ASC 606 is a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The revenue standard is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, ASC 606 provides that an entity should apply the following steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The revenue standard also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, and costs to obtain or fulfill contracts. The Company will apply ASC 606 prospectively to all contracts.  

Research and Development Expenses

Research and Development Expenses

All costs of research and development are expensed in the period incurred. Research and development costs primarily consist of fees paid to contract research organizations (“CROs”) and clinical trial sites, employee and consultant related expenses, which include salaries, benefits and stock-based compensation for research and development personnel, external research and development expenses incurred pursuant to agreements with third-party manufacturing organizations, facilities costs, travel costs, dues and subscriptions, depreciation and materials used in preclinical studies, clinical trials and research and development.

The Company estimates its preclinical study and clinical trial expenses based on the services it received pursuant to contracts with research institutions and CROs that conduct and manage preclinical studies and clinical trials on the Company’s behalf. Clinical trial-related contracts vary significantly in length, and may be for a fixed amount based on milestones or deliverables, a variable amount based on actual costs incurred, capped at a certain limit, or a combination of these elements. The Company accrues service fees based on work performed, which relies on estimates of total costs incurred based on milestones achieved, patient enrollment and other events. The majority of the Company’s service providers invoice the Company in arrears, and to the extent that amounts invoiced differ from its estimates of expenses incurred, the Company accrues for additional costs. The financial terms of these agreements vary from contract to contract and may result in uneven expenses and payment flows. Preclinical study and clinical trial expenses include:

 

•

fees paid to CROs, consultants and laboratories in connection with preclinical studies;

 

•

fees paid to CROs, clinical trial sites, investigators and consultants in connection with clinical trials; and

 

•

fees paid to contract manufacturers and service providers in connection with the production, testing and packaging of active pharmaceutical ingredients and drug materials for preclinical studies and clinical trials.

Payments under some of these agreements depend on factors such as the milestones accomplished, including enrollment of certain numbers of patients, site initiation and the completion of clinical trial milestones. To date, the Company has not experienced any events requiring it to make material adjustments to its accruals for service fees. If the Company does not identify costs that it has begun to incur or if it underestimates or overestimates the level of services performed or the costs of these services, its actual expenses could differ from its estimates which could materially affect its results of operations. Adjustments to the Company’s accruals are recorded as changes in estimates become evident. Furthermore, based on amounts invoiced to the Company by its service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expense in future periods as services are rendered.

In May 2014, the Company entered into a master license agreement, pursuant to which it acquired certain rights to a number of research and development programs from Ligand Pharmaceuticals Incorporated (“Ligand”). In doing so, the Company updated its policy on research and development to include the purchase of rights to intangible assets. In accordance with ASC Topic 730, Research and Development, intangible assets that are acquired and have an alternative future use, as defined, should be capitalized and reported as an intangible asset; however, the cost of acquired intangible assets that do not have alternative future uses should be reported as research and development expense as incurred. The Company notes that intangible assets acquired that are in the preclinical or clinical stages of development when acquired, and not approved by the U.S. Food and Drug Administration, are deemed to have not satisfied the definition of having an alternative future use, as defined. Accordingly, assets acquired in the preclinical and clinical stages of development are expensed as incurred in the Company’s statement of operations.
Patent Costs

Patent Costs

Costs related to filing and pursuing patent applications are expensed as incurred to general and administrative expense, as recoverability of such expenditures is uncertain.
Stock-Based Compensation

Stock-Based Compensation

The Company generally uses the straight-line method to allocate compensation cost to reporting periods over each optionee’s requisite service period, which is generally the vesting period, and estimates the fair value of stock-based awards or restricted stock units to employees and directors using the Black-Scholes option-valuation model (the “Black-Scholes model”). The Black-Scholes model requires the input of subjective assumptions, including volatility, the expected term and the fair value of the underlying common stock on the date of grant, among other inputs. For restricted stock and restricted stock unit awards, the Company generally uses the straight-line method to allocate compensation cost to reporting periods over the holder’s requisite service period, which is generally the vesting period, and uses the fair value at grant date to value the awards. For restricted stock that vests upon the satisfaction of certain performance conditions, the Company recognizes stock-based compensation expense when it becomes probable that the performance conditions will be met. At the grant date, the Company determines the grant date fair value, as a publicly traded company, using the intrinsic value, or the closing price of the Company’s common stock on the date of grant. At the point where the criteria are deemed probable of being met, the Company records stock-based compensation with a cumulative catch-up expense in the period first

recognized and then on a straight-line basis over the remaining period for which the performance criteria are expected to be completed.

For the Company’s 2014 Employee Stock Purchase Plan (the “ESPP”), the Company generally recognizes compensation expense for the fair value of the purchase options, as measured on the grant date, and uses the graded vesting method to allocate this compensation cost to each purchase period within the related two-year offering period. As the ESPP also allows for up to one increase in contributions during each purchase period, as an employee elects to increase his or her contributions, the Company treats this as an accounting modification. The pre- and post-modification values are calculated on the date of the modification, and the incremental expense is then amortized over the remaining purchase periods.    
Income Taxes

Income Taxes

The Company accounts for its income taxes using the liability method whereby deferred tax assets and liabilities are determined based on temporary differences between the basis used for financial reporting and income tax reporting purposes. Deferred income taxes are provided based on the enacted tax rates in effect at the time such temporary differences are expected to reverse. A valuation allowance is provided for deferred tax assets if it is more likely than not that the Company will not realize those tax assets through future operations.

ASC Topic 740-10, Income Taxes, clarifies the accounting for uncertainty in income taxes recognized in the Company’s financial statements in accordance with GAAP.  Income tax positions must meet a more-likely-than-not recognition threshold to be recognized. Income tax positions that previously failed to meet the more-likely-than-not threshold are recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not threshold are derecognized in the first subsequent financial reporting period in which that threshold is no longer met.

The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.
Net Loss per Common Share

Net Loss per Common Share

Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. For purposes of this calculation, the Company currently does not have any deemed common share equivalents; therefore, its basic and diluted net loss per share calculations are the same.

The following table presents the computation of basic and diluted net loss per common share (in thousands, except share and per share data):

 

 

 

Year Ended December 31,

 

 

 

2020

 

 

2019

 

Historical net loss per share

 

 

 

 

 

 

 

 

Numerator

 

 

 

 

 

 

 

 

Net loss

 

$

(39,495

)

 

$

(25,779

)

Denominator

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding

 

 

72,779,742

 

 

 

72,142,188

 

Less: Weighted-average shares subject to repurchase

 

 

(183,095

)

 

 

(183,095

)

Denominator for basic and diluted net loss per share

 

 

72,596,647

 

 

 

71,959,093

 

Basic and diluted net loss per share

 

$

(0.54

)

 

$

(0.36

)

 

 

 

Potentially dilutive securities that are not included in the calculation of diluted net loss per share because their effect is anti-dilutive are as follows (in common equivalent shares):

 

 

 

Year Ended December 31,

 

 

 

2020

 

 

2019

 

Common stock warrants

 

 

5,244,500

 

 

 

5,841,301

 

Restricted stock units

 

 

679,363

 

 

 

352,726

 

Common stock subject to repurchase

 

 

183,095

 

 

 

183,095

 

Common stock options

 

 

3,371,323

 

 

 

2,580,476

 

 

 

 

9,478,281

 

 

 

8,957,598

 

 
Segments

Segments

The Company operates in only one segment. Management uses cash flows as the primary measure to manage its business and does not segment its business for internal reporting or decision making purposes.
XML 33 R20.htm IDEA: XBRL DOCUMENT v3.20.4
Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Schedule of Computation of Basic and Diluted Net Loss per Common Share

The following table presents the computation of basic and diluted net loss per common share (in thousands, except share and per share data):

 

 

 

Year Ended December 31,

 

 

 

2020

 

 

2019

 

Historical net loss per share

 

 

 

 

 

 

 

 

Numerator

 

 

 

 

 

 

 

 

Net loss

 

$

(39,495

)

 

$

(25,779

)

Denominator

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding

 

 

72,779,742

 

 

 

72,142,188

 

Less: Weighted-average shares subject to repurchase

 

 

(183,095

)

 

 

(183,095

)

Denominator for basic and diluted net loss per share

 

 

72,596,647

 

 

 

71,959,093

 

Basic and diluted net loss per share

 

$

(0.54

)

 

$

(0.36

)

 

 

 
Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share

Potentially dilutive securities that are not included in the calculation of diluted net loss per share because their effect is anti-dilutive are as follows (in common equivalent shares):

 

 

 

Year Ended December 31,

 

 

 

2020

 

 

2019

 

Common stock warrants

 

 

5,244,500

 

 

 

5,841,301

 

Restricted stock units

 

 

679,363

 

 

 

352,726

 

Common stock subject to repurchase

 

 

183,095

 

 

 

183,095

 

Common stock options

 

 

3,371,323

 

 

 

2,580,476

 

 

 

 

9,478,281

 

 

 

8,957,598

 

 
XML 34 R21.htm IDEA: XBRL DOCUMENT v3.20.4
Investments in Marketable Securities (Tables)
 12 Months Ended
Dec. 31, 2020
Investments Debt And Equity Securities [Abstract]  
Summary of Investments Classified As Available-For-Sale Securities

Investments classified as available-for-sale as of December 31, 2020 consisted of the following (in thousands):

 

 

 

Amortized

Cost

 

 

Gross

Unrealized

Gains  (1)

 

 

Gross

Unrealized

Losses  (1)

 

 

Aggregate

Estimated

Fair Value

 

Commercial paper  (2)

 

$

27,973

 

 

$

—

 

 

$

—

 

 

$

27,973

 

Corporate debt securities  (2)

 

 

191,350

 

 

 

94

 

 

 

(148

)

 

 

191,296

 

 

 

$

219,323

 

 

$

94

 

 

$

(148

)

 

$

219,269

 

 

(1)

Unrealized gains and losses on available-for-sale securities are included as a component of comprehensive loss. At December 31, 2020, there were 38 securities in an unrealized gain position and 80 securities in an unrealized loss position. The unrealized gains were less than $35,000 individually and $94,000 in the aggregate. The unrealized losses were less than $21,000 individually and $148,000 in the aggregate.  Four of these securities have been in a continuous unrealized loss or unrealized gain position for more than 12 months. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell these investments before recovery of their amortized cost basis, which may be at maturity. The Company reviews its investments to identify and evaluate investments that have an indication of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the investee, and the Company’s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.  

(2)

At December 31, 2020, none of these securities were classified as cash and cash equivalents on the Company’s balance sheet and $53.4 million of the corporate debt securities were scheduled to mature outside of one year at the time of purchase.

Investments classified as available-for-sale as of December 31, 2019 consisted of the following (in thousands):

 

 

 

Amortized

Cost

 

 

Gross

Unrealized

Gains  (1)

 

 

Gross

Unrealized

Losses  (1)

 

 

Aggregate

Estimated

Fair Value

 

Commercial paper  (2)

 

$

1,495

 

 

$

—

 

 

$

—

 

 

$

1,495

 

Corporate debt securities  (2)

 

 

265,754

 

 

 

190

 

 

 

(178

)

 

 

265,766

 

 

 

$

267,249

 

 

$

190

 

 

$

(178

)

 

$

267,261

 

 

(1)

Unrealized gains and losses on available-for-sale securities are included as a component of comprehensive loss. At December 31, 2019, there were 87 securities in an unrealized gain position and 66 securities in an unrealized loss position. These unrealized gains were less than $22,000 individually and $190,000 in the aggregate. The unrealized losses were less than $32,000 individually and $178,000 in the aggregate.  Nine of these securities have been in a continuous unrealized loss or unrealized gain position for more than 12 months. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell these investments before recovery of their amortized cost basis, which may be at maturity. The Company reviews its investments to identify and evaluate investments that have an indication of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the investee, and the Company’s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.

(2)

At December 31, 2019, none of these securities were classified as cash and cash equivalents on the Company’s balance sheet and $5.9 million of the corporate debt securities were scheduled to mature outside of one year at the time of purchase.
XML 35 R22.htm IDEA: XBRL DOCUMENT v3.20.4
Fair Value of Financial Instruments (Tables)
 12 Months Ended
Dec. 31, 2020
Fair Value Disclosures [Abstract]  
Summary of Fair Values of Financial Instruments

The fair values of the Company’s financial instruments are presented below (in thousands):

 

 

 

 

 

 

Fair Value Measurements at December 31, 2020

 

 

 

Total

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Financial assets carried at fair value:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Government money market funds

 

$

26,868

 

 

$

26,868

 

 

$

—

 

 

$

—

 

Short-term investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Commercial paper, available for sale

 

 

27,973

 

 

 

—

 

 

 

27,973

 

 

 

—

 

Corporate debt securities, available-for-sale

 

 

191,296

 

 

 

—

 

 

 

191,296

 

 

 

—

 

Total financial assets

 

$

246,137

 

 

$

26,868

 

 

$

219,269

 

 

$

—

 

 

 

 

 

 

 

 

Fair Value Measurements at December 31, 2019

 

 

 

Total

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Financial assets carried at fair value:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Government money market funds

 

$

3,671

 

 

$

3,671

 

 

$

—

 

 

$

—

 

Corporate debt securities, available-for-sale

 

 

3,498

 

 

 

—

 

 

 

3,498

 

 

 

—

 

Short-term investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Commercial paper, available for sale

 

 

1,495

 

 

 

—

 

 

 

1,495

 

 

 

—

 

Corporate debt securities, available-for-sale

 

 

265,766

 

 

 

—

 

 

 

265,766

 

 

 

—

 

Total financial assets

 

$

274,430

 

 

$

3,671

 

 

$

270,759

 

 

$

—

 

 
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.20.4
Operating Leases - Right-of-Use Assets and Lease Liability Obligations (Tables)
 12 Months Ended
Dec. 31, 2020
Leases [Abstract]  
Schedule of Right-of-use Assets and Lease Liabilities

The Company has only one operating lease which is for office space that expires in January 2022. Below is a summary of the Company’s right-of-use assets and lease liabilities as of December 31, 2020 and 2019 (in thousands, except for years and %):

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31,

2020

 

 

 

December 31,

2019

 

 

Right of use assets

 

$

321

 

 

 

$

598

 

 

 

 

 

 

 

 

 

 

 

 

 

Lease liability obligations, current

 

$

330

 

 

 

$

302

 

 

Lease liability obligations, less current portion

 

 

29

 

 

 

 

360

 

 

Total lease liability obligations

 

$

359

 

 

 

$

662

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average remaining lease term

 

1.08  years

 

 

 

2.08  years

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average discount rate

 

 

6.00

 

%

 

 

6.00

 

%
Schedule of Future Minimum Lease Payments

Approximate future minimum lease payments for the Company’s right-of-use assets over the remaining lease period as of December 31, 2020 are as follows (in thousands):

 

 

 

 

 

2021

 

$

343

 

2022

 

 

29

 

Total minimum lease payments

 

$

372

 

Less: amount representing interest

 

$

(13

)

Total lease liability obligations

 

$

359

 
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2020
Summary of Stock-based Compensation Expense Recognized

During the years ended December 31, 2020 and 2019, the Company recognized the following stock-based compensation expense (in thousands):

 

 

Year Ended December 31,

 

 

 

2020

 

 

2019

 

Stock-based compensation expense by type of award:

 

 

 

 

 

 

 

 

Stock options

 

$

3,096

 

 

$

2,401

 

Restricted stock and restricted stock units

 

 

2,529

 

 

 

1,126

 

Employee stock purchase plan

 

 

193

 

 

 

216

 

Total stock-based compensation expense included

   in expenses

 

$

5,818

 

 

$

3,743

 

Stock-based compensation expense by line item:

 

 

 

 

 

 

 

 

Research and development expenses

 

$

1,359

 

 

$

953

 

General and administrative expenses

 

 

4,459

 

 

 

2,790

 

Total stock-based compensation expense included

   in expenses

 

$

5,818

 

 

$

3,743

 

 
Schedule of Unrecognized Stock-based Compensation Expense, Net of Estimated Forfeitures, by Type of Award and Weighted-average Recognition Period

The following table sets forth the Company’s unrecognized stock-based compensation expense, net of estimated forfeitures, by type of award and the weighted-average period over which that expense is expected to be recognized (in thousands, except for years):

 

 

 

As of December 31, 2020

 

 

 

Unrecognized

Expense

 

 

Weighted-

average

Recognition

Period

(in years)

 

 

 

 

 

 

 

 

 

 

Type of award:

 

 

 

 

 

 

 

 

Stock options

 

$

4,747

 

 

 

2.45

 

Restricted stock and restricted stock units

 

$

2,548

 

 

 

1.66

 

 

 
Summary of Stock Option Activity

The following table summarizes stock option activity during the years ended December 31, 2020 and 2019:

 

 

 

Shares

 

 

Weighted-

Average

Exercise

Price

 

 

Weighted-

Average

Remaining

Contractual

Term (in years)

 

 

Aggregate Intrinsic Value

 

Options outstanding at December 31, 2018

 

 

2,014,047

 

 

$

3.72

 

 

 

 

 

 

 

 

 

Granted

 

 

855,787

 

 

$

7.82

 

 

 

 

 

 

 

 

 

Exercised

 

 

(82,337

)

 

$

2.40

 

 

 

 

 

 

$

423,000

 

Cancelled

 

 

(207,021

)

 

$

6.51

 

 

 

 

 

 

 

 

 

Options outstanding at December 31, 2019

 

 

2,580,476

 

 

$

4.90

 

 

 

7.66

 

 

$

8,643,000

 

Granted

 

 

960,472

 

 

$

7.26

 

 

 

 

 

 

 

 

 

Exercised

 

 

(86,125

)

 

$

2.47

 

 

 

 

 

 

$

430,000

 

Cancelled

 

 

(83,500

)

 

$

7.35

 

 

 

 

 

 

 

 

 

Options outstanding at December 31, 2020

 

 

3,371,323

 

 

$

5.57

 

 

 

7.32

 

 

$

4,577,000

 

Options exercisable at December 31, 2020

 

 

1,787,377

 

 

$

4.58

 

 

 

6.35

 

 

$

3,821,000

 

 
Schedule of Weighted Average Assumptions using Black-Scholes Option Pricing Model the fair value of each employee option grant during the years ended December 31, 2020 and 2019 was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions:

 

 

Year ended December 31,

 

 

 

2020

 

 

2019

 

Expected volatility

 

 

77.3

%

 

 

77.9

%

Expected term (in years)

 

 

6.09

 

 

 

6.01

 

Risk-free interest rate

 

 

1.39

%

 

 

2.26

%

Expected dividend yield

 

 

0

%

 

 

0

%

    

Common Stock Reserved For Future Issuance

Common stock reserved for future issuance as of December 31, 2020 is as follows:

 

Common stock warrants

 

 

5,244,500

 

Restricted stock units

 

 

679,363

 

Common stock options

 

 

3,371,323

 

Available for grant under the 2014 Plan

 

 

4,081,253

 

Available for issuance under Employee Stock Purchase Plan

 

 

2,289,561

 

 

 

 

15,666,000

 

 
Restricted stock [Member]  
Summary of Shares Granted and Stock Activity

The following table is a summary of restricted shares granted during the years ended December 31, 2020 and 2019:

 

 

Shares

 

 

Weighted-

Average

Grant Date

Fair Value

 

Unvested at December 31, 2018

 

 

183,095

 

 

$

0.17

 

Granted

 

 

—

 

 

$

—

 

Vested

 

 

—

 

 

$

—

 

Forfeited

 

 

—

 

 

$

—

 

Repurchased

 

 

—

 

 

$

—

 

Unvested at December 31, 2019

 

 

183,095

 

 

$

0.17

 

Granted

 

 

—

 

 

$

—

 

Vested

 

 

—

 

 

$

—

 

Forfeited

 

 

—

 

 

$

—

 

Repurchased

 

 

—

 

 

$

—

 

Unvested at December 31, 2020

 

 

183,095

 

 

$

0.17

 

 
Restricted stock units [Member]  
Summary of Shares Granted and Stock Activity

The following table summarizes restricted stock unit activity during the years ended December 31, 2020 and 2019:

 

 

Shares

 

 

Weighted-

Average

Grant Date

Value

 

Unvested at December 31, 2018

 

 

128,125

 

 

$

5.37

 

Granted

 

 

343,524

 

 

$

7.80

 

Vested

 

 

(58,122

)

 

$

5.40

 

Forfeited

 

 

(60,801

)

 

$

7.57

 

Unvested at December 31, 2019

 

 

352,726

 

 

$

7.35

 

Granted

 

 

493,996

 

 

$

7.77

 

Vested

 

 

(128,859

)

 

$

7.12

 

Forfeited

 

 

(38,500

)

 

$

8.16

 

Unvested December 31, 2020

 

 

679,363

 

 

$

7.65

 
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2020
Income Tax Disclosure [Abstract]  
Schedule of Income Tax Expense (Benefit) from Continuing Operations

Income tax expense (benefit) from continuing operations consists of the following for the years ended December 31, 2020 and 2019 (in thousands):

 

 

December 31,

 

 

 

2020

 

 

2019

 

Current:

 

 

 

 

 

 

 

 

Federal

 

$

—

 

 

$

—

 

State

 

 

—

 

 

 

—

 

 

 

$

—

 

 

$

—

 

Deferred:

 

 

 

 

 

 

 

 

Federal

 

$

(9,368

)

 

$

(5,976

)

State

 

 

(3,356

)

 

 

(1,857

)

 

 

$

(12,724

)

 

$

(7,833

)

 

 

 

 

 

 

 

 

 

Change in valuation allowance

 

 

12,724

 

 

 

7,833

 

Total income tax expense (benefit)

 

$

—

 

 

$

—

 
Schedule of Reconciliations of the U.S. Federal Statutory Tax Rate to the Effective Income Tax Rate

 

The reconciliations of the U.S. federal statutory tax rate to the effective income tax rate for the years ended December 31, 2020 and 2019 are as follows:

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Tax provision at U.S. Federal statutory rates

 

 

21

%

 

 

21

%

State income taxes net of federal benefit

 

 

7

%

 

 

6

%

Non-deductible permanent items

 

 

(1

)%

 

 

(1

)%

Stock options

 

 

—

 

 

 

(1

)%

Research and development credits

 

 

5

%

 

 

5

%

Change in valuation allowance

 

 

(32

)%

 

 

(30

)%

Effective income tax rate

 

 

—

 

 

 

—

 
Schedule of Significant Components of Company's Deferred Taxes Significant components of the Company’s deferred taxes as of December 31, 2020 and 2019 are as follows (in thousands):

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Deferred tax assets:

 

 

 

 

 

 

 

 

Accrued liabilities

 

$

180

 

 

$

248

 

Intangible assets

 

 

32,435

 

 

 

24,463

 

Net operating loss carryforwards

 

 

8,649

 

 

 

7,017

 

Share-based compensation

 

 

2,604

 

 

 

1,632

 

Credits

 

 

6,518

 

 

 

4,398

 

Other

 

 

20

 

 

 

5

 

Total deferred tax assets

 

 

50,406

 

 

 

37,763

 

Valuation Allowance

 

 

(50,316

)

 

 

(37,592

)

Total deferred tax assets, net of allowance

 

$

90

 

 

$

171

 

Deferred tax liabilities:

 

 

 

 

 

 

 

 

Right of use assets

 

$

(90

)

 

$

(167

)

Other

 

 

—

 

 

 

(4

)

Total deferred tax liabilities:

 

$

(90

)

 

$

(171

)

Net deferred tax assets (liabilities):

 

$

—

 

 

$

—

 
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.20.4
Commitments and Contingencies (Tables)
 12 Months Ended
Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]  
Summary of Future Minimum Payments for Lease

Future minimum payments pursuant to the Lease are as follows (in thousands):

Year Ending December 31:

 

 

 

 

2021

 

$

343

 

2022

 

 

29

 

Total minimum lease payments

 

$

372

 
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.20.4
Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies - Additional Information (Detail)
 12 Months Ended
Dec. 31, 2020
Segment
Accounting Policies [Abstract]  
Date of incorporation Sep. 24, 2012
Entity Incorporation, State or Country Code DE
Highly liquid investments maturities Three months or less
Number of operating segment 1
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.20.4
Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies - Schedule of Computation of Basic and Diluted Net Loss per Common Share (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Numerator    
Net loss $ (39,495) $ (25,779)
Denominator    
Weighted-average common shares outstanding 72,779,742 72,142,188
Less: Weighted-average shares subject to repurchase (183,095) (183,095)
Denominator for basic and diluted net loss per share 72,596,647 71,959,093
Basic and diluted net loss per share $ (0.54) $ (0.36)
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.20.4
Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Detail) - shares
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities excluded in calculation of diluted net loss per share 9,478,281 8,957,598
Common stock warrants [Member]    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities excluded in calculation of diluted net loss per share 5,244,500 5,841,301
Restricted stock units [Member]    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities excluded in calculation of diluted net loss per share 679,363 352,726
Common stock subject to repurchase [Member]    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities excluded in calculation of diluted net loss per share 183,095 183,095
Common stock options [Member]    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities excluded in calculation of diluted net loss per share 3,371,323 2,580,476
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.20.4
Investments in Marketable Securities - Additional Information (Detail) - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Available For Sale Securities [Abstract]    
Proceeds from sales of available-for-sale securities $ 0 $ 0
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.20.4
Investments in Marketable Securities - Summary of Investments Classified As Available-For-Sale Securities (Detail) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost $ 219,323 $ 267,249
Gross Unrealized Gains 94 190
Gross Unrealized Losses (148) (178)
Aggregate Estimated Fair Value 219,269 267,261
Commercial paper [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 27,973 1,495
Aggregate Estimated Fair Value 27,973 1,495
Corporate debt securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 191,350 265,754
Gross Unrealized Gains 94 190
Gross Unrealized Losses (148) (178)
Aggregate Estimated Fair Value $ 191,296 $ 265,766
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.20.4
Investments in Marketable Securities - Summary of Investments Classified As Available-For-Sale Securities (Parenthetical) (Detail)
Dec. 31, 2020
USD ($)
Security
Dec. 31, 2019
USD ($)
Security
Schedule of Available-for-sale Securities [Line Items]    
Number of securities in unrealized loss position | Security 80 87
Unrealized losses, aggregate $ 148,000 $ 178,000
Number of securities in unrealized gain position | Security 38 66
Unrealized gains, aggregate $ 94,000 $ 190,000
Short-term investments - available for sale 219,269,000 267,261,000
Commercial paper [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Short-term investments - available for sale 27,973,000 1,495,000
Short-term investments classified as available-for-sale, noncurrent 53,400,000 5,900,000
Corporate debt securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Unrealized losses, aggregate 148,000 178,000
Unrealized gains, aggregate 94,000 190,000
Short-term investments - available for sale 191,296,000 265,766,000
Short-term investments classified as available-for-sale, noncurrent 53,400,000 5,900,000
Cash equivalents [Member] | Commercial paper [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Short-term investments - available for sale 0 0
Cash equivalents [Member] | Corporate debt securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Short-term investments - available for sale 0 0
Maximum [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Unrealized losses, individually 21,000 22,000
Unrealized losses, aggregate 148,000 190,000
Unrealized gains, individually 35,000 32,000
Unrealized gains, aggregate $ 94,000 $ 178,000
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.20.4
Fair Value of Financial Instruments - Summary of Fair Values of Financial Instruments (Detail) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Financial assets carried at fair value:    
Total financial assets $ 246,137 $ 274,430
Government money market funds [Member]    
Financial assets carried at fair value:    
Cash equivalents, fair value disclosure 26,868 3,671
Corporate debt securities, available-for-sale [Member]    
Financial assets carried at fair value:    
Cash equivalents, fair value disclosure   3,498
Short-term investments, available for sale 191,296 265,766
Commercial paper, available-for-sale [Member]    
Financial assets carried at fair value:    
Short-term investments, available for sale 27,973 1,495
Level 1 [Member]    
Financial assets carried at fair value:    
Total financial assets 26,868 3,671
Level 1 [Member] | Government money market funds [Member]    
Financial assets carried at fair value:    
Cash equivalents, fair value disclosure 26,868 3,671
Level 2 [Member]    
Financial assets carried at fair value:    
Total financial assets 219,269 270,759
Level 2 [Member] | Corporate debt securities, available-for-sale [Member]    
Financial assets carried at fair value:    
Cash equivalents, fair value disclosure   3,498
Short-term investments, available for sale 191,296 265,766
Level 2 [Member] | Commercial paper, available-for-sale [Member]    
Financial assets carried at fair value:    
Short-term investments, available for sale $ 27,973 $ 1,495
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.20.4
Agreements with Ligand Pharmaceuticals Incorporated - Additional Information (Detail) - USD ($)
 1 Months Ended 12 Months Ended
Apr. 13, 2016
May 31, 2014
Dec. 31, 2020
Dec. 31, 2019
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
License agreement entered date     2014-05  
Common stock issued as part of partial consideration of agreement 7,500,000   0 0
Ligand [Member]        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
One time nonrefundable mile stone payments maximum payable amount     $ 1,540,000,000  
Legal costs     $ 0  
Sale and transfer of price equals to percentage of cost of goods     125.00%  
Ligand [Member] | Management Rights Letter [Member]        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Date agreement might terminate   May 21, 2024    
Ligand [Member] | Maximum [Member] | Management Rights Letter [Member]        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Voting power of the surviving or acquiring entity   50.00%    
Ligand [Member] | Minimum [Member] | Management Rights Letter [Member]        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Percentage of voting interest beneficiary owned   7.50%    
IPO [Member] | Ligand [Member]        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Common stock issued as part of partial consideration of agreement     3,655,964  
Common stock issued value as part of partial consideration of agreement     $ 29,200,000  
XML 48 R35.htm IDEA: XBRL DOCUMENT v3.20.4
Operating Leases - Right-of-Use Assets and Lease Liability Obligations - Additional Information (Detail)
 12 Months Ended
Dec. 31, 2020
USD ($)
Lease
Leases [Abstract]  
Operating lease number of leases | Lease 1
Lease expiration date 2022-01
Operating lease expense | $ $ 308,000
Operating lease, option to extend true
Operating lease option to extend term 3 years
operating lease, option to extend, description The operating lease provides the Company with an option to extend the term of the lease for a period of three years beyond the expiration date of January 2022.
XML 49 R36.htm IDEA: XBRL DOCUMENT v3.20.4
Operating Leases - Right-of-Use Assets and Lease Liability Obligations - Schedule of Right-of-use Assets and Lease Liabilities (Detail) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Lessee Disclosure [Abstract]    
Right-of-use assets $ 321 $ 598
Lease liability, current 330 302
Lease liability, net of current portion 29 360
Total lease liability obligations $ 359 $ 662
Weighted-average remaining lease term 1 year 29 days 2 years 29 days
Weighted-average discount rate 6.00% 6.00%
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.20.4
Operating Leases - Right-of-Use Assets and Lease Liability Obligations - Schedule of Future Minimum Lease Payments (Detail) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Leases [Abstract]    
2021 $ 343  
2022 29  
Total minimum lease payments 372  
Less: amount representing interest (13)  
Total lease liability obligations $ 359 $ 662
XML 51 R38.htm IDEA: XBRL DOCUMENT v3.20.4
Stockholders' Equity - Additional Information (Detail)
 1 Months Ended 12 Months Ended 15 Months Ended
Mar. 17, 2020
USD ($)
Aug. 01, 2019
USD ($)
shares
Sep. 29, 2017
USD ($)
$ / shares
shares
Sep. 28, 2017
USD ($)
shares
Feb. 08, 2017
USD ($)
shares
Apr. 13, 2016
$ / shares
shares
May 31, 2015
USD ($)
$ / shares
shares
Feb. 28, 2014
Tranche
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Dec. 31, 2019
USD ($)
$ / shares
shares
Dec. 31, 2016
USD ($)
Feb. 20, 2014
USD ($)
Equity [Line Items]                        
Preferred stock, shares authorized                 10,000,000 10,000,000    
Preferred stock, par value | $ / shares                 $ 0.00001 $ 0.00001    
Preferred stock, shares outstanding                 0 0    
Common stock, shares authorized                 300,000,000 300,000,000    
Common stock, par value | $ / shares                 $ 0.00001 $ 0.00001    
Number of common stock for issuance in exchange for future services from founders               1,000,000        
Common stock price per share | $ / shares               $ 0.01        
Number of tranches | Tranche               2        
Unrecognized compensation expense | $             $ 62,000         $ 168,000
Common stock shares repurchased             633,810          
Repurchase of common stock from stockholders, per share | $ / shares             $ 0.00001          
Remaining number of repurchased shares             366,190          
Common stock sold           7,500,000     0 0    
Common stock, price per share | $ / shares           $ 1.25            
Shares issued under ESPP                 34,595 20,114    
Common stock [Member] | ATM Agreement [Member]                        
Equity [Line Items]                        
Common stock sold   0                    
Common stock [Member] | Maximum [Member] | ATM Agreement [Member]                        
Equity [Line Items]                        
Aggregate offering price, common stock | $   $ 75,000,000.0                    
Repurchase Program [Member]                        
Equity [Line Items]                        
Purchase of common stock and warrants | $ $ 50,000,000.0               $ 0      
PoC Capital, LLC [Member]                        
Equity [Line Items]                        
Prepaid clinical study costs | $         $ 1,800,000              
Amortization expense | $                 0 $ 140,000    
PoC Capital, LLC [Member] | Stock Purchase Agreement [Member] | Common stock [Member]                        
Equity [Line Items]                        
Common stock sold         1,286,173              
PoC Capital, LLC [Member] | Stock Purchase Agreement [Member] | Common stock [Member] | Clinical Studies [Member]                        
Equity [Line Items]                        
Common stock sold aggregate purchase price | $                 1,800,000      
LPC [Member] | Registered Offering Purchase Agreement [Member] | Common stock [Member]                        
Equity [Line Items]                        
Common stock sold     701,282                  
Common stock sold aggregate purchase price | $     $ 1,300,000                  
Common stock, price per share | $ / shares     $ 1.78                  
Registration statement commencement date     Jun. 20, 2016                  
LPC [Member] | Commitment Purchase Agreement [Member] | Common stock [Member] | Registration Rights Agreement [Member]                        
Equity [Line Items]                        
Common stock sold       343,051                
Common stock purchase agreement term       30 months                
Common stock issued as consideration for commitment       100,000                
Gross proceeds from common stock issuance | $       $ 802,000                
LPC [Member] | Commitment Purchase Agreement [Member] | Common stock [Member] | Registration Rights Agreement [Member] | Maximum [Member]                        
Equity [Line Items]                        
Total of purchase agreement and potential aggregate future purchases | $       $ 15,000,000                
Common stock to be sold, subject to certain limitations       75,000                
Total purchase proceeds per purchase date, subject to certain limitations | $       $ 1,000,000.0                
LPC [Member] | Commitment Purchase Agreement [Member] | Common stock [Member] | Registration Rights Agreement [Member] | Minimum [Member]                        
Equity [Line Items]                        
Percentage of shares may not sell if it is beneficial owning       4.99%                
Tranche One [Member]                        
Equity [Line Items]                        
Number of common stock for issuance in exchange for future services from founders               500,000        
Remaining number of repurchased shares             183,095          
Stock compensation expense | $                 $ 0 $ 0 $ 31,000  
Tranche Two [Member]                        
Equity [Line Items]                        
Number of common stock for issuance in exchange for future services from founders               500,000        
Remaining number of repurchased shares             183,095          
XML 52 R39.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation - Additional Information (Detail)
 1 Months Ended 12 Months Ended
Jan. 31, 2020
Milestone
shares
Jan. 31, 2019
Milestone
shares
Dec. 31, 2020
USD ($)
Period
Milestone
$ / shares
shares
Dec. 31, 2019
USD ($)
$ / shares
shares
Mar. 31, 2020
Milestone
Apr. 28, 2015
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Number of shares of common stock reserved for issuance     15,666,000      
Forfeited awards     83,500 207,021    
Stock-based compensation | $     $ 5,818,000 $ 3,743,000    
Cash proceeds from exercises of stock options | $     213,000 197,000    
Total fair value of stock options, vested | $     $ 2,600,000 $ 1,300,000    
Weighted average fair value of stock options granted to employees | $ / shares     $ 4.89 $ 5.34    
Excess tax benefit from stock-based awards | $     $ 0      
Performance Based Restricted Stock Units [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Issuance of performance based award 244,000 221,600        
Percentage of shares vested upon achievement of certain milestone 100.00% 100.00%        
Number of milestones to be achieve | Milestone 3 3        
Number of milestones deemed as achievable | Milestone     2   3  
Milestone achievement period 4 years 4 years        
Forfeited awards     40,000      
Stock-based compensation | $     $ 383,000 $ 734,000    
Forfeiture of performance based award     10,500      
Number of milestones achieved | Milestone     1      
Performance Based Restricted Stock Units [Member] | January 2020 [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Stock-based compensation | $     $ 1,200,000      
2014 Plan [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Number of shares of common stock reserved for issuance           1,527,770
Additional number of shares of common stock reserved for issuance     7,366,810      
Common stock reserved for issuance, description     Initially, a total of 1,527,770 shares of the Company’s common stock were reserved for issuance pursuant to the 2014 Plan. The number of shares available for issuance under the 2014 Plan will, unless otherwise determined by the Company’s Board of Directors or the Compensation Committee, be automatically increased on January 1st of each year commencing on January 1, 2016 and ending on (and including) January 1, 2024, in an amount equal to 3.5% of the total number of shares of the Company’s common stock outstanding on December 31st of the preceding calendar year.      
Percentage of common stock outstanding to increase shares reserved for issuance     3.50%      
2014 ESPP [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Number of shares of common stock reserved for issuance           458,331
Additional number of shares of common stock reserved for issuance     2,104,802      
Common stock reserved for issuance, description     The number of shares available for issuance under the ESPP will, unless otherwise determined by the Company’s Board of Directors or the Compensation Committee, be automatically increased on January 1st of each year commencing on January 1, 2016 and ending on (and including) January 1, 2024, in an amount equal to 1% of the total number of shares of the Company’s common stock outstanding on December 31st of the preceding calendar year.      
Percentage of common stock outstanding to increase shares reserved for issuance     1.00%      
Duration of employee stock purchase plan as determined by the compensation committee     24 months      
Duration for offering period, employee stock purchase plan     6 months      
Employee stock purchase plan, number of purchase periods | Period     4      
Maximum duration for purchase under employee stock purchase plan     1 year      
Maximum duration of employee stock purchase plan     27 months      
Percentage of purchase of common stock     85.00%      
Percentage of common stock on the date of purchase     85.00%      
XML 53 R40.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation - Summary of Stock-based Compensation Expense Recognized (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense included in expenses $ 5,818 $ 3,743
Research and development expenses [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense included in expenses 1,359 953
General and administrative expenses [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense included in expenses 4,459 2,790
Stock options [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense included in expenses 3,096 2,401
Restricted stock and restricted stock units [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense included in expenses 2,529 1,126
Employee Stock Purchase Plan [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense included in expenses $ 193 $ 216
XML 54 R41.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation - Schedule of Unrecognized Stock-based Compensation Expense, Net of Estimated Forfeitures, by Type of Award and Weighted-average Recognition Period (Detail) - USD ($)
 12 Months Ended
Dec. 31, 2020
May 31, 2015
Feb. 20, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Unrecognized Expense, Net of Estimated Forfeitures   $ 62,000 $ 168,000
Stock options [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Unrecognized Expense, Net of Estimated Forfeitures $ 4,747,000    
Weighted-average Recognition Period 2 years 5 months 12 days    
Restricted stock and restricted stock units [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Unrecognized Expense, Net of Estimated Forfeitures $ 2,548,000    
Weighted-average Recognition Period 1 year 7 months 28 days    
XML 55 R42.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation - Summary of Restricted Stock Activity (Detail) - Restricted stock [Member] - $ / shares
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares, Unvested, Beginning balance 183,095 183,095
Shares, Unvested, Ending balance 183,095 183,095
Weighted-Average Grant Date Fair Value, Unvested, Beginning balance $ 0.17 $ 0.17
Weighted-Average Grant Date Fair Value, Unvested, Ending balance   $ 0.17
XML 56 R43.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Detail) - Restricted stock units [Member] - $ / shares
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares, Unvested, Beginning balance 352,726 128,125
Shares, Granted 493,996 343,524
Shares, Vested (128,859) (58,122)
Shares, Forfeited (38,500) (60,801)
Shares, Unvested, Ending balance 679,363 352,726
Weighted-Average Grant Date Fair Value, Unvested, Beginning balance $ 7.35 $ 5.37
Weighted-Average Grant Date Fair Value, Granted 7.77 7.80
Weighted-Average Grant Date Fair Value, Vested 7.12 5.40
Weighted-Average Grant Date Fair Value, Forfeited 8.16 7.57
Weighted-Average Grant Date Fair Value, Unvested, Ending balance $ 7.65 $ 7.35
XML 57 R44.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation - Summary of Stock Option Activity (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]    
Options outstanding beginning balance, Shares Subject to Stock Options 2,580,476 2,014,047
Granted, Shares Subject to Stock Options 960,472 855,787
Exercised, Shares Subject to Stock Options (86,125) (82,337)
Cancelled, Shares Subject to Stock Options (83,500) (207,021)
Options outstanding ending balance, Shares Subject to Stock Options 3,371,323 2,580,476
Options exercisable, Shares Subject to Stock Options 1,787,377  
Options outstanding beginning balance, Weighted-Average Exercise Price $ 4.90 $ 3.72
Granted, Weighted-Average Exercise Price 7.26 7.82
Exercised, Weighted-Average Exercise Price 2.47 2.40
Cancelled, Weighted-Average Exercise Price 7.35 6.51
Options outstanding ending balance, Weighted-Average Exercise Price 5.57 $ 4.90
Options exercisable, Weighted-Average Exercise Price $ 4.58  
Options outstanding, Weighted-Average Remaining Contractual Term 7 years 3 months 25 days 7 years 7 months 28 days
Options exercisable, Weighted-Average Remaining Contractual Term 6 years 4 months 6 days  
Options outstanding, Aggregate Intrinsic Value $ 8,643,000  
Exercised, Aggregate Intrinsic Value 430,000 $ 423,000
Options outstanding, Aggregate Intrinsic Value 4,577,000 $ 8,643,000
Options exercisable, Aggregate Intrinsic Value $ 3,821,000  
XML 58 R45.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation - Schedule of Weighted Average Assumptions using Black-Scholes Option Pricing Model (Detail)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]    
Expected volatility 77.30% 77.90%
Expected term (in years) 6 years 1 month 2 days 6 years 3 days
Risk-free interest rate 1.39% 2.26%
Expected dividend yield 0.00% 0.00%
XML 59 R46.htm IDEA: XBRL DOCUMENT v3.20.4
Stock-Based Compensation - Common Stock Reserved for Future Issuance (Detail)
Dec. 31, 2020
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Common stock reserved for future issuance 15,666,000
Common stock warrants [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Common stock reserved for future issuance 5,244,500
Restricted stock units [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Common stock reserved for future issuance 679,363
Common stock options [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Common stock reserved for future issuance 3,371,323
Available for grant under the 2014 Plan [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Common stock reserved for future issuance 4,081,253
Available for issuance under Employee Stock Purchase Plan [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Common stock reserved for future issuance 2,289,561
XML 60 R47.htm IDEA: XBRL DOCUMENT v3.20.4
Warrants - Additional Information (Detail) - USD ($)
 12 Months Ended
Jun. 14, 2017
Apr. 13, 2016
Dec. 31, 2020
Dec. 31, 2019
Jan. 16, 2018
Class of Warrant or Right [Line Items]          
Issuance of shares of common stock   7,500,000 0 0  
Warrants sold   7,500,000 637,087    
Common stock, price per share   $ 1.25      
Exercise price of warrant   1.50      
Warrants expiry date     Apr. 13, 2021    
Public offering price per warrant   $ 0.01      
Warrants outstanding     3,647,413    
Warrants exercised     348,493 528,695  
Securities Purchase Agreement [Member]          
Class of Warrant or Right [Line Items]          
Warrants exercised     248,308 0  
Public offering price per share and per warrant $ 1.15        
Unexercised warrants         1,987,337
Loan and Security Agreement [Member] | Minimum [Member]          
Class of Warrant or Right [Line Items]          
Beneficial ownership of company's common stock   49.90%      
Ligand [Member] | Loan and Security Agreement [Member]          
Class of Warrant or Right [Line Items]          
Warrants sold   960,000      
Exercise price of warrant   $ 1.50      
Warrants expiry date     Apr. 13, 2021    
Repayments of notes payable in stock   $ 1,200,000      
Over-Allotment Option [Member]          
Class of Warrant or Right [Line Items]          
Warrants sold   1,125,000      
Private Placement and Registered Direct Offering [Member] | Securities Purchase Agreement [Member]          
Class of Warrant or Right [Line Items]          
Exercise price of warrant $ 1.30        
Warrants expiry date Dec. 19, 2022   Dec. 19, 2022    
Number of warrants issued for common stock 0.75        
Warrants exercisable date Dec. 19, 2017   Dec. 19, 2017    
Percentage of warrant exercise beneficial ownership limitation of common stock outstanding minimum 4.99%        
Prior notice period of increase beneficial ownership limitation 61 days        
Percentage of minimum beneficial ownership limitation 9.99%        
Description of beneficial ownership limitation     Each holder of a Warrant does not have the right to exercise any portion of its Warrant if the holder, together with its affiliates, would beneficially own in excess of 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise (the “Beneficial Ownership Limitation”); provided, however, that upon 61 days’ prior notice to the Company, the holder may increase the Beneficial Ownership Limitation; however, in no event shall the Beneficial Ownership Limitation exceed 9.99%.    
Private Placement and Registered Direct Offering [Member] | Common stock [Member] | Securities Purchase Agreement [Member]          
Class of Warrant or Right [Line Items]          
Issuance of shares of common stock 3,749,783        
Private Placement and Registered Direct Offering [Member] | Maximum [Member] | Common stock [Member] | Securities Purchase Agreement [Member]          
Class of Warrant or Right [Line Items]          
Warrants sold 2,812,337        
XML 61 R48.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes - Schedule of Income Tax Expense (Benefit) from Continuing Operations (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Current:    
Federal $ 0 $ 0
State 0 0
Total current 0 0
Deferred:    
Federal (9,368) (5,976)
State (3,356) (1,857)
Total deferred (12,724) (7,833)
Change in valuation allowance 12,724 7,833
Total income tax expense (benefit) $ 0 $ 0
XML 62 R49.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes - Schedule of Reconciliations of the U.S. Federal Statutory Tax Rate to the Effective Income Tax Rate (Detail)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Income Tax Disclosure [Abstract]    
Tax provision at U.S. Federal statutory rates 21.00% 21.00%
State income taxes net of federal benefit 7.00% 6.00%
Non-deductible permanent items (1.00%) (1.00%)
Stock options   (1.00%)
Research and development credits 5.00% 5.00%
Change in valuation allowance (32.00%) (30.00%)
Effective income tax rate 0.00% 0.00%
XML 63 R50.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes - Schedule of Significant Components of Company's Deferred Taxes (Detail) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Deferred tax assets:    
Accrued liabilities $ 180 $ 248
Intangible assets 32,435 24,463
Net operating loss carryforwards 8,649 7,017
Share-based compensation 2,604 1,632
Credits 6,518 4,398
Other 20 5
Total deferred tax assets 50,406 37,763
Valuation Allowance (50,316) (37,592)
Total deferred tax assets, net of allowance 90 171
Deferred tax liabilities:    
Right of use assets (90) (167)
Other   (4)
Total deferred tax liabilities: (90) (171)
Net deferred tax assets (liabilities): $ 0 $ 0
XML 64 R51.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes - Additional Information (Detail) - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Income Tax [Line Items]    
Valuation Allowance $ 50,316,000 $ 37,592,000
Federal net operating loss carryforwards 31,000,000.0  
Federal net operating loss carryforwards subject to expire $ 17,800,000  
Federal net operating loss carryforwards subject to expiration year 2032  
Remaining federal net operating loss carryforwards $ 13,200,000  
State net operating loss carryforwards $ 30,600,000  
State net operating loss carryforwards, begin to expiration year. 2034  
Description of the limitations on the use of all operating loss carryforwards Specifically, this limitation may arise in the event of an “ownership change,” which is defined by Section 382 of the Code as a cumulative change in ownership of the Company of more than 50% within a three-year period. If the Company undergoes one or more ownership changes in connection with any future transactions in its stock, the Company’s ability to utilize net operating loss carryforwards to offset federal taxable income, if any, could potentially result in increased future tax liability to the Company.  An ownership change under Section 382 of the Code occurred during the year ended December 31, 2018.  
Percentage of cumulative change in stock ownership. 50.00%  
Federal net operating loss carryforwards limited based on ownership change $ 18,300,000  
State net operating loss carryforwards limited based on ownership change 17,900,000  
Annual limitation 5,700,000  
Tax benefit not recognized 0 0
Deferred tax assets, research and development tax credit carry-forwards 6,518,000 4,398,000
Liability for uncertain tax positions 0 $ 0
Federal [Member]    
Income Tax [Line Items]    
Deferred tax assets, research and development tax credit carry-forwards $ 4,300,000  
Tax credit carry-forwards begin to expiration year 2036  
State [Member]    
Income Tax [Line Items]    
Deferred tax assets, research and development tax credit carry-forwards $ 2,300,000  
XML 65 R52.htm IDEA: XBRL DOCUMENT v3.20.4
Related Party Transactions - Additional Information (Detail)
Dec. 31, 2020
Ligand [Member]  
Related Party Transaction [Line Items]  
Equity method investment, beneficially ownership percentage 9.80%
XML 66 R53.htm IDEA: XBRL DOCUMENT v3.20.4
Commitments and Contingencies - Additional Information (Detail)
 12 Months Ended
May 25, 2018
USD ($)
ft²
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Commitments And Contingencies [Line Items]      
Operating lease option to extend term   3 years  
Rent expense   $ 319,000 $ 308,000
California [Member] | Office Lease [Member]      
Commitments And Contingencies [Line Items]      
Area of lease premises | ft² 7,149    
Lease commencement date Nov. 01, 2018    
Lease expiration date Jan. 31, 2022    
Monthly base rent payments $ 27,000    
Percentage of rent increase under lease 3.00%    
XML 67 R54.htm IDEA: XBRL DOCUMENT v3.20.4
Commitments and Contingencies - Summary of Future Minimum Payments for Lease (Detail)
$ in Thousands
Dec. 31, 2020
USD ($)
Operating Leases Future Minimum Payments Due [Abstract]  
2021 $ 343
2022 29
Total minimum lease payments $ 372
EXCEL 68 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 70 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 71 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 155 399 1 false 56 0 false 11 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Balance Sheets Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Balance Sheets (Parenthetical) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Statements of Operations and Comprehensive Loss Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 100040 - Statement - Statements of Stockholders' Equity Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity Statements of Stockholders' Equity Statements 5 false false R6.htm 100050 - Statement - Statements of Cash Flows Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows Statements of Cash Flows Statements 6 false false R7.htm 100060 - Disclosure - Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPolicies Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies Notes 7 false false R8.htm 100070 - Disclosure - Investments in Marketable Securities Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecurities Investments in Marketable Securities Notes 8 false false R9.htm 100080 - Disclosure - Fair Value of Financial Instruments Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstruments Fair Value of Financial Instruments Notes 9 false false R10.htm 100090 - Disclosure - Agreements with Ligand Pharmaceuticals Incorporated Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureAgreementsWithLigandPharmaceuticalsIncorporated Agreements with Ligand Pharmaceuticals Incorporated Notes 10 false false R11.htm 100100 - Disclosure - Operating Leases - Right-of-Use Assets and Lease Liability Obligations Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligations Operating Leases - Right-of-Use Assets and Lease Liability Obligations Notes 11 false false R12.htm 100110 - Disclosure - Stockholders' Equity Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquity Stockholders' Equity Notes 12 false false R13.htm 100120 - Disclosure - Stock-Based Compensation Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 13 false false R14.htm 100130 - Disclosure - Warrants Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrants Warrants Notes 14 false false R15.htm 100140 - Disclosure - Income Taxes Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxes Income Taxes Notes 15 false false R16.htm 100150 - Disclosure - Related Party Transactions Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions Related Party Transactions Notes 16 false false R17.htm 100160 - Disclosure - Commitments and Contingencies Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 100170 - Disclosure - Subsequent Events Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureSubsequentEvents Subsequent Events Notes 18 false false R19.htm 100180 - Disclosure - Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies (Policies) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesPolicies Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies (Policies) Policies http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPolicies 19 false false R20.htm 100190 - Disclosure - Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies (Tables) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesTables Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies (Tables) Tables http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPolicies 20 false false R21.htm 100200 - Disclosure - Investments in Marketable Securities (Tables) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesTables Investments in Marketable Securities (Tables) Tables http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecurities 21 false false R22.htm 100210 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstruments 22 false false R23.htm 100220 - Disclosure - Operating Leases - Right-of-Use Assets and Lease Liability Obligations (Tables) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsTables Operating Leases - Right-of-Use Assets and Lease Liability Obligations (Tables) Tables http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligations 23 false false R24.htm 100230 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensation 24 false false R25.htm 100240 - Disclosure - Income Taxes (Tables) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables Income Taxes (Tables) Tables http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxes 25 false false R26.htm 100250 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies 26 false false R27.htm 100260 - Disclosure - Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies - Additional Information (Detail) Details 27 false false R28.htm 100270 - Disclosure - Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies - Schedule of Computation of Basic and Diluted Net Loss per Common Share (Detail) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerCommonShareDetail Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies - Schedule of Computation of Basic and Diluted Net Loss per Common Share (Detail) Details 28 false false R29.htm 100280 - Disclosure - Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Detail) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetail Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Detail) Details 29 false false R30.htm 100290 - Disclosure - Investments in Marketable Securities - Additional Information (Detail) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesAdditionalInformationDetail Investments in Marketable Securities - Additional Information (Detail) Details 30 false false R31.htm 100300 - Disclosure - Investments in Marketable Securities - Summary of Investments Classified As Available-For-Sale Securities (Detail) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail Investments in Marketable Securities - Summary of Investments Classified As Available-For-Sale Securities (Detail) Details 31 false false R32.htm 100310 - Disclosure - Investments in Marketable Securities - Summary of Investments Classified As Available-For-Sale Securities (Parenthetical) (Detail) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesParentheticalDetail Investments in Marketable Securities - Summary of Investments Classified As Available-For-Sale Securities (Parenthetical) (Detail) Details 32 false false R33.htm 100320 - Disclosure - Fair Value of Financial Instruments - Summary of Fair Values of Financial Instruments (Detail) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValuesOfFinancialInstrumentsDetail Fair Value of Financial Instruments - Summary of Fair Values of Financial Instruments (Detail) Details 33 false false R34.htm 100330 - Disclosure - Agreements with Ligand Pharmaceuticals Incorporated - Additional Information (Detail) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureAgreementsWithLigandPharmaceuticalsIncorporatedAdditionalInformationDetail Agreements with Ligand Pharmaceuticals Incorporated - Additional Information (Detail) Details 34 false false R35.htm 100340 - Disclosure - Operating Leases - Right-of-Use Assets and Lease Liability Obligations - Additional Information (Detail) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsAdditionalInformationDetail Operating Leases - Right-of-Use Assets and Lease Liability Obligations - Additional Information (Detail) Details 35 false false R36.htm 100350 - Disclosure - Operating Leases - Right-of-Use Assets and Lease Liability Obligations - Schedule of Right-of-use Assets and Lease Liabilities (Detail) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsScheduleOfRightOfUseAssetsAndLeaseLiabilitiesDetail Operating Leases - Right-of-Use Assets and Lease Liability Obligations - Schedule of Right-of-use Assets and Lease Liabilities (Detail) Details 36 false false R37.htm 100360 - Disclosure - Operating Leases - Right-of-Use Assets and Lease Liability Obligations - Schedule of Future Minimum Lease Payments (Detail) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsScheduleOfFutureMinimumLeasePaymentsDetail Operating Leases - Right-of-Use Assets and Lease Liability Obligations - Schedule of Future Minimum Lease Payments (Detail) Details 37 false false R38.htm 100380 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail Stockholders' Equity - Additional Information (Detail) Details 38 false false R39.htm 100390 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail Stock-Based Compensation - Additional Information (Detail) Details 39 false false R40.htm 100400 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expense Recognized (Detail) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetail Stock-Based Compensation - Summary of Stock-based Compensation Expense Recognized (Detail) Details 40 false false R41.htm 100410 - Disclosure - Stock-Based Compensation - Schedule of Unrecognized Stock-based Compensation Expense, Net of Estimated Forfeitures, by Type of Award and Weighted-average Recognition Period (Detail) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfUnrecognizedStockBasedCompensationExpenseNetOfEstimatedForfeituresByTypeOfAwardAndWeightedAverageRecognitionPeriodDetail Stock-Based Compensation - Schedule of Unrecognized Stock-based Compensation Expense, Net of Estimated Forfeitures, by Type of Award and Weighted-average Recognition Period (Detail) Details 41 false false R42.htm 100420 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Detail) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetail Stock-Based Compensation - Summary of Restricted Stock Activity (Detail) Details 42 false false R43.htm 100430 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Detail) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitActivityDetail Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Detail) Details 43 false false R44.htm 100440 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail Stock-Based Compensation - Summary of Stock Option Activity (Detail) Details 44 false false R45.htm 100450 - Disclosure - Stock-Based Compensation - Schedule of Weighted Average Assumptions using Black-Scholes Option Pricing Model (Detail) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsingBlackScholesOptionPricingModelDetail Stock-Based Compensation - Schedule of Weighted Average Assumptions using Black-Scholes Option Pricing Model (Detail) Details 45 false false R46.htm 100460 - Disclosure - Stock-Based Compensation - Common Stock Reserved for Future Issuance (Detail) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationCommonStockReservedForFutureIssuanceDetail Stock-Based Compensation - Common Stock Reserved for Future Issuance (Detail) Details 46 false false R47.htm 100470 - Disclosure - Warrants - Additional Information (Detail) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail Warrants - Additional Information (Detail) Details 47 false false R48.htm 100480 - Disclosure - Income Taxes - Schedule of Income Tax Expense (Benefit) from Continuing Operations (Detail) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseBenefitFromContinuingOperationsDetail Income Taxes - Schedule of Income Tax Expense (Benefit) from Continuing Operations (Detail) Details 48 false false R49.htm 100490 - Disclosure - Income Taxes - Schedule of Reconciliations of the U.S. Federal Statutory Tax Rate to the Effective Income Tax Rate (Detail) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationsOfUSFederalStatutoryTaxRateToEffectiveIncomeTaxRateDetail Income Taxes - Schedule of Reconciliations of the U.S. Federal Statutory Tax Rate to the Effective Income Tax Rate (Detail) Details 49 false false R50.htm 100500 - Disclosure - Income Taxes - Schedule of Significant Components of Company's Deferred Taxes (Detail) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxesDetail Income Taxes - Schedule of Significant Components of Company's Deferred Taxes (Detail) Details 50 false false R51.htm 100510 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 51 false false R52.htm 100520 - Disclosure - Related Party Transactions - Additional Information (Detail) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail Related Party Transactions - Additional Information (Detail) Details 52 false false R53.htm 100530 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 53 false false R54.htm 100540 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Payments for Lease (Detail) Sheet http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsForLeaseDetail Commitments and Contingencies - Summary of Future Minimum Payments for Lease (Detail) Details 54 false false All Reports Book All Reports vktx-10k_20201231.htm vktx-20201231.xsd vktx-20201231_cal.xml vktx-20201231_def.xml vktx-20201231_lab.xml vktx-20201231_pre.xml vktx-ex231_6.htm vktx-ex311_7.htm vktx-ex312_9.htm vktx-ex321_10.htm vktx-ex45_8.htm gw5rupjpmffd000001.jpg http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/stpr/2018-01-31 true true JSON 74 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "vktx-10k_20201231.htm": { "axisCustom": 0, "axisStandard": 20, "contextCount": 155, "dts": { "calculationLink": { "local": [ "vktx-20201231_cal.xml" ] }, "definitionLink": { "local": [ "vktx-20201231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "vktx-10k_20201231.htm" ] }, "labelLink": { "local": [ "vktx-20201231_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "vktx-20201231_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "vktx-20201231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 501, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 13, "http://www.vikingtherapeutics.com/20201231": 2, "http://xbrl.sec.gov/dei/2020-01-31": 4, "total": 19 }, "keyCustom": 76, "keyStandard": 323, "memberCustom": 25, "memberStandard": 25, "nsprefix": "vktx", "nsuri": "http://www.vikingtherapeutics.com/20201231", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Agreements with Ligand Pharmaceuticals Incorporated", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureAgreementsWithLigandPharmaceuticalsIncorporated", "shortName": "Agreements with Ligand Pharmaceuticals Incorporated", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Operating Leases - Right-of-Use Assets and Lease Liability Obligations", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligations", "shortName": "Operating Leases - Right-of-Use Assets and Lease Liability Obligations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Stockholders' Equity", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Stock-Based Compensation", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "vktx:WarrantDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Warrants", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrants", "shortName": "Warrants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "vktx:WarrantDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Income Taxes", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Related Party Transactions", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Commitments and Contingencies", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Subsequent Events", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "vktx:BusinessDescriptionPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies (Policies)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "vktx:BusinessDescriptionPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Balance Sheets", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets", "shortName": "Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies (Tables)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesTables", "shortName": "Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Investments in Marketable Securities (Tables)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesTables", "shortName": "Investments in Marketable Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Fair Value of Financial Instruments (Tables)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables", "shortName": "Fair Value of Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Operating Leases - Right-of-Use Assets and Lease Liability Obligations (Tables)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsTables", "shortName": "Operating Leases - Right-of-Use Assets and Lease Liability Obligations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Income Taxes (Tables)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "vktx:BusinessDescriptionPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityIncorporationDateOfIncorporation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies - Additional Information (Detail)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "shortName": "Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "vktx:BusinessDescriptionPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityIncorporationDateOfIncorporation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies - Schedule of Computation of Basic and Diluted Net Loss per Common Share (Detail)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerCommonShareDetail", "shortName": "Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies - Schedule of Computation of Basic and Diluted Net Loss per Common Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": "0", "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Detail)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetail", "shortName": "Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - Balance Sheets (Parenthetical)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical", "shortName": "Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20201231", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Investments in Marketable Securities - Additional Information (Detail)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesAdditionalInformationDetail", "shortName": "Investments in Marketable Securities - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Investments in Marketable Securities - Summary of Investments Classified As Available-For-Sale Securities (Detail)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail", "shortName": "Investments in Marketable Securities - Summary of Investments Classified As Available-For-Sale Securities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "U_vktxSecurity", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Investments in Marketable Securities - Summary of Investments Classified As Available-For-Sale Securities (Parenthetical) (Detail)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesParentheticalDetail", "shortName": "Investments in Marketable Securities - Summary of Investments Classified As Available-For-Sale Securities (Parenthetical) (Detail)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "U_vktxSecurity", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Fair Value of Financial Instruments - Summary of Fair Values of Financial Instruments (Detail)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValuesOfFinancialInstrumentsDetail", "shortName": "Fair Value of Financial Instruments - Summary of Fair Values of Financial Instruments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "vktx:LicenseAgreementEnteredDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Agreements with Ligand Pharmaceuticals Incorporated - Additional Information (Detail)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureAgreementsWithLigandPharmaceuticalsIncorporatedAdditionalInformationDetail", "shortName": "Agreements with Ligand Pharmaceuticals Incorporated - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "vktx:LicenseAgreementEnteredDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": "INF", "first": true, "lang": null, "name": "vktx:OperatingLeaseNumberOfLeases", "reportCount": 1, "unique": true, "unitRef": "U_vktxLease", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Operating Leases - Right-of-Use Assets and Lease Liability Obligations - Additional Information (Detail)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsAdditionalInformationDetail", "shortName": "Operating Leases - Right-of-Use Assets and Lease Liability Obligations - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": "INF", "first": true, "lang": null, "name": "vktx:OperatingLeaseNumberOfLeases", "reportCount": 1, "unique": true, "unitRef": "U_vktxLease", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Operating Leases - Right-of-Use Assets and Lease Liability Obligations - Schedule of Right-of-use Assets and Lease Liabilities (Detail)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsScheduleOfRightOfUseAssetsAndLeaseLiabilitiesDetail", "shortName": "Operating Leases - Right-of-Use Assets and Lease Liability Obligations - Schedule of Right-of-use Assets and Lease Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20201231", "decimals": null, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Operating Leases - Right-of-Use Assets and Lease Liability Obligations - Schedule of Future Minimum Lease Payments (Detail)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsScheduleOfFutureMinimumLeasePaymentsDetail", "shortName": "Operating Leases - Right-of-Use Assets and Lease Liability Obligations - Schedule of Future Minimum Lease Payments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Stockholders' Equity - Additional Information (Detail)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "shortName": "Stockholders' Equity - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20140228", "decimals": "INF", "lang": null, "name": "us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "vktx:CommonStockReservedForFutureIssuanceTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Stock-Based Compensation - Additional Information (Detail)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail", "shortName": "Stock-Based Compensation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": "0", "lang": null, "name": "us-gaap:ProceedsFromStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Statements of Operations and Comprehensive Loss", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss", "shortName": "Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expense Recognized (Detail)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetail", "shortName": "Stock-Based Compensation - Summary of Stock-based Compensation Expense Recognized (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20150531", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Stock-Based Compensation - Schedule of Unrecognized Stock-based Compensation Expense, Net of Estimated Forfeitures, by Type of Award and Weighted-average Recognition Period (Detail)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfUnrecognizedStockBasedCompensationExpenseNetOfEstimatedForfeituresByTypeOfAwardAndWeightedAverageRecognitionPeriodDetail", "shortName": "Stock-Based Compensation - Schedule of Unrecognized Stock-based Compensation Expense, Net of Estimated Forfeitures, by Type of Award and Weighted-average Recognition Period (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231", "decimals": "-3", "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Detail)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetail", "shortName": "Stock-Based Compensation - Summary of Restricted Stock Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20181231", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Detail)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitActivityDetail", "shortName": "Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20181231", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail", "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20181231", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Stock-Based Compensation - Schedule of Weighted Average Assumptions using Black-Scholes Option Pricing Model (Detail)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsingBlackScholesOptionPricingModelDetail", "shortName": "Stock-Based Compensation - Schedule of Weighted Average Assumptions using Black-Scholes Option Pricing Model (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "vktx:CommonStockReservedForFutureIssuanceTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Stock-Based Compensation - Common Stock Reserved for Future Issuance (Detail)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationCommonStockReservedForFutureIssuanceDetail", "shortName": "Stock-Based Compensation - Common Stock Reserved for Future Issuance (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "vktx:CommonStockReservedForFutureIssuanceTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20201231", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "vktx:WarrantDisclosureTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20160412_20160413", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Warrants - Additional Information (Detail)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail", "shortName": "Warrants - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "vktx:WarrantDisclosureTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20160413", "decimals": "INF", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Income Taxes - Schedule of Income Tax Expense (Benefit) from Continuing Operations (Detail)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseBenefitFromContinuingOperationsDetail", "shortName": "Income Taxes - Schedule of Income Tax Expense (Benefit) from Continuing Operations (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Income Taxes - Schedule of Reconciliations of the U.S. Federal Statutory Tax Rate to the Effective Income Tax Rate (Detail)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationsOfUSFederalStatutoryTaxRateToEffectiveIncomeTaxRateDetail", "shortName": "Income Taxes - Schedule of Reconciliations of the U.S. Federal Statutory Tax Rate to the Effective Income Tax Rate (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Statements of Stockholders' Equity", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity", "shortName": "Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Income Taxes - Schedule of Significant Components of Company's Deferred Taxes (Detail)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxesDetail", "shortName": "Income Taxes - Schedule of Significant Components of Company's Deferred Taxes (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Income Taxes - Additional Information (Detail)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail", "shortName": "Income Taxes - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20201231", "decimals": "-5", "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_vktxLigandPharmaceuticalsIncorporatedMember_20201231", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Related Party Transactions - Additional Information (Detail)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail", "shortName": "Related Party Transactions - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_vktxLigandPharmaceuticalsIncorporatedMember_20201231", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeaseOptionToExtend", "p", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "vktx:OperatingLeaseOptionToExtendTerm", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": "0", "lang": null, "name": "us-gaap:OperatingLeasesRentExpenseNet", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Payments for Lease (Detail)", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsForLeaseDetail", "shortName": "Commitments and Contingencies - Summary of Future Minimum Payments for Lease (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Statements of Cash Flows", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows", "shortName": "Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100060 - Disclosure - Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPolicies", "shortName": "Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100070 - Disclosure - Investments in Marketable Securities", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecurities", "shortName": "Investments in Marketable Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Fair Value of Financial Instruments", "role": "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstruments", "shortName": "Fair Value of Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "vktx-10k_20201231.htm", "contextRef": "C_0001607678_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 56, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r441", "r442", "r443" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "verboseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r444" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated By Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "verboseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureAgreementsWithLigandPharmaceuticalsIncorporatedAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationDateOfIncorporation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date when an entity was incorporated", "label": "Entity Incorporation Date Of Incorporation", "terseLabel": "Date of incorporation" } } }, "localname": "EntityIncorporationDateOfIncorporation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well Known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r441", "r442", "r443" ], "lang": { "en-us": { "role": { "label": "Icfr Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureAgreementsWithLigandPharmaceuticalsIncorporatedAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_MaximumMember": { "auth_ref": [ "r197", "r198", "r341", "r342", "r343", "r344", "r345", "r346", "r365", "r400", "r402" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureAgreementsWithLigandPharmaceuticalsIncorporatedAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesParentheticalDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r197", "r198", "r341", "r342", "r343", "r344", "r345", "r346", "r365", "r400", "r402" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureAgreementsWithLigandPharmaceuticalsIncorporatedAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesParentheticalDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r187", "r197", "r198", "r341", "r342", "r343", "r344", "r345", "r346", "r365", "r400", "r402" ], "lang": { "en-us": { "role": { "label": "Range [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureAgreementsWithLigandPharmaceuticalsIncorporatedAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesParentheticalDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r187", "r197", "r198", "r341", "r342", "r343", "r344", "r345", "r346", "r365", "r400", "r402" ], "lang": { "en-us": { "role": { "label": "Range [Member]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureAgreementsWithLigandPharmaceuticalsIncorporatedAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesParentheticalDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r125", "r126", "r184", "r185", "r401", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435" ], "lang": { "en-us": { "role": { "label": "Segment Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r125", "r126", "r184", "r185", "r401", "r425", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436" ], "lang": { "en-us": { "role": { "label": "Statement Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "stpr_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CALIFORNIA", "terseLabel": "California [Member]" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r25" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10120.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r37" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10080.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax", "terseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r35", "r38", "r39", "r74", "r75", "r76", "r286", "r403", "r404" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalCashAndCashEquivalentRelatedText": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An element designated to encapsulate any additional information related to cash and cash equivalents not otherwise addressed by the existing taxonomy. Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Additional Cash And Cash Equivalent Related Text", "terseLabel": "Highly liquid investments maturities" } } }, "localname": "AdditionalCashAndCashEquivalentRelatedText", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r16" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10060.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid In Capital Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r74", "r75", "r76", "r233", "r234", "r235" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-In Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition", "terseLabel": "Employee stock-based compensation, net" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r200", "r229", "r238" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share Based Compensation Expense", "terseLabel": "Stock compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r91" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Antidilutive securities excluded in calculation of diluted net loss per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r91" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r91" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements And Nonarrangement Transactions [Member]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureAgreementsWithLigandPharmaceuticalsIncorporatedAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r70", "r107", "r116", "r122", "r149", "r282", "r287", "r300", "r380", "r393" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r3", "r4", "r33", "r70", "r149", "r282", "r287", "r300" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10150.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r293" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Fair Value Disclosure", "terseLabel": "Total financial assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValuesOfFinancialInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Fair Value Disclosure [Abstract]", "terseLabel": "Financial assets carried at fair value:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValuesOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r134" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail": { "order": 10010.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax", "terseLabel": "Gross Unrealized Gains", "verboseLabel": "Unrealized gains, aggregate" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r135" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail": { "order": 10020.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax", "negatedLabel": "Gross Unrealized Losses", "terseLabel": "Unrealized losses, aggregate" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r132", "r156" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Amortized Cost Basis", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Available For Sale Securities [Abstract]" } } }, "localname": "AvailableForSaleSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10200.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.", "label": "Available For Sale Securities Current", "terseLabel": "Short-term investments \u2013 available for sale" } } }, "localname": "AvailableForSaleSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r129", "r133", "r156", "r382" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Securities Debt Securities", "terseLabel": "Short-term investments, available for sale" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValuesOfFinancialInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r131", "r156" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail": { "order": 10030.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Available For Sale Securities Debt Securities Current", "terseLabel": "Short-term investments - available for sale", "verboseLabel": "Aggregate Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r131", "r156" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Available For Sale Securities Debt Securities Noncurrent", "terseLabel": "Short-term investments classified as available-for-sale, noncurrent" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r201", "r231" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]", "terseLabel": "Award Date" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted.", "label": "Award Date [Domain]", "terseLabel": "Award Date" } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r201", "r231" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationCommonStockReservedForFutureIssuanceDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfUnrecognizedStockBasedCompensationExpenseNetOfEstimatedForfeituresByTypeOfAwardAndWeightedAverageRecognitionPeriodDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitActivityDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis Of Accounting Policy Policy [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition Percentage Of Voting Interests Acquired", "terseLabel": "Voting power of the surviving or acquiring entity" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureAgreementsWithLigandPharmaceuticalsIncorporatedAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.", "label": "Business Combination Step Acquisition Equity Interest In Acquiree Percentage", "terseLabel": "Percentage of voting interest beneficiary owned" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureAgreementsWithLigandPharmaceuticalsIncorporatedAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r23", "r64" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10190.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash And Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash And Cash Equivalents Fair Value Disclosure", "terseLabel": "Cash equivalents, fair value disclosure" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValuesOfFinancialInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r11", "r65", "r67" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash And Cash Equivalents Policy [Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r60", "r64", "r66" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents end of period", "periodStartLabel": "Cash and cash equivalents beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r60", "r301" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Cash equivalents [Member]" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesParentheticalDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing transactions" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates Of Deposit [Member]", "terseLabel": "Certificates of deposit [Member]" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesParentheticalDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "Date the warrants or rights are exercisable, in CCYY-MM-DD format.", "label": "Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable", "terseLabel": "Warrants exercisable date" } } }, "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1", "verboseLabel": "Exercise price of warrant" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class Of Warrant Or Right [Line Items]", "terseLabel": "Class of Warrant or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right", "terseLabel": "Number of warrants issued for common stock" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights", "terseLabel": "Warrants sold" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r173", "r199" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class Of Warrant Or Right [Table]", "terseLabel": "Class Of Warrant Or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r275", "r276", "r278" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Agreements with Ligand Pharmaceuticals Incorporated" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureAgreementsWithLigandPharmaceuticalsIncorporated" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]", "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureAgreementsWithLigandPharmaceuticalsIncorporatedAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r169" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper, available-for-sale [Member]", "verboseLabel": "Commercial paper [Member]" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValuesOfFinancialInstrumentsDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesParentheticalDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r30", "r167", "r383", "r396" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10020.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments And Contingencies", "terseLabel": "Commitments and contingencies (Note 11)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments And Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r164", "r165", "r166", "r168" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments And Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock Capital Shares Reserved For Future Issuance", "terseLabel": "Number of shares of common stock reserved for issuance", "verboseLabel": "Common stock reserved for future issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r74", "r75" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r15", "r170" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r15" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10050.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "terseLabel": "Common stock, $0.00001 par value: 300,000,000 shares authorized at December 31, 2020 and 2019; 73,215,940 shares issued and outstanding at December 31, 2020 and 72,413,602 shares issued and outstanding at December 31, 2019" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r41", "r43", "r44", "r47", "r385", "r398" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r96", "r392" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk Credit Risk", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r188", "r196", "r408" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities [Member]", "verboseLabel": "Corporate debt securities, available-for-sale [Member]" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValuesOfFinancialInstrumentsDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesParentheticalDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": { "auth_ref": [], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseBenefitFromContinuingOperationsDetail": { "order": 10030.0, "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal State And Local Tax Expense Benefit", "totalLabel": "Total current" } } }, "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseBenefitFromContinuingOperationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r71", "r260", "r267" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseBenefitFromContinuingOperationsDetail": { "order": 10060.0, "parentTag": "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense Benefit", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseBenefitFromContinuingOperationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense Benefit Continuing Operations [Abstract]", "terseLabel": "Current:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseBenefitFromContinuingOperationsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r71", "r260", "r267" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseBenefitFromContinuingOperationsDetail": { "order": 10070.0, "parentTag": "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State And Local Tax Expense Benefit", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseBenefitFromContinuingOperationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "auth_ref": [ "r145" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10070.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities Available For Sale Realized Gain Loss", "terseLabel": "Realized gain on investments" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities Available For Sale Table [Text Block]", "terseLabel": "Summary of Investments Classified As Available-For-Sale Securities" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": { "auth_ref": [ "r140", "r157" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss", "terseLabel": "Unrealized losses, individually" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": { "auth_ref": [ "r141", "r158" ], "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities Available For Sale Unrealized Loss Position Number Of Positions", "terseLabel": "Number of securities in unrealized loss position" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesParentheticalDetail" ], "xbrltype": "integerItemType" }, "us-gaap_DeferredChargesPolicyTextBlock": { "auth_ref": [ "r24", "r67" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.", "label": "Deferred Charges Policy [Text Block]", "terseLabel": "Deferred Financing Costs" } } }, "localname": "DeferredChargesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of common shares reserved for future issuance related to deferred compensation arrangements with individuals.", "label": "Deferred Compensation Arrangement With Individual Common Stock Reserved For Future Issuance", "terseLabel": "Number of common stock for issuance in exchange for future services from founders" } } }, "localname": "DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice": { "auth_ref": [ "r206" ], "lang": { "en-us": { "role": { "documentation": "The per share price that the individual must pay to acquire shares under the deferred compensation arrangement.", "label": "Deferred Compensation Arrangement With Individual Exercise Price", "terseLabel": "Common stock price per share" } } }, "localname": "DeferredCompensationArrangementWithIndividualExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r71", "r261", "r267" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseBenefitFromContinuingOperationsDetail": { "order": 10040.0, "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense Benefit", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseBenefitFromContinuingOperationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": { "auth_ref": [], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseBenefitFromContinuingOperationsDetail": { "order": 10010.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal State And Local Tax Expense Benefit", "totalLabel": "Total deferred" } } }, "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseBenefitFromContinuingOperationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Federal State And Local Tax Expense Benefit [Abstract]", "terseLabel": "Deferred:" } } }, "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseBenefitFromContinuingOperationsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r71", "r261", "r267" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseBenefitFromContinuingOperationsDetail": { "order": 10050.0, "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State And Local Income Tax Expense Benefit", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseBenefitFromContinuingOperationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxesDetail": { "order": 10080.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Assets Goodwill And Intangible Assets", "terseLabel": "Intangible assets" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r252" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxesDetail": { "order": 10050.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r254" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets Liabilities Net", "totalLabel": "Net deferred tax assets (liabilities):" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r254" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxesDetail": { "order": 10010.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets Net", "totalLabel": "Total deferred tax assets, net of allowance" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets Net [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r258", "r259" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxesDetail": { "order": 10090.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": { "auth_ref": [ "r258", "r259" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.", "label": "Deferred Tax Assets Operating Loss Carryforwards Domestic", "terseLabel": "Federal net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "auth_ref": [ "r258", "r259" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.", "label": "Deferred Tax Assets Operating Loss Carryforwards State And Local", "terseLabel": "State net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.", "label": "Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration", "terseLabel": "Federal net operating loss carryforwards subject to expire" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r258", "r259" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxesDetail": { "order": 10120.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r257", "r258", "r259" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxesDetail": { "order": 10110.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Deferred Tax Assets Tax Credit Carryforwards Research", "terseLabel": "Credits", "verboseLabel": "Deferred tax assets, research and development tax credit carry-forwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r258", "r259" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxesDetail": { "order": 10100.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost", "terseLabel": "Share-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r258", "r259" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxesDetail": { "order": 10070.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities", "terseLabel": "Accrued liabilities" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r253" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxesDetail": { "order": 10060.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets Valuation Allowance", "negatedLabel": "Valuation Allowance", "terseLabel": "Valuation Allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r244", "r254" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxesDetail": { "order": 10020.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities", "negatedTotalLabel": "Total deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities Net [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r258", "r259" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxesDetail": { "order": 10040.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liabilities Other", "negatedLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsNoncurrent": { "auth_ref": [ "r24" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10180.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "Deposits Assets Noncurrent", "terseLabel": "Deposits" } } }, "localname": "DepositsAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Country [Member]", "terseLabel": "Federal [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r89" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share Basic And Diluted", "terseLabel": "Basic and diluted net loss per share" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerCommonShareDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r67", "r91", "r92" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share Policy [Text Block]", "terseLabel": "Net Loss per Common Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r246" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationsOfUSFederalStatutoryTaxRateToEffectiveIncomeTaxRateDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Continuing Operations", "totalLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationsOfUSFederalStatutoryTaxRateToEffectiveIncomeTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r246", "r268" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationsOfUSFederalStatutoryTaxRateToEffectiveIncomeTaxRateDetail": { "order": 10010.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate", "terseLabel": "Tax provision at U.S. Federal statutory rates" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationsOfUSFederalStatutoryTaxRateToEffectiveIncomeTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r246", "r268" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationsOfUSFederalStatutoryTaxRateToEffectiveIncomeTaxRateDetail": { "order": 10060.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance", "terseLabel": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationsOfUSFederalStatutoryTaxRateToEffectiveIncomeTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "auth_ref": [ "r246", "r268" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationsOfUSFederalStatutoryTaxRateToEffectiveIncomeTaxRateDetail": { "order": 10030.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense", "negatedLabel": "Non-deductible permanent items" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationsOfUSFederalStatutoryTaxRateToEffectiveIncomeTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r246", "r268" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationsOfUSFederalStatutoryTaxRateToEffectiveIncomeTaxRateDetail": { "order": 10040.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost", "terseLabel": "Stock options" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationsOfUSFederalStatutoryTaxRateToEffectiveIncomeTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r246", "r268" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationsOfUSFederalStatutoryTaxRateToEffectiveIncomeTaxRateDetail": { "order": 10020.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes", "terseLabel": "State income taxes net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationsOfUSFederalStatutoryTaxRateToEffectiveIncomeTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r246", "r268" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationsOfUSFederalStatutoryTaxRateToEffectiveIncomeTaxRateDetail": { "order": 10050.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation Tax Credits Research", "terseLabel": "Research and development credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationsOfUSFederalStatutoryTaxRateToEffectiveIncomeTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Service Share Based Compensation Aggregate Disclosures [Abstract]" } } }, "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r230" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized", "terseLabel": "Unrecognized compensation expense", "verboseLabel": "Unrecognized Expense, Net of Estimated Forfeitures" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfUnrecognizedStockBasedCompensationExpenseNetOfEstimatedForfeituresByTypeOfAwardAndWeightedAverageRecognitionPeriodDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1", "terseLabel": "Weighted-average Recognition Period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfUnrecognizedStockBasedCompensationExpenseNetOfEstimatedForfeituresByTypeOfAwardAndWeightedAverageRecognitionPeriodDetail" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r229" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "Employee Service Share Based Compensation Tax Benefit From Compensation Expense", "terseLabel": "Excess tax benefit from stock-based awards" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock options [Member]", "verboseLabel": "Common stock options [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfUnrecognizedStockBasedCompensationExpenseNetOfEstimatedForfeituresByTypeOfAwardAndWeightedAverageRecognitionPeriodDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r74", "r75", "r76", "r78", "r83", "r85", "r93", "r150", "r170", "r172", "r233", "r234", "r235", "r263", "r264", "r302", "r303", "r304", "r305", "r306", "r307", "r403", "r404", "r405" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationCommonStockReservedForFutureIssuanceDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment Ownership Percentage", "terseLabel": "Equity method investment, beneficially ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Abstract]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValuesOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r293", "r294", "r295", "r299" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValuesOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r293", "r294", "r295", "r298", "r299" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block]", "terseLabel": "Summary of Fair Values of Financial Instruments" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]", "terseLabel": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValuesOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r293", "r299" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Fair Value By Asset Class [Axis]", "terseLabel": "Asset Class" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValuesOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r196", "r294", "r338", "r339", "r340" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "terseLabel": "Level 2 [Member]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValuesOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r188", "r189", "r194", "r196", "r294", "r338" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValuesOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r188", "r189", "r194", "r196", "r294", "r339" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValuesOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r196", "r294", "r340" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValuesOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r196", "r338", "r339", "r340" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValuesOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r138", "r139", "r151", "r152", "r153", "r154", "r155", "r159", "r160", "r161", "r162", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r49" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10110.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General And Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General And Administrative Expense [Member]", "verboseLabel": "General and administrative expenses [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetail" ], "xbrltype": "domainItemType" }, "us-gaap_HealthCareCostsPolicyPolicyTextBlock": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accruing health care costs for a prepaid health care service provider.", "label": "Health Care Costs Policy Policy [Text Block]", "terseLabel": "Prepaid Clinical Trial and Preclinical Study Costs" } } }, "localname": "HealthCareCostsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "I P O [Member]", "terseLabel": "IPO [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureAgreementsWithLigandPharmaceuticalsIncorporatedAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r163" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r247", "r250", "r256", "r265", "r269", "r271", "r272", "r273" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r71", "r84", "r85", "r106", "r245", "r266", "r270", "r399" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseBenefitFromContinuingOperationsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense Benefit", "totalLabel": "Total income tax expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseBenefitFromContinuingOperationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r45", "r67", "r242", "r243", "r250", "r251", "r255", "r262", "r427" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax Policy [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r246" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseBenefitFromContinuingOperationsDetail": { "order": 10020.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance", "terseLabel": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxExpenseBenefitFromContinuingOperationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r62" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10190.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase Decrease In Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r62" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10200.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase Decrease In Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r62" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10170.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10060.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income Expense Nonoperating Net", "terseLabel": "Interest income, net" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeAmortizationOfPremium": { "auth_ref": [ "r50" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10100.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization of purchase premium on nonoperating securities.", "label": "Investment Income Amortization Of Premium", "terseLabel": "Amortization of investment premiums" } } }, "localname": "InvestmentIncomeAmortizationOfPremium", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investment Type Categorization [Member]", "terseLabel": "Investments" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesParentheticalDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments Debt And Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r147", "r379", "r390", "r424" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]", "terseLabel": "Investments in Marketable Securities" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]", "terseLabel": "Lease Contractual Term" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement.", "label": "Lease Contractual Term [Domain]", "terseLabel": "Lease Contractual Term" } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease Cost Table [Text Block]", "terseLabel": "Schedule of Right-of-use Assets and Lease Liabilities" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date which lease or group of leases is set to expire, in CCYY-MM-DD format.", "label": "Lease Expiration Date1", "terseLabel": "Lease expiration date" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "Leases Of Lessee Disclosure [Text Block]", "terseLabel": "Operating Leases - Right-of-Use Assets and Lease Liability Obligations" } } }, "localname": "LeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligations" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee Disclosure [Abstract]" } } }, "localname": "LesseeDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee Leases Policy [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether lessee has option to extend operating lease.", "label": "Lessee Operating Lease Existence Of Option To Extend", "terseLabel": "Operating lease, option to extend" } } }, "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsAdditionalInformationDetail" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee Operating Lease Liability Maturity Table [Text Block]", "terseLabel": "Schedule of Future Minimum Lease Payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r323" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsScheduleOfFutureMinimumLeasePaymentsDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsScheduleOfFutureMinimumLeasePaymentsDetail2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee Operating Lease Liability Payments Due", "totalLabel": "Total minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsScheduleOfFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r323" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsScheduleOfFutureMinimumLeasePaymentsDetail": { "order": 10010.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsScheduleOfFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r323" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsScheduleOfFutureMinimumLeasePaymentsDetail": { "order": 10020.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Two", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsScheduleOfFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r323" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsScheduleOfFutureMinimumLeasePaymentsDetail2": { "order": 10010.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee Operating Lease Liability Undiscounted Excess Amount", "negatedLabel": "Less: amount representing interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsScheduleOfFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lessee Operating Lease Option To Extend", "terseLabel": "operating lease, option to extend, description" } } }, "localname": "LesseeOperatingLeaseOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r26", "r70", "r117", "r149", "r283", "r287", "r288", "r300" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10010.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r20", "r70", "r149", "r300", "r381", "r395" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r28", "r70", "r149", "r283", "r287", "r288", "r300" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10090.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r8", "r9", "r10", "r12", "r13", "r70", "r149", "r283", "r287", "r288", "r300" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10100.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities Noncurrent", "totalLabel": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUncertainTaxPositionsNoncurrent": { "auth_ref": [ "r29" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for uncertainty in income taxes classified as noncurrent.", "label": "Liability For Uncertain Tax Positions Noncurrent", "terseLabel": "Liability for uncertain tax positions" } } }, "localname": "LiabilityForUncertainTaxPositionsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities Policy", "terseLabel": "Investments Available-for-Sale" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r188" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Government money market funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValuesOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r60" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10030.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r60" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r60", "r61", "r63" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r40", "r42", "r46", "r63", "r70", "r77", "r79", "r80", "r81", "r82", "r84", "r85", "r88", "r107", "r115", "r118", "r121", "r123", "r149", "r300", "r384", "r397" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10010.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerCommonShareDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income Loss [Abstract]", "terseLabel": "Numerator" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerCommonShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_NetRentableArea": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net rentable area for properties owned.", "label": "Net Rentable Area", "terseLabel": "Area of lease premises" } } }, "localname": "NetRentableArea", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "areaItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number Of Operating Segments", "terseLabel": "Number of operating segment" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10090.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r107", "r115", "r118", "r121", "r123" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10030.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r316" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease Expense", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r315" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsScheduleOfFutureMinimumLeasePaymentsDetail2": { "order": 10020.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsScheduleOfRightOfUseAssetsAndLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease Liability", "terseLabel": "Total lease liability obligations", "totalLabel": "Total lease liability obligations" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsScheduleOfFutureMinimumLeasePaymentsDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsScheduleOfRightOfUseAssetsAndLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r315" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsScheduleOfRightOfUseAssetsAndLeaseLiabilitiesDetail": { "order": 10010.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10140.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease Liability Current", "terseLabel": "Lease liability, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsScheduleOfRightOfUseAssetsAndLeaseLiabilitiesDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r315" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsScheduleOfRightOfUseAssetsAndLeaseLiabilitiesDetail": { "order": 10020.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10110.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease Liability Noncurrent", "terseLabel": "Lease liability, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsScheduleOfRightOfUseAssetsAndLeaseLiabilitiesDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r314" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10160.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease Right Of Use Asset", "terseLabel": "Right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsScheduleOfRightOfUseAssetsAndLeaseLiabilitiesDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r321", "r324" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease Weighted Average Discount Rate Percent", "terseLabel": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsScheduleOfRightOfUseAssetsAndLeaseLiabilitiesDetail" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r320", "r324" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease Weighted Average Remaining Lease Term1", "terseLabel": "Weighted-average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsScheduleOfRightOfUseAssetsAndLeaseLiabilitiesDetail" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r309", "r311" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsForLeaseDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases Future Minimum Payments Due", "totalLabel": "Total minimum lease payments" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsForLeaseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Leases Future Minimum Payments Due [Abstract]" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r309", "r311" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsForLeaseDetail": { "order": 10010.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases Future Minimum Payments Due Current", "terseLabel": "2021" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsForLeaseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r309", "r311" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsForLeaseDetail": { "order": 10020.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases Future Minimum Payments Due In Two Years", "terseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsForLeaseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesRentExpenseMinimumRentals": { "auth_ref": [ "r308", "r309", "r310" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes.", "label": "Operating Leases Rent Expense Minimum Rentals", "terseLabel": "Monthly base rent payments" } } }, "localname": "OperatingLeasesRentExpenseMinimumRentals", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesRentExpenseNet": { "auth_ref": [ "r310" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.", "label": "Operating Leases Rent Expense Net", "terseLabel": "Rent expense" } } }, "localname": "OperatingLeasesRentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.", "label": "Operating Loss Carryforwards Limitations On Use", "terseLabel": "Description of the limitations on the use of all operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwardsLimitationsOnUse", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r1", "r73", "r102", "r292" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block]", "terseLabel": "Organization, Liquidity and Management's Plan, and Summary of Significant Accounting Policies" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r5", "r6", "r7", "r27" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10130.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities Current", "terseLabel": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]", "terseLabel": "Other comprehensive gain (loss), net of tax:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r34", "r36" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10020.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax", "terseLabel": "Unrealized gain (loss) on securities", "verboseLabel": "Unrealized gain (loss) on investments" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r51" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10040.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income Expense", "totalLabel": "Total other income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income Expense [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over Allotment Option [Member]", "terseLabel": "Over-Allotment Option [Member]" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r58" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10040.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments Of Stock Issuance Costs", "negatedLabel": "Public offering and financing costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r57" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10050.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payments Related To Tax Withholding For Share Based Compensation", "negatedLabel": "Value of shares withheld related to employee tax withholding" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r55" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10070.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments To Acquire Investments", "negatedLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r201", "r231" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock Par Or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r14" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10040.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock Value", "terseLabel": "Preferred stock, $0.00001 par value: 10,000,000 shares authorized at December 31, 2020 and 2019; no shares issued and outstanding at December 31, 2020 and 2019" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r3", "r21", "r22" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10220.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense And Other Assets Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r54" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10080.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds From Sale Maturity And Collections Of Investments", "terseLabel": "Proceeds from sales and maturities of investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r52", "r53", "r130" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds From Sale Of Available For Sale Securities Debt", "terseLabel": "Proceeds from sales of available-for-sale securities" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r56", "r232" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds From Stock Options Exercised", "terseLabel": "Cash proceeds from exercises of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r0", "r40", "r42", "r59", "r70", "r77", "r84", "r85", "r107", "r115", "r118", "r121", "r123", "r149", "r281", "r284", "r285", "r290", "r291", "r300", "r386" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10090.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Profit Loss", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Reclassifications": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for classifying current financial statements, which may be different from classifications in the prior year's financial statements. Disclose any material changes in classification including an explanation of the reason for the change and the areas impacted.", "label": "Reclassifications", "terseLabel": "Reclassifications" } } }, "localname": "Reclassifications", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r195", "r327", "r328" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r195", "r327", "r330", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party Transactions By Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r325", "r326", "r328", "r331", "r332" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r240", "r437" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10100.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "verboseLabel": "Research and development expenses [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r67", "r240" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research And Development Expense Policy", "terseLabel": "Research and Development Expenses" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesParentheticalDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r91" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units R S U [Member]", "terseLabel": "Restricted stock units [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationCommonStockReservedForFutureIssuanceDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitActivityDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r17", "r172", "r236", "r394", "r406", "r407" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10070.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r74", "r75", "r76", "r78", "r83", "r85", "r150", "r233", "r234", "r235", "r263", "r264", "r403", "r405" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r104", "r105", "r114", "r119", "r120", "r124", "r125", "r127", "r183", "r184", "r366" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10080.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue From Contract With Customer Excluding Assessed Tax", "terseLabel": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r68", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r186" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue From Contract With Customer Policy [Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureAgreementsWithLigandPharmaceuticalsIncorporatedAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r91" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r91" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]", "terseLabel": "Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule Of Available For Sale Securities [Line Items]", "terseLabel": "Schedule of Available-for-sale Securities [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r136", "r137", "r142", "r143", "r144", "r146", "r387", "r388" ], "lang": { "en-us": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule Of Available For Sale Securities [Table]", "terseLabel": "Schedule Of Available For Sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]", "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureAgreementsWithLigandPharmaceuticalsIncorporatedAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]", "terseLabel": "Schedule of Income Tax Expense (Benefit) from Continuing Operations" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]", "terseLabel": "Schedule of Significant Components of Company's Deferred Taxes" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]", "terseLabel": "Schedule of Computation of Basic and Diluted Net Loss per Common Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]", "terseLabel": "Schedule of Reconciliations of the U.S. Federal Statutory Tax Rate to the Effective Income Tax Rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r200", "r228", "r238" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]", "terseLabel": "Summary of Stock-based Compensation Expense Recognized" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]", "terseLabel": "Summary of Future Minimum Payments for Lease" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r72", "r329", "r330" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule Of Related Party Transactions By Related Party [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r201", "r231" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationCommonStockReservedForFutureIssuanceDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfUnrecognizedStockBasedCompensationExpenseNetOfEstimatedForfeituresByTypeOfAwardAndWeightedAverageRecognitionPeriodDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitActivityDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r206" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]", "terseLabel": "Summary of Shares Granted and Stock Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r206", "r217", "r220" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]", "terseLabel": "Summary of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r222" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]", "terseLabel": "Schedule of Weighted Average Assumptions using Black-Scholes Option Pricing Model" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.", "label": "Schedule Of Unrecognized Compensation Cost Nonvested Awards Table [Text Block]", "terseLabel": "Schedule of Unrecognized Stock-based Compensation Expense, Net of Estimated Forfeitures, by Type of Award and Weighted-average Recognition Period" } } }, "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r67", "r108", "r109", "r110", "r111", "r112", "r113", "r125" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting Policy Policy [Text Block]", "terseLabel": "Segments" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r62" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10130.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share Based Compensation", "terseLabel": "Stock-based compensation", "verboseLabel": "Total stock-based compensation expense included in expenses" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": { "auth_ref": [ "r199", "r202" ], "lang": { "en-us": { "role": { "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Description", "terseLabel": "Common stock reserved for issuance, description" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Discount rate from fair value on offering date that participants pay for shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date", "terseLabel": "Percentage of purchase of common stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Discount rate from fair value on purchase date that participants pay for shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Purchase Date", "terseLabel": "Percentage of common stock on the date of purchase" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period", "negatedLabel": "Shares, Forfeited", "terseLabel": "Forfeiture of performance based award" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period", "terseLabel": "Shares, Granted", "verboseLabel": "Issuance of performance based award" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r213" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number", "periodEndLabel": "Shares, Unvested, Ending balance", "periodStartLabel": "Shares, Unvested, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r213" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted-Average Grant Date Fair Value, Unvested, Ending balance", "periodStartLabel": "Weighted-Average Grant Date Fair Value, Unvested, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period", "negatedLabel": "Shares, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsingBlackScholesOptionPricingModelDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsingBlackScholesOptionPricingModelDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsingBlackScholesOptionPricingModelDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationCommonStockReservedForFutureIssuanceDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfUnrecognizedStockBasedCompensationExpenseNetOfEstimatedForfeituresByTypeOfAwardAndWeightedAverageRecognitionPeriodDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitActivityDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r211" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised", "terseLabel": "Warrants exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r207", "r209" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number", "terseLabel": "Warrants outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number", "terseLabel": "Options exercisable, Shares Subject to Stock Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price", "terseLabel": "Options exercisable, Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r219" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value", "terseLabel": "Exercised, Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period", "negatedLabel": "Cancelled, Shares Subject to Stock Options", "terseLabel": "Forfeited awards" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross", "terseLabel": "Granted, Shares Subject to Stock Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average fair value of stock options granted to employees" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r231" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value", "periodEndLabel": "Options outstanding, Aggregate Intrinsic Value", "periodStartLabel": "Options outstanding, Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r208", "r231" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number", "periodEndLabel": "Options outstanding ending balance, Shares Subject to Stock Options", "periodStartLabel": "Options outstanding beginning balance, Shares Subject to Stock Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price", "periodEndLabel": "Options outstanding ending balance, Weighted-Average Exercise Price", "periodStartLabel": "Options outstanding beginning balance, Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r199", "r203" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationCommonStockReservedForFutureIssuanceDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfUnrecognizedStockBasedCompensationExpenseNetOfEstimatedForfeituresByTypeOfAwardAndWeightedAverageRecognitionPeriodDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitActivityDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price", "terseLabel": "Exercised, Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price", "terseLabel": "Cancelled, Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price", "terseLabel": "Granted, Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share Based Compensation Award Tranche One [Member]", "terseLabel": "Tranche One [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share Based Compensation Award Tranche Two [Member]", "terseLabel": "Tranche Two [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r67", "r201", "r204" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share Based Compensation Option And Incentive Plans Policy", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Public offering price per warrant" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r223", "r237" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsingBlackScholesOptionPricingModelDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r231" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1", "terseLabel": "Options exercisable, Aggregate Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1", "terseLabel": "Options exercisable, Weighted-Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r221" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2", "terseLabel": "Options outstanding, Weighted-Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r205" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1", "terseLabel": "Total fair value of stock options, vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares Issued", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued Price Per Share", "terseLabel": "Common stock, price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State And Local Jurisdiction [Member]", "terseLabel": "State [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r32", "r74", "r75", "r76", "r78", "r83", "r85", "r93", "r150", "r170", "r172", "r233", "r234", "r235", "r263", "r264", "r302", "r303", "r304", "r305", "r306", "r307", "r403", "r404", "r405" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationCommonStockReservedForFutureIssuanceDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r74", "r75", "r76", "r93", "r366" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r14", "r15", "r170", "r172" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period Shares Employee Stock Purchase Plans", "verboseLabel": "Shares issued under ESPP" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r14", "r15", "r170", "r172" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Shares New Issues", "positiveLabel": "Common stock issued as part of partial consideration of agreement", "positiveTerseLabel": "Issuance of shares of common stock", "verboseLabel": "Common stock sold" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureAgreementsWithLigandPharmaceuticalsIncorporatedAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock Issued During Period Shares Share Based Compensation Gross", "terseLabel": "Issuance of common stock under employee stock plans (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r14", "r15", "r170", "r172", "r211" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options Exercised", "negatedLabel": "Exercised, Shares Subject to Stock Options" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r14", "r15", "r170", "r172" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period Value New Issues", "terseLabel": "Common stock issued value as part of partial consideration of agreement", "verboseLabel": "Common stock sold aggregate purchase price" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureAgreementsWithLigandPharmaceuticalsIncorporatedAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock Issued During Period Value Share Based Compensation Gross", "terseLabel": "Issuance of common stock under employee stock plans" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.", "label": "Stock Repurchase Program Number Of Shares Authorized To Be Repurchased", "terseLabel": "Common stock shares repurchased" } } }, "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The remaining number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.", "label": "Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased", "terseLabel": "Remaining number of repurchased shares" } } }, "localname": "StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r15", "r18", "r19", "r70", "r128", "r149", "r300" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10030.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r70", "r74", "r75", "r76", "r78", "r83", "r149", "r150", "r172", "r233", "r234", "r235", "r263", "r264", "r279", "r280", "r289", "r300", "r302", "r303", "r307", "r404", "r405" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders Equity Including Portion Attributable To Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r69", "r172", "r174" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r333", "r334" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Subsidiary Sale Of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureAgreementsWithLigandPharmaceuticalsIncorporatedAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r138", "r139", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]", "terseLabel": "Financial Instruments" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type Of Arrangement [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureAgreementsWithLigandPharmaceuticalsIncorporatedAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r241", "r249" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Tax benefit not recognized" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r94", "r95", "r97", "r98", "r99", "r100", "r101" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use Of Estimates", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]", "terseLabel": "Vesting" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Common stock warrants [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationCommonStockReservedForFutureIssuanceDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants And Rights Note Disclosure [Abstract]" } } }, "localname": "WarrantsAndRightsNoteDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerCommonShareDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number Of Share Outstanding Basic And Diluted", "terseLabel": "Weighted-average shares used to compute basic and diluted net loss per share", "totalLabel": "Denominator for basic and diluted net loss per share" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerCommonShareDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation": { "auth_ref": [ "r87" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerCommonShareDetail": { "order": 10020.0, "parentTag": "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "weight": -1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).", "label": "Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation", "negatedLabel": "Less: Weighted-average shares subject to repurchase" } } }, "localname": "WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerCommonShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": { "auth_ref": [ "r86", "r87" ], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerCommonShareDetail": { "order": 10010.0, "parentTag": "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).", "label": "Weighted Average Number Of Shares Issued Basic", "terseLabel": "Weighted-average common shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesIssuedBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerCommonShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number Of Shares Outstanding [Abstract]", "terseLabel": "Denominator" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerCommonShareDetail" ], "xbrltype": "stringItemType" }, "vktx_AdditionalCommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional common stock capital shares reserved for future issuance.", "label": "Additional Common Stock Capital Shares Reserved For Future Issuance", "terseLabel": "Additional number of shares of common stock reserved for issuance" } } }, "localname": "AdditionalCommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "vktx_AggregateOfferingPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate offering price.", "label": "Aggregate Offering Price", "verboseLabel": "Aggregate offering price, common stock" } } }, "localname": "AggregateOfferingPrice", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vktx_AgreementTerminationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement termination date.", "label": "Agreement Termination Date", "terseLabel": "Date agreement might terminate" } } }, "localname": "AgreementTerminationDate", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureAgreementsWithLigandPharmaceuticalsIncorporatedAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "vktx_AmortizationOfClinicalStudyCostsPrepaidViaShareIssuance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortization of clinical study costs prepaid via share issuance.", "label": "Amortization Of Clinical Study Costs Prepaid Via Share Issuance", "terseLabel": "Amortization expense" } } }, "localname": "AmortizationOfClinicalStudyCostsPrepaidViaShareIssuance", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vktx_AmortizationOfFinancingCostsEquityTransactions": { "auth_ref": [], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10110.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10050.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortization of financing costs equity transactions.", "label": "Amortization Of Financing Costs Equity Transactions", "negatedLabel": "Amortization of financing costs", "terseLabel": "Amortization of financing costs" } } }, "localname": "AmortizationOfFinancingCostsEquityTransactions", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "vktx_AmortizationOfNonCashClinicalTrialCosts": { "auth_ref": [], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10120.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortization of non cash clinical trial costs.", "label": "Amortization Of Non Cash Clinical Trial Costs", "terseLabel": "Amortization of non-cash clinical trial costs" } } }, "localname": "AmortizationOfNonCashClinicalTrialCosts", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vktx_AtTheMarketEquityOfferingSalesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "At the market equity offering sales agreement.", "label": "At The Market Equity Offering Sales Agreement [Member]", "terseLabel": "ATM Agreement [Member]" } } }, "localname": "AtTheMarketEquityOfferingSalesAgreementMember", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vktx_AvailableForGrantUnderTwoThousandFourteenPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Available for grant under the two thousand fourteen plan Member.", "label": "Available For Grant Under Two Thousand Fourteen Plan [Member]", "terseLabel": "Available for grant under the 2014 Plan [Member]" } } }, "localname": "AvailableForGrantUnderTwoThousandFourteenPlanMember", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "vktx_AvailableForIssuanceUnderEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Available for issuance under Employee Stock Purchase Plan.", "label": "Available For Issuance Under Employee Stock Purchase Plan [Member]", "terseLabel": "Available for issuance under Employee Stock Purchase Plan [Member]" } } }, "localname": "AvailableForIssuanceUnderEmployeeStockPurchasePlanMember", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "vktx_AvailableForSaleSecuritiesInUnrealizedGainPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Available for sale securities in unrealized gain positions qualitative disclosure number of positions greater than or equal to one year", "label": "Available For Sale Securities In Unrealized Gain Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year", "terseLabel": "Number of securities in unrealized gain position" } } }, "localname": "AvailableForSaleSecuritiesInUnrealizedGainPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesParentheticalDetail" ], "xbrltype": "integerItemType" }, "vktx_BeneficialOwnershipOfCompanySCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Beneficial ownership of company's common stock.", "label": "Beneficial Ownership Of Company S Common Stock", "terseLabel": "Beneficial ownership of company's common stock" } } }, "localname": "BeneficialOwnershipOfCompanySCommonStock", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "vktx_BusinessDescriptionPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business description.", "label": "Business Description Policy [Text Block]", "terseLabel": "The Company" } } }, "localname": "BusinessDescriptionPolicyTextBlock", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "vktx_CapitalizedClinicalStudyCostsPaidViaSharesIssuance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Capitalized clinical study costs paid via shares issuance.", "label": "Capitalized Clinical Study Costs Paid Via Shares Issuance", "terseLabel": "Prepaid clinical study costs" } } }, "localname": "CapitalizedClinicalStudyCostsPaidViaSharesIssuance", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vktx_ChangeInAccruedInterestRelatingToMarketableSecuritiesHeldAsInvestments": { "auth_ref": [], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10180.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Change in accrued interest relating to marketable securities held as investments.", "label": "Change In Accrued Interest Relating To Marketable Securities Held As Investments", "negatedLabel": "Accrued interest, net of interest received on maturity of investments" } } }, "localname": "ChangeInAccruedInterestRelatingToMarketableSecuritiesHeldAsInvestments", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vktx_ClassOfWarrantsOrRightsExpiryDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrants or rights expiry date.", "label": "Class Of Warrants Or Rights Expiry Date", "terseLabel": "Warrants expiry date" } } }, "localname": "ClassOfWarrantsOrRightsExpiryDate", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "vktx_ClinicalStudiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Clinical studies.", "label": "Clinical Studies [Member]", "terseLabel": "Clinical Studies [Member]" } } }, "localname": "ClinicalStudiesMember", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vktx_CommitmentPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitment purchase agreement.", "label": "Commitment Purchase Agreement [Member]", "terseLabel": "Commitment Purchase Agreement [Member]" } } }, "localname": "CommitmentPurchaseAgreementMember", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vktx_CommitmentsAndContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Line Items]", "terseLabel": "Commitments And Contingencies [Line Items]" } } }, "localname": "CommitmentsAndContingenciesLineItems", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "vktx_CommonStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock options Member.", "label": "Common Stock Options [Member]", "terseLabel": "Common stock options [Member]" } } }, "localname": "CommonStockOptionsMember", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "vktx_CommonStockReservedForFutureIssuanceTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock reserved for issuance.", "label": "Common Stock Reserved For Future Issuance Table [Text Block]", "terseLabel": "Common Stock Reserved For Future Issuance" } } }, "localname": "CommonStockReservedForFutureIssuanceTableTextBlock", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "vktx_CommonStockSubjectToRepurchaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock subject to repurchase.", "label": "Common Stock Subject To Repurchase [Member]", "terseLabel": "Common stock subject to repurchase [Member]" } } }, "localname": "CommonStockSubjectToRepurchaseMember", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "vktx_DebtSecuritiesAvailableForSaleUnrealizedGainPositionAccumulatedGain": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt securities available for sale unrealized gain position accumulated gain.", "label": "Debt Securities Available For Sale Unrealized Gain Position Accumulated Gain", "terseLabel": "Unrealized gains, individually" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainPositionAccumulatedGain", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureInvestmentsInMarketableSecuritiesSummaryOfInvestmentsClassifiedAsAvailableForSaleSecuritiesParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "vktx_DeferredPublicOfferingAndOtherFinancingCostsNoncurrent": { "auth_ref": [], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10170.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred public offering and other financing costs noncurrent.", "label": "Deferred Public Offering And Other Financing Costs Noncurrent", "terseLabel": "Deferred public offering and other financing costs" } } }, "localname": "DeferredPublicOfferingAndOtherFinancingCostsNoncurrent", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "vktx_DeferredTaxLiabilitiesRightOfUseAssets": { "auth_ref": [], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxesDetail": { "order": 10030.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities right of use assets.", "label": "Deferred Tax Liabilities Right Of Use Assets", "negatedLabel": "Right of use assets" } } }, "localname": "DeferredTaxLiabilitiesRightOfUseAssets", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfCompanySDeferredTaxesDetail" ], "xbrltype": "monetaryItemType" }, "vktx_DescriptionOfBeneficialOwnershipLimitation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of beneficial ownership limitation.", "label": "Description Of Beneficial Ownership Limitation", "terseLabel": "Description of beneficial ownership limitation" } } }, "localname": "DescriptionOfBeneficialOwnershipLimitation", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "vktx_EmployeeStockPurchasePlanDurationOfOfferingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee stock purchase plan duration of offering period.", "label": "Employee Stock Purchase Plan Duration Of Offering Period", "terseLabel": "Duration for offering period, employee stock purchase plan" } } }, "localname": "EmployeeStockPurchasePlanDurationOfOfferingPeriod", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "vktx_EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee stock purchase plan.", "label": "Employee Stock Purchase Plan [Member]", "terseLabel": "Employee Stock Purchase Plan [Member]" } } }, "localname": "EmployeeStockPurchasePlanMember", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetail" ], "xbrltype": "domainItemType" }, "vktx_EmployeeStockPurchasePlanNumberOfPurchasePeriods": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee stock purchase plan number of purchase periods.", "label": "Employee Stock Purchase Plan Number Of Purchase Periods", "terseLabel": "Employee stock purchase plan, number of purchase periods" } } }, "localname": "EmployeeStockPurchasePlanNumberOfPurchasePeriods", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "vktx_EquityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity.", "label": "Equity [Line Items]", "terseLabel": "Equity [Line Items]" } } }, "localname": "EquityLineItems", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "vktx_EquityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity.", "label": "Equity [Table]", "terseLabel": "Equity [Table]" } } }, "localname": "EquityTable", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "vktx_FederalNetOperatingLossCarryForwardsSubjectToExpirationYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Federal net operating loss carry forwards begin subject to expiration year.", "label": "Federal Net Operating Loss Carry Forwards Subject To Expiration Year", "terseLabel": "Federal net operating loss carryforwards subject to expiration year" } } }, "localname": "FederalNetOperatingLossCarryForwardsSubjectToExpirationYear", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "gYearItemType" }, "vktx_IncomeTaxLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income tax.", "label": "Income Tax [Line Items]", "terseLabel": "Income Tax [Line Items]" } } }, "localname": "IncomeTaxLineItems", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "vktx_IncomeTaxTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income tax.", "label": "Income Tax [Table]", "terseLabel": "Income Tax [Table]" } } }, "localname": "IncomeTaxTable", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "vktx_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10210.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in operating lease liability.", "label": "Increase Decrease In Operating Lease Liability", "terseLabel": "Lease liability" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vktx_JanuaryTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "January 2020.", "label": "January Two Thousand Twenty [Member]", "terseLabel": "January 2020 [Member]" } } }, "localname": "JanuaryTwoThousandTwentyMember", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vktx_LeaseCommencementDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease commencement date.", "label": "Lease Commencement Date", "terseLabel": "Lease commencement date" } } }, "localname": "LeaseCommencementDate", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "vktx_LegalCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Legal costs.", "label": "Legal Costs", "terseLabel": "Legal costs" } } }, "localname": "LegalCosts", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureAgreementsWithLigandPharmaceuticalsIncorporatedAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vktx_LicenseAgreementEnteredDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreement entered date.", "label": "License Agreement Entered Date", "terseLabel": "License agreement entered date" } } }, "localname": "LicenseAgreementEnteredDate", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureAgreementsWithLigandPharmaceuticalsIncorporatedAdditionalInformationDetail" ], "xbrltype": "gYearMonthItemType" }, "vktx_LigandPharmaceuticalsIncorporatedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ligand Pharmaceuticals Incorporated.", "label": "Ligand Pharmaceuticals Incorporated [Member]", "terseLabel": "Ligand [Member]" } } }, "localname": "LigandPharmaceuticalsIncorporatedMember", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureAgreementsWithLigandPharmaceuticalsIncorporatedAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vktx_LincoInParkCapitalFundLimitedLiabilityCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lincoln Park Capital Fund, LLC.", "label": "Linco In Park Capital Fund Limited Liability Company [Member]", "terseLabel": "LPC [Member]" } } }, "localname": "LincoInParkCapitalFundLimitedLiabilityCompanyMember", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vktx_LoanAndSecurityAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan and security agreement.", "label": "Loan And Security Agreement [Member]", "terseLabel": "Loan and Security Agreement [Member]" } } }, "localname": "LoanAndSecurityAgreementMember", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vktx_ManagementRightsLetterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Management rights letter.", "label": "Management Rights Letter [Member]", "terseLabel": "Management Rights Letter [Member]" } } }, "localname": "ManagementRightsLetterMember", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureAgreementsWithLigandPharmaceuticalsIncorporatedAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vktx_MaximumDurationForPurchaseUnderEmployeeStockPurchasePlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum duration for purchase under employee stock purchase plan.", "label": "Maximum Duration For Purchase Under Employee Stock Purchase Plan", "terseLabel": "Maximum duration for purchase under employee stock purchase plan" } } }, "localname": "MaximumDurationForPurchaseUnderEmployeeStockPurchasePlan", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "vktx_MaximumDurationOfEmployeeStockPurchasePlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum duration of employee stock purchase plan.", "label": "Maximum Duration Of Employee Stock Purchase Plan", "terseLabel": "Maximum duration of employee stock purchase plan" } } }, "localname": "MaximumDurationOfEmployeeStockPurchasePlan", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "vktx_MilestoneAchievementPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone achievement period.", "label": "Milestone Achievement Period", "terseLabel": "Milestone achievement period" } } }, "localname": "MilestoneAchievementPeriod", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "vktx_NetOperatingLossCarryForwardAnnualLimitationFollowingOwnershipChange": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net operating loss carry forward annual limitation following ownership change.", "label": "Net Operating Loss Carry Forward Annual Limitation Following Ownership Change", "terseLabel": "Annual limitation" } } }, "localname": "NetOperatingLossCarryForwardAnnualLimitationFollowingOwnershipChange", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vktx_NetOperatingLossCarryForwardDomesticLimitedBasedOnOwnershipChange": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net operating loss carry forward limited domestic based on ownership change.", "label": "Net Operating Loss Carry Forward Domestic Limited Based On Ownership Change", "terseLabel": "Federal net operating loss carryforwards limited based on ownership change" } } }, "localname": "NetOperatingLossCarryForwardDomesticLimitedBasedOnOwnershipChange", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vktx_NetOperatingLossCarryForwardStateAndLocalLimitedBasedOnOwnershipChange": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net operating loss carry forward state and local limited based on ownership change.", "label": "Net Operating Loss Carry Forward State And Local Limited Based On Ownership Change", "terseLabel": "State net operating loss carryforwards limited based on ownership change" } } }, "localname": "NetOperatingLossCarryForwardStateAndLocalLimitedBasedOnOwnershipChange", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vktx_NumberOfMilestonesAchieved": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Milestones Achieved.", "label": "Number Of Milestones Achieved", "terseLabel": "Number of milestones achieved" } } }, "localname": "NumberOfMilestonesAchieved", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "vktx_NumberOfMilestonesDeemedAsAchievable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of milestones deemed as achievable.", "label": "Number Of Milestones Deemed As Achievable", "terseLabel": "Number of milestones deemed as achievable" } } }, "localname": "NumberOfMilestonesDeemedAsAchievable", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "vktx_NumberOfMilestonesToBeAchieved": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of milestones to be achieved.", "label": "Number Of Milestones To Be Achieved", "terseLabel": "Number of milestones to be achieve" } } }, "localname": "NumberOfMilestonesToBeAchieved", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "vktx_NumberOfTranches": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of tranches.", "label": "Number Of Tranches", "terseLabel": "Number of tranches" } } }, "localname": "NumberOfTranches", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "vktx_OfficeLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office lease.", "label": "Office Lease [Member]", "terseLabel": "Office Lease [Member]" } } }, "localname": "OfficeLeaseMember", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vktx_OneTimeNonrefundableMileStonePaymentsMaximumPayableAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "One time nonrefundable mile stone payments maximum payable amount.", "label": "One Time Nonrefundable Mile Stone Payments Maximum Payable Amount", "terseLabel": "One time nonrefundable mile stone payments maximum payable amount" } } }, "localname": "OneTimeNonrefundableMileStonePaymentsMaximumPayableAmount", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureAgreementsWithLigandPharmaceuticalsIncorporatedAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vktx_OpeatingLeaseExpirationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Opeating lease expiration period.", "label": "Opeating Lease Expiration Period", "terseLabel": "Lease expiration date" } } }, "localname": "OpeatingLeaseExpirationPeriod", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsAdditionalInformationDetail" ], "xbrltype": "gYearMonthItemType" }, "vktx_OperatingLeaseNumberOfLeases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease number of leases.", "label": "Operating Lease Number Of Leases", "terseLabel": "Operating lease number of leases" } } }, "localname": "OperatingLeaseNumberOfLeases", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "vktx_OperatingLeaseOptionToExtendTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease option to extend term.", "label": "Operating Lease Option To Extend Term", "terseLabel": "Operating lease option to extend term" } } }, "localname": "OperatingLeaseOptionToExtendTerm", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOperatingLeasesRightOfUseAssetsAndLeaseLiabilityObligationsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "vktx_OperatingLeaseRentalsAnnualIncreasePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease rentals annual increase percentage.", "label": "Operating Lease Rentals Annual Increase Percentage", "terseLabel": "Percentage of rent increase under lease" } } }, "localname": "OperatingLeaseRentalsAnnualIncreasePercentage", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "vktx_OperatingLeaseRightOfUseAssetAmortization": { "auth_ref": [], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10140.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating lease right of use asset amortization.", "label": "Operating Lease Right Of Use Asset Amortization", "terseLabel": "Amortization of right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortization", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vktx_OperatingLeasesInterestExpense": { "auth_ref": [], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10150.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating leases interest expense.", "label": "Operating Leases Interest Expense", "terseLabel": "Interest expense related to operating lease liability" } } }, "localname": "OperatingLeasesInterestExpense", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vktx_PatentCostsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Patent costs policy.", "label": "Patent Costs Policy [Text Block]", "terseLabel": "Patent Costs" } } }, "localname": "PatentCostsPolicyTextBlock", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "vktx_PaymentsForRepurchaseOfCommonStockAndWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments for repurchase of common stock and warrants.", "label": "Payments For Repurchase Of Common Stock And Warrants", "terseLabel": "Purchase of common stock and warrants" } } }, "localname": "PaymentsForRepurchaseOfCommonStockAndWarrants", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vktx_PercentageOfCommonStockOutstandingToIncreaseSharesReservedForIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of common stock outstanding to increase shares reserved for issuance.", "label": "Percentage Of Common Stock Outstanding To Increase Shares Reserved For Issuance", "terseLabel": "Percentage of common stock outstanding to increase shares reserved for issuance" } } }, "localname": "PercentageOfCommonStockOutstandingToIncreaseSharesReservedForIssuance", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "vktx_PercentageOfCumulativeChangeInStockOwnership": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of cumulative change in stock ownership.", "label": "Percentage Of Cumulative Change In Stock Ownership", "terseLabel": "Percentage of cumulative change in stock ownership." } } }, "localname": "PercentageOfCumulativeChangeInStockOwnership", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "vktx_PercentageOfMinimumBeneficialOwnershipLimitation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of minimum beneficial ownership limitation.", "label": "Percentage Of Minimum Beneficial Ownership Limitation", "terseLabel": "Percentage of minimum beneficial ownership limitation" } } }, "localname": "PercentageOfMinimumBeneficialOwnershipLimitation", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "vktx_PercentageOfSharesMayNotSellBeneficialOwnership": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of shares may not sell beneficial ownership.", "label": "Percentage Of Shares May Not Sell Beneficial Ownership", "terseLabel": "Percentage of shares may not sell if it is beneficial owning" } } }, "localname": "PercentageOfSharesMayNotSellBeneficialOwnership", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "vktx_PercentageOfSharesVestedUponAchievementOfCertainMilestone": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of shares vested upon achievement of certain milestone.", "label": "Percentage Of Shares Vested Upon Achievement Of Certain Milestone", "terseLabel": "Percentage of shares vested upon achievement of certain milestone" } } }, "localname": "PercentageOfSharesVestedUponAchievementOfCertainMilestone", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "vktx_PercentageOfWarrantExerciseBeneficialOwnershipLimitationOfCommonStockOutstandingMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of warrant exercise beneficial ownership limitation of common stock outstanding minimum.", "label": "Percentage Of Warrant Exercise Beneficial Ownership Limitation Of Common Stock Outstanding Minimum", "terseLabel": "Percentage of warrant exercise beneficial ownership limitation of common stock outstanding minimum" } } }, "localname": "PercentageOfWarrantExerciseBeneficialOwnershipLimitationOfCommonStockOutstandingMinimum", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "vktx_PerformanceBasedRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance based restricted stock units.", "label": "Performance Based Restricted Stock Units [Member]", "terseLabel": "Performance Based Restricted Stock Units [Member]" } } }, "localname": "PerformanceBasedRestrictedStockUnitsMember", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vktx_PoCCapitalLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PoC Capital, LLC.", "label": "Po C Capital L L C [Member]", "terseLabel": "PoC Capital, LLC [Member]" } } }, "localname": "PoCCapitalLLCMember", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vktx_PotentialProceedsFromSaleOfCommonStockPerPurchaseDateSubjectToCertainLimitations": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Potential proceeds from sale of common stock, per purchase date, subject to certain limitations.", "label": "Potential Proceeds From Sale Of Common Stock Per Purchase Date Subject To Certain Limitations", "terseLabel": "Total purchase proceeds per purchase date, subject to certain limitations" } } }, "localname": "PotentialProceedsFromSaleOfCommonStockPerPurchaseDateSubjectToCertainLimitations", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vktx_PrepaidClinicalTrialAndPreclinicalStudyCosts": { "auth_ref": [], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets": { "order": 10210.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid clinical trial and preclinical study costs.", "label": "Prepaid Clinical Trial And Preclinical Study Costs", "terseLabel": "Prepaid clinical trial and preclinical study costs" } } }, "localname": "PrepaidClinicalTrialAndPreclinicalStudyCosts", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "vktx_PriorNoticePeriodOfIncreaseBeneficialOwnershipLimitation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prior notice period of increase beneficial ownership limitation.", "label": "Prior Notice Period Of Increase Beneficial Ownership Limitation", "terseLabel": "Prior notice period of increase beneficial ownership limitation" } } }, "localname": "PriorNoticePeriodOfIncreaseBeneficialOwnershipLimitation", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "vktx_PrivatePlacementAndRegisteredDirectOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private placement and registered direct offering.", "label": "Private Placement And Registered Direct Offering [Member]", "terseLabel": "Private Placement and Registered Direct Offering [Member]" } } }, "localname": "PrivatePlacementAndRegisteredDirectOfferingMember", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vktx_ProceedsFromIssuanceOfCommonStockGross": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common stock gross.", "label": "Proceeds From Issuance Of Common Stock Gross", "verboseLabel": "Gross proceeds from common stock issuance" } } }, "localname": "ProceedsFromIssuanceOfCommonStockGross", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vktx_ProceedsFromStockIssuanceUnderEmployeeStockPurchasePlanAndWarrantExercises": { "auth_ref": [], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10060.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from stock issuance under employee stock purchase plan and warrant exercises.", "label": "Proceeds From Stock Issuance Under Employee Stock Purchase Plan And Warrant Exercises", "terseLabel": "Proceeds from stock issuance under employee stock purchase plan and warrant exercises" } } }, "localname": "ProceedsFromStockIssuanceUnderEmployeeStockPurchasePlanAndWarrantExercises", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vktx_PublicOfferingPricePerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public offering price per unit.", "label": "Public Offering Price Per Unit", "terseLabel": "Public offering price per share and per warrant" } } }, "localname": "PublicOfferingPricePerUnit", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "vktx_RealizedGainLossOnInvestmens": { "auth_ref": [], "calculation": { "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10160.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Realized Gain Loss on Investmens.", "label": "Realized Gain Loss On Investmens", "terseLabel": "Realized gain on investments" } } }, "localname": "RealizedGainLossOnInvestmens", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vktx_ReceivableFromExerciseOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Receivable from exercise of warrants.", "label": "Receivable From Exercise Of Warrants", "terseLabel": "Receivable from exercise of warrants" } } }, "localname": "ReceivableFromExerciseOfWarrants", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vktx_RegisteredOfferingPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Registered offering purchase agreement.", "label": "Registered Offering Purchase Agreement [Member]", "terseLabel": "Registered Offering Purchase Agreement [Member]" } } }, "localname": "RegisteredOfferingPurchaseAgreementMember", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vktx_RegistrationRightsAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Registration rights agreement.", "label": "Registration Rights Agreement [Member]", "terseLabel": "Registration Rights Agreement [Member]" } } }, "localname": "RegistrationRightsAgreementMember", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vktx_RegistrationStatementCommencementDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Registration statement commencement date.", "label": "Registration Statement Commencement Date", "terseLabel": "Registration statement commencement date" } } }, "localname": "RegistrationStatementCommencementDate", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "vktx_RemainingDeferredTaxAssetsOperatingLossCarryForwardsDomestic": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Remaining deferred tax assets operating loss carry forwards domestic.", "label": "Remaining Deferred Tax Assets Operating Loss Carry Forwards Domestic", "terseLabel": "Remaining federal net operating loss carryforwards" } } }, "localname": "RemainingDeferredTaxAssetsOperatingLossCarryForwardsDomestic", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vktx_RepaymentsOfNotesPayableInStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repayments of notes payable in stock.", "label": "Repayments Of Notes Payable In Stock", "terseLabel": "Repayments of notes payable in stock" } } }, "localname": "RepaymentsOfNotesPayableInStock", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vktx_RepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Repurchase program.", "label": "Repurchase Program [Member]", "terseLabel": "Repurchase Program [Member]" } } }, "localname": "RepurchaseProgramMember", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vktx_RestrictedStockAndRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted stock and restricted stock units.", "label": "Restricted Stock And Restricted Stock Units [Member]", "terseLabel": "Restricted stock and restricted stock units [Member]" } } }, "localname": "RestrictedStockAndRestrictedStockUnitsMember", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfUnrecognizedStockBasedCompensationExpenseNetOfEstimatedForfeituresByTypeOfAwardAndWeightedAverageRecognitionPeriodDetail", "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseRecognizedDetail" ], "xbrltype": "domainItemType" }, "vktx_RisksAndUncertaintiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Risks and uncertainties.", "label": "Risks And Uncertainties Policy [Text Block]", "terseLabel": "Risks And Uncertainties" } } }, "localname": "RisksAndUncertaintiesPolicyTextBlock", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationLiquidityAndManagementSPlanAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "vktx_SaleAndTransferOfPriceEqualsToPercentageOfCostOfGoods": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale and transfer of price equals to percentage of cost of goods.", "label": "Sale And Transfer Of Price Equals To Percentage Of Cost Of Goods", "terseLabel": "Sale and transfer of price equals to percentage of cost of goods" } } }, "localname": "SaleAndTransferOfPriceEqualsToPercentageOfCostOfGoods", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureAgreementsWithLigandPharmaceuticalsIncorporatedAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "vktx_SaleOfCommonStockSharesSubjectToCertainLimitations": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of common stock, shares, subject to certain limitations.", "label": "Sale Of Common Stock Shares Subject To Certain Limitations", "terseLabel": "Common stock to be sold, subject to certain limitations" } } }, "localname": "SaleOfCommonStockSharesSubjectToCertainLimitations", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "vktx_ScheduleOfCommitmentsAndContingenciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of commitments and contingencies.", "label": "Schedule Of Commitments And Contingencies [Table]", "terseLabel": "Schedule Of Commitments And Contingencies [Table]" } } }, "localname": "ScheduleOfCommitmentsAndContingenciesTable", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "vktx_SecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Securities purchase agreement.", "label": "Securities Purchase Agreement [Member]", "terseLabel": "Securities Purchase Agreement [Member]" } } }, "localname": "SecuritiesPurchaseAgreementMember", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanOfferingTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award employee stock purchase plan offering term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Employee Stock Purchase Plan Offering Term", "terseLabel": "Duration of employee stock purchase plan as determined by the compensation committee" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanOfferingTerm", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "vktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options repurchased in period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Repurchased In Period", "negatedLabel": "Shares, Repurchased" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetail" ], "xbrltype": "sharesItemType" }, "vktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options repurchased weighted average grant date fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Repurchased Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value, Repurchased" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedWeightedAverageGrantDateFairValue", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetail" ], "xbrltype": "perShareItemType" }, "vktx_SharesRepurchasePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares repurchase price per share.", "label": "Shares Repurchase Price Per Share", "terseLabel": "Repurchase of common stock from stockholders, per share" } } }, "localname": "SharesRepurchasePricePerShare", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "vktx_StateNetOperatingLossCarryForwardsBeginToExpirationYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "State net operating loss carry forwards begin to expiration year.", "label": "State Net Operating Loss Carry Forwards Begin To Expiration Year", "terseLabel": "State net operating loss carryforwards, begin to expiration year." } } }, "localname": "StateNetOperatingLossCarryForwardsBeginToExpirationYear", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "gYearItemType" }, "vktx_StockIssuedDuringPeriodSharesIssuedAsConsiderationForCommitment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares issued as consideration for commitment.", "label": "Stock Issued During Period Shares Issued As Consideration For Commitment", "verboseLabel": "Common stock issued as consideration for commitment" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedAsConsiderationForCommitment", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "vktx_StockIssuedDuringPeriodSharesWarrantExercises": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares warrant exercises.", "label": "Stock Issued During Period Shares Warrant Exercises", "terseLabel": "Issuance of common stock from warrant exercises (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesWarrantExercises", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "vktx_StockIssuedDuringPeriodValuePartialNewIssuesAndReservedForFutureIssuance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value partial new issues and reserved for future issuance.", "label": "Stock Issued During Period Value Partial New Issues And Reserved For Future Issuance", "verboseLabel": "Total of purchase agreement and potential aggregate future purchases" } } }, "localname": "StockIssuedDuringPeriodValuePartialNewIssuesAndReservedForFutureIssuance", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "vktx_StockIssuedDuringPeriodValueWarrantExercises": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value warrant exercises.", "label": "Stock Issued During Period Value Warrant Exercises", "terseLabel": "Issuance of common stock from warrant exercises" } } }, "localname": "StockIssuedDuringPeriodValueWarrantExercises", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "vktx_StockIssuedRepurchasedDuringPeriodSharesEmployeeShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued repurchased during period shares employee share based compensation.", "label": "Stock Issued Repurchased During Period Shares Employee Share Based Compensation", "negatedLabel": "Employee stock-based compensation, net (in shares)" } } }, "localname": "StockIssuedRepurchasedDuringPeriodSharesEmployeeShareBasedCompensation", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "vktx_StockPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock purchase agreement.", "label": "Stock Purchase Agreement [Member]", "terseLabel": "Stock Purchase Agreement [Member]" } } }, "localname": "StockPurchaseAgreementMember", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vktx_StockPurchaseAgreementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock purchase agreement term.", "label": "Stock Purchase Agreement Term", "terseLabel": "Common stock purchase agreement term" } } }, "localname": "StockPurchaseAgreementTerm", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "vktx_TaxCreditCarryforwardsBeginToExpirationYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax credit carryforwards, begin to expiration year.", "label": "Tax Credit Carryforwards Begin To Expiration Year", "terseLabel": "Tax credit carry-forwards begin to expiration year" } } }, "localname": "TaxCreditCarryforwardsBeginToExpirationYear", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "gYearItemType" }, "vktx_TwoThousandFourteenEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand fourteen employee stock purchase plan.", "label": "Two Thousand Fourteen Employee Stock Purchase Plan [Member]", "terseLabel": "2014 ESPP [Member]" } } }, "localname": "TwoThousandFourteenEmployeeStockPurchasePlanMember", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vktx_TwoThousandFourteenPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand fourteen plan.", "label": "Two Thousand Fourteen Plan [Member]", "terseLabel": "2014 Plan [Member]" } } }, "localname": "TwoThousandFourteenPlanMember", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "vktx_UnexercisedWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unexercised warrants.", "label": "Unexercised Warrants", "terseLabel": "Unexercised warrants" } } }, "localname": "UnexercisedWarrants", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "vktx_UnpaidDeferredInitialPublicOfferingAndOtherFinancingCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unpaid deferred initial public offering and financing costs.", "label": "Unpaid Deferred Initial Public Offering And Other Financing Costs", "terseLabel": "Unpaid deferred public offering and other financing costs" } } }, "localname": "UnpaidDeferredInitialPublicOfferingAndOtherFinancingCosts", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vktx_WarrantDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant.", "label": "Warrant Disclosure [Text Block]", "terseLabel": "Warrants" } } }, "localname": "WarrantDisclosureTextBlock", "nsuri": "http://www.vikingtherapeutics.com/20201231", "presentation": [ "http://www.vikingtherapeutics.com/20201231/taxonomy/role/DisclosureWarrants" ], "xbrltype": "textBlockItemType" } }, "unitCount": 11 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r102": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563" }, "r147": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r166": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r168": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r174": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r186": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r239": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r273": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r278": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r292": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121595440&loc=d3e34039-112682" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41499-112717" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717" }, "r313": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "http://asc.fasb.org/topic&trid=2208923" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r332": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r334": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r379": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r390": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r424": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491204&loc=d3e4879-115612" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r438": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r439": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r440": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r441": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r442": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r443": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r444": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r445": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r446": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r447": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r73": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2646-109256" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" } }, "version": "2.1" } ZIP 75 0001564590-21-006406-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-006406-xbrl.zip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┛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�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ʼ!J&- SAB33,]>&.-,S9 M]D;,5]1Z)RRVG36X?6,W/J/M' MX(?A^B!J]53%33G,\6#0&HWKRV"2B+AN$4$*DJA?Y00EZ49E\X^[J\EP)SVY M?PZR6GWR/3;C^I*1)""N7$Z3>B3J;RP:2$[I$++&ZRPN'=G_EFK ]\8K<( M5HI)K]EIZ*DD/%JJSVCU>M2KJ!R9[3T$B%3?=K6:VPSG;SA8DT)5$VVGB7? M;+-IGW1K[8;3)S^8,2>*@Z7I=*Q\K-$=M;J&KDQOB9+S])6ASG.O:B%UK(", M)Q91LFES6SV[$V:N6M<>EN3=7>MN2O*6J-TCI7F'G0&IW,L@4B5D/>E==7!! M?*(L;DCY7A:^B)<4Q@WI''5P07RB+&Y(YUP6OHB7CIZ.5;@757$D;+FM M\0*5FM%T>L+3=ME7FDZ_:SBX*O,Z//.VSMW3K:W!N-OJCX94CZ8:^2DJ.DBS M$O6KG#:E(FYE,Z3'U(X')$9+\J']SH0JM)6C/E5%,VE$HO[&HH'4(JA%>'$O M>=-VR*RV\[,]=VPXZFO9S,1GI@_!S<)+296<&V.*,A.I$J)^>#&D!!K(8-DK M03HZ]U90HRO[8,!LV3%7.AEBII36GBE'AXJ*"%*01/TJ._.D&\_MS%=F2G=7 MDR?:"KI&??((MU%?(1$)B"N7TZ0>B?H;BP;2DD^L;#EFX,J"9) M-3*CK: DZ]1JT%?0R4$5;08^7;IV<>ROH(?G87FM0HW5$D_N53-*2-KX> M$4\LHF3/)NV(.6V.=W>E>\JEH)NZ.7OUE4"1/+EZ64]Z5QU<$)\HBQM2OI>% M+^(EA7%#.D<=7!"?*(L;TCF7A2_BI:-G8P_-D*_+QMI^/'699G2:HX$V; H5 MB!/K0HWNN:H:UA@-#429NH5I&Q=3KD,>Y7/5P>66>T9K0>=5&R6[YWN-[GEW MD>Z>Y.VU>B.]U3-ZRE3!51ECESF M9&_OF!KW@!QO26IWT!FHT\!+TD-YR4Y:5AU<$)\HBQM2M3NHVLT[4WN\!LDX M\\Y48CO5V8[4DT*X(#XA)_"R4;5[3_+NDYR.LH?UD/[CUF T4JH#F<3)%;0E M-U ))XEP)B(T)KY_[8GP(U;/-1!EBC;#KB3"2[.BE B_#%P6$^''0V=3C;.J M1+A^I(DQ*-J/D@C76Z/QJ-4;U1>B/U95(AECYY#ODPCH,2 MX<1VU\YVI)X4P@7Q"3F!EXVJW1/AY>.NIIL=O^EFQR^?"->/E0GOM<:&7FLF MO"GR1!!B0H?K2/84B?!?(R0:^-1V'G=[^=R[_J**'A/$^"5^8(%CE;T0'M]8 ME$D@=5[H;LXT% 2F]ZP%S&+.([.UO^XL9_J%3HNO@6\Q9H>? O^AUDVAW;69 M&D/OE8H*S?3V>J]"X.RP]](G\KWTR6[OI4_*BX$TQ],L,YQK"WDN;08'2VH= M@)+\&5 E'%/S91F$S1>Y:A$@_IF90:@QH$,[+8?0DDH(#C$\: L((UPP>-XC M-^MK(3JQ1V#U"88XK[#89$5 *4NONV>K-Y3 @1K M)$0>!'JGV):=@&"%98E+=]IAD4$V"%+\FZ%H7F'3>[@9LFCD:^QAX?K/# [I MA!JG!@U^BDP+% #(P\OXY9H-?V>9'TD5?@.:U[_WX(UL+3#13'K6_$=@;[P% M2@*4 0M.12@N\%-SL7 =B]>RB0-UM+O<\^!RC2>"M">9G]%,D:!9*WQ*W^J8 M4J@J9=7OUYVR^@>^6M6(7O[E!X!]T_+B_[47[Q%@9@7ILRTYJG@E&!)1/]> M0G0IT*5&X1H$GB1N&H?)/=^Y)J . .>[:/6+)R\ T'C!@V\S5WMRHCF_=N:[ MKO^$7Q1T@[D$XNM5%Y>[O?"1A(F@C"P:$[@ !T@?G[O\,DK"71S<#H5Q$'AX M^F\98>'_SO'-:S.._#_:E8&X\4H@[CU :1HX1X _G #SDN@F*%!IW1]V M)AMF B? J@SE6P!N%M01R]\;7>6,M2?:_@T:8$4!I'TH9X]JGR):K08:E&O: M.K,C MBN3=Q>,5HR@D[YIH35<[H\+ OMYJOH])W/71=\W(<9WH6;G>:ZZ4KA<%BG:\ M;S/&OU&%KXKBR>ANI^JI%';=V(%%'+!<[G186^XT38=F,DZ)V/UG*G6_F='> M.>1>6NC1QK6OHY)2#^7(]D2FCC($^(MR&""U2FJ5\$1J]:1JM5B[<6:UNJ8, MJ:!6BU5:RI%MH]7JV78)4OQ BUCPH+UT/%&M]$JY369D[9QI%V"CQ)&B:)#& M3,-ME8US&OICG-/0G9QY80%QD^+<1*J$B+^I:"!5LITJF7!5HI,J40-CE&Q6 M G?G/!'>Q8PICE8.<+""/L7F7)!%%+P%+IJ+!I(P>\1UQ[4MSJV+*Z-@O,3 MR,W/4FP>DBSNYZ+:>J='46WER(^2Q22+FTCWBJ*!5.(^*K&^(?*UJ,0UB=Z\ M2C0Z1G%:D'(TV3310(E>11*]MO/HP/EL[=EAKJU<8(L,%0HG-A8-9*CL8ZB4 M#S.LNR;M@Y2;A_CN1LY046?7+\F%0QUWTH=7)8B;1O>*HH'TX3[ZL'RR[=GT MX=I!D:0/E::],J_]>@;[%_^KI;/^LU,/#Q]2*L[I1$# UH'OO8_/O^RGZ.1* M7XHP?/%6#!8NMI7S5+\6AW+&)Q^!F1TF+$94YFGC1T]P/F9QDC.,LX2/^9SP%R+G/FOEHPB^ _L0 Y,SM<'RF MS1Z9ZR_@X>D1EK=VQ$3-!=S[ 9@WCAP0/7S\YM3Q(V;-/>"Z^V>XSH[#*, _ MX,#)$<,(YV7"F>4S4$8B(*+E1H5.IECH\*FP9R:9.Q8\;*05@81DH01STQ&P M,6+]OXQ#YV]_&1M&]PT "# H\7\/]PDX"989%A UG[*/D@X@*V7&+'.=;UEQ MT"G:(Q(.!8-DBWE.J["Z#-BUQ<@Z>.=YD+SB B1Q>PK"X$?;G,$;OC;=)_,Y M?*']NFX^=4__T\8!U:.NV>M/Q^-VU]"-=M^VQNWQ0.^U>_IL8O7Z(8A*,PB>X8;HV"$9@F L3"-/Q[9O MOTAE4-C<\%$.1/_.@D>PX,J]SSOSYSOFL9D3X6JE[#UE9X'M2HS[ M4AZ@[ 'H@\_FU[Z!' \>I8C[Q$6Y]AGTO G4F(\+R$O+)@@"WFA1,&F%9"JXG(T>LU0[@7 P?^5 M-%@W*%869US&VH"C19/&7;XO^'K#1SE*!0')S6SU@GJ=R567?B@:W&]:+%55 M- PZ8X-R+.MS+,7E7(/"7*#CSRW?L-*066.ZR'NF9N/'_XN=Z!FM M9'@)D*$W/YTPN>A?0J[^SG7\5B;QZK;10DX;G*D66-5@P%8VH)QLBDNGKV/=DPY%8U%PUD MP^QEPQ2F$A_=AL%L5>8A49_U0L)"/>N%8C#[(N$F*?SD MB4ZY#EW6_#%5C-10,9-'L9-..SIC(6[_0,E+"^J MOGOR[^9^')H>/"4.(L8\E+0'V#K]5G>LMXP!16J4HU6%(C4YP^9L*VN5P4S> M $I+O(0-E)17F2;*[+@27>;OKN/@DPRQGF T+<]GK-,SV,:/T06LX M'+:Z-19+UZ01E+>C!&$E=+6.!$]A1EW/&)MT9LVRPW*[&3:[O2)_C2HA-I$G9Z;=G6^&F5D*]6]E+"/!+ M;R,'"W<&I1/,=F2X+.6O/W7:ALD M%T@UBZ-27CWDKLK8$+>>=K,('%?3>]C,K ];VB(.4-6GXYAN9S,01MY]*S<7 M ;2AO6ZZ094%4AR#C[8'6A?,_A#C<[["TWQ;F"$ !_Y5N'XDWK#;UXWDC]XN M]L<(^[1*S0\Q-8MW?./X BM;[HDC6I+^6SZ3)4D0Q O\YQY@*0S=?>^:87@[ MD^1]&W"K!?3"E 6WL^_, E#A&+#WINLR^]USP@;RPBW@=0HP13BBC,\:@^\% M%8DQ9'CY7[>:C5$)L?*QC*&@I*_X$" D_MD>L'BK=XQ!\5T7+)##U.#\!8I( M1EE(RA S@%(RF9N/#"[3V$\66$[(:@-$86!(*>E\E(_ED$F_3.E%WP](@Q*" MJ 122XSSF.T I-SG!!C__T%3_BC9X_[#QO.LL6-C:0PF_GMOF,F]UQ $I6?AKZJN78T6[ (D+( *<^ MM_ ]5@4NBE6>=WP"GF;!L3,-/\1#"OXW(_X_#PY?@M_ M7BJ=@/K,]##[2*EB<\O1I%32LAM/0P>H)7C^;KI MUQ;9-M>;@$$-PD$1-UH M&M7?7<[I+=T8;))S9?//3B?W"L6Y7,9QMMZ'A[M\*VL9#TL2RE-0.6?G1FW= M[#$+J>IE"X4[>\_>_>)[@CI$[_?GY0R\VS@*(Q W@"1!N36'.'JM87_4 M@7 MP9QR*1>,_O(@7/SM :]"XNT(\$HTB5W72*D"P/KC5G]2 J[]@#*J;QGAH4!9 M,[MYXU !8]P:3DILDCP-+?6#S8UI+JQ04X4: Q5CETPO0JCBB5HX_ C''3J/ MH)K7CM+J+_&MN_&_XV;/\8.'C8%); MJF%YP$^.!W8=&#%+IEG>RC>]&\^6IWR^N0\89\,#%/EDN-%=V:3&.PDV[XIX MQHF>1[#E1]NY@0?8\LHB_-C%@806CM5-""0AI&U%CAR/B*#4 M_"21*M M(:TPB+ZA N64 /_XW?&W1YN;J+M.TY4(3LZLJXH4A2GW<1/*#]A"6%W;B]0<;>?C =^2NP$. MO_@1"\&D0^GP>2-)*X"\-;'-[@97UJ@*V57(ES+C98WL\L&_O3AOC MQ]3XJP+ZW_L>N.Z1@V+Z:^ _ %7XP;.&",*IUX^.'X=N:G5-GW.V6$H[\IE5 MUNHQLH[7F /XW]ACFM[G9N^HF (0P^$EV2R-R65A?$JW)4D"_& /"[<0:SHX M4;#+%+B,RLLS_K98 MR'H[R[B@Z2V7X$Z@72(D1MVAWDO^Z.\6G1CU)ZW1N,3=%I!-%S3\J\Z$QZC8 M8WXT!Z9@F)@_BX;)M5+%3L1@M,:ZT>KU1CNE>:202 X2A#D+X8[O]GB8.AZ( M\91NA,.$D6J LJ T3FCXKW^5!![WH+!BT]]N%/;1M.;Y:P\)5RM'!V^QDFD= MGG,XEH/7D^.%PNTZT-N=Y,RTKSQ@GCPAR>#A'*O-<#\*@/2.7@20R.IAU0U& MUZ1*3,$B-D\$8@.+4*H3H50+//&O8R<&Q\5BOYJ#"1=(]'JGMR[*T-*R(0+[ M/W$H,FLFKC7R<=^*+0( CM<2*1ZGC34.YGBK^%T8H7.)"QW^ M-7=2893Q/]/'7C*2LG;+)L^T&J!;1U;N=E81! M?TO#Q%<"][=HV&IS<,T!M'R+9&)PIUO'N$G" W%(>J@+4^,$W?J%'XBPN7 & MDI\[PA@2=V[!K^X9ZDJQ20XO-&(.+_-^:=8DQLY:/// =SJ*;)F4EP'M"R6#33&";!2],RF)HB?& MKL<])KYOM-Q7R-8Q9!,S?-N8=N\\XA<,7E&866$,Y)C2U\O,CLLEEK043=H2 M3W*CY:N__64P>9/:9RT@P"= JH6!L,\R02.'WSQ(^%[.+Y]._LL M,SS7*!K6Z3"^Z,N. Q#(+]X."UD #3X/9>@8/1;PY#T.MY4MKJV,3- >S.=E MQ@P_WXAAQ&R*3Q .'HBB1[3(@?9<=YM[<'G"-A>.%(3)J%*82$'0"(JHEA*3 M4BG1*1"*6("<\VW1<]HH1GC:-DWB1MF[2$F4NM"\4'3**IPW&;L0=(,*#R/3 M_!'YI9OAP@4MA64P0&UALAB7?XH?6J(_SODOQR]^X@?WIB?_C1L]D^7&/.PN M -+2^!YE-#&FR_UUR<$[&L;>32\&(M"PW@3@/FYIZ\M'>'XL!#1H@B#$[KOE M3CQT/#\!'VO?V[KV\I,#%W[Q.UJOUVL;\+^N\4H(QFR@'O0RL[.[^/8+VD_T M',_\X:7E2,D;'SV4,^[J^G"WDL_)>+0VYIFAJGCY1IG"*XYBN=A5Z#4'[">9 MLOK^\7W>+A49J\HJR*;*^3O-M20CQF&68JRI5@7ZV;,>R MZ,G,/J1Z6FD%,VG 30R+@:K[::O7 M#Q>U@#5G=HSNS3*CSGUJP;9R.;5<75W;*N(R_AU.!/\.Q[K9'W2-MC[4]7:_ M.[;:DV&WU^X;O9'5[T]L0Q]<["YCB4+E/2B;:>\M)?WQ M%[%-_E,;JR-0SVH/1V!A8IC[H6_:+=2?9F8\N8ROUT>8= M#8>=R?@((^L5F9.BTF2ISO!$.QLX:,=G'[T#4(?#H?7Q]Q?#%PI@H-?M] JT M7BG3#Z;^K)%T$);V14FB" 5J0!NJQQ.G&;BN!CJ4F_$I9;]**_+/!M,YPC+X\-W7BS[78RXN[S2UA2;*38KA<'I-C4P\GNBJVXM.< Q;:F M78T4VV51DD)YV%.7,*KO3_,6^W-%EY2H^5$&%>I&^F@/^86@*A]1IS7C]1DW M@PKCALO/&\_^S;=4]-U/)<*5WRS>1#E!ZE4=7)!ZO0)4D7H]EGHM;F$]6+V> M(H) ZE4Q.4%)>37PH 3H*75QEN F%=^IG]N@HKN:#9CB[J=<\D/Q, %E0LXO ML$E/DIXD/:D,?DA/'D5/%C?8U:4GJ6+@:LA*H8J!(_KUBB/A YLQ7/M'K=OG M)W\UP-YX*:0&&J@Z45W<$(LH@092$$3]S44#*0AU<=-X%J$,+;5-DZ:F:%+3 M(\O-5L\O=X\<%_;P) $J*=LJ%O C$CO7@05UA.+H,3_V00Y94&N*PM" M+6?JITFHY:QNRZ8P<7TECW*\YNP=31NC-3+ZE$]1BMZH@H!T)^E.TIW7@+0] M=&=AJ'M]NK/6L,"H->[U2'4J16YJE"(M7>9>3TXHG(WM5/O5.YV,:BBPE86^XX"8,613^,Q&[-XG4K6N*=TWYX5-)>ZI]4U"DD"96!Q>DB:\ 5:2) MCZ6)"ZN_CJR)=Y@37D^VF12Q8A)%R:YXVX^G+M.,3G/4\IT?F:[F<';7(O.G MQD3QB/9R*LI'5.S;:R">#BC(.T737F6QUSK,-=*XVJ]H[U3=?,?%(UE=.:NK ML*_L" WU)UBYSZ(&:E1')LJ)SHD;4'9^9,"W)8"#5_ID7P\1^=[QUM M)OI_X,W,*([\X)E'< + G1;Y_#*68#8;XN$7P,/Y%<_,#$*-P>O:V@=FL8GI+0QQJIF=K*-HTX'S-#.&G&.0-7Y\0LBO(1'9#Z8@T*076WU\ @5O, M=5$D@7!+_RV%'?]W[J"O38#9&RGN0-2XYB)DKY,_WFA")$ZZL@RV$*I\<&S; M95=?;J6JO=W8_"V']_CL*A!0 8>#%P=<#%\HD!_L=3N]+?.#E1:Q!8!G01TF M<18!4]^U#\/DOF@K2/2SY\=.83>J ?OMDUX-T21*RS)2*\J@(E4KA@IJ1>_M M%9QIMMY!OX%4S1E5S;DEVEYL+QB?(0$GH*V-&ZO614H>[JOGJ1N6B5<4337,[+-_\>* Y_/I,X4W0$S_98 MA-5+2=&2["]3K\V8[!L:S-Q<--#DNSVLD\*^U&VLD_*=;BS% M_Q??:]O,CH$=L$=FP>!S#XZI 0T^4#+^LC0@106O' UDB*Q?C%9NB11VBFYC MB8!@7,I%V>)=C\=-60#E:.H5I<])Q#:2\E5% VFZ?31=80/H433=UOXV:3KE M:.H5);S/G?#VK1^:O^!3.M0+/Y'505&_YJ*!K([,N#'5D$,\H@0:2$,0]3<7 M#:0A]O%+"QN\]O5+O\_-@+TS0V:_]Q_P$[%NQ _WGKN)'BLGJO:17%<2"6JY MKI0KWAN5>8;?/Z2%$3/4"8'05O+CU,]3LJW"1*=E._%H(J4[[&4 M[UX#3>M2OKOG_WM=4KX708F*5 6L"U4T< /VQZI]DK2@7 7TJ!K+IQWEUX-+ MVE5^IN2.L>4,W/<^7T$-V+M=L$"L#3X@A%'+\O)3Z0'E]YOCW20CJZ3U 0Y)=1TMDVX,N;Q:V0"=.!3VWE\F^#R M2_S L?:#1BY=_]E%[;*'J_DD?@ 8U'&^?L_LF[X)J'&_$SZ@,U<8$\MFC,^ MGQ[#&8QS+(ZJC]C#P@_,X%FS'?@0:-*"WTQ9],28QW]CF4'P#&2NF0_ *5&( MOS)Y)),W4[B..75<)W+@9W!";>9XIF,_D5G$( MI\5?94(MR<4=[7]RA+ 40<:H((*^6W-FQRZ[G17BK3B2W M?NSF,[#0,A>H#H)8QFQ!OC'[)EJ>ZT_+B_[47[S]#N+&F3F6B2TF/H 8!Q-R MT.'K8P.8Z3USX35Z$X*@DX@3&#/YA86]]AJ>A(,01:0&\@.OG/D81@ZUEPZB MRX]#N"!\]7J5BSC7P4?RU*(")PO1Y.0GHOT5=D/&1U&-V)&B\^\OP!FTF(M[ M8RV@HO3?4NSR?^<.^MJ,(_^-%+P@]%QS$;+7R1]O-"&<)UU9<=R T2$7:S=> M00^X@LOFARKL7NYU.[T"K6(O,:K MF&O<[J'W.B.U\7!C64',]?<8Y8&33\53T,T+2XM<7*3NCW#7WT MQ_UXXRXX)%AZ2 7B:8;2M&8J23<4#NX6L+<[J5- MVKT7;_6Q.DW:Q/.*BU[2>$3]I/%(XVVI\0H[HT^B\8I-.WF-9_3'I/%4(ZYF M9'35=[P_>Y'IW>.R()G252\D148(10*;BP:R1/:Q1 H[O0N6R#]\WWYR7!?L MCJ4,%%_MX5]G>X2]^,'V(_E]UA#I&:U^C^:V*T=>JK(^*3ZB_N:B@13?/HJO ML#2T-L57[F9OI?B,?JL_[)'B4XV\*/NM!AZ^L$CSQ:@:[UYS_3 4LR_@AT]F M8%,J_/R,H0;8&R^?U$ #F2;[F":%):$%T^0VD8&_@0A\GY6 QW+)QZUA?T+9 M =6(2U7&)[5'U-]<-)#:VT?M%;:&UJ7V#G#(1ZVN/B*UIQIQ45)<#3Q\GYL! M:T]-G!&),Q29%_*QA>H%K,@@H3AA<]% !LD^!DEAH^<657KO,U+PQK/?,8_- MG"CD@O(=RLGL!>_],#J6PVZTAMT^91)4HT)5)03I1Z+^YJ*!].,^^K&P=//D M^O$ SUYO#6M<@4T20CW/GC+M!^#A/;"LLW^1.V46KBRDW7@QI 8:R%#9PU#I M%596EADJ0N+EL@K8 M :I(:QY+:VZ>2;=9:VZ:,*?.3!=2FI2%5QP)=WYDNL!*A65BZD7)*#-QIN D M+7JY!#S1HI>C6"Q;S*X+_/!H+?&#;JO?'5(.0S5"4E4*D)(D)4EX(B5Y6B6Y MQ9R[C4KR@#Q_;]0:U3C1CI2D>A[^I27Z%1:XQ!:O^Y#8. M'$RVQB&C)FY5>$$-L#=,)"D;36ZVPMZ])JR?3E5__!']S(:*?UM&KSA2;F=_ MA$S$CREW>F7LO'?U-.DQTF.7C ;28TJB90\]IM>MQS8F08>T4EPYPJFG4/G2 M>J'5=YUIZ+DRJ% WJ$"*FK1VA9_8T,WSCVVFGJ:%&0NTDGJX()TTA6@ MBG32T5SK=9LX,M[UX8/%^]0.?!$TI$8[,$T2.R<+Z1(3ZMMP_O5BA;3O]>"2M"]IWXSV M7;=%9%OM>TEMSZ1^+[L,P/;CJ2FG?**&A7G7$7E*"M#5IZ\O")6EKTM9+;;UY'\H.VGKSM';2UH<2 MEB">A';6D=DI!@3\&ID '?C4=A[?3B>F/%?!@Y\>6-1QG:YM_]E%S;* M'O!$CZP;PC=(Z7*A6SIJ'4YNU ",+G\= MS][G+38/63Y\ET3N+7JC3G$9T_(M(NT#L]C#E 6"V'IZ2T/0\/7&-OP]A_,Y$7[[X =,V8]:> M DQ^M,T9O.%KTWTRG\,7VJ] MHF#SP-G;!0L $][];WX8OC>#X!E>X,D,[/"##V")'.L@ =?3.\7"B%0T@)2> M,3 93%_@?""3C5 M'@02?=095X-$2A2@7A13#!_)-/B'?.42'8DX8 ^FXR$F]T"6D7NA;\FMMD#9 MISI)5^]UBDN0LJ0KJ-$"10$: (G5 >4@J49#43.#Y7@\W = MZ^J9-E)S!,+DQK-_\RW<^G0(:W?7:7V 3XB/VLC80L/N3O;]')7PUUI+]._P MY@>3?'^5Y'.X76-&*Z^6,G3)/,BM.4"W MA[;?2[P<#VETW^!%_$_]S:O.&G(I!->K6>0W/"XGD?#6^R/<9.&O$,EW,%N= MF0-L@H9K- ?#TDUOR"$"H \Y<>-KX+N*-5%>\DK^D\>"<.XL- NLT'O6DN\G M!0[KT02?!/;@=S WB-:/HY M#5QG$0_W/&;\P,8! H&D M? H!VS-SYCQ^YS5>BL@YG=1)5=)!!_VIDD9Z![H%=@'\$%A3).7!%.1>P.8K M[3?%97'UQ*$C#7('DB)TQ+28W1"#%(3IADQ[&D#@[<,D3I!V*' \/%V*,F-P MM06$5R=E3RO-U/UQP@A>"3DW*AR ]6L(A2P%'#C02>"+B8YA)Q0R);I621#3 MQ,(!H'2#9LO./->:0!/*S;>@Z7IAB2I%\1:SO*@'@X3<)S^)<%'X VT%R[2# MQ,*Z@*?-$KBX'E:2;P4#^K2?OU58O)K??_P4Y:"R^PL+D;7&6W>5:SRB@# G>D MJ6$GKTP3(!_^ 0+/T+TS@$8!/GH2@81&*B ( MA/:(()_%+S@N(_'E54ZI7_M;B!'M48C!8S#3'V0(T'[I8SPOOWPJ9 L/C!S@ M^YT?-5A/&:Z0WCPIQ1A6F6DYZ,@#_B[*#-\M_016#<_C.3NM!E0W"J3! M +-JU*<%$)\?G[@?%C()P'#B3$R,\C-2[,>,O>\\/5@AKM48\++CINC%0GHP M1UC7"NF;O%,%$WQ0*'0>S!"T>E6^SAO!-IF87*4J\MM=S>^H 7'$/+8C[LPF M,FWM[>0(6[\'?H.U@CY!'STE%F)0EO17K7ESR04Q+Z]@*B XT :4X^">OO+! MR@5Z@GQ >P!.(EI+PN0'J0N*,8MGYB=.ZGI#V&6!#^^G,NY7!_W/@9'B:'I%A%L JQUM ,\_7?ZY65H4O(2_R3SER?%(;.;ZU.$>F%/ U MY9]Y_?-TTOP2F8W5A&QBR,UX')$.O0<5 33O*0 &7V6@Y+!!XGD!^Z['P$5] M":@.8UWOSWM?+_J_B]Z (84,/;*I5Z05.UV+RIDTHC?6UNK<)4:%8#39RAGT M&JR^Q>?1XU+[A\C1>0L3;QJ!%VD=&PR3@F# K2[""*P_+RR")5RTBGR01$1) M@/>G\U'HLP!W(@?)T,B"OVSC?H:I<:?#A. -X"AE#6@H?H#+JX:8TU)C7((D M>P"?8$KQ-*6$#]P*=[AP-Q(^I")$#\G70PL!<-KZ4T@.L!M RC91V:A1R)& MU&HY4EN(E(&'="!Q?OW_RX^(U6$_S*]X6[HK*61D$*R-XG"! MZ&68D!@7K8Q9P:5BL76-?M-^7Y9 M>@+%?<[NNNQ:+J20Z@ET!N8[-?#,:I]F/2),,G,V(Z4+E7^N8YPY"*IS6,+A M7RD0XM]XH.IO<^FLC\H,P!*!FWD+HWX(].#[N0!V!?O8F1?[@/ M?PI;J]QJV1=8E#J/@:;I8_CBH^;Q4=51[4N6+.=5Y)T._*75Z\J5[3#IT$US M:[-H8T 39S*O3!T)OPZ*KC;!I/RN%CA:^W"(% A17KP48APW?]@$.#)8T "?2G%%PV^UQ'9%,KYJY M%1H, MC@K['%;$,)E;55-W!EZ(R8@M6$8\5G&^*SW M)IWS[[0R#_R;D:+0'L[$7IW1/W\#81]+7 ZC#K@R0#^&M0BHLNCCI)1WOOB1 M@'V^DN Q^YED)O;3?#GK)B0?IHH* M+ I@%>I0Z1M7B,I X&\51'H*=MD+XBF@F>8-I_#X9L7QJF(*I<;V)G%D?@SC MO.7MEMH:ODBX/*1=ZT72JU%N)HK[+CSU/XE(:'*/UI),J8DGT7G/V6":+[() MSBKQ@EL9C5.+RP2A2U+;VCYM'7>.\[:U56QF!:??U[']^;?_=AOMHXK*H=3&L#:Y*?.][4ZPGP;C5%PR.IP$C6[]:V1M#'&136K74*16*T!2S M[!62I_U:Z/.7%R98WF!!<*EMJ %Z+L"R0M IF7]@"8EU!5@7&#W*%146Y!UE?/JG; M+9719#6&E(!!;7W!"9HK\$O'R9CT=U!75_.B>[NH#N]T&S#%DA)OY,O];.%F MFGW"_5O6V^P6^WZ*Y+2TXW+-2SO,0N[FEFA:]#D/*XK"W^7KAW"HIOA6Y-A7@L\TOFK3,CJ7()NXLRKFSM.4Z+/AK5^7FQI51_ QT ML@).>A:%U19+@K>=HP;N>9KC5%@YP#?:/G%<)%4\H:4["%0H40W =:"SF8B M!V11D[B%9.58A0K&*#\B7FMGJ?R*\;U5X<"WD8_^.$R_>!O%@\5'->= MF=5M63SSRL,V,@D](5U,Y3>@&?S4Y#HY"5)#Z;FB1M3EUD?>R:7/QUK'-1;E MFBB!=4-(!]0XRP6,9M.=H/;2=">UHW%]^"PBVFE*@HJ;:LL4K(-M%YUE&U"" M\B<87&"J0"N#\O@./B17EQ=J._(9B6I\N=-; MD@]//:MT=6<.Y"J8]<>5^N2[I2.ZYH/OIX_3G-N!6H^+#]MGEEYLW7CYD)^FJ(WSESWB_N!>^DD@KX>?J.Z] MX#_=6,SX2489G--%[,VJ_(*5TN*"LYNSM5'S#H7?WEZTFV='&]B*G3&,M2?*;I'L55G& M_3:\^#8<-T\["VS%FS[,=5?WYI<7D7GO>WER3S;V9JCG6^[V8;.[V_N W1:K M"L,&7WKW"YOIK;[0[I?203OX+KJ]A5ZA3Z5;ZE.9<>L+,0#G_7],Y/E*C3;% MM\L='I7[6G>/KWXQR5XCNEC/"?@62KS F]1?!>3H; M_Y_'%_K7VN^L+[=^; M^TJVB@'+_MVXZPB2E#NML MXOUNNX]U;G7L!6DVC2MC7$YM6V&7&@RT?PG?SH3 ]B_A6U] 9XO;6,1'^Y?P MO1R .BTU0"T(H)X7#NJ6WPNR946_?_G>,U^^M\X&YN6/:=IV#W6I4*Z?W!GY M(\%:,GP_A=FW2^_;I9=HE^Z\G7;I3!($B\(;/.,E?]Q:=CJ>R59.+ZE)^V^X M-\:+TZZ9(5=7TW_*"&Z_$E_E1$RDZ(C^[(#H-W)7U6G\-4?RF&?Q\<.IF\K MR5$!IELN9KU+8O&(9\?A&72+3:-9.I)P]I!!/HW./K9B(WB.$7RIN*^(AHWI MF%7/Q^:9L9VPCO)4JYO4@N^Q6C??D:0LF M(8D9BM0"I&V=7Y\&0)"@> %)W>B$\S(RV=WH1G\ &HT+?_W;V]Q%+X0RQ_>^ M'?0/CP\0\2S?=KSIMX.0]3"S'.?@;[_]\S_]^B^]'KJ\OKE' RMP7LBEPRS7 M9R$E'Q[O?D)_/W^X18_6C,PQNO2M<$Z\ /70+ @69T='KZ^OA_;$\9COA@$4 MQ0XM?WZ$>CTE^((2S%^@2QP0)/Z=H9/CDW[O^*37_SP^.3X[^>7L^.2PWS\^ M_7S\Y=^.C\^.CS4!OTL;D/;O#)T>'A_V#T\_]S7"$;9^X"E!-Y<:X?$OU@D^ ML3Y]@O]^[I,O>-*W3[^33Y/CD5-?47RRI,YT%Z(/UDU 1[/4\XKID MB:X=#WN6@UWTJ"S]B&X\ZQ -7!<]<#:&'@@C](78AY'4-V:?,5ESX V/G7D@ M+YQ_.] J[^V9NH<^G1[9 3T*E@MR!$0]H"+4L0XB/ILX,9-@8,0ZG/HO1_#B M"#0][AWW>Y_ZBKQ"&6GY@ ?^F,5<$\R>!8=ZDU,*"Q8T7RO^!ACZ7U88:%!4 M3/PJKQS'*BC&L7+(7WX$;RGK7YP? /I@1BA>$'"=)3'*.?LG"1\7;0?IDKAJ M)\?'IT?RI69(K@DYVD#]33%>Y%8L?Y'G/0PJYELL7O&:_9QFX41.OLM!_4]' MT#X#@"]1])8?>@%=YA<2OYJA$WJQ9/A-_DV+ 04"=YS @USZ=7Y()#EUP8^C]%6+7F3C$ MAA[2);Q[2Q%HKP-,IR2XQW/"%M@BC5#&[+P:@?KK'_W][E;VLP?0>2 DN@]G MOO!I@&0O./>OT3,/\0A!T@+U?U(JP_FE1R?GMO%J9K*SIJ#]Z"09+=2AK?DW5T=M-_%=MA?):7T.-U'C% M?]358W6L:X8+?9B]EZ,@Q\=7CL_^+Y7PF3]2KZO.NKK4TR/CF;B[%+_J^B;3 MV3:K#9?2(TPMZKL$1DHKN'I;N-C#@2^:4:V*X>0I63V2"+N&O]?140CUR!1" M6KN18KJ #2@2K*-$\^XN"4?DSUX2F51"33:<::B(B@3YC[K078TB*SM#2,F$ M?T?$#9B(9\UZ%,:.&].!NYC5U$0R;4/7U2<[,6@*$S4O$;]ZR0RE&E!6 M9S4-:T6/_&7-1$_JU$O>]&&3^M0&CN+9FD:UH9,[==4TPI[G!T(-\4P]72P< M;^)'C^ A#T3/N&EC$(8<"-_'9 XC24!NQ02&OWIZN*DS&9 ];UI,O1E6K)Y2 MT"83QW.$,'*AI]SX)UAX"'Y3))D"TLX33E^IE$A))2%P B[B(B$2'F,?$7;C8CBH MOQTP:% NV>;,_&@_E0K>KUNI:<#DU^EE3&.LTCT9[N+GNH8#"W&+;;[EK]MJ M+G0L=8;L<49(P#07%A"8G-;G3HMYX7?$CB1_YZ3UG33"%![-"'!CU^BQ-+7) M?2?E[D,?4N)^ZMS9R)WQ#S:<#&&<$88QZ"0O_#G8.B,>S:]5^-33DA-'GSM-R;7! 2DCKWU8IQX[TB M0SK%GO./R"!H"3:T!>A@[["'I])Q(Q@6X!K!@!)">@5BD"R#+12"-)+Z0#1,+*0,RIO>DLP(TSLM1Q.GA@9, ;S M:QCLQ8M;!S\[+@S%PV<7G"&F8/E!Q!KR#$#I'V?C!54:DL7!(U%BSY_TH$PD M"Q4A@B! <;E(*[C#3C/LE,X42\E,GNYG/-W-"+?AO'-H$R)+0SR629F;2$U. M/,EW8D](0KJHSH?-?/@'IA07Q67Q2Y.?/F7\I%@[OS2=+ $9&>.WPFE1\M[D MG9]S)D"<&PGVSD/-//1 ^(X->X1IL!P#UAFVBF.:0F*3[TXSOHM$(2$+Z<(Z M3S;S)(PCF \2*@TCW$*\PRU5&;_)G-F&E28M6)#1YG4L;AB;A,R-_A6#3 MU4MAVB%#9')>-I.4B$!21N>P=J2G=YJFKIJN[F<35=M/5Z,/ZE>WM-T2<(YY MKGDWT(R*,@$SFT#;!3"E9K+N':"VDL$MP4HI@PD&V2QA43:W M<^SFTH>E0< JE7 MH61/)2+ M#X]<0MCMN#N999:5;\+>/K;P\0TBLM!S0 MO1] >.>&-K%O/.W0\W"20?3^6MPV+#"UQKWD\=.M43,;*;OU#!M8CI3I/ ^G MGUD']MPVVS76G:1EZT9K:PDT03F;^:^4P.T"J'VA)^X?-""#<3_&RP6:P%K]AIQTMYV4*AF0*K?#ST[Q\P06;!Q#.4)-.*IQ-J<<1[SL#DR[ MC#&'"S&;6!M$Q<),X,DNKM2('9$LLL/,KJ+$E3!IP%@X%RY@3PP*/'>Q]0.H M02B3KAE! X<7=[Y-RK;@[*)<$Q*S2R058S>E'(JT0YIZ*.3Z(:%@+])0H3;2 M$0DE.^AN!;K1:0G^3GW!'4)EF0Z] 3?QCWG4QF4-H2;099%SP2)[)* DMKEX[;E;^TTOTR)6\BE-N'R(U?D(34 0EFNA? MO^G@M@6X\7R,9SFN(RMY.'EZO"8VB';Y]TQ"_FUKX'C 1G[5Y,)X3%O(HD_ MKXO C95H F7>09%"4*YHQ1]!#:.GP\=#%*F'8OT$=KDF*/ %6:RG#FY!T(%V M"Z#5#I[Q8,7WB/QX#_S&WO+QDDP(I<067'7AV4"V 8BG>2=%"H&H'ZI+%%#' M64$%=21/::)NLNB MBF@U3_N5HG5!).\(Q@IF'1AV%8\7W35<5T8-)%CPD0V M6UY\FW*'D&TAI.2^FKH@:2C*A)-L-KS\/IP.*KN'2G(H2M_ I_;#7?M4;)!K MAIU:LDU@RF;'36#2SUFE-_W%V_UXPDCN /Q_ +%?C]Z8?887"P>:EG@6/?$\ M7VHB'_)GQ)5?D.0.YQ\T_W-$R0([]@4(YD>*QM3!+O@;'EO1H\<@M)<7/N/7 MA'MX+C]17H-'?K&+GB?Y>>, MOQW8Y-D)U"?3\RM#1;FC\-EUK"',LR@ #TP;\K89G>+SIL*P>YC!A90?)575 MTI3['5708.[3(+K'(SYC&9DD-UNFO_4@*Z8NUX8KQ YE4FP' ML@BI->-I[QIK(& M1?G?JS="+8<1EE,A59C>D=WB='!-LPMX6M->+.C]ZG4AT _RCQ>GAI+46%.9 MO#654*'32)_,6#F8H5NL:J$&P_NM!W;C!02:;! EZO.-SU*])XL?"';Y!LCO MV/'XQ5)#+[['(H9\.4YD54 ?X[]O*M(_H.X]H!I MUWNH>MF4M-;48)7N\L8#*C&;DO_?>.GF$!^-4K54@Z$U%5$!2B/J6X38C*\= MQJ,CYW[R;$+C>(B_&45Q4W1C7M$8NTF)[ZDFGSP^>5.3E1L^Y\1NE3F+JK@U M!+2FGJHTO0=B$>=%7'H$$%'>'DZ2CT*J_MI$]Z[,CM1.4C)C\A:\<'X6J.?[C\+/^2XUPM@E819UY 8Z'Q"[S%A7A;*M5CXX[ =/USV! MMVD \4.@OK^5M;,:;5LM'6%^P:?H5@KL*Z-HJU55MMV)R^4SUC;A? >U\!@^ M_P^Q@K&?I$/NR/R9T!R[2VA3EMK^'-"^93/EWZ43X<(K]6X\?E8JF02,?"82 MP^R_0GC(4[HO).E\[T-N([_I-Z+Z#KP0&H\A7![2J[^ 9^P//?+?!,>UMI^R M]6$0NALR)70G><[RE.]SH%T5NU(O^74!$Y!P'HJ54?XXR?]N0-0[2@;?.A:? M@,=7E5V)"9E]"<:H*BDET4V=47+XMDDKL ME@3@H;2!Y31MM IZG+$S)_<^M+E)Z-E* MQRFGY@+:TH"KA/JW9+J2;M6?M,62*JLPT,%"*"N6D29B0*+0\XCQAXW]$S/F"/B ^H4DV7_/%?>S8T+G,/46>SJT[KCXO>YK M&Y[LWY9TUDH%&C(%G)\97J79;+BQ.;,2C:_>%HZ4*M=W-+O*B-HZ<*;=(8^ MC?VK-YB'V1QQ^6[+HTO!,5)N__;)M>I;QQ/-(T9AYG%J%3+@^;"]CXC1,CMG M3ZL=/6J@LAV';4W[D7US@!4P^W-O;BW1LDONJC2%)*H\<]\-I M8\IIVFC5A;;?!^8\*U/S_)=MM ,:K^7?>"-,?T1PNH:H[]:90[%VO&(2[8E? M#?\;L+:Q#A[(U&%B>J:R^ :XUF!HH[W)-D.#G14(VVB?=(^4)"=NI7XL)6RC M?8-@/"-RR5<.90J%/)XOLK4F4QOM3K*;(^I/*9ZO>K/@=1MM42$[GWM9LR2P MSSYO93 OMZ'I-0X31_6QM'A4+R=*32/%L_W;%0UD/%EYD=G1.\*._;N#I5EJ M:2'N*QMPOJ,\0WHW6HZ%T,G*U=AJSMV8!N=(6IV0XX8=8Q6L^AA*0P'_K M&8F*Q.U+3Y3MT.2GI1SLWI-70< 760O7Y*KL^*PGKS58J9*!S)_RZ,F",HIV MI@EX*"'.\,8+DZ+#BY#1^*Z\D8+_H6IX:M'*)LYB[C.ZK*U,*]= M>@I /A^P"W"H8T<7>$"_F$S;*ATFJ"*FE6U-:PIJ$$@U!U"&Y6YZ+*-NS2!2 M)2B;PJ@PA98>IR%XA)VL>>2_;8V%589)[6QE,I%(^2W9EIKXNA[3NZJ0Y$"Q M9DXT^5 3+D/$M9:(C?8$F]G),G[UQS,_9-@#A4,:$.+Q_?\M%#YRTC^Y4>?D@V!3?G;"8<5>X:3NC50RM%.FU>_J^!5B"KJ M\;1Q]*T8.+[+*+'Y8"860K4ODXNC>V(+O[SA6[N*XF9EI]J."VUC F8G5;!R M._QWM/ $X\K[-D89^K$VT>^+ MD+]2[K$1:]OKH-JE$<4548^_C;5QX6+&DML.AE3N(13'%I;Z7H\*A.W;YW'K MBRL_HG.=RX)MA2:J-OHM.:IJVI9N)FRC?2/JO "$H/G(G41BNJIV+%\ZE%B! MRE:M),_K,[;1?HC7HP5 ?F]: -Z3!Q5OY%BC[1!^GB8SQB(:C45JT/;,C?SLF3[OO(;]7JH39?"\&@ MW60TG%0RNPY'*B>WB]..%2Q^\DC4LC.[8G)?M7 [A_;M%W6*#"*PE:L_6>*P M:M1MV>]8\>I#^:63S(G;O#<[AZ$Y HO53)V[77W:0/$='KW5=QC(FVJ<%Z)N MXI0C8MF.4S-/"_M+<1#AG@3).76?L0OH+)8P8>>Y6%D:[1_Q77]5_XETOK55UW6.ZH\Z)\O1'PF+)U4&?-JL;2P MGRKYVE$F^JQ&V\)X-/GN9(D)J5BU#D>KX]CA!&:P1-PWE$[VYKQH8S)7*%AT MB+;@9?L64U8^8\$G"2Z37:C*+B63A]A#]9CV.)^0G]UBT&;F^+?_!5!+ P04 M " WAE%2MX"[*6@/ EW@ %0 '9K='@M,C R,#$R,S%?8V%L+GAM M;.U=;7/;-A+^?C/W'WCJEW;N9+VX;A)/W8XBVZEG;,MC*6WO4P@ M4K;ZZP\@*9&4^ :0 @DWF4X3T^!B]P&PNU@L%S_^_+JTC34D%&'GHC,XZ7<, MZ)C80L[S1<>C74!-A#H___3/?_SXKV[7N+R^N3=&IHO6\!)1T\;4(_#;Z=UW MQN\?'V^-6^1\>0(4&I?8]);0<8VNL7#=U7FO]_+RS8?]\^,-Y?W@R&/3/WO7?_[O? M/^_W8P1^#:0P8G_.C;.3_LG@Y.S=(-;P 9A?P#,T;BYC#?L_F$,P-$]/V5_? M#^![,!]89^_/WK]_-SR=]X=G<4[Q:D/0\\(UOC6_\UED\CH.M&VX,:Z1 QP3 M =N8;B7]CW'CF"?&R+:-1_X:-1XAA60-K9.0JLUP.[>WX+$A<:C_XT4GAM[K M$[%/,'GN#?O]T]ZV=2=L_GK0_N74;SWX\.%#S__MKBE%:0T9V4'O][O;J;F M2]!E0^4R27@'%)U3_^$M-OTQ*L&7D=F"_]3=-NOR1]W!L'LZ.'FE5H>A81@! M'@3;\!'.#9_WS@A<=BI8KF[/D/UL0.+_HK+^XKXS,L#\8!D2^F4'6BLVB M6U]H3N?SXTV"YS7ZPF:XNX $K" ;)3.8CELJ/?Y.+TFFE\*:#&D7O&('+S=! M'U.7=!;7JV/XY1/]E2'K.6B(W,C##5P>BSQV;X:.IZUF:,Z?[8IG,L032?[WK&8[0& MB'%HPVM,IL"&4VAZ!+D(RHQ&"6(J9!H#NF"H\K^N_N>A->/$<>G('0-"-FR5 M_ IL#XK(59*@"MDNX0I3Q#KWI_@]=DSQ8M!^_)1N9DSGYB MF&S78FAWG6=_4HLQ7(F\BM&8K)B^=5GOMY#93-^)F,P_,T7$D149D@)"2C2! MK X6TK9U\BK.9!.SXA:!)V0C=R,!;1$E)=+X%M4TB0>M+0=RYJ&(DI*98YK8 M8\K[ 6RXH9*9[AD4&IQ9+DB<,$\:+2&;$N,E_ 64YKMS8VL/SWJ\OW#/61V:@9>!1=0_=VKP.T1N@ Y MT+H"Q&'+AL8$84X*,I'0Z)>AIF0V6!;B>TY@/["MR8TS!BOD IN-RA([4Q>; M7X0&MP0U)7N J$-Q=__@714Z\?;FF^7;J[L L?1/)^>,ORQN,\.Y&9T#J+G!+\B@E?(E@7 :&WQ[@? M24OJB-38:R2ZWNYACNA%P?,( @V=PY(0%)R&1!!HZ"?N'6GA_=^D2*FA8Y@M M9<$):"2UAG[@H=253K8C+#1T!K-G0'9:0B2PAEY<^KEZ?.]7+KLD D%#UZX0 MA!*I0SL AAHZ>ID 2.2%14!HZ.@5SH12*7T1!)(.WX^]?01NV<_'327=_8-. MYJ&YPTX0[(QM=?DF5RS/5)QNNY)0!?A7<%+Q"3J,!;[\1M:2+3[J#UTP+ M\D,- DSW-^0NQAYU\1*2JU?3]OAG'5S#L?\LP6P**?)J,E6?W%AP;L^^/T)@ MH[^@]0D@YU S%>6OBE%6(>V-XT("J1L$*L,9QGQ8O)UT]V()H>7H2>7KCI:8 MN.@O7\M.YLEM1A">G1'@4#:1N!HNG:$:_47;',=M5VR$R>VO FB[%>7'M\;/[ =,K9DDLZ.QX,* M!%EOR/F$:LRP2"F(@@_<+^$P=\W3D:61>DXD !%-8&Y?78.DVC$ G-EZ#4F M63P]JK)826)2P<;Q CC/$4A;K^T1VOZ,F.$[0+Y E_<0.2Z_0-L:T1MG#8-\ MSO)!R+JZ:V;\PJ//;5Y(ZA%HM4$MUX/42.][EQ-GAVCY\B#;:VX\4QD M78C5\RE-[^M!39$NW"K?8,^2Y)%IK27REF*JKQ1!-1_VXCER12/W\;<4<6E" M:%&^3^;!@CO@&2RR4^@K("Y="1+ MD,4PX]_0W%#J\7)MG]F>@ERQK0C>0.C_YL%C6UJF)!]LX#!(?P.$+6%FG" Q M4@5<>W5D$1PH\\%79 LGWH1*!R3PQ7J7M6#DZB@XY MN?ED4W"-V)[YXX:Y+K M!QEQ]UGOE 8YU&K?A6F= 2'A+*?,O/0MN53N0]MG5UED9*(Q6N=$2&Q(<'HP M3NL2&]5@*!E4U3J'0@ZA:BE[.A;LJ VGG%,3K.%D?F6@Y=EP,N=>I.>& M+C?S*Y')$^"1[;F0?U''[>*#_YD>+[W*?<]+7I74+I5!K0'_K4C?;C-."DY+ M?_-7&;1&:P;7,[SWED^0,,$X%S16]'?J/?T)37>&'^$JC&Y.R)B'/VU;.'FC MQDY5G"CGLLNCP$QA\D&M#8($S:8EG'@NO]N4'POL3=VZY,WKH7G36!$;+#/F M6I]$*P),3$]('3AW&_<]8CN4&R=M([,S1;&68QM0RLP2 RZG,K>4+Z&,GY;Y M!L>7N]%K99.?*-=ZR6P&Z2:NT=W[$#LJ;?^), \L*GW!_;&/<(X)%+U$K9X. MVXP-C]'Y[%0PUBM,$\%$DG1 MND,.6GI+O_TVB[4YLU>6I[=H[0IE5W%W+J]+!C/6S8X=#_X7 C)[P2*J59BT MDKN"2S)USZ;.[ 7::WB''789O3@,7Y[%ALR'C."<\)-5G3T9+_5)OYR>Z@ M<=F_6EMYTY$]K'];4UN*RO MZ*(OR>R NCMNF6FL44 5E5""T(U?EY9;; MJI)KM0F'LD@Z+#TV6OO9 K#4L6:USE.14P985NMK7>FI,E9EO0"M[ZNJ#:5R M_J!4L:>V8"7EBF4NOEQT-/Q*O29TRNLDRM8JM1!FFV<,QXQ7Y MU3;]Z\+JAB6MA[9(?X_Y2O-8LR=[>RU8>CTBGO9<-S*BO;<9-178M >!=$=/ MK,1WM7[:@L3(W3<7B<9U U+877.XI!U+5!<_G6KSGJX$!KCFH=8ZXG-\_+)U MA];AG^,#EVYZI.) K?E(KAG4\IP9K2-&QX%LN^S=P-M,8'-+U*6KM58>PB(1T"L]!=S/;+U8I<^"Y3T'E*>ZN M[YV.&P-"-G-,7@"QI.(0PJ2;DG>OWFC<+#)7+0SPTGI"$,?IOQ'DHEQ"3&EB M2*M-_ARRCC#N4@$[X?-HJ"8^]B,J&)V#\E(W9B:3G'_LY(R/ J1 M:P[SZG W--_O836K[;_?".Y2M;Z3KP(H>3$*K2_HJW5E202RM+Z[KQIXN:%1K>_JJ[+0 M]KP6V9OX&CD8XG7;45 @V[_9U+\S SIFO(AVHGK$]N/M:TQN@XMF) Z&:NZU M90=#=4FGO"8'3>7JTH,WSNP%\](V0M$4">+JRRUFLE6YF&0QY19)>P0QVZ#6 M1:7/+$-1/)A:AW..CU-\E1^OD$?X"_Z_)\;-3_\'4$L#!!0 ( #>&45+C MN%1F>BT *,T P 5 =FMT>"TR,#(P,3(S,5]D968N>&UL[3W;=N,X=5N.K9[)Y*4/34(2=RA"RXO;VJ]/ 10)2N(% M $D0I+@/LVY)*%05@*I"W?#G_WI=.DW]T=C,[!?T)7MFP[V0P_]Z].W?SOZWXO' MNZ,[V_WCV?#1T14VPR5R@Z/CHT40K+ZGYR?QK]]L?DZ^M8)D0/K'[T^B+Y.?[H'^ M>4Y_._K\^?,)_3;YJ6]G_1" CD[^]]O=D[E 2^,85C4 H@DNOOW%IQ_>89,N M)P<)1[F_(/\ZCG]V3#XZ'IT=GX_>OOK6&V#R@1S0[HNA_"=8K M]/6-;R]7#L&*?K;PT"P7FYA'9)+W!/R?#,=Y<[0!_/WQ=I^SMAN<6/;R9/.; M$SK@I&&L8$+DDFU^;*&9$3J!&(X9PQ5BC)>&[4HCO!G=.+YTGN,E6CXC3Q#9 M[:%-8[H $)X9/J/CA$MB^&8"2&/-B_++'\$KX'5V.CJ+#N>?I@A^!8+\C@J3 M78P(;2_V'Z!D@@7RC!4"06E&&B&&KJ,Y8ET5___8 MM:[=P [6M^X,>TLJQ M"GNPOM;%&A83>6![H"F0>0$S_;'-*X%(_.;?FS!N' ME@VXC8, @28D?+MQC#DO_D40&D X9M?4,^#(DZD>$3 M$&7W_O@&D1V[;F@X M@]$TTF1-)]X4_W2E M\$T/;QK5S?^!_D-G4LAN U"([J@JNJ,&T9T:K[<6R$-[9D=W,S%I50*D,;29 M5H?9Z+&YQ*$;>&MQ<5$"JC$2;FQ'4#7LCVL N2=DAAY,<_UJ+@QWCNZ-)3=# ML\F!WB-DHND";NLA&';FP?+LZ_ M(\.[=BT2+N*^U^:.;VYCP'R>X=RZ%GK]*Q(\9'N#&T/S$.*40.K8T]=2^0P[6#ACU]M+G'+":A!T9&* 4Z-9WZW2_YX M-<@2)^HM\$Q8JV7#V$::Q6;'GKD%W_#,&/8FNLZ9,!*-F7EXR8/.9DICHZ?7MZ^N9H!9J0>,.^OH$C$/J '5Z1WQL$!9I7\,7$;H!>@VN' M;KBO;WPT7T9NK,WW#O:1]?5-X(5[JUDO8S+S$C@8M;U1,?&\BU1WP3A:;(_MDSV=L90%LW%FA 76AF,SL_]H7/' M^DMH''&(NI9HE!7LD2V>4'AVUAL*=^Y C,1/O2$QYQ::D'K>MK*IG]0]ST!" M[+O3GA*[Y;-AY'[H#;D[7K2$Q/?]$4;9;LR$T@_].:@Y;N6$U(_].:;YOGY& M;7].:4DL)B'Y4]].;5[0C%'<'XLB)ZB9D/JY;X)J)\@<$PKWF9X1NA/P9X3V M34+E)&$D!(_Z)I^RLF08M7V33=NI2PF=9WT33,4Y90G=YWV34UNY?XS,ODFI MO&3,A.)W_1%3^WFRC,K^B*?L=.6$T@]].ZCIS/&$RH_]V;5<^?R,\/YLY)(J MC(3D3WU3N9FU,@FYG_MV@#,KF1BY?=.X&55F,;$D[M]+8O=* !G%?9-7V76: M";VC_@BK[=+9A,*S_LBG_:IE1F5_Q%)V\7A"Z7E_9%)^/3^CMC_RJ*C90D+O MN_[((X'F& GY[[F%U9]/=J@'//YHI$M+DOJ3_.%/9M0!L\ .X.U'^2,Q^86- M6@1AZ="KA1=E!VF)[C!?75O.0!6)N!/"7^*/]-""Y)>]H B#[RZH M:,?^![+^&]A'_-%PW@A:$W?C*;"1/_9L'[ZZ@G^Z\\AW"R1,9G#Y$B&[.1R* M.;B_^ M+V E_>^%X2.+["C83E3Z_^()'D7Y.5KD %V39AE0/D75G0NV5>B9"P)]G_/7 MH&+P&N5@(+.G*TVG8JW'UM]"/Z *;8KAFFA'!L:#85NW[J6QLN'"F(U?@CVA M]F%#)5RFYYZQ?$2@#L&814_(>[%-%%']B$P\C_2UR%YI#44E9XWNA&BS"!V@ MK7'*I,*6M0-ZU F)YGP@N1]@>@>!9S^' 2D#F.)[[)*2!C"? )4Y#>F N2\L M)&J84N*-;?$^647]!0F7QXT!"H'1(.>'$6"8>FKICQT_AW6#O)@Q@,B)'R&-R M%+S06T#2H)7X$1\-1J M^444,;VJ_6,;[4OL!W#U?P'LD47QK>6@59A.+5^2RUMTJ\U>V['C;![SG,P> M$[HB2X50Y%?D5NU(J(E%[V_XQZ?O,B'I0D MT%*9!I6XY^P681WFR%^ML MO4?_0SJLC5WKP3%<4A(J'A1N9OZ!)A-PC3@.SK6#_?5OC4K;R%1K4T+C7ANI3ZT!*K=BWV+B43 M<*JIYJYJC%F]"8G5X05@87G]LV]$V5*3 ZD++:/K91&/&Y)%V_O,E2KN:Q:$ M[_K1DHYWL-@[=\O\-F)N$V]N@/#BK.&3IW"Y M-+PU;!$;Q"WIB02;PS1)+RB:\.78IHU\MI,><$":)\'M;7UE.R'I\\;BL?5&?TM(M%9$KL$A49WY!5)*DRN@9Q!P$[2IE=4LELL5.&4 M IRM/7RO7R-D;T"R$&T2!AMTXR38&-'QDC!$R)E5SX1*BG_2N7V1MA!W:Q(+'8NC*5 597ROML!+KTXV*W0%[?UQ_$X9 ?"5S+DB]'T;4X9\@0MO ME^J8979 @4^B2X'()HVMFMQ4$J'*-KSFMS2PN&GY^LWP_D"TQ)D1GGA#4[^\ M= S?MV:>;)UO%K;$ A^> _2MY($?@ M0>I;512#15H$2NK[B/^_@LTP^1B(=0;MJ8)=>8-*7E4RIN="37@ MS9)TG*!)('YP8?B"CCIAV$H:P"%O\_@,\B>S*[3"OBWA)2\$HZ:1W:8G^C9; M99K:%0)2U92/%%F39A<$!YH?:1*50QC M&Q/1T$/6:,41@USCHTHPH RH+C1*.?,% ;=3="%%?+9;OFPQA7RYO?"X/UC M+.?_ 'E6ZEEEY0#:!3_(-V#FPN! MI*&WXHCY=C&SDU!SLS+6#R?9<#SAZ#S:-$6?6=7US25&9O\]NW>QY_?\) MX4.2 _""F$B+7C@F%4&;7_T"8P/D31>&._&N_PYCIGCBHM^1P5^IT0YR.I^D M0XB?\AX&6CNV?QA$'UNM93I=^;*W\YOF3,:$0W3R4"/&0Y15YRAK5Z*1EX:_ M("^3O(#0@7N0Q#[*!J"VPI,@,7:M'5RR/ZU2 "HSS\ )M5D!V3B(GL^1V!F@2_[(D",SY,@(YL@<2E4J?X[,SMGN2FEHM@S#F3*T([6:O"3I ME+N4'T;,4W\XTS#H0GUD&47;9I@V3UFJ2;$KLI;UZ:W)EVK'<7_(+'V5NQ$Q M[K2]];F2\=0Q)YV6HW_9<"T7<%SJ5=&F(:L&F;NM-UQM*WOU7/_CT$SVZKG^ MM?--)F^>MVV_MIV\>ZZOO5O;O;:FL&#"LT\'D/%;2Y"9<:QMO=+!A%;^5U.[ MQ[,6DV48?_6OVZC&WUIRM!B[VO9>:7R$\_+X/Q^ HI#.21_QN(X/A3OI1&#& M(&[;O(VD_1O#]LBK#,"<&]LU7'+'N'7ARA[2[.\D(SSYG9_]0ZFD_&8FUROI MOF8:522)^CX*_ 0?1HI0XF<^$)U2Y)O(C6\SF:/BJ@D 5;**>9MH_ SGPC#% M2AO*@0WIB8>3[OH-NV@=%4'=A*XE040>!!78)]LXVM7?D$%VLC5Q'PDS/=!4 MM(+WNXN?R9M#1&K=NJLP(,^]@69Q;.IXNEC3X;3$2[QA?W,X#!RLAH.JA,($ M_S0*HOF$!4"4TD YZ]^A%^2.42MT;$[UN5A7$!I\@ ^'UA:DWCXJ=*-5$(&%$%O0BW ;N+.-9] UD8&VIZ'@ M!_>8/*2:4EC"":@U3MH5'NT[G!3QZ:[E!-=FF(<;V4P'DB!;_YG/6HX2X=:5 M#%M)-9#%$5ZMUI%$7<6 MYU#7IQ) +W[Q9H=VH$I +=N*DZG;KB 09U?]=VB.8"GKV:E_6BA_(+FT="LS M&)[PXD/;!D1#O.#/?4A8\5'_S$PY5N1GMDAD2K>1\S6>>RBZ:_QF!XL[>VZX MUL/"\):&2<$8CG_KFK%RL<:694=(W[HS#+\B_Y#*]ZI_8KURO6JD3ZJI8CS] M%'E+VXW P40\'N82 "J\ZA>A#RK)]T$_/V\F?PK0:FR"\(WRFHD8#M:W;H \ MY >W+OT*4'X =0Y8&W.AH$,]\ZGD3 HUAL)D]BL.8+O&:/H;+"T97HC.(-7\ MDR@04*Q3SW#]&7/IHT _)-\';^0RHEBA1F4 MM(^GZ(K*N0F+.PIC:VJ#:^1S_I-V)M8?@ MD@;?>?6KY.X/8AR^Q]. MENLSO7=-)80EI'0*84AA](VM.%KIME= MKKXHN1()"FEN>.4<]&,6^LA\.\:AW>[90Y3TJWX82+1:ID-4F(F&J2:D9IV]\82_DSI,/$L2QYH M?:1*E9I_"I]]V[(-;YW"2535%P!1VY/S$CN &A&O]@O:-ZS,G*_35E:%!J7U MS:ZF8*HRMG:+USMM*FF@CK,MLDUK?ECJ0=-$&90'F$GA=2Q4M5P!85&]U M+"6T9@YT*_53P*[!F2:E-MF=FHB(S+N!/F]8%PN%HOL0SKZ1Z9/36GC8!2G3 M*$.UX!#GWJJQJ ]"FV1)34YQ7H?UCW=R#7NSBC9C5SCIZTENY&_:UFR M:G(F2P(+C%UM)W?Q&=[% 19<*4#$>-&V\N*RP)MB19H1;5]%.#+^)&.,F"LJ MS#BAK\1OVK]2'M-GS]FW;:BWQR71[ S&,_W/6$L\VTW782P[\,-8(9V+Y;6W MK>_;%FBIK#W&E /?6)*9EHQ_^MXB5,DRV;Q;5F71]F59'QY6R^-F'-6_W7.C MISJ_"("Q2.OR%FH?++ #R/K1RM=7P2(%6Z\B%3$2VLYYO@:FX36*L'X(/7-A M^.C!,=SZDJ"+II#*L(ID;CO8!/OYB*@\C]Q*I"R2:*IOQOH>!T_(<2Z0 M"S*,%%-/?KH@41;VBG])1.'*88]!D :DVCNU Z*0;&KU 9?XZ!-E]Q0^_PV9 MP123!ZA '=_92_IB">:3.PU-+%UMM35CQ.HZ*)0!+7^^8C9M&2AB1R<'1)UG MGKHA'@R/+'SBC0#)_(A(XP)DP8&\"0/0P[$0JGKX)2:4HO<1S6U2%1W9U[!5 M"?]H+P6 2?X6JOKAA*8DM3$E/:G" K[2SX0LC'P@6AFV]:MMT%F$-Y,T_,.M\,M9J4MC!=*-OB"4P<84#WWA19(! M?!XH[:V;LN6J M:97JX45R8P<#!Q8B^U3=8_KD*MR(?AJ>Y4]Q0#SX['LB1.&R\3NB3:3F+J%& MA$\-(B&UT^,5(EX^<\$G?G,&JEC#*S1#GK?-K92ODC10N74M^\6V0L.Y?B4- MNS;G3F21JLRB'1=2%ZU*MXD&)U?U@E)\>3:\B4>O#YMKD(3ES@5.,5V[4E:2 MGGTP*NB JT.TKU(X3,+ #PS83.Y[E8>3!FKK DJW?>@5-\\RI[ MV6L? ^&GO/) R/F6D]#M7N1*\-QR0*H@64AR=Q+SKXBI $3)'D2NB6]=L+K_ MV/C72;-Y&J-$21OM-;D3&^Y:N!^1!&RYG9&*!P@]P5LT6L49>T0.N>F0@*7$ M@X!9H[N(M2J)EIXYG?YWL4Y_(RKD1* J]IS(O:>],UB)#YO>](@HP"X)=PMO MJAP :F(1FX#]#@[";_^6 *HQ5T100!8#.:QNF'WNA9F;,W:YT=]W=Y>"6R=S MK(:M_@Z^T5]VQ(X&ZC:AL.E/+'ZZA,#J0>?$%?"22(%50>>OR"?5,N*:=&=@ M=W!5945N)A65R%O#I.1P9!9PMPO<'U-AUCN1QGO9XY0VSBM$'6VACS[OL0CR8AM^]%3OK:[7(Y:7.I4UJ9-'L=N+W:LXT+'OS8]W6K9 MRR)A&D9YV^TO^.X^$H&M',YDW(]:;]_&=;CK9D&: ?K?) HBLK@XRLT:@^DK MS#BZ#DMD&G2I)5I5HT4@C80]VZSOAJB++1QY0#$[1FUWY:Y%">8F9"5DMOY^ M/9_&*TM.2U_>:LZ]8ZQJ6R]P*<:6.)7BD\::I=&\4,R?);1Z+.^ MAU&B@"QI/"E6!L>XH>]!KN\RDU/%&#/A3./87UEB F_]:$+KJ.V06-VTYE< M,YK;%GG-K.]6,7="[)F^W<9YB2VLPF>$=O_4^*V;/3<87QH;O2+J>E3D+:N[8#Y]67N,'.1XQ-W9>,%1MI):S0^,D7KL-0 MTCPMH?-#]W5#7:WN&$_T#=3P\H2W^6%"L\:W6Z%](/"LT_EI=Q6_=*?2A/A1 M]\U]P3>ISCM\G:O6/CCA0.MYK34L>G[/YX3,MI/BJBXT9Y]N1F]W[;::FZPG M+'G7W9U>VCD_(5+CMQSYB)1XRH 1WW'M7?]+%0EK-'XXD(\UHF^4,,H[KN(K MOS63<$+C-^KX]@#GTT$)P9\Z+@SSWG&*"7S'4S"J,X&";VDQNKM[IKFNID5/ MH25,&'&;M*V]_K=?0%CO"X R\*-5U^H50"$R=.GK/S5>(\4;$'E<\66.NF9L ML8\'BZU_P-:9(_HE,>MN#-NC MMQT1-BI'31F_G\N)>LXAZE<:_HB)2I ?"3.V$1S4]!9/72>(P-E@%8?]!-N+ MEP*K]&X&>1+=)T^B^V-S8:,7/NQ*06@M&>*'D9-\W@G1)-.%X6Z8"P;2#-FI M+:1$*LB@U1Z?J[-$\UVRS?207/]4[H:BZ:5.?'),-Z>45L-PTU,*HB8I=$7\ M;'#%CF80:H'$!ZPF/$GPL@:)N0U&KFO?GJ\F4G_?5[#/V#K!/2_R6"63,1F5+)^6T3F73 M3_&M:WH(IHS3[Y) M? SQ#7-IK=60;[IV:MZ[G.B\\F]19;X:E-KLLG#VEL% MR2?G*\VAN/-_?:17 "ZUDG\QW-#PUM.?>+K H0]':OH3]HGHXR-E8)1TK:=[ M&TP?\<[&>T.[A:^J7LS)M*+=F'<&RNH=&A:"O4XE&IR$ (S>8%/3]=VU ]&G M:$1 :J%!_#R1'C4I!7K'KD4-.F,IL:V:F5_9SJ3SR^Q,-E!J9Z:DW@T.O0 A M-]< $]RA,J#KHJ$>=/DQJRGN([W[V]BW=6&K2@/$LXH>L^UQ2F2IN4!6Z,3. M4BFIQMW\OX%)M= W>3C>B;Q/4.=L2E\U:(!-N)&]TO/'%)H[TCA/0G7M.89, MN9Q!76WSD2!A(MG^I89-LC%IC-.$O:V_H97*^R5R%]B'#M(U2*>LL88 M=FCZI&*N(F--&R7"Y8M=>E)FP8X5U:GQMC3MMM-$_9D%1HR)AWDK;BH5I0]&*3_ M(Q::*8&BLF#&UD.3]V6%YEUXT$G3#2?3E8"]SW)H1EYI8PS&FD.[Z@IT-&'O MOQRT?FBD PY[A66XX"IJV\18?JAZN:Z&8^RI%&X/JS[=^)["Y=+PUIOWX?:^ MWA#)W@6IL5%?M:F[T,-/DL*A?5()]K_ B?0,9^Q:8VL):QUU17]!&X;R5^D( M E1!&PG#@FA< "Y78)TY>$6DF31E7.!4T'7KPD%"2=_Z.X*UO?< )0=%)8#Z M0XNJ(J8<)$1KF@K!U-LX0[ ,KYD2P9TDT.@%@JHEN&) 5>R.+>9%QJ:X%"H MHD5AUU!(W&HA\5#B.)0X#B6.0XGC_CJT41O4>N)M)VJ#.E!(V'1M$(=UTZ5J M1"6E5&(&KC;5C+JP3Z#^L^4HA1XROO!2RGBEC\0O*D;CN:B7TYY1J,;_C$R; M&J].\M/$ZZ_(^/Q-6-#KQSB@OVX2Y@"G1S?AP<'5M_!FIYSROPZK450KT2G? M72\)KQ1&8>Y1,)E=^X&]) ]DIU*9+M9$-4]FD:IV=V.KF^@-@13%7NN,D&E# M1B>B;>US2Y>'N>ZQ^T*3+2C^_A0'M!8U^9X\#'V/@]]1P(*/FZP,\@Q?0IS0 M TFJ,5/J_:Z;)BT8.T0^ALC'$/D8(A]#Y&.(? R1CR'R,40^ALC'$/D8(A]: M.*8:O/7HX_CO'7-S[NK=]B;&:=R[1]@,[!>@H8F<>*ZI.N&5XZ-([;-D9>6# MCVBUB:W6\SB[5NAJ?=OBK>PD3MI:ED8WC+N].MLE?AU9(&&DN[U&PJ6".JR1 M,-+=7J/$].K(\HC@J_@)4@'E*?*H=AM8=7M/9_1DT&'K9J#5;3YOJS,]F+R+ M4[04E0/G+XV2U4 9P'08G\,T>19XUZZNX9P*S4.K0^KWI*YU$$'7@M:2# M(N'UP;W,THK'C;'[T#J0MN%'9@]\'EHK7+TB(5UZ2+%KZR#=$/7T\T'W]]4C MPLX68[#AV\U'8>]1MMTDH+^:6609^/.!]4^@)!G/"I,H\Z?K$F^.F^,D.:VI"FU@\.#VEJ0YI:2VEJM);U\>E[ MY72U74!:[)6K*"A@$:EMUVJ"W,-(IH#JF&NL3_)?(,]@)!;D11NV%)4I"3&1KT*HIH/8(B##G'0(0XZQ$&'..@0!QWBH$,< M=(B##G'0;K"LQ+#MU6,1=;!*ZKJBS=/9.G)1[/ZJSJC,$N\%XU;;T4,N M%9I2[YZO(ZH')07(@'XP@LNRWT>G@7JQ2.%+891QC>GA7AKM^ M2AUB;C3Y 6KM@K_'FSR=O3R>6 "J*8WEPJ.CG$PI!H65L$+X*.,L%;["]&]& MR87,M^1A2C&M;&]-=!=_[+P<4FO:)#XEE%/[.(XJ:Y#R"93M(9].*)5ND<_Z5>"^5!\$&7O M7B]PUA\TA,X@M3<'<' G(Z?'$@R[4*2:28MOA>DZ(!_[=( '_WX9KP25PK_7LD8U!AND9M'$+?M04WA M]DB.MAAF6T,:Q8MW[^T,D-)V=]AP07)O5-5:5M65@5$B]XF^ 0/ IXAX+[8) MIL!D=F.[ADL\$:D['I'P?O97XN*KWGE5<"IC?E%YEPM";A?:<[AQ/X %N@3K MC@2/#,>_=4WLK; '@M42W8Z\\,JY[QOMCVD J3LT-YQH%MZ5SARF8G=.7I W=AP-ED%I)!NJO-/_+L%= MJ)(1:&1T]NO:4!(33LA^WPD+K#@TGB[4%@WL,T;H;V+))D1@_KP.Q@[]C[V8 M"T$V%X>UKM-_@XB['WESJMA3G&U;GDUPH7)"7<*>UB^TC6R2_,Q*1KC^O<1K MVA?E*;,)4\[;-AGK9 IOLG1"_;NV?9.-G85-XGI":>M&5&.4-EZBP'C81P'2 M;.%,PKL/O9,S_'58"1,^ZF^Q"C*AM&8NH;T#W<8;M\JR2AX3!GWNW0DIJGYE M9/=1J%:M5XZY_KMN&WV+2/K%$DV-5U1CZR(QH'IU+^+$74%*Z)UM/-L.[)@; M#.:+B3R8V 7$'K!/T2*/(8&MYT59C"G>%.>'"H&52OX'8)<> MY=PFE8 ^?( MQEL!I)G(;)" MPJ!5T/O=]9")YZ[]#XI8).W%RK-S04CMLGL43%:(++L[O\.^3WES$_%F[+JA MX3#U3>Q:KI<$$\#]_:K9[+:Z:1![;%KW0'F$09PX2,NDXG;!*4B MT]5.ZQ6(91_D>/-D-M++78 M.?$G[G=?J$A#!*I"7PK=).7%:-H$C'#1-^HXP*GK)%%+/[^$GJV;]FF7.EL*2@EZ[39%9J=VVJEVLFM]0FZ\(S3ARB7,BNUN?MFV9HYKDS ML8I-?2N]F^%!YM6Y"Y6^O!9-)8^*-I6\-3"BFL>,<4)?E=#0"=EVB;(BX4ZK MB&J><<:$7LA+D1 '([W[LE$LA,4H[[XPK"$2V87:^CK8(1)_9CSI_N&H)_N@ M"Y7K I(R-YM$GQ+N9NR#LFP@1G^G[2/QM*^$\ ^], 6$$O48[=PIUVVDFSXB MAS3Z>C"\8)TNS*\O][3"#'HEHLH0HNQQ@&\H6&#KUGT!\X2V'(R5#;/C1 (S M D#[UHZZ^HJD-XIX5"]KM&JLT]O[8IW^1C3")P)5210_>4F<#S/AOL62$[2X MPOLZ3WY=[UJ*80J3B"NO6,_#G_4<&"PG"70,GA:$$25$9PYCNAA4+%!W\HUF M.Q!=E)$U G85B[UQWYK;N$"0TZZ]>J3:+7-4*2%J4U M J2DV'\DO1E?22\0$@<0,0Y* $G=&+9A1BU'B,>!K-(4>?QOK9<#J@$_0C*( MN,@7&!=IBUW%9*"JK2397=Q-^?4&RWHVS"Y,%112))@OB_1K$'J_-GN\W#V9 M@"(2 P0$M1F%'@S.&:V"AW#0Z9J!,3B&;2K"OKVA>;R")Q[T$1E#Y0H2JW.0L#4=]'/@R)]\?\8.4!^J-/]*]C\E?Z M94/X[,?EF >[Y*=-O;#X%%UJ?T%X#J;1@MCZ_#N@!$#W<);-IGJQ[04]Z(P9^LKWNIB1%?M@].O; M*;:A_C/W>/EX?[O_^-EA\ S3+,8)__QNW??OOT=@,D*K^-D M^Q^_.V1G4;:*X]^!+(^2=81P O_C=Z\P^]W_^,__\__X]__K[ QX:7,?);X]1!L$%7AUV,,G!&7C*\_V/WWWW MY;.,DP.N2$>_;M"N^^ V=G!>GS%$;T#^ BRB%@__,C>/_V_;NSM^_/ MWOWQX?W;']__ZX]OWW_[[MV[/_SQ[1__G[=O?WS[5B+P,Q\6D/[G1_"';]]^ M^^[;/_SQG?3!VVCU6[2%X.I"^N#;?UV]C]ZOOO^>_.=?WL%_BS;OUG_XMS_\ MV[_]\?WWF[?O_R!+BO>O:;Q]RL$WJ]\S$,8P4Y *=GZ#_.BL^=D9_=?;N_=GW[[Y]R=:_ M(]H @.LCQ0C>P0V@__U\=]7)\X?OZ">^2^"6&,[Z.GJ$B,C,2#RE<-/^/92F MM:]1.7Z@+='1"O?68MZ W.WTC8)NA;X%J8Q7E\F MCI7<3M:/\/=YE#K6>A=AUP-X(/$-NA7]F*1SH7$>(<="'Y%T*+2!;>3'T6/W^WAC$?$_FA.1+RJ[]<)GFK[\75U,^GDZHY*?Z.H))F>?[U6)_04]-LPCA1D^I&RZ5=9H7KGO M?W(V0/ !C!$@G/[]NTJ@8_D7Z:HF192N"@'(CP,RB$]\M\)DF;#/SY!L])L4 M[WJU*=CB02U]Y]XZSC%9 R\>,\)LE:M:1>-+9M90(^+&"KC:_Y-1!K\6M/_W M],"W:QEW*L(#T,4^Y"K9X'3'UJX/T2."JIAW?]\,_BYZ[N-!N0.36(%?&;, M3&,0%ZRBKQ Q0#;J;S%YM1F=_J9I_^+7?R$KTQQ262[_=J Q%N_V9&.?Y-F" MS/@JCJ!(2!\-)<(>IDK&!51LIO4'/9RPEMJ"QD2X2LD)' %#IC/";6R':8SX M N^B.-%QE X"YF"T$O3O&&'X13\<6$E+0:H>M6L=_,J9C&WV1( =3NYSO/KM M$]P]PE3'Y%N^;*[S(V+N39VS !GE 7[E7"9>%PWC@ =5%)S.44W=]XKJ]F+? MOT1I&B6YOFTWOFBNXQHASS;]A?/* C/N=A!PKXZ"4K@P:$'9S)9=;&.OXP1> MD763T@I^F(:SK51)*!C$/7 M"?AW[/1+:7@T4#I3V^0[8K&G;H(1JE(3Y\N(V1YP4Y3:W1#9>/+=BY>(^8Q>'(^ M@#!BZ433FVT_%'A02\&IO1EBE37NTK _QMDJ0G^&4?J1_$9[*7ST=3LM-\BY MT?,S3!_QL8%S7H R XQ;.";>!0I6T%: #0-74/S[DV=>YF%L=<(N-"V1-!C M/!=*%T$F2(-O@Z;5Y(\T%B0,'6:OAH +PW]((YJ6?/^Z>\1(U=@;7S+3;(V( M>Z,6Y &G/[T9MRL:=^HB&*4B/7VZ2RN[@]N8)JXD^4VT4UY0MW_7)JFL3LM; M3EG%!E ^TUML+PIX2$.A:1R9*WO:],.ZX!J9ATY2^ YI6EOR:6YON[]OF-C7 M0<_#-0_G5%N(AK/1'<0%J^@K1 R0C?K=33Z_0(3^.\%?DGL893B!ZZLL.ZA= M:"H0L0F.'42]S4N4W]EOE"$H. +.%!)P6D=&2K:CKL97;91;(^7-H!D74+ )Q9S;$< #Z@E,V\A(T>[,^'X7(?3A MD,4)S#1C<^.K-HJMD?)FQHP+*-B$8L;M". !]02F;62D:'=F?+F#Z9:L:WY* M\9?\B::Q1XEF5.X@8:/H5I+>S+O@!C@[(/B%8N?]$&%%O04*![)#PJ$CO#RD M49+%- ^2WY-I>D'+]ZUT?D3/G_V_@(J7N"0,QOB[8<$JZ@H1 F2A?8<+F">( MD%' KW_3:D*5*/E;O5 FH07U5NWC?MV$I6EDHF2'QX75DZ?[IX@,8'G(6>4S M,GUH'AKV4K(ZI^JA["/!K#BTDMYKO0&<,Y!8A^(#2A!B/86?JQ$D+)G=> M='MX1/'J(\*1B5-Z/0ONHF&CYG::WNQ:8D=OL*/BNB(4&Q^ ":NJ+E1(D"4:+ASB M'JX.*6'_[OWC0YRK%T[14;I^/U-A-P'M.;;Z?6C^XQ9:V$I.'C&\Q!Y;I< M0:]PNL_?/BGB=XT.2IV03O-9,BA\@9;=XZR'M<5DM<7W#,G[(^B,%@C>@ MS$-Q #4LN>Z6& JTU*!RYTX/TL+ @6T3<.<9BO28CR,1_KN,$OM-SBE8"-IIO(>C- M&023-\4/M,<*!,LDF.FC#QZLI+4@H4!M*-1 >#>-\;^W-?[WKC7^?F3C?_B" MPS7^]ZK&_]Z'\3N"8MCXWX]H_.?DQV7Z@+\H%>'M_;H#;5?D_)L]Y46W#91; M8";? DJ;P3>U%2 [<;.5+\<4KUS6V=[CV5ZF^+G.%EI;J.[:#A0>H.F?],O MM\P%R\#LOPNH-B=H55ZHH+2[ X=CJ0*'H?\OWNL?++53<*#Z&D7_ MWL#9 <(OJ*.C7H#:/*%%;6&"T>X%RC XJ7! !YC"2,?JZ]\Q?$4OT?!0O8#I MDY /Q)!;M8R[-!&*1I&>,EV8(^W]B6Z?<*)Y1W7\/3,E-NFX-TW& 3 6P1PX M=FH=]VDE) TC?>6ZK)NW2))#A/CC:U63;?^N79DVF9;'0GF>0K+HI:YW:ZGT4S!3>3=&]T5^=?[P#@AF0N 52 MA%T!'JRFM#"A$-9/V1B@X#+>9U5J EQ_>+V#&YA"@LT#?,D_$$Z_Z4X "@3M MXM$@ W]31 9DWN"15E,4W,&OE#]@ @34)T8=7FRDY5E B7I1_*"/8L,!GW_+ M7YB/O7LO/(S^YB^W*=Q'\?JY.'-([0(EF37Z_$K^[SP_KU'&>Y4G4. M Z+Z\&@S<0/16F##PM_O_E,( IV(*8?HR3*%F17S V-V2\ZL^6K,@; M&JH9.R\F6X@"]ORA&1;",*/%5!RP*>3A)@N24J(0K-?2,K #2(8;M!?+' ?= MJI<;(4R$;C'?>ASUDN\Q=SUZ#OHD]]#WU"YYN0$E2U#P!+\67 /I^*@%:%MW MZT'%CF&6BRR#>69B@,UOFIM:G9*'5E^,?AA6TZ%OW*^-L'2+9+4J^:5'TQ4O M2S^O,H>R*K&OH? MVF#].4)T:[G(SZ,T?24+G)\C=%"Z5M$5_@!7G,/Q% M#T=LI,Y98(8DN A+P'Z0F()%#@JV@/$=>YYYCF+""\&/.+TG,HF'M#$LXHW6 MG#-,S"(*#A'W\(3[":?Y&?G-#L3),\QR?M+US__T;^_?O?L3B J)P :G((OZ MWL^/.ELI8XJUU1L\?L6,5F)#V '*#U0,U>JEA'FH)]NG_HG>'$>,ZH,M. /& MFD55B3E@W,%Y_V"]A%(AX.7+'B89+ YG:HLWG6"J1,[<'17(^S-8R+EFTCG> MJK;N#R.0ZB"*#50[ _0:SB<8,J]C+$%]ZS#E+MEX=^QL;^;(87 >(>$P#_3G M('UCT NQX@9*[X7L+N M)PC&X QOS@XDR(1D[FI(82W%!8V*<(^2$V"L .-%+S$^TUF LK-?4DYYX5C+ M2-&^;9SWV%%CV**:9R&$-,F7-36NTL?IF'ND%TT M?1@IYQ1&6!S$ ZOJ*%3=H[K:B_7N9![ ^>NO=>U77[Y6MR%-\PWM'BUGW:QC M/2Q@1[;"ZSAZC!$[3".S!*MD_H31FL0I>KB=OYK<6*K3-->_*@\/[]0JSFP] MD4F\V8'R'__$[G&F+G!KC# VU?),GEZP6*UHO4AL]OHE5X-F9P;=E"P6!&T M4O20)R;X@#UG%(8W#"""U?04IO910_&"QU1'C>R"8+5*#W!][/M:9XT#E"R. MM7HIN_<)?K@1<8;R7!&&4?B?I M45B0*+1,+B&8OZ'1.U*R-P,/V*P'C-FA"?LRW+'?XN4KW?U>"#W>'HWXO[NP$>Z]0[JEOLV%2F+3"KM1\&M M7[=ZB]$DY^7EC,C29(DC;\#__?;;M^1_WH%]E()GRO1'\.[M&_(K^K\@>XI2 MFFERR)]P&O^=?"_*P05<05K$%WS_[@V@NF6ST?NW[W[X$TAP\9TXR^BA.TMZ M/>193GY@2;!]WP_#)_OL BL %J -H";\C,$D3X7I-$D[.YJXW/%W[98%,BT_ MZS6<]'G:]V\M7.V/W[]Y_^X/;W[XE[>F+O?']V_^Y=WW;_[U[7MM"J'X:J@;QG/X@2L.-LP/$(#/ZROR?"Q0D!5K[<]4J)D#-DS=2WI9P0.L.9,PO$H#.*ROPO!! M$EY5L ,%/R C=C&$F*]TS$("EN]#W'N?PB>89/$SI.6$=_ :9UEWX9#%^J\' M7I3E!N;+S4/THC7#^6!OE8KH6AR_;B[J-LAB@IC)";Y!1-) SC-]6AD> ;X3 MM"AT;$P\X:\F(> B BHCZ*_G4PD*B*3T>3*1=?*36[L36[>'@KZN[$)_QM2# M2N_QK/MC6=_'L8&] #2\H>Z@Y>^-V AWV2?QWF_@_KM'MZ%CUY+BT?&N;])K MCMLH7::LOO::G2[=PO2>GOV9WWQT4W1U$-[%883[D?*P-@SWTL2R\[:B7Z/S MP*WC3H,PI;VJ.5M^@@H(8\ X3^IZ3()L41[PF[O<,257D#4IC^!B1Q R MLO;"Q:7?5:X&$!G-39;5+:ZMK]1(N05&(CV>UT@7W.&Z3AM^ _YSI,S L>KW MI*4*2KX355QLFI3(.4E*&&^[5,]P"6ROI(-?>[:(KUW2:%BUY92$M#^2%&&S M.>HEXP0F_]NBNBL%NB=2P:O=E5SOAKQCT^8Z4^^#C@:MOPGJ).$0"E_;GU87 M"6GO,X1/GVNXV?5XQ:+')2;9[QP-UG"STT_'(1A>MSFMWA'<'D<)LSX_<;B[ M\8]/C\>8[&LZ^D8O=K3HP=]9L^.R8:HH]LUOG![2*,FB%?V >CMS7;*&?:+U MV'CI#RV+0(M)-)M!\PM6D$MRA- 5VA!W;*'X,=KM\GR=L@6PRK=_!#!*8://A"^+)"._I#"ODTIO#>@G9!+@>PC[F M)T%#@QJHT#1(B5?A02-[S4\P(2Y,F\PNUKLXB:GO MYO$S-/";05+F\ R0=N\[@B%SG:C&,@SO484-:^HP<(A0'1WJ0G5N$WG1T6QK MM1)S.N_[2L''1^NO,#RC&XJ^99?SY9;G9=94]ET];#.RQA M'#6MPM)Q$IJ%MX#19N--+06H^",[EUXG3M'*XP8GN#[6HAFXR4Y;D:)E[XA! M#KY:?!3/DL4\\/M0]N%Z0#8;?2BJ=6C]>"NL'[@ TW@ MEB9P"?L!++B-T09 MV^EX7H@*/Z6L:\5+CDN;E'A3 <+;8KC;6OA;G7H[5)(V% '-A(J *6\A_&X= MQMTRC.P[9(HU.X-J?-%<^35"[AV!EEA"O3%I3,MO5S?NU490JD655B<^4^HH M$%84_[J%:8S7Y/K%]-ABCY?2*]NEY=%+ M2(=7;BRF.2LYP&;^UE&;W;H+XU7U[@"7"A1B@4*NZ1)>NG3Y.4G%"O>_,**Y M:L5">YE(B_(TSLB?+L@_DRT?FTF93W\RN+ M)&6.S0!I]S,L8\ 38#D+MM2G;@/V)$YF_=4=QG0@50"QIC8#!TLX4UDXOZRY M 3AT+$N6,QS9HWZ!\?:)L%T\PS3:PIL#[?.SW##AI&>J%HYFRL$<4C..[MVR MD.,LXH(4#[,/]$%-CME6G7 &C[-Q7TMKP6XPFJ=EH+I1 "$#X$+0^91'!$D. MB^C0\5RIT_4;_<[1%^A; (B7!-%P)D%Q8DJ\"55[#QCFXM_06XW["Q<#P$*. MP(Q9 _06FU55NTO39(7=7%MF!U&WAMG*9&R[9'4,9V66_8 /6&6/SL>HU5"6 MB2#KL.&&V$I]<)0(VC1F46#@N%=+416$+A,-^VB/N5'0 Q4;Z794XWR@V55& M5BB^Z<#<&"7WVU2IY SC$)H)U57?9BN28L)2\Y'[#FIXS+:^GUA39QVC'B#D MO$$L)^RUCR_E=R8UB/V5\PS$"=20&^[E*RLR:)10*T! "Z!1NO?J.T\7!7<- M8+VYRW&?U\#\9 "=GK:\;CS#)Q+")8[;[T[D"0H]00UF%G6B7KN9CN%"/=D+ MWURSW)BPG$L?<+VFMHXFIW'!15JX3N2JY<+SFD2.*_*C5C)YV[<=K*]+:EZW M,I0+8&P"\:(>+-KV- TMA:?WX[V-DLI':IQ,_(Z7,+RE#XAQLLCS-'X\Y'3[ M]8!O"%RT]"%&B+TKX:\>]7S##4>7[8%-)'!C"_S@E)A"FIX;)CAK)3?L=>7F#SII3B9OV MVQ1OTVAW1^O@9W$.[V'Z'*\@OSJZ@RN\36+5G)#)1;0Y^II$9/=+Y,LRE83* MV,S;8\"R['0-<(/4?#94HM,6EY+* T>M$&3PP' MB/& T:Z\GU+-\@+&+"SW-OHL/92P(C*P)3/>4-@@5@NFX<%@.3520JV2-[#:TD>IM',!6AAS2.$"LMK;(2 MUJ/GI$=N)_U1FN,FY#\KPAZL!'^04P%XH?$0WL?H@MO>#W= R49/MT MGM8=?02\W'S.(.VPF,OLE0U/@Z*AZ2ES\&)\59\,Q$J0I90_M<(#^4=$10"1 M)$,(YJT#1R&F: M)6&ODGI(OXZCQQB1/:6R7VA0-#1]90Y>K+NL5KLNJM72#A>-U2,J1 C!=O4Q MQF::-K+ VQ2O(%QGM$5\>?Q&M^&?Z=5&>V((,9!%LC:N.>&2I:$-NQ/!BY$7 MXO%#UZRL7L&.1]KOG(HL%WKYQ,J+!5G2PH.U84^0&GG3YV0?Q>L+N(%I2N<3 M,F%$Z/;PB.+5,.7IQ#2X-B?Y<'!+]F3S$ M :A N)F LTFN.%X #V!H+=P&*X+5S!^)DU/B)#*AQFN1$>I+,U'")DO#WL M)^QIBU@PY0&["+GT_$J$X2",3QD^K*7-D0L'T=/:CPA_R2SK!;70<5(FZ(BN MO^I E!5@O$(N"M0-6'LMH X%CF%F-S"GW,E:XCE>P_6'U\\9C:WELGNQRN-G M?O=J8'PFU*U:#VER2>QCV:H$\MM?Y_%!&U54Z [D0 M 'QX!50$FJI?';E74DS77(9(N(ESW29K\K?,4:JH3)7-,)8?M6@9=^LA'(T* M>^9DI^BH5GN]0Y^BD!4[@K5,F ?L<7+RP]_1:R9'\O@H+E:]5\HQ2 LYJZKN MY+?T9Y9)P8K!U\XK0YL&O5IAUQ,[I^B>HL6A8V-[P* 4$31Z0=(_SF12KJY1 MN/SUW)S;%.[BPTXGC"D2M.G3KL# 0Z!I9&=5%W1@SWD&$D'T$,5&BIT%>L)I M*XZ%B]:@)+MXP=4^?;H^F/JI'T]-?4BC)*-S#G:5+=%GHXWS5]<#])P>V3>R M!"=GG;F1,QLG:ADBL4K"E4\B!5_ &(/S_B'Z*])BU)EDB()E/1%/3Y3K9<[: M7VF'$>V'^WJHZ"M,%(H35^T7WX&FW/8%-)9O>X8W9V6^K8,P-O+X!%[5 I>Q M!8POC6B$,V"L:S.PZV'Z26:M/=%J)*[RM"[>9JPS$V8>PVR',"N+@P'!S7XT M_O-(91-%T(AA]F,8RPP#I+&YKN>#:KG'%+F0!=_Z04]937^Z4YZF M6LB>5TY?$6&]2%AAL[36-8TI!Y=0JW#T4=!)\"V6 ]R',:M/O3H029)<:44W MG2]K&4.O7ZM#,#/@%?R],(-"C&*MQ%J*\G+E"T<+^R!>/[3ZPJ+QY('7,F/G MI>4;")K31#Y"5F&[**?"O=8/5$]%08WF[OQ9"#&40D?EHKH0B]X;5(*!2C) M12/6 ZY4E#32%$*&@0]$D-OH5;=?EP(QE_&A0=Q+PPG& .PYAU #?1=DO3&] M57O!P],7J4NX;H?@&L^5:$2XKM;]UMYT1,\Q8@WZ7GR*1R&-1VZ+R45X/CW+BM%^=N*A#=8P$ M4$>VB?,("=N\F4]BDP'$1GF]X^7S3IO'&X:'\OV(K\3\7NK.(>[AYC\Q/RZ8 MS\5Q59 ?=N!!G<\/916'+H4((@>0[(**I@6KOQWB%&K6 U&C8Y%JWD/7RWFN M>)Z<:1U+C9;@KX(6UM%>D,@TG@4(1JPG!6ZN$?X(*&Y:G&5M+BQ6;(S,XB.KQ?2$$/K(@<0!($$$D,VEBJ7B^' M5EJSYY3'35W-TU-9^Q%)?2YAHG7WVJ7:HL+L9,9HLL>B/=YE.;RR7=;L ./ N:M'8U[?)*?JRN19-URR+_(LY6 M"&>'%)K<"MKSLG,2&]X>ZB0=]GO$*HA'"*Q+AK5J7=+U?^W.(I?*HH434IW8 M$7:-V=QM1HZM5!H@Q)&S"(AQM%Y!5C(IU]N?08<5V8N:[57:VJKPT@+.B_M- MK 544T#YB%[( <2E9R&)]*B^LI2!^S5518S3PZ1>GFBX@5D;+--ME(BJ8^=DIL$H7K-_$%NZ)4,M&LJ4I3LC5';%,$H;W^L-M%*2L'(XD.*ME!(?P)>+Z- MQ;L*$L;6\K59M\/I2]K$T.\,&#KXE8X$L*%,UQP@NX"/.9&65S&O"A.9U7=4 MI^JBT/P0%T_5Y@G0A"^#F'.6ZSF%MH0Q0+JU*6VRE6-%AW^9'#B%TYE\E%FN7*E.&DOC!:<]_BQM79? M\X#?J=I52W2^2JH +=G6<:QFKQ&YL$!(*PHYULXCIYNF/T9QRE*0*W&,)N9^ M.N:FT4?7*;R4$>#)V!*KX"9;);RPCO[&F%#;I#":%0<(N;4SC_.39&U87NI? M)02:0T"/U-60&S X9Q/%""@-A(/I(C5]U!X]8EK,Z1DNZ"$X/PFQ7&=JD;6X M/U1GXZ$ \4DQ55\YOFV-0I.56_:/$2VBJI0^NX7R=CK(0X MW^7F&I)= +2,W0K$;*VFA[B'H_]FZZ SW@"*]K8J&T#QVCZ-FJ-@^8A(4 \H M"4@=Z".K'-1Y\*#6H\-R SB_0&(RWZ:;Q.3F-\V!J%-RJG5Q"A%:3.[0.N[7 MR1@QF;U_I ]L22CB,MS@W#8V:Q"UZ*"HRL13:TO!FE_&BN.O,*Q-'U-LK-;9 MX(>.H2O.+"G?0,)S)<5R(S]O%Z_B6:(>>P+/^JH6C^9-PKDM)W/@[3@[M08) M=#)1R\*4=0B8.*"2!Y25"D*;9!S9#G:+U!B3F+*<'V0YC:8V:U8C^$T[:U\= MGG5K<03G#@-&8>(/?0C,W ",(JL M@R3TX1H@Z0:&-5ZQJQ)>3>@_!;MOIW4]53RPHI+&F#N*G'KZ$)">MV3U5:C) MTDJ9I'DH4&3AU.4+GOSA)N-ZO'0.;$VDBRXV5'&@44*>K8 MF9 MT0NR'7R(7NQB0R\9JQ9F761==\,B?%AEMH"]7@4KK*&\]!X/)RKY>C1YAFT0R#4:.4\E*SJ*+D,0[Y*6^ M&>C82N=C3#5*8ADFO>I1]FS.'N<I75[ X=/NUP^O;#X]:]Q M54@97M0,D_9RK5NP!>N*;PAWO!J@84T-!@Z0')L>GB#+?(B2@<3/D 8@G+JT M+(D?KYWR.N4"ZD.4Q=ERTRA+\VH0$70IFD=A-0[NS8_QI4]HY>HY84R/FC!B M,V7. S(DH[7<'-4J>K5RNXY9]2[.?J,[M,\$*E:!@59D,)U7U8@9!FX5XE[F M5L:8G0L<9-8A3*]:Z&%M10:/5.WB@,%$-_PUO@ZJNHXV'-0[D@!FW<^TFNUE MEL>[*-=K*-;\IGE(KE/R4"":5P4N.80Q479H'O?K)2PMHTK!2R4%>[J;7:$H MRUA%0'8KI7<#>_1EFPNZ!C$O=:_K+,*PYFX,\*!Z@M,WTE:UM\8<]*B]T4W* M?$.D2-"N7<(@ P^W/45?%;U&,F,VQE#'$1NIJFZK?2I*+YRA&E.W9!J=G]P2K,/Q* 2NLKKUP<1%NTUK-4[C, MZ/DV!)PD3_D;-+*Y.4_A.L[I3WKY"#UD;&ZJ.\GZR#20F-%M!F<&*+1UJ?::O3,05*A[Z/-/61-C,[) MMVE9.O"0TL*0$:\0ORI^>Y\?UJ\J38O& I/ [SA!0CN()L(-C M;E<%R&@E)EZ9R<+Y>LG8U*?J).O>U3B;,-Q'!1:LH:> (4"%]EE),%$C;'K' M*+K&G3]%Z=;*-X8H650_Z*7LWD/*3GI:??)&JVZAAAC6TU_8Z* &,()7 /YS M!Y]A065 '26R@TAF@AAJ +=H!TSTB[,@KNHUR M0E3:2>IG$_61,,Q,Z2;I)7.(L^/MH\&>,0PA:T@!&ZRHL$!QJ)T5<1 B6[ERMHP%IO.;AH.:M9XGQD"KAVDL%?L MUU.H^D=-U0D>[AENY^[N >IT[>9"D2M%@M MJ##PL/CC; .9=?1@PT;:FP5$J(8.*%F&2R@,#G1UM3P8[P MF:E9H(9%T!86(Q8UM-3>V!\9)\TKR\CG" M1YS2QPCF"R,]NC89,NI\?-11VNVB])6&$_E5Q[EXVT8L8"&_\?@HWGA(MA)& MK#&R FR#PIP0+S.D'G/9RTO6@/ &#-?)US-E.WO>V):LM8J&MD3B3S"BI?S6 MR^2.CB(E48A\X 8G:?%/5D[#W.E]<# T@5%S Y&7E9T1^9(1(9,GR M]!#0$8A'(\/^X3L]@Q+QJ3*@HJTUW6I)(H)"1K"D_<2$6.Q3LIR %]69/):Q M/&YZJ6\>D#I)6/:[/B;I=ZM3]BP_]/4L#V8Y,81R9:V=<+NB M[V(H/F=N 4?/@ Q4/T.T2S]FSX9* 1I1]144,DSOYHLO4;I^( ->O,1:I7@: M7S0'JT;(O=,Q\H#2#\.KVA6.>_41E')14Z_@5TH\C)S(!6U%N(4LBGYX/6JR MRX2N=)*L:0+83;2#%W@7Q8E]TJ0M?]>)=W;RG+XW>K6BP4Q,%^B")TUY&J]RN&8)R)_@[A&F.F&G M@X#5 YAC@EX>*@DV(*-\P*^<4R =)_IQP4KJ"A(#=*3^>T7UCV'_GY,XS^[N M/UO[09.0,RSJA$?PBP-E&+9W=*#6[25M2@P:H2ZO8;S ';@'GZ?R("DK9[=' M^!7">Y@^QRO8,9TCYD?L.EN\V/X[F]YDFZ3F6@@G^4INA?)Z2<,? M(CT>+W**!Z&5;&$$ _\&V)[ZY@/3DS6VMO0Y(2<0@H+NY74I+/U>)2[@\HIG MD4'DV'VFETQ"/'D,5,0;S!(H(-^N6%Q".V'GPM2,V?L]RY;%&HQG;UAZG%3A M?4V3'38PIN?AV1OP^,JW:^03?/-&;Z5^@?2Z"J[/HF>81MM:\1%AE:$%1WO+ M; V#EB9P E;8$MIJ!E@S.G:75@K%+2J B^A*F>W31=L2EY^\K/+XV>KBS3EK M%R;E1!2_RS0J809^2J.$&A(-2GQ+4,@26OQQ:UBML<@A:B=F1"TQJG.UU;') M%.>70LCP0Q:3G3^RS_Q'*15N_FQJF+O_+6-9T&!6\4?#2C1"CBH>\[<(G< B MFTD6>"21;Y=D7=+D0[Z!SK+#CO_.;52QX>S6GLPE\;N]*S9?8"$V7Y(<@+8G MW1([BLBFCWR)T,F*R'1+9C7ZQT]X#5&XXMUY<^P_5'G/*4O2O".2*&IA^%C$D;5GG39^6E"I]X MFLUOMU(A"-C@%,1"B!"*\EE CBWU/3-XZ_U4^+-[AFTA!7N\)/);"T'L*_]- M-5RD.=*0UE=T.8@3FB6SW)1UI<0Y[ >8P$UL\1+"BHV+*4V;K=]EDE13J[BZ M^T:(\7NP*0HMQ\F!KHE$:G P'2%=V$SK*L@0I!G;1\OZII*$_JO%4(0X(<6. MR\T&TBTC+%5W%^60WKLDJQC%S'B=5+DQX./DVE:;K^<'637.[,%F_@3!YV_O MOP4?X9J$"]I0*O[H(+IHL7!B%%DN_(>4^WB:L'S(K95U.0:*X5I2\ M_G.TQ]F?,E!V:@FH%JNMG;1&"P-P9FH3+3%"1KGK/7= X8'OJ\0#R3MZGH"* M]Y%DVU5_W.\V.="[+TYJ<.Y:]4;$J'FKYMJ5/WT*61[D7(7!++;*:U+P/HL+X2 MPX=)A +.$M08 :;.+-2@,U/F%ZO6:)OA,ZCC#;JHO^Y_-LA?HX0JTR-:!8Q MG4:TPK8&58LPKLS%OU(\#5E)/D#H7;D#?C8C3359=666=ZL7@BX0HD0]%S. 1IB+%)EL>\BR/ MDC6MUF?@"_JTS2'3Y>6C=W>"=W$2C@\90XMMU3HW&(53'B4' ,U>MT?2$K<3#O6L>/;E;B3PNCBJN4)V!Y[8AK.JQ1UJ>"YK* M'LHY\V8:(?FEE/)U?WC\*USE#_@.[HD>GJ(,+M-SFF^%D/+IB@>FGFQ!1PA+ M8_F!&TL"MW3_()R?%C#\\?C5K?#]C(M$U(-$_J0S=]V= -- M+8E2" <>,*C$ \L4R ):Y8VJJ$M:G32Z&CF:4G$>H>/5+KL[>RQ[6JU%YYB$ M;'%0T3DFZ^\<$WCW(GJY8W8/ZX9S".UBJ"0>4SR<]HNAL@9RX>/)"+WT**H@ M/BV#:[GC'VRR3[%L#C9]B>6AR*R[8881O :P\[PB,"= ML$VA7G/2CFL?7CM#Y"05LMO59U;M>IB6:SOQ6H6Z':8WK#1PR&&DO\BTFB)# M!VK *\VJ-P\_]&W9*ZM7I=4@9O_:LY.X_^>[K2<_@3W?'0:RY<'N@$Z#!ZWE M46X/8HKEA<,:(JJ-KN\,::+*O&4AT*JH@GY=ZQXBYH&[DZ@;9)YA^HC;S0^+ M&@UAU;,>1@HK*R]85(JTOK+LJUPU:B(7L=P27,<)O,KA;LP=M\1SLJU0*<-H M2V']0QTJ(V!"!N+DSFW-W:Z[@>>IV)7C_;2:2848IQ8[^@1AQ"!5,)S,DK@ MGL-35MD2+&PI3L J0JL#ORZD+PQ,[M)F%)<:MN4N*,D0GH0=.0Y'7+2Q.X>;ED.OU9^=3<1BWS?+J)>\JQI'@'Q;5R^(A@EK*RX8!%! M-3"(CU0/.@M&8\_2SU&,Z%WB1YS>1TB^(S!YQZE S2(N#E)W&_0*=NSI+658 MOXX([(6G.I!87Z7#+S[M3?$VQ2L(UQF=2Z@LRTVW=!?P4D]3Z)Z- 4\\4L6[/*E-1]VQP1*G M5^4+9]::6#,QJ^W;Y@@=4W/O8A6/@!IJ]X" A]43GL)1JZZG2>BIC_$\RN$6 MI_'?([.;1A5JKO!HH^[3(0)9$6H UNDYCJ.U ' 7-86@GZNJ+GC,"><@KL>KX?&:RDL"!10$?JOU54OR6D2]GOX[NL"E#Q8N_(P7-48 MW9X+6C7-S@U)U'GCWERDUG%F]7:F3IEHJ&BU.NP.K)#D3RG.LL])"B-$)?XI MBI,/D,PRM,N)0T]69>C-*-0$<#^-,VZ@8@9;"UW2/K(^6UGYN.M9;+_ M_^^!_)(^J7B&%W&V0C@[I&7QO?)3/Y'ODH7QPU.4+-/+OY'O/.!E O\,(_7* M"],(9U@48 IAO52&J.R0%C-LI.32AUF':C+9TB7JOI 4_*T:$%B7(P))^="C M^NB6CPKD9%B \('TN[2< 4X@>"5C"Z#ZQ*3.@2>WJ_X$^XZ TE@@-81O%UA> M1BD6,'+'R]#='?#VXKT7C1ONZ-B;N_P71-*ZD?XEA HP+NT)N\;.X E*EN;2 M:IG\J[E2)K_ZRQVQ/>5,U\87].VY1L##S18U3;)&79'X_@E&-!9-_\2O7ZT;I)/- R2P_ M12^T'ZF>83:^9*;"&A'WQBG(!Y)=TZUJW*F-8-2*=#7JSCIYMUQ-ZZQ_R5"- M,A$/UBG: =DG:VJQIW:"$:M2%>C?O(^[J-BD4C72=5#DB/MNA@= MMU\,Y(I% 2:LKKAP(4$2&BW-,">JMWP'LSR-5V3CUS[^]M_J9PO;\3%'U8;O M5^>*3HP!NU3^G($O]@^E()V-<+.>OTPX>5HYO'-/'M-%H18 8\^62K[GQ:G\ M>TLH]J]ZBDH3#HI3U*-+"!U_<<30'%LG OBLH]9Y3\<+)@H1PG!3M^:#O:!T M$J8BPL91DM!QND$S2Z@01.KX5\HV@V C7=G07_L.-4?LQK6>!GOW8>9S/9S0 MOBIQLHZ?X_4A0NAUOE&ERTXL8THK("=@$P[BB9R@2/_BI!UH0*F: VX3%;E[ M]GTZYIMUI+F"J64J?,UZ0RK9@E?)T4."4D(@#014(VF;Y($8#:##H3U\V8!H M6Q8R)/#GP2RM6272=#@M-3RMJ6Y6@S8*YC5[JF>;D[],&LP]O.:IYUT?6X:; M:#YI!G(M/^()I_D9^ N[Y6MN M)2[E<&H_U7,CP$5CUS.2<$5^W9HL%T$I'_N4+"%_,1]<]7HO=H=]XCI&17P7 M4FM7U7;(=%H_]%25V[4GAE2ZV[W!.?9!)Z6_ S,N3Q%^DOKAI6H_O)8__E<, M4V*#3Z_7\)F8LF;"FRI%!^;0R\%](&&DP?O ;O0U$6SS;P4]S@.M8\_\\"H] M_ 8E7\"QG"1EKM2"], B.U9-H^6]CN>I$78 J0HCKQ-Z!2C-BKM9_!R83VI! MW.::ZAJ>%9S'CBKS;G?97[D D[GK5;(_Y!D+'._T\]EZR3C [IBLKPGP7:@3 M8 ] ;:[5I;& P3AV&\Z)3V^W,1 MIV#TNX@*,*.YR/=N7.1[/R[RO5\7^7X&+M($:,!%OO?G(D[!Z'<1%6!\'T6P M\Y1S>M5F+'EH).=''Y.\&,&TV=Z?,@ \ MP$<-#,)I$-;L;]C1Q^U-6Q]YQV/UUCVPWJFNWL'1<&#!9GYY=M6G*D!K\Y06HF1H?E+*F?BEIJO7,"8)HPK$ M+'*%AXA[B"=Q$B5L+HHXRJN(P$;3PLF2CIK ,Y7DQS!B@SJ26%NIP:.&I+UX M[6I9>MZEDEX[8I&Q%IWH^)H&4=?UKEJ8^*^Q\D;R.*FT>AB^IX_P8+FR3B7/ M!DTD =E:MJC530-]4J4U#2K3]/]R9JQ'4V^T7L>-.B_J(FSP(FJL=U#3O7X* M95GJ9#GJ94'CWM,>:"M5L&DL0@/QJD& 5%:9WE:7HZTJ;=L/7</32]=.T0_$!4, 20C9K\Q.35<>?'\A/&=DOT4(8VB_6?'!WT?+< ME30>%E92<_2:E$ 6LSA#6G5] LBBAO62S:-%8O]8GY[UH2D-ST_,.SQF\3J. MTE>ZGEUN[G.\^DTWOZR'B(4-=!'U$$CH4AYO &,1B.I?A[.H0X;UE1<^/$A"IG0>RI'^ M2^(Y58;3U>U2/ZE)^I(Y B41]WY 2 >6H'2L9MRIB6!4*FSW"MP"%7VVV&=6 M&&@&5]]N\?-W:QASVR0_-$V2_.HOUW ;(;+#C/-7U95.Z]?T==A"QL=3$L( M< [3&F:?LG&/-@)2+#K6JQLFK'J381+5S@*\V+7+LG.3XCC\25!M$GP%.E>S[0,:VW$C'6[JG M2!T$S%>JK01]9&!WG>]1J.1_+_,GF(*<5L:N?2F,[4,_@%A)KT&")7R'J\ M4]&="CO6R)^B).+T[^+M$RT_D.?%DQ[EA7$_$ &,L0 MUKU*,&%ES04+2;W_>XD'9P,^V M9_F%.TY QFZU8R8";3.SC]*SW%!W:8-GL+EVT2= Y?G4&?NI/-+V3 MOSD\'1_M0'W81=N4/PN$AQV4O^LP\,^.(Y9E A_B'62/_6GU'YH,^RE&D(B0 MP-OHE2V\/D4O\>ZP(_^D?U[L\$&M8YLM!\.3 &..7DYN: /.G(A#F[%5\H = M$8BZ+_GK7H@$=EPF^@OVF8A)%<(1C[V98#?@S-,DY,AM;0_VR_^)M8$J15 Q M0$T.0 4!3!)0B *$+$ ( Q8#BE!,P:#91>Y^5"%K::I-+04A]/_3I0FRG*,\@'F.[BA$4ZK>?KW00, M/;V+H)>07AW!YA6W8!ZM#X*#E70VQG/U#X*VMEIZYK81"Q' (TS@)EZQ MQ\WX2])G(U,$"B>FTQ(V["$Z!3-IAA1)(D!%JL48+E095<@/15R!4ORQ7X#[ M7>S)GD&I2ID#.YK252[Z@A^) *]:KDI<]+(&NFX\]NPB+-E>PRB#-P>:X;;< ML'^H'PSU$S$]I.XAZN=JHF ($&4"$L:2QE/V[R".<93@PLH:-#ID)&0KJIKJFR,,[UZ6"OZ8[SJV%(G"7-3 MZB#I*#;1HKTB-O$"OGS.0 4;@!]1O&4>'D@MWR&4L*+J D6D8^8KN8P<8.MC M_072;21<+Y[);[?P#M(B&,4?Z1;MG;FSJ-!VA=DP+_=3?\'S+.),05IP%3Y' M-^R#X@U( \0$F0DBN3.==FDUU1]:CXL#+F2NW MTO:$= NO$5QY+;B"=' Y'X0/]Z&MZL.=FIX;LJH^7 @ J 3%J?"D/DQV7_1A ME;FCE@1<828(^C_4@)Q1B+[61*73H6K*"A*!#M>X'%*^Q[U^Q^*[2!*^H*\Q M7O*'+Q ]PT\XR9^T'@J9\[ ]*]#GZ=[)B.)[%B7C'QQ88'UTL&"JW[GB6C\C MZMQ.5MGU%^Q%T4L.N"R "Q.HC_\91NG#%^S#M4O2_I$7K+PX\OMY.7(34 /_ MK6ES9N 9>2N5@'@K#M1'?3CG&,#Z.EG=Q0E[OL07L,7SKGFYJ8U_CN68TWED M2([X.2D.)>#Z\F5%\SJ57^Q:,O $<1=#2[Q_X'@G<$L+N%Y7L/\H7EJ"%.X) M19IJ+"47SL!O!TU U8G[-3\ON#7=6Y8"<#$&WYV&R&<1Z8Y ;4/"M, M^R>UDCG-G^/LZ6/+2P6$PPFO?7<"K;%U+@/K.&IOXL1NC@/89[@-JGXCJ>_P MB8?"YQNPAMDJC=FOPXVE9@'4?]0UQ3%_7G2M4XZX_7N&2]\&'2\K M7WZ'.]HWA:; MXQ=?HI35@5H]P64"]9M=:9&U*+NKSL;#H3GG &B-RK"Z39N BBVT.B, A=):LO'GF(3%[!SS&%0MQVQH=48 ZCFF M&K1JV_1;?'X>[6.:D'-]KMDXKO6[AAO-%EI>MN^$#Q",W@#"*H2-?!\&>$@_ MH>F[5H*JH6R'O=^\R8\*T4$I.[@F_T]%>,6*S+1YP2V1ZRF2.@QI^EX_$=/Z MRCU$_9119GT<]H)C59,I!*]4@@DK:RY82&IE>!D>!3NI*Y4[Q_4_(&0]%B]K MVCN(:!;=;93FKW(;M@^O\E]TS_ETJ)HOB-2YN+=)P0$P%F&L9 V@Q.;*G ]L MJ 6Q>LO!#Z^@_M=)#BOET>N?6+9]VPU&OLXN W>A[F/,+N6$I^Y6T]<^UNQ8 M,9Z3C\2K"-WGAW4,F_W6AY:*'=\V7)"T4O.R."PX@8RS"F%1V(\$'M91>%JO M-1P!,A9>L0U2G*SP54)\^C>Q(_QX2-;7\2ZFKR**C'%Z8!,E MKYK.:43;M'&*/B\_'9BH'"BA0?*W.ORD&>R M(8F(POC3@M='E@J$$-)S&"&&LZAS![?@^D1AXKTDI&H.(4QH'9$#!845N!@H"Z]3_-&7'1A#%; M).M[F#['*S)%+SR*BS]C_IGRZ[Y6N.MDLYQO'30.K%>#$<[!.84S(2 M$4=*P5A#U5(T^KRWU70 $Z_[SZY.\OFRG[>%N*-%5#.[S7PO):O-7P]ECYMW MT3 C96S#6H>K0X?U%!DV3,=[ MK-CVT[;/QE% DZII'V8=+GZ:,^>LU>V.R4!;@K,2/<7!24;%""M:F,&-S14^ M'VCEB+)X^.0E@DPP+!%-B*42UH#S+IIGED=\C+V'Z'('B\.KVQ1OTVBGO9KH M^+[QY-1*S]/*H3RXVW-F(02 (42PBJ9"U'Y]05"J7G!RN@KP. HTP@"\E)9H M>T!/60#&(U2ID8' :I&O:+$H'L>H%Q Y_J*AMS4)>0ER-V6GRERP"2'(=2H? M]^IFC,IW%Y!,N6GC!5=*Q-BRF?>7.'^Z2M;Q<[P^1(@>Q=-NW'CUVQW,8/H, MUQ]Q^O&0'U)XE64'(KQ6S68/S,T/:9P+XSZ05=:]8OQ!QI+W-S@%L6 *X@3 M%Q*JB=CL#QLF$\C8V0Y95%&S)'\X)&M".(RC0'\VB+W#>W+V)J:@0KK& \M* M/D %!)6$@(L(^'N20DA I 1<3%#(.?(-A9:>+U]@NHKI4BKV&,H:7$:RH1I7 M/[?/94C:4QZTCS?(Z&/=&<:9=DLP#2@MNI\OZL8AHI %,&'LU^!^EI3M,VZQ MG@Q5:E03>+DIGL%;E^5FK^TS>9=)L+N%*?N]\C9B@(KIL\\^JGZ>XC*.M*!_ M=9A2"W4A[#?4(,/J2AQC)W*YVR/\"B&_A83MQ25NOGO MYSC+;W#^9YC?P17>)O'?H59I68]"F,=[;T*YCY>?D[2D3C,N*VF>HN.2#.2 "@TKBL0LW\8U< MX^"V6!CP@+PXY$\XI<(]X ^P^K!6/+-D9%$;R(:QY\U)UIS# ^E.X,8JL%,0 M9FT!(H(41Q)'=QC58EDLZRIY:.7N#U#ZDH/^!B.L5CMNG8Y.#.DA(/OQ"2-Z M$/A&=:\>R#@+9#EL-6CI%$&8<4B#B.MWD";%Q(LT"L;@ U^VK]F8'>85( MHDK1W K4./@JUQ7N;E032VRFT7G@5J2'%2R[=WN70Q J/OGDS]6I4\NU-U[I M1C&[C>+USW'$W5_GAMN8M.EK0VU6?EZ)5F* %9+JTKP2]R.2@#T1!3S'4;$' M*ZZM0S@UM; $; F#4>N8Q0ZG>?QWIOKEIH4?6>U(++7-UYB^:8ZM&3\_B=22 M+&SWU&K,7*#*GH,R9UOSP"Y@L5PR4F)P?7%@Y09@&F,^!64W\ O[DZ.[LV>8 M/N*.LR*R/W;P8GJB\%RK,BRLM'6D9&MIWM MEBS\N#1F_<0JA5>7]V0F9$DL>FT;:B8RU( MRQW'$2J7A(MD;?6.PC%#F]X+#@3PV#HCYGZZ/O!BATP^\$P%!'LN(4C@%_ZQ M#$3)&J1% KOTAB*DW;US,\->T#0ZV&KO?4';UNLY10<)IRU&*,E1>[X $K"# M>+FK@%)_VY=*=696$B%(-FK5PQ@^)]\?'O\*5_D#/H=I'L4)JT#+=*K^YM&$ MM*E5:;/R8VU$C&:6R!MQ2$_^RZ4!.08K+@] E4!!&*.Y,6!+)(R,]Q;G1/DD MEMZF> 7A.OM(QG(D 0F]A=?0I8D+TW;/V+BSFEM!/+7!$T+2D@E,2I$ZU>HN M=#]6!FRZ3IZ#YWBS1.P5:#.O@\0<"+A;6.2:?(I>;W!^#Q'Z !.XB6E%L^67 MA.R)GN*]NE/ITC7U&3T^?ERBE($Z@+C&W46O(,$YR(@@X+&4!.!"E" LW1!] M;*-]\P5PU]T7__TB.R>^$*\AW]&2Y7=5)]=VZZC.Q^V.497OV!M%*5>!_"W* M2-B71&,[Q%4I7 B6[LI^!O:$>GB916QISBAVEK5YXZ<49QJK'T5RIO%9B;R? ML%Q;GY35()J)WULJ0 @FJ@DL-M#P21QGU>][^8,F FK+N0 ]M=J7Z]7J'E@< M7A7?<'#7'Y:&:OF\XD">BP6X7( )!H1D@(C&/\:+WII5J@CET*B[ $/[P5'X M(ZK!V5+P_\'-*"8Z=NG$BVP0'R%+X1C:-,YW\ 6T=/-,LQOD@C'B0DW(0-/K MA13@VN70PSQUD*V"AWBY5".?U[4/%TY56<**JJ.9/?NF H!* E"*X&U9 M-.ZNMB<_4&W_>B)Z&%X5UE,X%AFHB<26@^<.M3+FWK!N!(QPXP![U30,-\O= M,0=9>'LM^A=,CV8 QMBZ.'VQJ2I;X*F6B>O]NNE[B59R?IY#E+O)JF,D91;" M2<( *%A!6P$"4'?A+OV_J3FR@R1HCR-"S:%4#1W[$]053PJC5]:#AL3MZE5N M+?:0W?XO$:U.EVL<&.I1-3TWU.'BY_A02, 6 VEWX0AZR/1%"!*"\YNACLWU M/A^$:YL!%3P=3/_CC[)8!13V2Y=MTJ/^YC* GOC],CA>?[5!NI;%92DN^73M MEJA;JZ6D,0M/S_2Z6?J8).]KUW2LP#6XO+^]#20[WA+^9DT/4YW/%&KE_5Q5 M+JY^@LQDL=X K-75:\"L3,Q"' M)^C4OV<.K4S'P_D)H0XH^3"\M579 MN$\9(2D6-71*5A^$]E0&V^@@KV&RQ3?M=>NRL_L,S+:A\A;#E142EGJ/C==1 MR_N'+_CA"1^R*"$;N$.:0YA0)IH-:@>H&!X/]%+U<@! .()>B]HX] M2-J=50VP&C$$P.*DHY'F''!H4#6!GGBAI/^9P7T46>A=C=_(,LJX>L--W^V$ MLS!T"],-3G?TZ)=M$.]@EJ?QBA9PIEP_)W&>:88?'9+FCUL56?AZUUJP!X]L M6YV6 HA@"9B-S.<227Y 4G$7?L?X.XPU8P\7.1^IGR8% M]$"*IMOKG@HUOFA1NEXFY*$4*3MQZR\;-N8.NUWAN%%0.3+] MTZ&CKSK0KZ_SH6#-M_N$J%4G@:FXQ8@='1+]SR@Y1.FKM+1]^$*6,*^:J[DA M,H:3?C]9+ZLVP1)0586P,E,$"&MH+& PY%@B(^%P937&,%!]!+6=&^NFC#KA9%NZUXN[ARI\R/'OLO8X%C^(V5GRN<1M+I0-, MO%"N^MW95+.>LP/TYF\_2#*=@9O\@8M\)=/Q$G>\9+=:$#>WBHGR6>4@Z\/S:@Q/!O\A.]UMM9O(T[MKFLLKA M3CQXP"ST@8Y4X=XX]$M?2LI8'O(L)^O<.-D^X*MDE4(R$1VI1OL-@R-N#LID M&G,?H7AFS05P)1TMZ!(+^5J?.H3TQL&M8;75VK2$<+06-29KSPN8K=)XSZQC MC)U:C=\$:VV)O^>"6JT.\P:L*P'"6&$Y-1T7&[(CB$[!3)QMRBY4[6=F$U5W MZ2CK6>JD](2.5-1\8BY)1:N+%7*U+O)Z,':TS(Z8HSJ'7=<6S&*857;V* MY:<:-0M _$!Q)0>JJ'[PF$F?VXM %;% U9T"*-ZUYWT M+PZI:$U:EN9AS]Z5?=. LJ&[:7/RXD&7??:_%I+0^:VJJ,2$"<$;S*T VV'@ MUF;YP>=R4_Z.<5(OOJ1/V+7%=C :WV"K$[3J]UR6H.UUR (&S;47 "-K_12] MQ+O#KO #L@HK:'^F%6,Z)5&V6G,&AM9KRM"+%0MAJ@A+=P*ES?*B/*'G\%N; M"':"C OS7FZ<&W0O235/L+Y+X^64<^BB@\0,M.CL=*WW>4Q9+]1-"XB)MBFM%DH$NU;+<2$5BF1 >Q^UUK2^CWK?0?].STI_KV%4@%SDR M!/#J]ZY&/>WZ6$;>=G$\=UV@NAI*/Z='X27NGWGASAYK<:X&[^O-7B,86&[, M;[1=,!/O-H,UL#O[.%OA0Y+3A@.?HO0WF+,"YL5,11]\C'.7KR+'%)>WPW+Y MOK/LJE\^]RM_#]4PF7FO0^J56[_6[Q9Q$&Y&=B4 M<; N1S@6*LLU;NY&P@XJUKR-2!DC3S,FMEJAQYAXC.HI6]P8,;'6K\]J$7Q4 M )@E#[$<+E^O(?GR%C,>!N47.@[W&V4E>&]=V](N>D0-SX)UF'@YXK]K%G.A MCSO#K?!BA#0V5O9L4)5]3 -2AP^2QQ\S.AHNCRZB>[63>B^ZJ1V:,<97J;HI MZM+U'=^&$#ITR\WYK"TW>B$YR_IJ08U+Y=Q\HKH$5PG969#1DY49]8QKZOET MB:I9YJF7C/GZN8>L>XOCS$#)#13LPMA7J2"%-507,"IH )!I2DEU#%N_L-0 M(>? ^"HZ-4^'Z:Y(I:"^H+$9=AO=XE5N'(<^E"&X/9%E[@5\A@COJ5B7+_24 M :JO/[7(F0.E0-Y'S\."+=O[K"O& '+.JCN?L;Q+!U1LH-T9 (@:R-%MG,01 M")93+>U^@@E,(T2D6JQW<1+3UE=Y_ R-'4^1H#ER2@Q\.)]@S'POJK$.U?WT MP,5&.IX%D*B.(/7!.D\--[0^V?=AFP^8]$PC[I UYT6)._QN7O M[#*NM)KMW>#D&68Y7+/+@(S)+/_]'&?Y#<[_#/,[N,+;)/X[=)2&6%?6YR0M MZ1? OP$W,*?W9)=9'N^BG+_8W<"8EF49NW>T-VWR)#O6KYO]BG[NG4YT'ULR MSQT[G4GJ?M_T"XRW3T2RLX@8+[W?E=@I9<<&U;S3O;'J=OIT#/7799A'9Y-# M?6=+^?G%;P;X!%7[#!T#^6 .R"A -8RBP3?-$I5',EW1A+\=XOSU*B%K!78Q MD"WS)Y@^/$4)OU3.[F!Q*["^2C3?:8\LU>AO>PRD#+7" AL*63F58P&8#@;D M3[3$@KC[3ZOQT$56.(_,IS%_^PH,Q@84="&PP6&5 90_E1@ELTY?J F2GG2% M=!--N!_?YU&:%RD_K+[/&_!9<'L#/L!MG"0TK?,Q0N'4=!W?1EWDW9G!_-78 MH[.,/"X^D.0'; " C@"((4C+.3Z(N>0L#X+S$R&19SJKMO%E"M&HZS)ZJL1/ MHBOC P/9Z8YNAJ,$TC8HOQ:3&SF,\B&03PT>X,PLC/[,)H>PPFA3IA!MNBZC MI4W_P&TZ@5MZ?-T(I)S3JHH7"+UN+['[NK0RC3%* MXW!DCC,]\.,'T)=)TQZKX^=+7H-^\.PYH-O2(L=AP5,"+WN$YB75CRAK@&5Y??U\5PF;@G./-37]X8GC('C/L_+H[UG&+<.V6ST/15 M.L!D-]'%^$"OGYW,T6#]^FLFLXFVT"%ZE.8@/*:"#\PH7^5E>6!3B)&Q_,/J MP[B/_]KFE/I5X$SF%&VA0_0NS4%,-Z=\C7D#@4TI1K;R#Z,/(S7A:YM2I$>S M,YE/]"0.T:]T1C#=3/*U)4SHN<"8N10:AO(/Z+?U5,,GYE^EYMS MF.91G'R*$?D[3M1S/RPX&*9K&'/TDF%1[P'!\B@R("Y)#GN::5&)Q+I$<*' MKI JA$0(>S/!;L Q:L-;--0K:64/^ ,4W-2+00R1,337?K)>;/*F;&M86ED& M<@P>86&-011%4,0-:RC2K(US05 R4,U"(GTD3-LT=Y+TTY:Y8%<+6.%4T% M"2MJSE&0N8"$\GJ1<2[1(U*?--6(.0LXQ\3'"SMKQINV<8Y*[B'8DQ:>W2&H M2[4A;MU]O.&MU_:[RK(#7;:REE!TQ_[)$TM90JG]_F[B]5]W S"#Q=_L MM8&.%+'<\&UH>1I/)0&2*/030ACPR9TBQEAGR=@/+[+F,294&P[!IF(&'C#X M OL'+CN>%/3(%)M\]*O M1]/'I_ZC/H[N8S_!$JM;'/NF@4K1P5_<*1B2BUNX(81.T&B4AS_*(W12.6*&VF_ETL^J1,+X>%A:3(ZX8 MDJU^X^G@F^+HX_[P^%>XRNEY .\D*;Y^&HNX;O-SN(3K0/;D3,WY\DV2+SVE<2O/@-S&,$ZD3M!8W(>Q8Y>AS%A MQXYDU/;II19<7QQ2$E"Y+-Q)V!^%N)EH<_-1R:LD/I=0 M8VX!V%[W,T*[$0<8DIP_X (4?ES +F,-2BFFS2?U=E37Z@OG=,N D+4OS'O] MVTR9;=MHP5I2K(6Z@ESO"N.GMW3C[^9;F$^W/#D2QOU*MS O6+&:RU3DSN79H>&H\MBLG]-HU72CF2HXL4Q*%2GX@3GVH>/6,I MA -,NM.(C[H&[.>L<]@*OA)C]7HN>O2X3=6@IPF]F=:QSFCAUZ58'JW:G9@> M#UY/(\1Z,%2=,.L:Z:_(*#7";69X@GMB0;>0/KRXJRG9A%:N):G[Z"N=1G\= M\=?,9EV&8 /$OR[[=!^(RT&<;BQN.;$/)AIKRS:AO6O*ZCXB2W SY"'U4H_1Z21G@#N)Q&)='[1GM#NZBF%Z'G>,D3Z-5?HC0 M TQW[[7#[=CB65KYN.+Z"\/2.J$E#)<" 4DB0$4**"1/9-C-\#R%17R%1BR' M[4>UJ/UH>N_9;?[O9Q;!NV?6+KC>C1G!C<2;SO@-Q)UJ(7WJ$=S&L!U&<&.+ M^ J-V'$$[UUV=YO_NYD=%47:L2\P#=@L=VF M[ $#*(50*0(^E\.+8?/SD_'7ANC)FIK7K#YELPPR_!W=-3_@/$+314(U>28_ M2NN5SVO*R(G'0RU[='^2JX#KUV![OLYP:W>.3'H]*SZ-Z4CA;M'(ST,_(:GK M&78Y]NG";XA6$Z^PC ML4OKTAL*Q,QM9)"XC[2Y[ GL!5] 7;>(+F2>IZ7IV7-F'-)S9G4\L;9J@\=. MN&G!#5!V^B4Q@EQEU/L,E_W51EUC=,LP7>3ODLE],."K^0UM+_=,61P%@#>B M1T48@<"[P3E<6/2#>*K&Y7A1<=2EN^J$.+A/UW#85+92J=!/VJ061 MN%3K"9Y@RY_LTBHQ<+='^!7"0)944UFSMYJ)X?;)GM)RG1\)#K_4U>S]&U:L M+M6_R++#CH]YD:P_P?P)KS'"V]?%8\9NSD>)SSKB3 ZN(%9LV580))=$!D M!Y+PX-="_/\]\Z!M8-8N K6N??1WVPPP-%R^[.&*!+^?,2)D4)R_WI&X-UEH MZ!(GD-#0+IZ/>U?.!SR7C$[0?P=LSY?_]H'X%=B9[RFHM-U*>$"EG\O)7A\> MXR52*T@QP0',H%0>0R'YY0Y\$R?@%49I]ON XJ%?*W-QH*>(V^E:E*-#O:&0 M-ZM$Y#;5W\79;Q]32*]K(=%S/NEBL%V80*;H-N'<1S_*Y6Q#V(!8\ %I[UPZ MV\5@K^7Y6@IV@WCR5N9[&4@E!U1T4,@^V2K0]:K\(GZ.US!9![%3K@L3B-FV M">=Q:;@6;,!K#%%(%[VC6)[O??(QB"=O9:/MD0O1IXB-E^(^[QZFS_$*MD/S M$+U\@ G09%H!T!5'<_MS(X&/4+:"60;RZ 4\O(N@E^;FG%DC68+S"Z&U^2 Z6$EI02)12P5N@^%7SFW@ MRG/Z@:#:&.H)L<-C4'/3Q7,4(YK1_A&G+*_A<[*&Z<,7_/"$#UF4K#\2L7,( MDUNB"DT/-J)M:%(&O+SX?2D'V."49T>! Q4%Y$\0Y%\P^2\7B'R 2P3V1*2 M8H.-26!;..8&OQQL^K$GGOKP M]4,7;:Y)BYTRYN7BC$;,6S*T)[(&LHQ?>@P<6+$.PQ$B62S$$09=+3;9K%2( MQ .+889V49;(-.'9)9VT!W2-(S 4Y ;7QNMD:X00P0[_XHH]IW2@O,\VL=Y MA-@N+[N#&=GU01+OTX\'6D2[D-"-$IYA^HC;%]6IX,P,9,-XEW9BO8=$498M M-[]$*N%XNFZ*B73ONI=(Q#"Z@H,%QIDC8H7;UF2>6*!$,YII.(G%>I+;@4BYH!T$O50 MT(*P.BMYB0,;Q57 6'XR#!16UEVPH* *#V" A]H2Y1I'R2)9W\/5(8WSU\4V MA>S:3W.K.43&<''23];+RH2R!'33GPFF("JXAK :4<0+:R@P8&SDN%0"4W $ M)4N'F[4Q1H6D 2U,!Z3FWH)T#+-B4V?JX0J4# UID+(7/Z^X@GVQWPW*T]6A MPWJ*#!LFV>4EC,HS"1]./]+0D)M1J7G^;1H_DZWF+8I6C# )-'=P&V(H60@EYS<3'8+)26@H UDP1@(4H(P<,< M?6RG^WDA+0>; N;;&LR5%("+ 0HY',:?B4:/N@:^L!WX>&=9UW$"KW*XRZS/ MLR1*C@].2LJ^SK5P=8*"RQ,4RA4PMH%LVA7Q&SK@:F@S;*R&#[J485+-0*:W M&O3VA$2. W577@6$7[/7^9IO9(W9.#8+H88 M^KAJ+]N([BE3Z<(WX(B@C/Q0'%!3^"Q1'O3Y>O]8Z2.2F_>\) \L>Z%U8I/R M%&8SD [<)% 9\G*PTWQF-6L^;F;_N2>6HC?'AY1O"K/AT0LW),I,:A@V*+^ MYM-+=UVW?37&GJQ=M%W_^ MT=*H:XA?.8*R6(^]2J35\&"'BYG'Q-Y>)OY1.V6+&BGVZ7=AZ;A\"Q8[?E:_2!^D87J<.T/5R35[QI,<\">4*]IPMB,71?PA7XZK8 M81U=]N?R=U@1KV&PBB.T_)*0F/H4[Y<;:O=1\GHOO911-B=U@H9VI%T#^38:&C$1&@&#<@V-'.&@- *6;HL6/!(JN& M'5S=PO1S$BMUKA@D89J)U4G23W)=Y]GH@; ,(7XKP(05=6>T2B 45E1?V^HV MIUC'MD2SZW@7<]VRN%96=ZEV_9_B)-X==NHVYHN_J8'ZD<>/=9>R2E>?Y599 ME$)K3(&HE+B9.".?/((=%SL(#_%LH7@,Y,U\,XUQ2F8'[N@Q7B\W5\DJA=& M1.K.9\S /!'7B*&OS&N,_#O1LKU2%I:)_J++Q8 MIL2>FN8,3-( 9FRH:R,S_)R4]R#%S8BRO;5^U]"P6FAYL2")3UG*)00[Z<,! M#^EHLL(LW9F[E]'JJ?Y9Z_Q3/6:CY2@?,W=_7B42DN7R0S%[,<&*0*F?. :: MN-YC+.:IZUVXS-XP;-/7J5Q'7W+P)M#S.9Q:@B)[P<,>0BJG*X8P.%0;5_EP MD>S\?CAA M>\JX;F 2 T%=%X!YPS\0SK.B\3GM&\ D:L^!+Z5R$.Q"/K"N30/>3ZM/7)GH M2(^2 98O8EJO@RM)Q(?5V MXB=CUW;<%[#HZ%CJ7P:E]K/Y.Z0I\7,2SO$./D0OHDF5Z&)UCI,\3@YD@E^2 M"9 91+9XS/(T6NF=\UEPL5CU&W/U4 ^'R_)C(/L[>]2Q.SW/%V%4 Q=P.5@; M."$)*-K!5;* 2ACP:R'.Z"6KN,0?X9K(@HXT9^#;W:2LX>TB[=Y+!:>@G'00 MHV-/[%=8X'@T?$HP:W.J:7SFGBR,X")97Q.O<.(Y0P2M\>IGX*$Z:A[.0:86 M9L>>I**Z6>#3\"K&DI539$S#\2[A[LZ=3)&NJ]@XBLOA/$+"Y1[HSV#%90C* M]?0 [9S+1G'$$<'KF.7"\\L+N(%$QK62;DSVAH8,S,$V8NCCN(F+$'4<>7I]G\-?75LH"WS!5^)ST-M((R!;?4U?DG$!K^F%SY@O.'YUO,C4)C[3. M\;7-7 LAPO)-XXVF@4YG!:#% G5D_RRCU!VDP,,0@A_H<7]=9S6!3=S0[#G[N&2DC&GE3&>"VX@*MB%X>T.302[ M!V/^YB""A31EUP4"PD:N$E &%/HI+A4HQ0*+8;OQ&T/,9W,/*VF_B^:C&3KF M\.4$&"@B^C<\GRG_?6!^/#P_>UHGC[$D#F;E>[G9P!7MB%/%&3+YUUU[(9]_ M'XA[O-8^K.-!3MB90^N O?O)E1K!/L7/<<:FU1Q\_O;^VW(QEA52@)1P'\A= M&\M)75H-]@#/"5B("!2E//)FF7)I3K^+^ET1-YG&=P*,+>V'$5"KB94='[^V MTL77TZF8-,'##"20]O@$&V$7CT,S3&@A9- X-&-'/QAS-@3=:-%]$M0Z0K3S\&L4;3PM#>(';A )W!)N:Q$;")^SBA%]L[2+ M$II>$-,VCO,)"+UVH!D,NG4_.\P-@T!-DF(?,A/O;Z\0?XXSK0V]#^[C6T^W M-#Y6&>RA+'LE-// H6!"#D+*$#BG9RY.PA#H[*Q !0TP2)%?GJ=P'>?9',_:8ZPXY_G$F!X+T(PC77J?)]JZ M\8#^7@@""DD"='A/EX_.6?LUFG]<2]H'#LL[2B\PG9C5Z,:@T"\SVY7<]J[5 M/O:T4W5M(&U4]5F46,I-Z$*N8@9>4H\08S9XWT.JA53L=^Y3&-KK^GDTQ(^2V%M@+JEZ<6O). MN_46,B;-K%)IW41X3?^RJ1PY^:'XG3ATHKO-]!EFBV2]6*W20X0R]E^XEOS= MRK.,>3I$W% &]QXK>,@S1J .:VLJ?IF$5/T* _EK\O3H<+T=@5=B$< M* SJ6L6@Q@DR/V&\_A(C1.2\(NNE9$L/N=47CF9T'5I%#Q_W :'B(";P0,.! M"JA]+C^HU#D!V..Z!6_FI1*XBP%PQW%-L5%,MM!I:.V@O30 J"C]2#,5(.IO,$Z1[2/C6GBY@30-J)>T[2D>[]P\O4&<"N MW5?ZU!@\3FU>)/%3SMX)*F&Q=95S=YR6.)/A*$+%![C< ,)W\MM623";HY9C M,JX]RL4)0*N]A7GLTHG+8&QS?0#C& -%)YGX*,8^I=!]@J"[O*ZZ'SSTKYGG MLA!0]Q _SC&*7TR]<:PO<:SVD$U2#O7E,=%4^S OA MJ5"/ZO& 7OJ? U!_1 ](J4#Z=:OV4+,R'Q-\-;5?02MI(^ 5%O/G2Y?1/[* M6#C8H?N0&>F+Z[<<].*0/^$TSE\7+['62KR+@H/*PS6*7FVEY!3&4F( E;;B MSRVZ"A.!8\LOF8!?*9OI7> "[Z(XL7."@H9+$#C-K]L1&MCTNH*LKU!QZ'4' MSFCT)Z)$DBR/5^?XD.3IZR>X>]0\KFPG8+&1:2/HK9,=^)4S&%@ZC+:O[(4# M*VDI2-47.T?! 0@6"NKW8O:UTL3_\Y#&V3I>T=6ZO@,,DC+'8X"TKX+:8;F$ M*E184V^!PX)D1*JJU3([1:"F/.CHVJY1-H#Q"5CXEGV;*[E'SZ22@;!)G>HX MP[F%1)XDC[9PN3D_[ XHHC6+BIIGK(+N\DM"9'B*]\HG/'I$#0\I=)AX.1VJ M!*#7\ZM2!+ J2_UEO )Q(48(ITA&@&-CG1L=+++8>0/SXZ>F'\6#C ]P&RRN9MQ\30QFV8>C'T4J#6N\E^XU\+ MP4(P=BZVKWA\>_PE5N'-2M>!@:O05/+S9?G(VHAO>,RQ9H MF'=A-=@54D9VW\>N<*OK>!?G<,V>A2^3L"K0A#S+Y?K8B$?@BNX,R3L%C;G;E$[H_'O&SKL/#B(.OMIO"1C MNP7:[@*Q4ZS":V;K+ ;FI>(QNC@Z=YM%DAP$9X;M1TQ/B&AY:P].H\[,@\NH M,I_&82(F'?<3OIK:%/+-SE>T;4K%4_3@FZ0T=7>%,YVMN!7Y4>JUN=U^M]W1 M=NU#9EN,KVUC;:WY&8)=W IK%ND#A113)^YWZZEE$^C)VULYC6(++9RGBP%' MAQ"A/C\WLQFS -&)T+SMPS1L"(' P:52/;WSY,?WSGQE^K0[@0T@NK*H.OM M-LL 'WM- _S9B3:FO].H=Y\L+C0V3I97\] :@Y>-7A4)C*#18=\?.!KN5'G M,%[54 MR^&E I-$:Z'@95[H=IKJ5"Q;)I\SK1I_.E3-(X Z%Q_UF+)5&N\9;'@#\B&US&8P*1B8 C8'8SZP"\?N#>L29[!,:/4@^V@V?DZI;.#. M$TK#'#(Z&NUR RK64C]CQAV4[.T'&TBN@M&V?_#J]634(PQD:$(O]W5 R"1: M*Y!@4(HEC,FO:L:^Q-=? DYM/&-K2-6"FH]T)C:D<:^V:^TMF]?6IS1056L0 M2JC$ J5<&H;@9<_P.4GA"F^3^.]L]UVTE-'9('22,%\6=I!T;YYTJ__(J8,$ MYZ!B&\8Z?@@>K*BS0*$0#B3S8*YA'12/1RB[.8 M'<7<$.<_$)M-M*IA:I$U=VD--N[-N&1.E#[E MJ=+*::J5-A=%>>M#Y7A)8@F;K2^I]N\+&&S6N]B P<9]B1PGGH/GS, PF.'8 M^ZM6F^@*%EG8FY7GU9=GS.B;;QP=5"NX,RL7, MY;/:+&)3C8;.&')#EA??^O&G)C' ':S>\7Z;?\"RHC.Q-E?8+7&9.)F!4'ON MM$'C+!L/Z%'!=;24)!J%RX@4( ,XZ3*OYZYP[?^ M.^J7]A\18*EWE<#_WMQ'JL=O4\"^%O9@)R'6,GF&1F9X:I)8Q8<5.(=/#@BM% A(4 MH%AAI)!&V<&Z&@N5"31$PC)G"%UZ8?-3A(:DN"7#5]"Q-L=0GR8TIK5P^1AQ M#]-X1)'(>GA]31/(0/3/1U$]:9G(.)/D)?O4H !$84)(,*DUCX?U$I:6Y6Z# MJ[@Q67SDO8<,]K)YH1_."X*: ML4FLX(5PN@_3 @> M5Y75LF6WW8X*9A:&RF93VS9/"GK3[(L4&ZFV\8L)BI\(LML_RPRK:-H@*OJF MO!72UR@A6)H=Y]A>Z^%U"^=3V[,^87HXY+']O:F@U/2;P:;[RY%T>TQH"ZZ, MLR-GST^^.U6VKNI"# :/?'R]J>'FI62+11.<9URT,_[&H/PRVJ"W M YO !Z0!X)=H0B [O&SI5SNFGN[G.&)'LV&1>>4 4\G>#3OR53^ J'9@9A2@ MI?;9-#?4R$V1@"68L^F1HD5J!6AJ9YL__\6TXLB4>;".<.\\=V!>G/3;JIST M JWF?MK7Z.HHM/'6;0Y((U@1'OT":+.ZK ='G8%;1TZ)R3R8.^4SO089)Y&O M;X>'.^S,1N9MK.>T773,BW;,\X+:\M5TWOEPJ:A"1V482:%Z75OWX! M\ **5P $00KDQOM.9]GFP<$#X.#@7/_R'Z\;YV0'/-^&[J]OSMZ=OCD!K@DM MVUW]^B;TWQJ^:=MO3OS <"W#@2[X]^&_^X]__Y__XR_]Z^_;DZN;V_F1F M!O8.7-F^Z4 _],"_/OWXMY/_OGB\.[FSW3]?#!^<7$$SW W.'E[L@Z"[2_O MW__\^?.=M;1='SIA@$;WWYEP\_[D[=N$]*4'#/R+DRLC "?D__URDOYY]_.3U_=W9V]NG+Z9?_?7KZR^EIAL!OT;1.,O_OEY-/[T[? MG;W[].4L\X9/SS];)X;Y^:'#^A_/IZ!K\;RS/KT]=/7KU_. M/RQ/SS]E.87;O6>OUL')OYK_1EA$\W5=X#A@?W)CNX9KVH9S\I3,]/^ZXOGO(/>ZOWY MZ>F']\E?OXG__+7P]S\_D+\^^_;MVWORV_1/?;OL#Q'9L_?__>/NR5R#C?$6 M+17:!28>P+=_\'G3 (UB>X/]]?KP]&'-G_XFV;+ &GK$%"&4SVDYH+4[/SC^Z ?EK#,7! M!^ U *X%K(0,GD#74R>\)=PYT#R @_MH[')_O*!^6X%=^\M8),1\3\(3F]/ MS^+=]2_H1RE0/CJ4T-M"#ZVZ=;%'RPD\) O! DWS HV4VP8.WOK02W[H&"_ M^?4-)\'W\J=S:RZ]66C9B+=9$ _6KL;QUBQ\E]'H0.&$[@6GN'Z-A[J$2#0 M EZXB]]WR.S,=4/#$6/T\-L.F,12V7E8H]OZ/MR\ (^5P>)W'3!WB0[T#%WM ME] "K(P=?M,!4Y&POXTQ7B-_MYUZS&_X/N/W NQ.PA 87LGK5E]ZQ#=A?&ZZV% MY*&]M",MDD]:-1#IC&UZJZ/1R+&YA*$;>'M^<=% JK,IW-@.Y]50_*X#YIZ M&7IHF.M7O5(-_ )X-+3XVR[[OCMD-\%9HP;Y[ M\&>P%H*U@D1W&V!C.,Y%Z*-;W?2]XEN@97T.-$,_=I9RS^!AUT M0QM>-" GCH6/NQ-7D;R.'IEHDV'E(N3DMHI&9TS_CN3,?[E(I7\"AH]>H=:M M[X>\.DHED2[>LA%"-[:/'LY_ X9W[5K86LW\KJW\OKN-@<;S#.?6M<#K?P'. M0U;XN#,V'\'*]M%8;L"C!)9_VP&3Z*;!U_73?O,"'5;N_-?=2EB1=QPFW6 M)=]TR%3&NX M'K/!G[W:3%NYCP[9 MRKI=9YYY0-+PS(0<^F?!YWKH6X__XOW6P(KF6W-M.^FS>NG!32DO\6BP"4KH M6<#[]GIFY,MNM^PC>O7-^=O3D(?,0:W^.\-!_\.^S\]8-U%&%2R M3/@-T/,(D+_L&9K&C0B9CPF%ZX.6G[7&J_Z*@;57(,7HZX11 MB5J3XH,0TA$?5A'5K*RF2)V/"JFBR@_+WA\4G;,)G>*;D<+S98*G^L6?PO1! M3PU %*:"!8<"]4TV4$C3?8''#M6!92X%Z^.G:5<5[:PI/)\FT5UM)$]1^CR) MIAJ'!X5)NF Z2IBJ/5@I4E\FJ<3@G4SA^CI)J687-$5KTC=KP@M2F+Y-0KTR M5(2"-(GTRI"?!"2D14T@-85PI6"=3;*\/CZ/(C7)\:J RQ2C\TF(LT;14LPF M^T%EK'0*TH=)IE.(J@+?4[0^3D+=*LUGH A-PCR+T&%*2HK2ITG=/-3)D\RB M%*$OTTG+RJ7:7#$*VG3X*&B5V8$I7%\GI8K"59K_2:&:!%8=5.<9J+Y-&E4! MJFS&=@+4^>DDX@M %5+Q*5J3;"^@E:NUD&)U-@EVXJ Y*)U!T9ED.?[;8L63 M%*'S281G__:P:$V*TH=)?A\$BQ5J$%&D)MF-_[:NN%2*U<=)=F?_EJ&0&(5. M@6#_R_L"#V" (#"4[KVO!<=.#\S$2NP-(V;:9,+!YJ2G:#9=F1F'XP;.O6 MO32V-GK>9+Q=7(O+0$UQXN=OAA,R9?%5?ZN"XX?DBA1CNO3S?F0@3UXB"Q55 M^\4F,@7?)Y?0Q;%?2.-!XH9WZU2243&/S+TH>)TJY_,>NB9[O; & BIXGV\! M]HFXJSM@(#TU9F0O-@\&8HK7@Z-X6]W7/:Z$P R:*"F9#=:&D!K@A>B=U&H] MFB@ITC*QM]!_,/98BQ.8116%?LZ#R*U61T7Q+$I?22WGU$!3R2[S_<(+NV%7 MQ5^HX.X*;*%O(UV C"EV0533J)]!T42!?X+(16IB%)AEN15W];D#X8\^6S#PBRXI=%@9"Z?2\B5 \_5/2RV:+'X/7K%KWQ M0;(7A&? 1$[H;,24+]%?VJ;A+#S;;\9_AJ_N-#_X&MHASC!;[#@TO"\/3JI_$8 -H+*S[K(E5U!0!WO MXDRKY3:UC<^7:1.E!QBYU\2L&BST>B]UPC5M6+U$M":#GMZTADU=0*9PXFB1 M 3V=V&P2"W)+V0Z+,QPG;@RW+JW1,(;#6(.9@!9&L=,SA()[OS'IW+J7O> _ MI57XR _T@H'A# N?.F :'M 4J#&(^TJ9)6I+T;VP"OL^J[:=48S&(.&;A52V M>HI\Z3TDZ23ZV&&W>^M>AT8BDM4O)$VSI#C\2]DS6N$)HX5$]-:X^-!J\GY2 MU/0^GYRH-7C =2]:(X9:W?XZZZ#JM@XW*4/("X50;_5,PA5:"EL'98!TV'D' M86X4++V?XZ)@U<8R4O#TO@U$P6-Y'^A:7HDC,OC0Q%@,8*8%@_16S8ZBI,+(PY(276F MYO&-)'KA?Q8&:W3&_]ER#EDRBN>!=O/<(QO=(BKQ _ (3X+SJ2:G/A6TU6%I M)-77?/B/3!V5OF8A=G":**F?C8SCPTIQ"N0=G%;(NG2T]Z/NYA@9.!8/-L5/ M=S.-//P2$4^QT]U0(P^[T@KUIYK6*93A[VA4_RB(NEMB6H-8(_XT;6DJ';R" M[-.T1*1TX,H%G_S6' .I5)?^PY\OX^@*Z$9>VXSU&=N=^2Q<_'0'9O'BF("" M5\GO $>Z VNV0YRLX@*P\R79LID=>V'XMHEXO+*=,.![68J.H.)-EOB2DLNT MQ30;22FR/N4].R+E\&K)*"L[4\+%L^L!P\$W]U^A@W?-=\-V\5&9NQEOE6?[ MZ%=7(4Y-B'ILB8#0'0]](H@933B)^$(_]W#0VQ6(_E?$%B%C-!6H(%XH8SP3 MS'VH; 7OT0V2A"9&#,3Y;MRK4T-)3=F9ER!S/'*NYL?X1"5'B6=VO)15S):T MSP)^< !T=@7N^:J[L-$3*C RV^"FLO\D6DBJXL897)'_E93SQKW D)K"PK00 MV?Y/E+#<8Z"HM)20F(0K_5PIWS%J8ES3CU7P_!VX:%RLCC7GD" MPKF1E)HRPCY 3V)<]^ *[( #M_B!(C";!D*][">A@UU-1,UZ[( ;@AL/;G"0 M,Q[X=SM87X9^@,ZF=_UJ.B%6/7&B)/K_+$[55HB\FGL3RY[TA2RRKU6GZ<,&.^P"EJ7R?4:A0W M6E%)OOP:4IRLB/S**N44)_F2ZUAQ8GR'T2)*IWH?1;Z7+A1\M%,XY4FV;Q&< M+EAA5_?Q LIGNJ'EA?36W<1QY#7S440UU^^$$6TR"]-Z1/*%Y9'>,SDW $5( MOCY\I C)\ 116#57F.7YZ!A6H+W?DA:1TENDF@.,I:LA&D562V"F5/9[_YP[%/GO*_6 M@.@D1L;T!_SX10(@"#S[)0SPZV(!<2DC;(&'CD,TY.@QQY>G(V-$E1@=793, M2"/%*B(ZR(:+3E:6:G3B?C<\S\ F?>"9-J.S782J3,Y)OH-LQBN(*I-!55 F M:A$@\13%Q^@1 ;(FW0+0/$3;G?L(MJ%GKC'U(O+72'& >U#! M@;C6'#E&9M'@*Y2WP[ $_!VM@FB M63\"$ZY= MSRNX05N!*_.HG(!2F93CP9^]VF+BJ9R0TKDLL*P78C[^4G$U$3D]E!D)]FXX MY9LXK%XE6KQ!;Y=[Q;XN0Z;\\%&@1E*DH5:8P4;!2_'2VTU6?W&5I\(G%RO% M2&\7+S-&#,&185M1:$=ZA:*C1:@W@RV-O1^)+ERZ#%)]$!12 M>86DAAE$SB%911Q78^D0W0I&!@W:WZ EZ%6_+6_QJ1*_2\,6QS?D2_1"7[' C.]QA=BTSXRU&4.* MCY<7RT+TSUMWAT1@Q%/*SLP,[!VYJZ]LWW2@'WI"Q;?:CZ4*$?S_XQMD9SCX M%#PB/CW;1"]3_ O$[N$/,G_)"X?P0"K#RX\#D2/ HCPW,%52KE_-M>&NP".2 MOM=(-O"?+I6<*4ILP(P^>'!GHWON8O_L8QE:(BTXLQZ8J0K=*HBR"8#EXZLJ M?5CBKFG/Z+;VRBV:CN&B!1(.FI9TVU&IFRJ92JFA9?&;F"[HH? M1H#M-GM2_MYQ0%199KZ,&-SPWOA"Y%6>S@6B:](#H!&OI#&N?2CR=M=1[ MG'5:GTOJZ2RE*J0Y%#6PE/8=_N^D]>Z>63'@H*BH8&B.G9EI>B&P,DV%>5:$ MC5YO,X,A5JZ-/6^$,@,QH?UU2=3X%*3$YDDT)+0C%O"'X?T)B'V46NC_"AQK MYG,*0*G#];-^#Q[(VFZ2"DVQM0:7X:?K"LPV'SZ+,3&]J+]$D\Y(K)O*I'O*(9//& M#C=\XHZ)H/(D;AP1A^!VP('[> $9=5D1R=_-^(I>O$L[X*VDDOUJ6.\;B:^Z MWM4@U\U% M0-= [ZRA3J]QR*VYT$A;O85&U["W+-ZN=[97#^#7/*)H67*]I;TJ2=.85?)I MDNBM=S>'08;BKG>69 ^X%^UU-&U@NC];@UUOMJ50ZWU;RM'2>0SU-"=#[QM1 MP"52BRB;LX>BJWN+'C%\I?H5:?Z,/'FL$]@<[F@*I=[RM@,@"^$**9;?)@E; M(0$XPEHHFGJ_+.1H CPA3A19^6^'(?5+D62/KPV*HXET>C\-6H0C9NWQM6&5 M*99G\N3G,*]U26B*1.%2D$2Y)BJ5$Q^=1B55!-/GSCRC2\F2KCDA+3WVCP.MM#9>SP7D2*5-D.W ='_.E MICIMEZZ#WLWHE:Y#!E;Y;N(A%WU4 6ZAU(Q\#_%P"_)P -RNM 9%5^^;3UK! M$]B^P$N*N>8^2NF8-U<#2J%5X:1469.*HC/W5H8;QW'6I')YH?A&JNH MCE.LYSZ%FXWA[=&KSEZY]M(V$4:Q X?41D-;-9-V65O/JOOAAU$+J\-YJFBR MFN'Y$KH^&MJ*#KQK/6103,,.#8?6_,JJ^=-25O; M-K,226&0-&#O=X-?.R?C ;AURX(L."\19GI#NQ6:&5>: MP(B8N (O ;F6$EZB&/),H5W7N@0>[L*R\ QL'HA"CNB_E'($UO#-LCI=DS=]"MB\ .#\IL,,I21FI#DZ1- M;"N0 BD+E"LQW;:!D J)5L:"B RKI].[U&*:)F1>F1$(F]G* Y%RBWV0=S;2 MCJV'M>%M#).0,1P?1^=[6^AA!R&G\!&D/C1AQ#L-)2V2'70T\7CV#LRP?2NR M.K34V[C(3B_H,;Z@N;;(""1H+KLKEU:'E=O#T./YBX,$R$&='%;;:ON1AB99 MVTQ)@?2)N)HO[P!B![24K0S$5$C4B T1T9C_LG<95S$5R(7Y"$14L04.I^2I M)C T@5+"J9(*1/E1[V'05EYP$%4A-R(61.1&_LO>Y4;%5&J;1E5B/Q;Y45DZ MD4>&--1?')@<*7*KX)QEE*-E=NPX7I@$B= (X33E143"M!Y*A=QA9O(ERZ2( MG&H[4N]R31)44.(.&8%TS',BS:"$1!5,AF8;P*A#P4OAR:0,BRJ*;V?#1< MZU"$.CJ*JNCG.1 LFU]-IG>)P3))R+HJ(Q 5L0;U8'CEM=,9Y483F:$)D4I^ M%9S#JK%;"A@NLBKD315#(D*GF5;ODH=YNE!PS48@C=#;;F-' 5NDO ,)9@6N M0 ( Z6AR:0ZEI6X\BN';^W-YZ.LI%4N"T]"?:3Y"/B<0*UGU^= $5H%/%2ZNW)AB+JUJ(DH:A>2&%VH24DFC=XG2.#W( MM!(CD!.RL_<&DBPYMJ1)E9A'_U?,5G(1E"):]_P7,0! M+AQ"G#DM9M5(2JG!K<5$JFGTUZQPOHT#.!%S:.O8.U*R*#H&3+U_6Y$7:ASX M@)[9;D#\A *+T4A"C3G%!^@2QM5(KL ..'"+SVUR9R:N:%;OZ0U$K MCP>L*>#P]LO0#]#.]UJ<'5[*2L((8CWE$FW]%1#9C*R4U 1QXGC&*+JQQ51J MR:B8QU^!X:"-87@@<[Y;3(B-GAH[!Q&B7A0N8?M_7J(M8P?X7WQ6C1HR*N91 MEL7,+_3JJ"A9C:B:5+Y0FOA&8R2H1HZ;CN'[1$LN\?TTB>K"QRIX?L9U>:[] MP-Z@RYV+X?R78@W"T?'!1K-G=+A(XC'=C_SZ"1LQ%:@BC<[VY\O<0ZF-/&6E M*+0*%Z%ON^@&N@*^Z=E$^11= Q924[K:F-+5F+>%4G.73@CSR@@*](<):.ZM MS';+4(P_31B+;.:\>D$!_3(!*@)HB8*98GHV25RQ%&RVQP?%>1*X0CC7O5HI MN).D%:PC4&/9H.A.8E<(739#&(7YVP2S",RU!M04W?/IGA-"M\G23@&>+CA! MY8S/44,!GRX]0< 9G'\4Y>GRXW\HU[F+*;+3?2>T?X4"!U+4/TSWH!#JU;$H M%-KI!A2"MC%>B2(\77EB(H,MSHWBK.#2TR/J=($M$WW'G!XRH7O$:3Q;%1& MYAI8H0/FRQGBP+*=$-^KU YU_8K;N0$KTMTWVS YGGF))A:&3O#=DC+.^@]&4B "-]K?'2G-BQ'T(:%;TE'D/?7T%5$ M2+)QT1R:7&-C7F6#$EKX.Z[YC7;N#V!@9JVY^XAW<]P\]1ZZ7O*?) 9-7/9U M,?K4UD6:%!1NZR)Q.4<@'5L4XQ!;A M. I^\+&^&0D&Q/!F2R_SEDX&.2/WA59V[V5YGIF!O6NE7\@8;0BHH T?>+89 M@&A-GUT;*8AXB;N'B'MHM7@]XQ<97+GV/P_9QNH >JYAPQBP"+]2#EJ+X11[ M-M$5 _< /"%!:9N@?&UG#IDW\6<\IO-Z .B:C[HVM/5]RF9""8:)WPA=P^ 6 M_9,K\[SL:T7U9PK']/'I^0?8O "/9P(-A'J82^LYJ.2]8H_3#IC^Q;[\MB;_ M9X%FAUV:CN'>&QMP!3>&[7+MOT[&5X$<'?_5YCIRN0^5R@@BY(7D0_SEU!QI M4!$>\ILCY1>'M] *&C3H& MA?GK!+-\F//J*,U-_:@WW(W2M.SA0='1_,Q7/]G*@RQEOTO'DHG."W0+! M%5B&<,7\<%!MGJ6?3-,'YKL5W+VW@!W-$/TC/S'THS^NT2X)]ECG]+;0BTW$ M:,1+O'^\_26TF(*"F$FIF<(5&C9ZK:4_:C&+4FI*=ESQ& NH '54>K_O&:8( M^19F+(_O5L@5#^98GM=LL(E(Y[$T(^%#L.;25MIL1 \=^] LF99PRM76N@?! M'?1Q0:?8PX8=EX/0Q*7QK[N^WAZH'AIIY[CC45(:2:G0MWX'N'0!L&8[M/PK MD(@NPM \#/S <*VX8(;@-$5'Z'OV?L95_Q2^_!V8P0(^@FWHF6O#1[O_$OOJ M'8=9U>Y@T-XQPB$+P")K)PV" YJ]SS"S145>(ORT5DUVX=J7+X68WF)U>_E*IS&TT^/;S/QR]:QM'03OM%8T3VXH\?2 MI*ES5/F4ORZBP+]%L+M@A8T\8P&^[AG296L;&!C.4##F$[V-;U>E355T,W0] M0-S@RC8<9W]5*&I^#[%J0.J:W[J7AF.&3FPI*5A(AF@$ZW!NXS&0=0&BBN=0 MNRK]LPT&A.OE)&= )4_%=JS>B=2[D3>F"H32Q$^:?<1?7::&2/TXZ0UVRH39SIVVO M&^ZJ1Y)'G@RO/3S89"_B:"HA=7/LH"+)-!;#NHI;IG'-QEBQB5EA@95ZU5BJ M+HE Q5Q!24%E@".!CN,E1>'3^Q(3V7DU#^4.ZW;M@/<"AP/@Y'E5\]-68C&HY$'(4P]?YB\O'CA,RY',%60[D/VYKH:FV:X"4G6 MV7H\B 77SA\3AX6PDH*Q $,8Z%"8"/2SUMH6\+>'%KR:@I M=!/E(.>VD,!,Z@FI*MH#/-Q#_ '=RY[('$H)J*GYEUSXN(#])<)QA;30*#R+ M?R(LU-3/BM'6:_%A2^UK=#)RO MO-'T&1%Z5<,VQ@(*K?R@ER&EE74-+:LYBN:CZ1UDU!O>.=,H;?DB#^]A)J=* M1[S1)$_[P4C?RV5*EG8>M0>RIFN F#&8.4)&6E(5(_^H[^A8I>(NUX"NS21ENJ+@4=G[7R)0,.!2W6/$M<:3N?9WC%R*)=SL$3*ZA[+5743P=*[4/?R$4UH'&HM8\D" M;Q4&4Z>2'HJ9,KF,(Y:0V"0=#X;'_4 M%K@.@J _Z'URNPF"_B#]?.H1!,T4Q_M!>G$A+78<6_SXATG[DQX$_57O#=DZ MCE&2GY7B/07R2\>[X/&G:$\A_K5HRXZ+_JIW5IDPWCU&3*5K\TWO+FOMUD9* MD!^%6D]C;N]BIRK]Y9OT2W5@3Y+^TC'.3O5^(RM#-AO_3L%58.OJ)]/EQK"] MWPPG1,#>V*[A8GO"K>L'7D@2)M(DBO3O_/(_%,IDZ6;PH66J2)ZE"F^[[X/ M3_FA4^%RLE<3&5)>21<))7U&2+5<-0ZB2E:Q:A,)A7TT$U,QIY2!B!^$]IUM MO-A.;$PS,$?6W'W$V\G#C45="UU*7O*?)(>[>-4QS%_RP%-,\'ABS'] %^RC M+,N;T+4$)E%%H8<35[+5R=Y^=N&+#[P=EO"W[C8,T*^1-H@."-$8+O;DE"*898 W&+>&B-(Y$%S].[ #S@?^C5Q+IJ]YG,N9QWG?\SB3,X^S M7N81G^G-@<;T5QN]%SQSO6\A,M@(*Y8#148(]"V$0BW%8]',N".M)0YZ+!B) M*.]RQ^W=GM4)C+"37366.''YI[]L/1K$G.Z!YH(721F2;+>B[O'J[;20,ES+ M]"C=X]P[1?&\&!^OM[.F$Q0_%%&<[B,9]U'^+3Z6)(1FFT:U/B71?#.6I)G. MC7"PV=A(L1[)-:8 :]:H8/GI-P,+_E +>GWPO^;).6JN1CEN,EJ,=E3R79); M,QO!T^R^I5CK'5#,[A9O3#PM=>VG.'[6VPHAA"-[%$@*XQ>]8WK%8*R.#U*: M%]!/W-ULY8'H7?R[':SO[)7A6@]KP]L8)B%C./ZM:R:JE26OH;7\@8<6;R=Q MAD+58)/A%\#;V&Y$#@W$XNQH(*#"OW,1^N@2]GVD8;[$@S\%8#LST941Q=/C MRR/8W[KH* $_N'7)KQ#+#T@AQ:N]XG)_R1E/)3(9UB@+\^5O,$#;-6'3C[FT M1+#@'4&H:C&^NI ZL/ ,UU^2/!7/-@%)2_$7,#LN[APR7WZ'T&+R[+:A+C23 M.[ R'$R&G;WL)T)CSEVPL#> :+#+T+6P/O##1LI %WP8.R)_(F+Q:#_Q+^> M;6#(5L"\[0A*JHX%T/SSUO=#8%V%6(%':VI#B]SE]^ G^0U?E5@V@CW.[0E= M(L"7.;D"1;']CTZ6Z]-[[YI("(OKTJFEH29:TD'\X"O9WH&9Y^&B0V2+1^]$ ML^+71, @#1/GUQ5?CTS!E3+'%5J_'X9K1%0?[=4:NSN"@"?6E8&(DECM GA& M.5[\,5[PO8$8+H'WGPT(_^0/<;>E2PQV06O^F *:*51J.PKFOI9TIJ M@S_,!0J;TX^4Z'$&3A@ENM>]L4'_S%P5_.&X+-24S"I\\6W+-KQ]AB/>NZ>& MB-J:Q1+TKQ;%C>6-K@*UN8<$9ERFZ1(-#1W;BNR\2(QF;&V9_-$G])-X1@)! MMY(&[-U +1>XTG).\G;26.)M.Y0!D$G0C276MOG"@'RWW%AB:CGT!UBJY(PE M;+;;HURJX^H>I5CW'H!E[Q'=PV(K7VV0]SE)D1I+4<4N3F5MAP3]RAL+=$C0 MM ZJ8(>$#WI>@8(=$C[JG0&B1K>O,* ?BJ+/VH)<[X" +=PG=)OJ?4.*NJP@ MD]-M+)&_:@Z[7$J0)6B (JQWL>&N$.8-'4GQ_B1=9I,>"8C] MD4.>#T6BB.LMWSN5(2W"W&B6@M[A]=W*\$PD) 5TVM#"@ I&OE+L)X6DC>P6 MC:&FN3IZ.X-4X=\NGI^NAMY]6#J51-6))!1>;1.LYEN 87-7=\#P@4_>Y_/E MLY])3\6_2')4]_,7QUX1YGQYR5;=,C&TQ*N.9JL@L.8."2R0XW].#L "7A.X M>*)F6*B))9W4D,1GG#VWI)&0BG"F,IRN7VT?<6&BJUKN M005A*ZE6-FBPTG M7*%8Y01$]]$!*=LS8CT)O7)Y-E$=%0D[/.F@%,D3P=V=)Z)F9^.Q1"+N\E_V MKJ%43 4R84T],7J_T)M!JCLI8XE#JT:I0#TKH?"):3* MU!T*E-[."K$=5KFMSA2(]:-[/E)W:--7I&2,VF=E"^8T>FZ*H*#\D? [P+P! M:[9#/UV1 CG8[_%H!(FI3/S]P$);_;,HQ]4CP'&>R2^QH#Z3-N-2VNIGG&Y. M\8EE2/3(?[9M8NN99(GU.*=+:1.Z[&\V.0$G/ID"(74FHG9MWZII#$ =:YA> MY=NHL!KC>42*0E8\C>-Y'K7&K*PMKA+U_[AARX(EWW8! \,Y?K!8-#.*HN[O M[I5@JY'++L-( M(\&V^ F<'?@!W6#-52-'?(S)QZS *\&V%.-Y%\O",#W'D]N57]9W:5(8UG.O M%6;5ZD 7QH5O$8 N6.$R$,<#(8-10=N'',G!6D,'3=2/(L;EA>4*T1[:PXIO M$GU7S;Y&L,$]B+A^"#USC1]QCN'**Z-=-X10,&(BV&^@]PBV,4&,)F<6JS\50]* )@.7?(.&' ME\X@D4J9Z7[WH,\!'R,YL9X(=?LK^OG,QP4$;0M$,7QH%?'8=K!A]!3*&4=L M)3)Y4-%0/XS]/0R>@.-< !\R^R MJ$);9O41+\G1QZDN3^'+WX$9+. E\) <1.(901A9E]BG)WU@X7X=!R-&4,N8 MH0AI\?.5P'20GL1W="I(R#SS)-G[P?#PPJ&,]"07%L*5_(Q+PZ@F M(G83;R!:T:CR+#IBZ -@# NDF*\_8I,[S)!,G0GX6!FOHX?VW@!> ?L6552=K1+%;FE#-CLXI MX%FH]+=NRI9+TBK)P2)]L2,%!RU$^:FZA^X.^#BRX:?A6?X"6T&SO\="%#TV M_@9((^V5BV?#@U.'3 CM]&2%<(Z_N>9(>RQ^J&(-KV+C8A:-3*4"W(+SUK7L MG6V%AG/]BIN6Q^>.9Y':C#(X%#(/K5:OB0X'5]/QC3Z>#6_ND>=#_ P2T-R9 MR"F>5U[*"LZG2$;%/!X2OT&&AWD8^(&!-I.[XIE+(RGU\Y&QY5@I]K5:8ANO MB9+0K19Y*.YX.C26?R=H\\BI09R=RBJ_%[,)!(LU^&%X?X(@FEYB9L=V.#^U M:7'RR$EUZK^E4?^MJ?]CA[Q-_1]++,=1O6M16<5 24D'U[A&(S:S1\\_)"XS M/PY],HTW#UWKUOZN MMR4?*[&NDE< /E+0Q8Y8[BU504"-E3QV)>=X\+GU['I"$J,8. 5-/1$E_C'! MYBTDJTO=IV.2QJ6SD!P6BFR_@>O+N[Y-PZI=]./=)K^>JE1WJY+XFX MD&(GS>(GY#]=7&2',<^YR_&"%B*K8IZ_ 1]'X_/?I+D/%?+**^,./FMAZ67N MR5[\1IUN))(\E_^R]S22BJG ,FAU;RU>N0%AQ0X?2W9@F30H8C*V_M[E\AP* MWD!C:?8M ;6,?D)3V?3LB%HGDJ;&YER-S<_UE$:-C;/1LVVM['TC^^ MWG/QGQV>P:_:X=7"4UF!:/$TZJF#,7BF8;W?G+9(UE-> M->KN=R)Q#V-I+-U6_>((B$DA_:KG1I0%*4,T5 +EV=EX[]?*8+:#R_1,/W!8 M P*SKW2IT8[I[M/T1NDT-A6RQ]]2G,=WRG/!TH=G6C^+;'DP.2P)94\WQ1<] M#U]5N#\L33B@:.AY1)K0.$P-H6CH^1ABLG959_4<"A%]C=+-V5%9O!A2NM)] M]4U/F2.0+)=65O&=E1;9G N"YIA[^.A%7GHV;(J+_6_"ND+N< M$61-.=,4)SWCC,1PJLZ8IWCIV9FKS;XZ*)R0 G6N9R\N5J!JJV50D+27VZP@ M,1R]#WKJ6ZQ@=5!5AT*K9T.%3J#-57.B&([S9J@H]45AT;-!'NO6ZK":6PJQ MIMY>5HA;%A9,8?RD?514]0%N*$298O1YW'>PK)*C%$\]'>JL>+(6L$WQTM3F MQK7_&,H9)WA]D-\I:P>\%SA\Q(3K7*?0:=I,NN56RY";]N56V[7KL MYEPL"2*WH[,(_6C/#*RK,]=$AM*G:6&\1JI.@.^AEIW69(W88_4[ZL^^V-,_ MB:4K<3S.R;'VOQ-)>NM& N-W@/,QD.:##B_2)\DOL1)^8]@>>5'SP*B<-65X MOS1/ZJ5B4K\1UV\RJ93Y,VY@.^%!3:^8S.,/"YR8JR34@K-=3".Q5GW0?M@. M @NZP)^AZQGLV+AK)#%HR1#I&YD\KCF^219KPXW!1*$3GQ[3^)22+&3F^322D"2%KK UUIK%HH2KS"D; M,4E\XB ("1+SD(Q8K>N"=2RZ_IZW:)_1=4)OS,B^F [.S':+$09]PAL%[J&" M-HQ+(,_3H!'&+R\8NN0%$6521=[0C/E;":I,?!PCDHF1K6\D#_D0NY^B]-^K MT(OC#BK-.NSW%0=)&3RCRSHA^NQ:P),^ XX!Q*J+5]%+;J[T9T3Z<#2:Y"8L MEW^Z!5*S-)_J(T!9O!.[T,51Q6#"5N3@9IQNUVRTUG0R!O-,QM8"WKJF!]"0 M20AP&@S!T_I9YFC#OE6 ;WKV5LY[CG<\L>ZNJ:TVLR9Q9&1A%?B;?KRE_)^&&QK>?O$3+M8P])&@6?Q$M'D; C:14=(! MBYQXI!#R=W0I?*J47]ZN+KD/1>\VXGI"YXGL*73: J18!W%N\K-K![S-%GE( M#N($^U6'*FIN@.8[PE MJ(RMYUG%_0S9-(BQ]#CC1ZE1+=2]T9D2699[+NC>*ZW^>=7<XB5+:@)=F^E*[7]M#A-PTK7Y.%W "M>& M.^6,KI-TB^9 2ODH>K5Q)E..I3EK!Z@W9=Y2:/6LRJH4VK*T:PKP9.?A53UK MLNY36#]K'L(UK"NSKC@#71*]_7TJET3_WL@#W>@B-6EH'\])C6]]EQ95E'/Y M73 TAI6CCI;NW585B)A.:K;1=9E,-NIU'.XBA;0=Z*3_\"^7K-*/H6;C>'MXU[OA5_' -'.@Q(+XK8;^CAJY0K.<2I3.++R!G)0^8ZDG&:61O;C7L&[4"\S=CS=SD)JI@;#L9!M\T:\7*%-'P';C'*PC-C(J=B7KITA[E&FXL_8[F!4(]SX2+J"M5VW(6?$25 M)D33]R3_N:TA,HA[9RK*T6M1CJF\@:KR!E3S)>&T*9N/P,$]?4GCRX(%0ZBV M0=N1>G_Z2H)JJFHPV#RBVDQ@?3'M.Q-8\^H(76<",^A48RFQH"3IFD\E'TV) M!A70Q#, ME]=^8&^PY2(3T'FQQXK8?!DI9FX^\B'V<&)*462$3#_R8*9Q)#[I_O$:2OG5 M>^CN2" 5X=]?P(!4QDA_CTUS]S#X&PBHBSZ.N,(-J=/)<;7K5,W98(K=BLQI M$, .Q+=T9#$-D[=S\G9.WL[)VSEY.R=OY^3MU,B8,7D[)V_G\?F!)F_GY.T< M /1'8V76W1':7SZ2F F"+HP20_6T-"W-;ATZ%HXDI2Q_ YB!O4/S[R*%C&FH M(S'/L\UI".8?X3((Z3%C2)!58-*4R.\?CGWJG"OO9MXT@4>PC8.>Y$ ^*'8' M80IM6Q($>]..Y#3P<7S->(^Z:"T-8(VZFCWN-]+WQM5F9 MJ)K2P."/F!J^5D7K>0U)>:)<'?<>+2F;-H1=6L+6<>-\J#@, ^0\3\>-<+XX M]! 0SO-TW @?PWTV<(R+=M1!!)1)*R23-:L)E8XI(S"(%9T"LJ: K%$$9#%Y M%S2A9+>46]+; 1/@>$%TW+),;:&I0O6D7YQ[4Y+IB!P M(5W'K](5^DE/5!\AE"[G-\U-:$>VD-SA>'0A-;=X'-E"\@6^ICT83ZLQ",[B/SY&'0E.U)U\BKK,61DX0Q0MJLS( CK+6ZZ8>6DC'EO4QY+U/> MR\ 0/@:I/'",B]8L??->2/6UQZ?GUODO>4*#6.$I#V;*@YGR8*8\F**K8\J# M&8C+:C8QY,7L&:\F&F?)AA[?NA1@=,^3#'L%Q3/LQQK-.4#W,L M*S7EPQS18C7F6,A+BIER+'K,L?@B/0IXTCUZS+'X.D4$#VDAQ7,LY.<^30NI M/,=B2GD:UBJ*!^AWD/-T1 'ZF:9D70;F-PYS9 'YU?-1Y8Q^:3Y%+_E3%)^5 MZU?@F;:/+96W;N#9KF^;Y&AP=17ODHM!N/2K9%',_SP,_,!P+;2]#OE7$LO1 MQ,11A",>[@20JL6D"U9_H++QF!+S[K*XPTW<$MG;>C0+R@-@T&;T[.C@+M6D-R?U#SL#4(G+65 MUL>!;^9J5YA&4CWX,6"6V0#J,2L,/BBM@/_B58E=Z?!*<,/FREO?#X%U%:(7 M^"H:G##K9VR9Z4W)!XL ]6/8+8=WV778N2H)+A5JS>,S3FO:-HJ$%%T0QO24J%'PVK MEKXH@W*^=[ < EG]BAACV.SPEJ7D!4_C>J9+ MHKE"3?I=O_H=XWF:M#Z1)5(=")4LU[E\#7!:+OGQ@NER39I%?[=5/G@V M713Y*L3TBI(6)IZNDGS]83HZ[7(CTJ7Y-*EVO5Y$A?R?=&6^*C@T@\K+2TM0 MY2[GF>^'FPBX9Q\->.$8YI_HKQ%1/P(4*\+H%S^@!1R9*7Q=<'0DV7Y2IS[D MP(TT.38SL^O7+< EX:[LG6TAV!^1G% 2R,'.S*"#82PD[O>NG*D&7\<;@V;0=QI(-Z@G8YQIV),?ITLFK8C"\JQ#,@:@?V_0*Q3_[A&QX^V =0.]FQ"[F7$LI^&:0.)+ MGW^XXWC&<\Q+@7:9X>;2V-J!X41!N)6L\>B* L0'K5'?Z=P?Z7<#LQ3P]T/* M?:BDZPNIOX;QA"Z"B[^!404!-?M2-1 J'XN1:&,?_+';(?D M#K:!HZ.9',IG)!R]M&T,/LP/H6>NT7;%K1S8]TO+ 5K/AT09DK$6/^%B#4/? M<)$("KT +?E5)AI"\TB(T=C;P4GJ]4$ILYKJ@HE3)W7ILYK4^>UJ?/:U'FM M;]/$U'E-.J93Y[6I\]H$-RO<#3HYM3".O,>"#)B%7FET!32_"E6O -^3GRZ# M]-XQPUJ&3CL]UIN)#C64M^!]2966&G^I64Z-+^\CJ8[ MZ_G([S"AUC "KJL.^W;N@/<"!^$:CD^[/[,L.YK+K;N$WH:,+^3]Y: X- 1VN@&]Z-MFQ\^4%<,'2-FW#F?]TT?%?V]L[ M>V-'B#,SQT-2B.<'-'6\#U9(+O^P77L3;N1PSD]8C'\L,NXAVH(@2N*:+V]= MTP-(=DF:A_ K=T\RI&'JA99,ZO@H+^Z5C^'[*]]Q[ MM%=K/^H>AF[ W]>VN4Z.>/3+()O%Q!6HT7(DL;T1OCBV.5^B>Q!7@/.B+8EM M3NS+6T.BKQ4*HLI/2"\$9HBN?QOXEX;C .MB?VVD.,9_VW:1. <36J='L(WS M[^9+)#F CY2H*$V.G [FQ6JD(\1=R3&.4@H-=_^4.<3,;+(3'(2_N4J[O8=Q M+\)"KT*QHLJ=\G&D2/9369B+'V7(BO4=8&H-4!45KM-#@K+%'GD2C$3'$#9'O*CDK#)/4Y^QKVERHD,4!O((]VA+E 5KMH4Q)=S#O6Z-_JE^0.2:X'QS#);3)SK4>PLGV"/_*@@H.=U4T>=?C9*/IZCX8XB*+YV+[P69>:#_RL\! M_>B/'\8K-@RQ[Y62CSKC+3):A5UT1&B=S']PU2 'S"" YV1:K ?'ECNX:+[2J9%RN6\'[YK_C% ME]QQ52!5,CZOO*LD(;8+[97A6@](G]X@[0Z[P@S'OW5-Z&VAARMS\6Y'5GK- M:/L)W#XPWZW@[KT%[ AI](\\P.A'?UR[ 3H![-NH^$T'3-V!E>%$H["N=.EG M*G;G? >\F>/ &^JR.3$KPO5$%&B5Q@D1 .K8CA$;;[,*,,"V3<,U)3,*GSQ M;44@*5N"=KN5,]LHR8T M#AU(% T]-2S!AS-/ N17;4&3G@#Y4>][BCD!LL3;3S'24TB+'<2*<(Z# WBF M+UCUX3#9&C*\P3PI@I_TUL]% Z@@>QP8A5)OZ<9G$12-^Z/-S_7>F'QRL"G> MD[:X'B%J=W59V:SQOQ1!Z77RM]!'$F0'%L>-9.L \K%T]Q;8I-59"!2T+Q-H MS?NQ.36%]BU74G/A*"!E36FBV.G=BD+P!.<[> OP;7T)WJGQ!DJ2%"J8(PG(:F2A(H$ MJW3P1V!"U[0=.^JBN<96CEOW*CZ21X\"?O!TK98RF I6$ MD1N ))GAD-B>F6O=H(',LVHRC5,-JE;=>2 MZ?W9Q#))*&?-1I,;VO[T%!&O%@@T*5!S?U(7L#;='F/I6M/EGF7'6'Y8(PP, M9R@8T?KGK'7];YEEK(?)RD+ MY1KVQI+5)0IMY5;\)#\=M; 5!^1F.=QB_GSY_)0YO"%Z0N[Q1D3G> &OETM@ MXGP"ND%Q\W=IGA?9O!R%,T;:I%44;2X=OTP3YS%&\%!54IJZE!\E+AWI0P\% M+_3#2\0K;M&.3AX2[VO9L)2-,)39WT,L3T+T9R\.B&^>\HCH2^AS&?*Z&'W( MJ*G 9C@(E+]2^-J0M!MG*$C,@ORE>/#'L@%I'&ZR]?>COTM9/&KTUSL4L@-L MJR4%-?GK'1;9 :CEEQ %5%Z0Y+<(4!>L< G'D4%:I_-0L/7.+^T ZC+%N\/V M\KK#*6;ETSQ'7PK.Y18%ZD*1?V\-V?#W9*]<>VF;AAO0\FHT/32S_8#$X&KQ M48_"F"

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�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end